# CANCER COUNTY PROFILES 2016-2020 Incidence Years 

## March 2023

## A Publication of the Cancer Data Registry of Idaho

## CDRI

## Editors:

Christopher J. Johnson, MPH, Epidemiologist Bożena M. Morawski, PhD, MPH, Epidemiologist

## Contributors:

Randi K. Rycroft, MSPH, CTR, Registry Manager Denise Jozwik, RHIT, CTR, Director of Data Quality Teresa Chapple, CTR, Data Quality \& Collection Coordinator Shannon Makinen, RHIT, CTR, Data Quality \& Collection Coordinator

Tessa Morrison, CTR, Data Quality \& Collection Coordinator Patti Rose, RHIT, CTR, Data Quality \& Collection Coordinator

Regina Eck, Database Administrator

## CANCER DATA REGISTRY OF IDAHO

P.O. Box 1278

Boise, Idaho 83701-1278
Phone: 208-489-1380
https://www.idcancer.org


A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS

## Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 11,968 cases of invasive cancer were diagnosed among Ada County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Ada County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Ada <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 11,968 | 45,610 |
| Female Breast | 1,983 | 6,687 |
| Prostate | 1,744 | 6,417 |
| Lung \& Bronchus | 1,167 | 4,887 |
| Colorectal | 780 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Ada County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected cases in Ada County. The table also shows the number of observed cases, person-years, and
crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Ada County was 509.8 cases per 100,000 personyears per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (523.7) gives an estimate of the relative burden of disease in Ada County.

The age- and sex-adjusted incidence rate of invasive cancer in Ada County, all sites combined, was 540.8 cases per 100,000 persons per year during 2016-2020. There were statistically significantly more cases of cancer in Ada County $(11,968)$ than expected $(11,588.4)$ based upon rates in the remainder of the state ( $\mathrm{p}<.001$ ).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 3,650 Ada County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Ada County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Ada <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 17,582 | 77,431 |
| Cancer Deaths | 3,650 | 15,121 |
| \% of All Deaths | $20.8 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 677 | 2,961 |
| Colorectal | 283 | 1,319 |
| Pancreas | 306 | 1,190 |
| Female Breast | 298 | 1,086 |
| Prostate | 200 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Ada County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Ada County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Ada County, all sites combined, was 164.3 deaths per 100,000 persons per year during 2017-2021, compared with 174.5 for the remainder of the state. There were statistically significantly fewer cancer deaths in Ada County $(3,650)$ than expected $(3,875.8)$ based upon rates in the remainder of the state ( $p<.001$ ).

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

COMPARISON BETWEEN ADA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Ada County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P-Value (4) | Observed Cases | Person Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 11,968 | 2,347,363 | 509.8 | 540.8 | 11,588.4 | 0.000 >> | 33,642 | 6,424,465 | 523.7 |
| All Sites Combined | Male | 6,199 | 1,175,230 | 527.5 | 582.6 | 5,974.1 | $0.004 \gg$ | 18,090 | 3,221,680 | 561.5 |
| All Sites Combined | Female | 5,769 | 1,172,133 | 492.2 | 504.9 | 5,548.0 | 0.003 >> | 15,552 | 3,202,785 | 485.6 |
| Bladder | Total | 575 | 2,347,363 | 24.5 | 27.1 | 530.6 | 0.059 | 1,609 | 6,424,465 | 25.0 |
| Bladder | Male | 446 | 1,175,230 | 38.0 | 43.8 | 412.7 | 0.109 | 1,305 | 3,221,680 | 40.5 |
| Bladder | Female | 129 | 1,172,133 | 11.0 | 11.7 | 104.6 | 0.023 >> | 304 | 3,202,785 | 9.5 |
| Brain - malignant | Total | 168 | 2,347,363 | 7.2 | 7.4 | 162.5 | 0.684 | 457 | 6,424,465 | 7.1 |
| Brain - malignant | Male | 101 | 1,175,230 | 8.6 | 8.9 | 96.4 | 0.664 | 274 | 3,221,680 | 8.5 |
| Brain - malignant | Female | 67 | 1,172,133 | 5.7 | 5.8 | 65.5 | 0.887 | 183 | 3,202,785 | 5.7 |
| Brain and other CNS - non-malignant | Total | 365 | 2,347,363 | 15.5 | 16.1 | 373.6 | 0.682 | 1,059 | 6,424,465 | 16.5 |
| Brain and other CNS - non-malignant | Male | 119 | 1,175,230 | 10.1 | 10.6 | 126.3 | 0.552 | 361 | 3,221,680 | 11.2 |
| Brain and other CNS - non-malignant | Female | 246 | 1,172,133 | 21.0 | 21.5 | 249.7 | 0.848 | 698 | 3,202,785 | 21.8 |
| Breast | Total | 2,004 | 2,347,363 | 85.4 | 87.7 | 1,686.1 | 0.000 >> | 4,742 | 6,424,465 | 73.8 |
| Breast | Male | 21 | 1,175,230 | 1.8 | 2.0 | 12.2 | 0.027 >> | 38 | 3,221,680 | 1.2 |
| Breast | Female | 1,983 | 1,172,133 | 169.2 | 171.1 | 1,701.9 | $0.000 \gg$ | 4,704 | 3,202,785 | 146.9 |
| Breast - in situ | Total | 415 | 2,347,363 | 17.7 | 17.9 | 296.9 | 0.000 >> | 824 | 6,424,465 | 12.8 |
| Breast - in situ | Male | 1 | 1,175,230 | 0.1 | 0.1 | 1.4 | 1.000 | 4 | 3,221,680 | 0.1 |
| Breast - in situ | Female | 414 | 1,172,133 | 35.3 | 35.4 | 299.7 | 0.000 >> | 820 | 3,202,785 | 25.6 |
| Cervix | Female | 57 | 1,172,133 | 4.9 | 4.5 | 97.7 | 0.000 << | 247 | 3,202,785 | 7.7 |
| Colorectal | Total | 780 | 2,347,363 | 33.2 | 35.0 | 927.8 | 0.000 << | 2,671 | 6,424,465 | 41.6 |
| Colorectal | Male | 405 | 1,175,230 | 34.5 | 37.0 | 508.7 | 0.000 << | 1,498 | 3,221,680 | 46.5 |
| Colorectal | Female | 375 | 1,172,133 | 32.0 | 33.0 | 415.7 | 0.046 << | 1,173 | 3,202,785 | 36.6 |
| Corpus Uteri | Female | 322 | 1,172,133 | 27.5 | 28.0 | 362.5 | 0.033 << | 1,008 | 3,202,785 | 31.5 |
| Esophagus | Total | 127 | 2,347,363 | 5.4 | 5.9 | 127.9 | 0.984 | 379 | 6,424,465 | 5.9 |
| Esophagus | Male | 106 | 1,175,230 | 9.0 | 10.1 | 104.1 | 0.877 | 318 | 3,221,680 | 9.9 |
| Esophagus | Female | 21 | 1,172,133 | 1.8 | 1.9 | 21.1 | 1.000 | 61 | 3,202,785 | 1.9 |
| Hodgkin Lymphoma | Total | 74 | 2,347,363 | 3.2 | 3.2 | 49.5 | 0.001 >> | 136 | 6,424,465 | 2.1 |
| Hodgkin Lymphoma | Male | 38 | 1,175,230 | 3.2 | 3.2 | 29.1 | 0.130 | 80 | 3,221,680 | 2.5 |
| Hodgkin Lymphoma | Female | 36 | 1,172,133 | 3.1 | 3.1 | 20.3 | 0.002 >> | 56 | 3,202,785 | 1.7 |
| Kidney and Renal Pelvis | Total | 424 | 2,347,363 | 18.1 | 18.9 | 484.8 | 0.005 << | 1,391 | 6,424,465 | 21.7 |
| Kidney and Renal Pelvis | Male | 281 | 1,175,230 | 23.9 | 25.5 | 307.8 | 0.130 | 901 | 3,221,680 | 28.0 |
| Kidney and Renal Pelvis | Female | 143 | 1,172,133 | 12.2 | 12.6 | 173.5 | 0.019 << | 490 | 3,202,785 | 15.3 |
| Larynx | Total | 44 | 2,347,363 | 1.9 | 2.0 | 57.8 | 0.072 | 171 | 6,424,465 | 2.7 |
| Larynx | Male | 34 | 1,175,230 | 2.9 | 3.2 | 41.0 | 0.309 | 126 | 3,221,680 | 3.9 |
| Larynx | Female | 10 | 1,172,133 | 0.9 | 0.9 | 15.7 | 0.174 | 45 | 3,202,785 | 1.4 |
| Leukemia | Total | 421 | 2,347,363 | 17.9 | 19.3 | 410.7 | 0.623 | 1,210 | 6,424,465 | 18.8 |
| Leukemia | Male | 250 | 1,175,230 | 21.3 | 23.5 | 244.2 | 0.726 | 739 | 3,221,680 | 22.9 |
| Leukemia | Female | 171 | 1,172,133 | 14.6 | 15.4 | 163.7 | 0.588 | 471 | 3,202,785 | 14.7 |
| Liver and Bile Duct | Total | 210 | 2,347,363 | 8.9 | 9.6 | 210.8 | 0.990 | 619 | 6,424,465 | 9.6 |
| Liver and Bile Duct | Male | 147 | 1,175,230 | 12.5 | 13.8 | 146.8 | 1.000 | 443 | 3,221,680 | 13.8 |
| Liver and Bile Duct | Female | 63 | 1,172,133 | 5.4 | 5.6 | 61.4 | 0.876 | 176 | 3,202,785 | 5.5 |
| Lung and Bronchus | Total | 1,167 | 2,347,363 | 49.7 | 54.9 | 1,231.0 | 0.069 | 3,720 | 6,424,465 | 57.9 |
| Lung and Bronchus | Male | 541 | 1,175,230 | 46.0 | 52.8 | 608.2 | 0.006 << | 1,911 | 3,221,680 | 59.3 |
| Lung and Bronchus | Female | 626 | 1,172,133 | 53.4 | 57.1 | 618.9 | 0.785 | 1,809 | 3,202,785 | 56.5 |
| Melanoma of the Skin | Total | 916 | 2,347,363 | 39.0 | 40.5 | 712.7 | 0.000 >> | 2,026 | 6,424,465 | 31.5 |
| Melanoma of the Skin | Male | 550 | 1,175,230 | 46.8 | 50.8 | 408.1 | 0.000 >> | 1,215 | 3,221,680 | 37.7 |
| Melanoma of the Skin | Female | 366 | 1,172,133 | 31.2 | 31.1 | 297.7 | 0.000 >> | 811 | 3,202,785 | 25.3 |
| Myeloma | Total | 181 | 2,347,363 | 7.7 | 8.4 | 176.8 | 0.775 | 527 | 6,424,465 | 8.2 |
| Myeloma | Male | 112 | 1,175,230 | 9.5 | 10.7 | 106.5 | 0.621 | 329 | 3,221,680 | 10.2 |
| Myeloma | Female | 69 | 1,172,133 | 5.9 | 6.2 | 68.7 | 1.000 | 198 | 3,202,785 | 6.2 |
| Non-Hodgkin Lymphoma | Total | 490 | 2,347,363 | 20.9 | 22.3 | 496.3 | 0.800 | 1,450 | 6,424,465 | 22.6 |
| Non-Hodgkin Lymphoma | Male | 299 | 1,175,230 | 25.4 | 27.8 | 277.3 | 0.204 | 830 | 3,221,680 | 25.8 |
| Non-Hodgkin Lymphoma | Female | 191 | 1,172,133 | 16.3 | 17.0 | 216.9 | 0.080 | 620 | 3,202,785 | 19.4 |
| Oral Cavity and Pharynx | Total | 337 | 2,347,363 | 14.4 | 15.1 | 332.9 | 0.835 | 958 | 6,424,465 | 14.9 |
| Oral Cavity and Pharynx | Male | 232 | 1,175,230 | 19.7 | 21.2 | 238.8 | 0.688 | 704 | 3,221,680 | 21.9 |
| Oral Cavity and Pharynx | Female | 105 | 1,172,133 | 9.0 | 9.2 | 90.2 | 0.139 | 254 | 3,202,785 | 7.9 |
| Ovary | Female | 123 | 1,172,133 | 10.5 | 10.7 | 147.8 | 0.041 << | 410 | 3,202,785 | 12.8 |
| Pancreas | Total | 356 | 2,347,363 | 15.2 | 16.5 | 358.4 | 0.925 | 1,067 | 6,424,465 | 16.6 |
| Pancreas | Male | 189 | 1,175,230 | 16.1 | 18.0 | 193.5 | 0.780 | 595 | 3,221,680 | 18.5 |
| Pancreas | Female | 167 | 1,172,133 | 14.2 | 15.1 | 163.0 | 0.776 | 472 | 3,202,785 | 14.7 |
| Prostate | Male | 1,744 | 1,175,230 | 148.4 | 166.1 | 1,523.4 | 0.000 >> | 4,673 | 3,221,680 | 145.0 |
| Stomach | Total | 111 | 2,347,363 | 4.7 | 5.1 | 121.3 | 0.373 | 356 | 6,424,465 | 5.5 |
| Stomach | Male | 73 | 1,175,230 | 6.2 | 6.9 | 77.2 | 0.685 | 236 | 3,221,680 | 7.3 |
| Stomach | Female | 38 | 1,172,133 | 3.2 | 3.3 | 42.6 | 0.537 | 120 | 3,202,785 | 3.7 |
| Testis | Male | 79 | 1,175,230 | 6.7 | 6.2 | 73.7 | 0.563 | 186 | 3,221,680 | 5.8 |
| Thyroid | Total | 336 | 2,347,363 | 14.3 | 13.8 | 335.1 | 0.975 | 884 | 6,424,465 | 13.8 |
| Thyroid | Male | 92 | 1,175,230 | 7.8 | 7.8 | 96.5 | 0.691 | 263 | 3,221,680 | 8.2 |
| Thyroid | Female | 244 | 1,172,133 | 20.8 | 19.9 | 237.9 | 0.711 | 621 | 3,202,785 | 19.4 |
| Pediatric Age 0 to 19 | Total | 116 | 613,273 | 18.9 | 19.0 | 101.0 | 0.154 | 305 | 1,847,250 | 16.5 |
| Pediatric Age 0 to 19 | Male | 56 | 313,621 | 17.9 | 17.9 | 55.3 | 0.959 | 167 | 942,889 | 17.7 |
| Pediatric Age 0 to 19 | Female | 60 | 299,652 | 20.0 | 20.1 | 45.7 | 0.048 >> | 138 | 904,361 | 15.3 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN ADA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Ada County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected <br> Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude <br> Rate (1) |
| All Causes of Death | Total | 17,582 | 2,414,365 | 728.2 | 790.5 | 20,247.8 | 0.000 << | 59,848 | 6,574,350 | 910.3 |
| All Causes of Death | Male | 9,010 | 1,210,250 | 744.5 | 828.7 | 10,553.5 | $0.000 \ll$ | 32,046 | 3,301,618 | 970.6 |
| All Causes of Death | Female | 8,572 | 1,204,115 | 711.9 | 757.0 | 9,619.7 | $0.000 \ll$ | 27,802 | 3,272,732 | 849.5 |
| All Malignant Cancers | Total | 3,650 | 2,414,365 | 151.2 | 164.3 | 3,875.8 | $0.000 \ll$ | 11,471 | 6,574,350 | 174.5 |
| All Malignant Cancers | Male | 1,868 | 1,210,250 | 154.3 | 174.3 | 2,047.0 | 0.000 << | 6,308 | 3,301,618 | 191.1 |
| All Malignant Cancers | Female | 1,782 | 1,204,115 | 148.0 | 155.8 | 1,804.1 | 0.614 | 5,163 | 3,272,732 | 157.8 |
| Bladder | Total | 121 | 2,414,365 | 5.0 | 5.6 | 120.6 | 0.996 | 368 | 6,574,350 | 5.6 |
| Bladder | Male | 87 | 1,210,250 | 7.2 | 8.4 | 91.2 | 0.711 | 291 | 3,301,618 | 8.8 |
| Bladder | Female | 34 | 1,204,115 | 2.8 | 3.1 | 26.1 | 0.156 | 77 | 3,272,732 | 2.4 |
| Brain and Other Nervous System | Total | 131 | 2,414,365 | 5.4 | 5.7 | 131.4 | 1.000 | 373 | 6,574,350 | 5.7 |
| Brain and Other Nervous System | Male | 76 | 1,210,250 | 6.3 | 6.7 | 76.4 | 1.000 | 222 | 3,301,618 | 6.7 |
| Brain and Other Nervous System | Female | 55 | 1,204,115 | 4.6 | 4.7 | 54.3 | 0.958 | 151 | 3,272,732 | 4.6 |
| Breast | Total | 302 | 2,414,365 | 12.5 | 13.2 | 277.5 | 0.152 | 800 | 6,574,350 | 12.2 |
| Breast | Male | 4 | 1,210,250 | 0.3 | 0.4 | 3.8 | 1.000 | 12 | 3,301,618 | 0.4 |
| Breast | Female | 298 | 1,204,115 | 24.7 | 25.6 | 280.2 | 0.302 | 788 | 3,272,732 | 24.1 |
| Cervix | Female | 23 | 1,204,115 | 1.9 | 1.8 | 23.1 | 1.000 | 60 | 3,272,732 | 1.8 |
| Colorectal | Total | 283 | 2,414,365 | 11.7 | 12.5 | 356.1 | 0.000 << | 1,036 | 6,574,350 | 15.8 |
| Colorectal | Male | 147 | 1,210,250 | 12.1 | 13.2 | 192.5 | 0.001 << | 572 | 3,301,618 | 17.3 |
| Colorectal | Female | 136 | 1,204,115 | 11.3 | 11.9 | 162.4 | 0.037 << | 464 | 3,272,732 | 14.2 |
| Corpus Uteri | Female | 55 | 1,204,115 | 4.6 | 4.8 | 41.2 | 0.046 >> | 118 | 3,272,732 | 3.6 |
| Esophagus | Total | 123 | 2,414,365 | 5.1 | 5.5 | 120.4 | 0.837 | 354 | 6,574,350 | 5.4 |
| Esophagus | Male | 102 | 1,210,250 | 8.4 | 9.3 | 98.8 | 0.774 | 299 | 3,301,618 | 9.1 |
| Esophagus | Female | 21 | 1,204,115 | 1.7 | 1.9 | 19.0 | 0.704 | 55 | 3,272,732 | 1.7 |
| Hodgkin Lymphoma | Total | 8 | 2,414,365 | 0.3 | 0.4 | 7.2 | 0.852 | 21 | 6,574,350 | 0.3 |
| Hodgkin Lymphoma | Male | 5 | 1,210,250 | 0.4 | 0.5 | 2.9 | 0.330 | 9 | 3,301,618 | 0.3 |
| Hodgkin Lymphoma | Female | 3 | 1,204,115 | 0.2 | 0.3 | 4.3 | 0.767 | 12 | 3,272,732 | 0.4 |
| Kidney | Total | 92 | 2,414,365 | 3.8 | 4.2 | 98.0 | 0.589 | 293 | 6,574,350 | 4.5 |
| Kidney | Male | 60 | 1,210,250 | 5.0 | 5.6 | 59.1 | 0.945 | 182 | 3,301,618 | 5.5 |
| Kidney | Female | 32 | 1,204,115 | 2.7 | 2.9 | 38.0 | 0.376 | 111 | 3,272,732 | 3.4 |
| Larynx | Total | 19 | 2,414,365 | 0.8 | 0.9 | 17.5 | 0.791 | 52 | 6,574,350 | 0.8 |
| Larynx | Male | 14 | 1,210,250 | 1.2 | 1.3 | 14.3 | 1.000 | 44 | 3,301,618 | 1.3 |
| Larynx | Female | 5 | 1,204,115 | 0.4 | 0.4 | 2.8 | 0.314 | 8 | 3,272,732 | 0.2 |
| Leukemia | Total | 183 | 2,414,365 | 7.6 | 8.3 | 159.3 | 0.071 | 477 | 6,574,350 | 7.3 |
| Leukemia | Male | 94 | 1,210,250 | 7.8 | 8.8 | 94.2 | 1.000 | 292 | 3,301,618 | 8.8 |
| Leukemia | Female | 89 | 1,204,115 | 7.4 | 7.9 | 63.6 | 0.003 >> | 185 | 3,272,732 | 5.7 |
| Liver and Bile Duct | Total | 148 | 2,414,365 | 6.1 | 6.6 | 154.3 | 0.648 | 455 | 6,574,350 | 6.9 |
| Liver and Bile Duct | Male | 100 | 1,210,250 | 8.3 | 9.2 | 101.1 | 0.964 | 308 | 3,301,618 | 9.3 |
| Liver and Bile Duct | Female | 48 | 1,204,115 | 4.0 | 4.2 | 51.3 | 0.712 | 147 | 3,272,732 | 4.5 |
| Lung and Bronchus | Total | 677 | 2,414,365 | 28.0 | 30.8 | 763.7 | $0.002 \ll$ | 2,284 | 6,574,350 | 34.7 |
| Lung and Bronchus | Male | 341 | 1,210,250 | 28.2 | 32.1 | 390.7 | 0.011 << | 1,215 | 3,301,618 | 36.8 |
| Lung and Bronchus | Female | 336 | 1,204,115 | 27.9 | 29.7 | 369.6 | 0.082 | 1,069 | 3,272,732 | 32.7 |
| Melanoma of the Skin | Total | 79 | 2,414,365 | 3.3 | 3.5 | 71.7 | 0.421 | 210 | 6,574,350 | 3.2 |
| Melanoma of the Skin | Male | 52 | 1,210,250 | 4.3 | 4.8 | 45.9 | 0.401 | 140 | 3,301,618 | 4.2 |
| Melanoma of the Skin | Female | 27 | 1,204,115 | 2.2 | 2.3 | 24.9 | 0.723 | 70 | 3,272,732 | 2.1 |
| Myeloma | Total | 90 | 2,414,365 | 3.7 | 4.2 | 79.3 | 0.252 | 241 | 6,574,350 | 3.7 |
| Myeloma | Male | 45 | 1,210,250 | 3.7 | 4.3 | 47.7 | 0.771 | 151 | 3,301,618 | 4.6 |
| Myeloma | Female | 45 | 1,204,115 | 3.7 | 4.0 | 30.7 | 0.018 >> | 90 | 3,272,732 | 2.7 |
| Non-Hodgkin Lymphoma | Total | 117 | 2,414,365 | 4.8 | 5.4 | 149.9 | 0.006 << | 452 | 6,574,350 | 6.9 |
| Non-Hodgkin Lymphoma | Male | 64 | 1,210,250 | 5.3 | 6.0 | 78.0 | 0.121 | 243 | 3,301,618 | 7.4 |
| Non-Hodgkin Lymphoma | Female | 53 | 1,204,115 | 4.4 | 4.7 | 71.4 | 0.028 << | 209 | 3,272,732 | 6.4 |
| Oral Cavity and Pharynx | Total | 67 | 2,414,365 | 2.8 | 3.0 | 67.8 | 0.986 | 199 | 6,574,350 | 3.0 |
| Oral Cavity and Pharynx | Male | 51 | 1,210,250 | 4.2 | 4.7 | 44.7 | 0.379 | 136 | 3,301,618 | 4.1 |
| Oral Cavity and Pharynx | Female | 16 | 1,204,115 | 1.3 | 1.4 | 22.3 | 0.213 | 63 | 3,272,732 | 1.9 |
| Ovary | Female | 85 | 1,204,115 | 7.1 | 7.4 | 93.2 | 0.428 | 265 | 3,272,732 | 8.1 |
| Pancreas | Total | 306 | 2,414,365 | 12.7 | 13.8 | 297.9 | 0.655 | 884 | 6,574,350 | 13.4 |
| Pancreas | Male | 160 | 1,210,250 | 13.2 | 14.9 | 156.9 | 0.825 | 482 | 3,301,618 | 14.6 |
| Pancreas | Female | 146 | 1,204,115 | 12.1 | 12.8 | 139.6 | 0.610 | 402 | 3,272,732 | 12.3 |
| Prostate | Male | 200 | 1,210,250 | 16.5 | 19.4 | 233.5 | 0.028 << | 749 | 3,301,618 | 22.7 |
| Stomach | Total | 50 | 2,414,365 | 2.1 | 2.2 | 51.4 | 0.921 | 148 | 6,574,350 | 2.3 |
| Stomach | Male | 25 | 1,210,250 | 2.1 | 2.3 | 31.9 | 0.255 | 96 | 3,301,618 | 2.9 |
| Stomach | Female | 25 | 1,204,115 | 2.1 | 2.1 | 18.9 | 0.203 | 52 | 3,272,732 | 1.6 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Ada County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 86.1\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 12.4\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 73.1\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% | 73.8\% |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 70.6\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 20.7\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 36.3\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 83.9\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 25.5\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 25.6\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to 64.8\% of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^0]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged $50-74$ reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

## ADAMS COUNTY CANCER PROPILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 164 cases of invasive cancer were diagnosed among Adams County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Adams County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Adams <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 164 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 15 | 6,687 |
| Prostate | 29 | 6,417 |
| Lung \& Bronchus | 23 | 4,887 |
| Colorectal | 7 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Adams County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Adams County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Adams County was 781.0 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.3) gives an estimate of the relative burden of disease in Adams County.

The age- and sex-adjusted incidence rate of invasive cancer in Adams County, all sites combined, was 480.4 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Adams County (164) than expected (177.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 63 Adams County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Adams County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Adams <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 236 | 77,431 |
| Cancer Deaths | 63 | 15,121 |
| \% of All Deaths | $26.7 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 16 | 2,961 |
| Colorectal | 4 | 1,319 |
| Pancreas | 4 | 1,190 |
| Female Breast | 6 | 1,086 |
| Prostate | 3 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Adams County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Adams County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Adams County, all sites combined, was 174.2 deaths per 100,000 persons per year during 2017-2021, compared with 167.9 for the remainder of the state. There were more cancer deaths in Adams County (63) than expected (60.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN ADAMS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

|  |  | Adams County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 164 | 20,999 | 781.0 | 480.4 | 177.3 | 0.337 | 45,446 | 8,750,829 | 519.3 |
| All Sites Combined | Male | 100 | 10,860 | 920.8 | 517.1 | 106.7 | 0.558 | 24,189 | 4,386,050 | 551.5 |
| All Sites Combined | Female | 64 | 10,139 | 631.2 | 422.4 | 73.8 | 0.277 | 21,257 | 4,364,779 | 487.0 |
| Bladder | Total | 12 | 20,999 | 57.1 | 33.0 | 9.0 | 0.401 | 2,172 | 8,750,829 | 24.8 |
| Bladder | Male | 11 | 10,860 | 101.3 | 53.7 | 8.1 | 0.394 | 1,740 | 4,386,050 | 39.7 |
| Bladder | Female | 1 | 10,139 | 9.9 | 6.2 | 1.6 | 1.000 | 432 | 4,364,779 | 9.9 |
| Brain - malignant | Total | - | 20,999 | - | - | 2.2 | 0.230 | 625 | 8,750,829 | 7.1 |
| Brain - malignant | Male | - | 10,860 | - | - | 1.4 | 0.491 | 375 | 4,386,050 | 8.5 |
| Brain - malignant | Female | - | 10,139 | - | - | 0.8 | 0.893 | 250 | 4,364,779 | 5.7 |
| Brain and other CNS - non-malignant | Total | 1 | 20,999 | 4.8 | 3.2 | 5.1 | 0.077 | 1,423 | 8,750,829 | 16.3 |
| Brain and other CNS - non-malignant | Male | - | 10,860 | - | - | 1.8 | 0.332 | 480 | 4,386,050 | 10.9 |
| Brain and other CNS - non-malignant | Female | 1 | 10,139 | 9.9 | 6.9 | 3.1 | 0.362 | 943 | 4,364,779 | 21.6 |
| Breast | Total | 16 | 20,999 | 76.2 | 48.7 | 25.2 | 0.068 | 6,730 | 8,750,829 | 76.9 |
| Breast | Male | 1 | 10,860 | 9.2 | 5.2 | 0.3 | 0.447 | 58 | 4,386,050 | 1.3 |
| Breast | Female | 15 | 10,139 | 147.9 | 98.8 | 23.2 | 0.095 | 6,672 | 4,364,779 | 152.9 |
| Breast - in situ | Total | 5 | 20,999 | 23.8 | 15.3 | 4.6 | 0.974 | 1,234 | 8,750,829 | 14.1 |
| Breast - in situ | Male | - | 10,860 | - | - | 0.0 | 1.000 | 5 | 4,386,050 | 0.1 |
| Breast - in situ | Female | 5 | 10,139 | 49.3 | 32.8 | 4.3 | 0.857 | 1,229 | 4,364,779 | 28.2 |
| Cervix | Female | - | 10,139 | - | - | 0.8 | 0.912 | 304 | 4,364,779 | 7.0 |
| Colorectal | Total | 7 | 20,999 | 33.3 | 21.0 | 13.1 | 0.102 | 3,444 | 8,750,829 | 39.4 |
| Colorectal | Male | 4 | 10,860 | 36.8 | 21.9 | 7.9 | 0.208 | 1,899 | 4,386,050 | 43.3 |
| Colorectal | Female | 3 | 10,139 | 29.6 | 19.9 | 5.3 | 0.444 | 1,545 | 4,364,779 | 35.4 |
| Corpus Uteri | Female | 1 | 10,139 | 9.9 | 6.3 | 4.8 | 0.092 | 1,329 | 4,364,779 | 30.4 |
| Esophagus | Total | 1 | 20,999 | 4.8 | 2.8 | 2.1 | 0.776 | 505 | 8,750,829 | 5.8 |
| Esophagus | Male | 1 | 10,860 | 9.2 | 5.1 | 1.9 | 0.867 | 423 | 4,386,050 | 9.6 |
| Esophagus | Female | - | 10,139 | - | - | 0.3 | 1.000 | 82 | 4,364,779 | 1.9 |
| Hodgkin Lymphoma | Total | 2 | 20,999 | 9.5 | 8.5 | 0.6 | 0.218 | 208 | 8,750,829 | 2.4 |
| Hodgkin Lymphoma | Male | 2 | 10,860 | 18.4 | 15.5 | 0.3 | 0.093 | 116 | 4,386,050 | 2.6 |
| Hodgkin Lymphoma | Female | - | 10,139 | - | - | 0.2 | 1.000 | 92 | 4,364,779 | 2.1 |
| Kidney and Renal Pelvis | Total | 5 | 20,999 | 23.8 | 14.9 | 6.9 | 0.620 | 1,810 | 8,750,829 | 20.7 |
| Kidney and Renal Pelvis | Male | 3 | 10,860 | 27.6 | 16.4 | 4.9 | 0.555 | 1,179 | 4,386,050 | 26.9 |
| Kidney and Renal Pelvis | Female | 2 | 10,139 | 19.7 | 13.1 | 2.2 | 1.000 | 631 | 4,364,779 | 14.5 |
| Larynx | Total | 1 | 20,999 | 4.8 | 2.8 | 0.9 | 1.000 | 214 | 8,750,829 | 2.4 |
| Larynx | Male | - | 10,860 | - | - | 0.7 | 0.958 | 160 | 4,386,050 | 3.6 |
| Larynx | Female | 1 | 10,139 | 9.9 | 6.2 | 0.2 | 0.362 | 54 | 4,364,779 | 1.2 |
| Leukemia | Total | 2 | 20,999 | 9.5 | 6.1 | 6.1 | 0.112 | 1,629 | 8,750,829 | 18.6 |
| Leukemia | Male | 2 | 10,860 | 18.4 | 11.0 | 4.1 | 0.449 | 987 | 4,386,050 | 22.5 |
| Leukemia | Female | - | 10,139 | - | - | 2.2 | 0.223 | 642 | 4,364,779 | 14.7 |
| Liver and Bile Duct | Total | 1 | 20,999 | 4.8 | 2.8 | 3.4 | 0.288 | 828 | 8,750,829 | 9.5 |
| Liver and Bile Duct | Male | 1 | 10,860 | 9.2 | 5.0 | 2.7 | 0.508 | 589 | 4,386,050 | 13.4 |
| Liver and Bile Duct | Female | - | 10,139 | - | - | 0.9 | 0.829 | 239 | 4,364,779 | 5.5 |
| Lung and Bronchus | Total | 23 | 20,999 | 109.5 | 62.3 | 20.5 | 0.640 | 4,864 | 8,750,829 | 55.6 |
| Lung and Bronchus | Male | 12 | 10,860 | 110.5 | 57.9 | 11.5 | 0.969 | 2,440 | 4,386,050 | 55.6 |
| Lung and Bronchus | Female | 11 | 10,139 | 108.5 | 66.7 | 9.2 | 0.626 | 2,424 | 4,364,779 | 55.5 |
| Melanoma of the Skin | Total | 13 | 20,999 | 61.9 | 40.4 | 10.8 | 0.571 | 2,929 | 8,750,829 | 33.5 |
| Melanoma of the Skin | Male | 8 | 10,860 | 73.7 | 43.4 | 7.4 | 0.914 | 1,757 | 4,386,050 | 40.1 |
| Melanoma of the Skin | Female | 5 | 10,139 | 49.3 | 35.8 | 3.8 | 0.646 | 1,172 | 4,364,779 | 26.9 |
| Myeloma | Total | 3 | 20,999 | 14.3 | 8.4 | 2.9 | 1.000 | 705 | 8,750,829 | 8.1 |
| Myeloma | Male | 2 | 10,860 | 18.4 | 10.0 | 2.0 | 1.000 | 439 | 4,386,050 | 10.0 |
| Myeloma | Female | 1 | 10,139 | 9.9 | 6.2 | 1.0 | 1.000 | 266 | 4,364,779 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 9 | 20,999 | 42.9 | 26.6 | 7.5 | 0.669 | 1,931 | 8,750,829 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 6 | 10,860 | 55.2 | 32.4 | 4.7 | 0.676 | 1,123 | 4,386,050 | 25.6 |
| Non-Hodgkin Lymphoma | Female | 3 | 10,139 | 29.6 | 19.4 | 2.9 | 1.000 | 808 | 4,364,779 | 18.5 |
| Oral Cavity and Pharynx | Total | 8 | 20,999 | 38.1 | 22.9 | 5.1 | 0.297 | 1,287 | 8,750,829 | 14.7 |
| Oral Cavity and Pharynx | Male | 5 | 10,860 | 46.0 | 26.3 | 4.0 | 0.757 | 931 | 4,386,050 | 21.2 |
| Oral Cavity and Pharynx | Female | 3 | 10,139 | 29.6 | 19.0 | 1.3 | 0.279 | 356 | 4,364,779 | 8.2 |
| Ovary | Female | 3 | 10,139 | 29.6 | 19.9 | 1.8 | 0.557 | 530 | 4,364,779 | 12.1 |
| Pancreas | Total | 7 | 20,999 | 33.3 | 19.6 | 5.8 | 0.712 | 1,416 | 8,750,829 | 16.2 |
| Pancreas | Male | 4 | 10,860 | 36.8 | 20.1 | 3.5 | 0.941 | 780 | 4,386,050 | 17.8 |
| Pancreas | Female | 3 | 10,139 | 29.6 | 18.8 | 2.3 | 0.819 | 636 | 4,364,779 | 14.6 |
| Prostate | Male | 29 | 10,860 | 267.0 | 141.0 | 30.0 | 0.958 | 6,388 | 4,386,050 | 145.6 |
| Stomach | Total | 1 | 20,999 | 4.8 | 2.9 | 1.8 | 0.916 | 466 | 8,750,829 | 5.3 |
| Stomach | Male | - | 10,860 | - | - | 1.4 | 0.514 | 309 | 4,386,050 | 7.0 |
| Stomach | Female | 1 | 10,139 | 9.9 | 6.8 | 0.5 | 0.818 | 157 | 4,364,779 | 3.6 |
| Testis | Male | - | 10,860 | - | - | 0.5 | 1.000 | 265 | 4,386,050 | 6.0 |
| Thyroid | Total | 4 | 20,999 | 19.0 | 15.9 | 3.5 | 0.925 | 1,216 | 8,750,829 | 13.9 |
| Thyroid | Male | 1 | 10,860 | 9.2 | 6.8 | 1.2 | 1.000 | 354 | 4,386,050 | 8.1 |
| Thyroid | Female | 3 | 10,139 | 29.6 | 26.0 | 2.3 | 0.798 | 862 | 4,364,779 | 19.7 |
| Pediatric Age 0 to 19 | Total | 2 | 3,954 | 50.6 | 51.6 | 0.7 | 0.285 | 419 | 2,456,569 | 17.1 |
| Pediatric Age 0 to 19 | Male | 1 | 2,085 | 48.0 | 49.0 | 0.4 | 0.606 | 222 | 1,254,425 | 17.7 |
| Pediatric Age 0 to 19 | Female | 1 | 1,869 | 53.5 | 54.0 | 0.3 | 0.524 | 197 | 1,202,144 | 16.4 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN ADAMS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Adams County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 236 | 21,680 | 1,088.6 | 698.0 | 291.1 | 0.001 << | 77,194 | 8,967,035 | 860.9 |
| All Causes of Death | Male | 141 | 11,248 | 1,253.6 | 750.8 | 170.7 | 0.022 << | 40,915 | 4,500,620 | 909.1 |
| All Causes of Death | Female | 95 | 10,432 | 910.7 | 621.8 | 124.1 | $0.008 \ll$ | 36,279 | 4,466,415 | 812.3 |
| All Malignant Cancers | Total | 63 | 21,680 | 290.6 | 174.2 | 60.7 | 0.803 | 15,058 | 8,967,035 | 167.9 |
| All Malignant Cancers | Male | 38 | 11,248 | 337.8 | 187.7 | 36.6 | 0.861 | 8,138 | 4,500,620 | 180.8 |
| All Malignant Cancers | Female | 25 | 10,432 | 239.6 | 154.0 | 25.1 | 1.000 | 6,920 | 4,466,415 | 154.9 |
| Bladder | Total | 1 | 21,680 | 4.6 | 2.8 | 2.0 | 0.837 | 488 | 8,967,035 | 5.4 |
| Bladder | Male | 1 | 11,248 | 8.9 | 5.0 | 1.7 | 0.992 | 377 | 4,500,620 | 8.4 |
| Bladder | Female | - | 10,432 |  | - | 0.4 | 1.000 | 111 | 4,466,415 | 2.5 |
| Brain and Other Nervous System | Total | 1 | 21,680 | 4.6 | 2.9 | 1.9 | 0.856 | 503 | 8,967,035 | 5.6 |
| Brain and Other Nervous System | Male | 1 | 11,248 | 8.9 | 5.4 | 1.2 | 1.000 | 297 | 4,500,620 | 6.6 |
| Brain and Other Nervous System | Female | - | 10,432 |  | - | 0.7 | 0.964 | 206 | 4,466,415 | 4.6 |
| Breast | Total | 6 | 21,680 | 27.7 | 17.3 | 4.2 | 0.507 | 1,096 | 8,967,035 | 12.2 |
| Breast | Male |  | 11,248 |  |  | 0.1 | 1.000 | 16 | 4,500,620 | 0.4 |
| Breast | Female | 6 | 10,432 | 57.5 | 37.7 | 3.8 | 0.382 | 1,080 | 4,466,415 | 24.2 |
| Cervix | Female | - | 10,432 |  | - | 0.2 | 1.000 | 83 | 4,466,415 | 1.9 |
| Colorectal | Total | 4 | 21,680 | 18.5 | 11.4 | 5.1 | 0.830 | 1,315 | 8,967,035 | 14.7 |
| Colorectal | Male | 2 | 11,248 | 17.8 | 10.4 | 3.1 | 0.812 | 717 | 4,500,620 | 15.9 |
| Colorectal | Female | 2 | 10,432 | 19.2 | 12.6 | 2.1 | 1.000 | 598 | 4,466,415 | 13.4 |
| Corpus Uteri | Female | - | 10,432 |  | - | 0.7 | 1.000 | 173 | 4,466,415 | 3.9 |
| Esophagus | Total | 2 | 21,680 | 9.2 | 5.4 | 1.9 | 1.000 | 475 | 8,967,035 | 5.3 |
| Esophagus | Male | 2 | 11,248 | 17.8 | 9.8 | 1.8 | 1.000 | 399 | 4,500,620 | 8.9 |
| Esophagus | Female | - | 10,432 | - | - | 0.3 | 1.000 | 76 | 4,466,415 | 1.7 |
| Hodgkin Lymphoma | Total | - | 21,680 | - | - | 0.1 | 1.000 | 29 | 8,967,035 | 0.3 |
| Hodgkin Lymphoma | Male | - | 11,248 | - | - | 0.1 | 1.000 | 14 | 4,500,620 | 0.3 |
| Hodgkin Lymphoma | Female | - | 10,432 |  | - | 0.1 | 1.000 | 15 | 4,466,415 | 0.3 |
| Kidney | Total | - | 21,680 |  | - | 1.6 | 0.410 | 385 | 8,967,035 | 4.3 |
| Kidney | Male | - | 11,248 | - | - | 1.1 | 0.665 | 242 | 4,500,620 | 5.4 |
| Kidney | Female | - | 10,432 | - | - | 0.5 | 1.000 | 143 | 4,466,415 | 3.2 |
| Larynx | Total | - | 21,680 |  | - | 0.3 | 1.000 | 71 | 8,967,035 | 0.8 |
| Larynx | Male | - | 11,248 | - | - | 0.3 | 1.000 | 58 | 4,500,620 | 1.3 |
| Larynx | Female | - | 10,432 | - | - | 0.0 | 1.000 | 13 | 4,466,415 | 0.3 |
| Leukemia | Total | 1 | 21,680 | 4.6 | 2.8 | 2.6 | 0.543 | 659 | 8,967,035 | 7.3 |
| Leukemia | Male | 1 | 11,248 | 8.9 | 5.1 | 1.7 | 0.996 | 385 | 4,500,620 | 8.6 |
| Leukemia | Female | - | 10,432 | - | - | 1.0 | 0.766 | 274 | 4,466,415 | 6.1 |
| Liver and Bile Duct | Total | 1 | 21,680 | 4.6 | 2.7 | 2.5 | 0.566 | 602 | 8,967,035 | 6.7 |
| Liver and Bile Duct | Male | 1 | 11,248 | 8.9 | 4.8 | 1.9 | 0.877 | 407 | 4,500,620 | 9.0 |
| Liver and Bile Duct | Female | - | 10,432 | - | - | 0.7 | 0.963 | 195 | 4,466,415 | 4.4 |
| Lung and Bronchus | Total | 16 | 21,680 | 73.8 | 42.5 | 12.4 | 0.365 | 2,945 | 8,967,035 | 32.8 |
| Lung and Bronchus | Male | 9 | 11,248 | 80.0 | 42.6 | 7.3 | 0.610 | 1,547 | 4,500,620 | 34.4 |
| Lung and Bronchus | Female | 7 | 10,432 | 67.1 | 41.7 | 5.3 | 0.552 | 1,398 | 4,466,415 | 31.3 |
| Melanoma of the Skin | Total | 2 | 21,680 | 9.2 | 5.7 | 1.1 | 0.621 | 287 | 8,967,035 | 3.2 |
| Melanoma of the Skin | Male | 2 | 11,248 | 17.8 | 10.2 | 0.8 | 0.403 | 190 | 4,500,620 | 4.2 |
| Melanoma of the Skin | Female | - | 10,432 | - | - | 0.3 | 1.000 | 97 | 4,466,415 | 2.2 |
| Myeloma | Total | 2 | 21,680 | 9.2 | 5.4 | 1.4 | 0.794 | 329 | 8,967,035 | 3.7 |
| Myeloma | Male | 2 | 11,248 | 17.8 | 9.5 | 0.9 | 0.462 | 194 | 4,500,620 | 4.3 |
| Myeloma | Female | - | 10,432 | - | - | 0.5 | 1.000 | 135 | 4,466,415 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 3 | 21,680 | 13.8 | 8.3 | 2.3 | 0.799 | 566 | 8,967,035 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 2 | 11,248 | 17.8 | 10.0 | 1.4 | 0.787 | 305 | 4,500,620 | 6.8 |
| Non-Hodgkin Lymphoma | Female |  | 10,432 | 9.6 | 6.1 | 1.0 | 1.000 | 261 | 4,466,415 | 5.8 |
| Oral Cavity and Pharynx | Total | 4 | 21,680 | 18.5 | 10.9 | 1.1 | 0.047 >> | 262 | 8,967,035 | 2.9 |
| Oral Cavity and Pharynx | Male | 3 | 11,248 | 26.7 | 14.7 | 0.8 | 0.104 | 184 | 4,500,620 | 4.1 |
| Oral Cavity and Pharynx | Female |  | 10,432 | 9.6 | 6.2 | 0.3 | 0.494 | 78 | 4,466,415 | 1.7 |
| Ovary | Female | 1 | 10,432 | 9.6 | 6.0 | 1.3 | 1.000 | 349 | 4,466,415 | 7.8 |
| Pancreas | Total | 4 | 21,680 | 18.5 | 10.8 | 4.9 | 0.909 | 1,186 | 8,967,035 | 13.2 |
| Pancreas | Male | 3 | 11,248 | 26.7 | 14.5 | 2.9 | 1.000 | 639 | 4,500,620 | 14.2 |
| Pancreas | Female | 1 | 10,432 | 9.6 | 6.0 | 2.1 | 0.785 | 547 | 4,466,415 | 12.2 |
| Prostate | Male | 3 | 11,248 | 26.7 | 14.7 | 4.3 | 0.758 | 946 | 4,500,620 | 21.0 |
| Stomach | Total |  | 21,680 |  |  | 0.8 | 0.944 | 198 | 8,967,035 | 2.2 |
| Stomach | Male | - | 11,248 | - | - | 0.5 | 1.000 | 121 | 4,500,620 | 2.7 |
| Stomach | Female | - | 10,432 | - | - | 0.3 | 1.000 | 77 | 4,466,415 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Adams County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | $\begin{gathered} 62.1 \% \\ 8.9 \% \end{gathered}$ |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% |  |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% |  |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% |  |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 24.7\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 24.7\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 68.3\% |
| Meet Physical Activity Guidelines ( $2011,2013,2015,2017,2019)$ | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 12.3\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 21.1\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, 12.6\% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^1]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# BANNOCK COUNTY CANCPR PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 1,884 cases of invasive cancer were diagnosed among Bannock County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Bannock County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Bannock <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 1,884 | 45,610 |
| Female Breast | 293 | 6,687 |
| Prostate | 216 | 6,417 |
| Lung \& Bronchus | 183 | 4,887 |
| Colorectal | 140 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Bannock County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Bannock County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Bannock County was 434.4 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (524.4) gives an estimate of the relative burden of disease in Bannock County.

The age- and sex-adjusted incidence rate of invasive cancer in Bannock County, all sites combined, was 475.6 cases per 100,000 persons per year during 2016-2020. There were statistically significantly fewer cases of cancer in Bannock County $(1,884)$ than expected $(2,077.4)$ based upon rates in the remainder of the state ( $\mathrm{p}<.001$ ).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 689 Bannock County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Bannock County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Bannock <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 4,061 | 77,431 |
| Cancer Deaths | 689 | 15,121 |
| \% of All Deaths | $17.0 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 126 | 2,961 |
| Colorectal | 60 | 1,319 |
| Pancreas | 62 | 1,190 |
| Female Breast | 47 | 1,086 |
| Prostate | 48 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Bannock County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Bannock County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Bannock County, all sites combined, was 175.2 deaths per 100,000 persons per year during 2017-2021, compared with 168.8 for the remainder of the state. There were more cancer deaths in Bannock County (689) than expected (663.9) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020 COMPARISON BETWEEN BANNOCK COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

|  |  | Bannock County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 1,884 | 433,711 | 434.4 | 475.6 | 2,077.4 | $0.000 \ll$ | 43,726 | 8,338,117 | 524.4 |
| All Sites Combined | Male | 964 | 215,729 | 446.9 | 494.8 | 1,086.8 | 0.000 << | 23,325 | 4,181,181 | 557.9 |
| All Sites Combined | Female | 920 | 217,982 | 422.1 | 457.3 | 987.4 | 0.032 << | 20,401 | 4,156,936 | 490.8 |
| Bladder | Total | 80 | 433,711 | 18.4 | 20.6 | 98.2 | 0.068 | 2,104 | 8,338,117 | 25.2 |
| Bladder | Male | 65 | 215,729 | 30.1 | 34.0 | 77.0 | 0.184 | 1,686 | 4,181,181 | 40.3 |
| Bladder | Female | 15 | 217,982 | 6.9 | 7.6 | 19.9 | 0.323 | 418 | 4,156,936 | 10.1 |
| Brain - malignant | Total | 36 | 433,711 | 8.3 | 8.8 | 28.8 | 0.215 | 589 | 8,338,117 | 7.1 |
| Brain - malignant | Male | 23 | 215,729 | 10.7 | 11.4 | 17.0 | 0.187 | 352 | 4,181,181 | 8.4 |
| Brain - malignant | Female | 13 | 217,982 | 6.0 | 6.3 | 11.7 | 0.783 | 237 | 4,156,936 | 5.7 |
| Brain and other CNS - non-malignant | Total | 42 | 433,711 | 9.7 | 10.5 | 66.4 | 0.002 << | 1,382 | 8,338,117 | 16.6 |
| Brain and other CNS - non-malignant | Male | 12 | 215,729 | 5.6 | 6.0 | 22.3 | 0.027 << | 468 | 4,181,181 | 11.2 |
| Brain and other CNS - non-malignant | Female | 30 | 217,982 | 13.8 | 14.8 | 44.5 | 0.028 << | 914 | 4,156,936 | 22.0 |
| Breast | Total | 296 | 433,711 | 68.2 | 74.5 | 307.2 | 0.544 | 6,450 | 8,338,117 | 77.4 |
| Breast | Male | 3 | 215,729 | 1.4 | 1.6 | 2.6 | 0.953 | 56 | 4,181,181 | 1.3 |
| Breast | Female | 293 | 217,982 | 134.4 | 146.0 | 308.8 | 0.386 | 6,394 | 4,156,936 | 153.8 |
| Breast - in situ | Total | 52 | 433,711 | 12.0 | 13.1 | 56.5 | 0.607 | 1,187 | 8,338,117 | 14.2 |
| Breast - in situ | Male | - | 215,729 | - | - | 0.2 | 1.000 | 5 | 4,181,181 | 0.1 |
| Breast - in situ | Female | 52 | 217,982 | 23.9 | 26.0 | 56.9 | 0.568 | 1,182 | 4,156,936 | 28.4 |
| Cervix | Female | 25 | 217,982 | 11.5 | 11.8 | 14.3 | $0.013 \gg$ | 279 | 4,156,936 | 6.7 |
| Colorectal | Total | 140 | 433,711 | 32.3 | 35.5 | 156.8 | 0.189 | 3,311 | 8,338,117 | 39.7 |
| Colorectal | Male | 76 | 215,729 | 35.2 | 39.1 | 85.0 | 0.360 | 1,827 | 4,181,181 | 43.7 |
| Colorectal | Female | 64 | 217,982 | 29.4 | 32.0 | 71.5 | 0.411 | 1,484 | 4,156,936 | 35.7 |
| Corpus Uteri | Female | 58 | 217,982 | 26.6 | 28.9 | 61.4 | 0.723 | 1,272 | 4,156,936 | 30.6 |
| Esophagus | Total | 20 | 433,711 | 4.6 | 5.1 | 22.9 | 0.640 | 486 | 8,338,117 | 5.8 |
| Esophagus | Male | 17 | 215,729 | 7.9 | 8.8 | 18.8 | 0.788 | 407 | 4,181,181 | 9.7 |
| Esophagus | Female | 3 | 217,982 | 1.4 | 1.5 | 3.8 | 0.953 | 79 | 4,156,936 | 1.9 |
| Hodgkin Lymphoma | Total | 11 | 433,711 | 2.5 | 2.6 | 10.3 | 0.897 | 199 | 8,338,117 | 2.4 |
| Hodgkin Lymphoma | Male | 7 | 215,729 | 3.2 | 3.3 | 5.6 | 0.665 | 111 | 4,181,181 | 2.7 |
| Hodgkin Lymphoma | Female | 4 | 217,982 | 1.8 | 1.8 | 4.6 | 1.000 | 88 | 4,156,936 | 2.1 |
| Kidney and Renal Pelvis | Total | 88 | 433,711 | 20.3 | 22.2 | 82.0 | 0.538 | 1,727 | 8,338,117 | 20.7 |
| Kidney and Renal Pelvis | Male | 66 | 215,729 | 30.6 | 33.8 | 52.1 | 0.071 | 1,116 | 4,181,181 | 26.7 |
| Kidney and Renal Pelvis | Female | 22 | 217,982 | 10.1 | 11.0 | 29.5 | 0.191 | 611 | 4,156,936 | 14.7 |
| Larynx | Total | 12 | 433,711 | 2.8 | 3.0 | 9.6 | 0.519 | 203 | 8,338,117 | 2.4 |
| Larynx | Male | 10 | 215,729 | 4.6 | 5.2 | 7.0 | 0.331 | 150 | 4,181,181 | 3.6 |
| Larynx | Female | 2 | 217,982 | 0.9 | 1.0 | 2.6 | 1.000 | 53 | 4,156,936 | 1.3 |
| Leukemia | Total | 64 | 433,711 | 14.8 | 16.1 | 74.6 | 0.238 | 1,567 | 8,338,117 | 18.8 |
| Leukemia | Male | 36 | 215,729 | 16.7 | 18.4 | 44.6 | 0.221 | 953 | 4,181,181 | 22.8 |
| Leukemia | Female | 28 | 217,982 | 12.8 | 13.9 | 29.7 | 0.855 | 614 | 4,156,936 | 14.8 |
| Liver and Bile Duct | Total | 41 | 433,711 | 9.5 | 10.4 | 37.4 | 0.593 | 788 | 8,338,117 | 9.5 |
| Liver and Bile Duct | Male | 26 | 215,729 | 12.1 | 13.3 | 26.4 | 1.000 | 564 | 4,181,181 | 13.5 |
| Liver and Bile Duct | Female | 15 | 217,982 | 6.9 | 7.5 | 10.7 | 0.255 | 224 | 4,156,936 | 5.4 |
| Lung and Bronchus | Total | 183 | 433,711 | 42.2 | 47.0 | 219.7 | 0.012 << | 4,704 | 8,338,117 | 56.4 |
| Lung and Bronchus | Male | 92 | 215,729 | 42.6 | 48.0 | 108.2 | 0.126 | 2,360 | 4,181,181 | 56.4 |
| Lung and Bronchus | Female | 91 | 217,982 | 41.7 | 46.1 | 111.3 | 0.055 | 2,344 | 4,156,936 | 56.4 |
| Melanoma of the Skin | Total | 138 | 433,711 | 31.8 | 34.5 | 134.5 | 0.786 | 2,804 | 8,338,117 | 33.6 |
| Melanoma of the Skin | Male | 80 | 215,729 | 37.1 | 41.0 | 78.6 | 0.906 | 1,685 | 4,181,181 | 40.3 |
| Melanoma of the Skin | Female | 58 | 217,982 | 26.6 | 28.3 | 55.2 | 0.743 | 1,119 | 4,156,936 | 26.9 |
| Myeloma | Total | 33 | 433,711 | 7.6 | 8.5 | 31.6 | 0.852 | 675 | 8,338,117 | 8.1 |
| Myeloma | Male | 20 | 215,729 | 9.3 | 10.4 | 19.3 | 0.928 | 421 | 4,181,181 | 10.1 |
| Myeloma | Female | 13 | 217,982 | 6.0 | 6.5 | 12.2 | 0.887 | 254 | 4,156,936 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 83 | 433,711 | 19.1 | 20.9 | 88.3 | 0.619 | 1,857 | 8,338,117 | 22.3 |
| Non-Hodgkin Lymphoma | Male | 50 | 215,729 | 23.2 | 25.5 | 50.6 | 1.000 | 1,079 | 4,181,181 | 25.8 |
| Non-Hodgkin Lymphoma | Female | 33 | 217,982 | 15.1 | 16.5 | 37.5 | 0.524 | 778 | 4,156,936 | 18.7 |
| Oral Cavity and Pharynx | Total | 46 | 433,711 | 10.6 | 11.6 | 59.3 | 0.089 | 1,249 | 8,338,117 | 15.0 |
| Oral Cavity and Pharynx | Male | 28 | 215,729 | 13.0 | 14.3 | 42.5 | 0.024 << | 908 | 4,181,181 | 21.7 |
| Oral Cavity and Pharynx | Female | 18 | 217,982 | 8.3 | 9.0 | 16.4 | 0.762 | 341 | 4,156,936 | 8.2 |
| Ovary | Female | 21 | 217,982 | 9.6 | 10.4 | 24.8 | 0.515 | 512 | 4,156,936 | 12.3 |
| Pancreas | Total | 77 | 433,711 | 17.8 | 19.7 | 63.1 | 0.098 | 1,346 | 8,338,117 | 16.1 |
| Pancreas | Male | 38 | 215,729 | 17.6 | 19.7 | 34.3 | 0.575 | 746 | 4,181,181 | 17.8 |
| Pancreas | Female | 39 | 217,982 | 17.9 | 19.7 | 28.6 | 0.073 | 600 | 4,156,936 | 14.4 |
| Prostate | Male | 216 | 215,729 | 100.1 | 110.8 | 289.0 | 0.000 << | 6,201 | 4,181,181 | 148.3 |
| Stomach | Total | 22 | 433,711 | 5.1 | 5.6 | 21.0 | 0.890 | 445 | 8,338,117 | 5.3 |
| Stomach | Male | 16 | 215,729 | 7.4 | 8.3 | 13.5 | 0.570 | 293 | 4,181,181 | 7.0 |
| Stomach | Female | 6 | 217,982 | 2.8 | 3.0 | 7.4 | 0.793 | 152 | 4,156,936 | 3.7 |
| Testis | Male | 10 | 215,729 | 4.6 | 4.5 | 13.7 | 0.393 | 255 | 4,181,181 | 6.1 |
| Thyroid | Total | 40 | 433,711 | 9.2 | 9.5 | 59.5 | 0.010 << | 1,180 | 8,338,117 | 14.2 |
| Thyroid | Male | 10 | 215,729 | 4.6 | 4.9 | 16.9 | 0.105 | 345 | 4,181,181 | 8.3 |
| Thyroid | Female | 30 | 217,982 | 13.8 | 14.0 | 43.0 | 0.048 << | 835 | 4,156,936 | 20.1 |
| Pediatric Age 0 to 19 | Total | 21 | 126,491 | 16.6 | 16.5 | 21.8 | 0.970 | 400 | 2,334,032 | 17.1 |
| Pediatric Age 0 to 19 | Male | 12 | 64,568 | 18.6 | 18.5 | 11.5 | 0.957 | 211 | 1,191,942 | 17.7 |
| Pediatric Age 0 to 19 | Female | 9 | 61,923 | 14.5 | 14.4 | 10.3 | 0.834 | 189 | 1,142,090 | 16.5 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN BANNOCK COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Bannock County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 4,061 | 437,212 | 928.8 | 1,027.7 | 3,390.3 | 0.000 >> | 73,369 | 8,551,503 | 858.0 |
| All Causes of Death | Male | 2,122 | 217,682 | 974.8 | 1,091.7 | 1,762.3 | $0.000 \gg$ | 38,934 | 4,294,186 | 906.7 |
| All Causes of Death | Female | 1,939 | 219,530 | 883.3 | 968.6 | 1,619.2 | 0.000 >> | 34,435 | 4,257,317 | 808.8 |
| All Malignant Cancers | Total | 689 | 437,212 | 157.6 | 175.2 | 663.9 | 0.339 | 14,432 | 8,551,503 | 168.8 |
| All Malignant Cancers | Male | 358 | 217,682 | 164.5 | 185.4 | 351.5 | 0.745 | 7,818 | 4,294,186 | 182.1 |
| All Malignant Cancers | Female | 331 | 219,530 | 150.8 | 165.9 | 310.0 | 0.245 | 6,614 | 4,257,317 | 155.4 |
| Bladder | Total | 17 | 437,212 | 3.9 | 4.4 | 21.4 | 0.400 | 472 | 8,551,503 | 5.5 |
| Bladder | Male | 11 | 217,682 | 5.1 | 5.8 | 16.2 | 0.238 | 367 | 4,294,186 | 8.5 |
| Bladder | Female | 6 | 219,530 | 2.7 | 3.0 | 4.9 | 0.722 | 105 | 4,257,317 | 2.5 |
| Brain and Other Nervous System | Total | 32 | 437,212 | 7.3 | 7.9 | 22.2 | 0.060 | 472 | 8,551,503 | 5.5 |
| Brain and Other Nervous System | Male | 17 | 217,682 | 7.8 | 8.5 | 13.0 | 0.333 | 281 | 4,294,186 | 6.5 |
| Brain and Other Nervous System | Female | 15 | 219,530 | 6.8 | 7.4 | 9.1 | 0.092 | 191 | 4,257,317 | 4.5 |
| Breast | Total | 48 | 437,212 | 11.0 | 12.1 | 48.8 | 0.983 | 1,054 | 8,551,503 | 12.3 |
| Breast | Male | 1 | 217,682 | 0.5 | 0.5 | 0.7 | 1.000 | 15 | 4,294,186 | 0.3 |
| Breast | Female | 47 | 219,530 | 21.4 | 23.4 | 48.9 | 0.856 | 1,039 | 4,257,317 | 24.4 |
| Cervix | Female | 6 | 219,530 | 2.7 | 2.9 | 3.8 | 0.356 | 77 | 4,257,317 | 1.8 |
| Colorectal | Total | 60 | 437,212 | 13.7 | 15.2 | 58.1 | 0.837 | 1,259 | 8,551,503 | 14.7 |
| Colorectal | Male | 30 | 217,682 | 13.8 | 15.4 | 31.3 | 0.914 | 689 | 4,294,186 | 16.0 |
| Colorectal | Female | 30 | 219,530 | 13.7 | 15.0 | 26.7 | 0.575 | 570 | 4,257,317 | 13.4 |
| Corpus Uteri | Female | 5 | 219,530 | 2.3 | 2.5 | 7.9 | 0.408 | 168 | 4,257,317 | 3.9 |
| Esophagus | Total | 12 | 437,212 | 2.7 | 3.1 | 21.4 | 0.041 << | 465 | 8,551,503 | 5.4 |
| Esophagus | Male | 11 | 217,682 | 5.1 | 5.7 | 17.6 | 0.129 | 390 | 4,294,186 | 9.1 |
| Esophagus | Female | 1 | 219,530 | 0.5 | 0.5 | 3.5 | 0.270 | 75 | 4,257,317 | 1.8 |
| Hodgkin Lymphoma | Total | 3 | 437,212 | 0.7 | 0.7 | 1.2 | 0.260 | 26 | 8,551,503 | 0.3 |
| Hodgkin Lymphoma | Male | 1 | 217,682 | 0.5 | 0.5 | 0.6 | 0.923 | 13 | 4,294,186 | 0.3 |
| Hodgkin Lymphoma | Female | 2 | 219,530 | 0.9 | 1.0 | 0.6 | 0.260 | 13 | 4,257,317 | 0.3 |
| Kidney | Total | 21 | 437,212 | 4.8 | 5.3 | 16.7 | 0.350 | 364 | 8,551,503 | 4.3 |
| Kidney | Male | 15 | 217,682 | 6.9 | 7.7 | 10.2 | 0.194 | 227 | 4,294,186 | 5.3 |
| Kidney | Female | 6 | 219,530 | 2.7 | 3.0 | 6.4 | 1.000 | 137 | 4,257,317 | 3.2 |
| Larynx | Total | 5 | 437,212 | 1.1 | 1.3 | 3.1 | 0.388 | 66 | 8,551,503 | 0.8 |
| Larynx | Male | 5 | 217,682 | 2.3 | 2.6 | 2.4 | 0.187 | 53 | 4,294,186 | 1.2 |
| Larynx | Female | - | 219,530 | - |  | 0.6 | 1.000 | 13 | 4,257,317 | 0.3 |
| Leukemia | Total | 29 | 437,212 | 6.6 | 7.4 | 29.0 | 1.000 | 631 | 8,551,503 | 7.4 |
| Leukemia | Male | 18 | 217,682 | 8.3 | 9.3 | 16.5 | 0.782 | 368 | 4,294,186 | 8.6 |
| Leukemia | Female | 11 | 219,530 | 5.0 | 5.5 | 12.3 | 0.854 | 263 | 4,257,317 | 6.2 |
| Liver and Bile Duct | Total | 33 | 437,212 | 7.5 | 8.3 | 26.4 | 0.236 | 570 | 8,551,503 | 6.7 |
| Liver and Bile Duct | Male | 21 | 217,682 | 9.6 | 10.7 | 17.7 | 0.489 | 387 | 4,294,186 | 9.0 |
| Liver and Bile Duct | Female | 12 | 219,530 | 5.5 | 6.0 | 8.5 | 0.309 | 183 | 4,257,317 | 4.3 |
| Lung and Bronchus | Total | 126 | 437,212 | 28.8 | 32.2 | 129.8 | 0.783 | 2,835 | 8,551,503 | 33.2 |
| Lung and Bronchus | Male | 61 | 217,682 | 28.0 | 31.6 | 67.2 | 0.492 | 1,495 | 4,294,186 | 34.8 |
| Lung and Bronchus | Female | 65 | 219,530 | 29.6 | 32.8 | 62.4 | 0.775 | 1,340 | 4,257,317 | 31.5 |
| Melanoma of the Skin | Total | 11 | 437,212 | 2.5 | 2.8 | 12.9 | 0.725 | 278 | 8,551,503 | 3.3 |
| Melanoma of the Skin | Male | 5 | 217,682 | 2.3 | 2.6 | 8.5 | 0.301 | 187 | 4,294,186 | 4.4 |
| Melanoma of the Skin | Female | 6 | 219,530 | 2.7 | 3.0 | 4.3 | 0.533 | 91 | 4,257,317 | 2.1 |
| Myeloma | Total | 14 | 437,212 | 3.2 | 3.6 | 14.4 | 1.000 | 317 | 8,551,503 | 3.7 |
| Myeloma | Male | 8 | 217,682 | 3.7 | 4.2 | 8.3 | 1.000 | 188 | 4,294,186 | 4.4 |
| Myeloma | Female | 6 | 219,530 | 2.7 | 3.0 | 6.0 | 1.000 | 129 | 4,257,317 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 29 | 437,212 | 6.6 | 7.4 | 24.7 | 0.442 | 540 | 8,551,503 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 11 | 217,682 | 5.1 | 5.7 | 13.3 | 0.646 | 296 | 4,294,186 | 6.9 |
| Non-Hodgkin Lymphoma | Female | 18 | 219,530 | 8.2 | 9.1 | 11.4 | 0.085 | 244 | 4,257,317 | 5.7 |
| Oral Cavity and Pharynx | Total | 10 | 437,212 | 2.3 | 2.5 | 11.8 | 0.741 | 256 | 8,551,503 | 3.0 |
| Oral Cavity and Pharynx | Male | 8 | 217,682 | 3.7 | 4.1 | 8.1 | 1.000 | 179 | 4,294,186 | 4.2 |
| Oral Cavity and Pharynx | Female | 2 | 219,530 | 0.9 | 1.0 | 3.6 | 0.596 | 77 | 4,257,317 | 1.8 |
| Ovary | Female | 17 | 219,530 | 7.7 | 8.5 | 15.6 | 0.794 | 333 | 4,257,317 | 7.8 |
| Pancreas | Total | 62 | 437,212 | 14.2 | 15.8 | 51.8 | 0.184 | 1,128 | 8,551,503 | 13.2 |
| Pancreas | Male | 31 | 217,682 | 14.2 | 16.0 | 27.6 | 0.559 | 611 | 4,294,186 | 14.2 |
| Pancreas | Female | 31 | 219,530 | 14.1 | 15.6 | 24.1 | 0.199 | 517 | 4,257,317 | 12.1 |
| Prostate | Male | 48 | 217,682 | 22.1 | 25.4 | 39.6 | 0.216 | 901 | 4,294,186 | 21.0 |
| Stomach | Total | 10 | 437,212 | 2.3 | 2.5 | 8.7 | 0.748 | 188 | 8,551,503 | 2.2 |
| Stomach | Male | 8 | 217,682 | 3.7 | 4.2 | 5.1 | 0.281 | 113 | 4,294,186 | 2.6 |
| Stomach | Female | 2 | 219,530 | 0.9 | 1.0 | 3.6 | 0.611 | 75 | 4,257,317 | 1.8 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Bannock County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 86.1\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 12.3\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 65.2\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% | 78.9\% |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 65.8\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 24.4\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 29.7\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 78.2\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 24.0\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 24.3\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, 83.1\% of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, 12.6\% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^2]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and 25.4\% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 170 cases of invasive cancer were diagnosed among Bear Lake County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Bear Lake County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Bear Lake <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 170 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 21 | 6,687 |
| Prostate | 13 | 6,417 |
| Lung \& Bronchus | 16 | 4,887 |
| Colorectal | 3,451 |  |

Table 3 (Cancer Incidence 2016-2020, Comparison between Bear Lake County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Bear Lake County. The table also shows the number of observed cases,
person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Bear Lake County was 561.6 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.8) gives an estimate of the relative burden of disease in Bear Lake County.

The age- and sex-adjusted incidence rate of invasive cancer in Bear Lake County, all sites combined, was 469.4 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Bear Lake County (170) than expected (188.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 62 Bear Lake County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Bear Lake County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Bear Lake <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 354 | 77,431 |
| Cancer Deaths | 62 | 15,121 |
| \% of All Deaths | $17.5 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 9 | 2,961 |
| Colorectal | 9 | 1,319 |
| Pancreas | 3 | 1,190 |
| Female Breast | 5 | 1,086 |
| Prostate | 4 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Bear Lake County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Bear Lake County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Bear Lake County, all sites combined, was 160.8 deaths per 100,000 persons per year during 2017-2021, compared with 168.1 for the remainder of the state. There were fewer cancer deaths in Bear Lake County (62) than expected (64.8) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020 COMPARISON BETWEEN BEAR LAKE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Bear Lake County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 170 | 30,269 | 561.6 | 469.4 | 188.2 | 0.193 | 45,440 | 8,741,559 | 519.8 |
| All Sites Combined | Male | 102 | 15,068 | 676.9 | 547.3 | 102.9 | 0.983 | 24,187 | 4,381,842 | 552.0 |
| All Sites Combined | Female | 68 | 15,201 | 447.3 | 386.3 | 85.8 | 0.055 | 21,253 | 4,359,717 | 487.5 |
| Bladder | Total | 8 | 30,269 | 26.4 | 20.7 | 9.6 | 0.757 | 2,176 | 8,741,559 | 24.9 |
| Bladder | Male | 7 | 15,068 | 46.5 | 35.6 | 7.8 | 0.955 | 1,744 | 4,381,842 | 39.8 |
| Bladder | Female | 1 | 15,201 | 6.6 | 5.3 | 1.9 | 0.891 | 432 | 4,359,717 | 9.9 |
| Brain - malignant | Total | 5 | 30,269 | 16.5 | 14.6 | 2.4 | 0.199 | 620 | 8,741,559 | 7.1 |
| Brain - malignant | Male | 2 | 15,068 | 13.3 | 11.6 | 1.5 | 0.859 | 373 | 4,381,842 | 8.5 |
| Brain - malignant | Female | 3 | 15,201 | 19.7 | 17.6 | 1.0 | 0.148 | 247 | 4,359,717 | 5.7 |
| Brain and other CNS - non-malignant | Total | 10 | 30,269 | 33.0 | 28.7 | 5.6 | 0.123 | 1,414 | 8,741,559 | 16.2 |
| Brain and other CNS - non-malignant | Male | 3 | 15,068 | 19.9 | 17.3 | 1.9 | 0.587 | 477 | 4,381,842 | 10.9 |
| Brain and other CNS - non-malignant | Female | 7 | 15,201 | 46.0 | 40.2 | 3.7 | 0.171 | 937 | 4,359,717 | 21.5 |
| Breast | Total | 21 | 30,269 | 69.4 | 60.2 | 26.8 | 0.303 | 6,725 | 8,741,559 | 76.9 |
| Breast | Male | - | 15,068 | - | - | 0.3 | 1.000 | 59 | 4,381,842 | 1.3 |
| Breast | Female | 21 | 15,201 | 138.1 | 121.7 | 26.4 | 0.343 | 6,666 | 4,359,717 | 152.9 |
| Breast - in situ | Total | 2 | 30,269 | 6.6 | 5.9 | 4.8 | 0.283 | 1,237 | 8,741,559 | 14.2 |
| Breast - in situ | Male | - | 15,068 | - | - | 0.0 | 1.000 | 5 | 4,381,842 | 0.1 |
| Breast - in situ | Female | 2 | 15,201 | 13.2 | 11.9 | 4.8 | 0.292 | 1,232 | 4,359,717 | 28.3 |
| Cervix | Female | 2 | 15,201 | 13.2 | 13.5 | 1.0 | 0.547 | 302 | 4,359,717 | 6.9 |
| Colorectal | Total | 16 | 30,269 | 52.9 | 44.5 | 14.1 | 0.689 | 3,435 | 8,741,559 | 39.3 |
| Colorectal | Male | 10 | 15,068 | 66.4 | 55.3 | 7.8 | 0.521 | 1,893 | 4,381,842 | 43.2 |
| Colorectal | Female | 6 | 15,201 | 39.5 | 33.4 | 6.4 | 1.000 | 1,542 | 4,359,717 | 35.4 |
| Corpus Uteri | Female | 3 | 15,201 | 19.7 | 17.5 | 5.2 | 0.470 | 1,327 | 4,359,717 | 30.4 |
| Esophagus | Total | 2 | 30,269 | 6.6 | 5.4 | 2.2 | 1.000 | 504 | 8,741,559 | 5.8 |
| Esophagus | Male | 2 | 15,068 | 13.3 | 10.6 | 1.8 | 1.000 | 422 | 4,381,842 | 9.6 |
| Esophagus | Female | - | 15,201 | - | - | 0.3 | 1.000 | 82 | 4,359,717 | 1.9 |
| Hodgkin Lymphoma | Total | 1 | 30,269 | 3.3 | 3.3 | 0.7 | 1.000 | 209 | 8,741,559 | 2.4 |
| Hodgkin Lymphoma | Male | - | 15,068 | - | - | 0.4 | 1.000 | 118 | 4,381,842 | 2.7 |
| Hodgkin Lymphoma | Female | 1 | 15,201 | 6.6 | 6.6 | 0.3 | 0.545 | 91 | 4,359,717 | 2.1 |
| Kidney and Renal Pelvis | Total | 5 | 30,269 | 16.5 | 14.0 | 7.4 | 0.508 | 1,810 | 8,741,559 | 20.7 |
| Kidney and Renal Pelvis | Male | 5 | 15,068 | 33.2 | 27.8 | 4.8 | 1.000 | 1,177 | 4,381,842 | 26.9 |
| Kidney and Renal Pelvis | Female | - | 15,201 | - | - | 2.6 | 0.151 | 633 | 4,359,717 | 14.5 |
| Larynx | Total | 2 | 30,269 | 6.6 | 5.4 | 0.9 | 0.458 | 213 | 8,741,559 | 2.4 |
| Larynx | Male | 1 | 15,068 | 6.6 | 5.3 | 0.7 | 0.996 | 159 | 4,381,842 | 3.6 |
| Larynx | Female | 1 | 15,201 | 6.6 | 5.7 | 0.2 | 0.393 | 54 | 4,359,717 | 1.2 |
| Leukemia | Total | 6 | 30,269 | 19.8 | 16.4 | 6.8 | 0.953 | 1,625 | 8,741,559 | 18.6 |
| Leukemia | Male | 5 | 15,068 | 33.2 | 27.0 | 4.2 | 0.806 | 984 | 4,381,842 | 22.5 |
| Leukemia | Female | 1 | 15,201 | 6.6 | 5.5 | 2.7 | 0.506 | 641 | 4,359,717 | 14.7 |
| Liver and Bile Duct | Total | 3 | 30,269 | 9.9 | 8.2 | 3.5 | 1.000 | 826 | 8,741,559 | 9.4 |
| Liver and Bile Duct | Male | 2 | 15,068 | 13.3 | 10.8 | 2.5 | 1.000 | 588 | 4,381,842 | 13.4 |
| Liver and Bile Duct | Female | 1 | 15,201 | 6.6 | 5.5 | 1.0 | 1.000 | 238 | 4,359,717 | 5.5 |
| Lung and Bronchus | Total | 13 | 30,269 | 42.9 | 33.9 | 21.4 | 0.072 | 4,874 | 8,741,559 | 55.8 |
| Lung and Bronchus | Male | 8 | 15,068 | 53.1 | 41.0 | 10.9 | 0.486 | 2,444 | 4,381,842 | 55.8 |
| Lung and Bronchus | Female | 5 | 15,201 | 32.9 | 26.4 | 10.6 | 0.098 | 2,430 | 4,359,717 | 55.7 |
| Melanoma of the Skin | Total | 13 | 30,269 | 42.9 | 36.9 | 11.8 | 0.804 | 2,929 | 8,741,559 | 33.5 |
| Melanoma of the Skin | Male | 8 | 15,068 | 53.1 | 43.7 | 7.3 | 0.902 | 1,757 | 4,381,842 | 40.1 |
| Melanoma of the Skin | Female | 5 | 15,201 | 32.9 | 29.8 | 4.5 | 0.940 | 1,172 | 4,359,717 | 26.9 |
| Myeloma | Total | 3 | 30,269 | 9.9 | 7.9 | 3.1 | 1.000 | 705 | 8,741,559 | 8.1 |
| Myeloma | Male | 3 | 15,068 | 19.9 | 15.6 | 1.9 | 0.601 | 438 | 4,381,842 | 10.0 |
| Myeloma | Female | - | 15,201 | - | - | 1.2 | 0.632 | 267 | 4,359,717 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 11 | 30,269 | 36.3 | 30.3 | 8.0 | 0.370 | 1,929 | 8,741,559 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 9 | 15,068 | 59.7 | 49.2 | 4.7 | 0.098 | 1,120 | 4,381,842 | 25.6 |
| Non-Hodgkin Lymphoma | Female | 2 | 15,201 | 13.2 | 11.0 | 3.4 | 0.694 | 809 | 4,359,717 | 18.6 |
| Oral Cavity and Pharynx | Total | 4 | 30,269 | 13.2 | 11.2 | 5.3 | 0.788 | 1,291 | 8,741,559 | 14.8 |
| Oral Cavity and Pharynx | Male | 3 | 15,068 | 19.9 | 16.6 | 3.9 | 0.926 | 933 | 4,381,842 | 21.3 |
| Oral Cavity and Pharynx | Female | 1 | 15,201 | 6.6 | 5.7 | 1.5 | 1.000 | 358 | 4,359,717 | 8.2 |
| Ovary | Female | 1 | 15,201 | 6.6 | 5.8 | 2.1 | 0.755 | 532 | 4,359,717 | 12.2 |
| Pancreas | Total | 3 | 30,269 | 9.9 | 7.9 | 6.1 | 0.278 | 1,420 | 8,741,559 | 16.2 |
| Pancreas | Male | 2 | 15,068 | 13.3 | 10.5 | 3.4 | 0.674 | 782 | 4,381,842 | 17.8 |
| Pancreas | Female | 1 | 15,201 | 6.6 | 5.3 | 2.7 | 0.484 | 638 | 4,359,717 | 14.6 |
| Prostate | Male | 24 | 15,068 | 159.3 | 127.2 | 27.5 | 0.578 | 6,393 | 4,381,842 | 145.9 |
| Stomach | Total | 1 | 30,269 | 3.3 | 2.7 | 2.0 | 0.828 | 466 | 8,741,559 | 5.3 |
| Stomach | Male | 1 | 15,068 | 6.6 | 5.3 | 1.3 | 1.000 | 308 | 4,381,842 | 7.0 |
| Stomach | Female | - | 15,201 | - | - | 0.7 | 1.000 | 158 | 4,359,717 | 3.6 |
| Testis | Male | 1 | 15,068 | 6.6 | 7.5 | 0.8 | 1.000 | 264 | 4,381,842 | 6.0 |
| Thyroid | Total | 6 | 30,269 | 19.8 | 19.6 | 4.2 | 0.510 | 1,214 | 8,741,559 | 13.9 |
| Thyroid | Male | 3 | 15,068 | 19.9 | 18.6 | 1.3 | 0.285 | 352 | 4,381,842 | 8.0 |
| Thyroid | Female | 3 | 15,201 | 19.7 | 20.1 | 2.9 | 1.000 | 862 | 4,359,717 | 19.8 |
| Pediatric Age 0 to 19 | Total | 3 | 8,859 | 33.9 | 34.0 | 1.5 | 0.384 | 418 | 2,451,664 | 17.0 |
| Pediatric Age 0 to 19 | Male | 2 | 4,463 | 44.8 | 44.5 | 0.8 | 0.377 | 221 | 1,252,047 | 17.7 |
| Pediatric Age 0 to 19 | Female | 1 | 4,396 | 22.7 | 23.1 | 0.7 | 1.000 | 197 | 1,199,617 | 16.4 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).
Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

## TABLE 4: CANCER MORTALITY 2017-2021

COMPARISON BETWEEN BEAR LAKE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Bear Lake County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 354 | 30,874 | 1,146.6 | 918.3 | 331.7 | 0.233 | 77,076 | 8,957,841 | 860.4 |
| All Causes of Death | Male | 191 | 15,415 | 1,239.1 | 986.0 | 176.0 | 0.277 | 40,865 | 4,496,453 | 908.8 |
| All Causes of Death | Female | 163 | 15,459 | 1,054.4 | 849.5 | 155.7 | 0.582 | 36,211 | 4,461,388 | 811.7 |
| All Malignant Cancers | Total | 62 | 30,874 | 200.8 | 160.8 | 64.8 | 0.790 | 15,059 | 8,957,841 | 168.1 |
| All Malignant Cancers | Male | 38 | 15,415 | 246.5 | 193.4 | 35.6 | 0.725 | 8,138 | 4,496,453 | 181.0 |
| All Malignant Cancers | Female | 24 | 15,459 | 155.2 | 126.7 | 29.4 | 0.371 | 6,921 | 4,461,388 | 155.1 |
| Bladder | Total | 2 | 30,874 | 6.5 | 5.0 | 2.2 | 1.000 | 487 | 8,957,841 | 5.4 |
| Bladder | Male | 2 | 15,415 | 13.0 | 9.7 | 1.7 | 1.000 | 376 | 4,496,453 | 8.4 |
| Bladder | Female | - | 15,459 | - | - | 0.5 | 1.000 | 111 | 4,461,388 | 2.5 |
| Brain and Other Nervous System | Total | 3 | 30,874 | 9.7 | 8.3 | 2.0 | 0.657 | 501 | 8,957,841 | 5.6 |
| Brain and Other Nervous System | Male | 1 | 15,415 | 6.5 | 5.5 | 1.2 | 1.000 | 297 | 4,496,453 | 6.6 |
| Brain and Other Nervous System | Female | 2 | 15,459 | 12.9 | 11.2 | 0.8 | 0.392 | 204 | 4,461,388 | 4.6 |
| Breast | Total | 5 | 30,874 | 16.2 | 13.4 | 4.6 | 0.961 | 1,097 | 8,957,841 | 12.2 |
| Breast | Male |  | 15,415 |  |  | 0.1 | 1.000 | 16 | 4,496,453 | 0.4 |
| Breast | Female | 5 | 15,459 | 32.3 | 27.3 | 4.4 | 0.915 | 1,081 | 4,461,388 | 24.2 |
| Cervix | Female | - | 15,459 |  | - | 0.3 | 1.000 | 83 | 4,461,388 | 1.9 |
| Colorectal | Total | 9 | 30,874 | 29.2 | 23.9 | 5.5 | 0.214 | 1,310 | 8,957,841 | 14.6 |
| Colorectal | Male | 5 | 15,415 | 32.4 | 26.5 | 3.0 | 0.370 | 714 | 4,496,453 | 15.9 |
| Colorectal | Female | 4 | 15,459 | 25.9 | 21.2 | 2.5 | 0.494 | 596 | 4,461,388 | 13.4 |
| Corpus Uteri | Female | 1 | 15,459 | 6.5 | 5.4 | 0.7 | 1.000 | 172 | 4,461,388 | 3.9 |
| Esophagus | Total | 2 | 30,874 | 6.5 | 5.3 | 2.0 | 1.000 | 475 | 8,957,841 | 5.3 |
| Esophagus | Male | 2 | 15,415 | 13.0 | 10.4 | 1.7 | 1.000 | 399 | 4,496,453 | 8.9 |
| Esophagus | Female | - | 15,459 | - | - | 0.3 | 1.000 | 76 | 4,461,388 | 1.7 |
| Hodgkin Lymphoma | Total | - | 30,874 | - | - | 0.1 | 1.000 | 29 | 8,957,841 | 0.3 |
| Hodgkin Lymphoma | Male | - | 15,415 | - | - | 0.1 | 1.000 | 14 | 4,496,453 | 0.3 |
| Hodgkin Lymphoma | Female | - | 15,459 | - | - | 0.1 | 1.000 | 15 | 4,461,388 | 0.3 |
| Kidney | Total | 1 | 30,874 | 3.2 | 2.6 | 1.7 | 1.000 | 384 | 8,957,841 | 4.3 |
| Kidney | Male | 1 | 15,415 | 6.5 | 5.1 | 1.1 | 1.000 | 241 | 4,496,453 | 5.4 |
| Kidney | Female | - | 15,459 | - | - | 0.6 | 1.000 | 143 | 4,461,388 | 3.2 |
| Larynx | Total | - | 30,874 |  | - | 0.3 | 1.000 | 71 | 8,957,841 | 0.8 |
| Larynx | Male | - | 15,415 | - | - | 0.3 | 1.000 | 58 | 4,496,453 | 1.3 |
| Larynx | Female | - | 15,459 | - | - | 0.1 | 1.000 | 13 | 4,461,388 | 0.3 |
| Leukemia | Total | 4 | 30,874 | 13.0 | 10.2 | 2.9 | 0.648 | 656 | 8,957,841 | 7.3 |
| Leukemia | Male | 3 | 15,415 | 19.5 | 15.2 | 1.7 | 0.475 | 383 | 4,496,453 | 8.5 |
| Leukemia | Female | 1 | 15,459 | 6.5 | 5.1 | 1.2 | 1.000 | 273 | 4,461,388 | 6.1 |
| Liver and Bile Duct | Total | 3 | 30,874 | 9.7 | 7.9 | 2.5 | 0.934 | 600 | 8,957,841 | 6.7 |
| Liver and Bile Duct | Male | - | 15,415 | - | - | 1.7 | 0.348 | 408 | 4,496,453 | 9.1 |
| Liver and Bile Duct | Female | 3 | 15,459 | 19.4 | 16.0 | 0.8 | 0.097 | 192 | 4,461,388 | 4.3 |
| Lung and Bronchus | Total | 9 | 30,874 | 29.2 | 23.0 | 12.9 | 0.349 | 2,952 | 8,957,841 | 33.0 |
| Lung and Bronchus | Male | 6 | 15,415 | 38.9 | 30.3 | 6.8 | 0.954 | 1,550 | 4,496,453 | 34.5 |
| Lung and Bronchus | Female | 3 | 15,459 | 19.4 | 15.5 | 6.1 | 0.288 | 1,402 | 4,461,388 | 31.4 |
| Melanoma of the Skin | Total | 2 | 30,874 | 6.5 | 5.3 | 1.2 | 0.686 | 287 | 8,957,841 | 3.2 |
| Melanoma of the Skin | Male | 2 | 15,415 | 13.0 | 10.3 | 0.8 | 0.399 | 190 | 4,496,453 | 4.2 |
| Melanoma of the Skin | Female | - | 15,459 | - | - | 0.4 | 1.000 | 97 | 4,461,388 | 2.2 |
| Myeloma | Total | 1 | 30,874 | 3.2 | 2.5 | 1.5 | 1.000 | 330 | 8,957,841 | 3.7 |
| Myeloma | Male | 1 | 15,415 | 6.5 | 4.9 | 0.9 | 1.000 | 195 | 4,496,453 | 4.3 |
| Myeloma | Female | - | 15,459 | - | - | 0.6 | 1.000 | 135 | 4,461,388 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 3 | 30,874 | 9.7 | 7.6 | 2.5 | 0.906 | 566 | 8,957,841 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 3 | 15,415 | 19.5 | 15.3 | 1.3 | 0.297 | 304 | 4,496,453 | 6.8 |
| Non-Hodgkin Lymphoma | Female | - | 15,459 | - | - | 1.2 | 0.621 | 262 | 4,461,388 | 5.9 |
| Oral Cavity and Pharynx | Total | 1 | 30,874 | 3.2 | 2.6 | 1.1 | 1.000 | 265 | 8,957,841 | 3.0 |
| Oral Cavity and Pharynx | Male | 1 | 15,415 | 6.5 | 5.2 | 0.8 | 1.000 | 186 | 4,496,453 | 4.1 |
| Oral Cavity and Pharynx | Female | - | 15,459 | - | - | 0.3 | 1.000 | 79 | 4,461,388 | 1.8 |
| Ovary | Female | 1 | 15,459 | 6.5 | 5.3 | 1.5 | 1.000 | 349 | 4,461,388 | 7.8 |
| Pancreas | Total | 3 | 30,874 | 9.7 | 7.8 | 5.1 | 0.498 | 1,187 | 8,957,841 | 13.3 |
| Pancreas | Male | 2 | 15,415 | 13.0 | 10.2 | 2.8 | 0.949 | 640 | 4,496,453 | 14.2 |
| Pancreas | Female | 1 | 15,459 | 6.5 | 5.2 | 2.3 | 0.644 | 547 | 4,461,388 | 12.3 |
| Prostate | Male | 4 | 15,415 | 25.9 | 19.3 | 4.3 | 1.000 | 945 | 4,496,453 | 21.0 |
| Stomach | Total |  | 30,874 |  |  | 0.8 | 0.876 | 198 | 8,957,841 | 2.2 |
| Stomach | Male | - | 15,415 | - | - | 0.5 | 1.000 | 121 | 4,496,453 | 2.7 |
| Stomach | Female | - | 15,459 | - | - | 0.3 | 1.000 | 77 | 4,461,388 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Bear Lake County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 85.4\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 11.1\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% |  |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% |  |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 17.9\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 30.6\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 79.2\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 18.9\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 33.7\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, 12.6\% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^3]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked 49 ${ }^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# BDNDWAH COUNTY CANCER PROFITE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 291 cases of invasive cancer were diagnosed among Benewah County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Benewah County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Benewah <br> County |  |
| :--- | ---: | ---: | | State of <br> Idaho |
| :---: |
| All Sites/Types |

Table 3 (Cancer Incidence 2016-2020, Comparison between Benewah County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Benewah County. The table also shows the number of observed cases,
person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Benewah County was 630.5 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.4) gives an estimate of the relative burden of disease in Benewah County.

The age- and sex-adjusted incidence rate of invasive cancer in Benewah County, all sites combined, was 474.9 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Benewah County (291) than expected (318.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 118 Benewah County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Benewah County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Benewah <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 655 | 77,431 |
| Cancer Deaths | 118 | 15,121 |
| \% of All Deaths | $18.0 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 30 | 2,961 |
| Colorectal | 5 | 1,319 |
| Pancreas | 7 | 1,190 |
| Female Breast | 9 | 1,086 |
| Prostate | 5 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Benewah County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Benewah County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Benewah County, all sites combined, was 188.0 deaths per 100,000 persons per year during 2017-2021, compared with 167.8 for the remainder of the state. There were more cancer deaths in Benewah County (118) than expected (105.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020 COMPARISON BETWEEN BENEWAH COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Benewah County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 291 | 46,155 | 630.5 | 474.9 | 318.2 | 0.131 | 45,319 | 8,725,673 | 519.4 |
| All Sites Combined | Male | 173 | 23,514 | 735.7 | 521.5 | 182.9 | 0.490 | 24,116 | 4,373,396 | 551.4 |
| All Sites Combined | Female | 118 | 22,641 | 521.2 | 414.2 | 138.8 | 0.079 | 21,203 | 4,352,277 | 487.2 |
| Bladder | Total | 19 | 46,155 | 41.2 | 29.8 | 15.8 | 0.484 | 2,165 | 8,725,673 | 24.8 |
| Bladder | Male | 16 | 23,514 | 68.0 | 46.2 | 13.7 | 0.612 | 1,735 | 4,373,396 | 39.7 |
| Bladder | Female | 3 | 22,641 | 13.3 | 10.2 | 2.9 | 1.000 | 430 | 4,352,277 | 9.9 |
| Brain - malignant | Total | 4 | 46,155 | 8.7 | 7.0 | 4.0 | 1.000 | 621 | 8,725,673 | 7.1 |
| Brain - malignant | Male | 2 | 23,514 | 8.5 | 6.7 | 2.5 | 1.000 | 373 | 4,373,396 | 8.5 |
| Brain - malignant | Female | 2 | 22,641 | 8.8 | 7.4 | 1.5 | 0.917 | 248 | 4,352,277 | 5.7 |
| Brain and other CNS - non-malignant | Total | 10 | 46,155 | 21.7 | 17.3 | 9.4 | 0.920 | 1,414 | 8,725,673 | 16.2 |
| Brain and other CNS - non-malignant | Male | 4 | 23,514 | 17.0 | 13.3 | 3.3 | 0.826 | 476 | 4,373,396 | 10.9 |
| Brain and other CNS - non-malignant | Female | 6 | 22,641 | 26.5 | 21.7 | 5.9 | 1.000 | 938 | 4,352,277 | 21.6 |
| Breast | Total | 39 | 46,155 | 84.5 | 65.0 | 46.2 | 0.328 | 6,707 | 8,725,673 | 76.9 |
| Breast | Male | 1 | 23,514 | 4.3 | 3.0 | 0.4 | 0.717 | 58 | 4,373,396 | 1.3 |
| Breast | Female | 38 | 22,641 | 167.8 | 132.1 | 44.0 | 0.415 | 6,649 | 4,352,277 | 152.8 |
| Breast - in situ | Total | 12 | 46,155 | 26.0 | 19.9 | 8.5 | 0.296 | 1,227 | 8,725,673 | 14.1 |
| Breast - in situ | Male | 1 | 23,514 | 4.3 | 3.5 | 0.0 | 0.052 | 4 | 4,373,396 | 0.1 |
| Breast - in situ | Female | 11 | 22,641 | 48.6 | 37.8 | 8.2 | 0.406 | 1,223 | 4,352,277 | 28.1 |
| Cervix | Female | 1 | 22,641 | 4.4 | 4.2 | 1.7 | 1.000 | 303 | 4,352,277 | 7.0 |
| Colorectal | Total | 21 | 46,155 | 45.5 | 34.7 | 23.8 | 0.661 | 3,430 | 8,725,673 | 39.3 |
| Colorectal | Male | 14 | 23,514 | 59.5 | 43.3 | 14.0 | 1.000 | 1,889 | 4,373,396 | 43.2 |
| Colorectal | Female | 7 | 22,641 | 30.9 | 24.8 | 10.0 | 0.443 | 1,541 | 4,352,277 | 35.4 |
| Corpus Uteri | Female | 6 | 22,641 | 26.5 | 20.4 | 9.0 | 0.422 | 1,324 | 4,352,277 | 30.4 |
| Esophagus | Total | 5 | 46,155 | 10.8 | 7.9 | 3.6 | 0.597 | 501 | 8,725,673 | 5.7 |
| Esophagus | Male | 5 | 23,514 | 21.3 | 14.8 | 3.2 | 0.450 | 419 | 4,373,396 | 9.6 |
| Esophagus | Female | - | 22,641 | - | - | 0.6 | 1.000 | 82 | 4,352,277 | 1.9 |
| Hodgkin Lymphoma | Total | - | 46,155 | - | - | 1.2 | 0.621 | 210 | 8,725,673 | 2.4 |
| Hodgkin Lymphoma | Male | - | 23,514 | - | - | 0.7 | 1.000 | 118 | 4,373,396 | 2.7 |
| Hodgkin Lymphoma | Female | - | 22,641 | - | - | 0.5 | 1.000 | 92 | 4,352,277 | 2.1 |
| Kidney and Renal Pelvis | Total | 17 | 46,155 | 36.8 | 27.9 | 12.5 | 0.266 | 1,798 | 8,725,673 | 20.6 |
| Kidney and Renal Pelvis | Male | 12 | 23,514 | 51.0 | 37.4 | 8.6 | 0.319 | 1,170 | 4,373,396 | 26.8 |
| Kidney and Renal Pelvis | Female | 5 | 22,641 | 22.1 | 17.4 | 4.1 | 0.797 | 628 | 4,352,277 | 14.4 |
| Larynx | Total | 2 | 46,155 | 4.3 | 3.1 | 1.6 | 0.919 | 213 | 8,725,673 | 2.4 |
| Larynx | Male | 2 | 23,514 | 8.5 | 5.9 | 1.2 | 0.695 | 158 | 4,373,396 | 3.6 |
| Larynx | Female | - | 22,641 | - | - | 0.4 | 1.000 | 55 | 4,352,277 | 1.3 |
| Leukemia | Total | 3 | 46,155 | 6.5 | 5.0 | 11.2 | 0.008 << | 1,628 | 8,725,673 | 18.7 |
| Leukemia | Male | 3 | 23,514 | 12.8 | 9.3 | 7.3 | 0.139 | 986 | 4,373,396 | 22.5 |
| Leukemia | Female | - | 22,641 | - | - | 4.2 | 0.031 << | 642 | 4,352,277 | 14.8 |
| Liver and Bile Duct | Total | 8 | 46,155 | 17.3 | 12.6 | 6.0 | 0.501 | 821 | 8,725,673 | 9.4 |
| Liver and Bile Duct | Male | 7 | 23,514 | 29.8 | 20.9 | 4.5 | 0.331 | 583 | 4,373,396 | 13.3 |
| Liver and Bile Duct | Female | 1 | 22,641 | 4.4 | 3.4 | 1.6 | 1.000 | 238 | 4,352,277 | 5.5 |
| Lung and Bronchus | Total | 37 | 46,155 | 80.2 | 57.3 | 35.9 | 0.893 | 4,850 | 8,725,673 | 55.6 |
| Lung and Bronchus | Male | 17 | 23,514 | 72.3 | 48.9 | 19.4 | 0.696 | 2,435 | 4,373,396 | 55.7 |
| Lung and Bronchus | Female | 20 | 22,641 | 88.3 | 66.4 | 16.7 | 0.481 | 2,415 | 4,352,277 | 55.5 |
| Melanoma of the Skin | Total | 7 | 46,155 | 15.2 | 11.9 | 19.8 | 0.002 << | 2,935 | 8,725,673 | 33.6 |
| Melanoma of the Skin | Male | 5 | 23,514 | 21.3 | 15.5 | 13.0 | 0.022 << | 1,760 | 4,373,396 | 40.2 |
| Melanoma of the Skin | Female | 2 | 22,641 | 8.8 | 7.4 | 7.3 | 0.046 << | 1,175 | 4,352,277 | 27.0 |
| Myeloma | Total | 10 | 46,155 | 21.7 | 15.8 | 5.1 | 0.069 | 698 | 8,725,673 | 8.0 |
| Myeloma | Male | 5 | 23,514 | 21.3 | 14.6 | 3.4 | 0.518 | 436 | 4,373,396 | 10.0 |
| Myeloma | Female | 5 | 22,641 | 22.1 | 16.9 | 1.8 | 0.070 | 262 | 4,352,277 | 6.0 |
| Non-Hodgkin Lymphoma | Total | 16 | 46,155 | 34.7 | 26.2 | 13.4 | 0.554 | 1,924 | 8,725,673 | 22.0 |
| Non-Hodgkin Lymphoma | Male | 9 | 23,514 | 38.3 | 27.8 | 8.3 | 0.894 | 1,120 | 4,373,396 | 25.6 |
| Non-Hodgkin Lymphoma | Female | 7 | 22,641 | 30.9 | 24.3 | 5.3 | 0.571 | 804 | 4,352,277 | 18.5 |
| Oral Cavity and Pharynx | Total | 10 | 46,155 | 21.7 | 16.1 | 9.2 | 0.866 | 1,285 | 8,725,673 | 14.7 |
| Oral Cavity and Pharynx | Male | 8 | 23,514 | 34.0 | 24.3 | 7.0 | 0.795 | 928 | 4,373,396 | 21.2 |
| Oral Cavity and Pharynx | Female | 2 | 22,641 | 8.8 | 6.9 | 2.4 | 1.000 | 357 | 4,352,277 | 8.2 |
| Ovary | Female | 4 | 22,641 | 17.7 | 14.1 | 3.5 | 0.906 | 529 | 4,352,277 | 12.2 |
| Pancreas | Total | 10 | 46,155 | 21.7 | 15.9 | 10.2 | 1.000 | 1,413 | 8,725,673 | 16.2 |
| Pancreas | Male | 6 | 23,514 | 25.5 | 17.7 | 6.0 | 1.000 | 778 | 4,373,396 | 17.8 |
| Pancreas | Female | 4 | 22,641 | 17.7 | 13.8 | 4.2 | 1.000 | 635 | 4,352,277 | 14.6 |
| Prostate | Male | 37 | 23,514 | 157.4 | 108.1 | 49.9 | 0.069 | 6,380 | 4,373,396 | 145.9 |
| Stomach | Total | 7 | 46,155 | 15.2 | 11.5 | 3.2 | 0.092 | 460 | 8,725,673 | 5.3 |
| Stomach | Male | 7 | 23,514 | 29.8 | 20.9 | 2.3 | 0.019 >> | 302 | 4,373,396 | 6.9 |
| Stomach | Female | - | 22,641 | - | - | 1.0 | 0.742 | 158 | 4,352,277 | 3.6 |
| Testis | Male | 3 | 23,514 | 12.8 | 15.1 | 1.2 | 0.237 | 262 | 4,373,396 | 6.0 |
| Thyroid | Total | 5 | 46,155 | 10.8 | 9.9 | 7.1 | 0.586 | 1,215 | 8,725,673 | 13.9 |
| Thyroid | Male | 1 | 23,514 | 4.3 | 3.6 | 2.2 | 0.687 | 354 | 4,373,396 | 8.1 |
| Thyroid | Female | 4 | 22,641 | 17.7 | 16.5 | 4.8 | 0.956 | 861 | 4,352,277 | 19.8 |
| Pediatric Age 0 to 19 | Total | 2 | 11,243 | 17.8 | 18.0 | 1.9 | 1.000 | 419 | 2,449,280 | 17.1 |
| Pediatric Age 0 to 19 | Male | 2 | 5,853 | 34.2 | 34.4 | 1.0 | 0.548 | 221 | 1,250,657 | 17.7 |
| Pediatric Age 0 to 19 | Female | - | 5,390 | - | - | 0.9 | 0.834 | 198 | 1,198,623 | 16.5 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN BENEWAH COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Benewah County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 655 | 47,053 | 1,392.0 | 1,106.9 | 508.1 | 0.000 >> | 76,775 | 8,941,662 | 858.6 |
| All Causes of Death | Male | 351 | 24,039 | 1,460.1 | 1,063.4 | 299.4 | $0.004 \gg$ | 40,705 | 4,487,829 | 907.0 |
| All Causes of Death | Female | 304 | 23,014 | 1,320.9 | 1,155.2 | 213.1 | 0.000 >> | 36,070 | 4,453,833 | 809.9 |
| All Malignant Cancers | Total | 118 | 47,053 | 250.8 | 188.0 | 105.3 | 0.238 | 15,003 | 8,941,662 | 167.8 |
| All Malignant Cancers | Male | 67 | 24,039 | 278.7 | 194.5 | 62.2 | 0.580 | 8,109 | 4,487,829 | 180.7 |
| All Malignant Cancers | Female | 51 | 23,014 | 221.6 | 176.6 | 44.7 | 0.382 | 6,894 | 4,453,833 | 154.8 |
| Bladder | Total | 6 | 47,053 | 12.8 | 9.7 | 3.3 | 0.240 | 483 | 8,941,662 | 5.4 |
| Bladder | Male | 6 | 24,039 | 25.0 | 17.2 | 2.9 | 0.146 | 372 | 4,487,829 | 8.3 |
| Bladder | Female | - | 23,014 | - | - | 0.7 | 0.993 | 111 | 4,453,833 | 2.5 |
| Brain and Other Nervous System | Total | 3 | 47,053 | 6.4 | 4.9 | 3.4 | 1.000 | 501 | 8,941,662 | 5.6 |
| Brain and Other Nervous System | Male | 1 | 24,039 | 4.2 | 3.1 | 2.1 | 0.742 | 297 | 4,487,829 | 6.6 |
| Brain and Other Nervous System | Female | 2 | 23,014 | 8.7 | 6.9 | 1.3 | 0.771 | 204 | 4,453,833 | 4.6 |
| Breast | Total | 10 | 47,053 | 21.3 | 16.4 | 7.5 | 0.438 | 1,092 | 8,941,662 | 12.2 |
| Breast | Male | 1 | 24,039 | 4.2 | 2.9 | 0.1 | 0.220 | 15 | 4,487,829 | 0.3 |
| Breast | Female | 9 | 23,014 | 39.1 | 31.6 | 6.9 | 0.511 | 1,077 | 4,453,833 | 24.2 |
| Cervix | Female | - | 23,014 |  | - | 0.5 | 1.000 | 83 | 4,453,833 | 1.9 |
| Colorectal | Total | 5 | 47,053 | 10.6 | 8.1 | 9.0 | 0.226 | 1,314 | 8,941,662 | 14.7 |
| Colorectal | Male | 4 | 24,039 | 16.6 | 12.0 | 5.3 | 0.770 | 715 | 4,487,829 | 15.9 |
| Colorectal | Female | 1 | 23,014 | 4.3 | 3.6 | 3.8 | 0.220 | 599 | 4,453,833 | 13.4 |
| Corpus Uteri | Female | 1 | 23,014 | 4.3 | 3.3 | 1.2 | 1.000 | 172 | 4,453,833 | 3.9 |
| Esophagus | Total | 6 | 47,053 | 12.8 | 9.4 | 3.4 | 0.249 | 471 | 8,941,662 | 5.3 |
| Esophagus | Male | 6 | 24,039 | 25.0 | 17.4 | 3.0 | 0.173 | 395 | 4,487,829 | 8.8 |
| Esophagus | Female | - | 23,014 | - | - | 0.5 | 1.000 | 76 | 4,453,833 | 1.7 |
| Hodgkin Lymphoma | Total |  | 47,053 | - | - | 0.2 | 1.000 | 29 | 8,941,662 | 0.3 |
| Hodgkin Lymphoma | Male | - | 24,039 | - | - | 0.1 | 1.000 | 14 | 4,487,829 | 0.3 |
| Hodgkin Lymphoma | Female | - | 23,014 |  | - | 0.1 | 1.000 | 15 | 4,453,833 | 0.3 |
| Kidney | Total | 5 | 47,053 | 10.6 | 7.9 | 2.7 | 0.272 | 380 | 8,941,662 | 4.2 |
| Kidney | Male | 4 | 24,039 | 16.6 | 11.6 | 1.8 | 0.227 | 238 | 4,487,829 | 5.3 |
| Kidney | Female | 1 | 23,014 | 4.3 | 3.5 | 0.9 | 1.000 | 142 | 4,453,833 | 3.2 |
| Larynx | Total | 1 | 47,053 | 2.1 | 1.6 | 0.5 | 0.788 | 70 | 8,941,662 | 0.8 |
| Larynx | Male | 1 | 24,039 | 4.2 | 2.9 | 0.4 | 0.713 | 57 | 4,487,829 | 1.3 |
| Larynx | Female | - | 23,014 | - | - | 0.1 | 1.000 | 13 | 4,453,833 | 0.3 |
| Leukemia | Total | 6 | 47,053 | 12.8 | 9.8 | 4.5 | 0.593 | 654 | 8,941,662 | 7.3 |
| Leukemia | Male | 4 | 24,039 | 16.6 | 11.8 | 2.9 | 0.658 | 382 | 4,487,829 | 8.5 |
| Leukemia | Female | 2 | 23,014 | 8.7 | 7.2 | 1.7 | 1.000 | 272 | 4,453,833 | 6.1 |
| Liver and Bile Duct | Total | 5 | 47,053 | 10.6 | 7.8 | 4.3 | 0.864 | 598 | 8,941,662 | 6.7 |
| Liver and Bile Duct | Male | 3 | 24,039 | 12.5 | 8.7 | 3.1 | 1.000 | 405 | 4,487,829 | 9.0 |
| Liver and Bile Duct | Female | 2 | 23,014 | 8.7 | 6.7 | 1.3 | 0.740 | 193 | 4,453,833 | 4.3 |
| Lung and Bronchus | Total | 30 | 47,053 | 63.8 | 46.3 | 21.2 | 0.084 | 2,931 | 8,941,662 | 32.8 |
| Lung and Bronchus | Male | 14 | 24,039 | 58.2 | 39.8 | 12.1 | 0.658 | 1,542 | 4,487,829 | 34.4 |
| Lung and Bronchus | Female | 16 | 23,014 | 69.5 | 53.6 | 9.3 | 0.057 | 1,389 | 4,453,833 | 31.2 |
| Melanoma of the Skin | Total | 1 | 47,053 | 2.1 | 1.6 | 2.0 | 0.819 | 288 | 8,941,662 | 3.2 |
| Melanoma of the Skin | Male | - | 24,039 | - | - | 1.4 | 0.473 | 192 | 4,487,829 | 4.3 |
| Melanoma of the Skin | Female | 1 | 23,014 | 4.3 | 3.5 | 0.6 | 0.921 | 96 | 4,453,833 | 2.2 |
| Myeloma | Total | 5 | 47,053 | 10.6 | 7.8 | 2.3 | 0.179 | 326 | 8,941,662 | 3.6 |
| Myeloma | Male | 2 | 24,039 | 8.3 | 5.6 | 1.5 | 0.909 | 194 | 4,487,829 | 4.3 |
| Myeloma | Female | 3 | 23,014 | 13.0 | 10.2 | 0.9 | 0.117 | 132 | 4,453,833 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 2 | 47,053 | 4.3 | 3.2 | 4.0 | 0.482 | 567 | 8,941,662 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 1 | 24,039 | 4.2 | 2.9 | 2.3 | 0.643 | 306 | 4,487,829 | 6.8 |
| Non-Hodgkin Lymphoma | Female |  | 23,014 | 4.3 | 3.5 | 1.7 | 1.000 | 261 | 4,453,833 | 5.9 |
| Oral Cavity and Pharynx | Total | 2 | 47,053 | 4.3 | 3.1 | 1.9 | 1.000 | 264 | 8,941,662 | 3.0 |
| Oral Cavity and Pharynx | Male | 2 | 24,039 | 8.3 | 5.8 | 1.4 | 0.834 | 185 | 4,487,829 | 4.1 |
| Oral Cavity and Pharynx | Female | - | 23,014 | - | - | 0.5 | 1.000 | 79 | 4,453,833 | 1.8 |
| Ovary | Female | - | 23,014 | - | - | 2.3 | 0.193 | 350 | 4,453,833 | 7.9 |
| Pancreas | Total | 7 | 47,053 | 14.9 | 10.9 | 8.5 | 0.770 | 1,183 | 8,941,662 | 13.2 |
| Pancreas | Male | 3 | 24,039 | 12.5 | 8.6 | 4.9 | 0.546 | 639 | 4,487,829 | 14.2 |
| Pancreas | Female | 4 | 23,014 | 17.4 | 13.4 | 3.6 | 0.986 | 544 | 4,453,833 | 12.2 |
| Prostate | Male | 5 | 24,039 | 20.8 | 14.3 | 7.4 | 0.512 | 944 | 4,487,829 | 21.0 |
| Stomach | Total | 3 | 47,053 | 6.4 | 5.0 | 1.3 | 0.296 | 195 | 8,941,662 | 2.2 |
| Stomach | Male | 3 | 24,039 | 12.5 | 8.9 | 0.9 | 0.122 | 118 | 4,487,829 | 2.6 |
| Stomach | Female | - | 23,014 | - | - | 0.5 | 1.000 | 77 | 4,453,833 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Benewah County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 82.0\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 10.1\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 45.9\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 58.3\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 27.1\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 33.5\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 72.5\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 22.7\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 15.5\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^4]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged $50-74$ reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and 25.4\% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# BINGHAM COUNTY CANCPR PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 1,059 cases of invasive cancer were diagnosed among Bingham County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Bingham County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Bingham <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 1,059 | 45,610 |
| Female Breast | 122 | 6,687 |
| Prostate | 140 | 6,417 |
| Lung \& Bronchus | 104 | 4,887 |
| Colorectal | 97 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Bingham County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Bingham County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Bingham County was 458.0 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (521.6) gives an estimate of the relative burden of disease in Bingham County.

The age- and sex-adjusted incidence rate of invasive cancer in Bingham County, all sites combined, was 500.8 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Bingham County $(1,059)$ than expected $(1,103.0)$ based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 360 Bingham County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Bingham County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Bingham <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 2,165 | 77,431 |
| Cancer Deaths | 360 | 15,121 |
| \% of All Deaths | $16.6 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 65 | 2,961 |
| Colorectal | 41 | 1,319 |
| Pancreas | 26 | 1,190 |
| Female Breast | 25 | 1,086 |
| Prostate | 25 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Bingham County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Bingham County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Bingham County, all sites combined, was 168.6 deaths per 100,000 persons per year during 2017-2021, compared with 168.6 for the remainder of the state. There were more cancer deaths in Bingham County (360) than expected (360.0) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020 COMPARISON BETWEEN BINGHAM COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

|  |  | Bingham County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 1,059 | 231,229 | 458.0 | 500.8 | 1,103.0 | 0.189 | 44,551 | 8,540,599 | 521.6 |
| All Sites Combined | Male | 572 | 115,694 | 494.4 | 532.1 | 595.6 | 0.345 | 23,717 | 4,281,216 | 554.0 |
| All Sites Combined | Female | 487 | 115,535 | 421.5 | 466.0 | 511.2 | 0.294 | 20,834 | 4,259,383 | 489.1 |
| Bladder | Total | 42 | 231,229 | 18.2 | 20.0 | 52.6 | 0.156 | 2,142 | 8,540,599 | 25.1 |
| Bladder | Male | 35 | 115,694 | 30.3 | 32.6 | 43.1 | 0.245 | 1,716 | 4,281,216 | 40.1 |
| Bladder | Female | 7 | 115,535 | 6.1 | 6.8 | 10.3 | 0.388 | 426 | 4,259,383 | 10.0 |
| Brain - malignant | Total | 12 | 231,229 | 5.2 | 5.5 | 15.6 | 0.441 | 613 | 8,540,599 | 7.2 |
| Brain - malignant | Male | 5 | 115,694 | 4.3 | 4.6 | 9.5 | 0.182 | 370 | 4,281,216 | 8.6 |
| Brain - malignant | Female | 7 | 115,535 | 6.1 | 6.5 | 6.2 | 0.844 | 243 | 4,259,383 | 5.7 |
| Brain and other CNS - non-malignant | Total | 31 | 231,229 | 13.4 | 14.5 | 34.9 | 0.582 | 1,393 | 8,540,599 | 16.3 |
| Brain and other CNS - non-malignant | Male | 8 | 115,694 | 6.9 | 7.3 | 12.0 | 0.308 | 472 | 4,281,216 | 11.0 |
| Brain and other CNS - non-malignant | Female | 23 | 115,535 | 19.9 | 21.9 | 22.7 | 1.000 | 921 | 4,259,383 | 21.6 |
| Breast | Total | 122 | 231,229 | 52.8 | 57.6 | 164.1 | 0.001 << | 6,624 | 8,540,599 | 77.6 |
| Breast | Male | - | 115,694 | - | - | 1.5 | 0.453 | 59 | 4,281,216 | 1.4 |
| Breast | Female | 122 | 115,535 | 105.6 | 116.8 | 161.0 | 0.002 << | 6,565 | 4,259,383 | 154.1 |
| Breast - in situ | Total | 23 | 231,229 | 9.9 | 10.9 | 30.1 | 0.224 | 1,216 | 8,540,599 | 14.2 |
| Breast - in situ | Male | - | 115,694 | - | - | 0.1 | 1.000 | 5 | 4,281,216 | 0.1 |
| Breast - in situ | Female | 23 | 115,535 | 19.9 | 22.0 | 29.7 | 0.253 | 1,211 | 4,259,383 | 28.4 |
| Cervix | Female | 10 | 115,535 | 8.7 | 9.2 | 7.5 | 0.448 | 294 | 4,259,383 | 6.9 |
| Colorectal | Total | 97 | 231,229 | 41.9 | 45.7 | 83.3 | 0.153 | 3,354 | 8,540,599 | 39.3 |
| Colorectal | Male | 56 | 115,694 | 48.4 | 51.8 | 46.6 | 0.198 | 1,847 | 4,281,216 | 43.1 |
| Colorectal | Female | 41 | 115,535 | 35.5 | 39.3 | 36.9 | 0.541 | 1,507 | 4,259,383 | 35.4 |
| Corpus Uteri | Female | 33 | 115,535 | 28.6 | 31.6 | 31.8 | 0.878 | 1,297 | 4,259,383 | 30.5 |
| Esophagus | Total | 10 | 231,229 | 4.3 | 4.7 | 12.3 | 0.643 | 496 | 8,540,599 | 5.8 |
| Esophagus | Male | 8 | 115,694 | 6.9 | 7.4 | 10.5 | 0.565 | 416 | 4,281,216 | 9.7 |
| Esophagus | Female | 2 | 115,535 | 1.7 | 1.9 | 2.0 | 1.000 | 80 | 4,259,383 | 1.9 |
| Hodgkin Lymphoma | Total | 2 | 231,229 | 0.9 | 0.9 | 5.4 | 0.194 | 208 | 8,540,599 | 2.4 |
| Hodgkin Lymphoma | Male | 1 | 115,694 | 0.9 | 0.9 | 3.0 | 0.397 | 117 | 4,281,216 | 2.7 |
| Hodgkin Lymphoma | Female | 1 | 115,535 | 0.9 | 0.9 | 2.4 | 0.635 | 91 | 4,259,383 | 2.1 |
| Kidney and Renal Pelvis | Total | 48 | 231,229 | 20.8 | 22.7 | 43.8 | 0.568 | 1,767 | 8,540,599 | 20.7 |
| Kidney and Renal Pelvis | Male | 27 | 115,694 | 23.3 | 25.1 | 29.0 | 0.798 | 1,155 | 4,281,216 | 27.0 |
| Kidney and Renal Pelvis | Female | 21 | 115,535 | 18.2 | 20.1 | 15.0 | 0.167 | 612 | 4,259,383 | 14.4 |
| Larynx | Total | 4 | 231,229 | 1.7 | 1.9 | 5.2 | 0.801 | 211 | 8,540,599 | 2.5 |
| Larynx | Male | 4 | 115,694 | 3.5 | 3.7 | 3.9 | 1.000 | 156 | 4,281,216 | 3.6 |
| Larynx | Female | - | 115,535 | - | - | 1.3 | 0.524 | 55 | 4,259,383 | 1.3 |
| Leukemia | Total | 39 | 231,229 | 16.9 | 18.2 | 40.0 | 0.960 | 1,592 | 8,540,599 | 18.6 |
| Leukemia | Male | 20 | 115,694 | 17.3 | 18.3 | 24.8 | 0.396 | 969 | 4,281,216 | 22.6 |
| Leukemia | Female | 19 | 115,535 | 16.4 | 18.1 | 15.4 | 0.416 | 623 | 4,259,383 | 14.6 |
| Liver and Bile Duct | Total | 22 | 231,229 | 9.5 | 10.4 | 19.9 | 0.704 | 807 | 8,540,599 | 9.4 |
| Liver and Bile Duct | Male | 15 | 115,694 | 13.0 | 13.9 | 14.5 | 0.957 | 575 | 4,281,216 | 13.4 |
| Liver and Bile Duct | Female | 7 | 115,535 | 6.1 | 6.7 | 5.6 | 0.675 | 232 | 4,259,383 | 5.4 |
| Lung and Bronchus | Total | 104 | 231,229 | 45.0 | 49.7 | 117.3 | 0.236 | 4,783 | 8,540,599 | 56.0 |
| Lung and Bronchus | Male | 64 | 115,694 | 55.3 | 59.9 | 59.6 | 0.605 | 2,388 | 4,281,216 | 55.8 |
| Lung and Bronchus | Female | 40 | 115,535 | 34.6 | 38.9 | 57.8 | 0.017 << | 2,395 | 4,259,383 | 56.2 |
| Melanoma of the Skin | Total | 56 | 231,229 | 24.2 | 26.4 | 71.6 | 0.066 | 2,886 | 8,540,599 | 33.8 |
| Melanoma of the Skin | Male | 39 | 115,694 | 33.7 | 36.3 | 43.4 | 0.569 | 1,726 | 4,281,216 | 40.3 |
| Melanoma of the Skin | Female | 17 | 115,535 | 14.7 | 16.1 | 28.8 | 0.026 << | 1,160 | 4,259,383 | 27.2 |
| Myeloma | Total | 16 | 231,229 | 6.9 | 7.6 | 17.0 | 0.936 | 692 | 8,540,599 | 8.1 |
| Myeloma | Male | 9 | 115,694 | 7.8 | 8.4 | 10.8 | 0.725 | 432 | 4,281,216 | 10.1 |
| Myeloma | Female | 7 | 115,535 | 6.1 | 6.8 | 6.3 | 0.882 | 260 | 4,259,383 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 53 | 231,229 | 22.9 | 25.0 | 46.9 | 0.409 | 1,887 | 8,540,599 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 25 | 115,694 | 21.6 | 23.1 | 27.9 | 0.669 | 1,104 | 4,281,216 | 25.8 |
| Non-Hodgkin Lymphoma | Female | 28 | 115,535 | 24.2 | 26.9 | 19.2 | 0.069 | 783 | 4,259,383 | 18.4 |
| Oral Cavity and Pharynx | Total | 26 | 231,229 | 11.2 | 12.3 | 31.4 | 0.384 | 1,269 | 8,540,599 | 14.9 |
| Oral Cavity and Pharynx | Male | 19 | 115,694 | 16.4 | 17.6 | 23.1 | 0.466 | 917 | 4,281,216 | 21.4 |
| Oral Cavity and Pharynx | Female | 7 | 115,535 | 6.1 | 6.7 | 8.6 | 0.747 | 352 | 4,259,383 | 8.3 |
| Ovary | Female | 16 | 115,535 | 13.8 | 15.2 | 12.7 | 0.428 | 517 | 4,259,383 | 12.1 |
| Pancreas | Total | 29 | 231,229 | 12.5 | 13.8 | 34.3 | 0.414 | 1,394 | 8,540,599 | 16.3 |
| Pancreas | Male | 18 | 115,694 | 15.6 | 16.8 | 19.2 | 0.898 | 766 | 4,281,216 | 17.9 |
| Pancreas | Female | 11 | 115,535 | 9.5 | 10.7 | 15.2 | 0.342 | 628 | 4,259,383 | 14.7 |
| Prostate | Male | 140 | 115,694 | 121.0 | 131.3 | 156.3 | 0.203 | 6,277 | 4,281,216 | 146.6 |
| Stomach | Total | 14 | 231,229 | 6.1 | 6.6 | 11.2 | 0.482 | 453 | 8,540,599 | 5.3 |
| Stomach | Male | 9 | 115,694 | 7.8 | 8.3 | 7.6 | 0.695 | 300 | 4,281,216 | 7.0 |
| Stomach | Female | 5 | 115,535 | 4.3 | 4.8 | 3.8 | 0.649 | 153 | 4,259,383 | 3.6 |
| Testis | Male | 5 | 115,694 | 4.3 | 4.7 | 6.5 | 0.731 | 260 | 4,281,216 | 6.1 |
| Thyroid | Total | 62 | 231,229 | 26.8 | 28.8 | 29.2 | 0.000 >> | 1,158 | 8,540,599 | 13.6 |
| Thyroid | Male | 18 | 115,694 | 15.6 | 16.8 | 8.5 | $0.006 \gg$ | 337 | 4,281,216 | 7.9 |
| Thyroid | Female | 44 | 115,535 | 38.1 | 40.8 | 20.8 | 0.000 >> | 821 | 4,259,383 | 19.3 |
| Pediatric Age 0 to 19 | Total | 14 | 77,207 | 18.1 | 18.4 | 13.0 | 0.850 | 407 | 2,383,316 | 17.1 |
| Pediatric Age 0 to 19 | Male | 7 | 39,334 | 17.8 | 18.0 | 6.9 | 1.000 | 216 | 1,217,176 | 17.7 |
| Pediatric Age 0 to 19 | Female | 7 | 37,873 | 18.5 | 18.9 | 6.1 | 0.806 | 191 | 1,166,140 | 16.4 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN BINGHAM COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Bingham County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 2,165 | 234,792 | 922.1 | 1,003.3 | 1,855.3 | 0.000 >> | 75,265 | 8,753,923 | 859.8 |
| All Causes of Death | Male | 1,168 | 117,603 | 993.2 | 1,057.6 | 1,002.5 | 0.000 >> | 39,888 | 4,394,265 | 907.7 |
| All Causes of Death | Female | 997 | 117,189 | 850.8 | 944.6 | 856.5 | 0.000 >> | 35,377 | 4,359,658 | 811.5 |
| All Malignant Cancers | Total | 360 | 234,792 | 153.3 | 168.6 | 360.0 | 1.000 | 14,761 | 8,753,923 | 168.6 |
| All Malignant Cancers | Male | 199 | 117,603 | 169.2 | 181.9 | 198.6 | 0.995 | 7,977 | 4,394,265 | 181.5 |
| All Malignant Cancers | Female | 161 | 117,189 | 137.4 | 154.0 | 162.7 | 0.933 | 6,784 | 4,359,658 | 155.6 |
| Bladder | Total | 14 | 234,792 | 6.0 | 6.6 | 11.6 | 0.552 | 475 | 8,753,923 | 5.4 |
| Bladder | Male | 10 | 117,603 | 8.5 | 9.1 | 9.3 | 0.891 | 368 | 4,394,265 | 8.4 |
| Bladder | Female | 4 | 117,189 | 3.4 | 3.9 | 2.5 | 0.500 | 107 | 4,359,658 | 2.5 |
| Brain and Other Nervous System | Total | 8 | 234,792 | 3.4 | 3.7 | 12.3 | 0.273 | 496 | 8,753,923 | 5.7 |
| Brain and Other Nervous System | Male | 5 | 117,603 | 4.3 | 4.5 | 7.4 | 0.516 | 293 | 4,394,265 | 6.7 |
| Brain and Other Nervous System | Female | 3 | 117,189 | 2.6 | 2.8 | 5.0 | 0.534 | 203 | 4,359,658 | 4.7 |
| Breast | Total | 25 | 234,792 | 10.6 | 11.6 | 26.4 | 0.886 | 1,077 | 8,753,923 | 12.3 |
| Breast | Male |  | 117,603 |  |  | 0.4 | 1.000 | 16 | 4,394,265 | 0.4 |
| Breast | Female | 25 | 117,189 | 21.3 | 23.8 | 25.6 | 1.000 | 1,061 | 4,359,658 | 24.3 |
| Cervix | Female | 3 | 117,189 | 2.6 | 2.8 | 2.0 | 0.637 | 80 | 4,359,658 | 1.8 |
| Colorectal | Total | 41 | 234,792 | 17.5 | 19.1 | 31.4 | 0.112 | 1,278 | 8,753,923 | 14.6 |
| Colorectal | Male | 27 | 117,603 | 23.0 | 24.6 | 17.3 | 0.037 >> | 692 | 4,394,265 | 15.7 |
| Colorectal | Female | 14 | 117,189 | 11.9 | 13.3 | 14.1 | 1.000 | 586 | 4,359,658 | 13.4 |
| Corpus Uteri | Female | 4 | 117,189 | 3.4 | 3.8 | 4.0 | 1.000 | 169 | 4,359,658 | 3.9 |
| Esophagus | Total | 10 | 234,792 | 4.3 | 4.7 | 11.4 | 0.836 | 467 | 8,753,923 | 5.3 |
| Esophagus | Male | 8 | 117,603 | 6.8 | 7.3 | 9.8 | 0.723 | 393 | 4,394,265 | 8.9 |
| Esophagus | Female | 2 | 117,189 | 1.7 | 1.9 | 1.8 | 1.000 | 74 | 4,359,658 | 1.7 |
| Hodgkin Lymphoma | Total | 1 | 234,792 | 0.4 | 0.5 | 0.7 | 0.999 | 28 | 8,753,923 | 0.3 |
| Hodgkin Lymphoma | Male |  | 117,603 |  |  | 0.3 | 1.000 | 14 | 4,394,265 | 0.3 |
| Hodgkin Lymphoma | Female | 1 | 117,189 | 0.9 | 0.9 | 0.3 | 0.585 | 14 | 4,359,658 | 0.3 |
| Kidney | Total | 14 | 234,792 | 6.0 | 6.6 | 9.0 | 0.151 | 371 | 8,753,923 | 4.2 |
| Kidney | Male | 9 | 117,603 | 7.7 | 8.2 | 5.8 | 0.263 | 233 | 4,394,265 | 5.3 |
| Kidney | Female | 5 | 117,189 | 4.3 | 4.8 | 3.3 | 0.473 | 138 | 4,359,658 | 3.2 |
| Larynx | Total |  | 234,792 |  | - | 1.8 | 0.347 | 71 | 8,753,923 | 0.8 |
| Larynx | Male | - | 117,603 | - | - | 1.5 | 0.462 | 58 | 4,394,265 | 1.3 |
| Larynx | Female | - | 117,189 | - | - | 0.3 | 1.000 | 13 | 4,359,658 | 0.3 |
| Leukemia | Total | 15 | 234,792 | 6.4 | 7.0 | 15.8 | 0.975 | 645 | 8,753,923 | 7.4 |
| Leukemia | Male | 6 | 117,603 | 5.1 | 5.5 | 9.5 | 0.330 | 380 | 4,394,265 | 8.6 |
| Leukemia | Female | 9 | 117,189 | 7.7 | 8.6 | 6.4 | 0.386 | 265 | 4,359,658 | 6.1 |
| Liver and Bile Duct | Total | 13 | 234,792 | 5.5 | 6.1 | 14.3 | 0.861 | 590 | 8,753,923 | 6.7 |
| Liver and Bile Duct | Male | 8 | 117,603 | 6.8 | 7.4 | 9.9 | 0.689 | 400 | 4,394,265 | 9.1 |
| Liver and Bile Duct | Female | 5 | 117,189 | 4.3 | 4.8 | 4.5 | 0.952 | 190 | 4,359,658 | 4.4 |
| Lung and Bronchus | Total | 65 | 234,792 | 27.7 | 30.7 | 70.1 | 0.590 | 2,896 | 8,753,923 | 33.1 |
| Lung and Bronchus | Male | 41 | 117,603 | 34.9 | 37.8 | 37.4 | 0.600 | 1,515 | 4,394,265 | 34.5 |
| Lung and Bronchus | Female | 24 | 117,189 | 20.5 | 23.1 | 32.9 | 0.134 | 1,381 | 4,359,658 | 31.7 |
| Melanoma of the Skin | Total | 2 | 234,792 | 0.9 | 0.9 | 7.0 | 0.058 | 287 | 8,753,923 | 3.3 |
| Melanoma of the Skin | Male | 1 | 117,603 | 0.9 | 0.9 | 4.8 | 0.099 | 191 | 4,394,265 | 4.3 |
| Melanoma of the Skin | Female | 1 | 117,189 | 0.9 | 0.9 | 2.3 | 0.653 | 96 | 4,359,658 | 2.2 |
| Myeloma | Total | 8 | 234,792 | 3.4 | 3.8 | 7.8 | 1.000 | 323 | 8,753,923 | 3.7 |
| Myeloma | Male | 5 | 117,603 | 4.3 | 4.6 | 4.7 | 1.000 | 191 | 4,394,265 | 4.3 |
| Myeloma | Female | 3 | 117,189 | 2.6 | 2.9 | 3.1 | 1.000 | 132 | 4,359,658 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 13 | 234,792 | 5.5 | 6.1 | 13.6 | 1.000 | 556 | 8,753,923 | 6.4 |
| Non-Hodgkin Lymphoma | Male | 5 | 117,603 | 4.3 | 4.6 | 7.5 | 0.473 | 302 | 4,394,265 | 6.9 |
| Non-Hodgkin Lymphoma | Female | 8 | 117,189 | 6.8 | 7.7 | 6.1 | 0.531 | 254 | 4,359,658 | 5.8 |
| Oral Cavity and Pharynx | Total |  | 234,792 | 2.1 | 2.4 | 6.3 | 0.786 | 261 | 8,753,923 | 3.0 |
| Oral Cavity and Pharynx | Male | 3 | 117,603 | 2.6 | 2.8 | 4.5 | 0.669 | 184 | 4,394,265 | 4.2 |
| Oral Cavity and Pharynx | Female | 2 | 117,189 | 1.7 | 1.9 | 1.9 | 1.000 | 77 | 4,359,658 | 1.8 |
| Ovary | Female | 15 | 117,189 | 12.8 | 14.4 | 8.0 | $0.035 \gg$ | 335 | 4,359,658 | 7.7 |
| Pancreas | Total | 26 | 234,792 | 11.1 | 12.3 | 28.2 | 0.776 | 1,164 | 8,753,923 | 13.3 |
| Pancreas | Male | 17 | 117,603 | 14.5 | 15.7 | 15.4 | 0.754 | 625 | 4,394,265 | 14.2 |
| Pancreas | Female | 9 | 117,189 | 7.7 | 8.7 | 12.8 | 0.357 | 539 | 4,359,658 | 12.4 |
| Prostate | Male | 25 | 117,603 | 21.3 | 22.7 | 23.2 | 0.757 | 924 | 4,394,265 | 21.0 |
| Stomach | Total | 6 | 234,792 | 2.6 | 2.8 | 4.7 | 0.669 | 192 | 8,753,923 | 2.2 |
| Stomach | Male | 4 | 117,603 | 3.4 | 3.7 | 2.9 | 0.668 | 117 | 4,394,265 | 2.7 |
| Stomach | Female | 2 | 117,189 | 1.7 | 1.9 | 1.8 | 1.000 | 75 | 4,359,658 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Bingham County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 86.3\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 11.3\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 61.3\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% | 50.7\% |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 55.2\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 22.1\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 24.8\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 75.5\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 18.9\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 24.1\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, 83.1\% of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, 12.6\% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^5]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked 49 ${ }^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

## BLAINE COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 693 cases of invasive cancer were diagnosed among Blaine County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Blaine County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Blaine <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 693 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 114 | 6,687 |
| Prostate | 109 | 6,417 |
| Lung \& Bronchus | 43 | 4,887 |
| Colorectal | 40 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Blaine County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Blaine County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Blaine County was 609.8 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.8) gives an estimate of the relative burden of disease in Blaine County.

The age- and sex-adjusted incidence rate of invasive cancer in Blaine County, all sites combined, was 510.5 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Blaine County (693) than expected (704.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 148 Blaine County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Blaine County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Blaine <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 648 | 77,431 |
| Cancer Deaths | 148 | 15,121 |
| \% of All Deaths | $22.8 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 16 | 2,961 |
| Colorectal | 13 | 1,319 |
| Pancreas | 10 | 1,190 |
| Female Breast | 10 | 1,086 |
| Prostate | 14 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Blaine County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Blaine County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Blaine County, all sites combined, was 106.9 deaths per 100,000 persons per year during 2017-2021, compared with 168.8 for the remainder of the state. There were statistically significantly fewer cancer deaths in Blaine County (148) than expected (233.7) based upon rates in the remainder of the state ( $p<.001$ ).

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN BLAINE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Blaine County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person Years | Crude <br> Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P -Value (4) | Observed Cases | Person Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 693 | 113,644 | 609.8 | 510.5 | 704.3 | 0.688 | 44,917 | 8,658,184 | 518.8 |
| All Sites Combined | Male | 376 | 56,989 | 659.8 | 533.7 | 388.2 | 0.557 | 23,913 | 4,339,921 | 551.0 |
| All Sites Combined | Female | 317 | 56,655 | 559.5 | 480.5 | 320.9 | 0.857 | 21,004 | 4,318,263 | 486.4 |
| Bladder | Total | 29 | 113,644 | 25.5 | 21.4 | 33.7 | 0.476 | 2,155 | 8,658,184 | 24.9 |
| Bladder | Male | 24 | 56,989 | 42.1 | 33.7 | 28.3 | 0.482 | 1,727 | 4,339,921 | 39.8 |
| Bladder | Female | 5 | 56,655 | 8.8 | 7.7 | 6.5 | 0.746 | 428 | 4,318,263 | 9.9 |
| Brain - malignant | Total | 10 | 113,644 | 8.8 | 7.7 | 9.2 | 0.879 | 615 | 8,658,184 | 7.1 |
| Brain - malignant | Male | 3 | 56,989 | 5.3 | 4.5 | 5.7 | 0.362 | 372 | 4,339,921 | 8.6 |
| Brain - malignant | Female | 7 | 56,655 | 12.4 | 11.1 | 3.6 | 0.140 | 243 | 4,318,263 | 5.6 |
| Brain and other CNS - non-malignant | Total | 22 | 113,644 | 19.4 | 16.7 | 21.3 | 0.938 | 1,402 | 8,658,184 | 16.2 |
| Brain and other CNS - non-malignant | Male | 7 | 56,989 | 12.3 | 10.5 | 7.3 | 1.000 | 473 | 4,339,921 | 10.9 |
| Brain and other CNS - non-malignant | Female | 15 | 56,655 | 26.5 | 23.2 | 13.9 | 0.837 | 929 | 4,318,263 | 21.5 |
| Breast | Total | 114 | 113,644 | 100.3 | 83.3 | 104.8 | 0.392 | 6,632 | 8,658,184 | 76.6 |
| Breast | Male |  | 56,989 |  |  | 0.9 | 0.775 | 59 | 4,339,921 | 1.4 |
| Breast | Female | 114 | 56,655 | 201.2 | 168.5 | 103.0 | 0.301 | 6,573 | 4,318,263 | 152.2 |
| Breast - in situ | Total | 22 | 113,644 | 19.4 | 15.8 | 19.6 | 0.645 | 1,217 | 8,658,184 | 14.1 |
| Breast - in situ | Male |  | 56,989 |  |  | 0.1 | 1.000 | 5 | 4,339,921 | 0.1 |
| Breast - in situ | Female | 22 | 56,655 | 38.8 | 31.6 | 19.6 | 0.638 | 1,212 | 4,318,263 | 28.1 |
| Cervix | Female | 4 | 56,655 | 7.1 | 6.4 | 4.4 | 1.000 | 300 | 4,318,263 | 6.9 |
| Colorectal | Total | 40 | 113,644 | 35.2 | 29.7 | 53.0 | 0.076 | 3,411 | 8,658,184 | 39.4 |
| Colorectal | Male | 25 | 56,989 | 43.9 | 35.9 | 30.1 | 0.403 | 1,878 | 4,339,921 | 43.3 |
| Colorectal | Female | 15 | 56,655 | 26.5 | 23.2 | 23.0 | 0.105 | 1,533 | 4,318,263 | 35.5 |
| Corpus Uteri | Female | 16 | 56,655 | 28.2 | 23.2 | 21.0 | 0.323 | 1,314 | 4,318,263 | 30.4 |
| Esophagus | Total | 7 | 113,644 | 6.2 | 5.1 | 7.9 | 0.931 | 499 | 8,658,184 | 5.8 |
| Esophagus | Male | 7 | 56,989 | 12.3 | 9.9 | 6.8 | 1.000 | 417 | 4,339,921 | 9.6 |
| Esophagus | Female | - | 56,655 | - | - | 1.3 | 0.563 | 82 | 4,318,263 | 1.9 |
| Hodgkin Lymphoma | Total | 2 | 113,644 | 1.8 | 1.7 | 2.9 | 0.915 | 208 | 8,658,184 | 2.4 |
| Hodgkin Lymphoma | Male |  | 56,989 | - | - | 1.7 | 0.380 | 118 | 4,339,921 | 2.7 |
| Hodgkin Lymphoma | Female | 2 | 56,655 | 3.5 | 3.5 | 1.2 | 0.662 | 90 | 4,318,263 | 2.1 |
| Kidney and Renal Pelvis | Total | 21 | 113,644 | 18.5 | 15.4 | 28.3 | 0.196 | 1,794 | 8,658,184 | 20.7 |
| Kidney and Renal Pelvis | Male | 10 | 56,989 | 17.5 | 14.3 | 18.9 | 0.040 << | 1,172 | 4,339,921 | 27.0 |
| Kidney and Renal Pelvis | Female | 11 | 56,655 | 19.4 | 16.6 | 9.5 | 0.719 | 622 | 4,318,263 | 14.4 |
| Larynx | Total | 2 | 113,644 | 1.8 | 1.4 | 3.4 | 0.677 | 213 | 8,658,184 | 2.5 |
| Larynx | Male | 1 | 56,989 | 1.8 | 1.4 | 2.6 | 0.528 | 159 | 4,339,921 | 3.7 |
| Larynx | Female | 1 | 56,655 | 1.8 | 1.5 | 0.9 | 1.000 | 54 | 4,318,263 | 1.3 |
| Leukemia | Total | 26 | 113,644 | 22.9 | 19.8 | 24.4 | 0.799 | 1,605 | 8,658,184 | 18.5 |
| Leukemia | Male | 15 | 56,989 | 26.3 | 22.0 | 15.3 | 1.000 | 974 | 4,339,921 | 22.4 |
| Leukemia | Female | 11 | 56,655 | 19.4 | 17.3 | 9.3 | 0.656 | 631 | 4,318,263 | 14.6 |
| Liver and Bile Duct | Total | 10 | 113,644 | 8.8 | 7.2 | 13.1 | 0.481 | 819 | 8,658,184 | 9.5 |
| Liver and Bile Duct | Male | 8 | 56,989 | 14.0 | 11.2 | 9.6 | 0.767 | 582 | 4,339,921 | 13.4 |
| Liver and Bile Duct | Female | 2 | 56,655 | 3.5 | 3.0 | 3.6 | 0.590 | 237 | 4,318,263 | 5.5 |
| Lung and Bronchus | Total | 43 | 113,644 | 37.8 | 31.2 | 77.1 | 0.000 << | 4,844 | 8,658,184 | 55.9 |
| Lung and Bronchus | Male | 25 | 56,989 | 43.9 | 34.7 | 40.3 | 0.013 << | 2,427 | 4,339,921 | 55.9 |
| Lung and Bronchus | Female | 18 | 56,655 | 31.8 | 27.1 | 37.1 | 0.001 << | 2,417 | 4,318,263 | 56.0 |
| Melanoma of the Skin | Total | 89 | 113,644 | 78.3 | 66.9 | 43.9 | 0.000 >> | 2,853 | 8,658,184 | 33.0 |
| Melanoma of the Skin | Male | 52 | 56,989 | 91.2 | 75.1 | 27.3 | $0.000 \gg$ | 1,713 | 4,339,921 | 39.5 |
| Melanoma of the Skin | Female | 37 | 56,655 | 65.3 | 57.4 | 17.0 | 0.000 >> | 1,140 | 4,318,263 | 26.4 |
| Myeloma | Total | 16 | 113,644 | 14.1 | 11.7 | 10.9 | 0.176 | 692 | 8,658,184 | 8.0 |
| Myeloma | Male | 11 | 56,989 | 19.3 | 15.4 | 7.1 | 0.208 | 430 | 4,339,921 | 9.9 |
| Myeloma | Female | 5 | 56,655 | 8.8 | 7.6 | 4.0 | 0.735 | 262 | 4,318,263 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 27 | 113,644 | 23.8 | 20.0 | 29.8 | 0.694 | 1,913 | 8,658,184 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 16 | 56,989 | 28.1 | 23.0 | 17.8 | 0.783 | 1,113 | 4,339,921 | 25.6 |
| Non-Hodgkin Lymphoma | Female | 11 | 56,655 | 19.4 | 16.8 | 12.1 | 0.899 | 800 | 4,318,263 | 18.5 |
| Oral Cavity and Pharynx | Total | 29 | 113,644 | 25.5 | 20.9 | 20.3 | 0.080 | 1,266 | 8,658,184 | 14.6 |
| Oral Cavity and Pharynx | Male | 23 | 56,989 | 40.4 | 32.5 | 14.9 | 0.061 | 913 | 4,339,921 | 21.0 |
| Oral Cavity and Pharynx | Female | 6 | 56,655 | 10.6 | 8.9 | 5.5 | 0.942 | 353 | 4,318,263 | 8.2 |
| Ovary | Female | 15 | 56,655 | 26.5 | 22.6 | 8.0 | 0.033 >> | 518 | 4,318,263 | 12.0 |
| Pancreas | Total | 14 | 113,644 | 12.3 | 10.3 | 22.1 | 0.093 | 1,409 | 8,658,184 | 16.3 |
| Pancreas | Male | 7 | 56,989 | 12.3 | 9.9 | 12.7 | 0.126 | 777 | 4,339,921 | 17.9 |
| Pancreas | Female | 7 | 56,655 | 12.4 | 10.8 | 9.5 | 0.541 | 632 | 4,318,263 | 14.6 |
| Prostate | Male | 109 | 56,989 | 191.3 | 150.5 | 105.2 | 0.740 | 6,308 | 4,339,921 | 145.3 |
| Stomach | Total | 4 | 113,644 | 3.5 | 3.0 | 7.2 | 0.314 | 463 | 8,658,184 | 5.3 |
| Stomach | Male | 2 | 56,989 | 3.5 | 2.8 | 5.0 | 0.252 | 307 | 4,339,921 | 7.1 |
| Stomach | Female | 2 | 56,655 | 3.5 | 3.2 | 2.3 | 1.000 | 156 | 4,318,263 | 3.6 |
| Testis | Male | 7 | 56,989 | 12.3 | 13.0 | 3.2 | 0.089 | 258 | 4,339,921 | 5.9 |
| Thyroid | Total | 15 | 113,644 | 13.2 | 12.0 | 17.4 | 0.674 | 1,205 | 8,658,184 | 13.9 |
| Thyroid | Male | 7 | 56,989 | 12.3 | 10.8 | 5.2 | 0.535 | 348 | 4,339,921 | 8.0 |
| Thyroid | Female | 8 | 56,655 | 14.1 | 13.0 | 12.2 | 0.281 | 857 | 4,318,263 | 19.8 |
| Pediatric Age 0 to 19 | Total | 6 | 27,113 | 22.1 | 22.3 | 4.6 | 0.623 | 415 | 2,433,410 | 17.1 |
| Pediatric Age 0 to 19 | Male | 2 | 13,885 | 14.4 | 14.7 | 2.4 | 1.000 | 221 | 1,242,625 | 17.8 |
| Pediatric Age 0 to 19 | Female | 4 | 13,228 | 30.2 | 30.1 | 2.2 | 0.349 | 194 | 1,190,785 | 16.3 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).
Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN BLAINE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Blaine County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 648 | 116,341 | 557.0 | 494.3 | 1,134.4 | 0.000 << | 76,782 | 8,872,374 | 865.4 |
| All Causes of Death | Male | 379 | 58,302 | 650.1 | 537.4 | 644.1 | $0.000 \ll$ | 40,677 | 4,453,566 | 913.4 |
| All Causes of Death | Female | 269 | 58,039 | 463.5 | 443.1 | 496.0 | $0.000 \ll$ | 36,105 | 4,418,808 | 817.1 |
| All Malignant Cancers | Total | 148 | 116,341 | 127.2 | 106.9 | 233.7 | $0.000 \ll$ | 14,973 | 8,872,374 | 168.8 |
| All Malignant Cancers | Male | 89 | 58,302 | 152.7 | 121.5 | 133.1 | 0.000 << | 8,087 | 4,453,566 | 181.6 |
| All Malignant Cancers | Female | 59 | 58,039 | 101.7 | 89.3 | 102.9 | $0.000 \ll$ | 6,886 | 4,418,808 | 155.8 |
| Bladder | Total | 4 | 116,341 | 3.4 | 3.0 | 7.3 | 0.300 | 485 | 8,872,374 | 5.5 |
| Bladder | Male | 3 | 58,302 | 5.1 | 4.2 | 6.1 | 0.290 | 375 | 4,453,566 | 8.4 |
| Bladder | Female | 1 | 58,039 | 1.7 | 1.6 | 1.6 | 1.000 | 110 | 4,418,808 | 2.5 |
| Brain and Other Nervous System | Total | 6 | 116,341 | 5.2 | 4.3 | 7.8 | 0.683 | 498 | 8,872,374 | 5.6 |
| Brain and Other Nervous System | Male | 2 | 58,302 | 3.4 | 2.8 | 4.7 | 0.297 | 296 | 4,453,566 | 6.6 |
| Brain and Other Nervous System | Female | 4 | 58,039 | 6.9 | 5.9 | 3.1 | 0.745 | 202 | 4,418,808 | 4.6 |
| Breast | Total | 10 | 116,341 | 8.6 | 7.3 | 16.9 | 0.102 | 1,092 | 8,872,374 | 12.3 |
| Breast | Male |  | 58,302 |  | - | 0.3 | 1.000 | 16 | 4,453,566 | 0.4 |
| Breast | Female | 10 | 58,039 | 17.2 | 15.0 | 16.2 | 0.141 | 1,076 | 4,418,808 | 24.4 |
| Cervix | Female | 1 | 58,039 | 1.7 | 1.5 | 1.2 | 1.000 | 82 | 4,418,808 | 1.9 |
| Colorectal | Total | 13 | 116,341 | 11.2 | 9.4 | 20.3 | 0.118 | 1,306 | 8,872,374 | 14.7 |
| Colorectal | Male | 9 | 58,302 | 15.4 | 12.4 | 11.6 | 0.566 | 710 | 4,453,566 | 15.9 |
| Colorectal | Female | 4 | 58,039 | 6.9 | 6.2 | 8.7 | 0.129 | 596 | 4,418,808 | 13.5 |
| Corpus Uteri | Female | 3 | 58,039 | 5.2 | 4.4 | 2.6 | 0.981 | 170 | 4,418,808 | 3.8 |
| Esophagus | Total | 4 | 116,341 | 3.4 | 2.8 | 7.6 | 0.256 | 473 | 8,872,374 | 5.3 |
| Esophagus | Male | 4 | 58,302 | 6.9 | 5.4 | 6.6 | 0.428 | 397 | 4,453,566 | 8.9 |
| Esophagus | Female | - | 58,039 | - | - | 1.1 | 0.640 | 76 | 4,418,808 | 1.7 |
| Hodgkin Lymphoma | Total |  | 116,341 | - | - | 0.4 | 1.000 | 29 | 8,872,374 | 0.3 |
| Hodgkin Lymphoma | Male | - | 58,302 | - | - | 0.2 | 1.000 | 14 | 4,453,566 | 0.3 |
| Hodgkin Lymphoma | Female | - | 58,039 | - | - | 0.2 | 1.000 | 15 | 4,418,808 | 0.3 |
| Kidney | Total | 2 | 116,341 | 1.7 | 1.4 | 6.0 | 0.125 | 383 | 8,872,374 | 4.3 |
| Kidney | Male | 1 | 58,302 | 1.7 | 1.4 | 4.0 | 0.187 | 241 | 4,453,566 | 5.4 |
| Kidney | Female | 1 | 58,039 | 1.7 | 1.6 | 2.1 | 0.780 | 142 | 4,418,808 | 3.2 |
| Larynx | Total | - | 116,341 | - | - | 1.1 | 0.652 | 71 | 8,872,374 | 0.8 |
| Larynx | Male | - | 58,302 | - | - | 1.0 | 0.772 | 58 | 4,453,566 | 1.3 |
| Larynx | Female | - | 58,039 | - | - | 0.2 | 1.000 | 13 | 4,418,808 | 0.3 |
| Leukemia | Total | 9 | 116,341 | 7.7 | 6.7 | 9.9 | 0.946 | 651 | 8,872,374 | 7.3 |
| Leukemia | Male | 6 | 58,302 | 10.3 | 8.3 | 6.2 | 1.000 | 380 | 4,453,566 | 8.5 |
| Leukemia | Female | 3 | 58,039 | 5.2 | 4.8 | 3.9 | 0.925 | 271 | 4,418,808 | 6.1 |
| Liver and Bile Duct | Total | 7 | 116,341 | 6.0 | 4.9 | 9.6 | 0.522 | 596 | 8,872,374 | 6.7 |
| Liver and Bile Duct | Male | 5 | 58,302 | 8.6 | 6.7 | 6.7 | 0.677 | 403 | 4,453,566 | 9.0 |
| Liver and Bile Duct | Female | 2 | 58,039 | 3.4 | 2.9 | 3.0 | 0.862 | 193 | 4,418,808 | 4.4 |
| Lung and Bronchus | Total | 16 | 116,341 | 13.8 | 11.3 | 46.9 | 0.000 << | 2,945 | 8,872,374 | 33.2 |
| Lung and Bronchus | Male | 7 | 58,302 | 12.0 | 9.4 | 26.0 | 0.000 << | 1,549 | 4,453,566 | 34.8 |
| Lung and Bronchus | Female | 9 | 58,039 | 15.5 | 13.4 | 21.2 | 0.005 << | 1,396 | 4,418,808 | 31.6 |
| Melanoma of the Skin | Total | 4 | 116,341 | 3.4 | 2.9 | 4.4 | 1.000 | 285 | 8,872,374 | 3.2 |
| Melanoma of the Skin | Male | 4 | 58,302 | 6.9 | 5.6 | 3.0 | 0.724 | 188 | 4,453,566 | 4.2 |
| Melanoma of the Skin | Female | - | 58,039 | - | - | 1.5 | 0.468 | 97 | 4,418,808 | 2.2 |
| Myeloma | Total | 5 | 116,341 | 4.3 | 3.6 | 5.1 | 1.000 | 326 | 8,872,374 | 3.7 |
| Myeloma | Male | 4 | 58,302 | 6.9 | 5.4 | 3.2 | 0.805 | 192 | 4,453,566 | 4.3 |
| Myeloma | Female | 1 | 58,039 | 1.7 | 1.5 | 2.0 | 0.822 | 134 | 4,418,808 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 4 | 116,341 | 3.4 | 2.9 | 8.7 | 0.131 | 565 | 8,872,374 | 6.4 |
| Non-Hodgkin Lymphoma | Male | 3 | 58,302 | 5.1 | 4.1 | 5.0 | 0.533 | 304 | 4,453,566 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 1 | 58,039 | 1.7 | 1.6 | 3.8 | 0.223 | 261 | 4,418,808 | 5.9 |
| Oral Cavity and Pharynx | Total | 1 | 116,341 | 0.9 | 0.7 | 4.2 | 0.150 | 265 | 8,872,374 | 3.0 |
| Oral Cavity and Pharynx | Male | 1 | 58,302 | 1.7 | 1.3 | 3.1 | 0.369 | 186 | 4,453,566 | 4.2 |
| Oral Cavity and Pharynx | Female | - | 58,039 | - |  | 1.2 | 0.609 | 79 | 4,418,808 | 1.8 |
| Ovary | Female | 5 | 58,039 | 8.6 | 7.4 | 5.3 | 1.000 | 345 | 4,418,808 | 7.8 |
| Pancreas | Total | 10 | 116,341 | 8.6 | 7.1 | 18.8 | 0.040 << | 1,180 | 8,872,374 | 13.3 |
| Pancreas | Male | 6 | 58,302 | 10.3 | 8.1 | 10.6 | 0.192 | 636 | 4,453,566 | 14.3 |
| Pancreas | Female | 4 | 58,039 | 6.9 | 5.9 | 8.3 | 0.166 | 544 | 4,418,808 | 12.3 |
| Prostate | Male | 14 | 58,302 | 24.0 | 19.3 | 15.2 | 0.891 | 935 | 4,453,566 | 21.0 |
| Stomach | Total |  | 116,341 |  |  | 3.0 | 0.095 | 198 | 8,872,374 | 2.2 |
| Stomach | Male | - | 58,302 | - | - | 2.0 | 0.276 | 121 | 4,453,566 | 2.7 |
| Stomach | Female | - | 58,039 | - | - | 1.1 | 0.666 | 77 | 4,418,808 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Blaine County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 79.5\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 11.7\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 73.6\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 (2018, 2020) | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 74.9\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 17.9\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 47.4\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 80.9\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 30.6\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 54.4\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^6]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 279 cases of invasive cancer were diagnosed among Boise County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Boise County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Boise <br> County |  |
| :--- | ---: | ---: | | State of <br> Idaho |
| :---: |
| All Sites/Types |

Table 3 (Cancer Incidence 2016-2020, Comparison between Boise County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Boise County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Boise County was 731.8 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.0) gives an estimate of the relative burden of disease in Boise County.

The age- and sex-adjusted incidence rate of invasive cancer in Boise County, all sites combined, was 481.9 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Boise County (279) than expected (300.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 61 Boise County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Boise County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Boise <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 342 | 77,431 |
| Cancer Deaths | 61 | 15,121 |
| \% of All Deaths | $17.8 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 17 | 2,961 |
| Colorectal | 3 | 1,319 |
| Pancreas | 8 | 1,190 |
| Female Breast | 7 | 1,086 |
| Prostate | 2 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Boise County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Boise County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Boise County, all sites combined, was 104.9 deaths per 100,000 persons per year during 2017-2021, compared with 168.3 for the remainder of the state. There were statistically significantly fewer cancer deaths in Boise County (61) than expected (97.9) based upon rates in the remainder of the state ( $p<.001$ ).

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020 COMPARISON BETWEEN BOISE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

|  |  | Boise County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 279 | 38,126 | 731.8 | 481.9 | 300.5 | 0.224 | 45,331 | 8,733,702 | 519.0 |
| All Sites Combined | Male | 170 | 19,672 | 864.2 | 511.9 | 183.0 | 0.357 | 24,119 | 4,377,238 | 551.0 |
| All Sites Combined | Female | 109 | 18,454 | 590.7 | 427.5 | 124.1 | 0.185 | 21,212 | 4,356,464 | 486.9 |
| Bladder | Total | 22 | 38,126 | 57.7 | 37.4 | 14.5 | 0.082 | 2,162 | 8,733,702 | 24.8 |
| Bladder | Male | 21 | 19,672 | 106.8 | 61.9 | 13.4 | 0.066 | 1,730 | 4,377,238 | 39.5 |
| Bladder | Female | 1 | 18,454 | 5.4 | 3.9 | 2.5 | 0.554 | 432 | 4,356,464 | 9.9 |
| Brain - malignant | Total | 1 | 38,126 | 2.6 | 1.9 | 3.7 | 0.226 | 624 | 8,733,702 | 7.1 |
| Brain - malignant | Male | 1 | 19,672 | 5.1 | 3.5 | 2.4 | 0.598 | 374 | 4,377,238 | 8.5 |
| Brain - malignant | Female | - | 18,454 | - | - | 1.4 | 0.507 | 250 | 4,356,464 | 5.7 |
| Brain and other CNS - non-malignant | Total | 8 | 38,126 | 21.0 | 15.0 | 8.7 | 0.999 | 1,416 | 8,733,702 | 16.2 |
| Brain and other CNS - non-malignant | Male | 4 | 19,672 | 20.3 | 13.8 | 3.1 | 0.772 | 476 | 4,377,238 | 10.9 |
| Brain and other CNS - non-malignant | Female | 4 | 18,454 | 21.7 | 16.4 | 5.3 | 0.795 | 940 | 4,356,464 | 21.6 |
| Breast | Total | 30 | 38,126 | 78.7 | 52.1 | 44.3 | 0.030 << | 6,716 | 8,733,702 | 76.9 |
| Breast | Male | - | 19,672 | - | - | 0.4 | 1.000 | 59 | 4,377,238 | 1.3 |
| Breast | Female | 30 | 18,454 | 162.6 | 114.0 | 40.2 | 0.115 | 6,657 | 4,356,464 | 152.8 |
| Breast - in situ | Total | 12 | 38,126 | 31.5 | 20.3 | 8.3 | 0.267 | 1,227 | 8,733,702 | 14.0 |
| Breast - in situ | Male | 1 | 19,672 | 5.1 | 3.8 | 0.0 | 0.047 >> | 4 | 4,377,238 | 0.1 |
| Breast - in situ | Female | 11 | 18,454 | 59.6 | 40.3 | 7.7 | 0.303 | 1,223 | 4,356,464 | 28.1 |
| Cervix | Female | 1 | 18,454 | 5.4 | 4.6 | 1.5 | 1.000 | 303 | 4,356,464 | 7.0 |
| Colorectal | Total | 11 | 38,126 | 28.9 | 19.5 | 22.2 | 0.013 << | 3,440 | 8,733,702 | 39.4 |
| Colorectal | Male | 5 | 19,672 | 25.4 | 15.7 | 13.8 | 0.013 << | 1,898 | 4,377,238 | 43.4 |
| Colorectal | Female | 6 | 18,454 | 32.5 | 24.2 | 8.8 | 0.457 | 1,542 | 4,356,464 | 35.4 |
| Corpus Uteri | Female | 7 | 18,454 | 37.9 | 25.2 | 8.4 | 0.789 | 1,323 | 4,356,464 | 30.4 |
| Esophagus | Total | 7 | 38,126 | 18.4 | 11.7 | 3.4 | 0.119 | 499 | 8,733,702 | 5.7 |
| Esophagus | Male | 6 | 19,672 | 30.5 | 17.8 | 3.2 | 0.215 | 418 | 4,377,238 | 9.5 |
| Esophagus | Female | 1 | 18,454 | 5.4 | 3.7 | 0.5 | 0.788 | 81 | 4,356,464 | 1.9 |
| Hodgkin Lymphoma | Total | 2 | 38,126 | 5.2 | 4.7 | 1.0 | 0.539 | 208 | 8,733,702 | 2.4 |
| Hodgkin Lymphoma | Male | - | 19,672 | - | - | 0.6 | 1.000 | 118 | 4,377,238 | 2.7 |
| Hodgkin Lymphoma | Female | 2 | 18,454 | 10.8 | 10.5 | 0.4 | 0.120 | 90 | 4,356,464 | 2.1 |
| Kidney and Renal Pelvis | Total | 8 | 38,126 | 21.0 | 13.9 | 11.9 | 0.323 | 1,807 | 8,733,702 | 20.7 |
| Kidney and Renal Pelvis | Male | 5 | 19,672 | 25.4 | 15.6 | 8.6 | 0.282 | 1,177 | 4,377,238 | 26.9 |
| Kidney and Renal Pelvis | Female | 3 | 18,454 | 16.3 | 11.8 | 3.7 | 0.998 | 630 | 4,356,464 | 14.5 |
| Larynx | Total | - | 38,126 | - | - | 1.5 | 0.444 | 215 | 8,733,702 | 2.5 |
| Larynx | Male | - | 19,672 | - | - | 1.3 | 0.568 | 160 | 4,377,238 | 3.7 |
| Larynx | Female | - | 18,454 | - | - | 0.3 | 1.000 | 55 | 4,356,464 | 1.3 |
| Leukemia | Total | 10 | 38,126 | 26.2 | 18.4 | 10.1 | 1.000 | 1,621 | 8,733,702 | 18.6 |
| Leukemia | Male | 6 | 19,672 | 30.5 | 19.5 | 6.9 | 0.922 | 983 | 4,377,238 | 22.5 |
| Leukemia | Female | 4 | 18,454 | 21.7 | 16.7 | 3.5 | 0.926 | 638 | 4,356,464 | 14.6 |
| Liver and Bile Duct | Total | 7 | 38,126 | 18.4 | 11.4 | 5.8 | 0.723 | 822 | 8,733,702 | 9.4 |
| Liver and Bile Duct | Male | 6 | 19,672 | 30.5 | 17.3 | 4.6 | 0.635 | 584 | 4,377,238 | 13.3 |
| Liver and Bile Duct | Female | 1 | 18,454 | 5.4 | 3.8 | 1.4 | 1.000 | 238 | 4,356,464 | 5.5 |
| Lung and Bronchus | Total | 31 | 38,126 | 81.3 | 51.4 | 33.5 | 0.747 | 4,856 | 8,733,702 | 55.6 |
| Lung and Bronchus | Male | 12 | 19,672 | 61.0 | 34.5 | 19.4 | 0.103 | 2,440 | 4,377,238 | 55.7 |
| Lung and Bronchus | Female | 19 | 18,454 | 103.0 | 72.8 | 14.5 | 0.291 | 2,416 | 4,356,464 | 55.5 |
| Melanoma of the Skin | Total | 21 | 38,126 | 55.1 | 38.1 | 18.4 | 0.607 | 2,921 | 8,733,702 | 33.4 |
| Melanoma of the Skin | Male | 10 | 19,672 | 50.8 | 31.6 | 12.7 | 0.559 | 1,755 | 4,377,238 | 40.1 |
| Melanoma of the Skin | Female | 11 | 18,454 | 59.6 | 45.2 | 6.5 | 0.135 | 1,166 | 4,356,464 | 26.8 |
| Myeloma | Total | 3 | 38,126 | 7.9 | 5.1 | 4.8 | 0.602 | 705 | 8,733,702 | 8.1 |
| Myeloma | Male | 3 | 19,672 | 15.3 | 8.9 | 3.4 | 1.000 | 438 | 4,377,238 | 10.0 |
| Myeloma | Female | - | 18,454 | - | - | 1.6 | 0.413 | 267 | 4,356,464 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 14 | 38,126 | 36.7 | 24.5 | 12.6 | 0.763 | 1,926 | 8,733,702 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 5 | 19,672 | 25.4 | 15.6 | 8.2 | 0.344 | 1,124 | 4,377,238 | 25.7 |
| Non-Hodgkin Lymphoma | Female | 9 | 18,454 | 48.8 | 35.5 | 4.7 | 0.098 | 802 | 4,356,464 | 18.4 |
| Oral Cavity and Pharynx | Total | 12 | 38,126 | 31.5 | 19.8 | 8.9 | 0.376 | 1,283 | 8,733,702 | 14.7 |
| Oral Cavity and Pharynx | Male | 11 | 19,672 | 55.9 | 32.7 | 7.1 | 0.214 | 925 | 4,377,238 | 21.1 |
| Oral Cavity and Pharynx | Female | 1 | 18,454 | 5.4 | 3.8 | 2.2 | 0.718 | 358 | 4,356,464 | 8.2 |
| Ovary | Female | 2 | 18,454 | 10.8 | 7.8 | 3.1 | 0.783 | 531 | 4,356,464 | 12.2 |
| Pancreas | Total | 9 | 38,126 | 23.6 | 15.4 | 9.5 | 1.000 | 1,414 | 8,733,702 | 16.2 |
| Pancreas | Male | 6 | 19,672 | 30.5 | 17.8 | 6.0 | 1.000 | 778 | 4,377,238 | 17.8 |
| Pancreas | Female | 3 | 18,454 | 16.3 | 11.9 | 3.7 | 0.998 | 636 | 4,356,464 | 14.6 |
| Prostate | Male | 61 | 19,672 | 310.1 | 170.5 | 52.0 | 0.239 | 6,356 | 4,377,238 | 145.2 |
| Stomach | Total | 6 | 38,126 | 15.7 | 10.6 | 3.0 | 0.166 | 461 | 8,733,702 | 5.3 |
| Stomach | Male | 4 | 19,672 | 20.3 | 12.1 | 2.3 | 0.401 | 305 | 4,377,238 | 7.0 |
| Stomach | Female | 2 | 18,454 | 10.8 | 8.5 | 0.8 | 0.415 | 156 | 4,356,464 | 3.6 |
| Testis | Male | - | 19,672 | - | - | 1.0 | 0.772 | 265 | 4,377,238 | 6.1 |
| Thyroid | Total | 8 | 38,126 | 21.0 | 17.2 | 6.4 | 0.637 | 1,212 | 8,733,702 | 13.9 |
| Thyroid | Male | 4 | 19,672 | 20.3 | 15.0 | 2.1 | 0.338 | 351 | 4,377,238 | 8.0 |
| Thyroid | Female | 4 | 18,454 | 21.7 | 18.4 | 4.3 | 1.000 | 861 | 4,356,464 | 19.8 |
| Pediatric Age 0 to 19 | Total | 5 | 6,998 | 71.4 | 70.9 | 1.2 | 0.015 >> | 416 | 2,453,525 | 17.0 |
| Pediatric Age 0 to 19 | Male | 1 | 3,727 | 26.8 | 27.2 | 0.7 | 0.957 | 222 | 1,252,783 | 17.7 |
| Pediatric Age 0 to 19 | Female | 4 | 3,271 | 122.3 | 118.5 | 0.5 | 0.005 >> | 194 | 1,200,742 | 16.2 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN BOISE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Boise County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 342 | 39,121 | 874.2 | 645.8 | 456.2 | 0.000 << | 77,088 | 8,949,594 | 861.4 |
| All Causes of Death | Male | 214 | 20,168 | 1,061.1 | 690.5 | 281.8 | $0.000 \ll$ | 40,842 | 4,491,700 | 909.3 |
| All Causes of Death | Female | 128 | 18,953 | 675.4 | 570.4 | 182.4 | $0.000 \ll$ | 36,246 | 4,457,894 | 813.1 |
| All Malignant Cancers | Total | 61 | 39,121 | 155.9 | 104.9 | 97.9 | $0.000 \ll$ | 15,060 | 8,949,594 | 168.3 |
| All Malignant Cancers | Male | 30 | 20,168 | 148.8 | 89.0 | 61.2 | 0.000 << | 8,146 | 4,491,700 | 181.4 |
| All Malignant Cancers | Female | 31 | 18,953 | 163.6 | 123.1 | 39.1 | 0.221 | 6,914 | 4,457,894 | 155.1 |
| Bladder | Total | 3 | 39,121 | 7.7 | 5.5 | 3.0 | 1.000 | 486 | 8,949,594 | 5.4 |
| Bladder | Male | 2 | 20,168 | 9.9 | 6.2 | 2.7 | 0.991 | 376 | 4,491,700 | 8.4 |
| Bladder | Female | 1 | 18,953 | 5.3 | 4.3 | 0.6 | 0.876 | 110 | 4,457,894 | 2.5 |
| Brain and Other Nervous System | Total | 1 | 39,121 | 2.6 | 1.7 | 3.3 | 0.327 | 503 | 8,949,594 | 5.6 |
| Brain and Other Nervous System | Male | 1 | 20,168 | 5.0 | 3.1 | 2.1 | 0.748 | 297 | 4,491,700 | 6.6 |
| Brain and Other Nervous System | Female | - | 18,953 | - | - | 1.2 | 0.594 | 206 | 4,457,894 | 4.6 |
| Breast | Total | 7 | 39,121 | 17.9 | 12.2 | 7.0 | 1.000 | 1,095 | 8,949,594 | 12.2 |
| Breast | Male |  | 20,168 |  |  | 0.1 | 1.000 | 16 | 4,491,700 | 0.4 |
| Breast | Female | 7 | 18,953 | 36.9 | 27.5 | 6.2 | 0.842 | 1,079 | 4,457,894 | 24.2 |
| Cervix | Female | 1 | 18,953 | 5.3 | 4.1 | 0.4 | 0.724 | 82 | 4,457,894 | 1.8 |
| Colorectal | Total | 3 | 39,121 | 7.7 | 5.2 | 8.4 | 0.064 | 1,316 | 8,949,594 | 14.7 |
| Colorectal | Male | 2 | 20,168 | 9.9 | 6.1 | 5.2 | 0.210 | 717 | 4,491,700 | 16.0 |
| Colorectal | Female | 1 | 18,953 | 5.3 | 4.1 | 3.3 | 0.322 | 599 | 4,457,894 | 13.4 |
| Corpus Uteri | Female | - | 18,953 | - | - | 1.1 | 0.696 | 173 | 4,457,894 | 3.9 |
| Esophagus | Total | 3 | 39,121 | 7.7 | 4.9 | 3.2 | 1.000 | 474 | 8,949,594 | 5.3 |
| Esophagus | Male | 2 | 20,168 | 9.9 | 5.8 | 3.1 | 0.808 | 399 | 4,491,700 | 8.9 |
| Esophagus | Female | 1 | 18,953 | 5.3 | 4.0 | 0.4 | 0.694 | 75 | 4,457,894 | 1.7 |
| Hodgkin Lymphoma | Total | - | 39,121 | - | - | 0.2 | 1.000 | 29 | 8,949,594 | 0.3 |
| Hodgkin Lymphoma | Male | - | 20,168 | - | - | 0.1 | 1.000 | 14 | 4,491,700 | 0.3 |
| Hodgkin Lymphoma | Female | - | 18,953 | - | - | 0.1 | 1.000 | 15 | 4,457,894 | 0.3 |
| Kidney | Total | - | 39,121 | - | - | 2.5 | 0.157 | 385 | 8,949,594 | 4.3 |
| Kidney | Male | - | 20,168 | - | - | 1.9 | 0.312 | 242 | 4,491,700 | 5.4 |
| Kidney | Female | - | 18,953 | - | - | 0.8 | 0.909 | 143 | 4,457,894 | 3.2 |
| Larynx | Total | - | 39,121 | - | - | 0.5 | 1.000 | 71 | 8,949,594 | 0.8 |
| Larynx | Male | - | 20,168 | - | - | 0.4 | 1.000 | 58 | 4,491,700 | 1.3 |
| Larynx | Female | - | 18,953 | - | - | 0.1 | 1.000 | 13 | 4,457,894 | 0.3 |
| Leukemia | Total |  | 39,121 |  | - | 4.0 | 0.035 << | 660 | 8,949,594 | 7.4 |
| Leukemia | Male | - | 20,168 | - | - | 2.8 | 0.125 | 386 | 4,491,700 | 8.6 |
| Leukemia | Female | - | 18,953 | - | - | 1.4 | 0.489 | 274 | 4,457,894 | 6.1 |
| Liver and Bile Duct | Total | 4 | 39,121 | 10.2 | 6.4 | 4.2 | 1.000 | 599 | 8,949,594 | 6.7 |
| Liver and Bile Duct | Male | 3 | 20,168 | 14.9 | 8.5 | 3.2 | 1.000 | 405 | 4,491,700 | 9.0 |
| Liver and Bile Duct | Female | 1 | 18,953 | 5.3 | 3.8 | 1.2 | 1.000 | 194 | 4,457,894 | 4.4 |
| Lung and Bronchus | Total | 17 | 39,121 | 43.5 | 28.2 | 19.9 | 0.615 | 2,944 | 8,949,594 | 32.9 |
| Lung and Bronchus | Male | 7 | 20,168 | 34.7 | 19.8 | 12.2 | 0.165 | 1,549 | 4,491,700 | 34.5 |
| Lung and Bronchus | Female | 10 | 18,953 | 52.8 | 39.0 | 8.0 | 0.572 | 1,395 | 4,457,894 | 31.3 |
| Melanoma of the Skin | Total | 2 | 39,121 | 5.1 | 3.5 | 1.8 | 1.000 | 287 | 8,949,594 | 3.2 |
| Melanoma of the Skin | Male | 2 | 20,168 | 9.9 | 6.1 | 1.4 | 0.813 | 190 | 4,491,700 | 4.2 |
| Melanoma of the Skin | Female | - | 18,953 | - | - | 0.5 | 1.000 | 97 | 4,457,894 | 2.2 |
| Myeloma | Total | 2 | 39,121 | 5.1 | 3.5 | 2.1 | 1.000 | 329 | 8,949,594 | 3.7 |
| Myeloma | Male | 1 | 20,168 | 5.0 | 2.9 | 1.5 | 1.000 | 195 | 4,491,700 | 4.3 |
| Myeloma | Female | 1 | 18,953 | 5.3 | 4.1 | 0.7 | 1.000 | 134 | 4,457,894 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 2 | 39,121 | 5.1 | 3.5 | 3.6 | 0.612 | 567 | 8,949,594 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 1 | 20,168 | 5.0 | 3.0 | 2.2 | 0.686 | 306 | 4,491,700 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 1 | 18,953 | 5.3 | 4.2 | 1.4 | 1.000 | 261 | 4,457,894 | 5.9 |
| Oral Cavity and Pharynx | Total | - | 39,121 | - | - | 1.8 | 0.327 | 266 | 8,949,594 | 3.0 |
| Oral Cavity and Pharynx | Male | - | 20,168 | - | - | 1.5 | 0.462 | 187 | 4,491,700 | 4.2 |
| Oral Cavity and Pharynx | Female | - | 18,953 | - | - | 0.5 | 1.000 | 79 | 4,457,894 | 1.8 |
| Ovary | Female | 2 | 18,953 | 10.6 | 7.6 | 2.1 | 1.000 | 348 | 4,457,894 | 7.8 |
| Pancreas | Total | 8 | 39,121 | 20.4 | 13.2 | 8.0 | 1.000 | 1,182 | 8,949,594 | 13.2 |
| Pancreas | Male | 4 | 20,168 | 19.8 | 11.4 | 5.0 | 0.894 | 638 | 4,491,700 | 14.2 |
| Pancreas | Female | 4 | 18,953 | 21.1 | 15.4 | 3.2 | 0.783 | 544 | 4,457,894 | 12.2 |
| Prostate | Male | 2 | 20,168 | 9.9 | 6.1 | 6.9 | 0.066 | 947 | 4,491,700 | 21.1 |
| Stomach | Total |  | 39,121 |  | - | 1.2 | 0.581 | 198 | 8,949,594 | 2.2 |
| Stomach | Male | - | 20,168 | - | - | 0.9 | 0.823 | 121 | 4,491,700 | 2.7 |
| Stomach | Female | - | 18,953 | - | - | 0.4 | 1.000 | 77 | 4,457,894 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Boise County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 81.1\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 9.6\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% |  |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% |  |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 18.1\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 32.2\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 74.3\% |
| Meet Physical Activity Guidelines (2011, 2013, $2015,2017,2019)$ | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 22.3\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 28.5\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^7]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged $50-74$ reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

## BONNIR COUNTY CANCDR PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 1,653 cases of invasive cancer were diagnosed among Bonner County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Bonner County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Bonner <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 1,653 | 45,610 |
| Female Breast | 223 | 6,687 |
| Prostate | 256 | 6,417 |
| Lung \& Bronchus | 189 | 4,887 |
| Colorectal | 150 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Bonner County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Bonner County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Bonner County was 739.8 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (514.2) gives an estimate of the relative burden of disease in Bonner County.

The age- and sex-adjusted incidence rate of invasive cancer in Bonner County, all sites combined, was 520.6 cases per 100,000 persons per year during 2016-2020. There were more cases of cancer in Bonner County $(1,653)$ than expected $(1,632.7)$ based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 563 Bonner County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Bonner County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Bonner <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 2,483 | 77,431 |
| Cancer Deaths | 563 | 15,121 |
| \% of All Deaths | $22.7 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 117 | 2,961 |
| Colorectal | 48 | 1,319 |
| Pancreas | 49 | 1,190 |
| Female Breast | 39 | 1,086 |
| Prostate | 42 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Bonner County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Bonner County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Bonner County, all sites combined, was 168.8 deaths per 100,000 persons per year during 2017-2021, compared with 166.2 for the remainder of the state. There were more cancer deaths in Bonner County (563) than expected (554.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN BONNER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Bonner County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P -Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 1,653 | 223,438 | 739.8 | 520.6 | 1,632.7 | 0.622 | 43,957 | 8,548,390 | 514.2 |
| All Sites Combined | Male | 931 | 111,621 | 834.1 | 549.6 | 923.3 | 0.808 | 23,358 | 4,285,289 | 545.1 |
| All Sites Combined | Female | 722 | 111,817 | 645.7 | 482.4 | 723.2 | 0.985 | 20,599 | 4,263,101 | 483.2 |
| Bladder | Total | 79 | 223,438 | 35.4 | 23.8 | 81.8 | 0.816 | 2,105 | 8,548,390 | 24.6 |
| Bladder | Male | 62 | 111,621 | 55.5 | 35.3 | 69.2 | 0.424 | 1,689 | 4,285,289 | 39.4 |
| Bladder | Female | 17 | 111,817 | 15.2 | 10.8 | 15.3 | 0.737 | 416 | 4,263,101 | 9.8 |
| Brain - malignant | Total | 24 | 223,438 | 10.7 | 8.3 | 20.3 | 0.467 | 601 | 8,548,390 | 7.0 |
| Brain - malignant | Male | 18 | 111,621 | 16.1 | 12.1 | 12.4 | 0.160 | 357 | 4,285,289 | 8.3 |
| Brain - malignant | Female | 6 | 111,817 | 5.4 | 4.3 | 8.0 | 0.615 | 244 | 4,263,101 | 5.7 |
| Brain and other CNS - non-malignant | Total | 48 | 223,438 | 21.5 | 16.2 | 47.8 | 1.000 | 1,376 | 8,548,390 | 16.1 |
| Brain and other CNS - non-malignant | Male | 18 | 111,621 | 16.1 | 12.0 | 16.2 | 0.721 | 462 | 4,285,289 | 10.8 |
| Brain and other CNS - non-malignant | Female | 30 | 111,817 | 26.8 | 20.7 | 31.0 | 0.945 | 914 | 4,263,101 | 21.4 |
| Breast | Total | 227 | 223,438 | 101.6 | 73.1 | 236.8 | 0.550 | 6,519 | 8,548,390 | 76.3 |
| Breast | Male | 4 | 111,621 | 3.6 | 2.4 | 2.1 | 0.337 | 55 | 4,285,289 | 1.3 |
| Breast | Female | 223 | 111,817 | 199.4 | 148.3 | 228.0 | 0.776 | 6,464 | 4,263,101 | 151.6 |
| Breast - in situ | Total | 45 | 223,438 | 20.1 | 14.4 | 43.5 | 0.860 | 1,194 | 8,548,390 | 14.0 |
| Breast - in situ | Male | - | 111,621 | - | - | 0.2 | 1.000 | 5 | 4,285,289 | 0.1 |
| Breast - in situ | Female | 45 | 111,817 | 40.2 | 29.7 | 42.2 | 0.709 | 1,189 | 4,263,101 | 27.9 |
| Cervix | Female | 11 | 111,817 | 9.8 | 8.9 | 8.5 | 0.469 | 293 | 4,263,101 | 6.9 |
| Colorectal | Total | 150 | 223,438 | 67.1 | 48.1 | 120.5 | 0.010 >> | 3,301 | 8,548,390 | 38.6 |
| Colorectal | Male | 81 | 111,621 | 72.6 | 49.8 | 69.2 | 0.180 | 1,822 | 4,285,289 | 42.5 |
| Colorectal | Female | 69 | 111,817 | 61.7 | 46.2 | 51.8 | 0.026 >> | 1,479 | 4,263,101 | 34.7 |
| Corpus Uteri | Female | 43 | 111,817 | 38.5 | 27.9 | 46.6 | 0.667 | 1,287 | 4,263,101 | 30.2 |
| Esophagus | Total | 24 | 223,438 | 10.7 | 7.3 | 18.5 | 0.250 | 482 | 8,548,390 | 5.6 |
| Esophagus | Male | 19 | 111,621 | 17.0 | 11.1 | 16.2 | 0.556 | 405 | 4,285,289 | 9.5 |
| Esophagus | Female | 5 | 111,817 | 4.5 | 3.2 | 2.8 | 0.318 | 77 | 4,263,101 | 1.8 |
| Hodgkin Lymphoma | Total | 3 | 223,438 | 1.3 | 1.2 | 5.8 | 0.331 | 207 | 8,548,390 | 2.4 |
| Hodgkin Lymphoma | Male | 2 | 111,621 | 1.8 | 1.6 | 3.4 | 0.675 | 116 | 4,285,289 | 2.7 |
| Hodgkin Lymphoma | Female | 1 | 111,817 | 0.9 | 0.9 | 2.5 | 0.594 | 91 | 4,263,101 | 2.1 |
| Kidney and Renal Pelvis | Total | 70 | 223,438 | 31.3 | 22.3 | 64.0 | 0.486 | 1,745 | 8,548,390 | 20.4 |
| Kidney and Renal Pelvis | Male | 42 | 111,621 | 37.6 | 25.8 | 43.4 | 0.917 | 1,140 | 4,285,289 | 26.6 |
| Kidney and Renal Pelvis | Female | 28 | 111,817 | 25.0 | 18.6 | 21.4 | 0.193 | 605 | 4,263,101 | 14.2 |
| Larynx | Total | 9 | 223,438 | 4.0 | 2.7 | 7.9 | 0.789 | 206 | 8,548,390 | 2.4 |
| Larynx | Male | 6 | 111,621 | 5.4 | 3.5 | 6.2 | 1.000 | 154 | 4,285,289 | 3.6 |
| Larynx | Female | 3 | 111,817 | 2.7 | 2.0 | 1.9 | 0.578 | 52 | 4,263,101 | 1.2 |
| Leukemia | Total | 59 | 223,438 | 26.4 | 19.2 | 56.6 | 0.788 | 1,572 | 8,548,390 | 18.4 |
| Leukemia | Male | 37 | 111,621 | 33.1 | 23.0 | 35.7 | 0.870 | 952 | 4,285,289 | 22.2 |
| Leukemia | Female | 22 | 111,817 | 19.7 | 14.9 | 21.5 | 0.978 | 620 | 4,263,101 | 14.5 |
| Liver and Bile Duct | Total | 39 | 223,438 | 17.5 | 11.8 | 30.6 | 0.160 | 790 | 8,548,390 | 9.2 |
| Liver and Bile Duct | Male | 33 | 111,621 | 29.6 | 19.0 | 22.5 | 0.045 >> | 557 | 4,285,289 | 13.0 |
| Liver and Bile Duct | Female | 6 | 111,817 | 5.4 | 3.8 | 8.5 | 0.506 | 233 | 4,263,101 | 5.5 |
| Lung and Bronchus | Total | 189 | 223,438 | 84.6 | 56.3 | 184.3 | 0.750 | 4,698 | 8,548,390 | 55.0 |
| Lung and Bronchus | Male | 103 | 111,621 | 92.3 | 58.0 | 97.4 | 0.599 | 2,349 | 4,285,289 | 54.8 |
| Lung and Bronchus | Female | 86 | 111,817 | 76.9 | 54.1 | 87.6 | 0.920 | 2,349 | 4,263,101 | 55.1 |
| Melanoma of the Skin | Total | 75 | 223,438 | 33.6 | 24.6 | 102.2 | 0.006 << | 2,867 | 8,548,390 | 33.5 |
| Melanoma of the Skin | Male | 48 | 111,621 | 43.0 | 29.4 | 65.5 | 0.029 << | 1,717 | 4,285,289 | 40.1 |
| Melanoma of the Skin | Female | 27 | 111,817 | 24.1 | 19.1 | 38.2 | 0.073 | 1,150 | 4,263,101 | 27.0 |
| Myeloma | Total | 25 | 223,438 | 11.2 | 7.6 | 26.3 | 0.901 | 683 | 8,548,390 | 8.0 |
| Myeloma | Male | 17 | 111,621 | 15.2 | 9.8 | 17.2 | 1.000 | 424 | 4,285,289 | 9.9 |
| Myeloma | Female | 8 | 111,817 | 7.2 | 5.1 | 9.5 | 0.782 | 259 | 4,263,101 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 58 | 223,438 | 26.0 | 18.4 | 69.4 | 0.186 | 1,882 | 8,548,390 | 22.0 |
| Non-Hodgkin Lymphoma | Male | 31 | 111,621 | 27.8 | 18.9 | 42.0 | 0.094 | 1,098 | 4,285,289 | 25.6 |
| Non-Hodgkin Lymphoma | Female | 27 | 111,817 | 24.1 | 17.8 | 28.0 | 0.955 | 784 | 4,263,101 | 18.4 |
| Oral Cavity and Pharynx | Total | 43 | 223,438 | 19.2 | 13.3 | 47.4 | 0.582 | 1,252 | 8,548,390 | 14.6 |
| Oral Cavity and Pharynx | Male | 31 | 111,621 | 27.8 | 18.4 | 35.7 | 0.495 | 905 | 4,285,289 | 21.1 |
| Oral Cavity and Pharynx | Female | 12 | 111,817 | 10.7 | 7.8 | 12.5 | 1.000 | 347 | 4,263,101 | 8.1 |
| Ovary | Female | 22 | 111,817 | 19.7 | 14.8 | 17.8 | 0.378 | 511 | 4,263,101 | 12.0 |
| Pancreas | Total | 59 | 223,438 | 26.4 | 18.1 | 52.1 | 0.376 | 1,364 | 8,548,390 | 16.0 |
| Pancreas | Male | 33 | 111,621 | 29.6 | 19.2 | 30.2 | 0.657 | 751 | 4,285,289 | 17.5 |
| Pancreas | Female | 26 | 111,817 | 23.3 | 16.8 | 22.3 | 0.487 | 613 | 4,263,101 | 14.4 |
| Prostate | Male | 256 | 111,621 | 229.3 | 143.2 | 256.9 | 0.987 | 6,161 | 4,285,289 | 143.8 |
| Stomach | Total | 13 | 223,438 | 5.8 | 4.1 | 16.8 | 0.425 | 454 | 8,548,390 | 5.3 |
| Stomach | Male | 9 | 111,621 | 8.1 | 5.3 | 11.8 | 0.513 | 300 | 4,285,289 | 7.0 |
| Stomach | Female | 4 | 111,817 | 3.6 | 2.7 | 5.3 | 0.786 | 154 | 4,263,101 | 3.6 |
| Testis | Male | 5 | 111,621 | 4.5 | 5.2 | 5.9 | 0.938 | 260 | 4,285,289 | 6.1 |
| Thyroid | Total | 31 | 223,438 | 13.9 | 12.1 | 35.7 | 0.491 | 1,189 | 8,548,390 | 13.9 |
| Thyroid | Male | 12 | 111,621 | 10.8 | 8.6 | 11.2 | 0.891 | 343 | 4,285,289 | 8.0 |
| Thyroid | Female | 19 | 111,817 | 17.0 | 15.4 | 24.5 | 0.309 | 846 | 4,263,101 | 19.8 |
| Pediatric Age 0 to 19 | Total | 5 | 48,024 | 10.4 | 10.4 | 8.3 | 0.333 | 416 | 2,412,499 | 17.2 |
| Pediatric Age 0 to 19 | Male | 3 | 24,279 | 12.4 | 12.4 | 4.3 | 0.750 | 220 | 1,232,231 | 17.9 |
| Pediatric Age 0 to 19 | Female | 2 | 23,745 | 8.4 | 8.4 | 4.0 | 0.485 | 196 | 1,180,268 | 16.6 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN BONNER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Bonner County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected <br> Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 2,483 | 230,506 | 1,077.2 | 785.2 | 2,706.1 | 0.000 << | 74,947 | 8,758,209 | 855.7 |
| All Causes of Death | Male | 1,377 | 115,499 | 1,192.2 | 827.8 | 1,501.3 | $0.001 \ll$ | 39,679 | 4,396,369 | 902.5 |
| All Causes of Death | Female | 1,106 | 115,007 | 961.7 | 732.6 | 1,220.6 | 0.001 << | 35,268 | 4,361,840 | 808.6 |
| All Malignant Cancers | Total | 563 | 230,506 | 244.2 | 168.8 | 554.3 | 0.724 | 14,558 | 8,758,209 | 166.2 |
| All Malignant Cancers | Male | 318 | 115,499 | 275.3 | 179.8 | 316.1 | 0.931 | 7,858 | 4,396,369 | 178.7 |
| All Malignant Cancers | Female | 245 | 115,007 | 213.0 | 155.1 | 242.7 | 0.897 | 6,700 | 4,361,840 | 153.6 |
| Bladder | Total | 23 | 230,506 | 10.0 | 6.9 | 17.6 | 0.250 | 466 | 8,758,209 | 5.3 |
| Bladder | Male | 21 | 115,499 | 18.2 | 12.0 | 14.2 | 0.109 | 357 | 4,396,369 | 8.1 |
| Bladder | Female | 2 | 115,007 | 1.7 | 1.3 | 3.9 | 0.494 | 109 | 4,361,840 | 2.5 |
| Brain and Other Nervous System | Total | 19 | 230,506 | 8.2 | 5.9 | 17.7 | 0.828 | 485 | 8,758,209 | 5.5 |
| Brain and Other Nervous System | Male | 12 | 115,499 | 10.4 | 7.2 | 10.9 | 0.812 | 286 | 4,396,369 | 6.5 |
| Brain and Other Nervous System | Female | 7 | 115,007 | 6.1 | 4.5 | 7.0 | 1.000 | 199 | 4,361,840 | 4.6 |
| Breast | Total | 40 | 230,506 | 17.4 | 12.3 | 39.3 | 0.954 | 1,062 | 8,758,209 | 12.1 |
| Breast | Male | 1 | 115,499 | 0.9 | 0.5 | 0.6 | 0.927 | 15 | 4,396,369 | 0.3 |
| Breast | Female | 39 | 115,007 | 33.9 | 25.1 | 37.4 | 0.830 | 1,047 | 4,361,840 | 24.0 |
| Cervix | Female | 1 | 115,007 | 0.9 | 0.7 | 2.6 | 0.523 | 82 | 4,361,840 | 1.9 |
| Colorectal | Total | 48 | 230,506 | 20.8 | 14.7 | 47.4 | 0.969 | 1,271 | 8,758,209 | 14.5 |
| Colorectal | Male | 28 | 115,499 | 24.2 | 16.4 | 26.9 | 0.885 | 691 | 4,396,369 | 15.7 |
| Colorectal | Female | 20 | 115,007 | 17.4 | 12.9 | 20.7 | 0.996 | 580 | 4,361,840 | 13.3 |
| Corpus Uteri | Female | 5 | 115,007 | 4.3 | 3.1 | 6.3 | 0.807 | 168 | 4,361,840 | 3.9 |
| Esophagus | Total | 28 | 230,506 | 12.1 | 8.3 | 17.3 | $0.022 \gg$ | 449 | 8,758,209 | 5.1 |
| Esophagus | Male | 23 | 115,499 | 19.9 | 12.9 | 15.3 | 0.078 | 378 | 4,396,369 | 8.6 |
| Esophagus | Female | 5 | 115,007 | 4.3 | 3.2 | 2.6 | 0.235 | 71 | 4,361,840 | 1.6 |
| Hodgkin Lymphoma | Total | 2 | 230,506 | 0.9 | 0.7 | 0.9 | 0.482 | 27 | 8,758,209 | 0.3 |
| Hodgkin Lymphoma | Male | 1 | 115,499 | 0.9 | 0.6 | 0.5 | 0.742 | 13 | 4,396,369 | 0.3 |
| Hodgkin Lymphoma | Female | 1 | 115,007 | 0.9 | 0.7 | 0.5 | 0.757 | 14 | 4,361,840 | 0.3 |
| Kidney | Total | 19 | 230,506 | 8.2 | 5.6 | 14.2 | 0.253 | 366 | 8,758,209 | 4.2 |
| Kidney | Male | 8 | 115,499 | 6.9 | 4.5 | 9.5 | 0.782 | 234 | 4,396,369 | 5.3 |
| Kidney | Female | 11 | 115,007 | 9.6 | 6.8 | 4.9 | 0.023 >> | 132 | 4,361,840 | 3.0 |
| Larynx | Total | 2 | 230,506 | 0.9 | 0.6 | 2.7 | 1.000 | 69 | 8,758,209 | 0.8 |
| Larynx | Male | 2 | 115,499 | 1.7 | 1.1 | 2.3 | 1.000 | 56 | 4,396,369 | 1.3 |
| Larynx | Female | - | 115,007 | - | - | 0.5 | 1.000 | 13 | 4,361,840 | 0.3 |
| Leukemia | Total | 27 | 230,506 | 11.7 | 8.3 | 23.5 | 0.526 | 633 | 8,758,209 | 7.2 |
| Leukemia | Male | 12 | 115,499 | 10.4 | 7.0 | 14.7 | 0.593 | 374 | 4,396,369 | 8.5 |
| Leukemia | Female | 15 | 115,007 | 13.0 | 9.7 | 9.2 | 0.093 | 259 | 4,361,840 | 5.9 |
| Liver and Bile Duct | Total | 27 | 230,506 | 11.7 | 7.8 | 22.6 | 0.409 | 576 | 8,758,209 | 6.6 |
| Liver and Bile Duct | Male | 22 | 115,499 | 19.0 | 12.1 | 16.0 | 0.176 | 386 | 4,396,369 | 8.8 |
| Liver and Bile Duct | Female | 5 | 115,007 | 4.3 | 3.1 | 7.1 | 0.587 | 190 | 4,361,840 | 4.4 |
| Lung and Bronchus | Total | 117 | 230,506 | 50.8 | 34.0 | 111.6 | 0.637 | 2,844 | 8,758,209 | 32.5 |
| Lung and Bronchus | Male | 59 | 115,499 | 51.1 | 32.2 | 62.4 | 0.729 | 1,497 | 4,396,369 | 34.1 |
| Lung and Bronchus | Female | 58 | 115,007 | 50.4 | 35.8 | 50.0 | 0.288 | 1,347 | 4,361,840 | 30.9 |
| Melanoma of the Skin | Total | 10 | 230,506 | 4.3 | 3.1 | 10.4 | 1.000 | 279 | 8,758,209 | 3.2 |
| Melanoma of the Skin | Male | 7 | 115,499 | 6.1 | 4.1 | 7.3 | 1.000 | 185 | 4,396,369 | 4.2 |
| Melanoma of the Skin | Female | 3 | 115,007 | 2.6 | 1.9 | 3.3 | 1.000 | 94 | 4,361,840 | 2.2 |
| Myeloma | Total | 1 | 230,506 | 0.4 | 0.3 | 12.9 | 0.000 << | 330 | 8,758,209 | 3.8 |
| Myeloma | Male | 1 | 115,499 | 0.9 | 0.5 | 8.1 | 0.006 << | 195 | 4,396,369 | 4.4 |
| Myeloma | Female | - | 115,007 | - | - | 5.0 | 0.014 << | 135 | 4,361,840 | 3.1 |
| Non-Hodgkin Lymphoma | Total | 14 | 230,506 | 6.1 | 4.2 | 21.1 | 0.137 | 555 | 8,758,209 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 7 | 115,499 | 6.1 | 4.0 | 12.0 | 0.182 | 300 | 4,396,369 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 7 | 115,007 | 6.1 | 4.4 | 9.3 | 0.588 | 255 | 4,361,840 | 5.8 |
| Oral Cavity and Pharynx | Total | 9 | 230,506 | 3.9 | 2.7 | 9.9 | 0.931 | 257 | 8,758,209 | 2.9 |
| Oral Cavity and Pharynx | Male | - | 115,499 | 5.2 | 3.3 | 7.4 | 0.782 | 181 | 4,396,369 | 4.1 |
| Oral Cavity and Pharynx | Female | 3 | 115,007 | 2.6 | 1.9 | 2.8 | 1.000 | 76 | 4,361,840 | 1.7 |
| Ovary | Female | 9 | 115,007 | 7.8 | 5.6 | 12.5 | 0.397 | 341 | 4,361,840 | 7.8 |
| Pancreas | Total | 49 | 230,506 | 21.3 | 14.4 | 44.5 | 0.537 | 1,141 | 8,758,209 | 13.0 |
| Pancreas | Male | 23 | 115,499 | 19.9 | 12.7 | 25.4 | 0.726 | 619 | 4,396,369 | 14.1 |
| Pancreas | Female | 26 | 115,007 | 22.6 | 16.1 | 19.4 | 0.173 | 522 | 4,361,840 | 12.0 |
| Prostate | Male | 42 | 115,499 | 36.4 | 23.8 | 36.4 | 0.389 | 907 | 4,396,369 | 20.6 |
| Stomach | Total | , | 230,506 | 2.6 | 1.9 | 7.0 | 0.901 | 192 | 8,758,209 | 2.2 |
| Stomach | Male | 4 | 115,499 | 3.5 | 2.3 | 4.5 | 1.000 | 117 | 4,396,369 | 2.7 |
| Stomach | Female | 2 | 115,007 | 1.7 | 1.4 | 2.5 | 1.000 | 75 | 4,361,840 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Bonner County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 80.4\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 12.8\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 65.5\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% | 68.9\% |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 57.8\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 28.8\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 36.1\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 79.2\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 22.3\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 24.3\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to 64.8\% of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^8]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged $50-74$ reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# BONNPVILLE COUNTY CANCER PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 2,722 cases of invasive cancer were diagnosed among Bonneville County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Bonneville County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Bonneville <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 2,722 | 45,610 |
| Female Breast | 375 | 6,687 |
| Prostate | 376 | 6,417 |
| Lung \& Bronchus | 204 | 4,887 |
| Colorectal | 221 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Bonneville County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Bonneville County. The table also shows the number of observed cases,
person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Bonneville County was 465.4 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (523.9) gives an estimate of the relative burden of disease in Bonneville County.

The age- and sex-adjusted incidence rate of invasive cancer in Bonneville County, all sites combined, was 543.0 cases per 100,000 persons per year during 2016-2020. There were more cases of cancer in Bonneville County $(2,722)$ than expected $(2,626.1)$ based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 815 Bonneville County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Bonneville County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Bonneville <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 5,016 | 77,431 |
| Cancer Deaths | 815 | 15,121 |
| \% of All Deaths | $16.2 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 132 | 2,961 |
| Colorectal | 82 | 1,319 |
| Pancreas | 60 | 1,190 |
| Female Breast | 65 | 1,086 |
| Prostate | 47 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Bonneville County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Bonneville County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Bonneville County, all sites combined, was 160.7 deaths per 100,000 persons per year during 2017-2021, compared with 170.6 for the remainder of the state. There were fewer cancer deaths in Bonneville County (815) than expected (864.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN BONNEVILLE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

|  |  | Bonneville County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P -Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 2,722 | 584,851 | 465.4 | 543.0 | 2,626.1 | 0.064 | 42,888 | 8,186,977 | 523.9 |
| All Sites Combined | Male | 1,423 | 291,696 | 487.8 | 579.3 | 1,368.2 | 0.143 | 22,866 | 4,105,214 | 557.0 |
| All Sites Combined | Female | 1,299 | 293,155 | 443.1 | 509.6 | 1,250.5 | 0.176 | 20,022 | 4,081,763 | 490.5 |
| Bladder | Total | 124 | 584,851 | 21.2 | 25.2 | 124.0 | 1.000 | 2,060 | 8,186,977 | 25.2 |
| Bladder | Male | 98 | 291,696 | 33.6 | 40.6 | 97.3 | 0.968 | 1,653 | 4,105,214 | 40.3 |
| Bladder | Female | 26 | 293,155 | 8.9 | 10.4 | 25.0 | 0.895 | 407 | 4,081,763 | 10.0 |
| Brain - malignant | Total | 42 | 584,851 | 7.2 | 8.0 | 37.4 | 0.491 | 583 | 8,186,977 | 7.1 |
| Brain - malignant | Male | 23 | 291,696 | 7.9 | 8.9 | 22.2 | 0.918 | 352 | 4,105,214 | 8.6 |
| Brain - malignant | Female | 19 | 293,155 | 6.5 | 7.1 | 15.0 | 0.368 | 231 | 4,081,763 | 5.7 |
| Brain and other CNS - non-malignant | Total | 108 | 584,851 | 18.5 | 21.0 | 82.7 | $0.009 \gg$ | 1,316 | 8,186,977 | 16.1 |
| Brain and other CNS - non-malignant | Male | 33 | 291,696 | 11.3 | 12.8 | 28.1 | 0.400 | 447 | 4,105,214 | 10.9 |
| Brain and other CNS - non-malignant | Female | 75 | 293,155 | 25.6 | 29.0 | 55.0 | $0.012 \gg$ | 869 | 4,081,763 | 21.3 |
| Breast | Total | 378 | 584,851 | 64.6 | 75.1 | 391.7 | 0.506 | 6,368 | 8,186,977 | 77.8 |
| Breast | Male | 3 | 291,696 | 1.0 | 1.2 | 3.4 | 1.000 | 56 | 4,105,214 | 1.4 |
| Breast | Female | 375 | 293,155 | 127.9 | 148.0 | 391.9 | 0.410 | 6,312 | 4,081,763 | 154.6 |
| Breast - in situ | Total | 69 | 584,851 | 11.8 | 13.8 | 71.7 | 0.812 | 1,170 | 8,186,977 | 14.3 |
| Breast - in situ | Male | - | 291,696 | - | - | 0.3 | 1.000 | 5 | 4,105,214 | 0.1 |
| Breast - in situ | Female | 69 | 293,155 | 23.5 | 27.4 | 71.8 | 0.798 | 1,165 | 4,081,763 | 28.5 |
| Cervix | Female | 18 | 293,155 | 6.1 | 6.6 | 19.2 | 0.910 | 286 | 4,081,763 | 7.0 |
| Colorectal | Total | 221 | 584,851 | 37.8 | 43.9 | 198.6 | 0.124 | 3,230 | 8,186,977 | 39.5 |
| Colorectal | Male | 113 | 291,696 | 38.7 | 45.4 | 108.6 | 0.697 | 1,790 | 4,105,214 | 43.6 |
| Colorectal | Female | 108 | 293,155 | 36.8 | 42.4 | 89.9 | 0.070 | 1,440 | 4,081,763 | 35.3 |
| Corpus Uteri | Female | 93 | 293,155 | 31.7 | 37.0 | 76.2 | 0.068 | 1,237 | 4,081,763 | 30.3 |
| Esophagus | Total | 26 | 584,851 | 4.4 | 5.3 | 29.0 | 0.662 | 480 | 8,186,977 | 5.9 |
| Esophagus | Male | 19 | 291,696 | 6.5 | 7.8 | 24.1 | 0.351 | 405 | 4,105,214 | 9.9 |
| Esophagus | Female | 7 | 293,155 | 2.4 | 2.8 | 4.6 | 0.355 | 75 | 4,081,763 | 1.8 |
| Hodgkin Lymphoma | Total | 9 | 584,851 | 1.5 | 1.6 | 13.5 | 0.276 | 201 | 8,186,977 | 2.5 |
| Hodgkin Lymphoma | Male | 8 | 291,696 | 2.7 | 3.0 | 7.3 | 0.879 | 110 | 4,105,214 | 2.7 |
| Hodgkin Lymphoma | Female | 1 | 293,155 | 0.3 | 0.4 | 6.2 | 0.029 << | 91 | 4,081,763 | 2.2 |
| Kidney and Renal Pelvis | Total | 114 | 584,851 | 19.5 | 22.6 | 104.7 | 0.385 | 1,701 | 8,186,977 | 20.8 |
| Kidney and Renal Pelvis | Male | 64 | 291,696 | 21.9 | 25.7 | 67.8 | 0.700 | 1,118 | 4,105,214 | 27.2 |
| Kidney and Renal Pelvis | Female | 50 | 293,155 | 17.1 | 19.5 | 36.5 | 0.039 >> | 583 | 4,081,763 | 14.3 |
| Larynx | Total | 5 | 584,851 | 0.9 | 1.0 | 12.7 | 0.027 << | 210 | 8,186,977 | 2.6 |
| Larynx | Male | 3 | 291,696 | 1.0 | 1.2 | 9.3 | 0.034 << | 157 | 4,105,214 | 3.8 |
| Larynx | Female | 2 | 293,155 | 0.7 | 0.8 | 3.2 | 0.742 | 53 | 4,081,763 | 1.3 |
| Leukemia | Total | 114 | 584,851 | 19.5 | 22.2 | 95.2 | 0.066 | 1,517 | 8,186,977 | 18.5 |
| Leukemia | Male | 69 | 291,696 | 23.7 | 27.2 | 56.9 | 0.132 | 920 | 4,105,214 | 22.4 |
| Leukemia | Female | 45 | 293,155 | 15.4 | 17.4 | 37.9 | 0.283 | 597 | 4,081,763 | 14.6 |
| Liver and Bile Duct | Total | 37 | 584,851 | 6.3 | 7.5 | 47.9 | 0.125 | 792 | 8,186,977 | 9.7 |
| Liver and Bile Duct | Male | 27 | 291,696 | 9.3 | 11.0 | 33.5 | 0.297 | 563 | 4,105,214 | 13.7 |
| Liver and Bile Duct | Female | 10 | 293,155 | 3.4 | 4.0 | 14.2 | 0.332 | 229 | 4,081,763 | 5.6 |
| Lung and Bronchus | Total | 204 | 584,851 | 34.9 | 41.6 | 280.3 | 0.000 << | 4,683 | 8,186,977 | 57.2 |
| Lung and Bronchus | Male | 108 | 291,696 | 37.0 | 45.0 | 137.0 | 0.012 << | 2,344 | 4,105,214 | 57.1 |
| Lung and Bronchus | Female | 96 | 293,155 | 32.7 | 38.5 | 142.8 | 0.000 << | 2,339 | 4,081,763 | 57.3 |
| Melanoma of the Skin | Total | 207 | 584,851 | 35.4 | 40.7 | 169.9 | $0.006 \gg$ | 2,735 | 8,186,977 | 33.4 |
| Melanoma of the Skin | Male | 119 | 291,696 | 40.8 | 47.9 | 99.6 | 0.064 | 1,646 | 4,105,214 | 40.1 |
| Melanoma of the Skin | Female | 88 | 293,155 | 30.0 | 33.8 | 69.4 | 0.036 >> | 1,089 | 4,081,763 | 26.7 |
| Myeloma | Total | 46 | 584,851 | 7.9 | 9.3 | 39.8 | 0.367 | 662 | 8,186,977 | 8.1 |
| Myeloma | Male | 29 | 291,696 | 9.9 | 12.0 | 24.2 | 0.379 | 412 | 4,105,214 | 10.0 |
| Myeloma | Female | 17 | 293,155 | 5.8 | 6.8 | 15.4 | 0.740 | 250 | 4,081,763 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 119 | 584,851 | 20.3 | 23.6 | 112.1 | 0.537 | 1,821 | 8,186,977 | 22.2 |
| Non-Hodgkin Lymphoma | Male | 67 | 291,696 | 23.0 | 26.9 | 64.4 | 0.783 | 1,062 | 4,105,214 | 25.9 |
| Non-Hodgkin Lymphoma | Female | 52 | 293,155 | 17.7 | 20.5 | 47.2 | 0.521 | 759 | 4,081,763 | 18.6 |
| Oral Cavity and Pharynx | Total | 73 | 584,851 | 12.5 | 14.7 | 74.2 | 0.946 | 1,222 | 8,186,977 | 14.9 |
| Oral Cavity and Pharynx | Male | 57 | 291,696 | 19.5 | 23.1 | 52.7 | 0.594 | 879 | 4,105,214 | 21.4 |
| Oral Cavity and Pharynx | Female | 16 | 293,155 | 5.5 | 6.3 | 21.2 | 0.305 | 343 | 4,081,763 | 8.4 |
| Ovary | Female | 27 | 293,155 | 9.2 | 10.6 | 31.6 | 0.473 | 506 | 4,081,763 | 12.4 |
| Pancreas | Total | 78 | 584,851 | 13.3 | 15.7 | 81.4 | 0.763 | 1,345 | 8,186,977 | 16.4 |
| Pancreas | Male | 40 | 291,696 | 13.7 | 16.4 | 44.1 | 0.601 | 744 | 4,105,214 | 18.1 |
| Pancreas | Female | 38 | 293,155 | 13.0 | 15.1 | 37.1 | 0.926 | 601 | 4,081,763 | 14.7 |
| Prostate | Male | 376 | 291,696 | 128.9 | 156.3 | 354.1 | 0.256 | 6,041 | 4,105,214 | 147.2 |
| Stomach | Total | 26 | 584,851 | 4.4 | 5.2 | 27.0 | 0.942 | 441 | 8,186,977 | 5.4 |
| Stomach | Male | 21 | 291,696 | 7.2 | 8.6 | 17.2 | 0.420 | 288 | 4,105,214 | 7.0 |
| Stomach | Female | 5 | 293,155 | 1.7 | 1.9 | 9.7 | 0.162 | 153 | 4,081,763 | 3.7 |
| Testis | Male | 18 | 291,696 | 6.2 | 6.3 | 17.2 | 0.916 | 247 | 4,105,214 | 6.0 |
| Thyroid | Total | 135 | 584,851 | 23.1 | 25.1 | 71.2 | $0.000 \gg$ | 1,085 | 8,186,977 | 13.3 |
| Thyroid | Male | 39 | 291,696 | 13.4 | 14.9 | 20.1 | $0.000 \gg$ | 316 | 4,105,214 | 7.7 |
| Thyroid | Female | 96 | 293,155 | 32.7 | 35.2 | 51.3 | $0.000 \gg$ | 769 | 4,081,763 | 18.8 |
| Pediatric Age 0 to 19 | Total | 34 | 193,841 | 17.5 | 17.7 | 32.9 | 0.888 | 387 | 2,266,682 | 17.1 |
| Pediatric Age 0 to 19 | Male | 19 | 98,908 | 19.2 | 19.2 | 17.5 | 0.778 | 204 | 1,157,602 | 17.6 |
| Pediatric Age 0 to 19 | Female | 15 | 94,933 | 15.8 | 16.1 | 15.4 | 1.000 | 183 | 1,109,080 | 16.5 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

| Cause of Death Cancer Site/Type | Sex | Bonneville County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | $P$-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 5,016 | 600,619 | 835.1 | 967.3 | 4,476.6 | 0.000 >> | 72,414 | 8,388,096 | 863.3 |
| All Causes of Death | Male | 2,606 | 300,057 | 868.5 | 1,019.0 | 2,334.7 | $0.000 \gg$ | 38,450 | 4,211,811 | 912.9 |
| All Causes of Death | Female | 2,410 | 300,562 | 801.8 | 919.7 | 2,131.1 | 0.000 >> | 33,964 | 4,176,285 | 813.3 |
| All Malignant Cancers | Total | 815 | 600,619 | 135.7 | 160.7 | 864.7 | 0.092 | 14,306 | 8,388,096 | 170.6 |
| All Malignant Cancers | Male | 428 | 300,057 | 142.6 | 171.7 | 458.4 | 0.160 | 7,748 | 4,211,811 | 184.0 |
| All Malignant Cancers | Female | 387 | 300,562 | 128.8 | 150.5 | 403.7 | 0.422 | 6,558 | 4,176,285 | 157.0 |
| Bladder | Total | 25 | 600,619 | 4.2 | 4.9 | 28.1 | 0.640 | 464 | 8,388,096 | 5.5 |
| Bladder | Male | 20 | 300,057 | 6.7 | 8.0 | 21.3 | 0.896 | 358 | 4,211,811 | 8.5 |
| Bladder | Female | 5 | 300,562 | 1.7 | 1.9 | 6.5 | 0.733 | 106 | 4,176,285 | 2.5 |
| Brain and Other Nervous System | Total | 39 | 600,619 | 6.5 | 7.5 | 28.8 | 0.080 | 465 | 8,388,096 | 5.5 |
| Brain and Other Nervous System | Male | 25 | 300,057 | 8.3 | 9.8 | 16.6 | 0.064 | 273 | 4,211,811 | 6.5 |
| Brain and Other Nervous System | Female | 14 | 300,562 | 4.7 | 5.3 | 12.1 | 0.655 | 192 | 4,176,285 | 4.6 |
| Breast | Total | 67 | 600,619 | 11.2 | 13.1 | 63.2 | 0.666 | 1,035 | 8,388,096 | 12.3 |
| Breast | Male | 2 | 300,057 | 0.7 | 0.8 | 0.8 | 0.406 | 14 | 4,211,811 | 0.3 |
| Breast | Female | 65 | 300,562 | 21.6 | 25.2 | 63.1 | 0.839 | 1,021 | 4,176,285 | 24.4 |
| Cervix | Female | 5 | 300,562 | 1.7 | 1.9 | 5.0 | 1.000 | 78 | 4,176,285 | 1.9 |
| Colorectal | Total | 82 | 600,619 | 13.7 | 16.1 | 75.3 | 0.469 | 1,237 | 8,388,096 | 14.7 |
| Colorectal | Male | 43 | 300,057 | 14.3 | 17.0 | 40.6 | 0.743 | 676 | 4,211,811 | 16.1 |
| Colorectal | Female | 39 | 300,562 | 13.0 | 15.1 | 34.7 | 0.506 | 561 | 4,176,285 | 13.4 |
| Corpus Uteri | Female | 4 | 300,562 | 1.3 | 1.6 | 10.2 | $0.050 \ll$ | 169 | 4,176,285 | 4.0 |
| Esophagus | Total | 23 | 600,619 | 3.8 | 4.6 | 27.2 | 0.487 | 454 | 8,388,096 | 5.4 |
| Esophagus | Male | 20 | 300,057 | 6.7 | 8.1 | 22.4 | 0.706 | 381 | 4,211,811 | 9.0 |
| Esophagus | Female | 3 | 300,562 | 1.0 | 1.2 | 4.5 | 0.697 | 73 | 4,176,285 | 1.7 |
| Hodgkin Lymphoma | Total | 3 | 600,619 | 0.5 | 0.6 | 1.6 | 0.444 | 26 | 8,388,096 | 0.3 |
| Hodgkin Lymphoma | Male | 1 | 300,057 | 0.3 | 0.4 | 0.8 | 1.000 | 13 | 4,211,811 | 0.3 |
| Hodgkin Lymphoma | Female | 2 | 300,562 | 0.7 | 0.8 | 0.8 | 0.398 | 13 | 4,176,285 | 0.3 |
| Kidney | Total | 19 | 600,619 | 3.2 | 3.8 | 22.0 | 0.609 | 366 | 8,388,096 | 4.4 |
| Kidney | Male | 13 | 300,057 | 4.3 | 5.2 | 13.5 | 1.000 | 229 | 4,211,811 | 5.4 |
| Kidney | Female | 6 | 300,562 | 2.0 | 2.3 | 8.4 | 0.533 | 137 | 4,176,285 | 3.3 |
| Larynx | Total | 3 | 600,619 | 0.5 | 0.6 | 4.1 | 0.829 | 68 | 8,388,096 | 0.8 |
| Larynx | Male | 3 | 300,057 | 1.0 | 1.2 | 3.3 | 1.000 | 55 | 4,211,811 | 1.3 |
| Larynx | Female | - | 300,562 | - | - | 0.8 | 0.913 | 13 | 4,176,285 | 0.3 |
| Leukemia | Total | 35 | 600,619 | 5.8 | 6.8 | 38.2 | 0.676 | 625 | 8,388,096 | 7.5 |
| Leukemia | Male | 22 | 300,057 | 7.3 | 8.7 | 21.8 | 1.000 | 364 | 4,211,811 | 8.6 |
| Leukemia | Female | 13 | 300,562 | 4.3 | 5.0 | 16.3 | 0.506 | 261 | 4,176,285 | 6.2 |
| Liver and Bile Duct | Total | 27 | 600,619 | 4.5 | 5.4 | 34.4 | 0.231 | 576 | 8,388,096 | 6.9 |
| Liver and Bile Duct | Male | 14 | 300,057 | 4.7 | 5.7 | 23.2 | 0.058 | 394 | 4,211,811 | 9.4 |
| Liver and Bile Duct | Female | 13 | 300,562 | 4.3 | 5.1 | 11.1 | 0.644 | 182 | 4,176,285 | 4.4 |
| Lung and Bronchus | Total | 132 | 600,619 | 22.0 | 26.4 | 168.8 | 0.004 << | 2,829 | 8,388,096 | 33.7 |
| Lung and Bronchus | Male | 72 | 300,057 | 24.0 | 29.3 | 86.5 | 0.127 | 1,484 | 4,211,811 | 35.2 |
| Lung and Bronchus | Female | 60 | 300,562 | 20.0 | 23.6 | 82.0 | 0.014 << | 1,345 | 4,176,285 | 32.2 |
| Melanoma of the Skin | Total | 19 | 600,619 | 3.2 | 3.7 | 16.5 | 0.592 | 270 | 8,388,096 | 3.2 |
| Melanoma of the Skin | Male | 11 | 300,057 | 3.7 | 4.4 | 10.8 | 1.000 | 181 | 4,211,811 | 4.3 |
| Melanoma of the Skin | Female | 8 | 300,562 | 2.7 | 3.1 | 5.5 | 0.385 | 89 | 4,176,285 | 2.1 |
| Myeloma | Total | 21 | 600,619 | 3.5 | 4.2 | 18.5 | 0.627 | 310 | 8,388,096 | 3.7 |
| Myeloma | Male | 13 | 300,057 | 4.3 | 5.3 | 10.6 | 0.547 | 183 | 4,211,811 | 4.3 |
| Myeloma | Female | 8 | 300,562 | 2.7 | 3.1 | 7.8 | 1.000 | 127 | 4,176,285 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 39 | 600,619 | 6.5 | 7.7 | 32.1 | 0.262 | 530 | 8,388,096 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 19 | 300,057 | 6.3 | 7.6 | 17.1 | 0.716 | 288 | 4,211,811 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 20 | 300,562 | 6.7 | 7.8 | 14.9 | 0.238 | 242 | 4,176,285 | 5.8 |
| Oral Cavity and Pharynx | Total | 13 | 600,619 | 2.2 | 2.6 | 15.2 | 0.693 | 253 | 8,388,096 | 3.0 |
| Oral Cavity and Pharynx | Male | 8 | 300,057 | 2.7 | 3.2 | 10.5 | 0.557 | 179 | 4,211,811 | 4.2 |
| Oral Cavity and Pharynx | Female | 5 | 300,562 | 1.7 | 2.0 | 4.5 | 0.947 | 74 | 4,176,285 | 1.8 |
| Ovary | Female | 26 | 300,562 | 8.7 | 10.2 | 19.8 | 0.206 | 324 | 4,176,285 | 7.8 |
| Pancreas | Total | 60 | 600,619 | 10.0 | 11.9 | 67.7 | 0.386 | 1,130 | 8,388,096 | 13.5 |
| Pancreas | Male | 27 | 300,057 | 9.0 | 10.9 | 36.1 | 0.145 | 615 | 4,211,811 | 14.6 |
| Pancreas | Female | 33 | 300,562 | 11.0 | 12.9 | 31.4 | 0.829 | 515 | 4,176,285 | 12.3 |
| Prostate | Male | 47 | 300,057 | 15.7 | 18.9 | 53.4 | 0.424 | 902 | 4,211,811 | 21.4 |
| Stomach | Total | 5 | 600,619 | 0.8 | 1.0 | 11.9 | 0.044 << | 193 | 8,388,096 | 2.3 |
| Stomach | Male | 5 | 300,057 | 1.7 | 2.0 | 6.9 | 0.620 | 116 | 4,211,811 | 2.8 |
| Stomach | Female | - | 300,562 | - | - | 4.9 | $0.015 \ll$ | 77 | 4,176,285 | 1.8 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Bonneville County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 85.7\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 14.8\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 70.5\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% | 68.6\% |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 69.2\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 20.3\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 30.5\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 78.8\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 21.0\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 21.9\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^9]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged $50-74$ reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# BOUNDARY COUNTY CANCER PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 410 cases of invasive cancer were diagnosed among Boundary County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Boundary County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Boundary <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 410 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 53 | 6,687 |
| Prostate | 55 | 6,417 |
| Lung \& Bronchus | 48 | 4,887 |
| Colorectal | 3,451 |  |

Table 3 (Cancer Incidence 2016-2020, Comparison between Boundary County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Boundary County. The table also shows the number of observed cases,
person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Boundary County was 674.6 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.9) gives an estimate of the relative burden of disease in Boundary County.

The age- and sex-adjusted incidence rate of invasive cancer in Boundary County, all sites combined, was 522.2 cases per 100,000 persons per year during 2016-2020. There were more cases of cancer in Boundary County (410) than expected (407.4) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 154 Boundary County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Boundary County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Boundary <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 669 | 77,431 |
| Cancer Deaths | 154 | 15,121 |
| \% of All Deaths | $23.0 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 33 | 2,961 |
| Colorectal | 12 | 1,319 |
| Pancreas | 4 | 1,190 |
| Female Breast | 8 | 1,086 |
| Prostate | 14 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Boundary County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Boundary County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Boundary County, all sites combined, was 186.5 deaths per 100,000 persons per year during 2017-2021, compared with 167.7 for the remainder of the state. There were more cancer deaths in Boundary County (154) than expected (138.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

| Cancer Site/Type | Sex | Boundary County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 410 | 60,778 | 674.6 | 522.2 | 407.4 | 0.910 | 45,200 | 8,711,050 | 518.9 |
| All Sites Combined | Male | 222 | 30,616 | 725.1 | 535.9 | 228.3 | 0.707 | 24,067 | 4,366,294 | 551.2 |
| All Sites Combined | Female | 188 | 30,162 | 623.3 | 502.9 | 181.8 | 0.667 | 21,133 | 4,344,756 | 486.4 |
| Bladder | Total | 14 | 60,778 | 23.0 | 17.0 | 20.5 | 0.175 | 2,170 | 8,711,050 | 24.9 |
| Bladder | Male | 12 | 30,616 | 39.2 | 27.9 | 17.1 | 0.257 | 1,739 | 4,366,294 | 39.8 |
| Bladder | Female | 2 | 30,162 | 6.6 | 5.1 | 3.9 | 0.503 | 431 | 4,344,756 | 9.9 |
| Brain - malignant | Total | 7 | 60,778 | 11.5 | 9.6 | 5.2 | 0.525 | 618 | 8,711,050 | 7.1 |
| Brain - malignant | Male | 3 | 30,616 | 9.8 | 8.0 | 3.2 | 1.000 | 372 | 4,366,294 | 8.5 |
| Brain - malignant | Female | 4 | 30,162 | 13.3 | 11.2 | 2.0 | 0.295 | 246 | 4,344,756 | 5.7 |
| Brain and other CNS - non-malignant | Total | 11 | 60,778 | 18.1 | 14.7 | 12.1 | 0.891 | 1,413 | 8,711,050 | 16.2 |
| Brain and other CNS - non-malignant | Male | 5 | 30,616 | 16.3 | 13.3 | 4.1 | 0.783 | 475 | 4,366,294 | 10.9 |
| Brain and other CNS - non-malignant | Female | 6 | 30,162 | 19.9 | 16.4 | 7.9 | 0.650 | 938 | 4,344,756 | 21.6 |
| Breast | Total | 53 | 60,778 | 87.2 | 69.1 | 58.9 | 0.486 | 6,693 | 8,711,050 | 76.8 |
| Breast | Male | - | 30,616 | - | - | 0.6 | 1.000 | 59 | 4,366,294 | 1.4 |
| Breast | Female | 53 | 30,162 | 175.7 | 142.3 | 56.9 | 0.667 | 6,634 | 4,344,756 | 152.7 |
| Breast - in situ | Total | 7 | 60,778 | 11.5 | 9.2 | 10.8 | 0.313 | 1,232 | 8,711,050 | 14.1 |
| Breast - in situ | Male | - | 30,616 | - | - | 0.0 | 1.000 | 5 | 4,366,294 | 0.1 |
| Breast - in situ | Female | 7 | 30,162 | 23.2 | 18.8 | 10.5 | 0.358 | 1,227 | 4,344,756 | 28.2 |
| Cervix | Female | 4 | 30,162 | 13.3 | 12.7 | 2.2 | 0.354 | 300 | 4,344,756 | 6.9 |
| Colorectal | Total | 48 | 60,778 | 79.0 | 61.8 | 30.3 | 0.004 >> | 3,403 | 8,711,050 | 39.1 |
| Colorectal | Male | 26 | 30,616 | 84.9 | 64.8 | 17.2 | 0.058 | 1,877 | 4,366,294 | 43.0 |
| Colorectal | Female | 22 | 30,162 | 72.9 | 58.6 | 13.2 | 0.033 >> | 1,526 | 4,344,756 | 35.1 |
| Corpus Uteri | Female | 16 | 30,162 | 53.0 | 42.2 | 11.5 | 0.240 | 1,314 | 4,344,756 | 30.2 |
| Esophagus | Total | 5 | 60,778 | 8.2 | 6.2 | 4.6 | 0.991 | 501 | 8,711,050 | 5.8 |
| Esophagus | Male | 4 | 30,616 | 13.1 | 9.5 | 4.0 | 1.000 | 420 | 4,366,294 | 9.6 |
| Esophagus | Female | 1 | 30,162 | 3.3 | 2.6 | 0.7 | 1.000 | 81 | 4,344,756 | 1.9 |
| Hodgkin Lymphoma | Total | - | 60,778 | - | - | 1.5 | 0.436 | 210 | 8,711,050 | 2.4 |
| Hodgkin Lymphoma | Male | - | 30,616 | - | - | 0.9 | 0.823 | 118 | 4,366,294 | 2.7 |
| Hodgkin Lymphoma | Female | - | 30,162 | - | - | 0.6 | 1.000 | 92 | 4,344,756 | 2.1 |
| Kidney and Renal Pelvis | Total | 11 | 60,778 | 18.1 | 14.2 | 16.1 | 0.246 | 1,804 | 8,711,050 | 20.7 |
| Kidney and Renal Pelvis | Male | 8 | 30,616 | 26.1 | 20.0 | 10.8 | 0.506 | 1,174 | 4,366,294 | 26.9 |
| Kidney and Renal Pelvis | Female | 3 | 30,162 | 9.9 | 8.0 | 5.4 | 0.418 | 630 | 4,344,756 | 14.5 |
| Larynx | Total | 3 | 60,778 | 4.9 | 3.7 | 2.0 | 0.623 | 212 | 8,711,050 | 2.4 |
| Larynx | Male | 1 | 30,616 | 3.3 | 2.4 | 1.5 | 1.000 | 159 | 4,366,294 | 3.6 |
| Larynx | Female | 2 | 30,162 | 6.6 | 5.2 | 0.5 | 0.163 | 53 | 4,344,756 | 1.2 |
| Leukemia | Total | 18 | 60,778 | 29.6 | 23.2 | 14.4 | 0.402 | 1,613 | 8,711,050 | 18.5 |
| Leukemia | Male | 12 | 30,616 | 39.2 | 29.9 | 9.0 | 0.392 | 977 | 4,366,294 | 22.4 |
| Leukemia | Female | 6 | 30,162 | 19.9 | 16.0 | 5.5 | 0.942 | 636 | 4,344,756 | 14.6 |
| Liver and Bile Duct | Total | 1 | 60,778 | 1.6 | 1.2 | 7.7 | 0.008 << | 828 | 8,711,050 | 9.5 |
| Liver and Bile Duct | Male | 1 | 30,616 | 3.3 | 2.4 | 5.7 | 0.047 << | 589 | 4,366,294 | 13.5 |
| Liver and Bile Duct | Female | - | 30,162 | - | - | 2.1 | 0.238 | 239 | 4,344,756 | 5.5 |
| Lung and Bronchus | Total | 50 | 60,778 | 82.3 | 60.7 | 45.7 | 0.566 | 4,837 | 8,711,050 | 55.5 |
| Lung and Bronchus | Male | 29 | 30,616 | 94.7 | 67.0 | 24.0 | 0.357 | 2,423 | 4,366,294 | 55.5 |
| Lung and Bronchus | Female | 21 | 30,162 | 69.6 | 53.4 | 21.9 | 0.967 | 2,414 | 4,344,756 | 55.6 |
| Melanoma of the Skin | Total | 22 | 60,778 | 36.2 | 29.0 | 25.4 | 0.581 | 2,920 | 8,711,050 | 33.5 |
| Melanoma of the Skin | Male | 15 | 30,616 | 49.0 | 37.3 | 16.1 | 0.912 | 1,750 | 4,366,294 | 40.1 |
| Melanoma of the Skin | Female | 7 | 30,162 | 23.2 | 19.7 | 9.6 | 0.522 | 1,170 | 4,344,756 | 26.9 |
| Myeloma | Total | 5 | 60,778 | 8.2 | 6.2 | 6.5 | 0.724 | 703 | 8,711,050 | 8.1 |
| Myeloma | Male | 4 | 30,616 | 13.1 | 9.4 | 4.2 | 1.000 | 437 | 4,366,294 | 10.0 |
| Myeloma | Female | 1 | 30,162 | 3.3 | 2.6 | 2.4 | 0.623 | 266 | 4,344,756 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 22 | 60,778 | 36.2 | 28.1 | 17.2 | 0.302 | 1,918 | 8,711,050 | 22.0 |
| Non-Hodgkin Lymphoma | Male | 14 | 30,616 | 45.7 | 34.7 | 10.3 | 0.319 | 1,115 | 4,366,294 | 25.5 |
| Non-Hodgkin Lymphoma | Female | 8 | 30,162 | 26.5 | 21.0 | 7.0 | 0.812 | 803 | 4,344,756 | 18.5 |
| Oral Cavity and Pharynx | Total | 9 | 60,778 | 14.8 | 11.4 | 11.7 | 0.540 | 1,286 | 8,711,050 | 14.8 |
| Oral Cavity and Pharynx | Male | 8 | 30,616 | 26.1 | 19.5 | 8.7 | 0.991 | 928 | 4,366,294 | 21.3 |
| Oral Cavity and Pharynx | Female | 1 | 30,162 | 3.3 | 2.6 | 3.1 | 0.358 | 358 | 4,344,756 | 8.2 |
| Ovary | Female | 9 | 30,162 | 29.8 | 24.1 | 4.5 | 0.080 | 524 | 4,344,756 | 12.1 |
| Pancreas | Total | 10 | 60,778 | 16.5 | 12.3 | 13.1 | 0.480 | 1,413 | 8,711,050 | 16.2 |
| Pancreas | Male | 8 | 30,616 | 26.1 | 19.0 | 7.5 | 0.946 | 776 | 4,366,294 | 17.8 |
| Pancreas | Female | 2 | 30,162 | 6.6 | 5.1 | 5.7 | 0.152 | 637 | 4,344,756 | 14.7 |
| Prostate | Male | 55 | 30,616 | 179.6 | 127.8 | 62.7 | 0.365 | 6,362 | 4,366,294 | 145.7 |
| Stomach | Total | 7 | 60,778 | 11.5 | 8.9 | 4.2 | 0.257 | 460 | 8,711,050 | 5.3 |
| Stomach | Male | 4 | 30,616 | 13.1 | 9.7 | 2.9 | 0.658 | 305 | 4,366,294 | 7.0 |
| Stomach | Female | 3 | 30,162 | 9.9 | 8.0 | 1.3 | 0.304 | 155 | 4,344,756 | 3.6 |
| Testis | Male | 2 | 30,616 | 6.5 | 7.7 | 1.6 | 0.929 | 263 | 4,366,294 | 6.0 |
| Thyroid | Total | 6 | 60,778 | 9.9 | 9.2 | 9.1 | 0.397 | 1,214 | 8,711,050 | 13.9 |
| Thyroid | Male | 1 | 30,616 | 3.3 | 2.8 | 2.8 | 0.447 | 354 | 4,366,294 | 8.1 |
| Thyroid | Female | 5 | 30,162 | 16.6 | 15.8 | 6.2 | 0.814 | 860 | 4,344,756 | 19.8 |
| Pediatric Age 0 to 19 | Total | 5 | 15,601 | 32.0 | 31.7 | 2.7 | 0.271 | 416 | 2,444,922 | 17.0 |
| Pediatric Age 0 to 19 | Male | 4 | 8,145 | 49.1 | 48.4 | 1.4 | 0.119 | 219 | 1,248,365 | 17.5 |
| Pediatric Age 0 to 19 | Female | 1 | 7,456 | 13.4 | 13.2 | 1.2 | 1.000 | 197 | 1,196,557 | 16.5 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ )
Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN BOUNDARY COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Boundary County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 669 | 61,625 | 1,085.6 | 823.3 | 698.7 | 0.269 | 76,761 | 8,927,090 | 859.9 |
| All Causes of Death | Male | 370 | 31,109 | 1,189.4 | 899.7 | 373.4 | 0.887 | 40,686 | 4,480,759 | 908.0 |
| All Causes of Death | Female | 299 | 30,516 | 979.8 | 738.5 | 328.5 | 0.107 | 36,075 | 4,446,331 | 811.3 |
| All Malignant Cancers | Total | 154 | 61,625 | 249.9 | 186.5 | 138.5 | 0.204 | 14,967 | 8,927,090 | 167.7 |
| All Malignant Cancers | Male | 83 | 31,109 | 266.8 | 193.5 | 77.5 | 0.559 | 8,093 | 4,480,759 | 180.6 |
| All Malignant Cancers | Female | 71 | 30,516 | 232.7 | 178.2 | 61.6 | 0.259 | 6,874 | 4,446,331 | 154.6 |
| Bladder | Total | 4 | 61,625 | 6.5 | 4.7 | 4.6 | 1.000 | 485 | 8,927,090 | 5.4 |
| Bladder | Male | 4 | 31,109 | 12.9 | 9.2 | 3.6 | 0.975 | 374 | 4,480,759 | 8.3 |
| Bladder | Female | - | 30,516 | - | - | 1.0 | 0.717 | 111 | 4,446,331 | 2.5 |
| Brain and Other Nervous System | Total | 6 | 61,625 | 9.7 | 7.7 | 4.4 | 0.548 | 498 | 8,927,090 | 5.6 |
| Brain and Other Nervous System | Male | 3 | 31,109 | 9.6 | 7.4 | 2.7 | 0.995 | 295 | 4,480,759 | 6.6 |
| Brain and Other Nervous System | Female | 3 | 30,516 | 9.8 | 7.9 | 1.7 | 0.505 | 203 | 4,446,331 | 4.6 |
| Breast | Total | 8 | 61,625 | 13.0 | 9.9 | 9.9 | 0.691 | 1,094 | 8,927,090 | 12.3 |
| Breast | Male |  | 31,109 |  |  | 0.2 | 1.000 | 16 | 4,480,759 | 0.4 |
| Breast | Female | 8 | 30,516 | 26.2 | 20.3 | 9.5 | 0.775 | 1,078 | 4,446,331 | 24.2 |
| Cervix | Female | 1 | 30,516 | 3.3 | 2.9 | 0.6 | 0.952 | 82 | 4,446,331 | 1.8 |
| Colorectal | Total | 12 | 61,625 | 19.5 | 14.8 | 11.9 | 1.000 | 1,307 | 8,927,090 | 14.6 |
| Colorectal | Male | 5 | 31,109 | 16.1 | 12.0 | 6.6 | 0.705 | 714 | 4,480,759 | 15.9 |
| Colorectal | Female | 7 | 30,516 | 22.9 | 17.5 | 5.3 | 0.574 | 593 | 4,446,331 | 13.3 |
| Corpus Uteri | Female | 3 | 30,516 | 9.8 | 7.4 | 1.5 | 0.406 | 170 | 4,446,331 | 3.8 |
| Esophagus | Total | 4 | 61,625 | 6.5 | 4.8 | 4.4 | 1.000 | 473 | 8,927,090 | 5.3 |
| Esophagus | Male | 3 | 31,109 | 9.6 | 7.0 | 3.8 | 0.946 | 398 | 4,480,759 | 8.9 |
| Esophagus | Female | 1 | 30,516 | 3.3 | 2.5 | 0.7 | 0.980 | 75 | 4,446,331 | 1.7 |
| Hodgkin Lymphoma | Total | 1 | 61,625 | 1.6 | 1.3 | 0.2 | 0.428 | 28 | 8,927,090 | 0.3 |
| Hodgkin Lymphoma | Male | 1 | 31,109 | 3.2 | 2.6 | 0.1 | 0.212 | 13 | 4,480,759 | 0.3 |
| Hodgkin Lymphoma | Female | - | 30,516 | - |  | 0.1 | 1.000 | 15 | 4,446,331 | 0.3 |
| Kidney | Total | 3 | 61,625 | 4.9 | 3.6 | 3.6 | 1.000 | 382 | 8,927,090 | 4.3 |
| Kidney | Male | 3 | 31,109 | 9.6 | 7.0 | 2.3 | 0.807 | 239 | 4,480,759 | 5.3 |
| Kidney | Female | - | 30,516 | - | - | 1.3 | 0.533 | 143 | 4,446,331 | 3.2 |
| Larynx | Total |  | 61,625 | - | - | 0.7 | 1.000 | 71 | 8,927,090 | 0.8 |
| Larynx | Male | - | 31,109 | - | - | 0.5 | 1.000 | 58 | 4,480,759 | 1.3 |
| Larynx | Female | - | 30,516 | - | - | 0.1 | 1.000 | 13 | 4,446,331 | 0.3 |
| Leukemia | Total | 6 | 61,625 | 9.7 | 7.3 | 6.0 | 1.000 | 654 | 8,927,090 | 7.3 |
| Leukemia | Male | 4 | 31,109 | 12.9 | 9.5 | 3.6 | 0.972 | 382 | 4,480,759 | 8.5 |
| Leukemia | Female | 2 | 30,516 | 6.6 | 5.0 | 2.4 | 1.000 | 272 | 4,446,331 | 6.1 |
| Liver and Bile Duct | Total | 2 | 61,625 | 3.2 | 2.4 | 5.6 | 0.163 | 601 | 8,927,090 | 6.7 |
| Liver and Bile Duct | Male | - | 31,109 | - | - | 4.0 | 0.038 << | 408 | 4,480,759 | 9.1 |
| Liver and Bile Duct | Female | 2 | 30,516 | 6.6 | 5.0 | 1.7 | 1.000 | 193 | 4,446,331 | 4.3 |
| Lung and Bronchus | Total | 33 | 61,625 | 53.5 | 39.3 | 27.5 | 0.342 | 2,928 | 8,927,090 | 32.8 |
| Lung and Bronchus | Male | 21 | 31,109 | 67.5 | 47.7 | 15.1 | 0.172 | 1,535 | 4,480,759 | 34.3 |
| Lung and Bronchus | Female | 12 | 30,516 | 39.3 | 29.8 | 12.6 | 1.000 | 1,393 | 4,446,331 | 31.3 |
| Melanoma of the Skin | Total | 1 | 61,625 | 1.6 | 1.2 | 2.6 | 0.536 | 288 | 8,927,090 | 3.2 |
| Melanoma of the Skin | Male | 1 | 31,109 | 3.2 | 2.4 | 1.8 | 0.941 | 191 | 4,480,759 | 4.3 |
| Melanoma of the Skin | Female | - | 30,516 | - | - | 0.8 | 0.867 | 97 | 4,446,331 | 2.2 |
| Myeloma | Total | 2 | 61,625 | 3.2 | 2.4 | 3.1 | 0.799 | 329 | 8,927,090 | 3.7 |
| Myeloma | Male | 1 | 31,109 | 3.2 | 2.3 | 1.9 | 0.852 | 195 | 4,480,759 | 4.4 |
| Myeloma | Female | 1 | 30,516 | 3.3 | 2.5 | 1.2 | 1.000 | 134 | 4,446,331 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 11 | 61,625 | 17.8 | 13.3 | 5.2 | 0.035 >> | 558 | 8,927,090 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 7 | 31,109 | 22.5 | 16.4 | 2.9 | 0.053 | 300 | 4,480,759 | 6.7 |
| Non-Hodgkin Lymphoma | Female | 4 | 30,516 | 13.1 | 9.9 | 2.3 | 0.419 | 258 | 4,446,331 | 5.8 |
| Oral Cavity and Pharynx | Total | 2 | 61,625 | 3.2 | 2.4 | 2.4 | 1.000 | 264 | 8,927,090 | 3.0 |
| Oral Cavity and Pharynx | Male | 1 | 31,109 | 3.2 | 2.3 | 1.8 | 0.939 | 186 | 4,480,759 | 4.2 |
| Oral Cavity and Pharynx | Female | 1 | 30,516 | 3.3 | 2.5 | 0.7 | 1.000 | 78 | 4,446,331 | 1.8 |
| Ovary | Female | 10 | 30,516 | 32.8 | 25.2 | 3.0 | $0.002 \gg$ | 340 | 4,446,331 | 7.6 |
| Pancreas | Total | 4 | 61,625 | 6.5 | 4.8 | 11.1 | 0.029 << | 1,186 | 8,927,090 | 13.3 |
| Pancreas | Male | 4 | 31,109 | 12.9 | 9.2 | 6.2 | 0.529 | 638 | 4,480,759 | 14.2 |
| Pancreas | Female | - | 30,516 | - | - | 4.9 | 0.014 << | 548 | 4,446,331 | 12.3 |
| Prostate | Male | 14 | 31,109 | 45.0 | 32.2 | 9.1 | 0.157 | 935 | 4,480,759 | 20.9 |
| Stomach | Total | 3 | 61,625 | 4.9 | 3.8 | 1.7 | 0.504 | 195 | 8,927,090 | 2.2 |
| Stomach | Male | 1 | 31,109 | 3.2 | 2.4 | 1.1 | 1.000 | 120 | 4,480,759 | 2.7 |
| Stomach | Female | 2 | 30,516 | 6.6 | 5.2 | 0.6 | 0.273 | 75 | 4,446,331 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Boundary County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 72.0\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 8.9\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% |  |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% |  |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 20.1\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 29.6\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 76.2\% |
| Meet Physical Activity Guidelines ( $2011,2013,2015,2017,2019)$ | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 21.3\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 17.4\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^10]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 88 cases of invasive cancer were diagnosed among Butte County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Butte County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Butte <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 88 | 45,610 |
| Female Breast | 8 | 6,687 |
| Prostate | 6 | 6,417 |
| Lung \& Bronchus | 14 | 4,887 |
| Colorectal | 5 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Butte County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Butte County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Butte County was 676.2 cases per 100,000 personyears per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.7) gives an estimate of the relative burden of disease in Butte County.

The age- and sex-adjusted incidence rate of invasive cancer in Butte County, all sites combined, was 496.0 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Butte County (88) than expected (92.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 37 Butte County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Butte County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Butte <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | $\mathbf{1 8 3}$ | 77,431 |
| Cancer Deaths | 37 | 15,121 |
| \% of All Deaths | $20.2 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 10 | 2,961 |
| Colorectal | $\mathbf{3}$ | 1,319 |
| Pancreas | $\mathbf{0}$ | 1,190 |
| Female Breast | $\mathbf{2}$ | 1,086 |
| Prostate | $\mathbf{0}$ | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Butte County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Butte County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Butte County, all sites combined, was 191.7 deaths per 100,000 persons per year during 2017-2021, compared with 168.1 for the remainder of the state. There were more cancer deaths in Butte County (37) than expected (32.4) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020 COMPARISON BETWEEN BUTTE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

|  |  | Butte County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 88 | 13,013 | 676.2 | 496.0 | 92.2 | 0.710 | 45,522 | 8,758,815 | 519.7 |
| All Sites Combined | Male | 49 | 6,622 | 740.0 | 507.5 | 53.3 | 0.613 | 24,240 | 4,390,288 | 552.1 |
| All Sites Combined | Female | 39 | 6,391 | 610.2 | 476.4 | 39.9 | 0.973 | 21,282 | 4,368,527 | 487.2 |
| Bladder | Total | 4 | 13,013 | 30.7 | 20.7 | 4.8 | 0.949 | 2,180 | 8,758,815 | 24.9 |
| Bladder | Male | 4 | 6,622 | 60.4 | 38.5 | 4.1 | 1.000 | 1,747 | 4,390,288 | 39.8 |
| Bladder | Female | - | 6,391 | - | - | 0.9 | 0.824 | 433 | 4,368,527 | 9.9 |
| Brain - malignant | Total | 3 | 13,013 | 23.1 | 18.5 | 1.2 | 0.220 | 622 | 8,758,815 | 7.1 |
| Brain - malignant | Male | 1 | 6,622 | 15.1 | 11.8 | 0.7 | 1.000 | 374 | 4,390,288 | 8.5 |
| Brain - malignant | Female | 2 | 6,391 | 31.3 | 25.5 | 0.4 | 0.148 | 248 | 4,368,527 | 5.7 |
| Brain and other CNS - non-malignant | Total | 3 | 13,013 | 23.1 | 17.9 | 2.7 | 1.000 | 1,421 | 8,758,815 | 16.2 |
| Brain and other CNS - non-malignant | Male | 2 | 6,622 | 30.2 | 23.2 | 0.9 | 0.484 | 478 | 4,390,288 | 10.9 |
| Brain and other CNS - non-malignant | Female | 1 | 6,391 | 15.6 | 12.4 | 1.7 | 0.964 | 943 | 4,368,527 | 21.6 |
| Breast | Total | 8 | 13,013 | 61.5 | 47.3 | 13.0 | 0.200 | 6,738 | 8,758,815 | 76.9 |
| Breast | Male | - | 6,622 | - | - | 0.1 | 1.000 | 59 | 4,390,288 | 1.3 |
| Breast | Female | 8 | 6,391 | 125.2 | 100.3 | 12.2 | 0.285 | 6,679 | 4,368,527 | 152.9 |
| Breast - in situ | Total | 4 | 13,013 | 30.7 | 24.4 | 2.3 | 0.406 | 1,235 | 8,758,815 | 14.1 |
| Breast - in situ | Male | - | 6,622 | - | - | 0.0 | 1.000 | 5 | 4,390,288 | 0.1 |
| Breast - in situ | Female | 4 | 6,391 | 62.6 | 51.8 | 2.2 | 0.351 | 1,230 | 4,368,527 | 28.2 |
| Cervix | Female | - | 6,391 | - | - | 0.4 | 1.000 | 304 | 4,368,527 | 7.0 |
| Colorectal | Total | 5 | 13,013 | 38.4 | 28.4 | 6.9 | 0.618 | 3,446 | 8,758,815 | 39.3 |
| Colorectal | Male | 3 | 6,622 | 45.3 | 32.5 | 4.0 | 0.869 | 1,900 | 4,390,288 | 43.3 |
| Colorectal | Female | 2 | 6,391 | 31.3 | 23.7 | 3.0 | 0.855 | 1,546 | 4,368,527 | 35.4 |
| Corpus Uteri | Female | 2 | 6,391 | 31.3 | 24.7 | 2.5 | 1.000 | 1,328 | 4,368,527 | 30.4 |
| Esophagus | Total | 1 | 13,013 | 7.7 | 5.4 | 1.1 | 1.000 | 505 | 8,758,815 | 5.8 |
| Esophagus | Male | 1 | 6,622 | 15.1 | 10.2 | 0.9 | 1.000 | 423 | 4,390,288 | 9.6 |
| Esophagus | Female | - | 6,391 | - | - | 0.2 | 1.000 | 82 | 4,368,527 | 1.9 |
| Hodgkin Lymphoma | Total | - | 13,013 | - | - | 0.3 | 1.000 | 210 | 8,758,815 | 2.4 |
| Hodgkin Lymphoma | Male | - | 6,622 | - | - | 0.2 | 1.000 | 118 | 4,390,288 | 2.7 |
| Hodgkin Lymphoma | Female | - | 6,391 | - | - | 0.1 | 1.000 | 92 | 4,368,527 | 2.1 |
| Kidney and Renal Pelvis | Total | 3 | 13,013 | 23.1 | 17.3 | 3.6 | 1.000 | 1,812 | 8,758,815 | 20.7 |
| Kidney and Renal Pelvis | Male | 2 | 6,622 | 30.2 | 21.8 | 2.5 | 1.000 | 1,180 | 4,390,288 | 26.9 |
| Kidney and Renal Pelvis | Female | 1 | 6,391 | 15.6 | 12.1 | 1.2 | 1.000 | 632 | 4,368,527 | 14.5 |
| Larynx | Total | - | 13,013 | - | - | 0.5 | 1.000 | 215 | 8,758,815 | 2.5 |
| Larynx | Male | - | 6,622 | - | - | 0.4 | 1.000 | 160 | 4,390,288 | 3.6 |
| Larynx | Female | - | 6,391 | - | - | 0.1 | 1.000 | 55 | 4,368,527 | 1.3 |
| Leukemia | Total | 5 | 13,013 | 38.4 | 28.0 | 3.3 | 0.482 | 1,626 | 8,758,815 | 18.6 |
| Leukemia | Male | 3 | 6,622 | 45.3 | 31.7 | 2.1 | 0.715 | 986 | 4,390,288 | 22.5 |
| Leukemia | Female | 2 | 6,391 | 31.3 | 23.7 | 1.2 | 0.702 | 640 | 4,368,527 | 14.7 |
| Liver and Bile Duct | Total | 1 | 13,013 | 7.7 | 5.5 | 1.7 | 0.977 | 828 | 8,758,815 | 9.5 |
| Liver and Bile Duct | Male | 1 | 6,622 | 15.1 | 10.4 | 1.3 | 1.000 | 589 | 4,390,288 | 13.4 |
| Liver and Bile Duct | Female | - | 6,391 | - | - | 0.5 | 1.000 | 239 | 4,368,527 | 5.5 |
| Lung and Bronchus | Total | 14 | 13,013 | 107.6 | 73.0 | 10.7 | 0.378 | 4,873 | 8,758,815 | 55.6 |
| Lung and Bronchus | Male | 8 | 6,622 | 120.8 | 77.3 | 5.8 | 0.448 | 2,444 | 4,390,288 | 55.7 |
| Lung and Bronchus | Female | 6 | 6,391 | 93.9 | 67.3 | 5.0 | 0.753 | 2,429 | 4,368,527 | 55.6 |
| Melanoma of the Skin | Total | 8 | 13,013 | 61.5 | 47.0 | 5.7 | 0.432 | 2,934 | 8,758,815 | 33.5 |
| Melanoma of the Skin | Male | 4 | 6,622 | 60.4 | 42.7 | 3.8 | 1.000 | 1,761 | 4,390,288 | 40.1 |
| Melanoma of the Skin | Female | 4 | 6,391 | 62.6 | 52.3 | 2.1 | 0.305 | 1,173 | 4,368,527 | 26.9 |
| Myeloma | Total | 6 | 13,013 | 46.1 | 31.9 | 1.5 | $0.009 \gg$ | 702 | 8,758,815 | 8.0 |
| Myeloma | Male | 5 | 6,622 | 75.5 | 49.3 | 1.0 | 0.008 >> | 436 | 4,390,288 | 9.9 |
| Myeloma | Female | 1 | 6,391 | 15.6 | 11.4 | 0.5 | 0.830 | 266 | 4,368,527 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 4 | 13,013 | 30.7 | 22.5 | 3.9 | 1.000 | 1,936 | 8,758,815 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 2 | 6,622 | 30.2 | 21.2 | 2.4 | 1.000 | 1,127 | 4,390,288 | 25.7 |
| Non-Hodgkin Lymphoma | Female | 2 | 6,391 | 31.3 | 23.5 | 1.6 | 0.934 | 809 | 4,368,527 | 18.5 |
| Oral Cavity and Pharynx | Total | 4 | 13,013 | 30.7 | 22.8 | 2.6 | 0.523 | 1,291 | 8,758,815 | 14.7 |
| Oral Cavity and Pharynx | Male | 3 | 6,622 | 45.3 | 32.4 | 2.0 | 0.630 | 933 | 4,390,288 | 21.3 |
| Oral Cavity and Pharynx | Female | 1 | 6,391 | 15.6 | 12.1 | 0.7 | 0.986 | 358 | 4,368,527 | 8.2 |
| Ovary | Female | 2 | 6,391 | 31.3 | 24.7 | 1.0 | 0.515 | 531 | 4,368,527 | 12.2 |
| Pancreas | Total | - | 13,013 | - | - | 3.1 | 0.094 | 1,423 | 8,758,815 | 16.2 |
| Pancreas | Male | - | 6,622 | - | - | 1.8 | 0.334 | 784 | 4,390,288 | 17.9 |
| Pancreas | Female | - | 6,391 | - | - | 1.3 | 0.547 | 639 | 4,368,527 | 14.6 |
| Prostate | Male | 6 | 6,622 | 90.6 | 60.6 | 14.5 | 0.021 << | 6,411 | 4,390,288 | 146.0 |
| Stomach | Total | 1 | 13,013 | 7.7 | 5.5 | 1.0 | 1.000 | 466 | 8,758,815 | 5.3 |
| Stomach | Male | - | 6,622 | - | - | 0.7 | 1.000 | 309 | 4,390,288 | 7.0 |
| Stomach | Female | 1 | 6,391 | 15.6 | 11.8 | 0.3 | 0.526 | 157 | 4,368,527 | 3.6 |
| Testis | Male | - | 6,622 | - | - | 0.3 | 1.000 | 265 | 4,390,288 | 6.0 |
| Thyroid | Total | 4 | 13,013 | 30.7 | 28.9 | 1.9 | 0.257 | 1,216 | 8,758,815 | 13.9 |
| Thyroid | Male | 1 | 6,622 | 15.1 | 12.8 | 0.6 | 0.935 | 354 | 4,390,288 | 8.1 |
| Thyroid | Female | 3 | 6,391 | 46.9 | 46.3 | 1.3 | 0.276 | 862 | 4,368,527 | 19.7 |
| Pediatric Age 0 to 19 | Total | 1 | 3,406 | 29.4 | 30.1 | 0.6 | 0.868 | 420 | 2,457,117 | 17.1 |
| Pediatric Age 0 to 19 | Male | - | 1,748 | - | - | 0.3 | 1.000 | 223 | 1,254,762 | 17.8 |
| Pediatric Age 0 to 19 | Female | 1 | 1,658 | 60.3 | 62.3 | 0.3 | 0.463 | 197 | 1,202,355 | 16.4 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN BUTTE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Butte County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 183 | 13,094 | 1,397.6 | 944.3 | 166.8 | 0.226 | 77,247 | 8,975,621 | 860.6 |
| All Causes of Death | Male | 114 | 6,647 | 1,715.1 | 1,164.7 | 89.0 | 0.012 >> | 40,942 | 4,505,221 | 908.8 |
| All Causes of Death | Female | 69 | 6,447 | 1,070.3 | 709.9 | 78.9 | 0.287 | 36,305 | 4,470,400 | 812.1 |
| All Malignant Cancers | Total | 37 | 13,094 | 282.6 | 191.7 | 32.4 | 0.467 | 15,084 | 8,975,621 | 168.1 |
| All Malignant Cancers | Male | 23 | 6,647 | 346.0 | 225.7 | 18.4 | 0.342 | 8,153 | 4,505,221 | 181.0 |
| All Malignant Cancers | Female | 14 | 6,447 | 217.2 | 153.1 | 14.2 | 1.000 | 6,931 | 4,470,400 | 155.0 |
| Bladder | Total | 2 | 13,094 | 15.3 | 9.7 | 1.1 | 0.616 | 487 | 8,975,621 | 5.4 |
| Bladder | Male | 2 | 6,647 | 30.1 | 18.9 | 0.9 | 0.443 | 376 | 4,505,221 | 8.3 |
| Bladder | Female | - | 6,447 | - | - | 0.2 | 1.000 | 111 | 4,470,400 | 2.5 |
| Brain and Other Nervous System | Total | 1 | 13,094 | 7.6 | 5.7 | 1.0 | 1.000 | 503 | 8,975,621 | 5.6 |
| Brain and Other Nervous System | Male | 1 | 6,647 | 15.0 | 10.9 | 0.6 | 0.909 | 297 | 4,505,221 | 6.6 |
| Brain and Other Nervous System | Female | - | 6,447 | - | - | 0.4 | 1.000 | 206 | 4,470,400 | 4.6 |
| Breast | Total | 3 | 13,094 | 22.9 | 16.2 | 2.3 | 0.793 | 1,099 | 8,975,621 | 12.2 |
| Breast | Male | 1 | 6,647 | 15.0 | 9.9 | 0.0 | 0.066 | 15 | 4,505,221 | 0.3 |
| Breast | Female | 2 | 6,447 | 31.0 | 22.5 | 2.2 | 1.000 | 1,084 | 4,470,400 | 24.2 |
| Cervix | Female | - | 6,447 |  | - | 0.1 | 1.000 | 83 | 4,470,400 | 1.9 |
| Colorectal | Total | 3 | 13,094 | 22.9 | 16.0 | 2.8 | 1.000 | 1,316 | 8,975,621 | 14.7 |
| Colorectal | Male | 2 | 6,647 | 30.1 | 20.8 | 1.5 | 0.904 | 717 | 4,505,221 | 15.9 |
| Colorectal | Female | 1 | 6,447 | 15.5 | 10.8 | 1.2 | 1.000 | 599 | 4,470,400 | 13.4 |
| Corpus Uteri | Female | - | 6,447 |  | - | 0.3 | 1.000 | 173 | 4,470,400 | 3.9 |
| Esophagus | Total |  | 13,094 |  | - | 1.0 | 0.729 | 477 | 8,975,621 | 5.3 |
| Esophagus | Male | - | 6,647 | - | - | 0.9 | 0.819 | 401 | 4,505,221 | 8.9 |
| Esophagus | Female | - | 6,447 | - | - | 0.2 | 1.000 | 76 | 4,470,400 | 1.7 |
| Hodgkin Lymphoma | Total | - | 13,094 | - | - | 0.1 | 1.000 | 29 | 8,975,621 | 0.3 |
| Hodgkin Lymphoma | Male | - | 6,647 | - | - | 0.0 | 1.000 | 14 | 4,505,221 | 0.3 |
| Hodgkin Lymphoma | Female | - | 6,447 |  | - | 0.0 | 1.000 | 15 | 4,470,400 | 0.3 |
| Kidney | Total | 2 | 13,094 | 15.3 | 10.2 | 0.8 | 0.409 | 383 | 8,975,621 | 4.3 |
| Kidney | Male | 2 | 6,647 | 30.1 | 19.6 | 0.5 | 0.207 | 240 | 4,505,221 | 5.3 |
| Kidney | Female | - | 6,447 | - | - | 0.3 | 1.000 | 143 | 4,470,400 | 3.2 |
| Larynx | Total | - | 13,094 |  | - | 0.2 | 1.000 | 71 | 8,975,621 | 0.8 |
| Larynx | Male | - | 6,647 | - | - | 0.1 | 1.000 | 58 | 4,505,221 | 1.3 |
| Larynx | Female | - | 6,447 | - | - | 0.0 | 1.000 | 13 | 4,470,400 | 0.3 |
| Leukemia | Total | 2 | 13,094 | 15.3 | 10.2 | 1.4 | 0.844 | 658 | 8,975,621 | 7.3 |
| Leukemia | Male | - | 6,647 |  | - | 0.9 | 0.834 | 386 | 4,505,221 | 8.6 |
| Leukemia | Female | 2 | 6,447 | 31.0 | 21.0 | 0.6 | 0.230 | 272 | 4,470,400 | 6.1 |
| Liver and Bile Duct | Total | 2 | 13,094 | 15.3 | 10.6 | 1.3 | 0.723 | 601 | 8,975,621 | 6.7 |
| Liver and Bile Duct | Male | 2 | 6,647 | 30.1 | 19.9 | 0.9 | 0.458 | 406 | 4,505,221 | 9.0 |
| Liver and Bile Duct | Female | - | 6,447 | - | - | 0.4 | 1.000 | 195 | 4,470,400 | 4.4 |
| Lung and Bronchus | Total | 10 | 13,094 | 76.4 | 51.0 | 6.4 | 0.237 | 2,951 | 8,975,621 | 32.9 |
| Lung and Bronchus | Male | 6 | 6,647 | 90.3 | 57.6 | 3.6 | 0.308 | 1,550 | 4,505,221 | 34.4 |
| Lung and Bronchus | Female | 4 | 6,447 | 62.0 | 43.2 | 2.9 | 0.662 | 1,401 | 4,470,400 | 31.3 |
| Melanoma of the Skin | Total | 1 | 13,094 | 7.6 | 5.3 | 0.6 | 0.906 | 288 | 8,975,621 | 3.2 |
| Melanoma of the Skin | Male | - | 6,647 | - | - | 0.4 | 1.000 | 192 | 4,505,221 | 4.3 |
| Melanoma of the Skin | Female | 1 | 6,447 | 15.5 | 11.5 | 0.2 | 0.341 | 96 | 4,470,400 | 2.1 |
| Myeloma | Total | 2 | 13,094 | 15.3 | 9.9 | 0.7 | 0.338 | 329 | 8,975,621 | 3.7 |
| Myeloma | Male | 2 | 6,647 | 30.1 | 18.8 | 0.5 | 0.156 | 194 | 4,505,221 | 4.3 |
| Myeloma | Female | - | 6,447 | - | - | 0.3 | 1.000 | 135 | 4,470,400 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 2 | 13,094 | 15.3 | 10.1 | 1.2 | 0.709 | 567 | 8,975,621 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 1 | 6,647 | 15.0 | 9.9 | 0.7 | 0.996 | 306 | 4,505,221 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 1 | 6,447 | 15.5 | 10.3 | 0.6 | 0.867 | 261 | 4,470,400 | 5.8 |
| Oral Cavity and Pharynx | Total | - | 13,094 | - | - | 0.6 | 1.000 | 266 | 8,975,621 | 3.0 |
| Oral Cavity and Pharynx | Male | - | 6,647 | - | - | 0.4 | 1.000 | 187 | 4,505,221 | 4.2 |
| Oral Cavity and Pharynx | Female | - | 6,447 | - | - | 0.2 | 1.000 | 79 | 4,470,400 | 1.8 |
| Ovary | Female | 1 | 6,447 | 15.5 | 11.1 | 0.7 | 1.000 | 349 | 4,470,400 | 7.8 |
| Pancreas | Total | - | 13,094 |  | - | 2.6 | 0.154 | 1,190 | 8,975,621 | 13.3 |
| Pancreas | Male | - | 6,647 | - | - | 1.5 | 0.463 | 642 | 4,505,221 | 14.3 |
| Pancreas | Female | - | 6,447 | - | - | 1.1 | 0.655 | 548 | 4,470,400 | 12.3 |
| Prostate | Male | - | 6,647 | - | - | 2.3 | 0.210 | 949 | 4,505,221 | 21.1 |
| Stomach | Total | 1 | 13,094 | 7.6 | 5.4 | 0.4 | 0.666 | 197 | 8,975,621 | 2.2 |
| Stomach | Male | - | 6,647 | - | - | 0.3 | 1.000 | 121 | 4,505,221 | 2.7 |
| Stomach | Female | 1 | 6,447 | 15.5 | 11.3 | 0.2 | 0.279 | 76 | 4,470,400 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Butte County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 77.8\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 9.9\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% |  |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% |  |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 24.8\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 33.0\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 71.6\% |
| Meet Physical Activity Guidelines ( $2011,2013,2015,2017,2019)$ | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 17.2\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 39.5\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, 12.6\% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^11]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged 50-75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

## CAMAS COUNTY CANCPR PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 35 cases of invasive cancer were diagnosed among Camas County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Camas County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Camas <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 35 | 45,610 |
| Female Breast | 2 | 6,687 |
| Prostate | 7 | 6,417 |
| Lung \& Bronchus | 5 | 4,887 |
| Colorectal | 3 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Camas County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Camas County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Camas County was 637.6 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.9) gives an estimate of the relative burden of disease in Camas County.

The age- and sex-adjusted incidence rate of invasive cancer in Camas County, all sites combined, was 485.6 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Camas County (35) than expected (37.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 16 Camas County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Camas County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Camas <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | $\mathbf{6 0}$ | $\mathbf{7 7 , 4 3 1}$ |
| Cancer Deaths | 16 | 15,121 |
| \% of All Deaths | $26.7 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 2 | 2,961 |
| Colorectal | 1 | 1,319 |
| Pancreas | $\mathbf{0}$ | 1,190 |
| Female Breast | $\mathbf{0}$ | 1,086 |
| Prostate | 4 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Camas County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Camas County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Camas County, all sites combined, was 217.2 deaths per 100,000 persons per year during 2017-2021, compared with 168.1 for the remainder of the state. There were more cancer deaths in Camas County (16) than expected (12.4) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN CAMAS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

|  |  | Camas County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person <br> Years | Crude Rate (1) | A.A.I. <br> Rate (1,2) | Expected <br> Cases (3) | P-Value (4) | Observed Cases | Person Years | Crude Rate (1) |
| All Sites Combined | Total | 35 | 5,489 | 637.6 | 485.6 | 37.5 | 0.766 | 45,575 | 8,766,339 | 519.9 |
| All Sites Combined | Male | 19 | 2,830 | 671.4 | 455.1 | 23.1 | 0.468 | 24,270 | 4,394,080 | 552.3 |
| All Sites Combined | Female | 16 | 2,659 | 601.7 | 510.1 | 15.3 | 0.922 | 21,305 | 4,372,259 | 487.3 |
| Bladder | Total | 1 | 5,489 | 18.2 | 13.5 | 1.8 | 0.897 | 2,183 | 8,766,339 | 24.9 |
| Bladder | Male | 1 | 2,830 | 35.3 | 23.2 | 1.7 | 0.976 | 1,750 | 4,394,080 | 39.8 |
| Bladder | Female |  | 2,659 | - | - | 0.3 | 1.000 | 433 | 4,372,259 | 9.9 |
| Brain - malignant | Total |  | 5,489 |  |  | 0.5 | 1.000 | 625 | 8,766,339 | 7.1 |
| Brain - malignant | Male |  | 2,830 | - | - | 0.3 | 1.000 | 375 | 4,394,080 | 8.5 |
| Brain - malignant | Female | - | 2,659 | - |  | 0.2 | 1.000 | 250 | 4,372,259 | 5.7 |
| Brain and other CNS - non-malignant | Total | 3 | 5,489 | 54.7 | 43.5 | 1.1 | 0.206 | 1,421 | 8,766,339 | 16.2 |
| Brain and other CNS - non-malignant | Male | 2 | 2,830 | 70.7 | 53.2 | 0.4 | 0.128 | 478 | 4,394,080 | 10.9 |
| Brain and other CNS - non-malignant | Female | 1 | 2,659 | 37.6 | 32.3 | 0.7 | 0.974 | 943 | 4,372,259 | 21.6 |
| Breast | Total | 2 | 5,489 | 36.4 | 27.9 | 5.5 | 0.174 | 6,744 | 8,766,339 | 76.9 |
| Breast | Male |  | 2,830 |  |  | 0.1 | 1.000 | 59 | 4,394,080 | 1.3 |
| Breast | Female | 2 | 2,659 | 75.2 | 62.8 | 4.9 | 0.272 | 6,685 | 4,372,259 | 152.9 |
| Breast - in situ | Total | - | 5,489 | - | - | 1.0 | 0.718 | 1,239 | 8,766,339 | 14.1 |
| Breast - in situ | Male | - | 2,830 | - | - | 0.0 | 1.000 | 5 | 4,394,080 | 0.1 |
| Breast - in situ | Female |  | 2,659 | - |  | 0.9 | 0.803 | 1,234 | 4,372,259 | 28.2 |
| Cervix | Female |  | 2,659 |  |  | 0.2 | 1.000 | 304 | 4,372,259 | 7.0 |
| Colorectal | Total | 3 | 5,489 | 54.7 | 42.4 | 2.8 | 1.000 | 3,448 | 8,766,339 | 39.3 |
| Colorectal | Male | 3 | 2,830 | 106.0 | 75.2 | 1.7 | 0.498 | 1,900 | 4,394,080 | 43.2 |
| Colorectal | Female | - | 2,659 | - | - | 1.1 | 0.662 | 1,548 | 4,372,259 | 35.4 |
| Corpus Uteri | Female | 1 | 2,659 | 37.6 | 30.9 | 1.0 | 1.000 | 1,329 | 4,372,259 | 30.4 |
| Esophagus | Total |  | 5,489 |  |  | 0.4 | 1.000 | 506 | 8,766,339 | 5.8 |
| Esophagus | Male |  | 2,830 | - | - | 0.4 | 1.000 | 424 | 4,394,080 | 9.6 |
| Esophagus | Female | - | 2,659 | - | - | 0.1 | 1.000 | 82 | 4,372,259 | 1.9 |
| Hodgkin Lymphoma | Total |  | 5,489 | - | - | 0.1 | 1.000 | 210 | 8,766,339 | 2.4 |
| Hodgkin Lymphoma | Male | - | 2,830 | - | - | 0.1 | 1.000 | 118 | 4,394,080 | 2.7 |
| Hodgkin Lymphoma | Female | - | 2,659 | - |  | 0.1 | 1.000 | 92 | 4,372,259 | 2.1 |
| Kidney and Renal Pelvis | Total | 1 | 5,489 | 18.2 | 14.0 | 1.5 | 1.000 | 1,814 | 8,766,339 | 20.7 |
| Kidney and Renal Pelvis | Male | - | 2,830 | - | - | 1.1 | 0.676 | 1,182 | 4,394,080 | 26.9 |
| Kidney and Renal Pelvis | Female | 1 | 2,659 | 37.6 | 32.1 | 0.5 | 0.726 | 632 | 4,372,259 | 14.5 |
| Larynx | Total |  | 5,489 | - | - | 0.2 | 1.000 | 215 | 8,766,339 | 2.5 |
| Larynx | Male | - | 2,830 | - | - | 0.2 | 1.000 | 160 | 4,394,080 | 3.6 |
| Larynx | Female | - | 2,659 | - |  | 0.0 | 1.000 | 55 | 4,372,259 | 1.3 |
| Leukemia | Total | 2 | 5,489 | 36.4 | 28.6 | 1.3 | 0.746 | 1,629 | 8,766,339 | 18.6 |
| Leukemia | Male | 1 | 2,830 | 35.3 | 25.2 | 0.9 | 1.000 | 988 | 4,394,080 | 22.5 |
| Leukemia | Female | 1 | 2,659 | 37.6 | 32.8 | 0.4 | 0.721 | 641 | 4,372,259 | 14.7 |
| Liver and Bile Duct | Total | 2 | 5,489 | 36.4 | 26.8 | 0.7 | 0.314 | 827 | 8,766,339 | 9.4 |
| Liver and Bile Duct | Male | 1 | 2,830 | 35.3 | 23.3 | 0.6 | 0.875 | 589 | 4,394,080 | 13.4 |
| Liver and Bile Duct | Female | 1 | 2,659 | 37.6 | 31.4 | 0.2 | 0.318 | 238 | 4,372,259 | 5.4 |
| Lung and Bronchus | Total | 5 | 5,489 | 91.1 | 67.1 | 4.2 | 0.802 | 4,882 | 8,766,339 | 55.7 |
| Lung and Bronchus | Male | 1 | 2,830 | 35.3 | 22.9 | 2.4 | 0.602 | 2,451 | 4,394,080 | 55.8 |
| Lung and Bronchus | Female | 4 | 2,659 | 150.4 | 126.3 | 1.8 | 0.205 | 2,431 | 4,372,259 | 55.6 |
| Melanoma of the Skin | Total | 1 | 5,489 | 18.2 | 14.3 | 2.3 | 0.642 | 2,941 | 8,766,339 | 33.5 |
| Melanoma of the Skin | Male | 1 | 2,830 | 35.3 | 24.8 | 1.6 | 1.000 | 1,764 | 4,394,080 | 40.1 |
| Melanoma of the Skin | Female | - | 2,659 | - | - | 0.8 | 0.880 | 1,177 | 4,372,259 | 26.9 |
| Myeloma | Total |  | 5,489 | - | - | 0.6 | 1.000 | 708 | 8,766,339 | 8.1 |
| Myeloma | Male | - | 2,830 | - | - | 0.4 | 1.000 | 441 | 4,394,080 | 10.0 |
| Myeloma | Female | - | 2,659 | - | - | 0.2 | 1.000 | 267 | 4,372,259 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 1 | 5,489 | 18.2 | 14.0 | 1.6 | 1.000 | 1,939 | 8,766,339 | 22.1 |
| Non-Hodgkin Lymphoma | Male | - | 2,830 | - | - | 1.1 | 0.697 | 1,129 | 4,394,080 | 25.7 |
| Non-Hodgkin Lymphoma | Female | 1 | 2,659 | 37.6 | 31.9 | 0.6 | 0.880 | 810 | 4,372,259 | 18.5 |
| Oral Cavity and Pharynx | Total | 2 | 5,489 | 36.4 | 27.2 | 1.1 | 0.590 | 1,293 | 8,766,339 | 14.7 |
| Oral Cavity and Pharynx | Male | 1 | 2,830 | 35.3 | 24.0 | 0.9 | 1.000 | 935 | 4,394,080 | 21.3 |
| Oral Cavity and Pharynx | Female | 1 | 2,659 | 37.6 | 31.2 | 0.3 | 0.462 | 358 | 4,372,259 | 8.2 |
| Ovary | Female | 1 | 2,659 | 37.6 | 31.8 | 0.4 | 0.636 | 532 | 4,372,259 | 12.2 |
| Pancreas | Total |  | 5,489 | - | - | 1.2 | 0.606 | 1,423 | 8,766,339 | 16.2 |
| Pancreas | Male | - | 2,830 | - | - | 0.8 | 0.939 | 784 | 4,394,080 | 17.8 |
| Pancreas | Female | - | 2,659 | - | - | 0.5 | 1.000 | 639 | 4,372,259 | 14.6 |
| Prostate | Male | 7 | 2,830 | 247.3 | 158.6 | 6.4 | 0.927 | 6,410 | 4,394,080 | 145.9 |
| Stomach | Total |  | 5,489 |  |  | 0.4 | 1.000 | 467 | 8,766,339 | 5.3 |
| Stomach | Male | - | 2,830 | - | - | 0.3 | 1.000 | 309 | 4,394,080 | 7.0 |
| Stomach | Female | - | 2,659 | - | - | 0.1 | 1.000 | 158 | 4,372,259 | 3.6 |
| Testis | Male | - | 2,830 | - | - | 0.1 | 1.000 | 265 | 4,394,080 | 6.0 |
| Thyroid | Total | 2 | 5,489 | 36.4 | 32.7 | 0.9 | 0.419 | 1,218 | 8,766,339 | 13.9 |
| Thyroid | Male | - | 2,830 | - | - | 0.3 | 1.000 | 355 | 4,394,080 | 8.1 |
| Thyroid | Female | 2 | 2,659 | 75.2 | 71.7 | 0.6 | 0.212 | 863 | 4,372,259 | 19.7 |
| Pediatric Age 0 to 19 | Total |  | 1,357 |  |  | 0.2 | 1.000 | 421 | 2,459,166 | 17.1 |
| Pediatric Age 0 to 19 | Male |  | 642 | - | - | 0.1 | 1.000 | 223 | 1,255,868 | 17.8 |
| Pediatric Age 0 to 19 | Female | - | 715 | - | - | 0.1 | 1.000 | 198 | 1,203,298 | 16.5 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ). Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN CAMAS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Camas County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 60 | 5,550 | 1,081.1 | 843.0 | 61.3 | 0.935 | 77,370 | 8,983,165 | 861.3 |
| All Causes of Death | Male | 40 | 2,861 | 1,398.1 | 1,035.5 | 35.1 | 0.454 | 41,016 | 4,509,007 | 909.6 |
| All Causes of Death | Female | 20 | 2,689 | 743.8 | 598.8 | 27.1 | 0.194 | 36,354 | 4,474,158 | 812.5 |
| All Malignant Cancers | Total | 16 | 5,550 | 288.3 | 217.2 | 12.4 | 0.370 | 15,105 | 8,983,165 | 168.1 |
| All Malignant Cancers | Male | 12 | 2,861 | 419.4 | 290.3 | 7.5 | 0.157 | 8,164 | 4,509,007 | 181.1 |
| All Malignant Cancers | Female | 4 | 2,689 | 148.8 | 121.8 | 5.1 | 0.849 | 6,941 | 4,474,158 | 155.1 |
| Bladder | Total | 2 | 5,550 | 36.0 | 27.3 | 0.4 | 0.121 | 487 | 8,983,165 | 5.4 |
| Bladder | Male | 2 | 2,861 | 69.9 | 50.6 | 0.3 | 0.087 | 376 | 4,509,007 | 8.3 |
| Bladder | Female | - | 2,689 | - | - | 0.1 | 1.000 | 111 | 4,474,158 | 2.5 |
| Brain and Other Nervous System | Total |  | 5,550 |  | - | 0.4 | 1.000 | 504 | 8,983,165 | 5.6 |
| Brain and Other Nervous System | Male | - | 2,861 | - | - | 0.3 | 1.000 | 298 | 4,509,007 | 6.6 |
| Brain and Other Nervous System | Female | - | 2,689 | - | - | 0.1 | 1.000 | 206 | 4,474,158 | 4.6 |
| Breast | Total | - | 5,550 |  | - | 0.9 | 0.814 | 1,102 | 8,983,165 | 12.3 |
| Breast | Male | - | 2,861 | - | - | 0.0 | 1.000 | 16 | 4,509,007 | 0.4 |
| Breast | Female | - | 2,689 |  | - | 0.8 | 0.895 | 1,086 | 4,474,158 | 24.3 |
| Cervix | Female | - | 2,689 |  | - | 0.1 | 1.000 | 83 | 4,474,158 | 1.9 |
| Colorectal | Total | 1 | 5,550 | 18.0 | 13.8 | 1.1 | 1.000 | 1,318 | 8,983,165 | 14.7 |
| Colorectal | Male | 1 | 2,861 | 35.0 | 24.7 | 0.6 | 0.951 | 718 | 4,509,007 | 15.9 |
| Colorectal | Female | - | 2,689 | - | - | 0.4 | 1.000 | 600 | 4,474,158 | 13.4 |
| Corpus Uteri | Female | - | 2,689 |  | - | 0.1 | 1.000 | 173 | 4,474,158 | 3.9 |
| Esophagus | Total |  | 5,550 |  | - | 0.4 | 1.000 | 477 | 8,983,165 | 5.3 |
| Esophagus | Male | - | 2,861 | - | - | 0.4 | 1.000 | 401 | 4,509,007 | 8.9 |
| Esophagus | Female | - | 2,689 | - | - | 0.1 | 1.000 | 76 | 4,474,158 | 1.7 |
| Hodgkin Lymphoma | Total | - | 5,550 | - | - | 0.0 | 1.000 | 29 | 8,983,165 | 0.3 |
| Hodgkin Lymphoma | Male | - | 2,861 | - | - | 0.0 | 1.000 | 14 | 4,509,007 | 0.3 |
| Hodgkin Lymphoma | Female | - | 2,689 |  | - | 0.0 | 1.000 | 15 | 4,474,158 | 0.3 |
| Kidney | Total |  | 5,550 |  | - | 0.3 | 1.000 | 385 | 8,983,165 | 4.3 |
| Kidney | Male | - | 2,861 | - | - | 0.2 | 1.000 | 242 | 4,509,007 | 5.4 |
| Kidney | Female | - | 2,689 | - | - | 0.1 | 1.000 | 143 | 4,474,158 | 3.2 |
| Larynx | Total | 1 | 5,550 | 18.0 | 13.9 | 0.1 | 0.109 | 70 | 8,983,165 | 0.8 |
| Larynx | Male | 1 | 2,861 | 35.0 | 25.2 | 0.1 | 0.098 | 57 | 4,509,007 | 1.3 |
| Larynx | Female | - | 2,689 | - | - | 0.0 | 1.000 | 13 | 4,474,158 | 0.3 |
| Leukemia | Total | 1 | 5,550 | 18.0 | 14.0 | 0.5 | 0.816 | 659 | 8,983,165 | 7.3 |
| Leukemia | Male | - | 2,861 | - | - | 0.3 | 1.000 | 386 | 4,509,007 | 8.6 |
| Leukemia | Female | 1 | 2,689 | 37.2 | 30.9 | 0.2 | 0.359 | 273 | 4,474,158 | 6.1 |
| Liver and Bile Duct | Total | 2 | 5,550 | 36.0 | 26.4 | 0.5 | 0.185 | 601 | 8,983,165 | 6.7 |
| Liver and Bile Duct | Male | 1 | 2,861 | 35.0 | 23.1 | 0.4 | 0.648 | 407 | 4,509,007 | 9.0 |
| Liver and Bile Duct | Female | 1 | 2,689 | 37.2 | 30.3 | 0.1 | 0.267 | 194 | 4,474,158 | 4.3 |
| Lung and Bronchus | Total | 2 | 5,550 | 36.0 | 26.7 | 2.5 | 1.000 | 2,959 | 8,983,165 | 32.9 |
| Lung and Bronchus | Male | 1 | 2,861 | 35.0 | 23.2 | 1.5 | 1.000 | 1,555 | 4,509,007 | 34.5 |
| Lung and Bronchus | Female | 1 | 2,689 | 37.2 | 30.7 | 1.0 | 1.000 | 1,404 | 4,474,158 | 31.4 |
| Melanoma of the Skin | Total | - | 5,550 |  | - | 0.2 | 1.000 | 289 | 8,983,165 | 3.2 |
| Melanoma of the Skin | Male | - | 2,861 | - | - | 0.2 | 1.000 | 192 | 4,509,007 | 4.3 |
| Melanoma of the Skin | Female | - | 2,689 | - | - | 0.1 | 1.000 | 97 | 4,474,158 | 2.2 |
| Myeloma | Total | - | 5,550 |  | - | 0.3 | 1.000 | 331 | 8,983,165 | 3.7 |
| Myeloma | Male | - | 2,861 | - | - | 0.2 | 1.000 | 196 | 4,509,007 | 4.3 |
| Myeloma | Female | - | 2,689 | - | - | 0.1 | 1.000 | 135 | 4,474,158 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 1 | 5,550 | 18.0 | 14.0 | 0.5 | 0.729 | 568 | 8,983,165 | 6.3 |
| Non-Hodgkin Lymphoma | Male | - | 2,861 | - | - | 0.3 | 1.000 | 307 | 4,509,007 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 1 | 2,689 | 37.2 | 31.1 | 0.2 | 0.342 | 261 | 4,474,158 | 5.8 |
| Oral Cavity and Pharynx | Total | - | 5,550 | - | - | 0.2 | 1.000 | 266 | 8,983,165 | 3.0 |
| Oral Cavity and Pharynx | Male | - | 2,861 | - | - | 0.2 | 1.000 | 187 | 4,509,007 | 4.1 |
| Oral Cavity and Pharynx | Female | - | 2,689 | - | - | 0.1 | 1.000 | 79 | 4,474,158 | 1.8 |
| Ovary | Female | - | 2,689 | - | - | 0.3 | 1.000 | 350 | 4,474,158 | 7.8 |
| Pancreas | Total | - | 5,550 |  | - | 1.0 | 0.738 | 1,190 | 8,983,165 | 13.2 |
| Pancreas | Male | - | 2,861 | - | - | 0.6 | 1.000 | 642 | 4,509,007 | 14.2 |
| Pancreas | Female | - | 2,689 | - | - | 0.4 | 1.000 | 548 | 4,474,158 | 12.2 |
| Prostate | Male | 4 | 2,861 | 139.8 | 99.9 | 0.8 | 0.021 >> | 945 | 4,509,007 | 21.0 |
| Stomach | Total |  | 5,550 |  |  | 0.2 | 1.000 | 198 | 8,983,165 | 2.2 |
| Stomach | Male | - | 2,861 | - | - | 0.1 | 1.000 | 121 | 4,509,007 | 2.7 |
| Stomach | Female | - | 2,689 | - | - | 0.1 | 1.000 | 77 | 4,474,158 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Camas County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% |  |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 14.0\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% |  |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% |  |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | . |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% |  |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 67.0\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | . |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | . |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^12]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and 25.4\% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# CANYON COUNTY CANCPR PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 5,395 cases of invasive cancer were diagnosed among Canyon County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Canyon County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Canyon <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 5,395 | 45,610 |
| Female Breast | 825 | 6,687 |
| Prostate | 721 | 6,417 |
| Lung \& Bronchus | 593 | 4,887 |
| Colorectal | 413 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Canyon County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Canyon County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Canyon County was 481.9 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (525.5) gives an estimate of the relative burden of disease in Canyon County.

The age- and sex-adjusted incidence rate of invasive cancer in Canyon County, all sites combined, was 548.8 cases per 100,000 persons per year during 2016-2020. There were statistically significantly more cases of cancer in Canyon County $(5,395)$ than expected $(5,166.5)$ based upon rates in the remainder of the state $(p=.002)$.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 1,723 Canyon County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Canyon County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Canyon <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 8,896 | 77,431 |
| Cancer Deaths | 1,723 | 15,121 |
| \% of All Deaths | $19.4 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 341 | 2,961 |
| Colorectal | 165 | 1,319 |
| Pancreas | 130 | 1,190 |
| Female Breast | 137 | 1,086 |
| Prostate | 90 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Canyon County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Canyon County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Canyon County, all sites combined, was 175.3 deaths per 100,000 persons per year during 2017-2021, compared with 170.9 for the remainder of the state. There were more cancer deaths in Canyon County $(1,723)$ than expected $(1,680.1)$ based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

| Cancer Site/Type | Sex | Canyon County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 5,395 | 1,119,451 | 481.9 | 548.8 | 5,166.5 | $0.002 \gg$ | 40,215 | 7,652,377 | 525.5 |
| All Sites Combined | Male | 2,808 | 555,176 | 505.8 | 585.9 | 2,679.6 | $0.014 \gg$ | 21,481 | 3,841,734 | 559.1 |
| All Sites Combined | Female | 2,587 | 564,275 | 458.5 | 514.2 | 2,473.4 | 0.024 >> | 18,734 | 3,810,643 | 491.6 |
| Bladder | Total | 256 | 1,119,451 | 22.9 | 26.7 | 241.1 | 0.354 | 1,928 | 7,652,377 | 25.2 |
| Bladder | Male | 208 | 555,176 | 37.5 | 44.4 | 188.3 | 0.165 | 1,543 | 3,841,734 | 40.2 |
| Bladder | Female | 48 | 564,275 | 8.5 | 9.9 | 49.2 | 0.940 | 385 | 3,810,643 | 10.1 |
| Brain - malignant | Total | 76 | 1,119,451 | 6.8 | 7.5 | 73.2 | 0.771 | 549 | 7,652,377 | 7.2 |
| Brain - malignant | Male | 47 | 555,176 | 8.5 | 9.4 | 42.8 | 0.564 | 328 | 3,841,734 | 8.5 |
| Brain - malignant | Female | 29 | 564,275 | 5.1 | 5.6 | 29.9 | 0.961 | 221 | 3,810,643 | 5.8 |
| Brain and other CNS - non-malignant | Total | 193 | 1,119,451 | 17.2 | 19.1 | 162.2 | 0.020 >> | 1,231 | 7,652,377 | 16.1 |
| Brain and other CNS - non-malignant | Male | 77 | 555,176 | 13.9 | 15.3 | 52.7 | 0.002 >> | 403 | 3,841,734 | 10.5 |
| Brain and other CNS - non-malignant | Female | 116 | 564,275 | 20.6 | 22.8 | 110.6 | 0.630 | 828 | 3,810,643 | 21.7 |
| Breast | Total | 827 | 1,119,451 | 73.9 | 83.0 | 771.0 | 0.048 >> | 5,919 | 7,652,377 | 77.3 |
| Breast | Male | 2 | 555,176 | 0.4 | 0.4 | 7.0 | 0.057 | 57 | 3,841,734 | 1.5 |
| Breast | Female | 825 | 564,275 | 146.2 | 163.0 | 778.4 | 0.101 | 5,862 | 3,810,643 | 153.8 |
| Breast - in situ | Total | 150 | 1,119,451 | 13.4 | 14.9 | 143.2 | 0.591 | 1,089 | 7,652,377 | 14.2 |
| Breast - in situ | Male | - | 555,176 | - | - | 0.6 | 1.000 | 5 | 3,841,734 | 0.1 |
| Breast - in situ | Female | 150 | 564,275 | 26.6 | 29.4 | 145.2 | 0.714 | 1,084 | 3,810,643 | 28.4 |
| Cervix | Female | 54 | 564,275 | 9.6 | 9.9 | 35.8 | 0.005 >> | 250 | 3,810,643 | 6.6 |
| Colorectal | Total | 413 | 1,119,451 | 36.9 | 42.0 | 390.4 | 0.265 | 3,038 | 7,652,377 | 39.7 |
| Colorectal | Male | 230 | 555,176 | 41.4 | 47.5 | 210.9 | 0.203 | 1,673 | 3,841,734 | 43.5 |
| Colorectal | Female | 183 | 564,275 | 32.4 | 36.7 | 178.6 | 0.759 | 1,365 | 3,810,643 | 35.8 |
| Corpus Uteri | Female | 166 | 564,275 | 29.4 | 33.1 | 153.2 | 0.318 | 1,164 | 3,810,643 | 30.5 |
| Esophagus | Total | 58 | 1,119,451 | 5.2 | 6.0 | 56.5 | 0.877 | 448 | 7,652,377 | 5.9 |
| Esophagus | Male | 47 | 555,176 | 8.5 | 9.9 | 46.5 | 0.982 | 377 | 3,841,734 | 9.8 |
| Esophagus | Female | 11 | 564,275 | 1.9 | 2.3 | 9.1 | 0.607 | 71 | 3,810,643 | 1.9 |
| Hodgkin Lymphoma | Total | 27 | 1,119,451 | 2.4 | 2.5 | 25.9 | 0.873 | 183 | 7,652,377 | 2.4 |
| Hodgkin Lymphoma | Male | 13 | 555,176 | 2.3 | 2.5 | 14.4 | 0.841 | 105 | 3,841,734 | 2.7 |
| Hodgkin Lymphoma | Female | 14 | 564,275 | 2.5 | 2.5 | 11.3 | 0.503 | 78 | 3,810,643 | 2.0 |
| Kidney and Renal Pelvis | Total | 241 | 1,119,451 | 21.5 | 24.4 | 203.5 | 0.011 >> | 1,574 | 7,652,377 | 20.6 |
| Kidney and Renal Pelvis | Male | 145 | 555,176 | 26.1 | 29.8 | 131.4 | 0.254 | 1,037 | 3,841,734 | 27.0 |
| Kidney and Renal Pelvis | Female | 96 | 564,275 | 17.0 | 19.1 | 70.8 | 0.005 >> | 537 | 3,810,643 | 14.1 |
| Larynx | Total | 31 | 1,119,451 | 2.8 | 3.2 | 23.1 | 0.134 | 184 | 7,652,377 | 2.4 |
| Larynx | Male | 24 | 555,176 | 4.3 | 5.1 | 16.6 | 0.105 | 136 | 3,841,734 | 3.5 |
| Larynx | Female | 7 | 564,275 | 1.2 | 1.4 | 6.2 | 0.860 | 48 | 3,810,643 | 1.3 |
| Leukemia | Total | 193 | 1,119,451 | 17.2 | 19.4 | 186.6 | 0.658 | 1,438 | 7,652,377 | 18.8 |
| Leukemia | Male | 112 | 555,176 | 20.2 | 22.9 | 111.7 | 1.000 | 877 | 3,841,734 | 22.8 |
| Leukemia | Female | 81 | 564,275 | 14.4 | 16.1 | 74.0 | 0.443 | 561 | 3,810,643 | 14.7 |
| Liver and Bile Duct | Total | 107 | 1,119,451 | 9.6 | 11.0 | 91.7 | 0.128 | 722 | 7,652,377 | 9.4 |
| Liver and Bile Duct | Male | 77 | 555,176 | 13.9 | 16.2 | 63.6 | 0.114 | 513 | 3,841,734 | 13.4 |
| Liver and Bile Duct | Female | 30 | 564,275 | 5.3 | 6.0 | 27.2 | 0.642 | 209 | 3,810,643 | 5.5 |
| Lung and Bronchus | Total | 593 | 1,119,451 | 53.0 | 61.8 | 538.4 | 0.021 >> | 4,294 | 7,652,377 | 56.1 |
| Lung and Bronchus | Male | 308 | 555,176 | 55.5 | 65.5 | 262.3 | $0.006 \gg$ | 2,144 | 3,841,734 | 55.8 |
| Lung and Bronchus | Female | 285 | 564,275 | 50.5 | 58.4 | 275.3 | 0.576 | 2,150 | 3,810,643 | 56.4 |
| Melanoma of the Skin | Total | 282 | 1,119,451 | 25.2 | 28.3 | 346.7 | 0.000 << | 2,660 | 7,652,377 | 34.8 |
| Melanoma of the Skin | Male | 167 | 555,176 | 30.1 | 34.5 | 201.6 | 0.014 << | 1,598 | 3,841,734 | 41.6 |
| Melanoma of the Skin | Female | 115 | 564,275 | 20.4 | 22.3 | 143.5 | 0.016 << | 1,062 | 3,810,643 | 27.9 |
| Myeloma | Total | 85 | 1,119,451 | 7.6 | 8.8 | 78.6 | 0.499 | 623 | 7,652,377 | 8.1 |
| Myeloma | Male | 43 | 555,176 | 7.7 | 9.1 | 49.2 | 0.423 | 398 | 3,841,734 | 10.4 |
| Myeloma | Female | 42 | 564,275 | 7.4 | 8.6 | 28.9 | 0.026 >> | 225 | 3,810,643 | 5.9 |
| Non-Hodgkin Lymphoma | Total | 232 | 1,119,451 | 20.7 | 23.6 | 219.7 | 0.424 | 1,708 | 7,652,377 | 22.3 |
| Non-Hodgkin Lymphoma | Male | 139 | 555,176 | 25.0 | 28.6 | 125.1 | 0.233 | 990 | 3,841,734 | 25.8 |
| Non-Hodgkin Lymphoma | Female | 93 | 564,275 | 16.5 | 18.7 | 93.7 | 1.000 | 718 | 3,810,643 | 18.8 |
| Oral Cavity and Pharynx | Total | 142 | 1,119,451 | 12.7 | 14.5 | 147.4 | 0.694 | 1,153 | 7,652,377 | 15.1 |
| Oral Cavity and Pharynx | Male | 108 | 555,176 | 19.5 | 22.5 | 103.5 | 0.683 | 828 | 3,841,734 | 21.6 |
| Oral Cavity and Pharynx | Female | 34 | 564,275 | 6.0 | 6.8 | 42.6 | 0.210 | 325 | 3,810,643 | 8.5 |
| Ovary | Female | 68 | 564,275 | 12.1 | 13.5 | 61.5 | 0.439 | 465 | 3,810,643 | 12.2 |
| Pancreas | Total | 157 | 1,119,451 | 14.0 | 16.3 | 159.5 | 0.882 | 1,266 | 7,652,377 | 16.5 |
| Pancreas | Male | 84 | 555,176 | 15.1 | 17.7 | 86.3 | 0.858 | 700 | 3,841,734 | 18.2 |
| Pancreas | Female | 73 | 564,275 | 12.9 | 14.9 | 72.7 | 1.000 | 566 | 3,810,643 | 14.9 |
| Prostate | Male | 721 | 555,176 | 129.9 | 152.5 | 701.2 | 0.464 | 5,696 | 3,841,734 | 148.3 |
| Stomach | Total | 66 | 1,119,451 | 5.9 | 6.8 | 50.9 | 0.048 >> | 401 | 7,652,377 | 5.2 |
| Stomach | Male | 40 | 555,176 | 7.2 | 8.4 | 33.3 | 0.287 | 269 | 3,841,734 | 7.0 |
| Stomach | Female | 26 | 564,275 | 4.6 | 5.3 | 17.2 | 0.055 | 132 | 3,810,643 | 3.5 |
| Testis | Male | 32 | 555,176 | 5.8 | 5.8 | 33.4 | 0.899 | 233 | 3,841,734 | 6.1 |
| Thyroid | Total | 113 | 1,119,451 | 10.1 | 10.7 | 153.4 | 0.001 << | 1,107 | 7,652,377 | 14.5 |
| Thyroid | Male | 27 | 555,176 | 4.9 | 5.3 | 43.8 | $0.009 \ll$ | 328 | 3,841,734 | 8.5 |
| Thyroid | Female | 86 | 564,275 | 15.2 | 15.9 | 110.9 | 0.017 << | 779 | 3,810,643 | 20.4 |
| Pediatric Age 0 to 19 | Total | 50 | 348,816 | 14.3 | 14.4 | 61.0 | 0.171 | 371 | 2,111,707 | 17.6 |
| Pediatric Age 0 to 19 | Male | 30 | 178,131 | 16.8 | 16.9 | 31.8 | 0.834 | 193 | 1,078,379 | 17.9 |
| Pediatric Age 0 to 19 | Female | 20 | 170,685 | 11.7 | 11.8 | 29.2 | 0.095 | 178 | 1,033,328 | 17.2 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ )

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN CANYON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Canyon County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 8,896 | 1,150,993 | 772.9 | 906.7 | 8,579.3 | 0.001 >> | 68,534 | 7,837,722 | 874.4 |
| All Causes of Death | Male | 4,752 | 571,865 | 831.0 | 973.7 | 4,496.9 | 0.000 >> | 36,304 | 3,940,003 | 921.4 |
| All Causes of Death | Female | 4,144 | 579,128 | 715.6 | 844.6 | 4,057.2 | 0.176 | 32,230 | 3,897,719 | 826.9 |
| All Malignant Cancers | Total | 1,723 | 1,150,993 | 149.7 | 175.3 | 1,680.1 | 0.301 | 13,398 | 7,837,722 | 170.9 |
| All Malignant Cancers | Male | 922 | 571,865 | 161.2 | 191.0 | 888.9 | 0.275 | 7,254 | 3,940,003 | 184.1 |
| All Malignant Cancers | Female | 801 | 579,128 | 138.3 | 160.6 | 786.2 | 0.608 | 6,144 | 3,897,719 | 157.6 |
| Bladder | Total | 37 | 1,150,993 | 3.2 | 3.9 | 55.3 | 0.012 << | 452 | 7,837,722 | 5.8 |
| Bladder | Male | 29 | 571,865 | 5.1 | 6.2 | 41.8 | 0.048 << | 349 | 3,940,003 | 8.9 |
| Bladder | Female | 8 | 579,128 | 1.4 | 1.6 | 12.9 | 0.207 | 103 | 3,897,719 | 2.6 |
| Brain and Other Nervous System | Total | 56 | 1,150,993 | 4.9 | 5.5 | 58.3 | 0.832 | 448 | 7,837,722 | 5.7 |
| Brain and Other Nervous System | Male | 31 | 571,865 | 5.4 | 6.2 | 34.0 | 0.689 | 267 | 3,940,003 | 6.8 |
| Brain and Other Nervous System | Female | 25 | 579,128 | 4.3 | 4.8 | 24.0 | 0.895 | 181 | 3,897,719 | 4.6 |
| Breast | Total | 137 | 1,150,993 | 11.9 | 13.8 | 122.2 | 0.200 | 965 | 7,837,722 | 12.3 |
| Breast | Male |  | 571,865 |  |  | 2.0 | 0.282 | 16 | 3,940,003 | 0.4 |
| Breast | Female | 137 | 579,128 | 23.7 | 27.2 | 122.4 | 0.207 | 949 | 3,897,719 | 24.3 |
| Cervix | Female | 16 | 579,128 | 2.8 | 3.0 | 9.3 | 0.057 | 67 | 3,897,719 | 1.7 |
| Colorectal | Total | 165 | 1,150,993 | 14.3 | 16.7 | 145.8 | 0.126 | 1,154 | 7,837,722 | 14.7 |
| Colorectal | Male | 88 | 571,865 | 15.4 | 17.9 | 78.6 | 0.317 | 631 | 3,940,003 | 16.0 |
| Colorectal | Female | 77 | 579,128 | 13.3 | 15.5 | 66.8 | 0.237 | 523 | 3,897,719 | 13.4 |
| Corpus Uteri | Female | 21 | 579,128 | 3.6 | 4.2 | 19.5 | 0.799 | 152 | 3,897,719 | 3.9 |
| Esophagus | Total | 67 | 1,150,993 | 5.8 | 6.8 | 51.6 | 0.045 >> | 410 | 7,837,722 | 5.2 |
| Esophagus | Male | 55 | 571,865 | 9.6 | 11.3 | 42.7 | 0.078 | 346 | 3,940,003 | 8.8 |
| Esophagus | Female | 12 | 579,128 | 2.1 | 2.4 | 8.1 | 0.243 | 64 | 3,897,719 | 1.6 |
| Hodgkin Lymphoma | Total | 7 | 1,150,993 | 0.6 | 0.7 | 2.9 | 0.057 | 22 | 7,837,722 | 0.3 |
| Hodgkin Lymphoma | Male | 3 | 571,865 | 0.5 | 0.6 | 1.4 | 0.347 | 11 | 3,940,003 | 0.3 |
| Hodgkin Lymphoma | Female | 4 | 579,128 | 0.7 | 0.8 | 1.5 | 0.120 | 11 | 3,897,719 | 0.3 |
| Kidney | Total | 56 | 1,150,993 | 4.9 | 5.7 | 40.9 | 0.028 >> | 329 | 7,837,722 | 4.2 |
| Kidney | Male | 32 | 571,865 | 5.6 | 6.6 | 25.7 | 0.258 | 210 | 3,940,003 | 5.3 |
| Kidney | Female | 24 | 579,128 | 4.1 | 4.9 | 14.9 | 0.036 >> | 119 | 3,897,719 | 3.1 |
| Larynx | Total | 14 | 1,150,993 | 1.2 | 1.4 | 7.1 | 0.028 >> | 57 | 7,837,722 | 0.7 |
| Larynx | Male | 12 | 571,865 | 2.1 | 2.5 | 5.6 | 0.024 >> | 46 | 3,940,003 | 1.2 |
| Larynx | Female | 2 | 579,128 | 0.3 | 0.4 | 1.4 | 0.840 | 11 | 3,897,719 | 0.3 |
| Leukemia | Total | 74 | 1,150,993 | 6.4 | 7.5 | 73.4 | 0.977 | 586 | 7,837,722 | 7.5 |
| Leukemia | Male | 51 | 571,865 | 8.9 | 10.5 | 41.3 | 0.160 | 335 | 3,940,003 | 8.5 |
| Leukemia | Female | 23 | 579,128 | 4.0 | 4.7 | 31.8 | 0.132 | 251 | 3,897,719 | 6.4 |
| Liver and Bile Duct | Total | 67 | 1,150,993 | 5.8 | 6.8 | 67.6 | 1.000 | 536 | 7,837,722 | 6.8 |
| Liver and Bile Duct | Male | 46 | 571,865 | 8.0 | 9.5 | 44.6 | 0.870 | 362 | 3,940,003 | 9.2 |
| Liver and Bile Duct | Female | 21 | 579,128 | 3.6 | 4.2 | 22.4 | 0.877 | 174 | 3,897,719 | 4.5 |
| Lung and Bronchus | Total | 341 | 1,150,993 | 29.6 | 34.8 | 327.1 | 0.456 | 2,620 | 7,837,722 | 33.4 |
| Lung and Bronchus | Male | 197 | 571,865 | 34.4 | 40.9 | 166.0 | 0.021 >> | 1,359 | 3,940,003 | 34.5 |
| Lung and Bronchus | Female | 144 | 579,128 | 24.9 | 29.1 | 160.4 | 0.207 | 1,261 | 3,897,719 | 32.4 |
| Melanoma of the Skin | Total | 29 | 1,150,993 | 2.5 | 2.9 | 32.9 | 0.570 | 260 | 7,837,722 | 3.3 |
| Melanoma of the Skin | Male | 22 | 571,865 | 3.8 | 4.5 | 20.9 | 0.864 | 170 | 3,940,003 | 4.3 |
| Melanoma of the Skin | Female | 7 | 579,128 | 1.2 | 1.4 | 11.8 | 0.202 | 90 | 3,897,719 | 2.3 |
| Myeloma | Total | 34 | 1,150,993 | 3.0 | 3.5 | 36.8 | 0.723 | 297 | 7,837,722 | 3.8 |
| Myeloma | Male | 18 | 571,865 | 3.1 | 3.8 | 21.5 | 0.527 | 178 | 3,940,003 | 4.5 |
| Myeloma | Female | 16 | 579,128 | 2.8 | 3.2 | 15.1 | 0.877 | 119 | 3,897,719 | 3.1 |
| Non-Hodgkin Lymphoma | Total | 65 | 1,150,993 | 5.6 | 6.7 | 62.7 | 0.800 | 504 | 7,837,722 | 6.4 |
| Non-Hodgkin Lymphoma | Male | 34 | 571,865 | 5.9 | 7.0 | 33.5 | 0.981 | 273 | 3,940,003 | 6.9 |
| Non-Hodgkin Lymphoma | Female | 31 | 579,128 | 5.4 | 6.4 | 28.9 | 0.748 | 231 | 3,897,719 | 5.9 |
| Oral Cavity and Pharynx | Total | 24 | 1,150,993 | 2.1 | 2.4 | 30.5 | 0.273 | 242 | 7,837,722 | 3.1 |
| Oral Cavity and Pharynx | Male | 13 | 571,865 | 2.3 | 2.7 | 21.6 | 0.068 | 174 | 3,940,003 | 4.4 |
| Oral Cavity and Pharynx | Female | 11 | 579,128 | 1.9 | 2.2 | 8.7 | 0.507 | 68 | 3,897,719 | 1.7 |
| Ovary | Female | 41 | 579,128 | 7.1 | 8.2 | 39.7 | 0.877 | 309 | 3,897,719 | 7.9 |
| Pancreas | Total | 130 | 1,150,993 | 11.3 | 13.2 | 133.2 | 0.824 | 1,060 | 7,837,722 | 13.5 |
| Pancreas | Male | 67 | 571,865 | 11.7 | 13.8 | 70.8 | 0.708 | 575 | 3,940,003 | 14.6 |
| Pancreas | Female | 63 | 579,128 | 10.9 | 12.6 | 62.1 | 0.944 | 485 | 3,897,719 | 12.4 |
| Prostate | Male | 90 | 571,865 | 15.7 | 19.2 | 102.4 | 0.236 | 859 | 3,940,003 | 21.8 |
| Stomach | Total | 35 | 1,150,993 | 3.0 | 3.5 | 20.7 | $0.005 \gg$ | 163 | 7,837,722 | 2.1 |
| Stomach | Male | 19 | 571,865 | 3.3 | 3.9 | 12.7 | 0.116 | 102 | 3,940,003 | 2.6 |
| Stomach | Female | 16 | 579,128 | 2.8 | 3.2 | 7.9 | 0.014 >> | 61 | 3,897,719 | 1.6 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Canyon County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 77.3\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 14.5\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 69.6\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% | 72.2\% |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 71.5\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 22.7\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 28.5\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 75.2\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 20.7\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 17.0\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, 12.6\% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^13]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked 49 ${ }^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# CARIBOU COUNTY CANCPR PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 199 cases of invasive cancer were diagnosed among Caribou County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Caribou County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Caribou <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 199 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 28 | 6,687 |
| Prostate | 16 | 6,417 |
| Lung \& Bronchus | 11 | 4,887 |
| Colorectal | 3,451 |  |

Table 3 (Cancer Incidence 2016-2020, Comparison between Caribou County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Caribou County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Caribou County was 566.3 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.8) gives an estimate of the relative burden of disease in Caribou County.

The age- and sex-adjusted incidence rate of invasive cancer in Caribou County, all sites combined, was 531.4 cases per 100,000 persons per year during 2016-2020. There were more cases of cancer in Caribou County (199) than expected (194.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 59 Caribou County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Caribou County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Caribou <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 381 | 77,431 |
| Cancer Deaths | 59 | 15,121 |
| \% of All Deaths | $15.5 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 12 | 2,961 |
| Colorectal | 2 | 1,319 |
| Pancreas | 4 | 1,190 |
| Female Breast | 3 | 1,086 |
| Prostate | 0 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Caribou County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Caribou County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Caribou County, all sites combined, was 152.9 deaths per 100,000 persons per year during 2017-2021, compared with 168.2 for the remainder of the state. There were fewer cancer deaths in Caribou County (59) than expected (64.9) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN CARIBOU COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Caribou County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person Years | Crude Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person Years | Crude Rate (1) |
| All Sites Combined | Total | 199 | 35,141 | 566.3 | 531.4 | 194.7 | 0.774 | 45,411 | 8,736,687 | 519.8 |
| All Sites Combined | Male | 115 | 17,849 | 644.3 | 608.5 | 104.3 | 0.319 | 24,174 | 4,379,061 | 552.0 |
| All Sites Combined | Female | 84 | 17,292 | 485.8 | 455.2 | 89.9 | 0.575 | 21,237 | 4,357,626 | 487.4 |
| Bladder | Total | 9 | 35,141 | 25.6 | 23.2 | 9.7 | 0.998 | 2,175 | 8,736,687 | 24.9 |
| Bladder | Male | 9 | 17,849 | 50.4 | 46.7 | 7.7 | 0.723 | 1,742 | 4,379,061 | 39.8 |
| Bladder | Female | - | 17,292 | - |  | 1.9 | 0.293 | 433 | 4,357,626 | 9.9 |
| Brain - malignant | Total | 5 | 35,141 | 14.2 | 13.6 | 2.6 | 0.246 | 620 | 8,736,687 | 7.1 |
| Brain - malignant | Male | 3 | 17,849 | 16.8 | 16.2 | 1.6 | 0.419 | 372 | 4,379,061 | 8.5 |
| Brain - malignant | Female | 2 | 17,292 | 11.6 | 11.0 | 1.0 | 0.557 | 248 | 4,357,626 | 5.7 |
| Brain and other CNS - non-malignant | Total | 12 | 35,141 | 34.1 | 32.4 | 6.0 | 0.039 >> | 1,412 | 8,736,687 | 16.2 |
| Brain and other CNS - non-malignant | Male | 2 | 17,849 | 11.2 | 10.9 | 2.0 | 1.000 | 478 | 4,379,061 | 10.9 |
| Brain and other CNS - non-malignant | Female | 10 | 17,292 | 57.8 | 54.2 | 4.0 | 0.015 >> | 934 | 4,357,626 | 21.4 |
| Breast | Total | 28 | 35,141 | 79.7 | 76.3 | 28.2 | 1.000 | 6,718 | 8,736,687 | 76.9 |
| Breast | Male |  | 17,849 |  |  | 0.3 | 1.000 | 59 | 4,379,061 | 1.3 |
| Breast | Female | 28 | 17,292 | 161.9 | 154.5 | 27.7 | 1.000 | 6,659 | 4,357,626 | 152.8 |
| Breast - in situ | Total | 2 | 35,141 | 5.7 | 5.5 | 5.1 | 0.232 | 1,237 | 8,736,687 | 14.2 |
| Breast - in situ | Male |  | 17,849 | - | - | 0.0 | 1.000 | 5 | 4,379,061 | 0.1 |
| Breast - in situ | Female | 2 | 17,292 | 11.6 | 11.3 | 5.0 | 0.248 | 1,232 | 4,357,626 | 28.3 |
| Cervix | Female | 3 | 17,292 | 17.3 | 17.8 | 1.2 | 0.225 | 301 | 4,357,626 | 6.9 |
| Colorectal | Total | 11 | 35,141 | 31.3 | 29.4 | 14.8 | 0.403 | 3,440 | 8,736,687 | 39.4 |
| Colorectal | Male | 5 | 17,849 | 28.0 | 26.7 | 8.1 | 0.363 | 1,898 | 4,379,061 | 43.3 |
| Colorectal | Female | 6 | 17,292 | 34.7 | 31.9 | 6.7 | 1.000 | 1,542 | 4,357,626 | 35.4 |
| Corpus Uteri | Female | 9 | 17,292 | 52.0 | 50.1 | 5.4 | 0.203 | 1,321 | 4,357,626 | 30.3 |
| Esophagus | Total |  | 35,141 | - | - | 2.2 | 0.222 | 506 | 8,736,687 | 5.8 |
| Esophagus | Male |  | 17,849 |  | - | 1.8 | 0.317 | 424 | 4,379,061 | 9.7 |
| Esophagus | Female | - | 17,292 |  |  | 0.4 | 1.000 | 82 | 4,357,626 | 1.9 |
| Hodgkin Lymphoma | Total | 3 | 35,141 | 8.5 | 8.7 | 0.8 | 0.101 | 207 | 8,736,687 | 2.4 |
| Hodgkin Lymphoma | Male | 1 | 17,849 | 5.6 | 5.6 | 0.5 | 0.757 | 117 | 4,379,061 | 2.7 |
| Hodgkin Lymphoma | Female | 2 | 17,292 | 11.6 | 11.9 | 0.3 | 0.096 | 90 | 4,357,626 | 2.1 |
| Kidney and Renal Pelvis | Total | 4 | 35,141 | 11.4 | 10.8 | 7.7 | 0.235 | 1,811 | 8,736,687 | 20.7 |
| Kidney and Renal Pelvis | Male | 4 | 17,849 | 22.4 | 21.5 | 5.0 | 0.876 | 1,178 | 4,379,061 | 26.9 |
| Kidney and Renal Pelvis | Female | - | 17,292 | - | - | 2.7 | 0.134 | 633 | 4,357,626 | 14.5 |
| Larynx | Total | 3 | 35,141 | 8.5 | 8.0 | 0.9 | 0.130 | 212 | 8,736,687 | 2.4 |
| Larynx | Male | 2 | 17,849 | 11.2 | 10.5 | 0.7 | 0.302 | 158 | 4,379,061 | 3.6 |
| Larynx | Female | 1 | 17,292 | 5.8 | 5.5 | 0.2 | 0.404 | 54 | 4,357,626 | 1.2 |
| Leukemia | Total | 8 | 35,141 | 22.8 | 21.0 | 7.1 | 0.821 | 1,623 | 8,736,687 | 18.6 |
| Leukemia | Male | 5 | 17,849 | 28.0 | 26.4 | 4.3 | 0.842 | 984 | 4,379,061 | 22.5 |
| Leukemia | Female | 3 | 17,292 | 17.3 | 15.8 | 2.8 | 1.000 | 639 | 4,357,626 | 14.7 |
| Liver and Bile Duct | Total | 3 | 35,141 | 8.5 | 8.0 | 3.6 | 1.000 | 826 | 8,736,687 | 9.5 |
| Liver and Bile Duct | Male | 2 | 17,849 | 11.2 | 10.5 | 2.6 | 1.000 | 588 | 4,379,061 | 13.4 |
| Liver and Bile Duct | Female | 1 | 17,292 | 5.8 | 5.3 | 1.0 | 1.000 | 238 | 4,357,626 | 5.5 |
| Lung and Bronchus | Total | 16 | 35,141 | 45.5 | 41.5 | 21.5 | 0.277 | 4,871 | 8,736,687 | 55.8 |
| Lung and Bronchus | Male | 9 | 17,849 | 50.4 | 46.9 | 10.7 | 0.747 | 2,443 | 4,379,061 | 55.8 |
| Lung and Bronchus | Female | 7 | 17,292 | 40.5 | 36.2 | 10.8 | 0.318 | 2,428 | 4,357,626 | 55.7 |
| Melanoma of the Skin | Total | 14 | 35,141 | 39.8 | 37.9 | 12.4 | 0.722 | 2,928 | 8,736,687 | 33.5 |
| Melanoma of the Skin | Male | 8 | 17,849 | 44.8 | 42.7 | 7.5 | 0.958 | 1,757 | 4,379,061 | 40.1 |
| Melanoma of the Skin | Female | 6 | 17,292 | 34.7 | 33.4 | 4.8 | 0.707 | 1,171 | 4,357,626 | 26.9 |
| Myeloma | Total | 6 | 35,141 | 17.1 | 15.6 | 3.1 | 0.185 | 702 | 8,736,687 | 8.0 |
| Myeloma | Male | 4 | 17,849 | 22.4 | 21.0 | 1.9 | 0.252 | 437 | 4,379,061 | 10.0 |
| Myeloma | Female | 2 | 17,292 | 11.6 | 10.4 | 1.2 | 0.650 | 265 | 4,357,626 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 11 | 35,141 | 31.3 | 29.3 | 8.3 | 0.430 | 1,929 | 8,736,687 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 9 | 17,849 | 50.4 | 47.7 | 4.8 | 0.115 | 1,120 | 4,379,061 | 25.6 |
| Non-Hodgkin Lymphoma | Female | 2 | 17,292 | 11.6 | 10.6 | 3.5 | 0.644 | 809 | 4,357,626 | 18.6 |
| Oral Cavity and Pharynx | Total | 5 | 35,141 | 14.2 | 13.5 | 5.5 | 1.000 | 1,290 | 8,736,687 | 14.8 |
| Oral Cavity and Pharynx | Male | 3 | 17,849 | 16.8 | 16.0 | 4.0 | 0.867 | 933 | 4,379,061 | 21.3 |
| Oral Cavity and Pharynx | Female | 2 | 17,292 | 11.6 | 10.9 | 1.5 | 0.890 | 357 | 4,357,626 | 8.2 |
| Ovary | Female | - | 17,292 |  |  | 2.2 | 0.216 | 533 | 4,357,626 | 12.2 |
| Pancreas | Total | 6 | 35,141 | 17.1 | 15.6 | 6.2 | 1.000 | 1,417 | 8,736,687 | 16.2 |
| Pancreas | Male | 4 | 17,849 | 22.4 | 21.0 | 3.4 | 0.879 | 780 | 4,379,061 | 17.8 |
| Pancreas | Female | 2 | 17,292 | 11.6 | 10.4 | 2.8 | 0.927 | 637 | 4,357,626 | 14.6 |
| Prostate | Male | 33 | 17,849 | 184.9 | 173.9 | 27.7 | 0.355 | 6,384 | 4,379,061 | 145.8 |
| Stomach | Total | 1 | 35,141 | 2.8 | 2.6 | 2.0 | 0.799 | 466 | 8,736,687 | 5.3 |
| Stomach | Male | 1 | 17,849 | 5.6 | 5.3 | 1.3 | 1.000 | 308 | 4,379,061 | 7.0 |
| Stomach | Female | - | 17,292 | - | - | 0.7 | 1.000 | 158 | 4,357,626 | 3.6 |
| Testis | Male | 2 | 17,849 | 11.2 | 12.2 | 1.0 | 0.518 | 263 | 4,379,061 | 6.0 |
| Thyroid | Total | 4 | 35,141 | 11.4 | 11.6 | 4.8 | 0.952 | 1,216 | 8,736,687 | 13.9 |
| Thyroid | Male | 4 | 17,849 | 22.4 | 22.3 | 1.4 | 0.116 | 351 | 4,379,061 | 8.0 |
| Thyroid | Female | - | 17,292 | - | - | 3.3 | 0.073 | 865 | 4,357,626 | 19.9 |
| Pediatric Age 0 to 19 | Total | 1 | 10,899 | 9.2 | 9.3 | 1.8 | 0.898 | 420 | 2,449,624 | 17.1 |
| Pediatric Age 0 to 19 | Male | - | 5,636 | - | - | 1.0 | 0.736 | 223 | 1,250,874 | 17.8 |
| Pediatric Age 0 to 19 | Female | 1 | 5,263 | 19.0 | 19.4 | 0.8 | 1.000 | 197 | 1,198,750 | 16.4 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN CARIBOU COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Caribou County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 381 | 35,382 | 1,076.8 | 974.0 | 336.6 | 0.019 >> | 77,049 | 8,953,333 | 860.6 |
| All Causes of Death | Male | 197 | 17,961 | 1,096.8 | 1,036.5 | 172.8 | 0.076 | 40,859 | 4,493,907 | 909.2 |
| All Causes of Death | Female | 184 | 17,421 | 1,056.2 | 912.4 | 163.7 | 0.125 | 36,190 | 4,459,426 | 811.5 |
| All Malignant Cancers | Total | 59 | 35,382 | 166.8 | 152.9 | 64.9 | 0.508 | 15,062 | 8,953,333 | 168.2 |
| All Malignant Cancers | Male | 33 | 17,961 | 183.7 | 172.7 | 34.6 | 0.871 | 8,143 | 4,493,907 | 181.2 |
| All Malignant Cancers | Female | 26 | 17,421 | 149.2 | 134.2 | 30.1 | 0.527 | 6,919 | 4,459,426 | 155.2 |
| Bladder | Total | 2 | 35,382 | 5.7 | 5.0 | 2.2 | 1.000 | 487 | 8,953,333 | 5.4 |
| Bladder | Male | 2 | 17,961 | 11.1 | 10.3 | 1.6 | 0.965 | 376 | 4,493,907 | 8.4 |
| Bladder | Female | - | 17,421 |  | - | 0.5 | 1.000 | 111 | 4,459,426 | 2.5 |
| Brain and Other Nervous System | Total | 2 | 35,382 | 5.7 | 5.4 | 2.1 | 1.000 | 502 | 8,953,333 | 5.6 |
| Brain and Other Nervous System | Male | 1 | 17,961 | 5.6 | 5.4 | 1.2 | 1.000 | 297 | 4,493,907 | 6.6 |
| Brain and Other Nervous System | Female | 1 | 17,421 | 5.7 | 5.4 | 0.8 | 1.000 | 205 | 4,459,426 | 4.6 |
| Breast | Total | 3 | 35,382 | 8.5 | 7.9 | 4.7 | 0.628 | 1,099 | 8,953,333 | 12.3 |
| Breast | Male |  | 17,961 |  | - | 0.1 | 1.000 | 16 | 4,493,907 | 0.4 |
| Breast | Female | 3 | 17,421 | 17.2 | 15.8 | 4.6 | 0.645 | 1,083 | 4,459,426 | 24.3 |
| Cervix | Female | - | 17,421 | - | - | 0.3 | 1.000 | 83 | 4,459,426 | 1.9 |
| Colorectal | Total | 2 | 35,382 | 5.7 | 5.2 | 5.6 | 0.161 | 1,317 | 8,953,333 | 14.7 |
| Colorectal | Male | 1 | 17,961 | 5.6 | 5.3 | 3.0 | 0.391 | 718 | 4,493,907 | 16.0 |
| Colorectal | Female | 1 | 17,421 | 5.7 | 5.1 | 2.6 | 0.527 | 599 | 4,459,426 | 13.4 |
| Corpus Uteri | Female | 1 | 17,421 | 5.7 | 5.3 | 0.7 | 1.000 | 172 | 4,459,426 | 3.9 |
| Esophagus | Total | 2 | 35,382 | 5.7 | 5.3 | 2.0 | 1.000 | 475 | 8,953,333 | 5.3 |
| Esophagus | Male | 2 | 17,961 | 11.1 | 10.5 | 1.7 | 1.000 | 399 | 4,493,907 | 8.9 |
| Esophagus | Female | - | 17,421 | - | - | 0.3 | 1.000 | 76 | 4,459,426 | 1.7 |
| Hodgkin Lymphoma | Total |  | 35,382 | - | - | 0.1 | 1.000 | 29 | 8,953,333 | 0.3 |
| Hodgkin Lymphoma | Male | - | 17,961 | - | - | 0.1 | 1.000 | 14 | 4,493,907 | 0.3 |
| Hodgkin Lymphoma | Female | - | 17,421 | - | - | 0.1 | 1.000 | 15 | 4,459,426 | 0.3 |
| Kidney | Total | - | 35,382 | - | - | 1.7 | 0.377 | 385 | 8,953,333 | 4.3 |
| Kidney | Male | - | 17,961 | - | - | 1.0 | 0.716 | 242 | 4,493,907 | 5.4 |
| Kidney | Female | - | 17,421 | - | - | 0.6 | 1.000 | 143 | 4,459,426 | 3.2 |
| Larynx | Total | - | 35,382 | - | - | 0.3 | 1.000 | 71 | 8,953,333 | 0.8 |
| Larynx | Male | - | 17,961 | - | - | 0.2 | 1.000 | 58 | 4,493,907 | 1.3 |
| Larynx | Female | - | 17,421 | - | - | 0.1 | 1.000 | 13 | 4,459,426 | 0.3 |
| Leukemia | Total | 5 | 35,382 | 14.1 | 12.8 | 2.9 | 0.325 | 655 | 8,953,333 | 7.3 |
| Leukemia | Male | 3 | 17,961 | 16.7 | 15.8 | 1.6 | 0.445 | 383 | 4,493,907 | 8.5 |
| Leukemia | Female | 2 | 17,421 | 11.5 | 9.9 | 1.2 | 0.694 | 272 | 4,459,426 | 6.1 |
| Liver and Bile Duct | Total | 2 | 35,382 | 5.7 | 5.3 | 2.5 | 1.000 | 601 | 8,953,333 | 6.7 |
| Liver and Bile Duct | Male | 1 | 17,961 | 5.6 | 5.3 | 1.7 | 0.974 | 407 | 4,493,907 | 9.1 |
| Liver and Bile Duct | Female | 1 | 17,421 | 5.7 | 5.2 | 0.8 | 1.000 | 194 | 4,459,426 | 4.4 |
| Lung and Bronchus | Total | 12 | 35,382 | 33.9 | 31.0 | 12.7 | 0.984 | 2,949 | 8,953,333 | 32.9 |
| Lung and Bronchus | Male | 7 | 17,961 | 39.0 | 36.5 | 6.6 | 0.980 | 1,549 | 4,493,907 | 34.5 |
| Lung and Bronchus | Female | 5 | 17,421 | 28.7 | 25.6 | 6.1 | 0.851 | 1,400 | 4,459,426 | 31.4 |
| Melanoma of the Skin | Total | 1 | 35,382 | 2.8 | 2.6 | 1.2 | 1.000 | 288 | 8,953,333 | 3.2 |
| Melanoma of the Skin | Male | 1 | 17,961 | 5.6 | 5.3 | 0.8 | 1.000 | 191 | 4,493,907 | 4.3 |
| Melanoma of the Skin | Female | - | 17,421 | - | - | 0.4 | 1.000 | 97 | 4,459,426 | 2.2 |
| Myeloma | Total | 4 | 35,382 | 11.3 | 10.2 | 1.4 | 0.116 | 327 | 8,953,333 | 3.7 |
| Myeloma | Male | 4 | 17,961 | 22.3 | 20.7 | 0.8 | 0.020 >> | 192 | 4,493,907 | 4.3 |
| Myeloma | Female | - | 17,421 | - |  | 0.6 | 1.000 | 135 | 4,459,426 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 3 | 35,382 | 8.5 | 7.7 | 2.5 | 0.894 | 566 | 8,953,333 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 2 | 17,961 | 11.1 | 10.5 | 1.3 | 0.741 | 305 | 4,493,907 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 1 | 17,421 | 5.7 | 5.0 | 1.2 | 1.000 | 261 | 4,459,426 | 5.9 |
| Oral Cavity and Pharynx | Total | 1 | 35,382 | 2.8 | 2.6 | 1.1 | 1.000 | 265 | 8,953,333 | 3.0 |
| Oral Cavity and Pharynx | Male | 1 | 17,961 | 5.6 | 5.3 | 0.8 | 1.000 | 186 | 4,493,907 | 4.1 |
| Oral Cavity and Pharynx | Female | - | 17,421 | - | - | 0.3 | 1.000 | 79 | 4,459,426 | 1.8 |
| Ovary | Female | 3 | 17,421 | 17.2 | 15.8 | 1.5 | 0.373 | 347 | 4,459,426 | 7.8 |
| Pancreas | Total | 4 | 35,382 | 11.3 | 10.4 | 5.1 | 0.852 | 1,186 | 8,953,333 | 13.2 |
| Pancreas | Male | 3 | 17,961 | 16.7 | 15.8 | 2.7 | 1.000 | 639 | 4,493,907 | 14.2 |
| Pancreas | Female | 1 | 17,421 | 5.7 | 5.2 | 2.4 | 0.630 | 547 | 4,459,426 | 12.3 |
| Prostate | Male | - | 17,961 | - | - | 4.1 | 0.033 << | 949 | 4,493,907 | 21.1 |
| Stomach | Total |  | 35,382 |  | - | 0.8 | 0.864 | 198 | 8,953,333 | 2.2 |
| Stomach | Male | - | 17,961 | - | - | 0.5 | 1.000 | 121 | 4,493,907 | 2.7 |
| Stomach | Female | - | 17,421 | - | - | 0.3 | 1.000 | 77 | 4,459,426 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Caribou County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 83.3\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 11.5\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% |  |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% |  |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 26.3\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 21.0\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 78.9\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 17.4\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 17.1\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, 12.6\% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^14]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked 49 ${ }^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged 50-75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

## CASSIA COUNTY CANCPR PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 486 cases of invasive cancer were diagnosed among Cassia County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Cassia County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Cassia <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 486 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 81 | 6,687 |
| Prostate | 55 | 6,417 |
| Lung \& Bronchus | 38 | 4,887 |
| Colorectal | 35 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Cassia County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Cassia County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Cassia County was 407.6 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (521.5) gives an estimate of the relative burden of disease in Cassia County.

The age- and sex-adjusted incidence rate of invasive cancer in Cassia County, all sites combined, was 450.4 cases per 100,000 persons per year during 2016-2020. There were statistically significantly fewer cases of cancer in Cassia County (486) than expected (562.7) based upon rates in the remainder of the state $(p=.001)$.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 172 Cassia County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Cassia County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Cassia <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 1,096 | 77,431 |
| Cancer Deaths | 172 | 15,121 |
| \% of All Deaths | $15.7 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 17 | 2,961 |
| Colorectal | 18 | 1,319 |
| Pancreas | 13 | 1,190 |
| Female Breast | 12 | 1,086 |
| Prostate | 13 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Cassia County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Cassia County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Cassia County, all sites combined, was 154.2 deaths per 100,000 persons per year during 2017-2021, compared with 168.6 for the remainder of the state. There were fewer cancer deaths in Cassia County (172) than expected (188.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN CASSIA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Cassia County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person Years | Crude Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person Years | Crude Rate (1) |
| All Sites Combined | Total | 486 | 119,236 | 407.6 | 450.4 | 562.7 | 0.001 << | 45,124 | 8,652,592 | 521.5 |
| All Sites Combined | Male | 252 | 60,911 | 413.7 | 464.2 | 300.9 | 0.004 << | 24,037 | 4,335,999 | 554.4 |
| All Sites Combined | Female | 234 | 58,325 | 401.2 | 437.7 | 261.1 | 0.096 | 21,087 | 4,316,593 | 488.5 |
| Bladder | Total | 32 | 119,236 | 26.8 | 29.3 | 27.2 | 0.399 | 2,152 | 8,652,592 | 24.9 |
| Bladder | Male | 25 | 60,911 | 41.0 | 46.0 | 21.6 | 0.524 | 1,726 | 4,335,999 | 39.8 |
| Bladder | Female | 7 | 58,325 | 12.0 | 12.9 | 5.4 | 0.588 | 426 | 4,316,593 | 9.9 |
| Brain - malignant | Total | 7 | 119,236 | 5.9 | 6.3 | 7.9 | 0.933 | 618 | 8,652,592 | 7.1 |
| Brain - malignant | Male | 5 | 60,911 | 8.2 | 9.0 | 4.8 | 1.000 | 370 | 4,335,999 | 8.5 |
| Brain - malignant | Female | 2 | 58,325 | 3.4 | 3.6 | 3.2 | 0.773 | 248 | 4,316,593 | 5.7 |
| Brain and other CNS - non-malignant | Total | 32 | 119,236 | 26.8 | 29.3 | 17.6 | 0.003 >> | 1,392 | 8,652,592 | 16.1 |
| Brain and other CNS - non-malignant | Male | 9 | 60,911 | 14.8 | 16.2 | 6.0 | 0.311 | 471 | 4,335,999 | 10.9 |
| Brain and other CNS - non-malignant | Female | 23 | 58,325 | 39.4 | 42.6 | 11.5 | 0.004 >> | 921 | 4,316,593 | 21.3 |
| Breast | Total | 82 | 119,236 | 68.8 | 76.8 | 82.2 | 1.000 | 6,664 | 8,652,592 | 77.0 |
| Breast | Male | 1 | 60,911 | 1.6 | 1.8 | 0.7 | 1.000 | 58 | 4,335,999 | 1.3 |
| Breast | Female | 81 | 58,325 | 138.9 | 154.2 | 80.4 | 0.976 | 6,606 | 4,316,593 | 153.0 |
| Breast - in situ | Total | 8 | 119,236 | 6.7 | 7.6 | 15.0 | 0.076 | 1,231 | 8,652,592 | 14.2 |
| Breast - in situ | Male |  | 60,911 |  |  | 0.1 | 1.000 | 5 | 4,335,999 | 0.1 |
| Breast - in situ | Female | 8 | 58,325 | 13.7 | 15.5 | 14.6 | 0.091 | 1,226 | 4,316,593 | 28.4 |
| Cervix | Female | 2 | 58,325 | 3.4 | 3.8 | 3.7 | 0.569 | 302 | 4,316,593 | 7.0 |
| Colorectal | Total | 35 | 119,236 | 29.4 | 32.3 | 42.8 | 0.260 | 3,416 | 8,652,592 | 39.5 |
| Colorectal | Male | 19 | 60,911 | 31.2 | 34.9 | 23.7 | 0.396 | 1,884 | 4,335,999 | 43.5 |
| Colorectal | Female | 16 | 58,325 | 27.4 | 29.5 | 19.2 | 0.549 | 1,532 | 4,316,593 | 35.5 |
| Corpus Uteri | Female | 9 | 58,325 | 15.4 | 17.3 | 15.9 | 0.090 | 1,321 | 4,316,593 | 30.6 |
| Esophagus | Total | 3 | 119,236 | 2.5 | 2.8 | 6.3 | 0.256 | 503 | 8,652,592 | 5.8 |
| Esophagus | Male | 3 | 60,911 | 4.9 | 5.5 | 5.3 | 0.459 | 421 | 4,335,999 | 9.7 |
| Esophagus | Female |  | 58,325 |  |  | 1.0 | 0.722 | 82 | 4,316,593 | 1.9 |
| Hodgkin Lymphoma | Total | 4 | 119,236 | 3.4 | 3.6 | 2.7 | 0.563 | 206 | 8,652,592 | 2.4 |
| Hodgkin Lymphoma | Male | 3 | 60,911 | 4.9 | 5.3 | 1.5 | 0.383 | 115 | 4,335,999 | 2.7 |
| Hodgkin Lymphoma | Female | 1 | 58,325 | 1.7 | 1.8 | 1.2 | 1.000 | 91 | 4,316,593 | 2.1 |
| Kidney and Renal Pelvis | Total | 21 | 119,236 | 17.6 | 19.5 | 22.3 | 0.892 | 1,794 | 8,652,592 | 20.7 |
| Kidney and Renal Pelvis | Male | 12 | 60,911 | 19.7 | 22.1 | 14.6 | 0.595 | 1,170 | 4,335,999 | 27.0 |
| Kidney and Renal Pelvis | Female | 9 | 58,325 | 15.4 | 16.8 | 7.7 | 0.744 | 624 | 4,316,593 | 14.5 |
| Larynx | Total | 1 | 119,236 | 0.8 | 0.9 | 2.7 | 0.510 | 214 | 8,652,592 | 2.5 |
| Larynx | Male |  | 60,911 |  |  | 2.0 | 0.267 | 160 | 4,335,999 | 3.7 |
| Larynx | Female | 1 | 58,325 | 1.7 | 1.9 | 0.7 | 0.968 | 54 | 4,316,593 | 1.3 |
| Leukemia | Total | 21 | 119,236 | 17.6 | 18.9 | 20.7 | 1.000 | 1,610 | 8,652,592 | 18.6 |
| Leukemia | Male | 14 | 60,911 | 23.0 | 25.1 | 12.5 | 0.755 | 975 | 4,335,999 | 22.5 |
| Leukemia | Female | 7 | 58,325 | 12.0 | 12.7 | 8.1 | 0.868 | 635 | 4,316,593 | 14.7 |
| Liver and Bile Duct | Total | 8 | 119,236 | 6.7 | 7.5 | 10.1 | 0.633 | 821 | 8,652,592 | 9.5 |
| Liver and Bile Duct | Male | 7 | 60,911 | 11.5 | 13.0 | 7.3 | 1.000 | 583 | 4,335,999 | 13.4 |
| Liver and Bile Duct | Female | 1 | 58,325 | 1.7 | 1.9 | 3.0 | 0.412 | 238 | 4,316,593 | 5.5 |
| Lung and Bronchus | Total | 38 | 119,236 | 31.9 | 35.1 | 60.6 | 0.003 << | 4,849 | 8,652,592 | 56.0 |
| Lung and Bronchus | Male | 23 | 60,911 | 37.8 | 42.6 | 30.3 | 0.212 | 2,429 | 4,335,999 | 56.0 |
| Lung and Bronchus | Female | 15 | 58,325 | 25.7 | 27.8 | 30.3 | 0.003 << | 2,420 | 4,316,593 | 56.1 |
| Melanoma of the Skin | Total | 39 | 119,236 | 32.7 | 36.1 | 36.3 | 0.693 | 2,903 | 8,652,592 | 33.6 |
| Melanoma of the Skin | Male | 22 | 60,911 | 36.1 | 40.4 | 21.9 | 1.000 | 1,743 | 4,335,999 | 40.2 |
| Melanoma of the Skin | Female | 17 | 58,325 | 29.1 | 31.9 | 14.3 | 0.546 | 1,160 | 4,316,593 | 26.9 |
| Myeloma | Total | 7 | 119,236 | 5.9 | 6.5 | 8.8 | 0.702 | 701 | 8,652,592 | 8.1 |
| Myeloma | Male | 4 | 60,911 | 6.6 | 7.4 | 5.5 | 0.728 | 437 | 4,335,999 | 10.1 |
| Myeloma | Female | 3 | 58,325 | 5.1 | 5.6 | 3.3 | 1.000 | 264 | 4,316,593 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 16 | 119,236 | 13.4 | 14.7 | 24.2 | 0.105 | 1,924 | 8,652,592 | 22.2 |
| Non-Hodgkin Lymphoma | Male | 11 | 60,911 | 18.1 | 20.1 | 14.1 | 0.499 | 1,118 | 4,335,999 | 25.8 |
| Non-Hodgkin Lymphoma | Female | 5 | 58,325 | 8.6 | 9.3 | 10.1 | 0.128 | 806 | 4,316,593 | 18.7 |
| Oral Cavity and Pharynx | Total | 13 | 119,236 | 10.9 | 12.2 | 15.8 | 0.586 | 1,282 | 8,652,592 | 14.8 |
| Oral Cavity and Pharynx | Male | 9 | 60,911 | 14.8 | 16.7 | 11.5 | 0.570 | 927 | 4,335,999 | 21.4 |
| Oral Cavity and Pharynx | Female | 4 | 58,325 | 6.9 | 7.6 | 4.3 | 1.000 | 355 | 4,316,593 | 8.2 |
| Ovary | Female | 4 | 58,325 | 6.9 | 7.5 | 6.5 | 0.442 | 529 | 4,316,593 | 12.3 |
| Pancreas | Total | 16 | 119,236 | 13.4 | 14.7 | 17.7 | 0.806 | 1,407 | 8,652,592 | 16.3 |
| Pancreas | Male | 6 | 60,911 | 9.9 | 11.0 | 9.7 | 0.294 | 778 | 4,335,999 | 17.9 |
| Pancreas | Female | 10 | 58,325 | 17.1 | 18.3 | 8.0 | 0.555 | 629 | 4,316,593 | 14.6 |
| Prostate | Male | 55 | 60,911 | 90.3 | 102.9 | 78.4 | 0.007 << | 6,362 | 4,335,999 | 146.7 |
| Stomach | Total | 5 | 119,236 | 4.2 | 4.6 | 5.8 | 0.949 | 462 | 8,652,592 | 5.3 |
| Stomach | Male | 2 | 60,911 | 3.3 | 3.7 | 3.9 | 0.520 | 307 | 4,335,999 | 7.1 |
| Stomach | Female | 3 | 58,325 | 5.1 | 5.4 | 2.0 | 0.637 | 155 | 4,316,593 | 3.6 |
| Testis | Male | 4 | 60,911 | 6.6 | 7.0 | 3.4 | 0.897 | 261 | 4,335,999 | 6.0 |
| Thyroid | Total | 18 | 119,236 | 15.1 | 16.6 | 15.1 | 0.512 | 1,202 | 8,652,592 | 13.9 |
| Thyroid | Male | 5 | 60,911 | 8.2 | 9.1 | 4.4 | 0.910 | 350 | 4,335,999 | 8.1 |
| Thyroid | Female | 13 | 58,325 | 22.3 | 24.5 | 10.5 | 0.513 | 852 | 4,316,593 | 19.7 |
| Pediatric Age 0 to 19 | Total | 11 | 41,175 | 26.7 | 26.9 | 6.9 | 0.187 | 410 | 2,419,348 | 16.9 |
| Pediatric Age 0 to 19 | Male | 6 | 21,363 | 28.1 | 28.2 | 3.7 | 0.350 | 217 | 1,235,147 | 17.6 |
| Pediatric Age 0 to 19 | Female | 5 | 19,812 | 25.2 | 25.5 | 3.2 | 0.436 | 193 | 1,184,201 | 16.3 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN CASSIA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Cassia County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 1,096 | 120,923 | 906.4 | 951.7 | 991.4 | 0.001 >> | 76,334 | 8,867,792 | 860.8 |
| All Causes of Death | Male | 567 | 61,850 | 916.7 | 1,004.5 | 513.6 | 0.021 >> | 40,489 | 4,450,018 | 909.9 |
| All Causes of Death | Female | 529 | 59,073 | 895.5 | 896.9 | 478.6 | 0.024 >> | 35,845 | 4,417,774 | 811.4 |
| All Malignant Cancers | Total | 172 | 120,923 | 142.2 | 154.2 | 188.1 | 0.254 | 14,949 | 8,867,792 | 168.6 |
| All Malignant Cancers | Male | 97 | 61,850 | 156.8 | 174.7 | 100.8 | 0.753 | 8,079 | 4,450,018 | 181.5 |
| All Malignant Cancers | Female | 75 | 59,073 | 127.0 | 134.4 | 86.8 | 0.222 | 6,870 | 4,417,774 | 155.5 |
| Bladder | Total | 10 | 120,923 | 8.3 | 8.7 | 6.2 | 0.203 | 479 | 8,867,792 | 5.4 |
| Bladder | Male | 7 | 61,850 | 11.3 | 12.4 | 4.7 | 0.393 | 371 | 4,450,018 | 8.3 |
| Bladder | Female | 3 | 59,073 | 5.1 | 5.2 | 1.4 | 0.343 | 108 | 4,417,774 | 2.4 |
| Brain and Other Nervous System | Total | 6 | 120,923 | 5.0 | 5.4 | 6.2 | 1.000 | 498 | 8,867,792 | 5.6 |
| Brain and Other Nervous System | Male | 5 | 61,850 | 8.1 | 9.0 | 3.7 | 0.612 | 293 | 4,450,018 | 6.6 |
| Brain and Other Nervous System | Female | 1 | 59,073 | 1.7 | 1.8 | 2.5 | 0.560 | 205 | 4,417,774 | 4.6 |
| Breast | Total | 12 | 120,923 | 9.9 | 10.8 | 13.7 | 0.784 | 1,090 | 8,867,792 | 12.3 |
| Breast | Male |  | 61,850 |  |  | 0.2 | 1.000 | 16 | 4,450,018 | 0.4 |
| Breast | Female | 12 | 59,073 | 20.3 | 21.7 | 13.5 | 0.828 | 1,074 | 4,417,774 | 24.3 |
| Cervix | Female | - | 59,073 |  | - | 1.0 | 0.733 | 83 | 4,417,774 | 1.9 |
| Colorectal | Total | 18 | 120,923 | 14.9 | 16.1 | 16.4 | 0.751 | 1,301 | 8,867,792 | 14.7 |
| Colorectal | Male | 5 | 61,850 | 8.1 | 9.0 | 8.9 | 0.245 | 714 | 4,450,018 | 16.0 |
| Colorectal | Female | 13 | 59,073 | 22.0 | 23.0 | 7.5 | 0.087 | 587 | 4,417,774 | 13.3 |
| Corpus Uteri | Female | 2 | 59,073 | 3.4 | 3.7 | 2.1 | 1.000 | 171 | 4,417,774 | 3.9 |
| Esophagus | Total | 2 | 120,923 | 1.7 | 1.8 | 5.9 | 0.135 | 475 | 8,867,792 | 5.4 |
| Esophagus | Male | 2 | 61,850 | 3.2 | 3.6 | 4.9 | 0.260 | 399 | 4,450,018 | 9.0 |
| Esophagus | Female | - | 59,073 | - | - | 1.0 | 0.767 | 76 | 4,417,774 | 1.7 |
| Hodgkin Lymphoma | Total |  | 120,923 | - | - | 0.4 | 1.000 | 29 | 8,867,792 | 0.3 |
| Hodgkin Lymphoma | Male |  | 61,850 | - | - | 0.2 | 1.000 | 14 | 4,450,018 | 0.3 |
| Hodgkin Lymphoma | Female | - | 59,073 |  | - | 0.2 | 1.000 | 15 | 4,417,774 | 0.3 |
| Kidney | Total | 6 | 120,923 | 5.0 | 5.4 | 4.8 | 0.687 | 379 | 8,867,792 | 4.3 |
| Kidney | Male | 4 | 61,850 | 6.5 | 7.2 | 3.0 | 0.686 | 238 | 4,450,018 | 5.3 |
| Kidney | Female | 2 | 59,073 | 3.4 | 3.5 | 1.8 | 1.000 | 141 | 4,417,774 | 3.2 |
| Larynx | Total | 1 | 120,923 | 0.8 | 0.9 | 0.9 | 1.000 | 70 | 8,867,792 | 0.8 |
| Larynx | Male |  | 61,850 |  |  | 0.7 | 0.964 | 58 | 4,450,018 | 1.3 |
| Larynx | Female | 1 | 59,073 | 1.7 | 1.9 | 0.1 | 0.269 | 12 | 4,417,774 | 0.3 |
| Leukemia | Total | 4 | 120,923 | 3.3 | 3.5 | 8.4 | 0.154 | 656 | 8,867,792 | 7.4 |
| Leukemia | Male | 2 | 61,850 | 3.2 | 3.6 | 4.9 | 0.274 | 384 | 4,450,018 | 8.6 |
| Leukemia | Female | 2 | 59,073 | 3.4 | 3.5 | 3.6 | 0.617 | 272 | 4,417,774 | 6.2 |
| Liver and Bile Duct | Total | 9 | 120,923 | 7.4 | 8.3 | 7.3 | 0.619 | 594 | 8,867,792 | 6.7 |
| Liver and Bile Duct | Male | 7 | 61,850 | 11.3 | 12.8 | 4.9 | 0.454 | 401 | 4,450,018 | 9.0 |
| Liver and Bile Duct | Female | 2 | 59,073 | 3.4 | 3.7 | 2.4 | 1.000 | 193 | 4,417,774 | 4.4 |
| Lung and Bronchus | Total | 17 | 120,923 | 14.1 | 15.4 | 36.7 | 0.000 << | 2,944 | 8,867,792 | 33.2 |
| Lung and Bronchus | Male | 14 | 61,850 | 22.6 | 25.5 | 19.0 | 0.295 | 1,542 | 4,450,018 | 34.7 |
| Lung and Bronchus | Female | 3 | 59,073 | 5.1 | 5.4 | 17.6 | $0.000 \ll$ | 1,402 | 4,417,774 | 31.7 |
| Melanoma of the Skin | Total | 7 | 120,923 | 5.8 | 6.3 | 3.5 | 0.136 | 282 | 8,867,792 | 3.2 |
| Melanoma of the Skin | Male | 3 | 61,850 | 4.9 | 5.4 | 2.4 | 0.844 | 189 | 4,450,018 | 4.2 |
| Melanoma of the Skin | Female | 4 | 59,073 | 6.8 | 7.3 | 1.2 | 0.060 | 93 | 4,417,774 | 2.1 |
| Myeloma | Total | 8 | 120,923 | 6.6 | 7.1 | 4.1 | 0.113 | 323 | 8,867,792 | 3.6 |
| Myeloma | Male | 5 | 61,850 | 8.1 | 9.0 | 2.4 | 0.188 | 191 | 4,450,018 | 4.3 |
| Myeloma | Female | 3 | 59,073 | 5.1 | 5.3 | 1.7 | 0.477 | 132 | 4,417,774 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 8 | 120,923 | 6.6 | 7.1 | 7.1 | 0.843 | 561 | 8,867,792 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 6 | 61,850 | 9.7 | 10.7 | 3.8 | 0.362 | 301 | 4,450,018 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 2 | 59,073 | 3.4 | 3.5 | 3.4 | 0.692 | 260 | 4,417,774 | 5.9 |
| Oral Cavity and Pharynx | Total | 3 | 120,923 | 2.5 | 2.7 | 3.2 | 1.000 | 263 | 8,867,792 | 3.0 |
| Oral Cavity and Pharynx | Male | 2 | 61,850 | 3.2 | 3.6 | 2.3 | 1.000 | 185 | 4,450,018 | 4.2 |
| Oral Cavity and Pharynx | Female | 1 | 59,073 | 1.7 | 1.8 | 1.0 | 1.000 | 78 | 4,417,774 | 1.8 |
| Ovary | Female | 2 | 59,073 | 3.4 | 3.7 | 4.3 | 0.396 | 348 | 4,417,774 | 7.9 |
| Pancreas | Total | 13 | 120,923 | 10.8 | 11.8 | 14.6 | 0.804 | 1,177 | 8,867,792 | 13.3 |
| Pancreas | Male | 5 | 61,850 | 8.1 | 9.1 | 7.9 | 0.406 | 637 | 4,450,018 | 14.3 |
| Pancreas | Female | 8 | 59,073 | 13.5 | 14.5 | 6.7 | 0.722 | 540 | 4,417,774 | 12.2 |
| Prostate | Male | 13 | 61,850 | 21.0 | 23.0 | 11.9 | 0.818 | 936 | 4,450,018 | 21.0 |
| Stomach | Total | 3 | 120,923 | 2.5 | 2.7 | 2.5 | 0.890 | 195 | 8,867,792 | 2.2 |
| Stomach | Male | 2 | 61,850 | 3.2 | 3.6 | 1.5 | 0.873 | 119 | 4,450,018 | 2.7 |
| Stomach | Female | 1 | 59,073 | 1.7 | 1.8 | 1.0 | 1.000 | 76 | 4,417,774 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Cassia County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 78.7\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 13.6\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 50.6\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 55.0\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 18.7\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 32.1\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 69.7\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 14.2\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 8.5\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^15]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 16 cases of invasive cancer were diagnosed among Clark County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Clark County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Clark <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 16 | 45,610 |
| Female Breast | 1 | 6,687 |
| Prostate | 1 | 6,417 |
| Lung \& Bronchus | 1 | 4,887 |
| Colorectal | 1 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Clark County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Clark County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Clark County was 373.8 cases per 100,000 personyears per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (520.0) gives an estimate of the relative burden of disease in Clark County.

The age- and sex-adjusted incidence rate of invasive cancer in Clark County, all sites combined, was 345.8 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Clark County (16) than expected (24.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 7 Clark County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Clark County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Clark <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | $\mathbf{3 2}$ | $\mathbf{7 7 , 4 3 1}$ |
| Cancer Deaths | 7 | 15,121 |
| \% of All Deaths | $21.9 \%$ | $19.5 \%$ |
| Lung \& Bronchus | $\mathbf{1}$ | 2,961 |
| Colorectal | $\mathbf{0}$ | 1,319 |
| Pancreas | $\mathbf{1}$ | 1,190 |
| Female Breast | $\mathbf{0}$ | 1,086 |
| Prostate | $\mathbf{0}$ | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Clark County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Clark County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Clark County, all sites combined, was 142.6 deaths per 100,000 persons per year during 2017-2021, compared with 168.2 for the remainder of the state. There were fewer cancer deaths in Clark County (7) than expected (8.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020 COMPARISON BETWEEN CLARK COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Clark County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P -Value (4) | Observed Cases | Person Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 16 | 4,280 | 373.8 | 345.8 | 24.1 | 0.110 | 45,594 | 8,767,548 | 520.0 |
| All Sites Combined | Male | 7 | 2,218 | 315.6 | 268.2 | 14.4 | 0.050 | 24,282 | 4,394,692 | 552.5 |
| All Sites Combined | Female | 9 | 2,062 | 436.5 | 435.3 | 10.1 | 0.897 | 21,312 | 4,372,856 | 487.4 |
| Bladder | Total |  | 4,280 |  | - | 1.2 | 0.601 | 2,184 | 8,767,548 | 24.9 |
| Bladder | Male |  | 2,218 |  | - | 1.1 | 0.665 | 1,751 | 4,394,692 | 39.8 |
| Bladder | Female | - | 2,062 | - | - | 0.2 | 1.000 | 433 | 4,372,856 | 9.9 |
| Brain - malignant | Total |  | 4,280 |  |  | 0.3 | 1.000 | 625 | 8,767,548 | 7.1 |
| Brain - malignant | Male | - | 2,218 | - | - | 0.2 | 1.000 | 375 | 4,394,692 | 8.5 |
| Brain - malignant | Female | - | 2,062 |  | - | 0.1 | 1.000 | 250 | 4,372,856 | 5.7 |
| Brain and other CNS - non-malignant | Total | 1 | 4,280 | 23.4 | 21.7 | 0.7 | 1.000 | 1,423 | 8,767,548 | 16.2 |
| Brain and other CNS - non-malignant | Male |  | 2,218 |  |  | 0.3 | 1.000 | 480 | 4,394,692 | 10.9 |
| Brain and other CNS - non-malignant | Female | 1 | 2,062 | 48.5 | 47.9 | 0.5 | 0.725 | 943 | 4,372,856 | 21.6 |
| Breast | Total | 1 | 4,280 | 23.4 | 22.1 | 3.5 | 0.274 | 6,745 | 8,767,548 | 76.9 |
| Breast | Male |  | 2,218 |  |  | 0.0 | 1.000 | 59 | 4,394,692 | 1.3 |
| Breast | Female | 1 | 2,062 | 48.5 | 48.9 | 3.1 | 0.363 | 6,686 | 4,372,856 | 152.9 |
| Breast - in situ | Total | - | 4,280 | - | - | 0.6 | 1.000 | 1,239 | 8,767,548 | 14.1 |
| Breast - in situ | Male | - | 2,218 | - | - | 0.0 | 1.000 | 5 | 4,394,692 | 0.1 |
| Breast - in situ | Female | - | 2,062 | - | - | 0.6 | 1.000 | 1,234 | 4,372,856 | 28.2 |
| Cervix | Female | - | 2,062 |  |  | 0.1 | 1.000 | 304 | 4,372,856 | 7.0 |
| Colorectal | Total | 1 | 4,280 | 23.4 | 21.3 | 1.8 | 0.899 | 3,450 | 8,767,548 | 39.3 |
| Colorectal | Male | 1 | 2,218 | 45.1 | 38.1 | 1.1 | 1.000 | 1,902 | 4,394,692 | 43.3 |
| Colorectal | Female | - | 2,062 | - | - | 0.7 | 0.952 | 1,548 | 4,372,856 | 35.4 |
| Corpus Uteri | Female | 2 | 2,062 | 97.0 | 99.8 | 0.6 | 0.250 | 1,328 | 4,372,856 | 30.4 |
| Esophagus | Total |  | 4,280 |  |  | 0.3 | 1.000 | 506 | 8,767,548 | 5.8 |
| Esophagus | Male | - | 2,218 | - | - | 0.3 | 1.000 | 424 | 4,394,692 | 9.6 |
| Esophagus | Female | - | 2,062 | - | - | 0.0 | 1.000 | 82 | 4,372,856 | 1.9 |
| Hodgkin Lymphoma | Total | - | 4,280 | - | - | 0.1 | 1.000 | 210 | 8,767,548 | 2.4 |
| Hodgkin Lymphoma | Male | - | 2,218 | - | - | 0.1 | 1.000 | 118 | 4,394,692 | 2.7 |
| Hodgkin Lymphoma | Female | - | 2,062 | - | - | 0.0 | 1.000 | 92 | 4,372,856 | 2.1 |
| Kidney and Renal Pelvis | Total | - | 4,280 |  | - | 1.0 | 0.772 | 1,815 | 8,767,548 | 20.7 |
| Kidney and Renal Pelvis | Male | - | 2,218 | - | - | 0.7 | 1.000 | 1,182 | 4,394,692 | 26.9 |
| Kidney and Renal Pelvis | Female | - | 2,062 | - | - | 0.3 | 1.000 | 633 | 4,372,856 | 14.5 |
| Larynx | Total | - | 4,280 | - | - | 0.1 | 1.000 | 215 | 8,767,548 | 2.5 |
| Larynx | Male | - | 2,218 | - | - | 0.1 | 1.000 | 160 | 4,394,692 | 3.6 |
| Larynx | Female | - | 2,062 |  | - | 0.0 | 1.000 | 55 | 4,372,856 | 1.3 |
| Leukemia | Total | 1 | 4,280 | 23.4 | 21.3 | 0.9 | 1.000 | 1,630 | 8,767,548 | 18.6 |
| Leukemia | Male | - | 2,218 | - | - | 0.6 | 1.000 | 989 | 4,394,692 | 22.5 |
| Leukemia | Female | 1 | 2,062 | 48.5 | 47.0 | 0.3 | 0.535 | 641 | 4,372,856 | 14.7 |
| Liver and Bile Duct | Total |  | 4,280 | - | - | 0.4 | 1.000 | 829 | 8,767,548 | 9.5 |
| Liver and Bile Duct | Male | - | 2,218 | - | - | 0.3 | 1.000 | 590 | 4,394,692 | 13.4 |
| Liver and Bile Duct | Female | - | 2,062 | - | - | 0.1 | 1.000 | 239 | 4,372,856 | 5.5 |
| Lung and Bronchus | Total | 1 | 4,280 | 23.4 | 21.0 | 2.7 | 0.514 | 4,886 | 8,767,548 | 55.7 |
| Lung and Bronchus | Male | 1 | 2,218 | 45.1 | 37.1 | 1.5 | 1.000 | 2,451 | 4,394,692 | 55.8 |
| Lung and Bronchus | Female | - | 2,062 | - | - | 1.2 | 0.617 | 2,435 | 4,372,856 | 55.7 |
| Melanoma of the Skin | Total | 2 | 4,280 | 46.7 | 43.4 | 1.5 | 0.914 | 2,940 | 8,767,548 | 33.5 |
| Melanoma of the Skin | Male | 2 | 2,218 | 90.2 | 76.4 | 1.1 | 0.566 | 1,763 | 4,394,692 | 40.1 |
| Melanoma of the Skin | Female | - | 2,062 | - | - | 0.6 | 1.000 | 1,177 | 4,372,856 | 26.9 |
| Myeloma | Total | - | 4,280 | - | - | 0.4 | 1.000 | 708 | 8,767,548 | 8.1 |
| Myeloma | Male | - | 2,218 | - | - | 0.3 | 1.000 | 441 | 4,394,692 | 10.0 |
| Myeloma | Female | - | 2,062 | - 6 | - | 0.1 | 1.000 | 267 | 4,372,856 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 2 | 4,280 | 46.7 | 43.0 | 1.0 | 0.549 | 1,938 | 8,767,548 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 1 | 2,218 | 45.1 | 38.8 | 0.7 | 0.967 | 1,128 | 4,394,692 | 25.7 |
| Non-Hodgkin Lymphoma | Female | 1 | 2,062 | 48.5 | 48.0 | 0.4 | 0.641 | 810 | 4,372,856 | 18.5 |
| Oral Cavity and Pharynx | Total | - | 4,280 | - | - | 0.7 | 1.000 | 1,295 | 8,767,548 | 14.8 |
| Oral Cavity and Pharynx | Male | - | 2,218 | - | - | 0.5 | 1.000 | 936 | 4,394,692 | 21.3 |
| Oral Cavity and Pharynx | Female | - | 2,062 | - | - | 0.2 | 1.000 | 359 | 4,372,856 | 8.2 |
| Ovary | Female |  | 2,062 | 48.5 | 48.9 | 0.2 | 0.441 | 532 | 4,372,856 | 12.2 |
| Pancreas | Total | 1 | 4,280 | 23.4 | 21.0 | 0.8 | 1.000 | 1,422 | 8,767,548 | 16.2 |
| Pancreas | Male | - | 2,218 | - | - | 0.5 | 1.000 | 784 | 4,394,692 | 17.8 |
| Pancreas | Female | 1 | 2,062 | 48.5 | 47.2 | 0.3 | 0.531 | 638 | 4,372,856 | 14.6 |
| Prostate | Male | 1 | 2,218 | 45.1 | 39.4 | 3.7 | 0.231 | 6,416 | 4,394,692 | 146.0 |
| Stomach | Total | 1 | 4,280 | 23.4 | 21.1 | 0.3 | 0.445 | 466 | 8,767,548 | 5.3 |
| Stomach | Male |  | 2,218 | - | - | 0.2 | 1.000 | 309 | 4,394,692 | 7.0 |
| Stomach | Female | 1 | 2,062 | 48.5 | 47.2 | 0.1 | 0.147 | 157 | 4,372,856 | 3.6 |
| Testis | Male | - | 2,218 | - | - | 0.1 | 1.000 | 265 | 4,394,692 | 6.0 |
| Thyroid | Total | 1 | 4,280 | 23.4 | 23.0 | 0.6 | 0.909 | 1,219 | 8,767,548 | 13.9 |
| Thyroid | Male | - | 2,218 | - | - | 0.2 | 1.000 | 355 | 4,394,692 | 8.1 |
| Thyroid | Female | 1 | 2,062 | 48.5 | 49.3 | 0.4 | 0.660 | 864 | 4,372,856 | 19.8 |
| Pediatric Age 0 to 19 | Total |  | 1,168 |  | - | 0.2 | 1.000 | 421 | 2,459,355 | 17.1 |
| Pediatric Age 0 to 19 | Male | - | 566 | - | - | 0.1 | 1.000 | 223 | 1,255,944 | 17.8 |
| Pediatric Age 0 to 19 | Female | - | 602 | - | - | 0.1 | 1.000 | 198 | 1,203,411 | 16.5 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ )
Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

## TABLE 4: CANCER MORTALITY 2017-2021

COMPARISON BETWEEN CLARK COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Clark County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 32 | 4,205 | 761.0 | 625.3 | 44.1 | 0.071 | 77,398 | 8,984,510 | 861.5 |
| All Causes of Death | Male | 15 | 2,166 | 692.5 | 512.5 | 26.6 | 0.021 < | 41,041 | 4,509,702 | 910.1 |
| All Causes of Death | Female | 17 | 2,039 | 833.7 | 762.6 | 18.1 | 0.916 | 36,357 | 4,474,808 | 812.5 |
| All Malignant Cancers | Total | 7 | 4,205 | 166.5 | 142.6 | 8.3 | 0.835 | 15,114 | 8,984,510 | 168.2 |
| All Malignant Cancers | Male | 2 | 2,166 | 92.3 | 70.1 | 5.2 | 0.222 | 8,174 | 4,509,702 | 181.3 |
| All Malignant Cancers | Female | 5 | 2,039 | 245.2 | 234.3 | 3.3 | 0.478 | 6,940 | 4,474,808 | 155.1 |
| Bladder | Total | - | 4,205 | - | - | 0.3 | 1.000 | 489 | 8,984,510 | 5.4 |
| Bladder | Male | - | 2,166 | - | - | 0.3 | 1.000 | 378 | 4,509,702 | 8.4 |
| Bladder | Female | - | 2,039 |  | - | 0.1 | 1.000 | 111 | 4,474,808 | 2.5 |
| Brain and Other Nervous System | Total | - | 4,205 |  | - | 0.3 | 1.000 | 504 | 8,984,510 | 5.6 |
| Brain and Other Nervous System | Male | - | 2,166 | - | - | 0.2 | 1.000 | 298 | 4,509,702 | 6.6 |
| Brain and Other Nervous System | Female | - | 2,039 | - | - | 0.1 | 1.000 | 206 | 4,474,808 | 4.6 |
| Breast | Total | - | 4,205 |  | - | 0.6 | 1.000 | 1,102 | 8,984,510 | 12.3 |
| Breast | Male | - | 2,166 | - | - | 0.0 | 1.000 | 16 | 4,509,702 | 0.4 |
| Breast | Female | - | 2,039 |  | - | 0.5 | 1.000 | 1,086 | 4,474,808 | 24.3 |
| Cervix | Female | - | 2,039 |  | - | 0.0 | 1.000 | 83 | 4,474,808 | 1.9 |
| Colorectal | Total | - | 4,205 |  | - | 0.7 | 0.974 | 1,319 | 8,984,510 | 14.7 |
| Colorectal | Male | - | 2,166 | - | - | 0.4 | 1.000 | 719 | 4,509,702 | 15.9 |
| Colorectal | Female | - | 2,039 | - | - | 0.3 | 1.000 | 600 | 4,474,808 | 13.4 |
| Corpus Uteri | Female | - | 2,039 |  | - | 0.1 | 1.000 | 173 | 4,474,808 | 3.9 |
| Esophagus | Total |  | 4,205 |  | - | 0.3 | 1.000 | 477 | 8,984,510 | 5.3 |
| Esophagus | Male | - | 2,166 | - | - | 0.2 | 1.000 | 401 | 4,509,702 | 8.9 |
| Esophagus | Female | - | 2,039 | - | - | 0.0 | 1.000 | 76 | 4,474,808 | 1.7 |
| Hodgkin Lymphoma | Total | - | 4,205 | - | - | 0.0 | 1.000 | 29 | 8,984,510 | 0.3 |
| Hodgkin Lymphoma | Male | - | 2,166 | - | - | 0.0 | 1.000 | 14 | 4,509,702 | 0.3 |
| Hodgkin Lymphoma | Female | - | 2,039 |  | - | 0.0 | 1.000 | 15 | 4,474,808 | 0.3 |
| Kidney | Total | 1 | 4,205 | 23.8 | 20.3 | 0.2 | 0.379 | 384 | 8,984,510 | 4.3 |
| Kidney | Male | 1 | 2,166 | 46.2 | 36.0 | 0.1 | 0.276 | 241 | 4,509,702 | 5.3 |
| Kidney | Female | - | 2,039 | - | - | 0.1 | 1.000 | 143 | 4,474,808 | 3.2 |
| Larynx | Total | - | 4,205 |  | - | 0.0 | 1.000 | 71 | 8,984,510 | 0.8 |
| Larynx | Male | - | 2,166 | - | - | 0.0 | 1.000 | 58 | 4,509,702 | 1.3 |
| Larynx | Female | - | 2,039 | - | - | 0.0 | 1.000 | 13 | 4,474,808 | 0.3 |
| Leukemia | Total | - | 4,205 |  | - | 0.4 | 1.000 | 660 | 8,984,510 | 7.3 |
| Leukemia | Male | - | 2,166 | - | - | 0.2 | 1.000 | 386 | 4,509,702 | 8.6 |
| Leukemia | Female | - | 2,039 | - | - | 0.1 | 1.000 | 274 | 4,474,808 | 6.1 |
| Liver and Bile Duct | Total | - | 4,205 |  | - | 0.3 | 1.000 | 603 | 8,984,510 | 6.7 |
| Liver and Bile Duct | Male | - | 2,166 | - | - | 0.2 | 1.000 | 408 | 4,509,702 | 9.0 |
| Liver and Bile Duct | Female | - | 2,039 | - | - | 0.1 | 1.000 | 195 | 4,474,808 | 4.4 |
| Lung and Bronchus | Total | 1 | 4,205 | 23.8 | 20.5 | 1.6 | 1.000 | 2,960 | 8,984,510 | 32.9 |
| Lung and Bronchus | Male | 1 | 2,166 | 46.2 | 36.0 | 1.0 | 1.000 | 1,555 | 4,509,702 | 34.5 |
| Lung and Bronchus | Female | - | 2,039 | - | - | 0.7 | 1.000 | 1,405 | 4,474,808 | 31.4 |
| Melanoma of the Skin | Total |  | 4,205 |  |  | 0.2 | 1.000 | 289 | 8,984,510 | 3.2 |
| Melanoma of the Skin | Male | - | 2,166 | - | - | 0.1 | 1.000 | 192 | 4,509,702 | 4.3 |
| Melanoma of the Skin | Female | - | 2,039 | - | - | 0.0 | 1.000 | 97 | 4,474,808 | 2.2 |
| Myeloma | Total | - | 4,205 |  | - | 0.2 | 1.000 | 331 | 8,984,510 | 3.7 |
| Myeloma | Male | - | 2,166 | - | - | 0.1 | 1.000 | 196 | 4,509,702 | 4.3 |
| Myeloma | Female | - | 2,039 | - | - | 0.1 | 1.000 | 135 | 4,474,808 | 3.0 |
| Non-Hodgkin Lymphoma | Total |  | 4,205 |  | - | 0.3 | 1.000 | 569 | 8,984,510 | 6.3 |
| Non-Hodgkin Lymphoma | Male | - | 2,166 | - | - | 0.2 | 1.000 | 307 | 4,509,702 | 6.8 |
| Non-Hodgkin Lymphoma | Female | - | 2,039 | - | - | 0.1 | 1.000 | 262 | 4,474,808 | 5.9 |
| Oral Cavity and Pharynx | Total | - | 4,205 | - | - | 0.1 | 1.000 | 266 | 8,984,510 | 3.0 |
| Oral Cavity and Pharynx | Male | - | 2,166 | - | - | 0.1 | 1.000 | 187 | 4,509,702 | 4.1 |
| Oral Cavity and Pharynx | Female | - | 2,039 | - | - | 0.0 | 1.000 | 79 | 4,474,808 | 1.8 |
| Ovary | Female | - | 2,039 | - | - | 0.2 | 1.000 | 350 | 4,474,808 | 7.8 |
| Pancreas | Total | 1 | 4,205 | 23.8 | 20.9 | 0.6 | 0.940 | 1,189 | 8,984,510 | 13.2 |
| Pancreas | Male | - | 2,166 | - | - | 0.4 | 1.000 | 642 | 4,509,702 | 14.2 |
| Pancreas | Female | 1 | 2,039 | 49.0 | 47.3 | 0.3 | 0.456 | 547 | 4,474,808 | 12.2 |
| Prostate | Male | - | 2,166 |  | - | 0.7 | 1.000 | 949 | 4,509,702 | 21.0 |
| Stomach | Total | 1 | 4,205 | 23.8 | 20.4 | 0.1 | 0.204 | 197 | 8,984,510 | 2.2 |
| Stomach | Male | - | 2,166 | - | - | 0.1 | 1.000 | 121 | 4,509,702 | 2.7 |
| Stomach | Female | 1 | 2,039 | 49.0 | 46.0 | 0.0 | 0.073 | 76 | 4,474,808 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ )
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Clark County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% |  |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 4.4\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% |  |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | . |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% |  |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% |  |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 64.3\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | . |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | . |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^16]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged $50-74$ reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and 25.4\% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 362 cases of invasive cancer were diagnosed among Clearwater County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Clearwater County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Clearwater <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 362 | 45,610 |
| Female Breast | 37 | 6,687 |
| Prostate | 57 | 6,417 |
| Lung \& Bronchus | 58 | 4,887 |
| Colorectal | 34 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Clearwater County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Clearwater County. The table also shows the number of observed cases,
person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Clearwater County was 828.8 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.4) gives an estimate of the relative burden of disease in Clearwater County.

The age- and sex-adjusted incidence rate of invasive cancer in Clearwater County, all sites combined, was 540.4 cases per 100,000 persons per year during 2016-2020. There were more cases of cancer in Clearwater County (362) than expected (347.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 139 Clearwater County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Clearwater County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Clearwater <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 569 | 77,431 |
| Cancer Deaths | 139 | 15,121 |
| \% of All Deaths | $24.4 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 42 | 2,961 |
| Colorectal | 15 | 1,319 |
| Pancreas | 6 | 1,190 |
| Female Breast | 4 | 1,086 |
| Prostate | 6 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Clearwater County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Clearwater County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Clearwater County, all sites combined, was 191.5 deaths per 100,000 persons per year during 2017-2021, compared with 167.5 for the remainder of the state. There were more cancer deaths in Clearwater County (139) than expected (121.6) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

|  |  | Clearwater County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 362 | 43,677 | 828.8 | 540.4 | 347.3 | 0.443 | 45,248 | 8,728,151 | 518.4 |
| All Sites Combined | Male | 217 | 24,114 | 899.9 | 580.9 | 205.6 | 0.446 | 24,072 | 4,372,796 | 550.5 |
| All Sites Combined | Female | 145 | 19,563 | 741.2 | 485.2 | 145.3 | 1.000 | 21,176 | 4,355,355 | 486.2 |
| Bladder | Total | 20 | 43,677 | 45.8 | 27.4 | 18.1 | 0.712 | 2,164 | 8,728,151 | 24.8 |
| Bladder | Male | 18 | 24,114 | 74.6 | 45.1 | 15.8 | 0.649 | 1,733 | 4,372,796 | 39.6 |
| Bladder | Female | 2 | 19,563 | 10.2 | 6.1 | 3.3 | 0.730 | 431 | 4,355,355 | 9.9 |
| Brain - malignant | Total | 3 | 43,677 | 6.9 | 5.0 | 4.2 | 0.773 | 622 | 8,728,151 | 7.1 |
| Brain - malignant | Male | 3 | 24,114 | 12.4 | 9.2 | 2.8 | 1.000 | 372 | 4,372,796 | 8.5 |
| Brain - malignant | Female | - | 19,563 | - | - | 1.6 | 0.412 | 250 | 4,355,355 | 5.7 |
| Brain and other CNS - non-malignant | Total | 11 | 43,677 | 25.2 | 17.4 | 10.2 | 0.887 | 1,413 | 8,728,151 | 16.2 |
| Brain and other CNS - non-malignant | Male | 4 | 24,114 | 16.6 | 11.9 | 3.6 | 0.988 | 476 | 4,372,796 | 10.9 |
| Brain and other CNS - non-malignant | Female | 7 | 19,563 | 35.8 | 24.0 | 6.3 | 0.876 | 937 | 4,355,355 | 21.5 |
| Breast | Total | 37 | 43,677 | 84.7 | 57.6 | 49.4 | 0.082 | 6,709 | 8,728,151 | 76.9 |
| Breast | Male | - | 24,114 | - | - | 0.5 | 1.000 | 59 | 4,372,796 | 1.3 |
| Breast | Female | 37 | 19,563 | 189.1 | 126.3 | 44.7 | 0.278 | 6,650 | 4,355,355 | 152.7 |
| Breast - in situ | Total | 6 | 43,677 | 13.7 | 9.6 | 8.9 | 0.439 | 1,233 | 8,728,151 | 14.1 |
| Breast - in situ | Male | - | 24,114 | - | - | 0.0 | 1.000 | 5 | 4,372,796 | 0.1 |
| Breast - in situ | Female | 6 | 19,563 | 30.7 | 21.0 | 8.1 | 0.611 | 1,228 | 4,355,355 | 28.2 |
| Cervix | Female | - | 19,563 | - | - | 1.5 | 0.431 | 304 | 4,355,355 | 7.0 |
| Colorectal | Total | 34 | 43,677 | 77.8 | 50.9 | 26.1 | 0.159 | 3,417 | 8,728,151 | 39.1 |
| Colorectal | Male | 22 | 24,114 | 91.2 | 60.8 | 15.6 | 0.143 | 1,881 | 4,372,796 | 43.0 |
| Colorectal | Female | 12 | 19,563 | 61.3 | 39.0 | 10.9 | 0.808 | 1,536 | 4,355,355 | 35.3 |
| Corpus Uteri | Female | 5 | 19,563 | 25.6 | 16.9 | 9.0 | 0.230 | 1,325 | 4,355,355 | 30.4 |
| Esophagus | Total | 10 | 43,677 | 22.9 | 14.3 | 4.0 | $0.016 \gg$ | 496 | 8,728,151 | 5.7 |
| Esophagus | Male | 10 | 24,114 | 41.5 | 26.3 | 3.6 | 0.008 >> | 414 | 4,372,796 | 9.5 |
| Esophagus | Female | - | 19,563 | - | - | 0.6 | 1.000 | 82 | 4,355,355 | 1.9 |
| Hodgkin Lymphoma | Total | - | 43,677 | - | - | 1.2 | 0.616 | 210 | 8,728,151 | 2.4 |
| Hodgkin Lymphoma | Male | - | 24,114 | - | - | 0.8 | 0.943 | 118 | 4,372,796 | 2.7 |
| Hodgkin Lymphoma | Female | - | 19,563 | - | - | 0.4 | 1.000 | 92 | 4,355,355 | 2.1 |
| Kidney and Renal Pelvis | Total | 17 | 43,677 | 38.9 | 25.8 | 13.6 | 0.415 | 1,798 | 8,728,151 | 20.6 |
| Kidney and Renal Pelvis | Male | 13 | 24,114 | 53.9 | 36.3 | 9.6 | 0.340 | 1,169 | 4,372,796 | 26.7 |
| Kidney and Renal Pelvis | Female | 4 | 19,563 | 20.4 | 13.3 | 4.4 | 1.000 | 629 | 4,355,355 | 14.4 |
| Larynx | Total | 4 | 43,677 | 9.2 | 5.8 | 1.7 | 0.176 | 211 | 8,728,151 | 2.4 |
| Larynx | Male | 2 | 24,114 | 8.3 | 5.3 | 1.4 | 0.791 | 158 | 4,372,796 | 3.6 |
| Larynx | Female | 2 | 19,563 | 10.2 | 6.5 | 0.4 | 0.110 | 53 | 4,355,355 | 1.2 |
| Leukemia | Total | 16 | 43,677 | 36.6 | 24.1 | 12.3 | 0.355 | 1,615 | 8,728,151 | 18.5 |
| Leukemia | Male | 10 | 24,114 | 41.5 | 27.7 | 8.1 | 0.585 | 979 | 4,372,796 | 22.4 |
| Leukemia | Female | 6 | 19,563 | 30.7 | 19.6 | 4.5 | 0.585 | 636 | 4,355,355 | 14.6 |
| Liver and Bile Duct | Total | 8 | 43,677 | 18.3 | 11.7 | 6.4 | 0.633 | 821 | 8,728,151 | 9.4 |
| Liver and Bile Duct | Male | 8 | 24,114 | 33.2 | 21.6 | 4.9 | 0.252 | 582 | 4,372,796 | 13.3 |
| Liver and Bile Duct | Female | - | 19,563 | - | - | 1.7 | 0.355 | 239 | 4,355,355 | 5.5 |
| Lung and Bronchus | Total | 58 | 43,677 | 132.8 | 80.1 | 40.1 | 0.009 >> | 4,829 | 8,728,151 | 55.3 |
| Lung and Bronchus | Male | 24 | 24,114 | 99.5 | 60.3 | 22.1 | 0.741 | 2,428 | 4,372,796 | 55.5 |
| Lung and Bronchus | Female | 34 | 19,563 | 173.8 | 102.8 | 18.2 | 0.001 >> | 2,401 | 4,355,355 | 55.1 |
| Melanoma of the Skin | Total | 14 | 43,677 | 32.1 | 21.8 | 21.6 | 0.114 | 2,928 | 8,728,151 | 33.5 |
| Melanoma of the Skin | Male | 8 | 24,114 | 33.2 | 21.9 | 14.7 | 0.089 | 1,757 | 4,372,796 | 40.2 |
| Melanoma of the Skin | Female | 6 | 19,563 | 30.7 | 21.8 | 7.4 | 0.787 | 1,171 | 4,355,355 | 26.9 |
| Myeloma | Total | - | 43,677 | - | - | 5.8 | 0.006 << | 708 | 8,728,151 | 8.1 |
| Myeloma | Male | - | 24,114 | - | - | 3.9 | 0.039 << | 441 | 4,372,796 | 10.1 |
| Myeloma | Female | - | 19,563 | - | - | 2.0 | 0.274 | 267 | 4,355,355 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 14 | 43,677 | 32.1 | 21.0 | 14.7 | 0.984 | 1,926 | 8,728,151 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 6 | 24,114 | 24.9 | 16.6 | 9.3 | 0.363 | 1,123 | 4,372,796 | 25.7 |
| Non-Hodgkin Lymphoma | Female | 8 | 19,563 | 40.9 | 25.8 | 5.7 | 0.438 | 803 | 4,355,355 | 18.4 |
| Oral Cavity and Pharynx | Total | 16 | 43,677 | 36.6 | 24.0 | 9.8 | 0.081 | 1,279 | 8,728,151 | 14.7 |
| Oral Cavity and Pharynx | Male | 10 | 24,114 | 41.5 | 27.7 | 7.7 | 0.483 | 926 | 4,372,796 | 21.2 |
| Oral Cavity and Pharynx | Female | 6 | 19,563 | 30.7 | 19.7 | 2.5 | 0.080 | 353 | 4,355,355 | 8.1 |
| Ovary | Female | 2 | 19,563 | 10.2 | 6.8 | 3.6 | 0.613 | 531 | 4,355,355 | 12.2 |
| Pancreas | Total | 12 | 43,677 | 27.5 | 16.9 | 11.5 | 0.954 | 1,411 | 8,728,151 | 16.2 |
| Pancreas | Male | 7 | 24,114 | 29.0 | 18.2 | 6.8 | 1.000 | 777 | 4,372,796 | 17.8 |
| Pancreas | Female | 5 | 19,563 | 25.6 | 15.3 | 4.8 | 1.000 | 634 | 4,355,355 | 14.6 |
| Prostate | Male | 57 | 24,114 | 236.4 | 148.9 | 55.7 | 0.893 | 6,360 | 4,372,796 | 145.4 |
| Stomach | Total | 2 | 43,677 | 4.6 | 2.9 | 3.7 | 0.581 | 465 | 8,728,151 | 5.3 |
| Stomach | Male | 1 | 24,114 | 4.1 | 2.6 | 2.7 | 0.508 | 308 | 4,372,796 | 7.0 |
| Stomach | Female | 1 | 19,563 | 5.1 | 3.2 | 1.1 | 1.000 | 157 | 4,355,355 | 3.6 |
| Testis | Male | - | 24,114 | - | - | 1.4 | 0.500 | 265 | 4,372,796 | 6.1 |
| Thyroid | Total | 5 | 43,677 | 11.4 | 9.7 | 7.2 | 0.552 | 1,215 | 8,728,151 | 13.9 |
| Thyroid | Male | 2 | 24,114 | 8.3 | 6.5 | 2.5 | 1.000 | 353 | 4,372,796 | 8.1 |
| Thyroid | Female | 3 | 19,563 | 15.3 | 13.5 | 4.4 | 0.722 | 862 | 4,355,355 | 19.8 |
| Pediatric Age 0 to 19 | Total | 1 | 7,688 | 13.0 | 12.9 | 1.3 | 1.000 | 420 | 2,452,835 | 17.1 |
| Pediatric Age 0 to 19 | Male | - | 4,343 | - | - | 0.8 | 0.920 | 223 | 1,252,167 | 17.8 |
| Pediatric Age 0 to 19 | Female | 1 | 3,345 | 29.9 | 29.8 | 0.6 | 0.846 | 197 | 1,200,668 | 16.4 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021 COMPARISON BETWEEN CLEARWATER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Clearwater County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 569 | 43,912 | 1,295.8 | 784.9 | 622.9 | 0.030 << | 76,861 | 8,944,803 | 859.3 |
| All Causes of Death | Male | 317 | 24,311 | 1,303.9 | 819.0 | 351.4 | 0.068 | 40,739 | 4,487,557 | 907.8 |
| All Causes of Death | Female | 252 | 19,601 | 1,285.6 | 730.9 | 279.4 | 0.104 | 36,122 | 4,457,246 | 810.4 |
| All Malignant Cancers | Total | 139 | 43,912 | 316.5 | 191.5 | 121.6 | 0.129 | 14,982 | 8,944,803 | 167.5 |
| All Malignant Cancers | Male | 76 | 24,311 | 312.6 | 190.6 | 72.0 | 0.665 | 8,100 | 4,487,557 | 180.5 |
| All Malignant Cancers | Female | 63 | 19,601 | 321.4 | 190.2 | 51.1 | 0.119 | 6,882 | 4,457,246 | 154.4 |
| Bladder | Total | 3 | 43,912 | 6.8 | 3.9 | 4.2 | 0.787 | 486 | 8,944,803 | 5.4 |
| Bladder | Male | 3 | 24,311 | 12.3 | 7.1 | 3.5 | 1.000 | 375 | 4,487,557 | 8.4 |
| Bladder | Female |  | 19,601 | - |  | 0.9 | 0.824 | 111 | 4,457,246 | 2.5 |
| Brain and Other Nervous System | Total | 2 | 43,912 | 4.6 | 3.1 | 3.6 | 0.591 | 502 | 8,944,803 | 5.6 |
| Brain and Other Nervous System | Male | 2 | 24,311 | 8.2 | 5.6 | 2.3 | 1.000 | 296 | 4,487,557 | 6.6 |
| Brain and Other Nervous System | Female |  | 19,601 |  |  | 1.4 | 0.508 | 206 | 4,457,246 | 4.6 |
| Breast | Total | 5 | 43,912 | 11.4 | 7.2 | 8.6 | 0.289 | 1,097 | 8,944,803 | 12.3 |
| Breast | Male | 1 | 24,311 | 4.1 | 2.6 | 0.1 | 0.244 | 15 | 4,487,557 | 0.3 |
| Breast | Female | 4 | 19,601 | 20.4 | 12.5 | 7.8 | 0.224 | 1,082 | 4,457,246 | 24.3 |
| Cervix | Female |  | 19,601 |  |  | 0.5 | 1.000 | 83 | 4,457,246 | 1.9 |
| Colorectal | Total | 15 | 43,912 | 34.2 | 21.2 | 10.3 | 0.201 | 1,304 | 8,944,803 | 14.6 |
| Colorectal | Male | 6 | 24,311 | 24.7 | 15.9 | 6.0 | 1.000 | 713 | 4,487,557 | 15.9 |
| Colorectal | Female | 9 | 19,601 | 45.9 | 27.0 | 4.4 | 0.073 | 591 | 4,457,246 | 13.3 |
| Corpus Uteri | Female | 3 | 19,601 | 15.3 | 9.2 | 1.2 | 0.260 | 170 | 4,457,246 | 3.8 |
| Esophagus | Total | 7 | 43,912 | 15.9 | 9.8 | 3.8 | 0.175 | 470 | 8,944,803 | 5.3 |
| Esophagus | Male | 7 | 24,311 | 28.8 | 18.0 | 3.4 | 0.119 | 394 | 4,487,557 | 8.8 |
| Esophagus | Female | - | 19,601 | - | - | 0.6 | 1.000 | 76 | 4,457,246 | 1.7 |
| Hodgkin Lymphoma | Total | 1 | 43,912 | 2.3 | 1.5 | 0.2 | 0.380 | 28 | 8,944,803 | 0.3 |
| Hodgkin Lymphoma | Male |  | 24,311 |  |  | 0.1 | 1.000 | 14 | 4,487,557 | 0.3 |
| Hodgkin Lymphoma | Female | 1 | 19,601 | 5.1 | 3.1 | 0.1 | 0.193 | 14 | 4,457,246 | 0.3 |
| Kidney | Total | 5 | 43,912 | 11.4 | 6.8 | 3.1 | 0.415 | 380 | 8,944,803 | 4.2 |
| Kidney | Male | 3 | 24,311 | 12.3 | 7.6 | 2.1 | 0.708 | 239 | 4,487,557 | 5.3 |
| Kidney | Female | 2 | 19,601 | 10.2 | 5.7 | 1.1 | 0.602 | 141 | 4,457,246 | 3.2 |
| Larynx | Total |  | 43,912 |  | - | 0.6 | 1.000 | 71 | 8,944,803 | 0.8 |
| Larynx | Male |  | 24,311 | - | - | 0.5 | 1.000 | 58 | 4,487,557 | 1.3 |
| Larynx | Female | - | 19,601 | - | - | 0.1 | 1.000 | 13 | 4,457,246 | 0.3 |
| Leukemia | Total | 2 | 43,912 | 4.6 | 2.7 | 5.4 | 0.187 | 658 | 8,944,803 | 7.4 |
| Leukemia | Male | 1 | 24,311 | 4.1 | 2.5 | 3.4 | 0.287 | 385 | 4,487,557 | 8.6 |
| Leukemia | Female | 1 | 19,601 | 5.1 | 2.9 | 2.1 | 0.760 | 273 | 4,457,246 | 6.1 |
| Liver and Bile Duct | Total | 4 | 43,912 | 9.1 | 5.6 | 4.8 | 0.962 | 599 | 8,944,803 | 6.7 |
| Liver and Bile Duct | Male | 3 | 24,311 | 12.3 | 7.7 | 3.5 | 1.000 | 405 | 4,487,557 | 9.0 |
| Liver and Bile Duct | Female | 1 | 19,601 | 5.1 | 3.0 | 1.4 | 1.000 | 194 | 4,457,246 | 4.4 |
| Lung and Bronchus | Total | 42 | 43,912 | 95.6 | 56.8 | 24.1 | 0.001 >> | 2,919 | 8,944,803 | 32.6 |
| Lung and Bronchus | Male | 18 | 24,311 | 74.0 | 44.4 | 13.9 | 0.330 | 1,538 | 4,487,557 | 34.3 |
| Lung and Bronchus | Female | 24 | 19,601 | 122.4 | 70.9 | 10.5 | 0.000 >> | 1,381 | 4,457,246 | 31.0 |
| Melanoma of the Skin | Total | 1 | 43,912 | 2.3 | 1.4 | 2.3 | 0.678 | 288 | 8,944,803 | 3.2 |
| Melanoma of the Skin | Male | 1 | 24,311 | 4.1 | 2.6 | 1.7 | 1.000 | 191 | 4,487,557 | 4.3 |
| Melanoma of the Skin | Female | - | 19,601 | - | - | 0.7 | 1.000 | 97 | 4,457,246 | 2.2 |
| Myeloma | Total | 1 | 43,912 | 2.3 | 1.3 | 2.8 | 0.459 | 330 | 8,944,803 | 3.7 |
| Myeloma | Male | - | 24,311 | - | - | 1.8 | 0.320 | 196 | 4,487,557 | 4.4 |
| Myeloma | Female | 1 | 19,601 | 5.1 | 2.9 | 1.0 | 1.000 | 134 | 4,457,246 | 3.0 |
| Non-Hodgkin Lymphoma | Total |  | 43,912 | 13.7 | 8.1 | 4.7 | 0.655 | 563 | 8,944,803 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 4 | 24,311 | 16.5 | 10.0 | 2.7 | 0.568 | 303 | 4,487,557 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 2 | 19,601 | 10.2 | 5.7 | 2.0 | 1.000 | 260 | 4,457,246 | 5.8 |
| Oral Cavity and Pharynx | Total | 7 | 43,912 | 15.9 | 9.8 | 2.1 | 0.011 >> | 259 | 8,944,803 | 2.9 |
| Oral Cavity and Pharynx | Male | 6 | 24,311 | 24.7 | 15.5 | 1.6 | 0.011 >> | 181 | 4,487,557 | 4.0 |
| Oral Cavity and Pharynx | Female |  | 19,601 | 5.1 | 3.0 | 0.6 | 0.874 | 78 | 4,457,246 | 1.7 |
| Ovary | Female | 4 | 19,601 | 20.4 | 12.3 | 2.5 | 0.498 | 346 | 4,457,246 | 7.8 |
| Pancreas | Total |  | 43,912 | 13.7 | 8.2 | 9.6 | 0.310 | 1,184 | 8,944,803 | 13.2 |
| Pancreas | Male | 3 | 24,311 | 12.3 | 7.5 | 5.7 | 0.368 | 639 | 4,487,557 | 14.2 |
| Pancreas | Female | 3 | 19,601 | 15.3 | 9.0 | 4.1 | 0.837 | 545 | 4,457,246 | 12.2 |
| Prostate | Male | 6 | 24,311 | 24.7 | 14.1 | 8.9 | 0.430 | 943 | 4,487,557 | 21.0 |
| Stomach | Total | 2 | 43,912 | 4.6 | 2.9 | 1.5 | 0.903 | 196 | 8,944,803 | 2.2 |
| Stomach | Male | 1 | 24,311 | 4.1 | 2.6 | 1.0 | 1.000 | 120 | 4,487,557 | 2.7 |
| Stomach | Female | 1 | 19,601 | 5.1 | 3.2 | 0.5 | 0.830 | 76 | 4,457,246 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Clearwater County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 82.3\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) Cancer Screening | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 14.4\% |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 59.8\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 (2018, 2020) | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) Tobacco Use | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 75.2\% |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 27.1\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 29.3\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 74.6\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 16.4\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 19.9\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, 12.6\% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^17]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

## CUSTPR COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 154 cases of invasive cancer were diagnosed among Custer County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Custer County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Custer <br> County |  |
| :--- | ---: | ---: | | State of <br> Idaho |
| :---: |
| All Sites/Types |

Table 3 (Cancer Incidence 2016-2020, Comparison between Custer County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Custer County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Custer County was 734.6 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.4) gives an estimate of the relative burden of disease in Custer County.

The age- and sex-adjusted incidence rate of invasive cancer in Custer County, all sites combined, was 460.4 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Custer County (154) than expected (173.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 73 Custer County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Custer County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Custer <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 270 | 77,431 |
| Cancer Deaths | 73 | 15,121 |
| \% of All Deaths | $27.0 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 18 | 2,961 |
| Colorectal | 9 | 1,319 |
| Pancreas | 5 | 1,190 |
| Female Breast | 8 | 1,086 |
| Prostate | 4 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Custer County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Custer County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Custer County, all sites combined, was 203.6 deaths per 100,000 persons per year during 2017-2021, compared with 167.8 for the remainder of the state. There were more cancer deaths in Custer County (73) than expected (60.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN CUSTER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Custer County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person Years | Crude Rate (1) | A.A.I. Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person Years | Crude Rate (1) |
| All Sites Combined | Total | 154 | 20,965 | 734.6 | 460.4 | 173.7 | 0.140 | 45,456 | 8,750,863 | 519.4 |
| All Sites Combined | Male | 99 | 10,868 | 910.9 | 524.1 | 104.2 | 0.655 | 24,190 | 4,386,042 | 551.5 |
| All Sites Combined | Female | 55 | 10,097 | 544.7 | 370.7 | 72.3 | 0.041 << | 21,266 | 4,364,821 | 487.2 |
| Bladder | Total | 10 | 20,965 | 47.7 | 27.8 | 8.9 | 0.809 | 2,174 | 8,750,863 | 24.8 |
| Bladder | Male | 7 | 10,868 | 64.4 | 35.1 | 7.9 | 0.928 | 1,744 | 4,386,042 | 39.8 |
| Bladder | Female | 3 | 10,097 | 29.7 | 18.6 | 1.6 | 0.429 | 430 | 4,364,821 | 9.9 |
| Brain - malignant | Total | 1 | 20,965 | 4.8 | 3.4 | 2.1 | 0.754 | 624 | 8,750,863 | 7.1 |
| Brain - malignant | Male | 1 | 10,868 | 9.2 | 6.2 | 1.4 | 1.000 | 374 | 4,386,042 | 8.5 |
| Brain - malignant | Female | - | 10,097 |  |  | 0.8 | 0.912 | 250 | 4,364,821 | 5.7 |
| Brain and other CNS - non-malignant | Total | 5 | 20,965 | 23.8 | 16.2 | 5.0 | 1.000 | 1,419 | 8,750,863 | 16.2 |
| Brain and other CNS - non-malignant | Male | 3 | 10,868 | 27.6 | 18.5 | 1.8 | 0.520 | 477 | 4,386,042 | 10.9 |
| Brain and other CNS - non-malignant | Female | 2 | 10,097 | 19.8 | 13.9 | 3.1 | 0.797 | 942 | 4,364,821 | 21.6 |
| Breast | Total | 16 | 20,965 | 76.3 | 49.7 | 24.7 | 0.084 | 6,730 | 8,750,863 | 76.9 |
| Breast | Male |  | 10,868 |  |  | 0.3 | 1.000 | 59 | 4,386,042 | 1.3 |
| Breast | Female | 16 | 10,097 | 158.5 | 108.9 | 22.5 | 0.199 | 6,671 | 4,364,821 | 152.8 |
| Breast - in situ | Total | 3 | 20,965 | 14.3 | 9.4 | 4.5 | 0.682 | 1,236 | 8,750,863 | 14.1 |
| Breast - in situ | Male |  | 10,868 |  |  | 0.0 | 1.000 | 5 | 4,386,042 | 0.1 |
| Breast - in situ | Female | 3 | 10,097 | 29.7 | 20.6 | 4.1 | 0.824 | 1,231 | 4,364,821 | 28.2 |
| Cervix | Female |  | 10,097 |  |  | 0.8 | 0.918 | 304 | 4,364,821 | 7.0 |
| Colorectal | Total | 14 | 20,965 | 66.8 | 42.8 | 12.9 | 0.823 | 3,437 | 8,750,863 | 39.3 |
| Colorectal | Male | 12 | 10,868 | 110.4 | 67.4 | 7.7 | 0.180 | 1,891 | 4,386,042 | 43.1 |
| Colorectal | Female | 2 | 10,097 | 19.8 | 13.3 | 5.3 | 0.199 | 1,546 | 4,364,821 | 35.4 |
| Corpus Uteri | Female | 3 | 10,097 | 29.7 | 20.0 | 4.6 | 0.662 | 1,327 | 4,364,821 | 30.4 |
| Esophagus | Total | 2 | 20,965 | 9.5 | 5.7 | 2.0 | 1.000 | 504 | 8,750,863 | 5.8 |
| Esophagus | Male | 2 | 10,868 | 18.4 | 10.4 | 1.8 | 1.000 | 422 | 4,386,042 | 9.6 |
| Esophagus | Female | - | 10,097 | - | - | 0.3 | 1.000 | 82 | 4,364,821 | 1.9 |
| Hodgkin Lymphoma | Total | - | 20,965 | - | - | 0.6 | 1.000 | 210 | 8,750,863 | 2.4 |
| Hodgkin Lymphoma | Male | - | 10,868 | - | - | 0.4 | 1.000 | 118 | 4,386,042 | 2.7 |
| Hodgkin Lymphoma | Female | - | 10,097 |  |  | 0.2 | 1.000 | 92 | 4,364,821 | 2.1 |
| Kidney and Renal Pelvis | Total | 6 | 20,965 | 28.6 | 18.3 | 6.8 | 0.965 | 1,809 | 8,750,863 | 20.7 |
| Kidney and Renal Pelvis | Male | 4 | 10,868 | 36.8 | 22.4 | 4.8 | 0.950 | 1,178 | 4,386,042 | 26.9 |
| Kidney and Renal Pelvis | Female | 2 | 10,097 | 19.8 | 13.3 | 2.2 | 1.000 | 631 | 4,364,821 | 14.5 |
| Larynx | Total | - | 20,965 | - | - | 0.9 | 0.853 | 215 | 8,750,863 | 2.5 |
| Larynx | Male | - | 10,868 | - | - | 0.7 | 0.991 | 160 | 4,386,042 | 3.6 |
| Larynx | Female | - | 10,097 |  |  | 0.2 | 1.000 | 55 | 4,364,821 | 1.3 |
| Leukemia | Total | 7 | 20,965 | 33.4 | 21.5 | 6.0 | 0.802 | 1,624 | 8,750,863 | 18.6 |
| Leukemia | Male | 6 | 10,868 | 55.2 | 33.8 | 4.0 | 0.421 | 983 | 4,386,042 | 22.4 |
| Leukemia | Female | 1 | 10,097 | 9.9 | 6.7 | 2.2 | 0.710 | 641 | 4,364,821 | 14.7 |
| Liver and Bile Duct | Total | 2 | 20,965 | 9.5 | 5.7 | 3.3 | 0.717 | 827 | 8,750,863 | 9.5 |
| Liver and Bile Duct | Male | 2 | 10,868 | 18.4 | 10.3 | 2.6 | 1.000 | 588 | 4,386,042 | 13.4 |
| Liver and Bile Duct | Female | - | 10,097 | - | - | 0.9 | 0.846 | 239 | 4,364,821 | 5.5 |
| Lung and Bronchus | Total | 19 | 20,965 | 90.6 | 52.6 | 20.1 | 0.923 | 4,868 | 8,750,863 | 55.6 |
| Lung and Bronchus | Male | 9 | 10,868 | 82.8 | 44.7 | 11.2 | 0.634 | 2,443 | 4,386,042 | 55.7 |
| Lung and Bronchus | Female | 10 | 10,097 | 99.0 | 61.6 | 9.0 | 0.829 | 2,425 | 4,364,821 | 55.6 |
| Melanoma of the Skin | Total | 8 | 20,965 | 38.2 | 25.2 | 10.6 | 0.532 | 2,934 | 8,750,863 | 33.5 |
| Melanoma of the Skin | Male | 7 | 10,868 | 64.4 | 38.8 | 7.2 | 1.000 | 1,758 | 4,386,042 | 40.1 |
| Melanoma of the Skin | Female | 1 | 10,097 | 9.9 | 7.3 | 3.7 | 0.233 | 1,176 | 4,364,821 | 26.9 |
| Myeloma | Total | 3 | 20,965 | 14.3 | 8.5 | 2.8 | 1.000 | 705 | 8,750,863 | 8.1 |
| Myeloma | Male | 2 | 10,868 | 18.4 | 10.3 | 1.9 | 1.000 | 439 | 4,386,042 | 10.0 |
| Myeloma | Female | 1 | 10,097 | 9.9 | 6.3 | 1.0 | 1.000 | 266 | 4,364,821 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 1 | 20,965 | 4.8 | 3.0 | 7.4 | 0.011 << | 1,939 | 8,750,863 | 22.2 |
| Non-Hodgkin Lymphoma | Male | 1 | 10,868 | 9.2 | 5.5 | 4.7 | 0.106 | 1,128 | 4,386,042 | 25.7 |
| Non-Hodgkin Lymphoma | Female | - | 10,097 | - | - | 2.8 | 0.117 | 811 | 4,364,821 | 18.6 |
| Oral Cavity and Pharynx | Total | 5 | 20,965 | 23.8 | 14.8 | 5.0 | 1.000 | 1,290 | 8,750,863 | 14.7 |
| Oral Cavity and Pharynx | Male | 4 | 10,868 | 36.8 | 21.5 | 4.0 | 1.000 | 932 | 4,386,042 | 21.2 |
| Oral Cavity and Pharynx | Female | 1 | 10,097 | 9.9 | 6.6 | 1.3 | 1.000 | 358 | 4,364,821 | 8.2 |
| Ovary | Female | 2 | 10,097 | 19.8 | 13.6 | 1.8 | 1.000 | 531 | 4,364,821 | 12.2 |
| Pancreas | Total | 5 | 20,965 | 23.8 | 14.2 | 5.7 | 0.994 | 1,418 | 8,750,863 | 16.2 |
| Pancreas | Male | 4 | 10,868 | 36.8 | 20.7 | 3.4 | 0.901 | 780 | 4,386,042 | 17.8 |
| Pancreas | Female | 1 | 10,097 | 9.9 | 6.3 | 2.3 | 0.649 | 638 | 4,364,821 | 14.6 |
| Prostate | Male | 28 | 10,868 | 257.6 | 139.0 | 29.4 | 0.899 | 6,389 | 4,386,042 | 145.7 |
| Stomach | Total | 1 | 20,965 | 4.8 | 3.0 | 1.8 | 0.929 | 466 | 8,750,863 | 5.3 |
| Stomach | Male | 1 | 10,868 | 9.2 | 5.3 | 1.3 | 1.000 | 308 | 4,386,042 | 7.0 |
| Stomach | Female | - | 10,097 | - | - | 0.5 | 1.000 | 158 | 4,364,821 | 3.6 |
| Testis | Male | - | 10,868 | - | - | 0.5 | 1.000 | 265 | 4,386,042 | 6.0 |
| Thyroid | Total | 4 | 20,965 | 19.1 | 16.0 | 3.5 | 0.917 | 1,216 | 8,750,863 | 13.9 |
| Thyroid | Male | 1 | 10,868 | 9.2 | 6.8 | 1.2 | 1.000 | 354 | 4,386,042 | 8.1 |
| Thyroid | Female | 3 | 10,097 | 29.7 | 26.5 | 2.2 | 0.772 | 862 | 4,364,821 | 19.7 |
| Pediatric Age 0 to 19 | Total | 1 | 3,910 | 25.6 | 25.3 | 0.7 | 0.983 | 420 | 2,456,613 | 17.1 |
| Pediatric Age 0 to 19 | Male |  | 2,007 | - | - | 0.4 | 1.000 | 223 | 1,254,503 | 17.8 |
| Pediatric Age 0 to 19 | Female | 1 | 1,903 | 52.5 | 52.3 | 0.3 | 0.538 | 197 | 1,202,110 | 16.4 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ). Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN CUSTER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Custer County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 270 | 21,304 | 1,267.4 | 780.8 | 297.5 | 0.113 | 77,160 | 8,967,411 | 860.4 |
| All Causes of Death | Male | 152 | 11,087 | 1,371.0 | 821.0 | 168.3 | 0.222 | 40,904 | 4,500,781 | 908.8 |
| All Causes of Death | Female | 118 | 10,217 | 1,154.9 | 721.5 | 132.8 | 0.213 | 36,256 | 4,466,630 | 811.7 |
| All Malignant Cancers | Total | 73 | 21,304 | 342.7 | 203.6 | 60.2 | 0.118 | 15,048 | 8,967,411 | 167.8 |
| All Malignant Cancers | Male | 42 | 11,087 | 378.8 | 212.3 | 35.8 | 0.335 | 8,134 | 4,500,781 | 180.7 |
| All Malignant Cancers | Female | 31 | 10,217 | 303.4 | 190.5 | 25.2 | 0.290 | 6,914 | 4,466,630 | 154.8 |
| Bladder | Total | 3 | 21,304 | 14.1 | 8.1 | 2.0 | 0.646 | 486 | 8,967,411 | 5.4 |
| Bladder | Male | 2 | 11,087 | 18.0 | 10.0 | 1.7 | 0.991 | 376 | 4,500,781 | 8.4 |
| Bladder | Female |  | 10,217 | 9.8 | 5.9 | 0.4 | 0.686 | 110 | 4,466,630 | 2.5 |
| Brain and Other Nervous System | Total | 2 | 21,304 | 9.4 | 6.1 | 1.8 | 1.000 | 502 | 8,967,411 | 5.6 |
| Brain and Other Nervous System | Male | 1 | 11,087 | 9.0 | 5.5 | 1.2 | 1.000 | 297 | 4,500,781 | 6.6 |
| Brain and Other Nervous System | Female | 1 | 10,217 | 9.8 | 6.6 | 0.7 | 0.999 | 205 | 4,466,630 | 4.6 |
| Breast | Total | 8 | 21,304 | 37.6 | 23.2 | 4.2 | 0.129 | 1,094 | 8,967,411 | 12.2 |
| Breast | Male |  | 11,087 |  |  | 0.1 | 1.000 | 16 | 4,500,781 | 0.4 |
| Breast | Female | 8 | 10,217 | 78.3 | 50.6 | 3.8 | 0.082 | 1,078 | 4,466,630 | 24.1 |
| Cervix | Female | - | 10,217 |  | - | 0.2 | 1.000 | 83 | 4,466,630 | 1.9 |
| Colorectal | Total | 9 | 21,304 | 42.2 | 25.9 | 5.1 | 0.146 | 1,310 | 8,967,411 | 14.6 |
| Colorectal | Male | 8 | 11,087 | 72.2 | 42.6 | 3.0 | 0.022 >> | 711 | 4,500,781 | 15.8 |
| Colorectal | Female | 1 | 10,217 | 9.8 | 6.2 | 2.2 | 0.724 | 599 | 4,466,630 | 13.4 |
| Corpus Uteri | Female | - | 10,217 | - | - | 0.6 | 1.000 | 173 | 4,466,630 | 3.9 |
| Esophagus | Total | 1 | 21,304 | 4.7 | 2.8 | 1.9 | 0.864 | 476 | 8,967,411 | 5.3 |
| Esophagus | Male | 1 | 11,087 | 9.0 | 5.1 | 1.8 | 0.950 | 400 | 4,500,781 | 8.9 |
| Esophagus | Female | - | 10,217 | - | - | 0.3 | 1.000 | 76 | 4,466,630 | 1.7 |
| Hodgkin Lymphoma | Total |  | 21,304 | - | - | 0.1 | 1.000 | 29 | 8,967,411 | 0.3 |
| Hodgkin Lymphoma | Male | - | 11,087 | - | - | 0.1 | 1.000 | 14 | 4,500,781 | 0.3 |
| Hodgkin Lymphoma | Female | - | 10,217 | - | - | 0.1 | 1.000 | 15 | 4,466,630 | 0.3 |
| Kidney | Total | 1 | 21,304 | 4.7 | 2.7 | 1.6 | 1.000 | 384 | 8,967,411 | 4.3 |
| Kidney | Male | 1 | 11,087 | 9.0 | 5.0 | 1.1 | 1.000 | 241 | 4,500,781 | 5.4 |
| Kidney | Female | - | 10,217 | - | - | 0.5 | 1.000 | 143 | 4,466,630 | 3.2 |
| Larynx | Total |  | 21,304 | - | - | 0.3 | 1.000 | 71 | 8,967,411 | 0.8 |
| Larynx | Male | - | 11,087 | - | - | 0.2 | 1.000 | 58 | 4,500,781 | 1.3 |
| Larynx | Female | - | 10,217 |  | - | 0.0 | 1.000 | 13 | 4,466,630 | 0.3 |
| Leukemia | Total | 1 | 21,304 | 4.7 | 2.8 | 2.6 | 0.534 | 659 | 8,967,411 | 7.3 |
| Leukemia | Male | - | 11,087 | - | - | 1.6 | 0.385 | 386 | 4,500,781 | 8.6 |
| Leukemia | Female | 1 | 10,217 | 9.8 | 6.1 | 1.0 | 1.000 | 273 | 4,466,630 | 6.1 |
| Liver and Bile Duct | Total | 3 | 21,304 | 14.1 | 8.2 | 2.4 | 0.882 | 600 | 8,967,411 | 6.7 |
| Liver and Bile Duct | Male | 2 | 11,087 | 18.0 | 9.9 | 1.8 | 1.000 | 406 | 4,500,781 | 9.0 |
| Liver and Bile Duct | Female | 1 | 10,217 | 9.8 | 6.1 | 0.7 | 1.000 | 194 | 4,466,630 | 4.3 |
| Lung and Bronchus | Total | 18 | 21,304 | 84.5 | 48.7 | 12.1 | 0.137 | 2,943 | 8,967,411 | 32.8 |
| Lung and Bronchus | Male | 9 | 11,087 | 81.2 | 43.7 | 7.1 | 0.563 | 1,547 | 4,500,781 | 34.4 |
| Lung and Bronchus | Female | 9 | 10,217 | 88.1 | 54.0 | 5.2 | 0.166 | 1,396 | 4,466,630 | 31.3 |
| Melanoma of the Skin | Total | 2 | 21,304 | 9.4 | 5.8 | 1.1 | 0.608 | 287 | 8,967,411 | 3.2 |
| Melanoma of the Skin | Male | 2 | 11,087 | 18.0 | 10.4 | 0.8 | 0.390 | 190 | 4,500,781 | 4.2 |
| Melanoma of the Skin | Female | - | 10,217 | - | - | 0.3 | 1.000 | 97 | 4,466,630 | 2.2 |
| Myeloma | Total | 1 | 21,304 | 4.7 | 2.7 | 1.4 | 1.000 | 330 | 8,967,411 | 3.7 |
| Myeloma | Male | - | 11,087 | - | - | 0.9 | 0.817 | 196 | 4,500,781 | 4.4 |
| Myeloma | Female | 1 | 10,217 | 9.8 | 6.0 | 0.5 | 0.791 | 134 | 4,466,630 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 1 | 21,304 | 4.7 | 2.8 | 2.3 | 0.672 | 568 | 8,967,411 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 1 | 11,087 | 9.0 | 5.1 | 1.3 | 1.000 | 306 | 4,500,781 | 6.8 |
| Non-Hodgkin Lymphoma | Female | - | 10,217 | - | - | 1.0 | 0.746 | 262 | 4,466,630 | 5.9 |
| Oral Cavity and Pharynx | Total | 2 | 21,304 | 9.4 | 5.6 | 1.1 | 0.568 | 264 | 8,967,411 | 2.9 |
| Oral Cavity and Pharynx | Male | 2 | 11,087 | 18.0 | 10.0 | 0.8 | 0.397 | 185 | 4,500,781 | 4.1 |
| Oral Cavity and Pharynx | Female | - | 10,217 | - | - | 0.3 | 1.000 | 79 | 4,466,630 | 1.8 |
| Ovary | Female | 1 | 10,217 | 9.8 | 6.2 | 1.3 | 1.000 | 349 | 4,466,630 | 7.8 |
| Pancreas | Total | 5 | 21,304 | 23.5 | 13.7 | 4.8 | 1.000 | 1,185 | 8,967,411 | 13.2 |
| Pancreas | Male | 3 | 11,087 | 27.1 | 14.9 | 2.9 | 1.000 | 639 | 4,500,781 | 14.2 |
| Pancreas | Female | 2 | 10,217 | 19.6 | 12.1 | 2.0 | 1.000 | 546 | 4,466,630 | 12.2 |
| Prostate | Male | 4 | 11,087 | 36.1 | 19.9 | 4.2 | 1.000 | 945 | 4,500,781 | 21.0 |
| Stomach | Total |  | 21,304 |  |  | 0.7 | 0.951 | 198 | 8,967,411 | 2.2 |
| Stomach | Male | - | 11,087 | - | - | 0.5 | 1.000 | 121 | 4,500,781 | 2.7 |
| Stomach | Female | - | 10,217 | - | - | 0.3 | 1.000 | 77 | 4,466,630 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Custer County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 82.1\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 12.0\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% |  |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% |  |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 28.1\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 34.1\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 75.1\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 27.5\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 43.2\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^18]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and 25.4\% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

## PHMORE COUNTY CANCPR PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 713 cases of invasive cancer were diagnosed among Elmore County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Elmore County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Elmore <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 713 | 45,610 |
| Female Breast | 78 | 6,687 |
| Prostate | 88 | 6,417 |
| Lung \& Bronchus | 111 | 4,887 |
| Colorectal | 63 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Elmore County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Elmore County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Elmore County was 527.3 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.8) gives an estimate of the relative burden of disease in Elmore County.

The age- and sex-adjusted incidence rate of invasive cancer in Elmore County, all sites combined, was 601.5 cases per 100,000 persons per year during 2016-2020. There were statistically significantly more cases of cancer in Elmore County (713) than expected (616.2) based upon rates in the remainder of the state ( $\mathrm{p}<.001$ ).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 245 Elmore County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Elmore County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Elmore <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 1,094 | 77,431 |
| Cancer Deaths | 245 | 15,121 |
| \% of All Deaths | $22.4 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 69 | 2,961 |
| Colorectal | 25 | 1,319 |
| Pancreas | 21 | 1,190 |
| Female Breast | 5 | 1,086 |
| Prostate | 10 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Elmore County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Elmore County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Elmore County, all sites combined, was 205.9 deaths per 100,000 persons per year during 2017-2021, compared with 168.1 for the remainder of the state. There were statistically significantly more cancer deaths in Elmore County (245) than expected (200.0) based upon rates in the remainder of the state $(p=.002)$.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

COMPARISON BETWEEN ELMORE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Elmore County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 713 | 135,215 | 527.3 | 601.5 | 616.2 | 0.000 >> | 44,897 | 8,636,613 | 519.8 |
| All Sites Combined | Male | 381 | 70,728 | 538.7 | 639.8 | 329.1 | $0.006 \ggg$ | 23,908 | 4,326,182 | 552.6 |
| All Sites Combined | Female | 332 | 64,487 | 514.8 | 565.3 | 286.0 | $0.008 \gg$ | 20,989 | 4,310,431 | 486.9 |
| Bladder | Total | 43 | 135,215 | 31.8 | 37.1 | 28.7 | $0.015 \gg$ | 2,141 | 8,636,613 | 24.8 |
| Bladder | Male | 35 | 70,728 | 49.5 | 60.6 | 22.9 | $0.022 \gg$ | 1,716 | 4,326,182 | 39.7 |
| Bladder | Female | 8 | 64,487 | 12.4 | 13.9 | 5.7 | 0.430 | 425 | 4,310,431 | 9.9 |
| Brain - malignant | Total | 8 | 135,215 | 5.9 | 6.5 | 8.8 | 0.952 | 617 | 8,636,613 | 7.1 |
| Brain - malignant | Male | 6 | 70,728 | 8.5 | 9.5 | 5.4 | 0.909 | 369 | 4,326,182 | 8.5 |
| Brain - malignant | Female | 2 | 64,487 | 3.1 | 3.3 | 3.5 | 0.645 | 248 | 4,310,431 | 5.8 |
| Brain and other CNS - non-malignant | Total | 24 | 135,215 | 17.7 | 20.0 | 19.4 | 0.352 | 1,400 | 8,636,613 | 16.2 |
| Brain and other CNS - non-malignant | Male | 8 | 70,728 | 11.3 | 13.0 | 6.7 | 0.713 | 472 | 4,326,182 | 10.9 |
| Brain and other CNS - non-malignant | Female | 16 | 64,487 | 24.8 | 27.2 | 12.7 | 0.413 | 928 | 4,310,431 | 21.5 |
| Breast | Total | 79 | 135,215 | 58.4 | 66.9 | 91.2 | 0.217 | 6,667 | 8,636,613 | 77.2 |
| Breast | Male | 1 | 70,728 | 1.4 | 1.7 | 0.8 | 1.000 | 58 | 4,326,182 | 1.3 |
| Breast | Female | 78 | 64,487 | 121.0 | 133.7 | 89.4 | 0.245 | 6,609 | 4,310,431 | 153.3 |
| Breast - in situ | Total | 20 | 135,215 | 14.8 | 17.0 | 16.6 | 0.469 | 1,219 | 8,636,613 | 14.1 |
| Breast - in situ | Male | - | 70,728 | - | - | 0.1 | 1.000 | 5 | 4,326,182 | 0.1 |
| Breast - in situ | Female | 20 | 64,487 | 31.0 | 34.5 | 16.3 | 0.425 | 1,214 | 4,310,431 | 28.2 |
| Cervix | Female | 5 | 64,487 | 7.8 | 8.3 | 4.2 | 0.815 | 299 | 4,310,431 | 6.9 |
| Colorectal | Total | 63 | 135,215 | 46.6 | 53.2 | 46.4 | $0.024 \gg$ | 3,388 | 8,636,613 | 39.2 |
| Colorectal | Male | 38 | 70,728 | 53.7 | 63.6 | 25.8 | 0.028 >> | 1,865 | 4,326,182 | 43.1 |
| Colorectal | Female | 25 | 64,487 | 38.8 | 42.7 | 20.7 | 0.393 | 1,523 | 4,310,431 | 35.3 |
| Corpus Uteri | Female | 18 | 64,487 | 27.9 | 30.8 | 17.8 | 1.000 | 1,312 | 4,310,431 | 30.4 |
| Esophagus | Total | 10 | 135,215 | 7.4 | 8.5 | 6.7 | 0.286 | 496 | 8,636,613 | 5.7 |
| Esophagus | Male | 9 | 70,728 | 12.7 | 15.3 | 5.6 | 0.236 | 415 | 4,326,182 | 9.6 |
| Esophagus | Female | 1 | 64,487 | 1.6 | 1.7 | 1.1 | 1.000 | 81 | 4,310,431 | 1.9 |
| Hodgkin Lymphoma | Total | 3 | 135,215 | 2.2 | 2.2 | 3.2 | 1.000 | 207 | 8,636,613 | 2.4 |
| Hodgkin Lymphoma | Male | - | 70,728 | - | - | 1.9 | 0.301 | 118 | 4,326,182 | 2.7 |
| Hodgkin Lymphoma | Female | 3 | 64,487 | 4.7 | 4.6 | 1.3 | 0.307 | 89 | 4,310,431 | 2.1 |
| Kidney and Renal Pelvis | Total | 32 | 135,215 | 23.7 | 26.9 | 24.5 | 0.168 | 1,783 | 8,636,613 | 20.6 |
| Kidney and Renal Pelvis | Male | 22 | 70,728 | 31.1 | 36.8 | 16.0 | 0.182 | 1,160 | 4,326,182 | 26.8 |
| Kidney and Renal Pelvis | Female | 10 | 64,487 | 15.5 | 17.0 | 8.5 | 0.700 | 623 | 4,310,431 | 14.5 |
| Larynx | Total | 3 | 135,215 | 2.2 | 2.5 | 2.9 | 1.000 | 212 | 8,636,613 | 2.5 |
| Larynx | Male | 2 | 70,728 | 2.8 | 3.4 | 2.2 | 1.000 | 158 | 4,326,182 | 3.7 |
| Larynx | Female | 1 | 64,487 | 1.6 | 1.7 | 0.7 | 1.000 | 54 | 4,310,431 | 1.3 |
| Leukemia | Total | 26 | 135,215 | 19.2 | 21.7 | 22.3 | 0.486 | 1,605 | 8,636,613 | 18.6 |
| Leukemia | Male | 19 | 70,728 | 26.9 | 31.4 | 13.6 | 0.189 | 970 | 4,326,182 | 22.4 |
| Leukemia | Female | 7 | 64,487 | 10.9 | 11.8 | 8.7 | 0.708 | 635 | 4,310,431 | 14.7 |
| Liver and Bile Duct | Total | 14 | 135,215 | 10.4 | 11.9 | 11.1 | 0.456 | 815 | 8,636,613 | 9.4 |
| Liver and Bile Duct | Male | 10 | 70,728 | 14.1 | 16.9 | 7.9 | 0.554 | 580 | 4,326,182 | 13.4 |
| Liver and Bile Duct | Female | 4 | 64,487 | 6.2 | 6.8 | 3.2 | 0.789 | 235 | 4,310,431 | 5.5 |
| Lung and Bronchus | Total | 111 | 135,215 | 82.1 | 95.2 | 64.5 | 0.000 >> | 4,776 | 8,636,613 | 55.3 |
| Lung and Bronchus | Male | 53 | 70,728 | 74.9 | 91.1 | 32.2 | $0.001 \gg$ | 2,399 | 4,326,182 | 55.5 |
| Lung and Bronchus | Female | 58 | 64,487 | 89.9 | 99.4 | 32.2 | $0.000 \gg$ | 2,377 | 4,310,431 | 55.1 |
| Melanoma of the Skin | Total | 34 | 135,215 | 25.1 | 28.4 | 40.4 | 0.357 | 2,908 | 8,636,613 | 33.7 |
| Melanoma of the Skin | Male | 15 | 70,728 | 21.2 | 25.1 | 24.2 | 0.064 | 1,750 | 4,326,182 | 40.5 |
| Melanoma of the Skin | Female | 19 | 64,487 | 29.5 | 31.9 | 16.0 | 0.518 | 1,158 | 4,310,431 | 26.9 |
| Myeloma | Total | 10 | 135,215 | 7.4 | 8.6 | 9.4 | 0.939 | 698 | 8,636,613 | 8.1 |
| Myeloma | Male | 5 | 70,728 | 7.1 | 8.6 | 5.9 | 0.933 | 436 | 4,326,182 | 10.1 |
| Myeloma | Female | 5 | 64,487 | 7.8 | 8.6 | 3.5 | 0.559 | 262 | 4,310,431 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 29 | 135,215 | 21.4 | 24.4 | 26.3 | 0.655 | 1,911 | 8,636,613 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 17 | 70,728 | 24.0 | 28.2 | 15.5 | 0.770 | 1,112 | 4,326,182 | 25.7 |
| Non-Hodgkin Lymphoma | Female | 12 | 64,487 | 18.6 | 20.4 | 10.9 | 0.817 | 799 | 4,310,431 | 18.5 |
| Oral Cavity and Pharynx | Total | 17 | 135,215 | 12.6 | 14.4 | 17.5 | 1.000 | 1,278 | 8,636,613 | 14.8 |
| Oral Cavity and Pharynx | Male | 9 | 70,728 | 12.7 | 15.1 | 12.8 | 0.361 | 927 | 4,326,182 | 21.4 |
| Oral Cavity and Pharynx | Female | 8 | 64,487 | 12.4 | 13.7 | 4.7 | 0.216 | 351 | 4,310,431 | 8.1 |
| Ovary | Female | 8 | 64,487 | 12.4 | 13.6 | 7.2 | 0.847 | 525 | 4,310,431 | 12.2 |
| Pancreas | Total | 25 | 135,215 | 18.5 | 21.5 | 18.8 | 0.200 | 1,398 | 8,636,613 | 16.2 |
| Pancreas | Male | 13 | 70,728 | 18.4 | 22.3 | 10.4 | 0.495 | 771 | 4,326,182 | 17.8 |
| Pancreas | Female | 12 | 64,487 | 18.6 | 20.7 | 8.4 | 0.291 | 627 | 4,310,431 | 14.5 |
| Prostate | Male | 88 | 70,728 | 124.4 | 149.4 | 86.2 | 0.873 | 6,329 | 4,326,182 | 146.3 |
| Stomach | Total | 8 | 135,215 | 5.9 | 6.8 | 6.3 | 0.585 | 459 | 8,636,613 | 5.3 |
| Stomach | Male | 6 | 70,728 | 8.5 | 10.1 | 4.2 | 0.481 | 303 | 4,326,182 | 7.0 |
| Stomach | Female | 2 | 64,487 | 3.1 | 3.4 | 2.1 | 1.000 | 156 | 4,310,431 | 3.6 |
| Testis | Male | 5 | 70,728 | 7.1 | 6.3 | 4.8 | 1.000 | 260 | 4,326,182 | 6.0 |
| Thyroid | Total | 22 | 135,215 | 16.3 | 17.0 | 17.9 | 0.389 | 1,198 | 8,636,613 | 13.9 |
| Thyroid | Male | 5 | 70,728 | 7.1 | 7.8 | 5.2 | 1.000 | 350 | 4,326,182 | 8.1 |
| Thyroid | Female | 17 | 64,487 | 26.4 | 27.3 | 12.3 | 0.234 | 848 | 4,310,431 | 19.7 |
| Pediatric Age 0 to 19 | Total | 7 | 37,552 | 18.6 | 18.4 | 6.5 | 0.950 | 414 | 2,422,971 | 17.1 |
| Pediatric Age 0 to 19 | Male | 4 | 19,397 | 20.6 | 20.2 | 3.5 | 0.928 | 219 | 1,237,113 | 17.7 |
| Pediatric Age 0 to 19 | Female | 3 | 18,155 | 16.5 | 16.4 | 3.0 | 1.000 | 195 | 1,185,858 | 16.4 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN ELMORE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Elmore County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude <br> Rate (1) | A.A.M. Rate (1,2) | Expected <br> Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 1,094 | 137,864 | 793.5 | 918.5 | 1,027.3 | 0.040 >> | 76,336 | 8,850,851 | 862.5 |
| All Causes of Death | Male | 601 | 72,204 | 832.4 | 990.7 | 552.8 | 0.045 >> | 40,455 | 4,439,664 | 911.2 |
| All Causes of Death | Female | 493 | 65,660 | 750.8 | 841.1 | 476.8 | 0.470 | 35,881 | 4,411,187 | 813.4 |
| All Malignant Cancers | Total | 245 | 137,864 | 177.7 | 205.9 | 200.0 | $0.002 \gg$ | 14,876 | 8,850,851 | 168.1 |
| All Malignant Cancers | Male | 147 | 72,204 | 203.6 | 246.4 | 107.9 | 0.000 >> | 8,029 | 4,439,664 | 180.8 |
| All Malignant Cancers | Female | 98 | 65,660 | 149.3 | 165.6 | 91.8 | 0.547 | 6,847 | 4,411,187 | 155.2 |
| Bladder | Total | 4 | 137,864 | 2.9 | 3.4 | 6.4 | 0.474 | 485 | 8,850,851 | 5.5 |
| Bladder | Male | 4 | 72,204 | 5.5 | 6.9 | 4.9 | 0.925 | 374 | 4,439,664 | 8.4 |
| Bladder | Female |  | 65,660 | - | - | 1.5 | 0.463 | 111 | 4,411,187 | 2.5 |
| Brain and Other Nervous System | Total | 6 | 137,864 | 4.4 | 4.9 | 6.9 | 0.926 | 498 | 8,850,851 | 5.6 |
| Brain and Other Nervous System | Male | 4 | 72,204 | 5.5 | 6.4 | 4.1 | 1.000 | 294 | 4,439,664 | 6.6 |
| Brain and Other Nervous System | Female | 2 | 65,660 | 3.0 | 3.3 | 2.8 | 0.943 | 204 | 4,411,187 | 4.6 |
| Breast | Total | 5 | 137,864 | 3.6 | 4.2 | 14.8 | 0.007 << | 1,097 | 8,850,851 | 12.4 |
| Breast | Male |  | 72,204 | - | - | 0.2 | 1.000 | 16 | 4,439,664 | 0.4 |
| Breast | Female | 5 | 65,660 | 7.6 | 8.5 | 14.5 | 0.008 << | 1,081 | 4,411,187 | 24.5 |
| Cervix | Female | 2 | 65,660 | 3.0 | 3.3 | 1.1 | 0.602 | 81 | 4,411,187 | 1.8 |
| Colorectal | Total | 25 | 137,864 | 18.1 | 21.0 | 17.4 | 0.101 | 1,294 | 8,850,851 | 14.6 |
| Colorectal | Male | 16 | 72,204 | 22.2 | 26.6 | 9.5 | 0.069 | 703 | 4,439,664 | 15.8 |
| Colorectal | Female | 9 | 65,660 | 13.7 | 15.3 | 7.9 | 0.786 | 591 | 4,411,187 | 13.4 |
| Corpus Uteri | Female | 1 | 65,660 | 1.5 | 1.7 | 2.3 | 0.667 | 172 | 4,411,187 | 3.9 |
| Esophagus | Total | 11 | 137,864 | 8.0 | 9.2 | 6.3 | 0.112 | 466 | 8,850,851 | 5.3 |
| Esophagus | Male | 9 | 72,204 | 12.5 | 14.9 | 5.3 | 0.181 | 392 | 4,439,664 | 8.8 |
| Esophagus | Female | 2 | 65,660 | 3.0 | 3.4 | 1.0 | 0.526 | 74 | 4,411,187 | 1.7 |
| Hodgkin Lymphoma | Total | 2 | 137,864 | 1.5 | 1.7 | 0.4 | 0.106 | 27 | 8,850,851 | 0.3 |
| Hodgkin Lymphoma | Male | 2 | 72,204 | 2.8 | 3.2 | 0.2 | 0.025 >> | 12 | 4,439,664 | 0.3 |
| Hodgkin Lymphoma | Female | - | 65,660 | - | - | 0.2 | 1.000 | 15 | 4,411,187 | 0.3 |
| Kidney | Total | 4 | 137,864 | 2.9 | 3.4 | 5.1 | 0.850 | 381 | 8,850,851 | 4.3 |
| Kidney | Male | 2 | 72,204 | 2.8 | 3.3 | 3.2 | 0.747 | 240 | 4,439,664 | 5.4 |
| Kidney | Female | 2 | 65,660 | 3.0 | 3.4 | 1.9 | 1.000 | 141 | 4,411,187 | 3.2 |
| Larynx | Total | 1 | 137,864 | 0.7 | 0.8 | 1.0 | 1.000 | 70 | 8,850,851 | 0.8 |
| Larynx | Male | 1 | 72,204 | 1.4 | 1.6 | 0.8 | 1.000 | 57 | 4,439,664 | 1.3 |
| Larynx | Female | - | 65,660 | - | - | 0.2 | 1.000 | 13 | 4,411,187 | 0.3 |
| Leukemia | Total | 11 | 137,864 | 8.0 | 9.2 | 8.7 | 0.529 | 649 | 8,850,851 | 7.3 |
| Leukemia | Male | 7 | 72,204 | 9.7 | 11.6 | 5.1 | 0.518 | 379 | 4,439,664 | 8.5 |
| Leukemia | Female | 4 | 65,660 | 6.1 | 6.8 | 3.6 | 0.974 | 270 | 4,411,187 | 6.1 |
| Liver and Bile Duct | Total | 11 | 137,864 | 8.0 | 9.2 | 8.0 | 0.365 | 592 | 8,850,851 | 6.7 |
| Liver and Bile Duct | Male | 6 | 72,204 | 8.3 | 9.9 | 5.5 | 0.931 | 402 | 4,439,664 | 9.1 |
| Liver and Bile Duct | Female | 5 | 65,660 | 7.6 | 8.4 | 2.6 | 0.231 | 190 | 4,411,187 | 4.3 |
| Lung and Bronchus | Total | 69 | 137,864 | 50.0 | 58.0 | 38.8 | 0.000 >> | 2,892 | 8,850,851 | 32.7 |
| Lung and Bronchus | Male | 37 | 72,204 | 51.2 | 62.2 | 20.4 | 0.001 >> | 1,519 | 4,439,664 | 34.2 |
| Lung and Bronchus | Female | 32 | 65,660 | 48.7 | 53.9 | 18.5 | 0.005 >> | 1,373 | 4,411,187 | 31.1 |
| Melanoma of the Skin | Total | 1 | 137,864 | 0.7 | 0.8 | 3.9 | 0.196 | 288 | 8,850,851 | 3.3 |
| Melanoma of the Skin | Male | 1 | 72,204 | 1.4 | 1.7 | 2.6 | 0.536 | 191 | 4,439,664 | 4.3 |
| Melanoma of the Skin | Female | - | 65,660 | - | - | 1.3 | 0.535 | 97 | 4,411,187 | 2.2 |
| Myeloma | Total | 6 | 137,864 | 4.4 | 5.1 | 4.4 | 0.544 | 325 | 8,850,851 | 3.7 |
| Myeloma | Male | 3 | 72,204 | 4.2 | 5.1 | 2.6 | 0.943 | 193 | 4,439,664 | 4.3 |
| Myeloma | Female | 3 | 65,660 | 4.6 | 5.0 | 1.8 | 0.530 | 132 | 4,411,187 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 13 | 137,864 | 9.4 | 10.9 | 7.5 | 0.085 | 556 | 8,850,851 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 11 | 72,204 | 15.2 | 18.3 | 4.0 | 0.006 >> | 296 | 4,439,664 | 6.7 |
| Non-Hodgkin Lymphoma | Female | 2 | 65,660 | 3.0 | 3.4 | 3.5 | 0.640 | 260 | 4,411,187 | 5.9 |
| Oral Cavity and Pharynx | Total | 1 | 137,864 | 0.7 | 0.8 | 3.6 | 0.254 | 265 | 8,850,851 | 3.0 |
| Oral Cavity and Pharynx | Male | - | 72,204 | - | - | 2.5 | 0.158 | 187 | 4,439,664 | 4.2 |
| Oral Cavity and Pharynx | Female | 1 | 65,660 | 1.5 | 1.7 | 1.0 | 1.000 | 78 | 4,411,187 | 1.8 |
| Ovary | Female | 8 | 65,660 | 12.2 | 13.5 | 4.6 | 0.190 | 342 | 4,411,187 | 7.8 |
| Pancreas | Total | 21 | 137,864 | 15.2 | 17.7 | 15.7 | 0.232 | 1,169 | 8,850,851 | 13.2 |
| Pancreas | Male | 15 | 72,204 | 20.8 | 25.1 | 8.4 | 0.052 | 627 | 4,439,664 | 14.1 |
| Pancreas | Female | 6 | 65,660 | 9.1 | 10.2 | 7.2 | 0.827 | 542 | 4,411,187 | 12.3 |
| Prostate | Male | 10 | 72,204 | 13.8 | 17.3 | 12.2 | 0.646 | 939 | 4,439,664 | 21.2 |
| Stomach | Total | 4 | 137,864 | 2.9 | 3.3 | 2.6 | 0.547 | 194 | 8,850,851 | 2.2 |
| Stomach | Male | 4 | 72,204 | 5.5 | 6.6 | 1.6 | 0.159 | 117 | 4,439,664 | 2.6 |
| Stomach | Female | - | 65,660 | - | - | 1.0 | 0.713 | 77 | 4,411,187 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Elmore County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 84.1\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 13.8\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% |  |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% |  |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 41.6\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 28.5\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 74.0\% |
| Meet Physical Activity Guidelines (2011, 2013, $2015,2017,2019)$ | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 21.0\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 12.3\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^19]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 300 cases of invasive cancer were diagnosed among Franklin County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Franklin County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Franklin <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 300 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 48 | 6,687 |
| Prostate | 8 | 6,417 |
| Lung \& Bronchus | 34 | 4,887 |
| Colorectal | 3,451 |  |

Table 3 (Cancer Incidence 2016-2020, Comparison between Franklin County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Franklin County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Franklin County was 436.8 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (520.6) gives an estimate of the relative burden of disease in Franklin County.

The age- and sex-adjusted incidence rate of invasive cancer in Franklin County, all sites combined, was 478.5 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Franklin County (300) than expected (326.4) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 91 Franklin County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Franklin County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Franklin <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 584 | 77,431 |
| Cancer Deaths | 91 | 15,121 |
| \% of All Deaths | $15.6 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 8 | 2,961 |
| Colorectal | 14 | 1,319 |
| Pancreas | 7 | 1,190 |
| Female Breast | 10 | 1,086 |
| Prostate | 5 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Franklin County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Franklin County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Franklin County, all sites combined, was 140.0 deaths per 100,000 persons per year during 2017-2021, compared with 168.5 for the remainder of the state. There were fewer cancer deaths in Franklin County (91) than expected (109.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020 COMPARISON BETWEEN FRANKLIN COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Franklin County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person Years | Crude Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person Years | Crude Rate (1) |
| All Sites Combined | Total | 300 | 68,677 | 436.8 | 478.5 | 326.4 | 0.149 | 45,310 | 8,703,151 | 520.6 |
| All Sites Combined | Male | 159 | 35,105 | 452.9 | 492.0 | 178.8 | 0.146 | 24,130 | 4,361,805 | 553.2 |
| All Sites Combined | Female | 141 | 33,572 | 420.0 | 460.7 | 149.3 | 0.527 | 21,180 | 4,341,346 | 487.9 |
| Bladder | Total | 21 | 68,677 | 30.6 | 33.2 | 15.7 | 0.233 | 2,163 | 8,703,151 | 24.9 |
| Bladder | Male | 19 | 35,105 | 54.1 | 57.8 | 13.1 | 0.144 | 1,732 | 4,361,805 | 39.7 |
| Bladder | Female | 2 | 33,572 | 6.0 | 6.5 | 3.0 | 0.827 | 431 | 4,341,346 | 9.9 |
| Brain - malignant | Total | 10 | 68,677 | 14.6 | 15.6 | 4.5 | 0.036 >> | 615 | 8,703,151 | 7.1 |
| Brain - malignant | Male | 6 | 35,105 | 17.1 | 18.3 | 2.8 | 0.125 | 369 | 4,361,805 | 8.5 |
| Brain - malignant | Female | 4 | 33,572 | 11.9 | 12.7 | 1.8 | 0.214 | 246 | 4,341,346 | 5.7 |
| Brain and other CNS - non-malignant | Total | 7 | 68,677 | 10.2 | 11.0 | 10.4 | 0.376 | 1,417 | 8,703,151 | 16.3 |
| Brain and other CNS - non-malignant | Male | 3 | 35,105 | 8.5 | 9.1 | 3.6 | 1.000 | 477 | 4,361,805 | 10.9 |
| Brain and other CNS - non-malignant | Female | 4 | 33,572 | 11.9 | 12.9 | 6.7 | 0.402 | 940 | 4,341,346 | 21.7 |
| Breast | Total | 50 | 68,677 | 72.8 | 80.0 | 48.1 | 0.822 | 6,696 | 8,703,151 | 76.9 |
| Breast | Male | 2 | 35,105 | 5.7 | 6.1 | 0.4 | 0.138 | 57 | 4,361,805 | 1.3 |
| Breast | Female | 48 | 33,572 | 143.0 | 157.7 | 46.6 | 0.871 | 6,639 | 4,341,346 | 152.9 |
| Breast - in situ | Total | 2 | 68,677 | 2.9 | 3.2 | 8.8 | 0.015 << | 1,237 | 8,703,151 | 14.2 |
| Breast - in situ | Male |  | 35,105 | - | - | 0.0 | 1.000 | 5 | 4,361,805 | 0.1 |
| Breast - in situ | Female | 2 | 33,572 | 6.0 | 6.6 | 8.6 | 0.017 << | 1,232 | 4,341,346 | 28.4 |
| Cervix | Female | 1 | 33,572 | 3.0 | 3.2 | 2.2 | 0.714 | 303 | 4,341,346 | 7.0 |
| Colorectal | Total | 34 | 68,677 | 49.5 | 53.7 | 24.8 | 0.093 | 3,417 | 8,703,151 | 39.3 |
| Colorectal | Male | 21 | 35,105 | 59.8 | 64.4 | 14.1 | 0.099 | 1,882 | 4,361,805 | 43.1 |
| Colorectal | Female | 13 | 33,572 | 38.7 | 42.1 | 10.9 | 0.604 | 1,535 | 4,341,346 | 35.4 |
| Corpus Uteri | Female | 8 | 33,572 | 23.8 | 26.5 | 9.2 | 0.864 | 1,322 | 4,341,346 | 30.5 |
| Esophagus | Total |  | 68,677 | - | - | 3.6 | 0.052 | 506 | 8,703,151 | 5.8 |
| Esophagus | Male |  | 35,105 |  | - | 3.2 | 0.085 | 424 | 4,361,805 | 9.7 |
| Esophagus | Female | - | 33,572 |  |  | 0.6 | 1.000 | 82 | 4,341,346 | 1.9 |
| Hodgkin Lymphoma | Total | 1 | 68,677 | 1.5 | 1.5 | 1.6 | 1.000 | 209 | 8,703,151 | 2.4 |
| Hodgkin Lymphoma | Male |  | 35,105 | - | - | 0.9 | 0.825 | 118 | 4,361,805 | 2.7 |
| Hodgkin Lymphoma | Female | 1 | 33,572 | 3.0 | 3.1 | 0.7 | 0.974 | 91 | 4,341,346 | 2.1 |
| Kidney and Renal Pelvis | Total | 11 | 68,677 | 16.0 | 17.6 | 13.0 | 0.710 | 1,804 | 8,703,151 | 20.7 |
| Kidney and Renal Pelvis | Male | 6 | 35,105 | 17.1 | 18.6 | 8.7 | 0.470 | 1,176 | 4,361,805 | 27.0 |
| Kidney and Renal Pelvis | Female | 5 | 33,572 | 14.9 | 16.4 | 4.4 | 0.906 | 628 | 4,341,346 | 14.5 |
| Larynx | Total | - | 68,677 | - | - | 1.5 | 0.428 | 215 | 8,703,151 | 2.5 |
| Larynx | Male | - | 35,105 | - | - | 1.2 | 0.604 | 160 | 4,361,805 | 3.7 |
| Larynx | Female | - | 33,572 | - |  | 0.4 | 1.000 | 55 | 4,341,346 | 1.3 |
| Leukemia | Total | 16 | 68,677 | 23.3 | 24.9 | 11.9 | 0.303 | 1,615 | 8,703,151 | 18.6 |
| Leukemia | Male | 13 | 35,105 | 37.0 | 39.0 | 7.5 | 0.082 | 976 | 4,361,805 | 22.4 |
| Leukemia | Female | 3 | 33,572 | 8.9 | 9.6 | 4.6 | 0.654 | 639 | 4,341,346 | 14.7 |
| Liver and Bile Duct | Total | 3 | 68,677 | 4.4 | 4.8 | 5.9 | 0.324 | 826 | 8,703,151 | 9.5 |
| Liver and Bile Duct | Male | - | 35,105 | - | - | 4.3 | 0.027 << | 590 | 4,361,805 | 13.5 |
| Liver and Bile Duct | Female | 3 | 33,572 | 8.9 | 9.9 | 1.6 | 0.459 | 236 | 4,341,346 | 5.4 |
| Lung and Bronchus | Total | 8 | 68,677 | 11.6 | 12.8 | 35.1 | $0.000 \ll$ | 4,879 | 8,703,151 | 56.1 |
| Lung and Bronchus | Male | 4 | 35,105 | 11.4 | 12.3 | 18.2 | $0.000 \ll$ | 2,448 | 4,361,805 | 56.1 |
| Lung and Bronchus | Female | 4 | 33,572 | 11.9 | 13.2 | 16.9 | $0.000 \ll$ | 2,431 | 4,341,346 | 56.0 |
| Melanoma of the Skin | Total | 23 | 68,677 | 33.5 | 36.6 | 21.1 | 0.735 | 2,919 | 8,703,151 | 33.5 |
| Melanoma of the Skin | Male | 17 | 35,105 | 48.4 | 52.3 | 13.0 | 0.334 | 1,748 | 4,361,805 | 40.1 |
| Melanoma of the Skin | Female | 6 | 33,572 | 17.9 | 19.5 | 8.3 | 0.559 | 1,171 | 4,341,346 | 27.0 |
| Myeloma | Total | 4 | 68,677 | 5.8 | 6.4 | 5.1 | 0.855 | 704 | 8,703,151 | 8.1 |
| Myeloma | Male | 3 | 35,105 | 8.5 | 9.2 | 3.3 | 1.000 | 438 | 4,361,805 | 10.0 |
| Myeloma | Female | , | 33,572 | 3.0 | 3.3 | 1.8 | 0.898 | 266 | 4,341,346 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 9 | 68,677 | 13.1 | 14.2 | 14.0 | 0.217 | 1,931 | 8,703,151 | 22.2 |
| Non-Hodgkin Lymphoma | Male | 4 | 35,105 | 11.4 | 12.3 | 8.4 | 0.159 | 1,125 | 4,361,805 | 25.8 |
| Non-Hodgkin Lymphoma | Female | 5 | 33,572 | 14.9 | 16.4 | 5.7 | 0.998 | 806 | 4,341,346 | 18.6 |
| Oral Cavity and Pharynx | Total | 3 | 68,677 | 4.4 | 4.8 | 9.2 | 0.037 << | 1,292 | 8,703,151 | 14.8 |
| Oral Cavity and Pharynx | Male | 2 | 35,105 | 5.7 | 6.3 | 6.8 | 0.067 | 934 | 4,361,805 | 21.4 |
| Oral Cavity and Pharynx | Female | 1 | 33,572 | 3.0 | 3.3 | 2.5 | 0.575 | 358 | 4,341,346 | 8.2 |
| Ovary | Female | 8 | 33,572 | 17.9 | 19.6 | 3.7 | 0.346 | 527 | 4,341,346 | 12.1 |
| Pancreas | Total | 8 | 68,677 | 11.6 | 12.7 | 10.3 | 0.608 | 1,415 | 8,703,151 | 16.3 |
| Pancreas | Male | 3 | 35,105 | 8.5 | 9.2 | 5.8 | 0.332 | 781 | 4,361,805 | 17.9 |
| Pancreas | Female | 5 | 33,572 | 14.9 | 16.3 | 4.5 | 0.930 | 634 | 4,341,346 | 14.6 |
| Prostate | Male | 43 | 35,105 | 122.5 | 136.4 | 46.1 | 0.723 | 6,374 | 4,361,805 | 146.1 |
| Stomach | Total | 3 | 68,677 | 4.4 | 4.7 | 3.4 | 1.000 | 464 | 8,703,151 | 5.3 |
| Stomach | Male | 1 | 35,105 | 2.8 | 3.1 | 2.3 | 0.655 | 308 | 4,361,805 | 7.1 |
| Stomach | Female | 2 | 33,572 | 6.0 | 6.4 | 1.1 | 0.615 | 156 | 4,341,346 | 3.6 |
| Testis | Male | - | 35,105 | - | - | 1.9 | 0.296 | 265 | 4,361,805 | 6.1 |
| Thyroid | Total | 13 | 68,677 | 18.9 | 20.7 | 8.7 | 0.211 | 1,207 | 8,703,151 | 13.9 |
| Thyroid | Male | 3 | 35,105 | 8.5 | 9.4 | 2.6 | 0.955 | 352 | 4,361,805 | 8.1 |
| Thyroid | Female | 10 | 33,572 | 29.8 | 32.1 | 6.1 | 0.186 | 855 | 4,341,346 | 19.7 |
| Pediatric Age 0 to 19 | Total | 8 | 24,005 | 33.3 | 33.6 | 4.0 | 0.107 | 413 | 2,436,518 | 17.0 |
| Pediatric Age 0 to 19 | Male | 6 | 12,680 | 47.3 | 47.7 | 2.2 | 0.049 >> | 217 | 1,243,830 | 17.4 |
| Pediatric Age 0 to 19 | Female | 2 | 11,325 | 17.7 | 17.8 | 1.8 | 1.000 | 196 | 1,192,688 | 16.4 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN FRANKLIN COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Franklin County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 584 | 69,998 | 834.3 | 871.0 | 577.7 | 0.805 | 76,846 | 8,918,717 | 861.6 |
| All Causes of Death | Male | 310 | 35,844 | 864.9 | 892.3 | 316.2 | 0.753 | 40,746 | 4,476,024 | 910.3 |
| All Causes of Death | Female | 274 | 34,154 | 802.2 | 842.6 | 264.2 | 0.563 | 36,100 | 4,442,693 | 812.6 |
| All Malignant Cancers | Total | 91 | 69,998 | 130.0 | 140.0 | 109.5 | 0.079 | 15,030 | 8,918,717 | 168.5 |
| All Malignant Cancers | Male | 50 | 35,844 | 139.5 | 147.3 | 61.6 | 0.150 | 8,126 | 4,476,024 | 181.5 |
| All Malignant Cancers | Female | 41 | 34,154 | 120.0 | 130.7 | 48.7 | 0.298 | 6,904 | 4,442,693 | 155.4 |
| Bladder | Total | 1 | 69,998 | 1.4 | 1.5 | 3.7 | 0.238 | 488 | 8,918,717 | 5.5 |
| Bladder | Male | 1 | 35,844 | 2.8 | 2.8 | 3.0 | 0.399 | 377 | 4,476,024 | 8.4 |
| Bladder | Female | - | 34,154 | - |  | 0.8 | 0.898 | 111 | 4,442,693 | 2.5 |
| Brain and Other Nervous System | Total | 6 | 69,998 | 8.6 | 9.3 | 3.6 | 0.311 | 498 | 8,918,717 | 5.6 |
| Brain and Other Nervous System | Male | 4 | 35,844 | 11.2 | 12.0 | 2.2 | 0.358 | 294 | 4,476,024 | 6.6 |
| Brain and Other Nervous System | Female | 2 | 34,154 | 5.9 | 6.4 | 1.4 | 0.845 | 204 | 4,442,693 | 4.6 |
| Breast | Total | 10 | 69,998 | 14.3 | 15.4 | 8.0 | 0.561 | 1,092 | 8,918,717 | 12.2 |
| Breast | Male |  | 35,844 |  |  | 0.1 | 1.000 | 16 | 4,476,024 | 0.4 |
| Breast | Female | 10 | 34,154 | 29.3 | 31.8 | 7.6 | 0.477 | 1,076 | 4,442,693 | 24.2 |
| Cervix | Female | - | 34,154 | - | - | 0.6 | 1.000 | 83 | 4,442,693 | 1.9 |
| Colorectal | Total | 14 | 69,998 | 20.0 | 21.4 | 9.6 | 0.211 | 1,305 | 8,918,717 | 14.6 |
| Colorectal | Male | 10 | 35,844 | 27.9 | 29.6 | 5.3 | 0.093 | 709 | 4,476,024 | 15.8 |
| Colorectal | Female | 4 | 34,154 | 11.7 | 12.6 | 4.3 | 1.000 | 596 | 4,442,693 | 13.4 |
| Corpus Uteri | Female | - | 34,154 | - | - | 1.2 | 0.601 | 173 | 4,442,693 | 3.9 |
| Esophagus | Total | - | 69,998 | - |  | 3.4 | 0.065 | 477 | 8,918,717 | 5.3 |
| Esophagus | Male | - | 35,844 | - | - | 3.0 | 0.102 | 401 | 4,476,024 | 9.0 |
| Esophagus | Female | - | 34,154 | - | - | 0.5 | 1.000 | 76 | 4,442,693 | 1.7 |
| Hodgkin Lymphoma | Total | - | 69,998 | - |  | 0.2 | 1.000 | 29 | 8,918,717 | 0.3 |
| Hodgkin Lymphoma | Male | - | 35,844 | - | - | 0.1 | 1.000 | 14 | 4,476,024 | 0.3 |
| Hodgkin Lymphoma | Female | - | 34,154 | - | - | 0.1 | 1.000 | 15 | 4,442,693 | 0.3 |
| Kidney | Total | 2 | 69,998 | 2.9 | 3.1 | 2.8 | 0.945 | 383 | 8,918,717 | 4.3 |
| Kidney | Male | 1 | 35,844 | 2.8 | 3.0 | 1.8 | 0.922 | 241 | 4,476,024 | 5.4 |
| Kidney | Female | 1 | 34,154 | 2.9 | 3.2 | 1.0 | 1.000 | 142 | 4,442,693 | 3.2 |
| Larynx | Total | - | 69,998 | - | - | 0.5 | 1.000 | 71 | 8,918,717 | 0.8 |
| Larynx | Male | - | 35,844 | - | - | 0.4 | 1.000 | 58 | 4,476,024 | 1.3 |
| Larynx | Female | - | 34,154 | - |  | 0.1 | 1.000 | 13 | 4,442,693 | 0.3 |
| Leukemia | Total | 5 | 69,998 | 7.1 | 7.5 | 4.9 | 1.000 | 655 | 8,918,717 | 7.3 |
| Leukemia | Male | 2 | 35,844 | 5.6 | 5.8 | 3.0 | 0.861 | 384 | 4,476,024 | 8.6 |
| Leukemia | Female | 3 | 34,154 | 8.8 | 9.4 | 2.0 | 0.622 | 271 | 4,442,693 | 6.1 |
| Liver and Bile Duct | Total | 2 | 69,998 | 2.9 | 3.2 | 4.3 | 0.401 | 601 | 8,918,717 | 6.7 |
| Liver and Bile Duct | Male | - | 35,844 | - | - | 3.0 | 0.101 | 408 | 4,476,024 | 9.1 |
| Liver and Bile Duct | Female | 2 | 34,154 | 5.9 | 6.5 | 1.3 | 0.778 | 193 | 4,442,693 | 4.3 |
| Lung and Bronchus | Total | 8 | 69,998 | 11.4 | 12.5 | 21.3 | 0.002 << | 2,953 | 8,918,717 | 33.1 |
| Lung and Bronchus | Male | 6 | 35,844 | 16.7 | 18.0 | 11.5 | 0.119 | 1,550 | 4,476,024 | 34.6 |
| Lung and Bronchus | Female | 2 | 34,154 | 5.9 | 6.4 | 9.8 | 0.007 << | 1,403 | 4,442,693 | 31.6 |
| Melanoma of the Skin | Total | 3 | 69,998 | 4.3 | 4.6 | 2.1 | 0.689 | 286 | 8,918,717 | 3.2 |
| Melanoma of the Skin | Male | 3 | 35,844 | 8.4 | 8.9 | 1.4 | 0.347 | 189 | 4,476,024 | 4.2 |
| Melanoma of the Skin | Female | - | 34,154 | - | - | 0.7 | 1.000 | 97 | 4,442,693 | 2.2 |
| Myeloma | Total | 3 | 69,998 | 4.3 | 4.6 | 2.4 | 0.857 | 328 | 8,918,717 | 3.7 |
| Myeloma | Male | 2 | 35,844 | 5.6 | 5.9 | 1.5 | 0.872 | 194 | 4,476,024 | 4.3 |
| Myeloma | Female | 1 | 34,154 | 2.9 | 3.2 | 0.9 | 1.000 | 134 | 4,442,693 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 3 | 69,998 | 4.3 | 4.6 | 4.2 | 0.804 | 566 | 8,918,717 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 1 | 35,844 | 2.8 | 2.9 | 2.3 | 0.641 | 306 | 4,476,024 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 2 | 34,154 | 5.9 | 6.4 | 1.8 | 1.000 | 260 | 4,442,693 | 5.9 |
| Oral Cavity and Pharynx | Total | - | 69,998 | - | - | 1.9 | 0.298 | 266 | 8,918,717 | 3.0 |
| Oral Cavity and Pharynx | Male | - | 35,844 | - | - | 1.4 | 0.507 | 187 | 4,476,024 | 4.2 |
| Oral Cavity and Pharynx | Female | - | 34,154 | - | - | 0.5 | 1.000 | 79 | 4,442,693 | 1.8 |
| Ovary | Female | 2 | 34,154 | 5.9 | 6.5 | 2.4 | 1.000 | 348 | 4,442,693 | 7.8 |
| Pancreas | Total | 7 | 69,998 | 10.0 | 10.9 | 8.5 | 0.774 | 1,183 | 8,918,717 | 13.3 |
| Pancreas | Male | 4 | 35,844 | 11.2 | 12.0 | 4.7 | 0.976 | 638 | 4,476,024 | 14.3 |
| Pancreas | Female | 3 | 34,154 | 8.8 | 9.7 | 3.8 | 0.944 | 545 | 4,442,693 | 12.3 |
| Prostate | Male | 5 | 35,844 | 13.9 | 14.1 | 7.5 | 0.488 | 944 | 4,476,024 | 21.1 |
| Stomach | Total | 3 | 69,998 | 4.3 | 4.6 | 1.4 | 0.347 | 195 | 8,918,717 | 2.2 |
| Stomach | Male | 1 | 35,844 | 2.8 | 2.9 | 0.9 | 1.000 | 120 | 4,476,024 | 2.7 |
| Stomach | Female | 2 | 34,154 | 5.9 | 6.3 | 0.5 | 0.205 | 75 | 4,442,693 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ )
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Franklin County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 83.4\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 7.4\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 68.3\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 (2018, 2020) | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% |  |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 12.0\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 30.8\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 71.7\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 9.7\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 10.8\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, 12.6\% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^20]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked 49 ${ }^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# FRDMONT COUNTY CANCER PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 336 cases of invasive cancer were diagnosed among Fremont County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Fremont County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Fremont <br> County |  |
| :--- | ---: | ---: | | State of <br> Idaho |
| :---: |
| All Sites/Types |

Table 3 (Cancer Incidence 2016-2020, Comparison between Fremont County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Fremont County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Fremont County was 512.5 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (520.0) gives an estimate of the relative burden of disease in Fremont County.

The age- and sex-adjusted incidence rate of invasive cancer in Fremont County, all sites combined, was 481.6 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Fremont County (336) than expected (362.8) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 102 Fremont County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Fremont County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Fremont <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 610 | 77,431 |
| Cancer Deaths | 102 | 15,121 |
| \% of All Deaths | $16.7 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 19 | 2,961 |
| Colorectal | 12 | 1,319 |
| Pancreas | 14 | 1,190 |
| Female Breast | 7 | 1,086 |
| Prostate | 8 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Fremont County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Fremont County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Fremont County, all sites combined, was 144.1 deaths per 100,000 persons per year during 2017-2021, compared with 168.3 for the remainder of the state. There were fewer cancer deaths in Fremont County (102) than expected (119.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN FREMONT COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Fremont County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person Years | Crude Rate (1) | A.A.I. Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person Years | Crude Rate (1) |
| All Sites Combined | Total | 336 | 65,557 | 512.5 | 481.6 | 362.8 | 0.165 | 45,274 | 8,706,271 | 520.0 |
| All Sites Combined | Male | 179 | 34,244 | 522.7 | 475.4 | 208.1 | 0.044 << | 24,110 | 4,362,666 | 552.6 |
| All Sites Combined | Female | 157 | 31,313 | 501.4 | 484.4 | 157.9 | 0.984 | 21,164 | 4,343,605 | 487.2 |
| Bladder | Total | 15 | 65,557 | 22.9 | 21.2 | 17.6 | 0.633 | 2,169 | 8,706,271 | 24.9 |
| Bladder | Male | 12 | 34,244 | 35.0 | 31.2 | 15.4 | 0.479 | 1,739 | 4,362,666 | 39.9 |
| Bladder | Female | 3 | 31,313 | 9.6 | 9.2 | 3.2 | 1.000 | 430 | 4,343,605 | 9.9 |
| Brain - malignant | Total | 3 | 65,557 | 4.6 | 4.4 | 4.9 | 0.562 | 622 | 8,706,271 | 7.1 |
| Brain - malignant | Male | 1 | 34,244 | 2.9 | 2.7 | 3.1 | 0.363 | 374 | 4,362,666 | 8.6 |
| Brain - malignant | Female | 2 | 31,313 | 6.4 | 6.2 | 1.8 | 1.000 | 248 | 4,343,605 | 5.7 |
| Brain and other CNS - non-malignant | Total | 11 | 65,557 | 16.8 | 16.0 | 11.2 | 1.000 | 1,413 | 8,706,271 | 16.2 |
| Brain and other CNS - non-malignant | Male | 2 | 34,244 | 5.8 | 5.5 | 4.0 | 0.473 | 478 | 4,362,666 | 11.0 |
| Brain and other CNS - non-malignant | Female | 9 | 31,313 | 28.7 | 28.0 | 6.9 | 0.523 | 935 | 4,343,605 | 21.5 |
| Breast | Total | 43 | 65,557 | 65.6 | 62.1 | 53.3 | 0.171 | 6,703 | 8,706,271 | 77.0 |
| Breast | Male |  | 34,244 |  |  | 0.5 | 1.000 | 59 | 4,362,666 | 1.4 |
| Breast | Female | 43 | 31,313 | 137.3 | 132.3 | 49.7 | 0.380 | 6,644 | 4,343,605 | 153.0 |
| Breast - in situ | Total | 6 | 65,557 | 9.2 | 8.7 | 9.8 | 0.287 | 1,233 | 8,706,271 | 14.2 |
| Breast - in situ | Male |  | 34,244 |  |  | 0.0 | 1.000 | 5 | 4,362,666 | 0.1 |
| Breast - in situ | Female | 6 | 31,313 | 19.2 | 18.4 | 9.2 | 0.373 | 1,228 | 4,343,605 | 28.3 |
| Cervix | Female |  | 31,313 |  |  | 2.2 | 0.231 | 304 | 4,343,605 | 7.0 |
| Colorectal | Total | 28 | 65,557 | 42.7 | 40.2 | 27.4 | 0.959 | 3,423 | 8,706,271 | 39.3 |
| Colorectal | Male | 13 | 34,244 | 38.0 | 34.5 | 16.3 | 0.499 | 1,890 | 4,362,666 | 43.3 |
| Colorectal | Female | 15 | 31,313 | 47.9 | 46.5 | 11.4 | 0.351 | 1,533 | 4,343,605 | 35.3 |
| Corpus Uteri | Female | 13 | 31,313 | 41.5 | 39.9 | 9.9 | 0.394 | 1,317 | 4,343,605 | 30.3 |
| Esophagus | Total |  | 65,557 |  |  | 4.1 | 0.033 << | 506 | 8,706,271 | 5.8 |
| Esophagus | Male |  | 34,244 | - |  | 3.7 | 0.050 << | 424 | 4,362,666 | 9.7 |
| Esophagus | Female |  | 31,313 |  |  | 0.6 | 1.000 | 82 | 4,343,605 | 1.9 |
| Hodgkin Lymphoma | Total | 1 | 65,557 | 1.5 | 1.5 | 1.6 | 1.000 | 209 | 8,706,271 | 2.4 |
| Hodgkin Lymphoma | Male |  | 34,244 | - | - | 0.9 | 0.775 | 118 | 4,362,666 | 2.7 |
| Hodgkin Lymphoma | Female | 1 | 31,313 | 3.2 | 3.2 | 0.7 | 0.971 | 91 | 4,343,605 | 2.1 |
| Kidney and Renal Pelvis | Total | 11 | 65,557 | 16.8 | 15.8 | 14.4 | 0.451 | 1,804 | 8,706,271 | 20.7 |
| Kidney and Renal Pelvis | Male | 7 | 34,244 | 20.4 | 18.8 | 10.0 | 0.432 | 1,175 | 4,362,666 | 26.9 |
| Kidney and Renal Pelvis | Female | 4 | 31,313 | 12.8 | 12.3 | 4.7 | 0.982 | 629 | 4,343,605 | 14.5 |
| Larynx | Total | 3 | 65,557 | 4.6 | 4.2 | 1.7 | 0.496 | 212 | 8,706,271 | 2.4 |
| Larynx | Male | 3 | 34,244 | 8.8 | 7.8 | 1.4 | 0.321 | 157 | 4,362,666 | 3.6 |
| Larynx | Female |  | 31,313 | - | - | 0.4 | 1.000 | 55 | 4,343,605 | 1.3 |
| Leukemia | Total | 12 | 65,557 | 18.3 | 17.2 | 13.0 | 0.933 | 1,619 | 8,706,271 | 18.6 |
| Leukemia | Male | 7 | 34,244 | 20.4 | 18.7 | 8.4 | 0.787 | 982 | 4,362,666 | 22.5 |
| Leukemia | Female | 5 | 31,313 | 16.0 | 15.4 | 4.8 | 1.000 | 637 | 4,343,605 | 14.7 |
| Liver and Bile Duct | Total | 8 | 65,557 | 12.2 | 11.4 | 6.6 | 0.691 | 821 | 8,706,271 | 9.4 |
| Liver and Bile Duct | Male | 6 | 34,244 | 17.5 | 16.0 | 5.0 | 0.780 | 584 | 4,362,666 | 13.4 |
| Liver and Bile Duct | Female | 2 | 31,313 | 6.4 | 6.1 | 1.8 | 1.000 | 237 | 4,343,605 | 5.5 |
| Lung and Bronchus | Total | 31 | 65,557 | 47.3 | 43.7 | 39.6 | 0.191 | 4,856 | 8,706,271 | 55.8 |
| Lung and Bronchus | Male | 14 | 34,244 | 40.9 | 36.6 | 21.4 | 0.122 | 2,438 | 4,362,666 | 55.9 |
| Lung and Bronchus | Female | 17 | 31,313 | 54.3 | 51.4 | 18.4 | 0.864 | 2,418 | 4,343,605 | 55.7 |
| Melanoma of the Skin | Total | 20 | 65,557 | 30.5 | 29.0 | 23.2 | 0.597 | 2,922 | 8,706,271 | 33.6 |
| Melanoma of the Skin | Male | 14 | 34,244 | 40.9 | 37.3 | 15.0 | 0.922 | 1,751 | 4,362,666 | 40.1 |
| Melanoma of the Skin | Female | 6 | 31,313 | 19.2 | 18.8 | 8.6 | 0.492 | 1,171 | 4,343,605 | 27.0 |
| Myeloma | Total | 4 | 65,557 | 6.1 | 5.7 | 5.7 | 0.650 | 704 | 8,706,271 | 8.1 |
| Myeloma | Male | 2 | 34,244 | 5.8 | 5.2 | 3.8 | 0.522 | 439 | 4,362,666 | 10.1 |
| Myeloma | Female | 2 | 31,313 | 6.4 | 6.1 | 2.0 | 1.000 | 265 | 4,343,605 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 14 | 65,557 | 21.4 | 20.0 | 15.4 | 0.841 | 1,926 | 8,706,271 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 5 | 34,244 | 14.6 | 13.4 | 9.6 | 0.164 | 1,124 | 4,362,666 | 25.8 |
| Non-Hodgkin Lymphoma | Female | 9 | 31,313 | 28.7 | 27.7 | 6.0 | 0.306 | 802 | 4,343,605 | 18.5 |
| Oral Cavity and Pharynx | Total | 13 | 65,557 | 19.8 | 18.6 | 10.3 | 0.471 | 1,282 | 8,706,271 | 14.7 |
| Oral Cavity and Pharynx | Male | 12 | 34,244 | 35.0 | 32.0 | 7.9 | 0.214 | 924 | 4,362,666 | 21.2 |
| Oral Cavity and Pharynx | Female | 1 | 31,313 | 3.2 | 3.1 | 2.7 | 0.505 | 358 | 4,343,605 | 8.2 |
| Ovary | Female | 3 | 31,313 | 9.6 | 9.3 | 3.9 | 0.889 | 530 | 4,343,605 | 12.2 |
| Pancreas | Total | 10 | 65,557 | 15.3 | 14.2 | 11.4 | 0.821 | 1,413 | 8,706,271 | 16.2 |
| Pancreas | Male | 5 | 34,244 | 14.6 | 13.1 | 6.8 | 0.651 | 779 | 4,362,666 | 17.9 |
| Pancreas | Female | 5 | 31,313 | 16.0 | 15.4 | 4.8 | 1.000 | 634 | 4,343,605 | 14.6 |
| Prostate | Male | 60 | 34,244 | 175.2 | 159.7 | 54.7 | 0.511 | 6,357 | 4,362,666 | 145.7 |
| Stomach | Total | 1 | 65,557 | 1.5 | 1.4 | 3.7 | 0.226 | 466 | 8,706,271 | 5.4 |
| Stomach | Male |  | 34,244 | - | - | 2.7 | 0.135 | 309 | 4,362,666 | 7.1 |
| Stomach | Female | 1 | 31,313 | 3.2 | 3.1 | 1.1 | 1.000 | 157 | 4,343,605 | 3.6 |
| Testis | Male | 3 | 34,244 | 8.8 | 9.2 | 2.0 | 0.629 | 262 | 4,362,666 | 6.0 |
| Thyroid | Total | 9 | 65,557 | 13.7 | 13.6 | 9.2 | 1.000 | 1,211 | 8,706,271 | 13.9 |
| Thyroid | Male | 1 | 34,244 | 2.9 | 2.8 | 2.9 | 0.433 | 354 | 4,362,666 | 8.1 |
| Thyroid | Female | 8 | 31,313 | 25.5 | 25.7 | 6.1 | 0.551 | 857 | 4,343,605 | 19.7 |
| Pediatric Age 0 to 19 | Total | 5 | 18,570 | 26.9 | 26.6 | 3.2 | 0.441 | 416 | 2,441,953 | 17.0 |
| Pediatric Age 0 to 19 | Male | 4 | 9,666 | 41.4 | 41.1 | 1.7 | 0.189 | 219 | 1,246,844 | 17.6 |
| Pediatric Age 0 to 19 | Female | 1 | 8,904 | 11.2 | 11.1 | 1.5 | 1.000 | 197 | 1,195,109 | 16.5 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ )

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN FREMONT COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Fremont County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 610 | 66,217 | 921.2 | 874.7 | 600.4 | 0.706 | 76,820 | 8,922,498 | 861.0 |
| All Causes of Death | Male | 332 | 34,675 | 957.5 | 852.4 | 354.3 | 0.246 | 40,724 | 4,477,193 | 909.6 |
| All Causes of Death | Female | 278 | 31,542 | 881.4 | 893.7 | 252.6 | 0.120 | 36,096 | 4,445,305 | 812.0 |
| All Malignant Cancers | Total | 102 | 66,217 | 154.0 | 144.1 | 119.2 | 0.121 | 15,019 | 8,922,498 | 168.3 |
| All Malignant Cancers | Male | 49 | 34,675 | 141.3 | 125.5 | 70.9 | 0.008 << | 8,127 | 4,477,193 | 181.5 |
| All Malignant Cancers | Female | 53 | 31,542 | 168.0 | 163.6 | 50.2 | 0.731 | 6,892 | 4,445,305 | 155.0 |
| Bladder | Total | 4 | 66,217 | 6.0 | 5.7 | 3.8 | 1.000 | 485 | 8,922,498 | 5.4 |
| Bladder | Male | 3 | 34,675 | 8.7 | 7.5 | 3.4 | 1.000 | 375 | 4,477,193 | 8.4 |
| Bladder | Female | 1 | 31,542 | 3.2 | 3.1 | 0.8 | 1.000 | 110 | 4,445,305 | 2.5 |
| Brain and Other Nervous System | Total | 4 | 66,217 | 6.0 | 5.7 | 3.9 | 1.000 | 500 | 8,922,498 | 5.6 |
| Brain and Other Nervous System | Male | 2 | 34,675 | 5.8 | 5.3 | 2.5 | 1.000 | 296 | 4,477,193 | 6.6 |
| Brain and Other Nervous System | Female | 2 | 31,542 | 6.3 | 6.1 | 1.5 | 0.884 | 204 | 4,445,305 | 4.6 |
| Breast | Total | 7 | 66,217 | 10.6 | 10.0 | 8.6 | 0.744 | 1,095 | 8,922,498 | 12.3 |
| Breast | Male |  | 34,675 |  |  | 0.1 | 1.000 | 16 | 4,477,193 | 0.4 |
| Breast | Female | 7 | 31,542 | 22.2 | 21.7 | 7.8 | 0.959 | 1,079 | 4,445,305 | 24.3 |
| Cervix | Female | 2 | 31,542 | 6.3 | 6.3 | 0.6 | 0.228 | 81 | 4,445,305 | 1.8 |
| Colorectal | Total | 12 | 66,217 | 18.1 | 17.0 | 10.3 | 0.684 | 1,307 | 8,922,498 | 14.6 |
| Colorectal | Male | 8 | 34,675 | 23.1 | 20.6 | 6.2 | 0.556 | 711 | 4,477,193 | 15.9 |
| Colorectal | Female | 4 | 31,542 | 12.7 | 12.5 | 4.3 | 1.000 | 596 | 4,445,305 | 13.4 |
| Corpus Uteri | Female | 1 | 31,542 | 3.2 | 3.0 | 1.3 | 1.000 | 172 | 4,445,305 | 3.9 |
| Esophagus | Total | 1 | 66,217 | 1.5 | 1.4 | 3.8 | 0.217 | 476 | 8,922,498 | 5.3 |
| Esophagus | Male | 1 | 34,675 | 2.9 | 2.6 | 3.5 | 0.281 | 400 | 4,477,193 | 8.9 |
| Esophagus | Female | - | 31,542 | - | - | 0.6 | 1.000 | 76 | 4,445,305 | 1.7 |
| Hodgkin Lymphoma | Total |  | 66,217 | - | - | 0.2 | 1.000 | 29 | 8,922,498 | 0.3 |
| Hodgkin Lymphoma | Male | - | 34,675 | - | - | 0.1 | 1.000 | 14 | 4,477,193 | 0.3 |
| Hodgkin Lymphoma | Female | - | 31,542 |  |  | 0.1 | 1.000 | 15 | 4,445,305 | 0.3 |
| Kidney | Total | 3 | 66,217 | 4.5 | 4.2 | 3.0 | 1.000 | 382 | 8,922,498 | 4.3 |
| Kidney | Male | 2 | 34,675 | 5.8 | 5.2 | 2.1 | 1.000 | 240 | 4,477,193 | 5.4 |
| Kidney | Female | 1 | 31,542 | 3.2 | 3.1 | 1.0 | 1.000 | 142 | 4,445,305 | 3.2 |
| Larynx | Total | 1 | 66,217 | 1.5 | 1.4 | 0.6 | 0.857 | 70 | 8,922,498 | 0.8 |
| Larynx | Male | 1 | 34,675 | 2.9 | 2.5 | 0.5 | 0.792 | 57 | 4,477,193 | 1.3 |
| Larynx | Female | - | 31,542 |  | - | 0.1 | 1.000 | 13 | 4,445,305 | 0.3 |
| Leukemia | Total | 2 | 66,217 | 3.0 | 2.8 | 5.2 | 0.217 | 658 | 8,922,498 | 7.4 |
| Leukemia | Male | 1 | 34,675 | 2.9 | 2.6 | 3.4 | 0.302 | 385 | 4,477,193 | 8.6 |
| Leukemia | Female | 1 | 31,542 | 3.2 | 3.1 | 2.0 | 0.831 | 273 | 4,445,305 | 6.1 |
| Liver and Bile Duct | Total | 5 | 66,217 | 7.6 | 7.0 | 4.8 | 1.000 | 598 | 8,922,498 | 6.7 |
| Liver and Bile Duct | Male | 3 | 34,675 | 8.7 | 7.8 | 3.5 | 1.000 | 405 | 4,477,193 | 9.0 |
| Liver and Bile Duct | Female | 2 | 31,542 | 6.3 | 6.1 | 1.4 | 0.834 | 193 | 4,445,305 | 4.3 |
| Lung and Bronchus | Total | 19 | 66,217 | 28.7 | 26.6 | 23.5 | 0.410 | 2,942 | 8,922,498 | 33.0 |
| Lung and Bronchus | Male | 7 | 34,675 | 20.2 | 18.0 | 13.5 | 0.085 | 1,549 | 4,477,193 | 34.6 |
| Lung and Bronchus | Female | 12 | 31,542 | 38.0 | 36.6 | 10.3 | 0.672 | 1,393 | 4,445,305 | 31.3 |
| Melanoma of the Skin | Total | 2 | 66,217 | 3.0 | 2.8 | 2.3 | 1.000 | 287 | 8,922,498 | 3.2 |
| Melanoma of the Skin | Male | 1 | 34,675 | 2.9 | 2.6 | 1.6 | 1.000 | 191 | 4,477,193 | 4.3 |
| Melanoma of the Skin | Female | 1 | 31,542 | 3.2 | 3.1 | 0.7 | 1.000 | 96 | 4,445,305 | 2.2 |
| Myeloma | Total | 1 | 66,217 | 1.5 | 1.4 | 2.6 | 0.516 | 330 | 8,922,498 | 3.7 |
| Myeloma | Male | - | 34,675 | - | - | 1.7 | 0.354 | 196 | 4,477,193 | 4.4 |
| Myeloma | Female | 1 | 31,542 | 3.2 | 3.1 | 1.0 | 1.000 | 134 | 4,445,305 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 6 | 66,217 | 9.1 | 8.4 | 4.5 | 0.589 | 563 | 8,922,498 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 1 | 34,675 | 2.9 | 2.6 | 2.7 | 0.505 | 306 | 4,477,193 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 5 | 31,542 | 15.9 | 15.6 | 1.9 | 0.081 | 257 | 4,445,305 | 5.8 |
| Oral Cavity and Pharynx | Total | 1 | 66,217 | 1.5 | 1.4 | 2.1 | 0.756 | 265 | 8,922,498 | 3.0 |
| Oral Cavity and Pharynx | Male | 1 | 34,675 | 2.9 | 2.6 | 1.6 | 1.000 | 186 | 4,477,193 | 4.2 |
| Oral Cavity and Pharynx | Female | - | 31,542 | - | - | 0.6 | 1.000 | 79 | 4,445,305 | 1.8 |
| Ovary | Female | 3 | 31,542 | 9.5 | 9.2 | 2.6 | 0.939 | 347 | 4,445,305 | 7.8 |
| Pancreas | Total | 14 | 66,217 | 21.1 | 19.7 | 9.4 | 0.188 | 1,176 | 8,922,498 | 13.2 |
| Pancreas | Male | 7 | 34,675 | 20.2 | 18.1 | 5.5 | 0.623 | 635 | 4,477,193 | 14.2 |
| Pancreas | Female | 7 | 31,542 | 22.2 | 21.4 | 4.0 | 0.219 | 541 | 4,445,305 | 12.2 |
| Prostate | Male | 8 | 34,675 | 23.1 | 20.0 | 8.4 | 1.000 | 941 | 4,477,193 | 21.0 |
| Stomach | Total |  | 66,217 |  |  | 1.6 | 0.422 | 198 | 8,922,498 | 2.2 |
| Stomach | Male | - | 34,675 | - | - | 1.1 | 0.698 | 121 | 4,477,193 | 2.7 |
| Stomach | Female | - | 31,542 | - | - | 0.5 | 1.000 | 77 | 4,445,305 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ )
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Fremont County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 78.4\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 8.7\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 49.8\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% |  |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 17.1\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 25.1\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 78.9\% |
| Meet Physical Activity Guidelines ( $2011,2013,2015,2017,2019)$ | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 14.2\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 14.8\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^21]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged $50-74$ reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 640 cases of invasive cancer were diagnosed among Gem County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Gem County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Gem <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 640 | 45,610 |
| :--- | ---: | ---: | ---: |
| Female Breast | 78 | 6,687 |
| Prostate | 97 | 6,417 |
| Lung \& Bronchus | 70 | 4,887 |
| Colorectal | 63 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Gem County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected cases in Gem County. The table also shows the number of observed cases, person-years, and
crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Gem County was 720.3 cases per 100,000 personyears per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (517.9) gives an estimate of the relative burden of disease in Gem County.

The age- and sex-adjusted incidence rate of invasive cancer in Gem County, all sites combined, was 558.6 cases per 100,000 persons per year during 2016-2020. There were more cases of cancer in Gem County (640) than expected (593.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 206 Gem County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Gem County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Gem <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 1,212 | 77,431 |
| Cancer Deaths | 206 | 15,121 |
| \% of All Deaths | $17.0 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 48 | 2,961 |
| Colorectal | 20 | 1,319 |
| Pancreas | 16 | 1,190 |
| Female Breast | 13 | 1,086 |
| Prostate | 10 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Gem County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Gem County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Gem County, all sites combined, was 167.7 deaths per 100,000 persons per year during 2017-2021, compared with 167.6 for the remainder of the state. There were more cancer deaths in Gem County (206) than expected (205.9) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020

| Cancer Site/Type | Sex | Gem County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person <br> Years | Crude Rate (1) | A.A.I. <br> Rate (1,2) | Expected <br> Cases (3) | P-Value (4) | Observed Cases | Person Years | Crude Rate (1) |
| All Sites Combined | Total | 640 | 88,855 | 720.3 | 558.6 | 593.3 | 0.060 | 44,970 | 8,682,973 | 517.9 |
| All Sites Combined | Male | 359 | 44,532 | 806.2 | 596.8 | 330.7 | 0.130 | 23,930 | 4,352,378 | 549.8 |
| All Sites Combined | Female | 281 | 44,323 | 634.0 | 511.3 | 267.0 | 0.408 | 21,040 | 4,330,595 | 485.8 |
| Bladder | Total | 37 | 88,855 | 41.6 | 30.5 | 30.0 | 0.239 | 2,147 | 8,682,973 | 24.7 |
| Bladder | Male | 32 | 44,532 | 71.9 | 50.1 | 25.2 | 0.217 | 1,719 | 4,352,378 | 39.5 |
| Bladder | Female | 5 | 44,323 | 11.3 | 8.7 | 5.7 | 0.987 | 428 | 4,330,595 | 9.9 |
| Brain - malignant | Total | 8 | 88,855 | 9.0 | 7.5 | 7.6 | 0.969 | 617 | 8,682,973 | 7.1 |
| Brain - malignant | Male | 5 | 44,532 | 11.2 | 9.3 | 4.6 | 0.968 | 370 | 4,352,378 | 8.5 |
| Brain - malignant | Female | 3 | 44,323 | 6.8 | 5.7 | 3.0 | 1.000 | 247 | 4,330,595 | 5.7 |
| Brain and other CNS - non-malignant | Total | 18 | 88,855 | 20.3 | 16.4 | 17.8 | 1.000 | 1,406 | 8,682,973 | 16.2 |
| Brain and other CNS - non-malignant | Male | 6 | 44,532 | 13.5 | 10.8 | 6.0 | 1.000 | 474 | 4,352,378 | 10.9 |
| Brain and other CNS - non-malignant | Female | 12 | 44,323 | 27.1 | 22.2 | 11.6 | 0.988 | 932 | 4,330,595 | 21.5 |
| Breast | Total | 78 | 88,855 | 87.8 | 70.1 | 85.4 | 0.460 | 6,668 | 8,682,973 | 76.8 |
| Breast | Male |  | 44,532 |  |  | 0.8 | 0.861 | 59 | 4,352,378 | 1.4 |
| Breast | Female | 78 | 44,323 | 176.0 | 142.6 | 83.5 | 0.595 | 6,609 | 4,330,595 | 152.6 |
| Breast - in situ | Total | 11 | 88,855 | 12.4 | 10.0 | 15.5 | 0.307 | 1,228 | 8,682,973 | 14.1 |
| Breast - in situ | Male |  | 44,532 |  |  | 0.1 | 1.000 | 5 | 4,352,378 | 0.1 |
| Breast - in situ | Female | 11 | 44,323 | 24.8 | 20.2 | 15.4 | 0.324 | 1,223 | 4,330,595 | 28.2 |
| Cervix | Female | 5 | 44,323 | 11.3 | 10.7 | 3.2 | 0.450 | 299 | 4,330,595 | 6.9 |
| Colorectal | Total | 63 | 88,855 | 70.9 | 55.2 | 44.6 | 0.011 >> | 3,388 | 8,682,973 | 39.0 |
| Colorectal | Male | 33 | 44,532 | 74.1 | 56.0 | 25.3 | 0.161 | 1,870 | 4,352,378 | 43.0 |
| Colorectal | Female | 30 | 44,323 | 67.7 | 54.1 | 19.4 | 0.031 >> | 1,518 | 4,330,595 | 35.1 |
| Corpus Uteri | Female | 17 | 44,323 | 38.4 | 30.8 | 16.7 | 1.000 | 1,313 | 4,330,595 | 30.3 |
| Esophagus | Total | 10 | 88,855 | 11.3 | 8.5 | 6.7 | 0.290 | 496 | 8,682,973 | 5.7 |
| Esophagus | Male | 7 | 44,532 | 15.7 | 11.4 | 5.9 | 0.746 | 417 | 4,352,378 | 9.6 |
| Esophagus | Female | 3 | 44,323 | 6.8 | 5.2 | 1.0 | 0.178 | 79 | 4,330,595 | 1.8 |
| Hodgkin Lymphoma | Total | 1 | 88,855 | 1.1 | 1.1 | 2.2 | 0.693 | 209 | 8,682,973 | 2.4 |
| Hodgkin Lymphoma | Male |  | 44,532 |  | - | 1.3 | 0.557 | 118 | 4,352,378 | 2.7 |
| Hodgkin Lymphoma | Female | 1 | 44,323 | 2.3 | 2.2 | 0.9 | 1.000 | 91 | 4,330,595 | 2.1 |
| Kidney and Renal Pelvis | Total | 34 | 88,855 | 38.3 | 30.0 | 23.2 | 0.043 >> | 1,781 | 8,682,973 | 20.5 |
| Kidney and Renal Pelvis | Male | 22 | 44,532 | 49.4 | 37.8 | 15.5 | 0.139 | 1,160 | 4,352,378 | 26.7 |
| Kidney and Renal Pelvis | Female | 12 | 44,323 | 27.1 | 21.7 | 7.9 | 0.214 | 621 | 4,330,595 | 14.3 |
| Larynx | Total | - | 88,855 | - | - | 2.9 | 0.109 | 215 | 8,682,973 | 2.5 |
| Larynx | Male |  | 44,532 | - | - | 2.3 | 0.210 | 160 | 4,352,378 | 3.7 |
| Larynx | Female | - | 44,323 |  |  | 0.7 | 0.979 | 55 | 4,330,595 | 1.3 |
| Leukemia | Total | 17 | 88,855 | 19.1 | 14.8 | 21.3 | 0.419 | 1,614 | 8,682,973 | 18.6 |
| Leukemia | Male | 9 | 44,532 | 20.2 | 15.2 | 13.4 | 0.286 | 980 | 4,352,378 | 22.5 |
| Leukemia | Female | 8 | 44,323 | 18.0 | 14.4 | 8.1 | 1.000 | 634 | 4,330,595 | 14.6 |
| Liver and Bile Duct | Total | 16 | 88,855 | 18.0 | 13.7 | 10.9 | 0.177 | 813 | 8,682,973 | 9.4 |
| Liver and Bile Duct | Male | 14 | 44,532 | 31.4 | 23.4 | 7.9 | 0.064 | 576 | 4,352,378 | 13.2 |
| Liver and Bile Duct | Female | 2 | 44,323 | 4.5 | 3.5 | 3.1 | 0.803 | 237 | 4,330,595 | 5.5 |
| Lung and Bronchus | Total | 70 | 88,855 | 78.8 | 57.8 | 67.2 | 0.764 | 4,817 | 8,682,973 | 55.5 |
| Lung and Bronchus | Male | 35 | 44,532 | 78.6 | 55.3 | 35.2 | 1.000 | 2,417 | 4,352,378 | 55.5 |
| Lung and Bronchus | Female | 35 | 44,323 | 79.0 | 60.1 | 32.3 | 0.678 | 2,400 | 4,330,595 | 55.4 |
| Melanoma of the Skin | Total | 44 | 88,855 | 49.5 | 39.7 | 37.0 | 0.288 | 2,898 | 8,682,973 | 33.4 |
| Melanoma of the Skin | Male | 24 | 44,532 | 53.9 | 40.7 | 23.6 | 0.982 | 1,741 | 4,352,378 | 40.0 |
| Melanoma of the Skin | Female | 20 | 44,323 | 45.1 | 38.2 | 14.0 | 0.153 | 1,157 | 4,330,595 | 26.7 |
| Myeloma | Total | 3 | 88,855 | 3.4 | 2.5 | 9.7 | 0.026 << | 705 | 8,682,973 | 8.1 |
| Myeloma | Male | 3 | 44,532 | 6.7 | 4.8 | 6.3 | 0.253 | 438 | 4,352,378 | 10.1 |
| Myeloma | Female | - | 44,323 | - |  | 3.5 | 0.059 | 267 | 4,330,595 | 6.2 |
| Non-Hodgkin Lymphoma | Total | 21 | 88,855 | 23.6 | 18.4 | 25.3 | 0.460 | 1,919 | 8,682,973 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 15 | 44,532 | 33.7 | 25.6 | 15.0 | 1.000 | 1,114 | 4,352,378 | 25.6 |
| Non-Hodgkin Lymphoma | Female | 6 | 44,323 | 13.5 | 10.7 | 10.4 | 0.215 | 805 | 4,330,595 | 18.6 |
| Oral Cavity and Pharynx | Total | 17 | 88,855 | 19.1 | 14.8 | 16.9 | 1.000 | 1,278 | 8,682,973 | 14.7 |
| Oral Cavity and Pharynx | Male | 13 | 44,532 | 29.2 | 22.1 | 12.5 | 0.954 | 923 | 4,352,378 | 21.2 |
| Oral Cavity and Pharynx | Female | 4 | 44,323 | 9.0 | 7.2 | 4.6 | 1.000 | 355 | 4,330,595 | 8.2 |
| Ovary | Female | 7 | 44,323 | 15.8 | 12.9 | 6.6 | 0.982 | 526 | 4,330,595 | 12.1 |
| Pancreas | Total | 21 | 88,855 | 23.6 | 17.6 | 19.3 | 0.750 | 1,402 | 8,682,973 | 16.1 |
| Pancreas | Male | 12 | 44,532 | 26.9 | 19.3 | 11.0 | 0.846 | 772 | 4,352,378 | 17.7 |
| Pancreas | Female | 9 | 44,323 | 20.3 | 15.7 | 8.4 | 0.913 | 630 | 4,330,595 | 14.5 |
| Prostate | Male | 97 | 44,532 | 217.8 | 159.2 | 88.5 | 0.390 | 6,320 | 4,352,378 | 145.2 |
| Stomach | Total | 11 | 88,855 | 12.4 | 9.5 | 6.1 | 0.094 | 456 | 8,682,973 | 5.3 |
| Stomach | Male | 6 | 44,532 | 13.5 | 9.8 | 4.2 | 0.508 | 303 | 4,352,378 | 7.0 |
| Stomach | Female | 5 | 44,323 | 11.3 | 9.1 | 1.9 | 0.096 | 153 | 4,330,595 | 3.5 |
| Testis | Male | 1 | 44,532 | 2.2 | 2.6 | 2.4 | 0.639 | 264 | 4,352,378 | 6.1 |
| Thyroid | Total | 17 | 88,855 | 19.1 | 17.8 | 13.2 | 0.361 | 1,203 | 8,682,973 | 13.9 |
| Thyroid | Male | 7 | 44,532 | 15.7 | 13.8 | 4.0 | 0.232 | 348 | 4,352,378 | 8.0 |
| Thyroid | Female | 10 | 44,323 | 22.6 | 21.3 | 9.3 | 0.891 | 855 | 4,330,595 | 19.7 |
| Pediatric Age 0 to 19 | Total | 2 | 22,230 | 9.0 | 9.0 | 3.8 | 0.535 | 419 | 2,438,293 | 17.2 |
| Pediatric Age 0 to 19 | Male | 2 | 11,714 | 17.1 | 17.1 | 2.1 | 1.000 | 221 | 1,244,796 | 17.8 |
| Pediatric Age 0 to 19 | Female |  | 10,516 | - | - | 1.7 | 0.352 | 198 | 1,193,497 | 16.6 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).
Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

## TABLE 4: CANCER MORTALITY 2017-2021

COMPARISON BETWEEN GEM COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Gem County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 1,212 | 91,642 | 1,322.5 | 999.3 | 1,039.0 | 0.000 >> | 76,218 | 8,897,073 | 856.7 |
| All Causes of Death | Male | 647 | 46,053 | 1,404.9 | 1,015.6 | 576.4 | $0.004 \gg$ | 40,409 | 4,465,815 | 904.9 |
| All Causes of Death | Female | 565 | 45,589 | 1,239.3 | 976.7 | 467.5 | 0.000 >> | 35,809 | 4,431,258 | 808.1 |
| All Malignant Cancers | Total | 206 | 91,642 | 224.8 | 167.7 | 205.9 | 1.000 | 14,915 | 8,897,073 | 167.6 |
| All Malignant Cancers | Male | 116 | 46,053 | 251.9 | 178.4 | 117.4 | 0.949 | 8,060 | 4,465,815 | 180.5 |
| All Malignant Cancers | Female | 90 | 45,589 | 197.4 | 153.8 | 90.5 | 1.000 | 6,855 | 4,431,258 | 154.7 |
| Bladder | Total | 11 | 91,642 | 12.0 | 8.7 | 6.8 | 0.171 | 478 | 8,897,073 | 5.4 |
| Bladder | Male | 9 | 46,053 | 19.5 | 13.2 | 5.7 | 0.238 | 369 | 4,465,815 | 8.3 |
| Bladder | Female | 2 | 45,589 | 4.4 | 3.3 | 1.5 | 0.868 | 109 | 4,431,258 | 2.5 |
| Brain and Other Nervous System | Total | 7 | 91,642 | 7.6 | 6.1 | 6.4 | 0.925 | 497 | 8,897,073 | 5.6 |
| Brain and Other Nervous System | Male | 4 | 46,053 | 8.7 | 6.8 | 3.9 | 1.000 | 294 | 4,465,815 | 6.6 |
| Brain and Other Nervous System | Female | 3 | 45,589 | 6.6 | 5.3 | 2.6 | 0.951 | 203 | 4,431,258 | 4.6 |
| Breast | Total | 13 | 91,642 | 14.2 | 10.9 | 14.6 | 0.795 | 1,089 | 8,897,073 | 12.2 |
| Breast | Male |  | 46,053 |  |  | 0.2 | 1.000 | 16 | 4,465,815 | 0.4 |
| Breast | Female | 13 | 45,589 | 28.5 | 22.6 | 13.9 | 0.940 | 1,073 | 4,431,258 | 24.2 |
| Cervix | Female | 2 | 45,589 | 4.4 | 3.9 | 0.9 | 0.487 | 81 | 4,431,258 | 1.8 |
| Colorectal | Total | 20 | 91,642 | 21.8 | 16.6 | 17.6 | 0.630 | 1,299 | 8,897,073 | 14.6 |
| Colorectal | Male | 10 | 46,053 | 21.7 | 16.0 | 9.9 | 1.000 | 709 | 4,465,815 | 15.9 |
| Colorectal | Female | 10 | 45,589 | 21.9 | 17.2 | 7.7 | 0.501 | 590 | 4,431,258 | 13.3 |
| Corpus Uteri | Female | 2 | 45,589 | 4.4 | 3.4 | 2.3 | 1.000 | 171 | 4,431,258 | 3.9 |
| Esophagus | Total | 9 | 91,642 | 9.8 | 7.4 | 6.4 | 0.402 | 468 | 8,897,073 | 5.3 |
| Esophagus | Male | 7 | 46,053 | 15.2 | 11.0 | 5.6 | 0.669 | 394 | 4,465,815 | 8.8 |
| Esophagus | Female | 2 | 45,589 | 4.4 | 3.4 | 1.0 | 0.514 | 74 | 4,431,258 | 1.7 |
| Hodgkin Lymphoma | Total |  | 91,642 | - | - | 0.4 | 1.000 | 29 | 8,897,073 | 0.3 |
| Hodgkin Lymphoma | Male | - | 46,053 | - | - | 0.2 | 1.000 | 14 | 4,465,815 | 0.3 |
| Hodgkin Lymphoma | Female | - | 45,589 | - | - | 0.2 | 1.000 | 15 | 4,431,258 | 0.3 |
| Kidney | Total | 1 | 91,642 | 1.1 | 0.8 | 5.4 | 0.060 | 384 | 8,897,073 | 4.3 |
| Kidney | Male | 1 | 46,053 | 2.2 | 1.5 | 3.5 | 0.274 | 241 | 4,465,815 | 5.4 |
| Kidney | Female | - | 45,589 | - | - | 1.9 | 0.293 | 143 | 4,431,258 | 3.2 |
| Larynx | Total |  | 91,642 |  | - | 1.0 | 0.751 | 71 | 8,897,073 | 0.8 |
| Larynx | Male | - | 46,053 | - | - | 0.8 | 0.856 | 58 | 4,465,815 | 1.3 |
| Larynx | Female | - | 45,589 | - | - | 0.2 | 1.000 | 13 | 4,431,258 | 0.3 |
| Leukemia | Total | 6 | 91,642 | 6.5 | 4.9 | 9.1 | 0.402 | 654 | 8,897,073 | 7.4 |
| Leukemia | Male | 5 | 46,053 | 10.9 | 7.7 | 5.6 | 1.000 | 381 | 4,465,815 | 8.5 |
| Leukemia | Female | 1 | 45,589 | 2.2 | 1.7 | 3.6 | 0.249 | 273 | 4,431,258 | 6.2 |
| Liver and Bile Duct | Total | 9 | 91,642 | 9.8 | 7.4 | 8.2 | 0.858 | 594 | 8,897,073 | 6.7 |
| Liver and Bile Duct | Male | 7 | 46,053 | 15.2 | 11.1 | 5.7 | 0.686 | 401 | 4,465,815 | 9.0 |
| Liver and Bile Duct | Female | 2 | 45,589 | 4.4 | 3.4 | 2.6 | 1.000 | 193 | 4,431,258 | 4.4 |
| Lung and Bronchus | Total | 48 | 91,642 | 52.4 | 38.4 | 40.9 | 0.302 | 2,913 | 8,897,073 | 32.7 |
| Lung and Bronchus | Male | 26 | 46,053 | 56.5 | 39.7 | 22.5 | 0.508 | 1,530 | 4,465,815 | 34.3 |
| Lung and Bronchus | Female | 22 | 45,589 | 48.3 | 36.9 | 18.6 | 0.492 | 1,383 | 4,431,258 | 31.2 |
| Melanoma of the Skin | Total | 4 | 91,642 | 4.4 | 3.3 | 3.8 | 1.000 | 285 | 8,897,073 | 3.2 |
| Melanoma of the Skin | Male | 1 | 46,053 | 2.2 | 1.6 | 2.7 | 0.487 | 191 | 4,465,815 | 4.3 |
| Melanoma of the Skin | Female | 3 | 45,589 | 6.6 | 5.3 | 1.2 | 0.242 | 94 | 4,431,258 | 2.1 |
| Myeloma | Total | 1 | 91,642 | 1.1 | 0.8 | 4.7 | 0.104 | 330 | 8,897,073 | 3.7 |
| Myeloma | Male | - | 46,053 | - | - | 3.0 | 0.103 | 196 | 4,465,815 | 4.4 |
| Myeloma | Female | 1 | 45,589 | 2.2 | 1.7 | 1.8 | 0.920 | 134 | 4,431,258 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 9 | 91,642 | 9.8 | 7.2 | 7.8 | 0.764 | 560 | 8,897,073 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 6 | 46,053 | 13.0 | 9.2 | 4.4 | 0.552 | 301 | 4,465,815 | 6.7 |
| Non-Hodgkin Lymphoma | Female | 3 | 45,589 | 6.6 | 5.1 | 3.5 | 1.000 | 259 | 4,431,258 | 5.8 |
| Oral Cavity and Pharynx | Total | 4 | 91,642 | 4.4 | 3.3 | 3.6 | 0.967 | 262 | 8,897,073 | 2.9 |
| Oral Cavity and Pharynx | Male | 3 | 46,053 | 6.5 | 4.7 | 2.6 | 0.975 | 184 | 4,465,815 | 4.1 |
| Oral Cavity and Pharynx | Female |  | 45,589 | 2.2 | 1.7 | 1.0 | 1.000 | 78 | 4,431,258 | 1.8 |
| Ovary | Female | 4 | 45,589 | 8.8 | 6.8 | 4.6 | 1.000 | 346 | 4,431,258 | 7.8 |
| Pancreas | Total | 16 | 91,642 | 17.5 | 12.9 | 16.3 | 1.000 | 1,174 | 8,897,073 | 13.2 |
| Pancreas | Male | 9 | 46,053 | 19.5 | 13.9 | 9.2 | 1.000 | 633 | 4,465,815 | 14.2 |
| Pancreas | Female | 7 | 45,589 | 15.4 | 11.8 | 7.2 | 1.000 | 541 | 4,431,258 | 12.2 |
| Prostate | Male | 10 | 46,053 | 21.7 | 14.5 | 14.5 | 0.295 | 939 | 4,465,815 | 21.0 |
| Stomach | Total | 3 | 91,642 | 3.3 | 2.5 | 2.6 | 0.970 | 195 | 8,897,073 | 2.2 |
| Stomach | Male | 3 | 46,053 | 6.5 | 4.7 | 1.7 | 0.474 | 118 | 4,465,815 | 2.6 |
| Stomach | Female | - | 45,589 | - | - | 1.0 | 0.758 | 77 | 4,431,258 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ )
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Gem County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 82.6\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 16.4\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 61.0\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 73.1\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 26.4\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 27.2\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 74.1\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 16.5\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 18.5\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, 12.6\% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^22]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# GOODING COUNTY CANCER PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 402 cases of invasive cancer were diagnosed among Gooding County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Gooding County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Gooding <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 402 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 43 | 6,687 |
| Prostate | 49 | 6,417 |
| Lung \& Bronchus | 34 | 4,887 |
| Colorectal | 3,451 |  |

Table 3 (Cancer Incidence 2016-2020, Comparison between Gooding County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Gooding County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Gooding County was 526.2 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.9) gives an estimate of the relative burden of disease in Gooding County.

The age- and sex-adjusted incidence rate of invasive cancer in Gooding County, all sites combined, was 491.1 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Gooding County (402) than expected (425.6) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 146 Gooding County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Gooding County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Gooding <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 783 | 77,431 |
| Cancer Deaths | 146 | 15,121 |
| \% of All Deaths | $18.6 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 36 | 2,961 |
| Colorectal | 7 | 1,319 |
| Pancreas | 9 | 1,190 |
| Female Breast | 10 | 1,086 |
| Prostate | 13 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Gooding County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Gooding County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Gooding County, all sites combined, was 168.4 deaths per 100,000 persons per year during 2017-2021, compared with 168.0 for the remainder of the state. There were more cancer deaths in Gooding County (146) than expected (145.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN GOODING COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

|  |  | Gooding County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 402 | 76,400 | 526.2 | 491.1 | 425.6 | 0.262 | 45,208 | 8,695,428 | 519.9 |
| All Sites Combined | Male | 208 | 38,981 | 533.6 | 486.2 | 236.4 | 0.066 | 24,081 | 4,357,929 | 552.6 |
| All Sites Combined | Female | 194 | 37,419 | 518.5 | 494.2 | 191.2 | 0.858 | 21,127 | 4,337,499 | 487.1 |
| Bladder | Total | 19 | 76,400 | 24.9 | 22.2 | 21.3 | 0.717 | 2,165 | 8,695,428 | 24.9 |
| Bladder | Male | 18 | 38,981 | 46.2 | 40.0 | 17.9 | 1.000 | 1,733 | 4,357,929 | 39.8 |
| Bladder | Female | 1 | 37,419 | 2.7 | 2.4 | 4.1 | 0.174 | 432 | 4,337,499 | 10.0 |
| Brain - malignant | Total | 6 | 76,400 | 7.9 | 7.5 | 5.7 | 1.000 | 619 | 8,695,428 | 7.1 |
| Brain - malignant | Male | 4 | 38,981 | 10.3 | 9.8 | 3.5 | 0.910 | 371 | 4,357,929 | 8.5 |
| Brain - malignant | Female | 2 | 37,419 | 5.3 | 5.1 | 2.2 | 1.000 | 248 | 4,337,499 | 5.7 |
| Brain and other CNS - non-malignant | Total | 19 | 76,400 | 24.9 | 23.4 | 13.1 | 0.149 | 1,405 | 8,695,428 | 16.2 |
| Brain and other CNS - non-malignant | Male | 8 | 38,981 | 20.5 | 19.1 | 4.5 | 0.179 | 472 | 4,357,929 | 10.8 |
| Brain and other CNS - non-malignant | Female | 11 | 37,419 | 29.4 | 28.0 | 8.4 | 0.460 | 933 | 4,337,499 | 21.5 |
| Breast | Total | 57 | 76,400 | 74.6 | 71.2 | 61.6 | 0.614 | 6,689 | 8,695,428 | 76.9 |
| Breast | Male | 1 | 38,981 | 2.6 | 2.3 | 0.6 | 0.889 | 58 | 4,357,929 | 1.3 |
| Breast | Female | 56 | 37,419 | 149.7 | 145.0 | 59.1 | 0.754 | 6,631 | 4,337,499 | 152.9 |
| Breast - in situ | Total | 11 | 76,400 | 14.4 | 14.0 | 11.1 | 1.000 | 1,228 | 8,695,428 | 14.1 |
| Breast - in situ | Male | - | 38,981 | - | - | 0.0 | 1.000 | 5 | 4,357,929 | 0.1 |
| Breast - in situ | Female | 11 | 37,419 | 29.4 | 29.0 | 10.7 | 1.000 | 1,223 | 4,337,499 | 28.2 |
| Cervix | Female | 2 | 37,419 | 5.3 | 5.6 | 2.5 | 1.000 | 302 | 4,337,499 | 7.0 |
| Colorectal | Total | 34 | 76,400 | 44.5 | 41.2 | 32.4 | 0.825 | 3,417 | 8,695,428 | 39.3 |
| Colorectal | Male | 16 | 38,981 | 41.0 | 37.5 | 18.5 | 0.669 | 1,887 | 4,357,929 | 43.3 |
| Colorectal | Female | 18 | 37,419 | 48.1 | 45.1 | 14.1 | 0.359 | 1,530 | 4,337,499 | 35.3 |
| Corpus Uteri | Female | 8 | 37,419 | 21.4 | 20.9 | 11.7 | 0.354 | 1,322 | 4,337,499 | 30.5 |
| Esophagus | Total | 11 | 76,400 | 14.4 | 13.2 | 4.7 | 0.019 >> | 495 | 8,695,428 | 5.7 |
| Esophagus | Male | 10 | 38,981 | 25.7 | 23.0 | 4.1 | 0.020 >> | 414 | 4,357,929 | 9.5 |
| Esophagus | Female | 1 | 37,419 | 2.7 | 2.5 | 0.7 | 1.000 | 81 | 4,337,499 | 1.9 |
| Hodgkin Lymphoma | Total | 1 | 76,400 | 1.3 | 1.3 | 1.8 | 0.918 | 209 | 8,695,428 | 2.4 |
| Hodgkin Lymphoma | Male | - | 38,981 | - | - | 1.0 | 0.702 | 118 | 4,357,929 | 2.7 |
| Hodgkin Lymphoma | Female | 1 | 37,419 | 2.7 | 2.7 | 0.8 | 1.000 | 91 | 4,337,499 | 2.1 |
| Kidney and Renal Pelvis | Total | 19 | 76,400 | 24.9 | 23.4 | 16.8 | 0.649 | 1,796 | 8,695,428 | 20.7 |
| Kidney and Renal Pelvis | Male | 11 | 38,981 | 28.2 | 26.2 | 11.3 | 1.000 | 1,171 | 4,357,929 | 26.9 |
| Kidney and Renal Pelvis | Female | 8 | 37,419 | 21.4 | 20.3 | 5.7 | 0.430 | 625 | 4,337,499 | 14.4 |
| Larynx | Total | 4 | 76,400 | 5.2 | 4.9 | 2.0 | 0.282 | 211 | 8,695,428 | 2.4 |
| Larynx | Male | 3 | 38,981 | 7.7 | 7.0 | 1.5 | 0.399 | 157 | 4,357,929 | 3.6 |
| Larynx | Female | 1 | 37,419 | 2.7 | 2.6 | 0.5 | 0.772 | 54 | 4,337,499 | 1.2 |
| Leukemia | Total | 11 | 76,400 | 14.4 | 13.2 | 15.6 | 0.301 | 1,620 | 8,695,428 | 18.6 |
| Leukemia | Male | 5 | 38,981 | 12.8 | 11.6 | 9.8 | 0.153 | 984 | 4,357,929 | 22.6 |
| Leukemia | Female | 6 | 37,419 | 16.0 | 14.8 | 5.9 | 1.000 | 636 | 4,337,499 | 14.7 |
| Liver and Bile Duct | Total | 6 | 76,400 | 7.9 | 7.4 | 7.7 | 0.697 | 823 | 8,695,428 | 9.5 |
| Liver and Bile Duct | Male | 5 | 38,981 | 12.8 | 11.9 | 5.7 | 1.000 | 585 | 4,357,929 | 13.4 |
| Liver and Bile Duct | Female | 1 | 37,419 | 2.7 | 2.5 | 2.2 | 0.717 | 238 | 4,337,499 | 5.5 |
| Lung and Bronchus | Total | 49 | 76,400 | 64.1 | 58.0 | 47.0 | 0.806 | 4,838 | 8,695,428 | 55.6 |
| Lung and Bronchus | Male | 23 | 38,981 | 59.0 | 52.5 | 24.4 | 0.875 | 2,429 | 4,357,929 | 55.7 |
| Lung and Bronchus | Female | 26 | 37,419 | 69.5 | 63.7 | 22.7 | 0.539 | 2,409 | 4,337,499 | 55.5 |
| Melanoma of the Skin | Total | 16 | 76,400 | 20.9 | 19.8 | 27.2 | 0.029 << | 2,926 | 8,695,428 | 33.6 |
| Melanoma of the Skin | Male | 10 | 38,981 | 25.7 | 23.4 | 17.2 | 0.089 | 1,755 | 4,357,929 | 40.3 |
| Melanoma of the Skin | Female | 6 | 37,419 | 16.0 | 15.7 | 10.3 | 0.223 | 1,171 | 4,337,499 | 27.0 |
| Myeloma | Total | 8 | 76,400 | 10.5 | 9.5 | 6.8 | 0.735 | 700 | 8,695,428 | 8.1 |
| Myeloma | Male | 5 | 38,981 | 12.8 | 11.4 | 4.4 | 0.892 | 436 | 4,357,929 | 10.0 |
| Myeloma | Female | 3 | 37,419 | 8.0 | 7.4 | 2.5 | 0.895 | 264 | 4,337,499 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 20 | 76,400 | 26.2 | 24.3 | 18.2 | 0.729 | 1,920 | 8,695,428 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 10 | 38,981 | 25.7 | 23.5 | 10.9 | 0.941 | 1,119 | 4,357,929 | 25.7 |
| Non-Hodgkin Lymphoma | Female | 10 | 37,419 | 26.7 | 25.0 | 7.4 | 0.422 | 801 | 4,337,499 | 18.5 |
| Oral Cavity and Pharynx | Total | 18 | 76,400 | 23.6 | 22.3 | 11.9 | 0.116 | 1,277 | 8,695,428 | 14.7 |
| Oral Cavity and Pharynx | Male | 13 | 38,981 | 33.3 | 31.0 | 8.9 | 0.231 | 923 | 4,357,929 | 21.2 |
| Oral Cavity and Pharynx | Female | 5 | 37,419 | 13.4 | 12.8 | 3.2 | 0.436 | 354 | 4,337,499 | 8.2 |
| Ovary | Female | 4 | 37,419 | 10.7 | 10.3 | 4.8 | 0.970 | 529 | 4,337,499 | 12.2 |
| Pancreas | Total | 13 | 76,400 | 17.0 | 15.4 | 13.7 | 0.990 | 1,410 | 8,695,428 | 16.2 |
| Pancreas | Male | 8 | 38,981 | 20.5 | 18.2 | 7.8 | 1.000 | 776 | 4,357,929 | 17.8 |
| Pancreas | Female | 5 | 37,419 | 13.4 | 12.2 | 6.0 | 0.902 | 634 | 4,337,499 | 14.6 |
| Prostate | Male | 43 | 38,981 | 110.3 | 102.0 | 61.6 | 0.016 << | 6,374 | 4,357,929 | 146.3 |
| Stomach | Total | 5 | 76,400 | 6.5 | 6.0 | 4.4 | 0.911 | 462 | 8,695,428 | 5.3 |
| Stomach | Male | 3 | 38,981 | 7.7 | 6.9 | 3.0 | 1.000 | 306 | 4,357,929 | 7.0 |
| Stomach | Female | 2 | 37,419 | 5.3 | 5.0 | 1.4 | 0.849 | 156 | 4,337,499 | 3.6 |
| Testis | Male | 2 | 38,981 | 5.1 | 5.5 | 2.2 | 1.000 | 263 | 4,357,929 | 6.0 |
| Thyroid | Total | 7 | 76,400 | 9.2 | 9.3 | 10.5 | 0.359 | 1,213 | 8,695,428 | 13.9 |
| Thyroid | Male | 2 | 38,981 | 5.1 | 5.0 | 3.2 | 0.755 | 353 | 4,357,929 | 8.1 |
| Thyroid | Female | 5 | 37,419 | 13.4 | 13.8 | 7.2 | 0.561 | 860 | 4,337,499 | 19.8 |
| Pediatric Age 0 to 19 | Total | 1 | 22,749 | 4.4 | 4.4 | 3.9 | 0.201 | 420 | 2,437,774 | 17.2 |
| Pediatric Age 0 to 19 | Male | 1 | 11,567 | 8.6 | 8.7 | 2.1 | 0.781 | 222 | 1,244,943 | 17.8 |
| Pediatric Age 0 to 19 | Female | - | 11,182 | - | - | 1.8 | 0.325 | 198 | 1,192,831 | 16.6 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN GOODING COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Gooding County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 783 | 77,022 | 1,016.6 | 876.7 | 768.1 | 0.601 | 76,647 | 8,911,693 | 860.1 |
| All Causes of Death | Male | 440 | 39,280 | 1,120.2 | 939.8 | 425.2 | 0.484 | 40,616 | 4,472,588 | 908.1 |
| All Causes of Death | Female | 343 | 37,742 | 908.8 | 803.6 | 346.4 | 0.882 | 36,031 | 4,439,105 | 811.7 |
| All Malignant Cancers | Total | 146 | 77,022 | 189.6 | 168.4 | 145.7 | 1.000 | 14,975 | 8,911,693 | 168.0 |
| All Malignant Cancers | Male | 87 | 39,280 | 221.5 | 189.7 | 83.0 | 0.686 | 8,089 | 4,472,588 | 180.9 |
| All Malignant Cancers | Female | 59 | 37,742 | 156.3 | 142.8 | 64.1 | 0.575 | 6,886 | 4,439,105 | 155.1 |
| Bladder | Total | 4 | 77,022 | 5.2 | 4.4 | 5.0 | 0.881 | 485 | 8,911,693 | 5.4 |
| Bladder | Male | 3 | 39,280 | 7.6 | 6.0 | 4.2 | 0.795 | 375 | 4,472,588 | 8.4 |
| Bladder | Female | 1 | 37,742 | 2.6 | 2.3 | 1.1 | 1.000 | 110 | 4,439,105 | 2.5 |
| Brain and Other Nervous System | Total | 2 | 77,022 | 2.6 | 2.4 | 4.6 | 0.323 | 502 | 8,911,693 | 5.6 |
| Brain and Other Nervous System | Male | 1 | 39,280 | 2.5 | 2.4 | 2.8 | 0.457 | 297 | 4,472,588 | 6.6 |
| Brain and Other Nervous System | Female | 1 | 37,742 | 2.6 | 2.5 | 1.8 | 0.908 | 205 | 4,439,105 | 4.6 |
| Breast | Total | 10 | 77,022 | 13.0 | 11.7 | 10.5 | 1.000 | 1,092 | 8,911,693 | 12.3 |
| Breast | Male |  | 39,280 |  |  | 0.2 | 1.000 | 16 | 4,472,588 | 0.4 |
| Breast | Female | 10 | 37,742 | 26.5 | 24.6 | 9.9 | 1.000 | 1,076 | 4,439,105 | 24.2 |
| Cervix | Female | 2 | 37,742 | 5.3 | 5.3 | 0.7 | 0.300 | 81 | 4,439,105 | 1.8 |
| Colorectal | Total | 7 | 77,022 | 9.1 | 8.1 | 12.7 | 0.127 | 1,312 | 8,911,693 | 14.7 |
| Colorectal | Male | 5 | 39,280 | 12.7 | 11.2 | 7.1 | 0.570 | 714 | 4,472,588 | 16.0 |
| Colorectal | Female | 2 | 37,742 | 5.3 | 4.8 | 5.6 | 0.163 | 598 | 4,439,105 | 13.5 |
| Corpus Uteri | Female | - | 37,742 | - | - | 1.6 | 0.411 | 173 | 4,439,105 | 3.9 |
| Esophagus | Total | 11 | 77,022 | 14.3 | 12.9 | 4.4 | $0.012 \gg$ | 466 | 8,911,693 | 5.2 |
| Esophagus | Male | 9 | 39,280 | 22.9 | 20.3 | 3.9 | 0.037 >> | 392 | 4,472,588 | 8.8 |
| Esophagus | Female | 2 | 37,742 | 5.3 | 4.8 | 0.7 | 0.303 | 74 | 4,439,105 | 1.7 |
| Hodgkin Lymphoma | Total | - | 77,022 |  | - | 0.3 | 1.000 | 29 | 8,911,693 | 0.3 |
| Hodgkin Lymphoma | Male | - | 39,280 | - | - | 0.1 | 1.000 | 14 | 4,472,588 | 0.3 |
| Hodgkin Lymphoma | Female | - | 37,742 | - | - | 0.1 | 1.000 | 15 | 4,439,105 | 0.3 |
| Kidney | Total | 4 | 77,022 | 5.2 | 4.6 | 3.7 | 1.000 | 381 | 8,911,693 | 4.3 |
| Kidney | Male | 1 | 39,280 | 2.5 | 2.2 | 2.4 | 0.600 | 241 | 4,472,588 | 5.4 |
| Kidney | Female | 3 | 37,742 | 7.9 | 7.1 | 1.3 | 0.303 | 140 | 4,439,105 | 3.2 |
| Larynx | Total | 2 | 77,022 | 2.6 | 2.4 | 0.7 | 0.282 | 69 | 8,911,693 | 0.8 |
| Larynx | Male | 2 | 39,280 | 5.1 | 4.4 | 0.6 | 0.220 | 56 | 4,472,588 | 1.3 |
| Larynx | Female | - | 37,742 | - | - | 0.1 | 1.000 | 13 | 4,439,105 | 0.3 |
| Leukemia | Total | 7 | 77,022 | 9.1 | 7.9 | 6.5 | 0.945 | 653 | 8,911,693 | 7.3 |
| Leukemia | Male | 3 | 39,280 | 7.6 | 6.4 | 4.0 | 0.873 | 383 | 4,472,588 | 8.6 |
| Leukemia | Female | 4 | 37,742 | 10.6 | 9.4 | 2.6 | 0.524 | 270 | 4,439,105 | 6.1 |
| Liver and Bile Duct | Total | 1 | 77,022 | 1.3 | 1.2 | 5.7 | 0.045 << | 602 | 8,911,693 | 6.8 |
| Liver and Bile Duct | Male | 1 | 39,280 | 2.5 | 2.3 | 4.0 | 0.186 | 407 | 4,472,588 | 9.1 |
| Liver and Bile Duct | Female | - | 37,742 | - | - | 1.8 | 0.332 | 195 | 4,439,105 | 4.4 |
| Lung and Bronchus | Total | 36 | 77,022 | 46.7 | 41.7 | 28.4 | 0.186 | 2,925 | 8,911,693 | 32.8 |
| Lung and Bronchus | Male | 18 | 39,280 | 45.8 | 39.9 | 15.5 | 0.592 | 1,538 | 4,472,588 | 34.4 |
| Lung and Bronchus | Female | 18 | 37,742 | 47.7 | 43.2 | 13.0 | 0.219 | 1,387 | 4,439,105 | 31.2 |
| Melanoma of the Skin | Total | 3 | 77,022 | 3.9 | 3.5 | 2.7 | 1.000 | 286 | 8,911,693 | 3.2 |
| Melanoma of the Skin | Male | 3 | 39,280 | 7.6 | 6.6 | 1.9 | 0.604 | 189 | 4,472,588 | 4.2 |
| Melanoma of the Skin | Female | - | 37,742 | - | - | 0.9 | 0.828 | 97 | 4,439,105 | 2.2 |
| Myeloma | Total | 1 | 77,022 | 1.3 | 1.1 | 3.3 | 0.323 | 330 | 8,911,693 | 3.7 |
| Myeloma | Male | 1 | 39,280 | 2.5 | 2.1 | 2.0 | 0.791 | 195 | 4,472,588 | 4.4 |
| Myeloma | Female | - | 37,742 |  | - | 1.3 | 0.551 | 135 | 4,439,105 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 5 | 77,022 | 6.5 | 5.7 | 5.6 | 1.000 | 564 | 8,911,693 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 3 | 39,280 | 7.6 | 6.5 | 3.1 | 1.000 | 304 | 4,472,588 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 2 | 37,742 | 5.3 | 4.7 | 2.5 | 1.000 | 260 | 4,439,105 | 5.9 |
| Oral Cavity and Pharynx | Total | 4 | 77,022 | 5.2 | 4.7 | 2.5 | 0.478 | 262 | 8,911,693 | 2.9 |
| Oral Cavity and Pharynx | Male | 4 | 39,280 | 10.2 | 9.1 | 1.8 | 0.217 | 183 | 4,472,588 | 4.1 |
| Oral Cavity and Pharynx | Female | - | 37,742 | - | - | 0.7 | 0.969 | 79 | 4,439,105 | 1.8 |
| Ovary | Female | 1 | 37,742 | 2.6 | 2.5 | 3.2 | 0.344 | 349 | 4,439,105 | 7.9 |
| Pancreas | Total | 9 | 77,022 | 11.7 | 10.5 | 11.3 | 0.610 | 1,181 | 8,911,693 | 13.3 |
| Pancreas | Male | 6 | 39,280 | 15.3 | 13.4 | 6.3 | 1.000 | 636 | 4,472,588 | 14.2 |
| Pancreas | Female | 3 | 37,742 | 7.9 | 7.3 | 5.1 | 0.515 | 545 | 4,439,105 | 12.3 |
| Prostate | Male | 13 | 39,280 | 33.1 | 26.1 | 10.4 | 0.500 | 936 | 4,472,588 | 20.9 |
| Stomach | Total | 1 | 77,022 | 1.3 | 1.2 | 1.9 | 0.874 | 197 | 8,911,693 | 2.2 |
| Stomach | Male | - | 39,280 | - | - | 1.2 | 0.595 | 121 | 4,472,588 | 2.7 |
| Stomach | Female | 1 | 37,742 | 2.6 | 2.5 | 0.7 | 1.000 | 76 | 4,439,105 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Gooding County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 72.2\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 13.2\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 52.4\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% |  |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 21.1\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 28.8\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 66.4\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 16.8\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 12.5\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^23]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

## IDAHO COUNTY

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 613 cases of invasive cancer were diagnosed among Idaho County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Idaho County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Idaho <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 613 | 45,610 |
| Female Breast | 76 | 6,687 |
| Prostate | 100 | 6,417 |
| Lung \& Bronchus | 77 | 4,887 |
| Colorectal | 51 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Idaho County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Idaho County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Idaho County was 742.5 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (517.8) gives an estimate of the relative burden of disease in Idaho County.

The age- and sex-adjusted incidence rate of invasive cancer in Idaho County, all sites combined, was 486.2 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Idaho County (613) than expected (652.9) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 234 Idaho County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Idaho County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Idaho <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 1,042 | 77,431 |
| Cancer Deaths | 234 | 15,121 |
| \% of All Deaths | $22.5 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 41 | 2,961 |
| Colorectal | 24 | 1,319 |
| Pancreas | 24 | 1,190 |
| Female Breast | 13 | 1,086 |
| Prostate | 18 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Idaho County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Idaho County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Idaho County, all sites combined, was 169.8 deaths per 100,000 persons per year during 2017-2021, compared with 167.2 for the remainder of the state. There were more cancer deaths in Idaho County (234) than expected (230.4) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020 COMPARISON BETWEEN IDAHO COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Idaho County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 613 | 82,554 | 742.5 | 486.2 | 652.9 | 0.121 | 44,997 | 8,689,274 | 517.8 |
| All Sites Combined | Male | 351 | 43,359 | 809.5 | 499.4 | 386.5 | 0.072 | 23,938 | 4,353,551 | 549.8 |
| All Sites Combined | Female | 262 | 39,195 | 668.5 | 461.4 | 275.8 | 0.424 | 21,059 | 4,335,723 | 485.7 |
| Bladder | Total | 33 | 82,554 | 40.0 | 23.9 | 34.2 | 0.923 | 2,151 | 8,689,274 | 24.8 |
| Bladder | Male | 25 | 43,359 | 57.7 | 32.7 | 30.4 | 0.382 | 1,726 | 4,353,551 | 39.6 |
| Bladder | Female | 8 | 39,195 | 20.4 | 12.8 | 6.1 | 0.543 | 425 | 4,335,723 | 9.8 |
| Brain - malignant | Total | 4 | 82,554 | 4.8 | 3.6 | 8.0 | 0.197 | 621 | 8,689,274 | 7.1 |
| Brain - malignant | Male | 4 | 43,359 | 9.2 | 6.7 | 5.1 | 0.842 | 371 | 4,353,551 | 8.5 |
| Brain - malignant | Female | - | 39,195 | - | - | 3.1 | 0.094 | 250 | 4,335,723 | 5.8 |
| Brain and other CNS - non-malignant | Total | 19 | 82,554 | 23.0 | 16.2 | 19.0 | 1.000 | 1,405 | 8,689,274 | 16.2 |
| Brain and other CNS - non-malignant | Male | 8 | 43,359 | 18.5 | 13.0 | 6.6 | 0.698 | 472 | 4,353,551 | 10.8 |
| Brain and other CNS - non-malignant | Female | 11 | 39,195 | 28.1 | 19.9 | 11.9 | 0.952 | 933 | 4,335,723 | 21.5 |
| Breast | Total | 78 | 82,554 | 94.5 | 65.2 | 91.9 | 0.158 | 6,668 | 8,689,274 | 76.7 |
| Breast | Male | 2 | 43,359 | 4.6 | 2.8 | 1.0 | 0.492 | 57 | 4,353,551 | 1.3 |
| Breast | Female | 76 | 39,195 | 193.9 | 136.0 | 85.2 | 0.347 | 6,611 | 4,335,723 | 152.5 |
| Breast - in situ | Total | 3 | 82,554 | 3.6 | 2.6 | 16.6 | 0.000 << | 1,236 | 8,689,274 | 14.2 |
| Breast - in situ | Male | - | 43,359 | - | - | 0.1 | 1.000 | 5 | 4,353,551 | 0.1 |
| Breast - in situ | Female | 3 | 39,195 | 7.7 | 5.5 | 15.6 | 0.000 << | 1,231 | 4,335,723 | 28.4 |
| Cervix | Female | 4 | 39,195 | 10.2 | 9.6 | 2.9 | 0.659 | 300 | 4,335,723 | 6.9 |
| Colorectal | Total | 51 | 82,554 | 61.8 | 40.9 | 48.8 | 0.788 | 3,400 | 8,689,274 | 39.1 |
| Colorectal | Male | 21 | 43,359 | 48.4 | 31.3 | 29.0 | 0.151 | 1,882 | 4,353,551 | 43.2 |
| Colorectal | Female | 30 | 39,195 | 76.5 | 51.9 | 20.2 | 0.050 >> | 1,518 | 4,335,723 | 35.0 |
| Corpus Uteri | Female | 20 | 39,195 | 51.0 | 35.2 | 17.2 | 0.557 | 1,310 | 4,335,723 | 30.2 |
| Esophagus | Total | 10 | 82,554 | 12.1 | 7.6 | 7.5 | 0.455 | 496 | 8,689,274 | 5.7 |
| Esophagus | Male | 9 | 43,359 | 20.8 | 12.5 | 6.9 | 0.504 | 415 | 4,353,551 | 9.5 |
| Esophagus | Female | 1 | 39,195 | 2.6 | 1.6 | 1.1 | 1.000 | 81 | 4,335,723 | 1.9 |
| Hodgkin Lymphoma | Total | 2 | 82,554 | 2.4 | 2.2 | 2.2 | 1.000 | 208 | 8,689,274 | 2.4 |
| Hodgkin Lymphoma | Male | 2 | 43,359 | 4.6 | 4.0 | 1.3 | 0.763 | 116 | 4,353,551 | 2.7 |
| Hodgkin Lymphoma | Female | - | 39,195 | - | - | 0.9 | 0.840 | 92 | 4,335,723 | 2.1 |
| Kidney and Renal Pelvis | Total | 23 | 82,554 | 27.9 | 18.7 | 25.4 | 0.727 | 1,792 | 8,689,274 | 20.6 |
| Kidney and Renal Pelvis | Male | 14 | 43,359 | 32.3 | 21.2 | 17.8 | 0.449 | 1,168 | 4,353,551 | 26.8 |
| Kidney and Renal Pelvis | Female | 9 | 39,195 | 23.0 | 15.7 | 8.2 | 0.881 | 624 | 4,335,723 | 14.4 |
| Larynx | Total | 2 | 82,554 | 2.4 | 1.5 | 3.2 | 0.759 | 213 | 8,689,274 | 2.5 |
| Larynx | Male | 1 | 43,359 | 2.3 | 1.4 | 2.6 | 0.529 | 159 | 4,353,551 | 3.7 |
| Larynx | Female | 1 | 39,195 | 2.6 | 1.7 | 0.7 | 1.000 | 54 | 4,335,723 | 1.2 |
| Leukemia | Total | 19 | 82,554 | 23.0 | 15.1 | 23.3 | 0.440 | 1,612 | 8,689,274 | 18.6 |
| Leukemia | Male | 13 | 43,359 | 30.0 | 19.1 | 15.3 | 0.673 | 976 | 4,353,551 | 22.4 |
| Leukemia | Female | 6 | 39,195 | 15.3 | 10.3 | 8.5 | 0.510 | 636 | 4,335,723 | 14.7 |
| Liver and Bile Duct | Total | 14 | 82,554 | 17.0 | 10.8 | 12.2 | 0.681 | 815 | 8,689,274 | 9.4 |
| Liver and Bile Duct | Male | 10 | 43,359 | 23.1 | 14.3 | 9.3 | 0.909 | 580 | 4,353,551 | 13.3 |
| Liver and Bile Duct | Female | 4 | 39,195 | 10.2 | 6.6 | 3.3 | 0.822 | 235 | 4,335,723 | 5.4 |
| Lung and Bronchus | Total | 77 | 82,554 | 93.3 | 56.0 | 76.1 | 0.952 | 4,810 | 8,689,274 | 55.4 |
| Lung and Bronchus | Male | 46 | 43,359 | 106.1 | 60.7 | 41.9 | 0.562 | 2,406 | 4,353,551 | 55.3 |
| Lung and Bronchus | Female | 31 | 39,195 | 79.1 | 49.4 | 34.8 | 0.587 | 2,404 | 4,335,723 | 55.4 |
| Melanoma of the Skin | Total | 40 | 82,554 | 48.5 | 33.4 | 40.0 | 1.000 | 2,902 | 8,689,274 | 33.4 |
| Melanoma of the Skin | Male | 27 | 43,359 | 62.3 | 39.8 | 27.1 | 1.000 | 1,738 | 4,353,551 | 39.9 |
| Melanoma of the Skin | Female | 13 | 39,195 | 33.2 | 24.8 | 14.1 | 0.918 | 1,164 | 4,335,723 | 26.8 |
| Myeloma | Total | 5 | 82,554 | 6.1 | 3.7 | 10.9 | 0.080 | 703 | 8,689,274 | 8.1 |
| Myeloma | Male | 2 | 43,359 | 4.6 | 2.7 | 7.5 | 0.042 << | 439 | 4,353,551 | 10.1 |
| Myeloma | Female | 3 | 39,195 | 7.7 | 4.9 | 3.7 | 0.973 | 264 | 4,335,723 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 27 | 82,554 | 32.7 | 21.5 | 27.7 | 0.994 | 1,913 | 8,689,274 | 22.0 |
| Non-Hodgkin Lymphoma | Male | 15 | 43,359 | 34.6 | 22.2 | 17.3 | 0.685 | 1,114 | 4,353,551 | 25.6 |
| Non-Hodgkin Lymphoma | Female | 12 | 39,195 | 30.6 | 20.4 | 10.8 | 0.802 | 799 | 4,335,723 | 18.4 |
| Oral Cavity and Pharynx | Total | 22 | 82,554 | 26.6 | 17.5 | 18.4 | 0.457 | 1,273 | 8,689,274 | 14.7 |
| Oral Cavity and Pharynx | Male | 16 | 43,359 | 36.9 | 23.7 | 14.2 | 0.709 | 920 | 4,353,551 | 21.1 |
| Oral Cavity and Pharynx | Female | 6 | 39,195 | 15.3 | 10.3 | 4.7 | 0.675 | 353 | 4,335,723 | 8.1 |
| Ovary | Female | 5 | 39,195 | 12.8 | 9.0 | 6.8 | 0.653 | 528 | 4,335,723 | 12.2 |
| Pancreas | Total | 28 | 82,554 | 33.9 | 20.9 | 21.5 | 0.205 | 1,395 | 8,689,274 | 16.1 |
| Pancreas | Male | 19 | 43,359 | 43.8 | 26.0 | 12.8 | 0.127 | 765 | 4,353,551 | 17.6 |
| Pancreas | Female | 9 | 39,195 | 23.0 | 14.6 | 9.0 | 1.000 | 630 | 4,335,723 | 14.5 |
| Prostate | Male | 100 | 43,359 | 230.6 | 138.2 | 105.0 | 0.673 | 6,317 | 4,353,551 | 145.1 |
| Stomach | Total | 5 | 82,554 | 6.1 | 3.9 | 6.9 | 0.640 | 462 | 8,689,274 | 5.3 |
| Stomach | Male | 4 | 43,359 | 9.2 | 5.6 | 5.0 | 0.887 | 305 | 4,353,551 | 7.0 |
| Stomach | Female | 1 | 39,195 | 2.6 | 1.7 | 2.1 | 0.763 | 157 | 4,335,723 | 3.6 |
| Testis | Male | 5 | 43,359 | 11.5 | 13.6 | 2.2 | 0.144 | 260 | 4,353,551 | 6.0 |
| Thyroid | Total | 8 | 82,554 | 9.7 | 8.5 | 13.1 | 0.194 | 1,212 | 8,689,274 | 13.9 |
| Thyroid | Male | 2 | 43,359 | 4.6 | 3.7 | 4.4 | 0.367 | 353 | 4,353,551 | 8.1 |
| Thyroid | Female | 6 | 39,195 | 15.3 | 14.1 | 8.4 | 0.532 | 859 | 4,335,723 | 19.8 |
| Pediatric Age 0 to 19 | Total | 1 | 17,737 | 5.6 | 5.7 | 3.0 | 0.387 | 420 | 2,442,786 | 17.2 |
| Pediatric Age 0 to 19 | Male | 1 | 9,392 | 10.6 | 10.6 | 1.7 | 1.000 | 222 | 1,247,118 | 17.8 |
| Pediatric Age 0 to 19 | Female | - | 8,345 | - | - | 1.4 | 0.512 | 198 | 1,195,668 | 16.6 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN IDAHO COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Idaho County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude <br> Rate (1) | A.A.M. Rate (1,2) | Expected <br> Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 1,042 | 83,347 | 1,250.2 | 760.9 | 1,174.6 | 0.000 << | 76,388 | 8,905,368 | 857.8 |
| All Causes of Death | Male | 600 | 43,796 | 1,370.0 | 806.5 | 673.6 | $0.004 \ll$ | 40,456 | 4,468,072 | 905.4 |
| All Causes of Death | Female | 442 | 39,551 | 1,117.5 | 695.7 | 514.5 | 0.001 << | 35,932 | 4,437,296 | 809.8 |
| All Malignant Cancers | Total | 234 | 83,347 | 280.8 | 169.8 | 230.4 | 0.828 | 14,887 | 8,905,368 | 167.2 |
| All Malignant Cancers | Male | 134 | 43,796 | 306.0 | 175.0 | 137.8 | 0.786 | 8,042 | 4,468,072 | 180.0 |
| All Malignant Cancers | Female | 100 | 39,551 | 252.8 | 159.9 | 96.5 | 0.745 | 6,845 | 4,437,296 | 154.3 |
| Bladder | Total | 11 | 83,347 | 13.2 | 7.5 | 7.9 | 0.346 | 478 | 8,905,368 | 5.4 |
| Bladder | Male | 7 | 43,796 | 16.0 | 8.5 | 6.9 | 1.000 | 371 | 4,468,072 | 8.3 |
| Bladder | Female | 4 | 39,551 | 10.1 | 6.0 | 1.6 | 0.158 | 107 | 4,437,296 | 2.4 |
| Brain and Other Nervous System | Total | 3 | 83,347 | 3.6 | 2.4 | 6.9 | 0.169 | 501 | 8,905,368 | 5.6 |
| Brain and Other Nervous System | Male | 3 | 43,796 | 6.8 | 4.5 | 4.4 | 0.713 | 295 | 4,468,072 | 6.6 |
| Brain and Other Nervous System | Female |  | 39,551 |  |  | 2.7 | 0.139 | 206 | 4,437,296 | 4.6 |
| Breast | Total | 13 | 83,347 | 15.6 | 9.9 | 16.1 | 0.534 | 1,089 | 8,905,368 | 12.2 |
| Breast | Male |  | 43,796 | - |  | 0.3 | 1.000 | 16 | 4,468,072 | 0.4 |
| Breast | Female | 13 | 39,551 | 32.9 | 21.5 | 14.6 | 0.796 | 1,073 | 4,437,296 | 24.2 |
| Cervix | Female | 1 | 39,551 | 2.5 | 2.1 | 0.9 | 1.000 | 82 | 4,437,296 | 1.8 |
| Colorectal | Total | 24 | 83,347 | 28.8 | 18.0 | 19.4 | 0.349 | 1,295 | 8,905,368 | 14.5 |
| Colorectal | Male | 9 | 43,796 | 20.5 | 12.6 | 11.4 | 0.601 | 710 | 4,468,072 | 15.9 |
| Colorectal | Female | 15 | 39,551 | 37.9 | 24.1 | 8.2 | 0.042 >> | 585 | 4,437,296 | 13.2 |
| Corpus Uteri | Female | 3 | 39,551 | 7.6 | 4.8 | 2.4 | 0.866 | 170 | 4,437,296 | 3.8 |
| Esophagus | Total | 8 | 83,347 | 9.6 | 5.9 | 7.2 | 0.848 | 469 | 8,905,368 | 5.3 |
| Esophagus | Male | 6 | 43,796 | 13.7 | 8.1 | 6.6 | 1.000 | 395 | 4,468,072 | 8.8 |
| Esophagus | Female | 2 | 39,551 | 5.1 | 3.2 | 1.0 | 0.561 | 74 | 4,437,296 | 1.7 |
| Hodgkin Lymphoma | Total |  | 83,347 |  |  | 0.4 | 1.000 | 29 | 8,905,368 | 0.3 |
| Hodgkin Lymphoma | Male | - | 43,796 | - | - | 0.2 | 1.000 | 14 | 4,468,072 | 0.3 |
| Hodgkin Lymphoma | Female | - | 39,551 | - | - | 0.2 | 1.000 | 15 | 4,437,296 | 0.3 |
| Kidney | Total | 3 | 83,347 | 3.6 | 2.1 | 6.0 | 0.296 | 382 | 8,905,368 | 4.3 |
| Kidney | Male |  | 43,796 |  |  | 4.1 | 0.032 << | 242 | 4,468,072 | 5.4 |
| Kidney | Female | 3 | 39,551 | 7.6 | 4.6 | 2.1 | 0.682 | 140 | 4,437,296 | 3.2 |
| Larynx | Total | 1 | 83,347 | 1.2 | 0.7 | 1.1 | 1.000 | 70 | 8,905,368 | 0.8 |
| Larynx | Male | 1 | 43,796 | 2.3 | 1.3 | 1.0 | 1.000 | 57 | 4,468,072 | 1.3 |
| Larynx | Female | - | 39,551 | - | - | 0.2 | 1.000 | 13 | 4,437,296 | 0.3 |
| Leukemia | Total | 9 | 83,347 | 10.8 | 6.5 | 10.2 | 0.868 | 651 | 8,905,368 | 7.3 |
| Leukemia | Male | 8 | 43,796 | 18.3 | 10.4 | 6.5 | 0.656 | 378 | 4,468,072 | 8.5 |
| Leukemia | Female | 1 | 39,551 | 2.5 | 1.6 | 3.9 | 0.194 | 273 | 4,437,296 | 6.2 |
| Liver and Bile Duct | Total | 12 | 83,347 | 14.4 | 8.8 | 9.1 | 0.406 | 591 | 8,905,368 | 6.6 |
| Liver and Bile Duct | Male | 8 | 43,796 | 18.3 | 10.7 | 6.7 | 0.703 | 400 | 4,468,072 | 9.0 |
| Liver and Bile Duct | Female | 4 | 39,551 | 10.1 | 6.4 | 2.7 | 0.573 | 191 | 4,437,296 | 4.3 |
| Lung and Bronchus | Total | 41 | 83,347 | 49.2 | 29.1 | 46.3 | 0.492 | 2,920 | 8,905,368 | 32.8 |
| Lung and Bronchus | Male | 25 | 43,796 | 57.1 | 32.1 | 26.7 | 0.846 | 1,531 | 4,468,072 | 34.3 |
| Lung and Bronchus | Female | 16 | 39,551 | 40.5 | 24.9 | 20.1 | 0.428 | 1,389 | 4,437,296 | 31.3 |
| Melanoma of the Skin | Total | 3 | 83,347 | 3.6 | 2.3 | 4.3 | 0.764 | 286 | 8,905,368 | 3.2 |
| Melanoma of the Skin | Male | 3 | 43,796 | 6.8 | 4.0 | 3.1 | 1.000 | 189 | 4,468,072 | 4.2 |
| Melanoma of the Skin | Female | - | 39,551 | - | - | 1.3 | 0.549 | 97 | 4,437,296 | 2.2 |
| Myeloma | Total | 7 | 83,347 | 8.4 | 4.8 | 5.3 | 0.556 | 324 | 8,905,368 | 3.6 |
| Myeloma | Male | 2 | 43,796 | 4.6 | 2.5 | 3.5 | 0.632 | 194 | 4,468,072 | 4.3 |
| Myeloma | Female | , | 39,551 | 12.6 | 7.7 | 1.9 | 0.088 | 130 | 4,437,296 | 2.9 |
| Non-Hodgkin Lymphoma | Total | 7 | 83,347 | 8.4 | 5.0 | 8.9 | 0.674 | 562 | 8,905,368 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 2 | 43,796 | 4.6 | 2.6 | 5.2 | 0.214 | 305 | 4,468,072 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 5 | 39,551 | 12.6 | 7.7 | 3.8 | 0.652 | 257 | 4,437,296 | 5.8 |
| Oral Cavity and Pharynx | Total | 4 | 83,347 | 4.8 | 3.0 | 4.0 | 1.000 | 262 | 8,905,368 | 2.9 |
| Oral Cavity and Pharynx | Male | 3 | 43,796 | 6.8 | 4.1 | 3.0 | 1.000 | 184 | 4,468,072 | 4.1 |
| Oral Cavity and Pharynx | Female | 1 | 39,551 | 2.5 | 1.6 | 1.1 | 1.000 | 78 | 4,437,296 | 1.8 |
| Ovary | Female | 3 | 39,551 | 7.6 | 4.8 | 4.9 | 0.573 | 347 | 4,437,296 | 7.8 |
| Pancreas | Total | 24 | 83,347 | 28.8 | 17.3 | 18.1 | 0.215 | 1,166 | 8,905,368 | 13.1 |
| Pancreas | Male | 17 | 43,796 | 38.8 | 22.5 | 10.6 | 0.084 | 625 | 4,468,072 | 14.0 |
| Pancreas | Female | 7 | 39,551 | 17.7 | 11.0 | 7.8 | 0.976 | 541 | 4,437,296 | 12.2 |
| Prostate | Male | 18 | 43,796 | 41.1 | 21.6 | 17.4 | 0.942 | 931 | 4,468,072 | 20.8 |
| Stomach | Total | - | 83,347 | - | - | 2.9 | 0.110 | 198 | 8,905,368 | 2.2 |
| Stomach | Male | - | 43,796 | - | - | 2.0 | 0.283 | 121 | 4,468,072 | 2.7 |
| Stomach | Female | - | 39,551 | - | - | 1.0 | 0.726 | 77 | 4,437,296 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Idaho County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 63.7\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) Cancer Screening | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 14.7\% |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 74.6\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 (2018, 2020) | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% | 64.2\% |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) Tobacco Use | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 61.7\% |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | $22.4 \%$ |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 32.3\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 68.8\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 14.3\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 9.6\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^24]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked 49 ${ }^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# JPFFPRSON COUNTY CANCER PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 578 cases of invasive cancer were diagnosed among Jefferson County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Jefferson County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Jefferson <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 578 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 79 | 6,687 |
| Prostate | 83 | 6,417 |
| Lung \& Bronchus | 48 | 4,887 |
| Colorectal | 47 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Jefferson County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Jefferson County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Jefferson County was 395.4 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (522.1) gives an estimate of the relative burden of disease in Jefferson County.

The age- and sex-adjusted incidence rate of invasive cancer in Jefferson County, all sites combined, was 497.4 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Jefferson County (578) than expected (606.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 172 Jefferson County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Jefferson County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Jefferson <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 969 | 77,431 |
| Cancer Deaths | 172 | 15,121 |
| \% of All Deaths | $17.8 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 26 | 2,961 |
| Colorectal | 15 | 1,319 |
| Pancreas | 17 | 1,190 |
| Female Breast | 17 | 1,086 |
| Prostate | 11 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Jefferson County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Jefferson County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Jefferson County, all sites combined, was 152.5 deaths per 100,000 persons per year during 2017-2021, compared with 169.1 for the remainder of the state. There were fewer cancer deaths in Jefferson County (172) than expected (190.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN JEFFERSON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Jefferson County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person Years | Crude Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person Years | Crude Rate (1) |
| All Sites Combined | Total | 578 | 146,192 | 395.4 | 497.4 | 606.7 | 0.252 | 45,032 | 8,625,636 | 522.1 |
| All Sites Combined | Male | 314 | 74,341 | 422.4 | 528.7 | 329.4 | 0.413 | 23,975 | 4,322,569 | 554.6 |
| All Sites Combined | Female | 264 | 71,851 | 367.4 | 462.9 | 279.1 | 0.384 | 21,057 | 4,303,067 | 489.3 |
| Bladder | Total | 28 | 146,192 | 19.2 | 25.5 | 27.4 | 0.961 | 2,156 | 8,625,636 | 25.0 |
| Bladder | Male | 21 | 74,341 | 28.2 | 37.1 | 22.6 | 0.837 | 1,730 | 4,322,569 | 40.0 |
| Bladder | Female | 7 | 71,851 | 9.7 | 13.1 | 5.3 | 0.566 | 426 | 4,303,067 | 9.9 |
| Brain - malignant | Total | 10 | 146,192 | 6.8 | 8.0 | 9.0 | 0.813 | 615 | 8,625,636 | 7.1 |
| Brain - malignant | Male | 5 | 74,341 | 6.7 | 7.7 | 5.5 | 1.000 | 370 | 4,322,569 | 8.6 |
| Brain - malignant | Female | 5 | 71,851 | 7.0 | 8.2 | 3.5 | 0.540 | 245 | 4,303,067 | 5.7 |
| Brain and other CNS - non-malignant | Total | 24 | 146,192 | 16.4 | 19.9 | 19.6 | 0.368 | 1,400 | 8,625,636 | 16.2 |
| Brain and other CNS - non-malignant | Male | 10 | 74,341 | 13.5 | 15.8 | 6.9 | 0.314 | 470 | 4,322,569 | 10.9 |
| Brain and other CNS - non-malignant | Female | 14 | 71,851 | 19.5 | 24.2 | 12.5 | 0.748 | 930 | 4,303,067 | 21.6 |
| Breast | Total | 80 | 146,192 | 54.7 | 67.1 | 92.2 | 0.221 | 6,666 | 8,625,636 | 77.3 |
| Breast | Male | 1 | 74,341 | 1.3 | 1.7 | 0.8 | 1.000 | 58 | 4,322,569 | 1.3 |
| Breast | Female | 79 | 71,851 | 109.9 | 137.0 | 88.6 | 0.335 | 6,608 | 4,303,067 | 153.6 |
| Breast - in situ | Total | 17 | 146,192 | 11.6 | 14.0 | 17.1 | 1.000 | 1,222 | 8,625,636 | 14.2 |
| Breast - in situ | Male |  | 74,341 | - | - | 0.1 | 1.000 | 5 | 4,322,569 | 0.1 |
| Breast - in situ | Female | 17 | 71,851 | 23.7 | 29.1 | 16.5 | 0.969 | 1,217 | 4,303,067 | 28.3 |
| Cervix | Female | 4 | 71,851 | 5.6 | 6.1 | 4.6 | 1.000 | 300 | 4,303,067 | 7.0 |
| Colorectal | Total | 47 | 146,192 | 32.1 | 40.5 | 45.8 | 0.902 | 3,404 | 8,625,636 | 39.5 |
| Colorectal | Male | 30 | 74,341 | 40.4 | 49.7 | 26.2 | 0.504 | 1,873 | 4,322,569 | 43.3 |
| Colorectal | Female | 17 | 71,851 | 23.7 | 30.4 | 19.9 | 0.614 | 1,531 | 4,303,067 | 35.6 |
| Corpus Uteri | Female | 17 | 71,851 | 23.7 | 29.6 | 17.6 | 1.000 | 1,313 | 4,303,067 | 30.5 |
| Esophagus | Total | 3 | 146,192 | 2.1 | 2.7 | 6.6 | 0.210 | 503 | 8,625,636 | 5.8 |
| Esophagus | Male | 2 | 74,341 | 2.7 | 3.4 | 5.7 | 0.151 | 422 | 4,322,569 | 9.8 |
| Esophagus | Female | 1 | 71,851 | 1.4 | 1.8 | 1.0 | 1.000 | 81 | 4,303,067 | 1.9 |
| Hodgkin Lymphoma | Total | 4 | 146,192 | 2.7 | 3.0 | 3.2 | 0.791 | 206 | 8,625,636 | 2.4 |
| Hodgkin Lymphoma | Male | 2 | 74,341 | 2.7 | 2.9 | 1.8 | 1.000 | 116 | 4,322,569 | 2.7 |
| Hodgkin Lymphoma | Female | 2 | 71,851 | 2.8 | 3.0 | 1.4 | 0.806 | 90 | 4,303,067 | 2.1 |
| Kidney and Renal Pelvis | Total | 13 | 146,192 | 8.9 | 11.0 | 24.6 | 0.016 << | 1,802 | 8,625,636 | 20.9 |
| Kidney and Renal Pelvis | Male | 10 | 74,341 | 13.5 | 16.4 | 16.5 | 0.124 | 1,172 | 4,322,569 | 27.1 |
| Kidney and Renal Pelvis | Female | 3 | 71,851 | 4.2 | 5.2 | 8.4 | 0.066 | 630 | 4,303,067 | 14.6 |
| Larynx | Total | 1 | 146,192 | 0.7 | 0.9 | 2.8 | 0.447 | 214 | 8,625,636 | 2.5 |
| Larynx | Male | - | 74,341 | - | - | 2.2 | 0.224 | 160 | 4,322,569 | 3.7 |
| Larynx | Female | 1 | 71,851 | 1.4 | 1.8 | 0.7 | 1.000 | 54 | 4,303,067 | 1.3 |
| Leukemia | Total | 17 | 146,192 | 11.6 | 14.4 | 22.1 | 0.330 | 1,614 | 8,625,636 | 18.7 |
| Leukemia | Male | 16 | 74,341 | 21.5 | 26.2 | 13.8 | 0.613 | 973 | 4,322,569 | 22.5 |
| Leukemia | Female | 1 | 71,851 | 1.4 | 1.8 | 8.5 | 0.004 << | 641 | 4,303,067 | 14.9 |
| Liver and Bile Duct | Total | 8 | 146,192 | 5.5 | 6.9 | 11.0 | 0.469 | 821 | 8,625,636 | 9.5 |
| Liver and Bile Duct | Male | 6 | 74,341 | 8.1 | 10.0 | 8.1 | 0.600 | 584 | 4,322,569 | 13.5 |
| Liver and Bile Duct | Female | 2 | 71,851 | 2.8 | 3.6 | 3.1 | 0.821 | 237 | 4,303,067 | 5.5 |
| Lung and Bronchus | Total | 48 | 146,192 | 32.8 | 43.4 | 62.0 | 0.078 | 4,839 | 8,625,636 | 56.1 |
| Lung and Bronchus | Male | 30 | 74,341 | 40.4 | 52.6 | 32.0 | 0.817 | 2,422 | 4,322,569 | 56.0 |
| Lung and Bronchus | Female | 18 | 71,851 | 25.1 | 33.6 | 30.1 | 0.025 << | 2,417 | 4,303,067 | 56.2 |
| Melanoma of the Skin | Total | 46 | 146,192 | 31.5 | 38.8 | 39.8 | 0.362 | 2,896 | 8,625,636 | 33.6 |
| Melanoma of the Skin | Male | 24 | 74,341 | 32.3 | 40.0 | 24.2 | 1.000 | 1,741 | 4,322,569 | 40.3 |
| Melanoma of the Skin | Female | 22 | 71,851 | 30.6 | 37.1 | 15.9 | 0.170 | 1,155 | 4,303,067 | 26.8 |
| Myeloma | Total | 5 | 146,192 | 3.4 | 4.5 | 9.1 | 0.219 | 703 | 8,625,636 | 8.2 |
| Myeloma | Male | 3 | 74,341 | 4.0 | 5.2 | 5.8 | 0.332 | 438 | 4,322,569 | 10.1 |
| Myeloma | Female | 2 | 71,851 | 2.8 | 3.7 | 3.4 | 0.696 | 265 | 4,303,067 | 6.2 |
| Non-Hodgkin Lymphoma | Total | 30 | 146,192 | 20.5 | 25.7 | 25.8 | 0.461 | 1,910 | 8,625,636 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 14 | 74,341 | 18.8 | 23.0 | 15.7 | 0.794 | 1,115 | 4,322,569 | 25.8 |
| Non-Hodgkin Lymphoma | Female | 16 | 71,851 | 22.3 | 28.6 | 10.3 | 0.122 | 795 | 4,303,067 | 18.5 |
| Oral Cavity and Pharynx | Total | 18 | 146,192 | 12.3 | 15.4 | 17.3 | 0.927 | 1,277 | 8,625,636 | 14.8 |
| Oral Cavity and Pharynx | Male | 13 | 74,341 | 17.5 | 21.4 | 13.0 | 1.000 | 923 | 4,322,569 | 21.4 |
| Oral Cavity and Pharynx | Female | 5 | 71,851 | 7.0 | 8.9 | 4.6 | 0.985 | 354 | 4,303,067 | 8.2 |
| Ovary | Female | 6 | 71,851 | 8.4 | 10.4 | 7.0 | 0.889 | 527 | 4,303,067 | 12.2 |
| Pancreas | Total | 20 | 146,192 | 13.7 | 17.9 | 18.1 | 0.722 | 1,403 | 8,625,636 | 16.3 |
| Pancreas | Male | 12 | 74,341 | 16.1 | 20.7 | 10.3 | 0.683 | 772 | 4,322,569 | 17.9 |
| Pancreas | Female | 8 | 71,851 | 11.1 | 14.9 | 7.9 | 1.000 | 631 | 4,303,067 | 14.7 |
| Prostate | Male | 83 | 74,341 | 111.6 | 141.0 | 86.2 | 0.781 | 6,334 | 4,322,569 | 146.5 |
| Stomach | Total | 10 | 146,192 | 6.8 | 8.8 | 6.0 | 0.174 | 457 | 8,625,636 | 5.3 |
| Stomach | Male | 5 | 74,341 | 6.7 | 8.5 | 4.1 | 0.796 | 304 | 4,322,569 | 7.0 |
| Stomach | Female | 5 | 71,851 | 7.0 | 8.9 | 2.0 | 0.103 | 153 | 4,303,067 | 3.6 |
| Testis | Male | 3 | 74,341 | 4.0 | 4.3 | 4.2 | 0.778 | 262 | 4,322,569 | 6.1 |
| Thyroid | Total | 29 | 146,192 | 19.8 | 22.3 | 18.0 | 0.021 >> | 1,191 | 8,625,636 | 13.8 |
| Thyroid | Male | 12 | 74,341 | 16.1 | 18.5 | 5.2 | 0.014 >> | 343 | 4,322,569 | 7.9 |
| Thyroid | Female | 17 | 71,851 | 23.7 | 26.4 | 12.7 | 0.288 | 848 | 4,303,067 | 19.7 |
| Pediatric Age 0 to 19 | Total | 6 | 53,391 | 11.2 | 11.4 | 9.1 | 0.404 | 415 | 2,407,132 | 17.2 |
| Pediatric Age 0 to 19 | Male | 4 | 27,191 | 14.7 | 14.8 | 4.8 | 0.951 | 219 | 1,229,319 | 17.8 |
| Pediatric Age 0 to 19 | Female | 2 | 26,200 | 7.6 | 7.8 | 4.2 | 0.409 | 196 | 1,177,813 | 16.6 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN JEFFERSON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Jefferson County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 969 | 150,567 | 643.6 | 865.8 | 968.2 | 0.988 | 76,461 | 8,838,148 | 865.1 |
| All Causes of Death | Male | 543 | 76,770 | 707.3 | 921.1 | 538.5 | 0.858 | 40,513 | 4,435,098 | 913.5 |
| All Causes of Death | Female | 426 | 73,797 | 577.3 | 801.9 | 433.7 | 0.735 | 35,948 | 4,403,050 | 816.4 |
| All Malignant Cancers | Total | 172 | 150,567 | 114.2 | 152.5 | 190.7 | 0.184 | 14,949 | 8,838,148 | 169.1 |
| All Malignant Cancers | Male | 103 | 76,770 | 134.2 | 176.7 | 106.1 | 0.810 | 8,073 | 4,435,098 | 182.0 |
| All Malignant Cancers | Female | 69 | 73,797 | 93.5 | 126.2 | 85.4 | 0.079 | 6,876 | 4,403,050 | 156.2 |
| Bladder | Total | 8 | 150,567 | 5.3 | 7.5 | 5.8 | 0.451 | 481 | 8,838,148 | 5.4 |
| Bladder | Male | 7 | 76,770 | 9.1 | 12.7 | 4.6 | 0.363 | 371 | 4,435,098 | 8.4 |
| Bladder | Female | 1 | 73,797 | 1.4 | 1.9 | 1.3 | 1.000 | 110 | 4,403,050 | 2.5 |
| Brain and Other Nervous System | Total | 7 | 150,567 | 4.6 | 5.7 | 6.9 | 1.000 | 497 | 8,838,148 | 5.6 |
| Brain and Other Nervous System | Male | 4 | 76,770 | 5.2 | 6.3 | 4.2 | 1.000 | 294 | 4,435,098 | 6.6 |
| Brain and Other Nervous System | Female | 3 | 73,797 | 4.1 | 5.1 | 2.7 | 1.000 | 203 | 4,403,050 | 4.6 |
| Breast | Total | 17 | 150,567 | 11.3 | 14.7 | 14.2 | 0.522 | 1,085 | 8,838,148 | 12.3 |
| Breast | Male |  | 76,770 |  |  | 0.2 | 1.000 | 16 | 4,435,098 | 0.4 |
| Breast | Female | 17 | 73,797 | 23.0 | 30.5 | 13.5 | 0.412 | 1,069 | 4,403,050 | 24.3 |
| Cervix | Female | - | 73,797 |  | - | 1.2 | 0.611 | 83 | 4,403,050 | 1.9 |
| Colorectal | Total | 15 | 150,567 | 10.0 | 13.1 | 16.9 | 0.759 | 1,304 | 8,838,148 | 14.8 |
| Colorectal | Male | 9 | 76,770 | 11.7 | 14.9 | 9.7 | 0.993 | 710 | 4,435,098 | 16.0 |
| Colorectal | Female | 6 | 73,797 | 8.1 | 11.0 | 7.3 | 0.804 | 594 | 4,403,050 | 13.5 |
| Corpus Uteri | Female | 2 | 73,797 | 2.7 | 3.6 | 2.1 | 1.000 | 171 | 4,403,050 | 3.9 |
| Esophagus | Total | 3 | 150,567 | 2.0 | 2.6 | 6.1 | 0.281 | 474 | 8,838,148 | 5.4 |
| Esophagus | Male | 3 | 76,770 | 3.9 | 5.0 | 5.3 | 0.440 | 398 | 4,435,098 | 9.0 |
| Esophagus | Female | - | 73,797 | - | - | 0.9 | 0.783 | 76 | 4,403,050 | 1.7 |
| Hodgkin Lymphoma | Total | 1 | 150,567 | 0.7 | 0.9 | 0.4 | 0.616 | 28 | 8,838,148 | 0.3 |
| Hodgkin Lymphoma | Male |  | 76,770 |  |  | 0.2 | 1.000 | 14 | 4,435,098 | 0.3 |
| Hodgkin Lymphoma | Female | 1 | 73,797 | 1.4 | 1.8 | 0.2 | 0.323 | 14 | 4,403,050 | 0.3 |
| Kidney | Total | 3 | 150,567 | 2.0 | 2.7 | 4.8 | 0.583 | 382 | 8,838,148 | 4.3 |
| Kidney | Male | 1 | 76,770 | 1.3 | 1.7 | 3.2 | 0.345 | 241 | 4,435,098 | 5.4 |
| Kidney | Female | 2 | 73,797 | 2.7 | 3.8 | 1.7 | 1.000 | 141 | 4,403,050 | 3.2 |
| Larynx | Total | - | 150,567 |  | - | 0.9 | 0.795 | 71 | 8,838,148 | 0.8 |
| Larynx | Male | - | 76,770 | - | - | 0.8 | 0.925 | 58 | 4,435,098 | 1.3 |
| Larynx | Female | - | 73,797 | - | - | 0.2 | 1.000 | 13 | 4,403,050 | 0.3 |
| Leukemia | Total | 6 | 150,567 | 4.0 | 5.4 | 8.3 | 0.567 | 654 | 8,838,148 | 7.4 |
| Leukemia | Male | 5 | 76,770 | 6.5 | 8.6 | 5.0 | 1.000 | 381 | 4,435,098 | 8.6 |
| Leukemia | Female | 1 | 73,797 | 1.4 | 1.9 | 3.3 | 0.312 | 273 | 4,403,050 | 6.2 |
| Liver and Bile Duct | Total | 8 | 150,567 | 5.3 | 7.0 | 7.7 | 1.000 | 595 | 8,838,148 | 6.7 |
| Liver and Bile Duct | Male | 7 | 76,770 | 9.1 | 11.7 | 5.4 | 0.597 | 401 | 4,435,098 | 9.0 |
| Liver and Bile Duct | Female | 1 | 73,797 | 1.4 | 1.8 | 2.4 | 0.610 | 194 | 4,403,050 | 4.4 |
| Lung and Bronchus | Total | 26 | 150,567 | 17.3 | 23.3 | 37.0 | 0.073 | 2,935 | 8,838,148 | 33.2 |
| Lung and Bronchus | Male | 17 | 76,770 | 22.1 | 29.3 | 20.1 | 0.577 | 1,539 | 4,435,098 | 34.7 |
| Lung and Bronchus | Female | 9 | 73,797 | 12.2 | 16.7 | 17.1 | 0.051 | 1,396 | 4,403,050 | 31.7 |
| Melanoma of the Skin | Total | 5 | 150,567 | 3.3 | 4.3 | 3.7 | 0.631 | 284 | 8,838,148 | 3.2 |
| Melanoma of the Skin | Male | 5 | 76,770 | 6.5 | 8.4 | 2.5 | 0.218 | 187 | 4,435,098 | 4.2 |
| Melanoma of the Skin | Female | - | 73,797 | - | - | 1.3 | 0.571 | 97 | 4,403,050 | 2.2 |
| Myeloma | Total | 2 | 150,567 | 1.3 | 1.8 | 4.1 | 0.460 | 329 | 8,838,148 | 3.7 |
| Myeloma | Male | 2 | 76,770 | 2.6 | 3.6 | 2.5 | 1.000 | 194 | 4,435,098 | 4.4 |
| Myeloma | Female | - | 73,797 | - | - | 1.6 | 0.394 | 135 | 4,403,050 | 3.1 |
| Non-Hodgkin Lymphoma | Total | 7 | 150,567 | 4.6 | 6.3 | 7.1 | 1.000 | 562 | 8,838,148 | 6.4 |
| Non-Hodgkin Lymphoma | Male | 4 | 76,770 | 5.2 | 6.9 | 4.0 | 1.000 | 303 | 4,435,098 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 3 | 73,797 | 4.1 | 5.7 | 3.1 | 1.000 | 259 | 4,403,050 | 5.9 |
| Oral Cavity and Pharynx | Total | 1 | 150,567 | 0.7 | 0.9 | 3.4 | 0.285 | 265 | 8,838,148 | 3.0 |
| Oral Cavity and Pharynx | Male | 1 | 76,770 | 1.3 | 1.7 | 2.5 | 0.574 | 186 | 4,435,098 | 4.2 |
| Oral Cavity and Pharynx | Female | - | 73,797 | - | - | 1.0 | 0.738 | 79 | 4,403,050 | 1.8 |
| Ovary | Female | 2 | 73,797 | 2.7 | 3.6 | 4.4 | 0.376 | 348 | 4,403,050 | 7.9 |
| Pancreas | Total | 17 | 150,567 | 11.3 | 15.1 | 15.0 | 0.665 | 1,173 | 8,838,148 | 13.3 |
| Pancreas | Male | 9 | 76,770 | 11.7 | 15.3 | 8.4 | 0.919 | 633 | 4,435,098 | 14.3 |
| Pancreas | Female | 8 | 73,797 | 10.8 | 14.8 | 6.6 | 0.698 | 540 | 4,403,050 | 12.3 |
| Prostate | Male | 11 | 76,770 | 14.3 | 20.1 | 11.6 | 1.000 | 938 | 4,435,098 | 21.1 |
| Stomach | Total | 1 | 150,567 | 0.7 | 0.9 | 2.6 | 0.539 | 197 | 8,838,148 | 2.2 |
| Stomach | Male | 1 | 76,770 | 1.3 | 1.7 | 1.6 | 1.000 | 120 | 4,435,098 | 2.7 |
| Stomach | Female | - | 73,797 | - | - | 1.0 | 0.734 | 77 | 4,403,050 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Jefferson County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 84.0\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 12.3\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 63.8\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% | 55.3\% |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 59.5\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 12.2\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 26.5\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 77.1\% |
| Meet Physical Activity Guidelines ( $2011,2013,2015,2017,2019)$ | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 16.8\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 20.5\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to 64.8\% of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^25]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged $50-74$ reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# JPROME COUNTY CANCER PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 489 cases of invasive cancer were diagnosed among Jerome County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Jerome County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Jerome <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 489 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 61 | 6,687 |
| Prostate | 54 | 6,417 |
| Lung \& Bronchus | 42 | 4,887 |
| Colorectal | 3,451 |  |

Table 3 (Cancer Incidence 2016-2020, Comparison between Jerome County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Jerome County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Jerome County was 406.2 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (521.5) gives an estimate of the relative burden of disease in Jerome County.

The age- and sex-adjusted incidence rate of invasive cancer in Jerome County, all sites combined, was 470.7 cases per 100,000 persons per year during 2016-2020. There were statistically significantly fewer cases of cancer in Jerome County (489) than expected (541.8) based upon rates in the remainder of the state $(p=.023)$.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 165 Jerome County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Jerome County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Jerome <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 925 | 77,431 |
| Cancer Deaths | 165 | 15,121 |
| \% of All Deaths | $17.8 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 29 | 2,961 |
| Colorectal | 21 | 1,319 |
| Pancreas | 11 | 1,190 |
| Female Breast | 10 | 1,086 |
| Prostate | 16 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Jerome County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Jerome County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Jerome County, all sites combined, was 162.5 deaths per 100,000 persons per year during 2017-2021, compared with 168.7 for the remainder of the state. There were fewer cancer deaths in Jerome County (165) than expected (171.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN JEROME COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Jerome County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person Years | Crude <br> Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 489 | 120,371 | 406.2 | 470.7 | 541.8 | 0.023 << | 45,121 | 8,651,457 | 521.5 |
| All Sites Combined | Male | 245 | 61,720 | 397.0 | 463.4 | 293.3 | 0.004 << | 24,044 | 4,335,190 | 554.6 |
| All Sites Combined | Female | 244 | 58,651 | 416.0 | 479.3 | 248.6 | 0.803 | 21,077 | 4,316,267 | 488.3 |
| Bladder | Total | 20 | 120,371 | 16.6 | 19.9 | 25.1 | 0.357 | 2,164 | 8,651,457 | 25.0 |
| Bladder | Male | 14 | 61,720 | 22.7 | 27.4 | 20.5 | 0.174 | 1,737 | 4,335,190 | 40.1 |
| Bladder | Female | 6 | 58,651 | 10.2 | 12.2 | 4.9 | 0.728 | 427 | 4,316,267 | 9.9 |
| Brain - malignant | Total | 5 | 120,371 | 4.2 | 4.6 | 7.8 | 0.418 | 620 | 8,651,457 | 7.2 |
| Brain - malignant | Male |  | 61,720 |  |  | 4.8 | 0.016 << | 375 | 4,335,190 | 8.7 |
| Brain - malignant | Female | 5 | 58,651 | 8.5 | 9.4 | 3.0 | 0.376 | 245 | 4,316,267 | 5.7 |
| Brain and other CNS - non-malignant | Total | 6 | 120,371 | 5.0 | 5.6 | 17.4 | $0.003 \ll$ | 1,418 | 8,651,457 | 16.4 |
| Brain and other CNS - non-malignant | Male | 3 | 61,720 | 4.9 | 5.4 | 6.1 | 0.285 | 477 | 4,335,190 | 11.0 |
| Brain and other CNS - non-malignant | Female | 3 | 58,651 | 5.1 | 5.8 | 11.2 | 0.009 << | 941 | 4,316,267 | 21.8 |
| Breast | Total | 61 | 120,371 | 50.7 | 58.0 | 81.3 | $0.023 \ll$ | 6,685 | 8,651,457 | 77.3 |
| Breast | Male |  | 61,720 |  |  | 0.7 | 0.980 | 59 | 4,335,190 | 1.4 |
| Breast | Female | 61 | 58,651 | 104.0 | 119.6 | 78.3 | 0.051 | 6,626 | 4,316,267 | 153.5 |
| Breast - in situ | Total | 15 | 120,371 | 12.5 | 14.2 | 15.0 | 1.000 | 1,224 | 8,651,457 | 14.1 |
| Breast - in situ | Male |  | 61,720 |  |  | 0.1 | 1.000 | 5 | 4,335,190 | 0.1 |
| Breast - in situ | Female | 15 | 58,651 | 25.6 | 29.3 | 14.4 | 0.953 | 1,219 | 4,316,267 | 28.2 |
| Cervix | Female | 5 | 58,651 | 8.5 | 9.2 | 3.8 | 0.645 | 299 | 4,316,267 | 6.9 |
| Colorectal | Total | 42 | 120,371 | 34.9 | 40.2 | 41.1 | 0.932 | 3,409 | 8,651,457 | 39.4 |
| Colorectal | Male | 20 | 61,720 | 32.4 | 37.1 | 23.4 | 0.560 | 1,883 | 4,335,190 | 43.4 |
| Colorectal | Female | 22 | 58,651 | 37.5 | 43.5 | 17.9 | 0.386 | 1,526 | 4,316,267 | 35.4 |
| Corpus Uteri | Female | 22 | 58,651 | 37.5 | 43.3 | 15.4 | 0.133 | 1,308 | 4,316,267 | 30.3 |
| Esophagus | Total | 7 | 120,371 | 5.8 | 6.8 | 5.9 | 0.757 | 499 | 8,651,457 | 5.8 |
| Esophagus | Male | 6 | 61,720 | 9.7 | 11.4 | 5.1 | 0.789 | 418 | 4,335,190 | 9.6 |
| Esophagus | Female | 1 | 58,651 | 1.7 | 2.0 | 0.9 | 1.000 | 81 | 4,316,267 | 1.9 |
| Hodgkin Lymphoma | Total | 3 | 120,371 | 2.5 | 2.6 | 2.7 | 1.000 | 207 | 8,651,457 | 2.4 |
| Hodgkin Lymphoma | Male | 2 | 61,720 | 3.2 | 3.4 | 1.6 | 0.925 | 116 | 4,335,190 | 2.7 |
| Hodgkin Lymphoma | Female | 1 | 58,651 | 1.7 | 1.8 | 1.2 | 1.000 | 91 | 4,316,267 | 2.1 |
| Kidney and Renal Pelvis | Total | 20 | 120,371 | 16.6 | 19.0 | 21.8 | 0.806 | 1,795 | 8,651,457 | 20.7 |
| Kidney and Renal Pelvis | Male | 15 | 61,720 | 24.3 | 27.7 | 14.6 | 0.978 | 1,167 | 4,335,190 | 26.9 |
| Kidney and Renal Pelvis | Female | 5 | 58,651 | 8.5 | 9.8 | 7.4 | 0.497 | 628 | 4,316,267 | 14.5 |
| Larynx | Total | 6 | 120,371 | 5.0 | 5.8 | 2.5 | 0.083 | 209 | 8,651,457 | 2.4 |
| Larynx | Male | 5 | 61,720 | 8.1 | 9.5 | 1.9 | 0.086 | 155 | 4,335,190 | 3.6 |
| Larynx | Female | 1 | 58,651 | 1.7 | 2.0 | 0.6 | 0.934 | 54 | 4,316,267 | 1.3 |
| Leukemia | Total | 16 | 120,371 | 13.3 | 15.2 | 19.7 | 0.484 | 1,615 | 8,651,457 | 18.7 |
| Leukemia | Male | 7 | 61,720 | 11.3 | 12.9 | 12.3 | 0.157 | 982 | 4,335,190 | 22.7 |
| Leukemia | Female | 9 | 58,651 | 15.3 | 17.6 | 7.5 | 0.681 | 633 | 4,316,267 | 14.7 |
| Liver and Bile Duct | Total | 8 | 120,371 | 6.6 | 7.8 | 9.8 | 0.719 | 821 | 8,651,457 | 9.5 |
| Liver and Bile Duct | Male | 7 | 61,720 | 11.3 | 13.2 | 7.1 | 1.000 | 583 | 4,335,190 | 13.4 |
| Liver and Bile Duct | Female | 1 | 58,651 | 1.7 | 2.0 | 2.8 | 0.473 | 238 | 4,316,267 | 5.5 |
| Lung and Bronchus | Total | 54 | 120,371 | 44.9 | 53.5 | 56.4 | 0.815 | 4,833 | 8,651,457 | 55.9 |
| Lung and Bronchus | Male | 25 | 61,720 | 40.5 | 48.7 | 28.7 | 0.559 | 2,427 | 4,335,190 | 56.0 |
| Lung and Bronchus | Female | 29 | 58,651 | 49.4 | 58.4 | 27.7 | 0.850 | 2,406 | 4,316,267 | 55.7 |
| Melanoma of the Skin | Total | 42 | 120,371 | 34.9 | 39.9 | 35.3 | 0.295 | 2,900 | 8,651,457 | 33.5 |
| Melanoma of the Skin | Male | 28 | 61,720 | 45.4 | 52.4 | 21.4 | 0.194 | 1,737 | 4,335,190 | 40.1 |
| Melanoma of the Skin | Female | 14 | 58,651 | 23.9 | 27.0 | 14.0 | 1.000 | 1,163 | 4,316,267 | 26.9 |
| Myeloma | Total | 7 | 120,371 | 5.8 | 6.9 | 8.2 | 0.838 | 701 | 8,651,457 | 8.1 |
| Myeloma | Male | 5 | 61,720 | 8.1 | 9.6 | 5.2 | 1.000 | 436 | 4,335,190 | 10.1 |
| Myeloma | Female | 2 | 58,651 | 3.4 | 4.0 | 3.1 | 0.820 | 265 | 4,316,267 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 21 | 120,371 | 17.4 | 20.2 | 23.1 | 0.762 | 1,919 | 8,651,457 | 22.2 |
| Non-Hodgkin Lymphoma | Male | 14 | 61,720 | 22.7 | 26.1 | 13.8 | 1.000 | 1,115 | 4,335,190 | 25.7 |
| Non-Hodgkin Lymphoma | Female | 7 | 58,651 | 11.9 | 13.8 | 9.4 | 0.553 | 804 | 4,316,267 | 18.6 |
| Oral Cavity and Pharynx | Total | 8 | 120,371 | 6.6 | 7.7 | 15.5 | 0.058 | 1,287 | 8,651,457 | 14.9 |
| Oral Cavity and Pharynx | Male | 3 | 61,720 | 4.9 | 5.6 | 11.6 | 0.006 << | 933 | 4,335,190 | 21.5 |
| Oral Cavity and Pharynx | Female | 5 | 58,651 | 8.5 | 9.9 | 4.1 | 0.795 | 354 | 4,316,267 | 8.2 |
| Ovary | Female | 8 | 58,651 | 13.6 | 15.6 | 6.2 | 0.573 | 525 | 4,316,267 | 12.2 |
| Pancreas | Total | 20 | 120,371 | 16.6 | 19.7 | 16.5 | 0.443 | 1,403 | 8,651,457 | 16.2 |
| Pancreas | Male | 8 | 61,720 | 13.0 | 15.4 | 9.3 | 0.830 | 776 | 4,335,190 | 17.9 |
| Pancreas | Female | 12 | 58,651 | 20.5 | 24.2 | 7.2 | 0.126 | 627 | 4,316,267 | 14.5 |
| Prostate | Male | 57 | 61,720 | 92.4 | 109.3 | 76.5 | 0.024 << | 6,360 | 4,335,190 | 146.7 |
| Stomach | Total | 5 | 120,371 | 4.2 | 4.9 | 5.5 | 1.000 | 462 | 8,651,457 | 5.3 |
| Stomach | Male | 4 | 61,720 | 6.5 | 7.6 | 3.7 | 1.000 | 305 | 4,335,190 | 7.0 |
| Stomach | Female | 1 | 58,651 | 1.7 | 2.0 | 1.8 | 0.910 | 157 | 4,316,267 | 3.6 |
| Testis | Male | 4 | 61,720 | 6.5 | 6.6 | 3.7 | 0.998 | 261 | 4,335,190 | 6.0 |
| Thyroid | Total | 11 | 120,371 | 9.1 | 9.8 | 15.6 | 0.295 | 1,209 | 8,651,457 | 14.0 |
| Thyroid | Male | 4 | 61,720 | 6.5 | 7.0 | 4.6 | 1.000 | 351 | 4,335,190 | 8.1 |
| Thyroid | Female | 7 | 58,651 | 11.9 | 12.9 | 10.8 | 0.319 | 858 | 4,316,267 | 19.9 |
| Pediatric Age 0 to 19 | Total | 2 | 39,823 | 5.0 | 5.1 | 6.8 | 0.068 | 419 | 2,420,700 | 17.3 |
| Pediatric Age 0 to 19 | Male |  | 20,169 | - | - | 3.6 | 0.053 | 223 | 1,236,341 | 18.0 |
| Pediatric Age 0 to 19 | Female | 2 | 19,654 | 10.2 | 10.4 | 3.2 | 0.768 | 196 | 1,184,359 | 16.5 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN JEROME COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Jerome County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 925 | 121,595 | 760.7 | 913.3 | 873.8 | 0.089 | 76,505 | 8,867,120 | 862.8 |
| All Causes of Death | Male | 521 | 62,495 | 833.7 | 989.9 | 479.5 | 0.064 | 40,535 | 4,449,373 | 911.0 |
| All Causes of Death | Female | 404 | 59,100 | 683.6 | 827.4 | 397.6 | 0.760 | 35,970 | 4,417,747 | 814.2 |
| All Malignant Cancers | Total | 165 | 121,595 | 135.7 | 162.5 | 171.3 | 0.668 | 14,956 | 8,867,120 | 168.7 |
| All Malignant Cancers | Male | 82 | 62,495 | 131.2 | 157.6 | 94.6 | 0.208 | 8,094 | 4,449,373 | 181.9 |
| All Malignant Cancers | Female | 83 | 59,100 | 140.4 | 167.5 | 77.0 | 0.522 | 6,862 | 4,417,747 | 155.3 |
| Bladder | Total | 5 | 121,595 | 4.1 | 5.1 | 5.4 | 1.000 | 484 | 8,867,120 | 5.5 |
| Bladder | Male | 4 | 62,495 | 6.4 | 8.0 | 4.2 | 1.000 | 374 | 4,449,373 | 8.4 |
| Bladder | Female | 1 | 59,100 | 1.7 | 2.1 | 1.2 | 1.000 | 110 | 4,417,747 | 2.5 |
| Brain and Other Nervous System | Total | 4 | 121,595 | 3.3 | 3.8 | 6.0 | 0.570 | 500 | 8,867,120 | 5.6 |
| Brain and Other Nervous System | Male | 1 | 62,495 | 1.6 | 1.8 | 3.7 | 0.241 | 297 | 4,449,373 | 6.7 |
| Brain and Other Nervous System | Female | 3 | 59,100 | 5.1 | 5.8 | 2.4 | 0.848 | 203 | 4,417,747 | 4.6 |
| Breast | Total | 10 | 121,595 | 8.2 | 9.7 | 12.7 | 0.559 | 1,092 | 8,867,120 | 12.3 |
| Breast | Male |  | 62,495 |  | - | 0.2 | 1.000 | 16 | 4,449,373 | 0.4 |
| Breast | Female | 10 | 59,100 | 16.9 | 20.0 | 12.2 | 0.660 | 1,076 | 4,417,747 | 24.4 |
| Cervix | Female | 1 | 59,100 | 1.7 | 1.9 | 1.0 | 1.000 | 82 | 4,417,747 | 1.9 |
| Colorectal | Total | 21 | 121,595 | 17.3 | 20.4 | 15.1 | 0.171 | 1,298 | 8,867,120 | 14.6 |
| Colorectal | Male | 10 | 62,495 | 16.0 | 18.7 | 8.5 | 0.703 | 709 | 4,449,373 | 15.9 |
| Colorectal | Female | 11 | 59,100 | 18.6 | 22.2 | 6.6 | 0.146 | 589 | 4,417,747 | 13.3 |
| Corpus Uteri | Female | 6 | 59,100 | 10.2 | 12.1 | 1.9 | 0.024 >> | 167 | 4,417,747 | 3.8 |
| Esophagus | Total | 5 | 121,595 | 4.1 | 4.9 | 5.4 | 1.000 | 472 | 8,867,120 | 5.3 |
| Esophagus | Male | 5 | 62,495 | 8.0 | 9.5 | 4.7 | 1.000 | 396 | 4,449,373 | 8.9 |
| Esophagus | Female | - | 59,100 | - | - | 0.9 | 0.854 | 76 | 4,417,747 | 1.7 |
| Hodgkin Lymphoma | Total |  | 121,595 | - | - | 0.3 | 1.000 | 29 | 8,867,120 | 0.3 |
| Hodgkin Lymphoma | Male | - | 62,495 | - | - | 0.2 | 1.000 | 14 | 4,449,373 | 0.3 |
| Hodgkin Lymphoma | Female | - | 59,100 | - | - | 0.2 | 1.000 | 15 | 4,417,747 | 0.3 |
| Kidney | Total | 1 | 121,595 | 0.8 | 1.0 | 4.4 | 0.137 | 384 | 8,867,120 | 4.3 |
| Kidney | Male | 1 | 62,495 | 1.6 | 1.9 | 2.8 | 0.455 | 241 | 4,449,373 | 5.4 |
| Kidney | Female | - | 59,100 | - | - | 1.6 | 0.416 | 143 | 4,417,747 | 3.2 |
| Larynx | Total | 1 | 121,595 | 0.8 | 1.0 | 0.8 | 1.000 | 70 | 8,867,120 | 0.8 |
| Larynx | Male | 1 | 62,495 | 1.6 | 1.9 | 0.7 | 0.982 | 57 | 4,449,373 | 1.3 |
| Larynx | Female | - | 59,100 | - | - | 0.1 | 1.000 | 13 | 4,417,747 | 0.3 |
| Leukemia | Total | 2 | 121,595 | 1.6 | 2.0 | 7.5 | 0.040 << | 658 | 8,867,120 | 7.4 |
| Leukemia | Male | 2 | 62,495 | 3.2 | 3.8 | 4.5 | 0.350 | 384 | 4,449,373 | 8.6 |
| Leukemia | Female | - | 59,100 | - | - | 3.0 | 0.095 | 274 | 4,417,747 | 6.2 |
| Liver and Bile Duct | Total | 4 | 121,595 | 3.3 | 3.9 | 6.9 | 0.366 | 599 | 8,867,120 | 6.8 |
| Liver and Bile Duct | Male | 3 | 62,495 | 4.8 | 5.7 | 4.8 | 0.595 | 405 | 4,449,373 | 9.1 |
| Liver and Bile Duct | Female | 1 | 59,100 | 1.7 | 2.0 | 2.2 | 0.719 | 194 | 4,417,747 | 4.4 |
| Lung and Bronchus | Total | 29 | 121,595 | 23.8 | 28.8 | 33.4 | 0.515 | 2,932 | 8,867,120 | 33.1 |
| Lung and Bronchus | Male | 14 | 62,495 | 22.4 | 27.1 | 17.9 | 0.430 | 1,542 | 4,449,373 | 34.7 |
| Lung and Bronchus | Female | 15 | 59,100 | 25.4 | 30.4 | 15.5 | 1.000 | 1,390 | 4,417,747 | 31.5 |
| Melanoma of the Skin | Total | 3 | 121,595 | 2.5 | 2.9 | 3.3 | 1.000 | 286 | 8,867,120 | 3.2 |
| Melanoma of the Skin | Male | 2 | 62,495 | 3.2 | 3.8 | 2.2 | 1.000 | 190 | 4,449,373 | 4.3 |
| Melanoma of the Skin | Female | 1 | 59,100 | 1.7 | 2.0 | 1.1 | 1.000 | 96 | 4,417,747 | 2.2 |
| Myeloma | Total | 2 | 121,595 | 1.6 | 2.0 | 3.7 | 0.567 | 329 | 8,867,120 | 3.7 |
| Myeloma | Male | 1 | 62,495 | 1.6 | 2.0 | 2.2 | 0.693 | 195 | 4,449,373 | 4.4 |
| Myeloma | Female | 1 | 59,100 | 1.7 | 2.0 | 1.5 | 1.000 | 134 | 4,417,747 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 7 | 121,595 | 5.8 | 6.9 | 6.4 | 0.917 | 562 | 8,867,120 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 2 | 62,495 | 3.2 | 3.8 | 3.6 | 0.613 | 305 | 4,449,373 | 6.9 |
| Non-Hodgkin Lymphoma | Female | 5 | 59,100 | 8.5 | 10.2 | 2.9 | 0.322 | 257 | 4,417,747 | 5.8 |
| Oral Cavity and Pharynx | Total | 2 | 121,595 | 1.6 | 2.0 | 3.1 | 0.824 | 264 | 8,867,120 | 3.0 |
| Oral Cavity and Pharynx | Male | - | 62,495 | - | - | 2.2 | 0.217 | 187 | 4,449,373 | 4.2 |
| Oral Cavity and Pharynx | Female | 2 | 59,100 | 3.4 | 4.0 | 0.9 | 0.431 | 77 | 4,417,747 | 1.7 |
| Ovary | Female | 4 | 59,100 | 6.8 | 8.0 | 3.9 | 1.000 | 346 | 4,417,747 | 7.8 |
| Pancreas | Total | 11 | 121,595 | 9.0 | 10.9 | 13.5 | 0.618 | 1,179 | 8,867,120 | 13.3 |
| Pancreas | Male | 2 | 62,495 | 3.2 | 3.8 | 7.5 | 0.041 << | 640 | 4,449,373 | 14.4 |
| Pancreas | Female | 9 | 59,100 | 15.2 | 18.3 | 6.0 | 0.306 | 539 | 4,417,747 | 12.2 |
| Prostate | Male | 16 | 62,495 | 25.6 | 32.0 | 10.5 | 0.136 | 933 | 4,449,373 | 21.0 |
| Stomach | Total | 1 | 121,595 | 0.8 | 1.0 | 2.3 | 0.659 | 197 | 8,867,120 | 2.2 |
| Stomach | Male | - | 62,495 | - | - | 1.5 | 0.464 | 121 | 4,449,373 | 2.7 |
| Stomach | Female | 1 | 59,100 | 1.7 | 2.0 | 0.9 | 1.000 | 76 | 4,417,747 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Jerome County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 73.7\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 14.7\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 70.5\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | . |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 23.7\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 29.2\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 70.4\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 14.4\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 13.3\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^26]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and 25.4\% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# KOOTPNAI COUNTY CANCPR PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 5,018 cases of invasive cancer were diagnosed among Kootenai County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Kootenai County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Kootenai <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 5,018 | 45,610 |
| Female Breast | 736 | 6,687 |
| Prostate | 705 | 6,417 |
| Lung \& Bronchus | 644 | 4,887 |
| Colorectal | 365 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Kootenai County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Kootenai County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Kootenai County was 620.7 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (509.7) gives an estimate of the relative burden of disease in Kootenai County.

The age- and sex-adjusted incidence rate of invasive cancer in Kootenai County, all sites combined, was 535.3 cases per 100,000 persons per year during 2016-2020. There were statistically significantly more cases of cancer in Kootenai County $(5,018)$ than expected $(4,778.6)$ based upon rates in the remainder of the state ( $\mathrm{p}<.001$ ).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 1,805 Kootenai County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Kootenai County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Kootenai <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 8,331 | 77,431 |
| Cancer Deaths | 1,805 | 15,121 |
| \% of All Deaths | $21.7 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 381 | 2,961 |
| Colorectal | 135 | 1,319 |
| Pancreas | 141 | 1,190 |
| Female Breast | 128 | 1,086 |
| Prostate | 122 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Kootenai County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Kootenai County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Kootenai County, all sites combined, was 184.2 deaths per 100,000 persons per year during 2017-2021, compared with 163.3 for the remainder of the state. There were statistically significantly more cancer deaths in Kootenai County $(1,805)$ than expected $(1,600.5)$ based upon rates in the remainder of the state ( $\mathrm{p}<.001$ ).

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

|  |  | Kootenai County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person Years | Crude <br> Rate (1) | A.A.I. <br> Rate (1,2) | Expected <br> Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 5,018 | 808,378 | 620.7 | 535.3 | 4,778.6 | 0.001 >> | 40,592 | 7,963,450 | 509.7 |
| All Sites Combined | Male | 2,651 | 399,587 | 663.4 | 569.6 | 2,519.4 | $0.009 \gg$ | 21,638 | 3,997,323 | 541.3 |
| All Sites Combined | Female | 2,367 | 408,791 | 579.0 | 502.5 | 2,251.0 | $0.016 \gg$ | 18,954 | 3,966,127 | 477.9 |
| Bladder | Total | 235 | 808,378 | 29.1 | 24.5 | 235.1 | 1.000 | 1,949 | 7,963,450 | 24.5 |
| Bladder | Male | 182 | 399,587 | 45.5 | 38.3 | 186.5 | 0.781 | 1,569 | 3,997,323 | 39.3 |
| Bladder | Female | 53 | 408,791 | 13.0 | 11.0 | 46.3 | 0.362 | 380 | 3,966,127 | 9.6 |
| Brain - malignant | Total | 58 | 808,378 | 7.2 | 6.4 | 64.1 | 0.488 | 567 | 7,963,450 | 7.1 |
| Brain - malignant | Male | 34 | 399,587 | 8.5 | 7.7 | 37.8 | 0.602 | 341 | 3,997,323 | 8.5 |
| Brain - malignant | Female | 24 | 408,791 | 5.9 | 5.2 | 26.1 | 0.782 | 226 | 3,966,127 | 5.7 |
| Brain and other CNS - non-malignant | Total | 138 | 808,378 | 17.1 | 15.1 | 147.5 | 0.462 | 1,286 | 7,963,450 | 16.1 |
| Brain and other CNS - non-malignant | Male | 45 | 399,587 | 11.3 | 10.1 | 48.5 | 0.678 | 435 | 3,997,323 | 10.9 |
| Brain and other CNS - non-malignant | Female | 93 | 408,791 | 22.8 | 20.0 | 99.8 | 0.534 | 851 | 3,966,127 | 21.5 |
| Breast | Total | 743 | 808,378 | 91.9 | 80.1 | 699.3 | 0.104 | 6,003 | 7,963,450 | 75.4 |
| Breast | Male | 7 | 399,587 | 1.8 | 1.5 | 6.1 | 0.809 | 52 | 3,997,323 | 1.3 |
| Breast | Female | 736 | 408,791 | 180.0 | 156.2 | 706.9 | 0.282 | 5,951 | 3,966,127 | 150.0 |
| Breast - in situ | Total | 129 | 808,378 | 16.0 | 13.9 | 129.0 | 1.000 | 1,110 | 7,963,450 | 13.9 |
| Breast - in situ | Male | 1 | 399,587 | 0.3 | 0.2 | 0.4 | 0.714 | 4 | 3,997,323 | 0.1 |
| Breast - in situ | Female | 128 | 408,791 | 31.3 | 27.2 | 131.3 | 0.817 | 1,106 | 3,966,127 | 27.9 |
| Cervix | Female | 36 | 408,791 | 8.8 | 8.3 | 29.2 | 0.249 | 268 | 3,966,127 | 6.8 |
| Colorectal | Total | 365 | 808,378 | 45.2 | 39.1 | 362.0 | 0.889 | 3,086 | 7,963,450 | 38.8 |
| Colorectal | Male | 199 | 399,587 | 49.8 | 43.2 | 196.2 | 0.863 | 1,704 | 3,997,323 | 42.6 |
| Colorectal | Female | 166 | 408,791 | 40.6 | 35.1 | 164.7 | 0.941 | 1,382 | 3,966,127 | 34.8 |
| Corpus Uteri | Female | 155 | 408,791 | 37.9 | 32.7 | 140.4 | 0.238 | 1,175 | 3,966,127 | 29.6 |
| Esophagus | Total | 45 | 808,378 | 5.6 | 4.7 | 55.1 | 0.191 | 461 | 7,963,450 | 5.8 |
| Esophagus | Male | 40 | 399,587 | 10.0 | 8.5 | 45.0 | 0.511 | 384 | 3,997,323 | 9.6 |
| Esophagus | Female | 5 | 408,791 | 1.2 | 1.0 | 9.4 | 0.191 | 77 | 3,966,127 | 1.9 |
| Hodgkin Lymphoma | Total | 19 | 808,378 | 2.4 | 2.3 | 19.9 | 0.955 | 191 | 7,963,450 | 2.4 |
| Hodgkin Lymphoma | Male | 12 | 399,587 | 3.0 | 2.9 | 11.0 | 0.846 | 106 | 3,997,323 | 2.7 |
| Hodgkin Lymphoma | Female | 7 | 408,791 | 1.7 | 1.7 | 8.8 | 0.697 | 85 | 3,966,127 | 2.1 |
| Kidney and Renal Pelvis | Total | 216 | 808,378 | 26.7 | 23.2 | 187.3 | 0.043 >> | 1,599 | 7,963,450 | 20.1 |
| Kidney and Renal Pelvis | Male | 139 | 399,587 | 34.8 | 30.3 | 119.8 | 0.093 | 1,043 | 3,997,323 | 26.1 |
| Kidney and Renal Pelvis | Female | 77 | 408,791 | 18.8 | 16.3 | 66.2 | 0.211 | 556 | 3,966,127 | 14.0 |
| Larynx | Total | 22 | 808,378 | 2.7 | 2.3 | 23.0 | 0.946 | 193 | 7,963,450 | 2.4 |
| Larynx | Male | 17 | 399,587 | 4.3 | 3.6 | 16.8 | 1.000 | 143 | 3,997,323 | 3.6 |
| Larynx | Female | 5 | 408,791 | 1.2 | 1.1 | 6.0 | 0.904 | 50 | 3,966,127 | 1.3 |
| Leukemia | Total | 179 | 808,378 | 22.1 | 19.3 | 169.2 | 0.473 | 1,452 | 7,963,450 | 18.2 |
| Leukemia | Male | 115 | 399,587 | 28.8 | 25.1 | 100.2 | 0.158 | 874 | 3,997,323 | 21.9 |
| Leukemia | Female | 64 | 408,791 | 15.7 | 13.6 | 68.4 | 0.646 | 578 | 3,966,127 | 14.6 |
| Liver and Bile Duct | Total | 105 | 808,378 | 13.0 | 11.1 | 86.3 | 0.056 | 724 | 7,963,450 | 9.1 |
| Liver and Bile Duct | Male | 69 | 399,587 | 17.3 | 14.8 | 60.8 | 0.324 | 521 | 3,997,323 | 13.0 |
| Liver and Bile Duct | Female | 36 | 408,791 | 8.8 | 7.5 | 24.6 | $0.036 \gg$ | 203 | 3,966,127 | 5.1 |
| Lung and Bronchus | Total | 644 | 808,378 | 79.7 | 66.9 | 513.3 | $0.000 \ggg$ | 4,243 | 7,963,450 | 53.3 |
| Lung and Bronchus | Male | 316 | 399,587 | 79.1 | 66.4 | 254.5 | $0.000 \gg$ | 2,136 | 3,997,323 | 53.4 |
| Lung and Bronchus | Female | 328 | 408,791 | 80.2 | 67.4 | 258.4 | $0.000 \gg$ | 2,107 | 3,966,127 | 53.1 |
| Melanoma of the Skin | Total | 266 | 808,378 | 32.9 | 28.8 | 310.5 | 0.011 << | 2,676 | 7,963,450 | 33.6 |
| Melanoma of the Skin | Male | 163 | 399,587 | 40.8 | 35.4 | 184.7 | 0.115 | 1,602 | 3,997,323 | 40.1 |
| Melanoma of the Skin | Female | 103 | 408,791 | 25.2 | 22.4 | 124.8 | 0.052 | 1,074 | 3,966,127 | 27.1 |
| Myeloma | Total | 91 | 808,378 | 11.3 | 9.5 | 74.0 | 0.062 | 617 | 7,963,450 | 7.7 |
| Myeloma | Male | 58 | 399,587 | 14.5 | 12.3 | 45.2 | 0.075 | 383 | 3,997,323 | 9.6 |
| Myeloma | Female | 33 | 408,791 | 8.1 | 6.8 | 28.5 | 0.441 | 234 | 3,966,127 | 5.9 |
| Non-Hodgkin Lymphoma | Total | 205 | 808,378 | 25.4 | 22.0 | 203.4 | 0.930 | 1,735 | 7,963,450 | 21.8 |
| Non-Hodgkin Lymphoma | Male | 120 | 399,587 | 30.0 | 26.1 | 115.9 | 0.725 | 1,009 | 3,997,323 | 25.2 |
| Non-Hodgkin Lymphoma | Female | 85 | 408,791 | 20.8 | 17.9 | 86.9 | 0.897 | 726 | 3,966,127 | 18.3 |
| Oral Cavity and Pharynx | Total | 142 | 808,378 | 17.6 | 15.1 | 136.3 | 0.645 | 1,153 | 7,963,450 | 14.5 |
| Oral Cavity and Pharynx | Male | 100 | 399,587 | 25.0 | 21.6 | 96.8 | 0.775 | 836 | 3,997,323 | 20.9 |
| Oral Cavity and Pharynx | Female | 42 | 408,791 | 10.3 | 8.8 | 38.0 | 0.555 | 317 | 3,966,127 | 8.0 |
| Ovary | Female | 56 | 408,791 | 13.7 | 11.9 | 56.5 | 1.000 | 477 | 3,966,127 | 12.0 |
| Pancreas | Total | 153 | 808,378 | 18.9 | 16.0 | 152.1 | 0.964 | 1,270 | 7,963,450 | 15.9 |
| Pancreas | Male | 79 | 399,587 | 19.8 | 16.8 | 83.0 | 0.716 | 705 | 3,997,323 | 17.6 |
| Pancreas | Female | 74 | 408,791 | 18.1 | 15.3 | 68.7 | 0.554 | 565 | 3,966,127 | 14.2 |
| Prostate | Male | 705 | 399,587 | 176.4 | 149.4 | 674.4 | 0.248 | 5,712 | 3,997,323 | 142.9 |
| Stomach | Total | 54 | 808,378 | 6.7 | 5.7 | 48.8 | 0.492 | 413 | 7,963,450 | 5.2 |
| Stomach | Male | 40 | 399,587 | 10.0 | 8.6 | 31.4 | 0.159 | 269 | 3,997,323 | 6.7 |
| Stomach | Female | 14 | 408,791 | 3.4 | 3.0 | 17.1 | 0.553 | 144 | 3,966,127 | 3.6 |
| Testis | Male | 20 | 399,587 | 5.0 | 5.2 | 23.7 | 0.521 | 245 | 3,997,323 | 6.1 |
| Thyroid | Total | 102 | 808,378 | 12.6 | 11.8 | 120.9 | 0.089 | 1,118 | 7,963,450 | 14.0 |
| Thyroid | Male | 28 | 399,587 | 7.0 | 6.4 | 35.6 | 0.228 | 327 | 3,997,323 | 8.2 |
| Thyroid | Female | 74 | 408,791 | 18.1 | 17.1 | 86.3 | 0.201 | 791 | 3,966,127 | 19.9 |
| Pediatric Age 0 to 19 | Total | 28 | 201,782 | 13.9 | 13.9 | 35.1 | 0.264 | 393 | 2,258,741 | 17.4 |
| Pediatric Age 0 to 19 | Male | 14 | 104,139 | 13.4 | 13.4 | 18.9 | 0.310 | 209 | 1,152,371 | 18.1 |
| Pediatric Age 0 to 19 | Female | 14 | 97,643 | 14.3 | 14.4 | 16.2 | 0.702 | 184 | 1,106,370 | 16.6 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN KOOTENAI COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Kootenai County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 8,331 | 834,946 | 997.8 | 864.8 | 8,163.4 | 0.065 | 69,099 | 8,153,769 | 847.4 |
| All Causes of Death | Male | 4,344 | 413,567 | 1,050.4 | 914.4 | 4,255.4 | 0.178 | 36,712 | 4,098,301 | 895.8 |
| All Causes of Death | Female | 3,987 | 421,379 | 946.2 | 818.3 | 3,891.0 | 0.126 | 32,387 | 4,055,468 | 798.6 |
| All Malignant Cancers | Total | 1,805 | 834,946 | 216.2 | 184.2 | 1,600.5 | 0.000 >> | 13,316 | 8,153,769 | 163.3 |
| All Malignant Cancers | Male | 972 | 413,567 | 235.0 | 200.3 | 853.0 | 0.000 >> | 7,204 | 4,098,301 | 175.8 |
| All Malignant Cancers | Female | 833 | 421,379 | 197.7 | 168.7 | 744.2 | 0.001 >> | 6,112 | 4,055,468 | 150.7 |
| Bladder | Total | 55 | 834,946 | 6.6 | 5.6 | 52.4 | 0.755 | 434 | 8,153,769 | 5.3 |
| Bladder | Male | 42 | 413,567 | 10.2 | 8.6 | 39.9 | 0.776 | 336 | 4,098,301 | 8.2 |
| Bladder | Female | 13 | 421,379 | 3.1 | 2.6 | 12.0 | 0.855 | 98 | 4,055,468 | 2.4 |
| Brain and Other Nervous System | Total | 58 | 834,946 | 6.9 | 6.1 | 52.2 | 0.461 | 446 | 8,153,769 | 5.5 |
| Brain and Other Nervous System | Male | 41 | 413,567 | 9.9 | 8.7 | 29.5 | 0.052 | 257 | 4,098,301 | 6.3 |
| Brain and Other Nervous System | Female | 17 | 421,379 | 4.0 | 3.5 | 22.6 | 0.281 | 189 | 4,055,468 | 4.7 |
| Breast | Total | 129 | 834,946 | 15.5 | 13.3 | 115.5 | 0.229 | 973 | 8,153,769 | 11.9 |
| Breast | Male | 1 | 413,567 | 0.2 | 0.2 | 1.8 | 0.951 | 15 | 4,098,301 | 0.4 |
| Breast | Female | 128 | 421,379 | 30.4 | 26.1 | 115.7 | 0.275 | 958 | 4,055,468 | 23.6 |
| Cervix | Female | 4 | 421,379 | 0.9 | 0.9 | 9.0 | 0.108 | 79 | 4,055,468 | 1.9 |
| Colorectal | Total | 135 | 834,946 | 16.2 | 13.9 | 140.9 | 0.658 | 1,184 | 8,153,769 | 14.5 |
| Colorectal | Male | 74 | 413,567 | 17.9 | 15.5 | 75.2 | 0.948 | 645 | 4,098,301 | 15.7 |
| Colorectal | Female | 61 | 421,379 | 14.5 | 12.4 | 65.2 | 0.658 | 539 | 4,055,468 | 13.3 |
| Corpus Uteri | Female | 21 | 421,379 | 5.0 | 4.2 | 18.7 | 0.646 | 152 | 4,055,468 | 3.7 |
| Esophagus | Total | 53 | 834,946 | 6.3 | 5.4 | 51.1 | 0.830 | 424 | 8,153,769 | 5.2 |
| Esophagus | Male | 47 | 413,567 | 11.4 | 9.7 | 41.9 | 0.471 | 354 | 4,098,301 | 8.6 |
| Esophagus | Female | 6 | 421,379 | 1.4 | 1.2 | 8.6 | 0.500 | 70 | 4,055,468 | 1.7 |
| Hodgkin Lymphoma | Total | - | 834,946 | - | - | 3.4 | 0.069 | 29 | 8,153,769 | 0.4 |
| Hodgkin Lymphoma | Male | - | 413,567 | - | - | 1.6 | 0.407 | 14 | 4,098,301 | 0.3 |
| Hodgkin Lymphoma | Female | - | 421,379 | - | - | 1.8 | 0.342 | 15 | 4,055,468 | 0.4 |
| Kidney | Total | 43 | 834,946 | 5.2 | 4.4 | 41.3 | 0.833 | 342 | 8,153,769 | 4.2 |
| Kidney | Male | 22 | 413,567 | 5.3 | 4.5 | 26.0 | 0.499 | 220 | 4,098,301 | 5.4 |
| Kidney | Female | 21 | 421,379 | 5.0 | 4.2 | 15.0 | 0.165 | 122 | 4,055,468 | 3.0 |
| Larynx | Total | 7 | 834,946 | 0.8 | 0.7 | 7.7 | 0.997 | 64 | 8,153,769 | 0.8 |
| Larynx | Male | 5 | 413,567 | 1.2 | 1.0 | 6.3 | 0.805 | 53 | 4,098,301 | 1.3 |
| Larynx | Female | 2 | 421,379 | 0.5 | 0.4 | 1.3 | 0.773 | 11 | 4,055,468 | 0.3 |
| Leukemia | Total | 72 | 834,946 | 8.6 | 7.4 | 70.4 | 0.883 | 588 | 8,153,769 | 7.2 |
| Leukemia | Male | 40 | 413,567 | 9.7 | 8.3 | 40.8 | 0.978 | 346 | 4,098,301 | 8.4 |
| Leukemia | Female | 32 | 421,379 | 7.6 | 6.5 | 29.4 | 0.676 | 242 | 4,055,468 | 6.0 |
| Liver and Bile Duct | Total | 73 | 834,946 | 8.7 | 7.4 | 64.0 | 0.289 | 530 | 8,153,769 | 6.5 |
| Liver and Bile Duct | Male | 54 | 413,567 | 13.1 | 11.1 | 42.0 | 0.083 | 354 | 4,098,301 | 8.6 |
| Liver and Bile Duct | Female | 19 | 421,379 | 4.5 | 3.8 | 21.6 | 0.678 | 176 | 4,055,468 | 4.3 |
| Lung and Bronchus | Total | 381 | 834,946 | 45.6 | 38.4 | 313.7 | 0.000 >> | 2,580 | 8,153,769 | 31.6 |
| Lung and Bronchus | Male | 184 | 413,567 | 44.5 | 37.5 | 164.2 | 0.136 | 1,372 | 4,098,301 | 33.5 |
| Lung and Bronchus | Female | 197 | 421,379 | 46.8 | 39.5 | 148.7 | 0.000 >> | 1,208 | 4,055,468 | 29.8 |
| Melanoma of the Skin | Total | 40 | 834,946 | 4.8 | 4.1 | 29.6 | 0.080 | 249 | 8,153,769 | 3.1 |
| Melanoma of the Skin | Male | 32 | 413,567 | 7.7 | 6.6 | 18.8 | 0.007 >> | 160 | 4,098,301 | 3.9 |
| Melanoma of the Skin | Female | 8 | 421,379 | 1.9 | 1.6 | 10.7 | 0.524 | 89 | 4,055,468 | 2.2 |
| Myeloma | Total | 28 | 834,946 | 3.4 | 2.8 | 37.0 | 0.155 | 303 | 8,153,769 | 3.7 |
| Myeloma | Male | 22 | 413,567 | 5.3 | 4.5 | 20.9 | 0.868 | 174 | 4,098,301 | 4.2 |
| Myeloma | Female | 6 | 421,379 | 1.4 | 1.2 | 15.9 | 0.009 << | 129 | 4,055,468 | 3.2 |
| Non-Hodgkin Lymphoma | Total | 62 | 834,946 | 7.4 | 6.3 | 61.1 | 0.939 | 507 | 8,153,769 | 6.2 |
| Non-Hodgkin Lymphoma | Male | 37 | 413,567 | 8.9 | 7.6 | 31.9 | 0.412 | 270 | 4,098,301 | 6.6 |
| Non-Hodgkin Lymphoma | Female | 25 | 421,379 | 5.9 | 5.0 | 29.0 | 0.522 | 237 | 4,055,468 | 5.8 |
| Oral Cavity and Pharynx | Total | 37 | 834,946 | 4.4 | 3.8 | 27.6 | 0.102 | 229 | 8,153,769 | 2.8 |
| Oral Cavity and Pharynx | Male | 27 | 413,567 | 6.5 | 5.5 | 19.0 | 0.097 | 160 | 4,098,301 | 3.9 |
| Oral Cavity and Pharynx | Female | 10 | 421,379 | 2.4 | 2.0 | 8.4 | 0.666 | 69 | 4,055,468 | 1.7 |
| Ovary | Female | 34 | 421,379 | 8.1 | 6.9 | 38.6 | 0.515 | 316 | 4,055,468 | 7.8 |
| Pancreas | Total | 141 | 834,946 | 16.9 | 14.3 | 127.1 | 0.236 | 1,049 | 8,153,769 | 12.9 |
| Pancreas | Male | 76 | 413,567 | 18.4 | 15.6 | 67.3 | 0.320 | 566 | 4,098,301 | 13.8 |
| Pancreas | Female | 65 | 421,379 | 15.4 | 13.0 | 59.5 | 0.508 | 483 | 4,055,468 | 11.9 |
| Prostate | Male | 122 | 413,567 | 29.5 | 25.0 | 98.6 | 0.025 >> | 827 | 4,098,301 | 20.2 |
| Stomach | Total | 16 | 834,946 | 1.9 | 1.7 | 21.6 | 0.272 | 182 | 8,153,769 | 2.2 |
| Stomach | Male | 10 | 413,567 | 2.4 | 2.1 | 13.1 | 0.493 | 111 | 4,098,301 | 2.7 |
| Stomach | Female | 6 | 421,379 | 1.4 | 1.2 | 8.4 | 0.530 | 71 | 4,055,468 | 1.8 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Kootenai County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 83.9\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 11.2\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 72.4\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% | 75.6\% |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 72.9\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 26.3\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 32.4\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 80.1\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 23.3\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 34.7\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^27]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged $50-74$ reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute
Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 807 cases of invasive cancer were diagnosed among Latah County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Latah County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Latah <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 807 | 45,610 |
| Female Breast | 130 | 6,687 |
| Prostate | 149 | 6,417 |
| Lung \& Bronchus | 92 | 4,887 |
| Colorectal | 50 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Latah County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Latah County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Latah County was 403.0 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (522.7) gives an estimate of the relative burden of disease in Latah County.

The age- and sex-adjusted incidence rate of invasive cancer in Latah County, all sites combined, was 468.6 cases per 100,000 persons per year during 2016-2020. There were statistically significantly fewer cases of cancer in Latah County (807) than expected (900.2) based upon rates in the remainder of the state $(p=.002)$.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 267 Latah County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Latah County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Latah <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 1,189 | 77,431 |
| Cancer Deaths | 267 | 15,121 |
| \% of All Deaths | $22.5 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 51 | 2,961 |
| Colorectal | 19 | 1,319 |
| Pancreas | 20 | 1,190 |
| Female Breast | 20 | 1,086 |
| Prostate | 17 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Latah County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Latah County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Latah County, all sites combined, was 152.5 deaths per 100,000 persons per year during 2017-2021, compared with 169.0 for the remainder of the state. There were fewer cancer deaths in Latah County (267) than expected (295.9) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020 COMPARISON BETWEEN LATAH COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Latah County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 807 | 200,258 | 403.0 | 468.6 | 900.2 | 0.002 << | 44,803 | 8,571,570 | 522.7 |
| All Sites Combined | Male | 430 | 102,192 | 420.8 | 493.2 | 484.4 | 0.013 << | 23,859 | 4,294,718 | 555.5 |
| All Sites Combined | Female | 377 | 98,066 | 384.4 | 442.4 | 417.3 | 0.049 << | 20,944 | 4,276,852 | 489.7 |
| Bladder | Total | 37 | 200,258 | 18.5 | 21.7 | 42.8 | 0.425 | 2,147 | 8,571,570 | 25.0 |
| Bladder | Male | 28 | 102,192 | 27.4 | 32.4 | 34.7 | 0.293 | 1,723 | 4,294,718 | 40.1 |
| Bladder | Female | 9 | 98,066 | 9.2 | 10.6 | 8.4 | 0.927 | 424 | 4,276,852 | 9.9 |
| Brain - malignant | Total | 14 | 200,258 | 7.0 | 7.9 | 12.7 | 0.791 | 611 | 8,571,570 | 7.1 |
| Brain - malignant | Male | 10 | 102,192 | 9.8 | 11.0 | 7.7 | 0.502 | 365 | 4,294,718 | 8.5 |
| Brain - malignant | Female | 4 | 98,066 | 4.1 | 4.6 | 5.0 | 0.866 | 246 | 4,276,852 | 5.8 |
| Brain and other CNS - non-malignant | Total | 28 | 200,258 | 14.0 | 16.0 | 28.4 | 1.000 | 1,396 | 8,571,570 | 16.3 |
| Brain and other CNS - non-malignant | Male | 10 | 102,192 | 9.8 | 11.3 | 9.7 | 0.996 | 470 | 4,294,718 | 10.9 |
| Brain and other CNS - non-malignant | Female | 18 | 98,066 | 18.4 | 20.9 | 18.7 | 1.000 | 926 | 4,276,852 | 21.7 |
| Breast | Total | 130 | 200,258 | 64.9 | 76.9 | 130.5 | 1.000 | 6,616 | 8,571,570 | 77.2 |
| Breast | Male | - | 102,192 | - | - | 1.2 | 0.612 | 59 | 4,294,718 | 1.4 |
| Breast | Female | 130 | 98,066 | 132.6 | 155.7 | 128.0 | 0.886 | 6,557 | 4,276,852 | 153.3 |
| Breast - in situ | Total | 30 | 200,258 | 15.0 | 17.9 | 23.6 | 0.232 | 1,209 | 8,571,570 | 14.1 |
| Breast - in situ | Male | 1 | 102,192 | 1.0 | 1.2 | 0.1 | 0.153 | 4 | 4,294,718 | 0.1 |
| Breast - in situ | Female | 29 | 98,066 | 29.6 | 35.0 | 23.3 | 0.284 | 1,205 | 4,276,852 | 28.2 |
| Cervix | Female | 5 | 98,066 | 5.1 | 5.8 | 6.0 | 0.899 | 299 | 4,276,852 | 7.0 |
| Colorectal | Total | 50 | 200,258 | 25.0 | 29.2 | 68.0 | 0.028 << | 3,401 | 8,571,570 | 39.7 |
| Colorectal | Male | 29 | 102,192 | 28.4 | 33.6 | 37.6 | 0.178 | 1,874 | 4,294,718 | 43.6 |
| Colorectal | Female | 21 | 98,066 | 21.4 | 24.7 | 30.4 | 0.094 | 1,527 | 4,276,852 | 35.7 |
| Corpus Uteri | Female | 27 | 98,066 | 27.5 | 32.2 | 25.5 | 0.822 | 1,303 | 4,276,852 | 30.5 |
| Esophagus | Total | 11 | 200,258 | 5.5 | 6.5 | 9.8 | 0.789 | 495 | 8,571,570 | 5.8 |
| Esophagus | Male | 8 | 102,192 | 7.8 | 9.3 | 8.3 | 1.000 | 416 | 4,294,718 | 9.7 |
| Esophagus | Female | 3 | 98,066 | 3.1 | 3.6 | 1.6 | 0.409 | 79 | 4,276,852 | 1.8 |
| Hodgkin Lymphoma | Total | 3 | 200,258 | 1.5 | 1.3 | 5.4 | 0.428 | 207 | 8,571,570 | 2.4 |
| Hodgkin Lymphoma | Male | 2 | 102,192 | 2.0 | 1.9 | 2.9 | 0.890 | 116 | 4,294,718 | 2.7 |
| Hodgkin Lymphoma | Female | 1 | 98,066 | 1.0 | 0.9 | 2.5 | 0.580 | 91 | 4,276,852 | 2.1 |
| Kidney and Renal Pelvis | Total | 23 | 200,258 | 11.5 | 13.6 | 35.4 | 0.036 << | 1,792 | 8,571,570 | 20.9 |
| Kidney and Renal Pelvis | Male | 18 | 102,192 | 17.6 | 21.0 | 23.2 | 0.329 | 1,164 | 4,294,718 | 27.1 |
| Kidney and Renal Pelvis | Female | 5 | 98,066 | 5.1 | 6.0 | 12.3 | 0.033 << | 628 | 4,276,852 | 14.7 |
| Larynx | Total | 2 | 200,258 | 1.0 | 1.2 | 4.3 | 0.395 | 213 | 8,571,570 | 2.5 |
| Larynx | Male |  | 102,192 | 1.0 | 1.2 | 3.2 | 0.346 | 159 | 4,294,718 | 3.7 |
| Larynx | Female | 1 | 98,066 | 1.0 | 1.1 | 1.1 | 1.000 | 54 | 4,276,852 | 1.3 |
| Leukemia | Total | 23 | 200,258 | 11.5 | 13.2 | 32.6 | 0.100 | 1,608 | 8,571,570 | 18.8 |
| Leukemia | Male | 9 | 102,192 | 8.8 | 10.3 | 19.9 | 0.011 << | 980 | 4,294,718 | 22.8 |
| Leukemia | Female | 14 | 98,066 | 14.3 | 16.1 | 12.8 | 0.802 | 628 | 4,276,852 | 14.7 |
| Liver and Bile Duct | Total | 14 | 200,258 | 7.0 | 8.2 | 16.2 | 0.695 | 815 | 8,571,570 | 9.5 |
| Liver and Bile Duct | Male | 13 | 102,192 | 12.7 | 15.1 | 11.6 | 0.749 | 577 | 4,294,718 | 13.4 |
| Liver and Bile Duct | Female | 1 | 98,066 | 1.0 | 1.2 | 4.7 | 0.102 | 238 | 4,276,852 | 5.6 |
| Lung and Bronchus | Total | 92 | 200,258 | 45.9 | 54.1 | 95.1 | 0.801 | 4,795 | 8,571,570 | 55.9 |
| Lung and Bronchus | Male | 39 | 102,192 | 38.2 | 45.2 | 48.5 | 0.189 | 2,413 | 4,294,718 | 56.2 |
| Lung and Bronchus | Female | 53 | 98,066 | 54.0 | 63.2 | 46.7 | 0.391 | 2,382 | 4,276,852 | 55.7 |
| Melanoma of the Skin | Total | 38 | 200,258 | 19.0 | 21.9 | 58.8 | 0.005 << | 2,904 | 8,571,570 | 33.9 |
| Melanoma of the Skin | Male | 17 | 102,192 | 16.6 | 19.5 | 35.5 | 0.001 << | 1,748 | 4,294,718 | 40.7 |
| Melanoma of the Skin | Female | 21 | 98,066 | 21.4 | 24.2 | 23.4 | 0.713 | 1,156 | 4,276,852 | 27.0 |
| Myeloma | Total | 13 | 200,258 | 6.5 | 7.7 | 13.8 | 0.980 | 695 | 8,571,570 | 8.1 |
| Myeloma | Male | 9 | 102,192 | 8.8 | 10.5 | 8.6 | 0.991 | 432 | 4,294,718 | 10.1 |
| Myeloma | Female | 4 | 98,066 | 4.1 | 4.8 | 5.2 | 0.826 | 263 | 4,276,852 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 36 | 200,258 | 18.0 | 20.7 | 38.6 | 0.750 | 1,904 | 8,571,570 | 22.2 |
| Non-Hodgkin Lymphoma | Male | 24 | 102,192 | 23.5 | 27.2 | 22.7 | 0.838 | 1,105 | 4,294,718 | 25.7 |
| Non-Hodgkin Lymphoma | Female | 12 | 98,066 | 12.2 | 14.0 | 16.0 | 0.382 | 799 | 4,276,852 | 18.7 |
| Oral Cavity and Pharynx | Total | 25 | 200,258 | 12.5 | 14.7 | 25.2 | 1.000 | 1,270 | 8,571,570 | 14.8 |
| Oral Cavity and Pharynx | Male | 20 | 102,192 | 19.6 | 23.3 | 18.3 | 0.752 | 916 | 4,294,718 | 21.3 |
| Oral Cavity and Pharynx | Female | 5 | 98,066 | 5.1 | 5.9 | 7.0 | 0.600 | 354 | 4,276,852 | 8.3 |
| Ovary | Female | 6 | 98,066 | 6.1 | 7.0 | 10.6 | 0.192 | 527 | 4,276,852 | 12.3 |
| Pancreas | Total | 22 | 200,258 | 11.0 | 12.9 | 27.9 | 0.303 | 1,401 | 8,571,570 | 16.3 |
| Pancreas | Male | 11 | 102,192 | 10.8 | 12.7 | 15.5 | 0.304 | 773 | 4,294,718 | 18.0 |
| Pancreas | Female | 11 | 98,066 | 11.2 | 13.0 | 12.4 | 0.825 | 628 | 4,276,852 | 14.7 |
| Prostate | Male | 149 | 102,192 | 145.8 | 172.7 | 125.9 | $0.049 \gg$ | 6,268 | 4,294,718 | 145.9 |
| Stomach | Total | 8 | 200,258 | 4.0 | 4.7 | 9.2 | 0.864 | 459 | 8,571,570 | 5.4 |
| Stomach | Male | 6 | 102,192 | 5.9 | 7.0 | 6.1 | 1.000 | 303 | 4,294,718 | 7.1 |
| Stomach | Female | 2 | 98,066 | 2.0 | 2.3 | 3.1 | 0.785 | 156 | 4,276,852 | 3.6 |
| Testis | Male | 5 | 102,192 | 4.9 | 4.1 | 7.3 | 0.519 | 260 | 4,294,718 | 6.1 |
| Thyroid | Total | 17 | 200,258 | 8.5 | 8.9 | 26.8 | 0.061 | 1,203 | 8,571,570 | 14.0 |
| Thyroid | Male | 4 | 102,192 | 3.9 | 4.4 | 7.5 | 0.270 | 351 | 4,294,718 | 8.2 |
| Thyroid | Female | 13 | 98,066 | 13.3 | 13.6 | 19.0 | 0.193 | 852 | 4,276,852 | 19.9 |
| Pediatric Age 0 to 19 | Total | 7 | 49,640 | 14.1 | 13.3 | 9.0 | 0.638 | 414 | 2,410,883 | 17.2 |
| Pediatric Age 0 to 19 | Male | 5 | 25,020 | 20.0 | 19.5 | 4.5 | 0.954 | 218 | 1,231,490 | 17.7 |
| Pediatric Age 0 to 19 | Female | 2 | 24,620 | 8.1 | 7.4 | 4.5 | 0.349 | 196 | 1,179,393 | 16.6 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN LATAH COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Latah County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 1,189 | 201,414 | 590.3 | 654.5 | 1,576.2 | 0.000 << | 76,241 | 8,787,301 | 867.6 |
| All Causes of Death | Male | 623 | 102,700 | 606.6 | 681.8 | 837.9 | $0.000 \ll$ | 40,433 | 4,409,168 | 917.0 |
| All Causes of Death | Female | 566 | 98,714 | 573.4 | 623.9 | 741.9 | $0.000 \ll$ | 35,808 | 4,378,133 | 817.9 |
| All Malignant Cancers | Total | 267 | 201,414 | 132.6 | 152.5 | 295.9 | 0.095 | 14,854 | 8,787,301 | 169.0 |
| All Malignant Cancers | Male | 141 | 102,700 | 137.3 | 159.2 | 161.4 | 0.113 | 8,035 | 4,409,168 | 182.2 |
| All Malignant Cancers | Female | 126 | 98,714 | 127.6 | 145.6 | 134.8 | 0.479 | 6,819 | 4,378,133 | 155.8 |
| Bladder | Total | 10 | 201,414 | 5.0 | 5.6 | 9.7 | 1.000 | 479 | 8,787,301 | 5.5 |
| Bladder | Male | 8 | 102,700 | 7.8 | 8.9 | 7.5 | 0.958 | 370 | 4,409,168 | 8.4 |
| Bladder | Female | 2 | 98,714 | 2.0 | 2.3 | 2.2 | 1.000 | 109 | 4,378,133 | 2.5 |
| Brain and Other Nervous System | Total | 10 | 201,414 | 5.0 | 5.7 | 9.9 | 1.000 | 494 | 8,787,301 | 5.6 |
| Brain and Other Nervous System | Male | 6 | 102,700 | 5.8 | 6.6 | 6.0 | 1.000 | 292 | 4,409,168 | 6.6 |
| Brain and Other Nervous System | Female | 4 | 98,714 | 4.1 | 4.7 | 3.9 | 1.000 | 202 | 4,378,133 | 4.6 |
| Breast | Total | 20 | 201,414 | 9.9 | 11.5 | 21.5 | 0.860 | 1,082 | 8,787,301 | 12.3 |
| Breast | Male |  | 102,700 |  |  | 0.3 | 1.000 | 16 | 4,409,168 | 0.4 |
| Breast | Female | 20 | 98,714 | 20.3 | 23.1 | 21.1 | 0.932 | 1,066 | 4,378,133 | 24.3 |
| Cervix | Female | - | 98,714 |  | - | 1.7 | 0.383 | 83 | 4,378,133 | 1.9 |
| Colorectal | Total | 19 | 201,414 | 9.4 | 10.9 | 25.8 | 0.206 | 1,300 | 8,787,301 | 14.8 |
| Colorectal | Male | 8 | 102,700 | 7.8 | 9.1 | 14.1 | 0.118 | 711 | 4,409,168 | 16.1 |
| Colorectal | Female | 11 | 98,714 | 11.1 | 12.6 | 11.8 | 0.980 | 589 | 4,378,133 | 13.5 |
| Corpus Uteri | Female | 5 | 98,714 | 5.1 | 5.8 | 3.3 | 0.472 | 168 | 4,378,133 | 3.8 |
| Esophagus | Total | 12 | 201,414 | 6.0 | 6.9 | 9.1 | 0.421 | 465 | 8,787,301 | 5.3 |
| Esophagus | Male | 10 | 102,700 | 9.7 | 11.4 | 7.7 | 0.505 | 391 | 4,409,168 | 8.9 |
| Esophagus | Female | 2 | 98,714 | 2.0 | 2.3 | 1.5 | 0.856 | 74 | 4,378,133 | 1.7 |
| Hodgkin Lymphoma | Total | - | 201,414 | - | - | 0.6 | 1.000 | 29 | 8,787,301 | 0.3 |
| Hodgkin Lymphoma | Male | - | 102,700 | - | - | 0.3 | 1.000 | 14 | 4,409,168 | 0.3 |
| Hodgkin Lymphoma | Female | - | 98,714 |  | - | 0.3 | 1.000 | 15 | 4,378,133 | 0.3 |
| Kidney | Total | 2 | 201,414 | 1.0 | 1.1 | 7.6 | 0.037 < | 383 | 8,787,301 | 4.4 |
| Kidney | Male | 2 | 102,700 | 1.9 | 2.3 | 4.8 | 0.288 | 240 | 4,409,168 | 5.4 |
| Kidney | Female | - | 98,714 | - | - | 2.9 | 0.113 | 143 | 4,378,133 | 3.3 |
| Larynx | Total | - | 201,414 |  | - | 1.4 | 0.492 | 71 | 8,787,301 | 0.8 |
| Larynx | Male | - | 102,700 | - | - | 1.2 | 0.627 | 58 | 4,409,168 | 1.3 |
| Larynx | Female | - | 98,714 | - | - | 0.3 | 1.000 | 13 | 4,378,133 | 0.3 |
| Leukemia | Total | 18 | 201,414 | 8.9 | 10.1 | 13.0 | 0.217 | 642 | 8,787,301 | 7.3 |
| Leukemia | Male | 9 | 102,700 | 8.8 | 10.0 | 7.7 | 0.733 | 377 | 4,409,168 | 8.6 |
| Leukemia | Female | 9 | 98,714 | 9.1 | 10.2 | 5.3 | 0.183 | 265 | 4,378,133 | 6.1 |
| Liver and Bile Duct | Total | 14 | 201,414 | 7.0 | 8.1 | 11.6 | 0.554 | 589 | 8,787,301 | 6.7 |
| Liver and Bile Duct | Male | 10 | 102,700 | 9.7 | 11.4 | 7.9 | 0.550 | 398 | 4,409,168 | 9.0 |
| Liver and Bile Duct | Female | 4 | 98,714 | 4.1 | 4.7 | 3.7 | 1.000 | 191 | 4,378,133 | 4.4 |
| Lung and Bronchus | Total | 51 | 201,414 | 25.3 | 29.4 | 57.4 | 0.438 | 2,910 | 8,787,301 | 33.1 |
| Lung and Bronchus | Male | 26 | 102,700 | 25.3 | 29.6 | 30.5 | 0.476 | 1,530 | 4,409,168 | 34.7 |
| Lung and Bronchus | Female | 25 | 98,714 | 25.3 | 29.2 | 27.0 | 0.797 | 1,380 | 4,378,133 | 31.5 |
| Melanoma of the Skin | Total | 9 | 201,414 | 4.5 | 5.1 | 5.6 | 0.226 | 280 | 8,787,301 | 3.2 |
| Melanoma of the Skin | Male | 4 | 102,700 | 3.9 | 4.5 | 3.8 | 1.000 | 188 | 4,409,168 | 4.3 |
| Melanoma of the Skin | Female |  | 98,714 | 5.1 | 5.8 | 1.8 | 0.076 | 92 | 4,378,133 | 2.1 |
| Myeloma | Total | 7 | 201,414 | 3.5 | 4.0 | 6.4 | 0.924 | 324 | 8,787,301 | 3.7 |
| Myeloma | Male | 4 | 102,700 | 3.9 | 4.5 | 3.9 | 1.000 | 192 | 4,409,168 | 4.4 |
| Myeloma | Female | 3 | 98,714 | 3.0 | 3.5 | 2.6 | 0.952 | 132 | 4,378,133 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 12 | 201,414 | 6.0 | 6.8 | 11.2 | 0.880 | 557 | 8,787,301 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 7 | 102,700 | 6.8 | 7.8 | 6.1 | 0.810 | 300 | 4,409,168 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 5 | 98,714 | 5.1 | 5.8 | 5.1 | 1.000 | 257 | 4,378,133 | 5.9 |
| Oral Cavity and Pharynx | Total | 5 | 201,414 | 2.5 | 2.9 | 5.1 | 1.000 | 261 | 8,787,301 | 3.0 |
| Oral Cavity and Pharynx | Male | 5 | 102,700 | 4.9 | 5.7 | 3.6 | 0.584 | 182 | 4,409,168 | 4.1 |
| Oral Cavity and Pharynx | Female | - | 98,714 | - | - | 1.5 | 0.428 | 79 | 4,378,133 | 1.8 |
| Ovary | Female | 4 | 98,714 | 4.1 | 4.7 | 6.7 | 0.395 | 346 | 4,378,133 | 7.9 |
| Pancreas | Total | 20 | 201,414 | 9.9 | 11.6 | 23.1 | 0.612 | 1,170 | 8,787,301 | 13.3 |
| Pancreas | Male | 7 | 102,700 | 6.8 | 8.0 | 12.6 | 0.132 | 635 | 4,409,168 | 14.4 |
| Pancreas | Female | 13 | 98,714 | 13.2 | 15.2 | 10.5 | 0.511 | 535 | 4,378,133 | 12.2 |
| Prostate | Male | 17 | 102,700 | 16.6 | 19.0 | 18.9 | 0.767 | 932 | 4,409,168 | 21.1 |
| Stomach | Total | 3 | 201,414 | 1.5 | 1.7 | 3.9 | 0.924 | 195 | 8,787,301 | 2.2 |
| Stomach | Male | 2 | 102,700 | 1.9 | 2.3 | 2.4 | 1.000 | 119 | 4,409,168 | 2.7 |
| Stomach | Female | 1 | 98,714 | 1.0 | 1.1 | 1.5 | 1.000 | 76 | 4,378,133 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Latah County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 91.1\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 11.3\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 75.8\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% | 76.0\% |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 77.1\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 21.7\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 36.4\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 84.1\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 23.4\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 21.0\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^28]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and 25.4\% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

## LDMHIT COUNTY

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 308 cases of invasive cancer were diagnosed among Lemhi County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Lemhi County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Lemhi <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 308 | 45,610 |
| Female Breast | 33 | 6,687 |
| Prostate | 71 | 6,417 |
| Lung \& Bronchus | 33 | 4,887 |
| Colorectal | 24 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Lemhi County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Lemhi County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Lemhi County was 776.9 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.8) gives an estimate of the relative burden of disease in Lemhi County.

The age- and sex-adjusted incidence rate of invasive cancer in Lemhi County, all sites combined, was 476.5 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Lemhi County (308) than expected (335.4) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 131 Lemhi County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Lemhi County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Lemhi <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 614 | 77,431 |
| Cancer Deaths | 131 | 15,121 |
| \% of All Deaths | $21.3 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 29 | 2,961 |
| Colorectal | 14 | 1,319 |
| Pancreas | 10 | 1,190 |
| Female Breast | 10 | 1,086 |
| Prostate | 11 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Lemhi County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Lemhi County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Lemhi County, all sites combined, was 182.6 deaths per 100,000 persons per year during 2017-2021, compared with 167.5 for the remainder of the state. There were more cancer deaths in Lemhi County (131) than expected (120.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN LEMHI COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Lemhi County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 308 | 39,647 | 776.9 | 476.5 | 335.4 | 0.140 | 45,302 | 8,732,181 | 518.8 |
| All Sites Combined | Male | 191 | 20,072 | 951.6 | 536.1 | 196.2 | 0.746 | 24,098 | 4,376,838 | 550.6 |
| All Sites Combined | Female | 117 | 19,575 | 597.7 | 396.6 | 143.6 | 0.025 << | 21,204 | 4,355,343 | 486.9 |
| Bladder | Total | 18 | 39,647 | 45.4 | 25.0 | 17.9 | 1.000 | 2,166 | 8,732,181 | 24.8 |
| Bladder | Male | 14 | 20,072 | 69.7 | 35.5 | 15.6 | 0.802 | 1,737 | 4,376,838 | 39.7 |
| Bladder | Female | 4 | 19,575 | 20.4 | 12.1 | 3.2 | 0.814 | 429 | 4,355,343 | 9.8 |
| Brain - malignant | Total | 2 | 39,647 | 5.0 | 3.5 | 4.0 | 0.466 | 623 | 8,732,181 | 7.1 |
| Brain - malignant | Male | 1 | 20,072 | 5.0 | 3.4 | 2.5 | 0.561 | 374 | 4,376,838 | 8.5 |
| Brain - malignant | Female | 1 | 19,575 | 5.1 | 3.7 | 1.6 | 1.000 | 249 | 4,355,343 | 5.7 |
| Brain and other CNS - non-malignant | Total | 10 | 39,647 | 25.2 | 16.7 | 9.7 | 1.000 | 1,414 | 8,732,181 | 16.2 |
| Brain and other CNS - non-malignant | Male | 3 | 20,072 | 14.9 | 9.8 | 3.3 | 1.000 | 477 | 4,376,838 | 10.9 |
| Brain and other CNS - non-malignant | Female | 7 | 19,575 | 35.8 | 24.3 | 6.2 | 0.847 | 937 | 4,355,343 | 21.5 |
| Breast | Total | 33 | 39,647 | 83.2 | 54.3 | 46.7 | 0.045 << | 6,713 | 8,732,181 | 76.9 |
| Breast | Male | - | 20,072 | - | - | 0.5 | 1.000 | 59 | 4,376,838 | 1.3 |
| Breast | Female | 33 | 19,575 | 168.6 | 114.5 | 44.0 | 0.103 | 6,654 | 4,355,343 | 152.8 |
| Breast - in situ | Total | 3 | 39,647 | 7.6 | 5.1 | 8.3 | 0.070 | 1,236 | 8,732,181 | 14.2 |
| Breast - in situ | Male | - | 20,072 | - | - | 0.0 | 1.000 | 5 | 4,376,838 | 0.1 |
| Breast - in situ | Female | 3 | 19,575 | 15.3 | 10.7 | 7.9 | 0.089 | 1,231 | 4,355,343 | 28.3 |
| Cervix | Female | 1 | 19,575 | 5.1 | 4.7 | 1.5 | 1.000 | 303 | 4,355,343 | 7.0 |
| Colorectal | Total | 24 | 39,647 | 60.5 | 37.7 | 25.0 | 0.945 | 3,427 | 8,732,181 | 39.2 |
| Colorectal | Male | 16 | 20,072 | 79.7 | 47.4 | 14.5 | 0.770 | 1,887 | 4,376,838 | 43.1 |
| Colorectal | Female | 8 | 19,575 | 40.9 | 26.5 | 10.7 | 0.526 | 1,540 | 4,355,343 | 35.4 |
| Corpus Uteri | Female | 7 | 19,575 | 35.8 | 23.8 | 8.9 | 0.666 | 1,323 | 4,355,343 | 30.4 |
| Esophagus | Total | 7 | 39,647 | 17.7 | 10.3 | 3.9 | 0.198 | 499 | 8,732,181 | 5.7 |
| Esophagus | Male | 7 | 20,072 | 34.9 | 19.1 | 3.5 | 0.129 | 417 | 4,376,838 | 9.5 |
| Esophagus | Female | - | 19,575 | - | - | 0.6 | 1.000 | 82 | 4,355,343 | 1.9 |
| Hodgkin Lymphoma | Total | - | 39,647 | - | - | 1.1 | 0.689 | 210 | 8,732,181 | 2.4 |
| Hodgkin Lymphoma | Male | - | 20,072 | - | - | 0.6 | 1.000 | 118 | 4,376,838 | 2.7 |
| Hodgkin Lymphoma | Female | - | 19,575 | - | - | 0.4 | 1.000 | 92 | 4,355,343 | 2.1 |
| Kidney and Renal Pelvis | Total | 11 | 39,647 | 27.7 | 17.5 | 13.0 | 0.709 | 1,804 | 8,732,181 | 20.7 |
| Kidney and Renal Pelvis | Male | 7 | 20,072 | 34.9 | 21.1 | 8.9 | 0.667 | 1,175 | 4,376,838 | 26.8 |
| Kidney and Renal Pelvis | Female | 4 | 19,575 | 20.4 | 13.4 | 4.3 | 1.000 | 629 | 4,355,343 | 14.4 |
| Larynx | Total | - | 39,647 | - | - | 1.6 | 0.387 | 215 | 8,732,181 | 2.5 |
| Larynx | Male | - | 20,072 | - | - | 1.3 | 0.533 | 160 | 4,376,838 | 3.7 |
| Larynx | Female | - | 19,575 | - | - | 0.4 | 1.000 | 55 | 4,355,343 | 1.3 |
| Leukemia | Total | 9 | 39,647 | 22.7 | 13.9 | 12.0 | 0.485 | 1,622 | 8,732,181 | 18.6 |
| Leukemia | Male | 6 | 20,072 | 29.9 | 17.3 | 7.8 | 0.684 | 983 | 4,376,838 | 22.5 |
| Leukemia | Female | 3 | 19,575 | 15.3 | 9.9 | 4.5 | 0.699 | 639 | 4,355,343 | 14.7 |
| Liver and Bile Duct | Total | 4 | 39,647 | 10.1 | 6.0 | 6.3 | 0.491 | 825 | 8,732,181 | 9.4 |
| Liver and Bile Duct | Male | 1 | 20,072 | 5.0 | 2.8 | 4.8 | 0.099 | 589 | 4,376,838 | 13.5 |
| Liver and Bile Duct | Female | 3 | 19,575 | 15.3 | 9.5 | 1.7 | 0.491 | 236 | 4,355,343 | 5.4 |
| Lung and Bronchus | Total | 33 | 39,647 | 83.2 | 46.2 | 39.7 | 0.324 | 4,854 | 8,732,181 | 55.6 |
| Lung and Bronchus | Male | 21 | 20,072 | 104.6 | 54.0 | 21.6 | 1.000 | 2,431 | 4,376,838 | 55.5 |
| Lung and Bronchus | Female | 12 | 19,575 | 61.3 | 36.4 | 18.4 | 0.158 | 2,423 | 4,355,343 | 55.6 |
| Melanoma of the Skin | Total | 12 | 39,647 | 30.3 | 19.6 | 20.5 | 0.062 | 2,930 | 8,732,181 | 33.6 |
| Melanoma of the Skin | Male | 7 | 20,072 | 34.9 | 20.4 | 13.8 | 0.071 | 1,758 | 4,376,838 | 40.2 |
| Melanoma of the Skin | Female | 5 | 19,575 | 25.5 | 18.5 | 7.3 | 0.536 | 1,172 | 4,355,343 | 26.9 |
| Myeloma | Total | 4 | 39,647 | 10.1 | 5.7 | 5.6 | 0.678 | 704 | 8,732,181 | 8.1 |
| Myeloma | Male | 3 | 20,072 | 14.9 | 7.9 | 3.8 | 0.949 | 438 | 4,376,838 | 10.0 |
| Myeloma | Female | 1 | 19,575 | 5.1 | 3.1 | 2.0 | 0.834 | 266 | 4,355,343 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 9 | 39,647 | 22.7 | 13.9 | 14.3 | 0.192 | 1,931 | 8,732,181 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 8 | 20,072 | 39.9 | 23.4 | 8.8 | 0.972 | 1,121 | 4,376,838 | 25.6 |
| Non-Hodgkin Lymphoma | Female | 1 | 19,575 | 5.1 | 3.3 | 5.7 | 0.045 << | 810 | 4,355,343 | 18.6 |
| Oral Cavity and Pharynx | Total | 12 | 39,647 | 30.3 | 18.7 | 9.4 | 0.477 | 1,283 | 8,732,181 | 14.7 |
| Oral Cavity and Pharynx | Male | 10 | 20,072 | 49.8 | 29.6 | 7.2 | 0.371 | 926 | 4,376,838 | 21.2 |
| Oral Cavity and Pharynx | Female | 2 | 19,575 | 10.2 | 6.6 | 2.5 | 1.000 | 357 | 4,355,343 | 8.2 |
| Ovary | Female | 5 | 19,575 | 25.5 | 17.3 | 3.5 | 0.550 | 528 | 4,355,343 | 12.1 |
| Pancreas | Total | 10 | 39,647 | 25.2 | 14.4 | 11.3 | 0.860 | 1,413 | 8,732,181 | 16.2 |
| Pancreas | Male | 5 | 20,072 | 24.9 | 13.4 | 6.6 | 0.696 | 779 | 4,376,838 | 17.8 |
| Pancreas | Female | 5 | 19,575 | 25.5 | 15.4 | 4.7 | 1.000 | 634 | 4,355,343 | 14.6 |
| Prostate | Male | 71 | 20,072 | 353.7 | 193.4 | 53.2 | $0.023 \gg$ | 6,346 | 4,376,838 | 145.0 |
| Stomach | Total | 4 | 39,647 | 10.1 | 6.0 | 3.5 | 0.932 | 463 | 8,732,181 | 5.3 |
| Stomach | Male | 3 | 20,072 | 14.9 | 8.3 | 2.5 | 0.924 | 306 | 4,376,838 | 7.0 |
| Stomach | Female | 1 | 19,575 | 5.1 | 3.3 | 1.1 | 1.000 | 157 | 4,355,343 | 3.6 |
| Testis | Male | - | 20,072 | - | - | 1.0 | 0.752 | 265 | 4,376,838 | 6.1 |
| Thyroid | Total | 5 | 39,647 | 12.6 | 10.9 | 6.4 | 0.766 | 1,215 | 8,732,181 | 13.9 |
| Thyroid | Male | - | 20,072 | - | - | 2.2 | 0.233 | 355 | 4,376,838 | 8.1 |
| Thyroid | Female | 5 | 19,575 | 25.5 | 23.2 | 4.3 | 0.845 | 860 | 4,355,343 | 19.7 |
| Pediatric Age 0 to 19 | Total | 1 | 8,001 | 12.5 | 12.5 | 1.4 | 1.000 | 420 | 2,452,522 | 17.1 |
| Pediatric Age 0 to 19 | Male | - | 4,206 | - | - | 0.7 | 0.946 | 223 | 1,252,304 | 17.8 |
| Pediatric Age 0 to 19 | Female | 1 | 3,795 | 26.4 | 26.3 | 0.6 | 0.929 | 197 | 1,200,218 | 16.4 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN LEMHI COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Lemhi County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 614 | 40,094 | 1,531.4 | 855.6 | 616.0 | 0.956 | 76,816 | 8,948,621 | 858.4 |
| All Causes of Death | Male | 350 | 20,290 | 1,725.0 | 923.7 | 343.4 | 0.736 | 40,706 | 4,491,578 | 906.3 |
| All Causes of Death | Female | 264 | 19,804 | 1,333.1 | 770.6 | 277.6 | 0.435 | 36,110 | 4,457,043 | 810.2 |
| All Malignant Cancers | Total | 131 | 40,094 | 326.7 | 182.6 | 120.2 | 0.344 | 14,990 | 8,948,621 | 167.5 |
| All Malignant Cancers | Male | 81 | 20,290 | 399.2 | 207.3 | 70.4 | 0.232 | 8,095 | 4,491,578 | 180.2 |
| All Malignant Cancers | Female | 50 | 19,804 | 252.5 | 150.5 | 51.4 | 0.920 | 6,895 | 4,457,043 | 154.7 |
| Bladder | Total | 5 | 40,094 | 12.5 | 6.4 | 4.2 | 0.822 | 484 | 8,948,621 | 5.4 |
| Bladder | Male | 5 | 20,290 | 24.6 | 11.7 | 3.5 | 0.568 | 373 | 4,491,578 | 8.3 |
| Bladder | Female | - | 19,804 |  | - | 0.9 | 0.815 | 111 | 4,457,043 | 2.5 |
| Brain and Other Nervous System | Total | 1 | 40,094 | 2.5 | 1.6 | 3.5 | 0.265 | 503 | 8,948,621 | 5.6 |
| Brain and Other Nervous System | Male |  | 20,290 | - | - | 2.2 | 0.221 | 298 | 4,491,578 | 6.6 |
| Brain and Other Nervous System | Female | 1 | 19,804 | 5.0 | 3.3 | 1.4 | 1.000 | 205 | 4,457,043 | 4.6 |
| Breast | Total | 10 | 40,094 | 24.9 | 14.7 | 8.3 | 0.648 | 1,092 | 8,948,621 | 12.2 |
| Breast | Male |  | 20,290 |  |  | 0.1 | 1.000 | 16 | 4,491,578 | 0.4 |
| Breast | Female | 10 | 19,804 | 50.5 | 31.2 | 7.7 | 0.500 | 1,076 | 4,457,043 | 24.1 |
| Cervix | Female | - | 19,804 |  | - | 0.5 | 1.000 | 83 | 4,457,043 | 1.9 |
| Colorectal | Total | 14 | 40,094 | 34.9 | 20.2 | 10.1 | 0.283 | 1,305 | 8,948,621 | 14.6 |
| Colorectal | Male | 12 | 20,290 | 59.1 | 33.2 | 5.7 | 0.028 >> | 707 | 4,491,578 | 15.7 |
| Colorectal | Female | 2 | 19,804 | 10.1 | 6.0 | 4.4 | 0.359 | 598 | 4,457,043 | 13.4 |
| Corpus Uteri | Female | - | 19,804 |  | - | 1.3 | 0.550 | 173 | 4,457,043 | 3.9 |
| Esophagus | Total | 3 | 40,094 | 7.5 | 4.3 | 3.7 | 0.979 | 474 | 8,948,621 | 5.3 |
| Esophagus | Male | 3 | 20,290 | 14.8 | 8.0 | 3.3 | 1.000 | 398 | 4,491,578 | 8.9 |
| Esophagus | Female | - | 19,804 | - | - | 0.6 | 1.000 | 76 | 4,457,043 | 1.7 |
| Hodgkin Lymphoma | Total |  | 40,094 | - | - | 0.2 | 1.000 | 29 | 8,948,621 | 0.3 |
| Hodgkin Lymphoma | Male | - | 20,290 | - | - | 0.1 | 1.000 | 14 | 4,491,578 | 0.3 |
| Hodgkin Lymphoma | Female | - | 19,804 |  | - | 0.1 | 1.000 | 15 | 4,457,043 | 0.3 |
| Kidney | Total | 4 | 40,094 | 10.0 | 5.4 | 3.1 | 0.762 | 381 | 8,948,621 | 4.3 |
| Kidney | Male | 3 | 20,290 | 14.8 | 7.7 | 2.1 | 0.680 | 239 | 4,491,578 | 5.3 |
| Kidney | Female | 1 | 19,804 | 5.0 | 2.8 | 1.1 | 1.000 | 142 | 4,457,043 | 3.2 |
| Larynx | Total | - | 40,094 |  | - | 0.6 | 1.000 | 71 | 8,948,621 | 0.8 |
| Larynx | Male | - | 20,290 | - | - | 0.5 | 1.000 | 58 | 4,491,578 | 1.3 |
| Larynx | Female | - | 19,804 | - | - | 0.1 | 1.000 | 13 | 4,457,043 | 0.3 |
| Leukemia | Total | 5 | 40,094 | 12.5 | 6.9 | 5.3 | 1.000 | 655 | 8,948,621 | 7.3 |
| Leukemia | Male | 3 | 20,290 | 14.8 | 7.6 | 3.4 | 1.000 | 383 | 4,491,578 | 8.5 |
| Leukemia | Female | 2 | 19,804 | 10.1 | 5.8 | 2.1 | 1.000 | 272 | 4,457,043 | 6.1 |
| Liver and Bile Duct | Total | 7 | 40,094 | 17.5 | 9.9 | 4.7 | 0.392 | 596 | 8,948,621 | 6.7 |
| Liver and Bile Duct | Male | 3 | 20,290 | 14.8 | 8.0 | 3.4 | 1.000 | 405 | 4,491,578 | 9.0 |
| Liver and Bile Duct | Female | 4 | 19,804 | 20.2 | 12.0 | 1.4 | 0.114 | 191 | 4,457,043 | 4.3 |
| Lung and Bronchus | Total | 29 | 40,094 | 72.3 | 39.4 | 24.1 | 0.365 | 2,932 | 8,948,621 | 32.8 |
| Lung and Bronchus | Male | 17 | 20,290 | 83.8 | 42.8 | 13.6 | 0.425 | 1,539 | 4,491,578 | 34.3 |
| Lung and Bronchus | Female | 12 | 19,804 | 60.6 | 35.1 | 10.7 | 0.763 | 1,393 | 4,457,043 | 31.3 |
| Melanoma of the Skin | Total | 3 | 40,094 | 7.5 | 4.4 | 2.2 | 0.751 | 286 | 8,948,621 | 3.2 |
| Melanoma of the Skin | Male | 3 | 20,290 | 14.8 | 7.9 | 1.6 | 0.428 | 189 | 4,491,578 | 4.2 |
| Melanoma of the Skin | Female | - | 19,804 | - | - | 0.7 | 1.000 | 97 | 4,457,043 | 2.2 |
| Myeloma | Total | 2 | 40,094 | 5.0 | 2.6 | 2.8 | 0.946 | 329 | 8,948,621 | 3.7 |
| Myeloma | Male | 1 | 20,290 | 4.9 | 2.4 | 1.8 | 0.919 | 195 | 4,491,578 | 4.3 |
| Myeloma | Female | 1 | 19,804 | 5.0 | 2.9 | 1.0 | 1.000 | 134 | 4,457,043 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 3 | 40,094 | 7.5 | 4.1 | 4.6 | 0.641 | 566 | 8,948,621 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 3 | 20,290 | 14.8 | 7.7 | 2.6 | 0.978 | 304 | 4,491,578 | 6.8 |
| Non-Hodgkin Lymphoma | Female | - | 19,804 | - | - | 2.0 | 0.261 | 262 | 4,457,043 | 5.9 |
| Oral Cavity and Pharynx | Total | 3 | 40,094 | 7.5 | 4.3 | 2.1 | 0.674 | 263 | 8,948,621 | 2.9 |
| Oral Cavity and Pharynx | Male | 2 | 20,290 | 9.9 | 5.3 | 1.6 | 0.918 | 185 | 4,491,578 | 4.1 |
| Oral Cavity and Pharynx | Female | 1 | 19,804 | 5.0 | 3.1 | 0.6 | 0.861 | 78 | 4,457,043 | 1.8 |
| Ovary | Female | 3 | 19,804 | 15.1 | 9.2 | 2.5 | 0.934 | 347 | 4,457,043 | 7.8 |
| Pancreas | Total | 10 | 40,094 | 24.9 | 13.9 | 9.5 | 0.960 | 1,180 | 8,948,621 | 13.2 |
| Pancreas | Male | 5 | 20,290 | 24.6 | 13.0 | 5.5 | 1.000 | 637 | 4,491,578 | 14.2 |
| Pancreas | Female | 5 | 19,804 | 25.2 | 14.8 | 4.1 | 0.791 | 543 | 4,457,043 | 12.2 |
| Prostate | Male | 11 | 20,290 | 54.2 | 25.5 | 9.0 | 0.587 | 938 | 4,491,578 | 20.9 |
| Stomach | Total | 3 | 40,094 | 7.5 | 4.5 | 1.5 | 0.361 | 195 | 8,948,621 | 2.2 |
| Stomach | Male | 2 | 20,290 | 9.9 | 5.5 | 1.0 | 0.498 | 119 | 4,491,578 | 2.6 |
| Stomach | Female | 1 | 19,804 | 5.0 | 3.2 | 0.5 | 0.819 | 76 | 4,457,043 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Lemhi County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 82.1\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 11.0\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 49.4\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 65.0\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 26.4\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 38.3\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 76.0\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 18.9\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 24.3\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to 64.8\% of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^29]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged $50-74$ reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and 25.4\% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

## LDWIS COUNTY CANCPR PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 140 cases of invasive cancer were diagnosed among Lewis County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Lewis County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Lewis <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 140 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 21 | 6,687 |
| Prostate | 21 | 6,417 |
| Lung \& Bronchus | 25 | 4,887 |
| Colorectal | 9 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Lewis County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Lewis County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Lewis County was 727.2 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.5) gives an estimate of the relative burden of disease in Lewis County.

The age- and sex-adjusted incidence rate of invasive cancer in Lewis County, all sites combined, was 494.1 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Lewis County (140) than expected (147.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 55 Lewis County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Lewis County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Lewis <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 273 | 77,431 |
| Cancer Deaths | 55 | 15,121 |
| \% of All Deaths | $20.1 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 13 | 2,961 |
| Colorectal | 5 | 1,319 |
| Pancreas | 2 | 1,190 |
| Female Breast | 0 | 1,086 |
| Prostate | 5 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Lewis County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Lewis County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Lewis County, all sites combined, was 179.1 deaths per 100,000 persons per year during 2017-2021, compared with 168.0 for the remainder of the state. There were more cancer deaths in Lewis County (55) than expected (51.6) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN LEWIS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Lewis County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 140 | 19,251 | 727.2 | 494.1 | 147.2 | 0.587 | 45,470 | 8,752,577 | 519.5 |
| All Sites Combined | Male | 86 | 9,732 | 883.7 | 556.2 | 85.3 | 0.968 | 24,203 | 4,387,178 | 551.7 |
| All Sites Combined | Female | 54 | 9,519 | 567.3 | 413.3 | 63.7 | 0.248 | 21,267 | 4,365,399 | 487.2 |
| Bladder | Total | 9 | 19,251 | 46.8 | 28.8 | 7.8 | 0.753 | 2,175 | 8,752,577 | 24.8 |
| Bladder | Male | 6 | 9,732 | 61.7 | 35.5 | 6.7 | 0.981 | 1,745 | 4,387,178 | 39.8 |
| Bladder | Female | 3 | 9,519 | 31.5 | 20.9 | 1.4 | 0.341 | 430 | 4,365,399 | 9.9 |
| Brain - malignant | Total | - | 19,251 | - | - | 1.8 | 0.326 | 625 | 8,752,577 | 7.1 |
| Brain - malignant | Male | - | 9,732 | - | - | 1.1 | 0.648 | 375 | 4,387,178 | 8.5 |
| Brain - malignant | Female | - | 9,519 | - | - | 0.7 | 0.992 | 250 | 4,365,399 | 5.7 |
| Brain and other CNS - non-malignant | Total | 3 | 19,251 | 15.6 | 11.3 | 4.3 | 0.752 | 1,421 | 8,752,577 | 16.2 |
| Brain and other CNS - non-malignant | Male | 2 | 9,732 | 20.6 | 14.8 | 1.5 | 0.869 | 478 | 4,387,178 | 10.9 |
| Brain and other CNS - non-malignant | Female | 1 | 9,519 | 10.5 | 7.8 | 2.8 | 0.474 | 943 | 4,365,399 | 21.6 |
| Breast | Total | 21 | 19,251 | 109.1 | 78.5 | 20.5 | 0.978 | 6,725 | 8,752,577 | 76.8 |
| Breast | Male | - | 9,732 | - | - | 0.2 | 1.000 | 59 | 4,387,178 | 1.3 |
| Breast | Female | 21 | 9,519 | 220.6 | 164.6 | 19.5 | 0.790 | 6,666 | 4,365,399 | 152.7 |
| Breast - in situ | Total | 2 | 19,251 | 10.4 | 7.8 | 3.6 | 0.589 | 1,237 | 8,752,577 | 14.1 |
| Breast - in situ | Male | - | 9,732 | - | - | 0.0 | 1.000 | 5 | 4,387,178 | 0.1 |
| Breast - in situ | Female | 2 | 9,519 | 21.0 | 16.1 | 3.5 | 0.640 | 1,232 | 4,365,399 | 28.2 |
| Cervix | Female | - | 9,519 | - | - | 0.7 | 1.000 | 304 | 4,365,399 | 7.0 |
| Colorectal | Total | 9 | 19,251 | 46.8 | 32.0 | 11.1 | 0.668 | 3,442 | 8,752,577 | 39.3 |
| Colorectal | Male | 7 | 9,732 | 71.9 | 47.1 | 6.4 | 0.921 | 1,896 | 4,387,178 | 43.2 |
| Colorectal | Female | 2 | 9,519 | 21.0 | 14.9 | 4.7 | 0.297 | 1,546 | 4,365,399 | 35.4 |
| Corpus Uteri | Female | 1 | 9,519 | 10.5 | 7.8 | 3.9 | 0.198 | 1,329 | 4,365,399 | 30.4 |
| Esophagus | Total | 2 | 19,251 | 10.4 | 6.7 | 1.7 | 1.000 | 504 | 8,752,577 | 5.8 |
| Esophagus | Male | 1 | 9,732 | 10.3 | 6.3 | 1.5 | 1.000 | 423 | 4,387,178 | 9.6 |
| Esophagus | Female | 1 | 9,519 | 10.5 | 7.2 | 0.3 | 0.455 | 81 | 4,365,399 | 1.9 |
| Hodgkin Lymphoma | Total | - | 19,251 | - | - | 0.5 | 1.000 | 210 | 8,752,577 | 2.4 |
| Hodgkin Lymphoma | Male | - | 9,732 | - | - | 0.3 | 1.000 | 118 | 4,387,178 | 2.7 |
| Hodgkin Lymphoma | Female | - | 9,519 | - | - | 0.2 | 1.000 | 92 | 4,365,399 | 2.1 |
| Kidney and Renal Pelvis | Total | 8 | 19,251 | 41.6 | 28.8 | 5.7 | 0.439 | 1,807 | 8,752,577 | 20.6 |
| Kidney and Renal Pelvis | Male | 5 | 9,732 | 51.4 | 34.3 | 3.9 | 0.708 | 1,177 | 4,387,178 | 26.8 |
| Kidney and Renal Pelvis | Female | 3 | 9,519 | 31.5 | 22.6 | 1.9 | 0.600 | 630 | 4,365,399 | 14.4 |
| Larynx | Total | 2 | 19,251 | 10.4 | 6.8 | 0.7 | 0.323 | 213 | 8,752,577 | 2.4 |
| Larynx | Male | 2 | 9,732 | 20.6 | 12.6 | 0.6 | 0.226 | 158 | 4,387,178 | 3.6 |
| Larynx | Female | - | 9,519 | - | - | 0.2 | 1.000 | 55 | 4,365,399 | 1.3 |
| Leukemia | Total | 3 | 19,251 | 15.6 | 10.5 | 5.3 | 0.446 | 1,628 | 8,752,577 | 18.6 |
| Leukemia | Male | 3 | 9,732 | 30.8 | 19.8 | 3.4 | 1.000 | 986 | 4,387,178 | 22.5 |
| Leukemia | Female | - | 9,519 | - | - | 2.0 | 0.272 | 642 | 4,365,399 | 14.7 |
| Liver and Bile Duct | Total | 4 | 19,251 | 20.8 | 13.8 | 2.7 | 0.587 | 825 | 8,752,577 | 9.4 |
| Liver and Bile Duct | Male | 4 | 9,732 | 41.1 | 26.1 | 2.1 | 0.304 | 586 | 4,387,178 | 13.4 |
| Liver and Bile Duct | Female | - | 9,519 | - | - | 0.8 | 0.941 | 239 | 4,365,399 | 5.5 |
| Lung and Bronchus | Total | 25 | 19,251 | 129.9 | 80.5 | 17.3 | 0.094 | 4,862 | 8,752,577 | 55.5 |
| Lung and Bronchus | Male | 14 | 9,732 | 143.9 | 83.9 | 9.3 | 0.177 | 2,438 | 4,387,178 | 55.6 |
| Lung and Bronchus | Female | 11 | 9,519 | 115.6 | 75.7 | 8.1 | 0.382 | 2,424 | 4,365,399 | 55.5 |
| Melanoma of the Skin | Total | 6 | 19,251 | 31.2 | 22.2 | 9.0 | 0.405 | 2,936 | 8,752,577 | 33.5 |
| Melanoma of the Skin | Male | 5 | 9,732 | 51.4 | 33.4 | 6.0 | 0.892 | 1,760 | 4,387,178 | 40.1 |
| Melanoma of the Skin | Female | 1 | 9,519 | 10.5 | 8.3 | 3.3 | 0.329 | 1,176 | 4,365,399 | 26.9 |
| Myeloma | Total | 4 | 19,251 | 20.8 | 13.1 | 2.4 | 0.463 | 704 | 8,752,577 | 8.0 |
| Myeloma | Male | 3 | 9,732 | 30.8 | 18.4 | 1.6 | 0.449 | 438 | 4,387,178 | 10.0 |
| Myeloma | Female | 1 | 9,519 | 10.5 | 7.0 | 0.9 | 1.000 | 266 | 4,365,399 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 3 | 19,251 | 15.6 | 10.6 | 6.3 | 0.254 | 1,937 | 8,752,577 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 3 | 9,732 | 30.8 | 20.1 | 3.8 | 0.932 | 1,126 | 4,387,178 | 25.7 |
| Non-Hodgkin Lymphoma | Female | - | 9,519 | - | - | 2.5 | 0.161 | 811 | 4,365,399 | 18.6 |
| Oral Cavity and Pharynx | Total | 6 | 19,251 | 31.2 | 21.5 | 4.1 | 0.467 | 1,289 | 8,752,577 | 14.7 |
| Oral Cavity and Pharynx | Male | 4 | 9,732 | 41.1 | 27.0 | 3.1 | 0.771 | 932 | 4,387,178 | 21.2 |
| Oral Cavity and Pharynx | Female | 2 | 9,519 | 21.0 | 15.1 | 1.1 | 0.589 | 357 | 4,365,399 | 8.2 |
| Ovary | Female | - | 9,519 | - | - | 1.6 | 0.419 | 533 | 4,365,399 | 12.2 |
| Pancreas | Total | 5 | 19,251 | 26.0 | 16.5 | 4.9 | 1.000 | 1,418 | 8,752,577 | 16.2 |
| Pancreas | Male | 2 | 9,732 | 20.6 | 12.4 | 2.9 | 0.900 | 782 | 4,387,178 | 17.8 |
| Pancreas | Female | 3 | 9,519 | 31.5 | 21.0 | 2.1 | 0.690 | 636 | 4,365,399 | 14.6 |
| Prostate | Male | 21 | 9,732 | 215.8 | 133.0 | 23.0 | 0.777 | 6,396 | 4,387,178 | 145.8 |
| Stomach | Total | 2 | 19,251 | 10.4 | 6.9 | 1.5 | 0.916 | 465 | 8,752,577 | 5.3 |
| Stomach | Male | - | 9,732 | - | - | 1.1 | 0.658 | 309 | 4,387,178 | 7.0 |
| Stomach | Female | 2 | 9,519 | 21.0 | 15.0 | 0.5 | 0.167 | 156 | 4,365,399 | 3.6 |
| Testis | Male | - | 9,732 | - | - | 0.5 | 1.000 | 265 | 4,387,178 | 6.0 |
| Thyroid | Total | 4 | 19,251 | 20.8 | 19.0 | 2.9 | 0.669 | 1,216 | 8,752,577 | 13.9 |
| Thyroid | Male | 2 | 9,732 | 20.6 | 16.9 | 1.0 | 0.492 | 353 | 4,387,178 | 8.0 |
| Thyroid | Female | 2 | 9,519 | 21.0 | 20.0 | 2.0 | 1.000 | 863 | 4,365,399 | 19.8 |
| Pediatric Age 0 to 19 | Total | 2 | 4,778 | 41.9 | 42.4 | 0.8 | 0.386 | 419 | 2,455,745 | 17.1 |
| Pediatric Age 0 to 19 | Male | 2 | 2,525 | 79.2 | 79.9 | 0.4 | 0.146 | 221 | 1,253,985 | 17.6 |
| Pediatric Age 0 to 19 | Female | - | 2,253 | - | - | 0.4 | 1.000 | 198 | 1,201,760 | 16.5 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN LEWIS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Lewis County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 273 | 19,116 | 1,428.1 | 893.7 | 262.8 | 0.543 | 77,157 | 8,969,599 | 860.2 |
| All Causes of Death | Male | 168 | 9,680 | 1,735.5 | 1,034.2 | 147.5 | 0.105 | 40,888 | 4,502,188 | 908.2 |
| All Causes of Death | Female | 105 | 9,436 | 1,112.8 | 727.2 | 117.2 | 0.278 | 36,269 | 4,467,411 | 811.9 |
| All Malignant Cancers | Total | 55 | 19,116 | 287.7 | 179.1 | 51.6 | 0.670 | 15,066 | 8,969,599 | 168.0 |
| All Malignant Cancers | Male | 42 | 9,680 | 433.9 | 251.3 | 30.2 | 0.048 >> | 8,134 | 4,502,188 | 180.7 |
| All Malignant Cancers | Female | 13 | 9,436 | 137.8 | 91.4 | 22.1 | 0.054 | 6,932 | 4,467,411 | 155.2 |
| Bladder | Total | 4 | 19,116 | 20.9 | 12.2 | 1.8 | 0.211 | 485 | 8,969,599 | 5.4 |
| Bladder | Male | 3 | 9,680 | 31.0 | 16.6 | 1.5 | 0.387 | 375 | 4,502,188 | 8.3 |
| Bladder | Female | 1 | 9,436 | 10.6 | 6.6 | 0.4 | 0.625 | 110 | 4,467,411 | 2.5 |
| Brain and Other Nervous System | Total | 2 | 19,116 | 10.5 | 7.3 | 1.5 | 0.906 | 502 | 8,969,599 | 5.6 |
| Brain and Other Nervous System | Male | 2 | 9,680 | 20.7 | 13.8 | 1.0 | 0.496 | 296 | 4,502,188 | 6.6 |
| Brain and Other Nervous System | Female | - | 9,436 | - | - | 0.6 | 1.000 | 206 | 4,467,411 | 4.6 |
| Breast | Total |  | 19,116 |  | - | 3.6 | 0.055 | 1,102 | 8,969,599 | 12.3 |
| Breast | Male | - | 9,680 | - | - | 0.1 | 1.000 | 16 | 4,502,188 | 0.4 |
| Breast | Female | - | 9,436 | - | - | 3.3 | 0.072 | 1,086 | 4,467,411 | 24.3 |
| Cervix | Female | - | 9,436 | - | - | 0.2 | 1.000 | 83 | 4,467,411 | 1.9 |
| Colorectal | Total | 5 | 19,116 | 26.2 | 16.8 | 4.4 | 0.880 | 1,314 | 8,969,599 | 14.6 |
| Colorectal | Male | 4 | 9,680 | 41.3 | 25.6 | 2.5 | 0.477 | 715 | 4,502,188 | 15.9 |
| Colorectal | Female | 1 | 9,436 | 10.6 | 7.1 | 1.9 | 0.867 | 599 | 4,467,411 | 13.4 |
| Corpus Uteri | Female | - | 9,436 | - | - | 0.5 | 1.000 | 173 | 4,467,411 | 3.9 |
| Esophagus | Total | 2 | 19,116 | 10.5 | 6.6 | 1.6 | 0.949 | 475 | 8,969,599 | 5.3 |
| Esophagus | Male | 1 | 9,680 | 10.3 | 6.2 | 1.4 | 1.000 | 400 | 4,502,188 | 8.9 |
| Esophagus | Female | 1 | 9,436 | 10.6 | 7.0 | 0.2 | 0.425 | 75 | 4,467,411 | 1.7 |
| Hodgkin Lymphoma | Total | - | 19,116 | - | - | 0.1 | 1.000 | 29 | 8,969,599 | 0.3 |
| Hodgkin Lymphoma | Male | - | 9,680 | - | - | 0.0 | 1.000 | 14 | 4,502,188 | 0.3 |
| Hodgkin Lymphoma | Female | - | 9,436 | - | - | 0.0 | 1.000 | 15 | 4,467,411 | 0.3 |
| Kidney | Total | 2 | 19,116 | 10.5 | 6.4 | 1.3 | 0.770 | 383 | 8,960,599 | 4.3 |
| Kidney | Male | 2 | 9,680 | 20.7 | 12.1 | 0.9 | 0.443 | 240 | 4,502,188 | 5.3 |
| Kidney | Female | - | 9,436 | - | - | 0.5 | 1.000 | 143 | 4,467,411 | 3.2 |
| Larynx | Total | 2 | 19,116 | 10.5 | 6.5 | 0.2 | 0.048 >> | 69 | 8,969,599 | 0.8 |
| Larynx | Male | 1 | 9,680 | 10.3 | 5.9 | 0.2 | 0.387 | 57 | 4,502,188 | 1.3 |
| Larynx | Female | 1 | 9,436 | 10.6 | 7.5 | 0.0 | 0.070 | 12 | 4,467,411 | 0.3 |
| Leukemia | Total | 1 | 19,116 | 5.2 | 3.2 | 2.3 | 0.661 | 659 | 8,969,599 | 7.3 |
| Leukemia | Male | 1 | 9,680 | 10.3 | 5.9 | 1.4 | 1.000 | 385 | 4,502,188 | 8.6 |
| Leukemia | Female | - | 9,436 | - | - | 0.9 | 0.811 | 274 | 4,467,411 | 6.1 |
| Liver and Bile Duct | Total | 2 | 19,116 | 10.5 | 6.6 | 2.0 | 1.000 | 601 | 8,969,599 | 6.7 |
| Liver and Bile Duct | Male | 2 | 9,680 | 20.7 | 12.4 | 1.4 | 0.850 | 406 | 4,502,188 | 9.0 |
| Liver and Bile Duct | Female | - | 9,436 | - | - | 0.6 | 1.000 | 195 | 4,467,411 | 4.4 |
| Lung and Bronchus | Total | 13 | 19,116 | 68.0 | 41.3 | 10.3 | 0.482 | 2,948 | 8,969,599 | 32.9 |
| Lung and Bronchus | Male | 6 | 9,680 | 62.0 | 35.5 | 5.8 | 1.000 | 1,550 | 4,502,188 | 34.4 |
| Lung and Bronchus | Female | 7 | 9,436 | 74.2 | 47.7 | 4.6 | 0.362 | 1,398 | 4,467,411 | 31.3 |
| Melanoma of the Skin | Total | - | 19,116 | - | - | 1.0 | 0.768 | 289 | 8,969,599 | 3.2 |
| Melanoma of the Skin | Male | - | 9,680 | - | - | 0.7 | 1.000 | 192 | 4,502,188 | 4.3 |
| Melanoma of the Skin | Female | - | 9,436 | - | - | 0.3 | 1.000 | 97 | 4,467,411 | 2.2 |
| Myeloma | Total | 3 | 19,116 | 15.7 | 9.2 | 1.2 | 0.238 | 328 | 8,969,599 | 3.7 |
| Myeloma | Male | 3 | 9,680 | 31.0 | 16.8 | 0.8 | 0.085 | 193 | 4,502,188 | 4.3 |
| Myeloma | Female | - | 9,436 | - | - | 0.5 | 1.000 | 135 | 4,467,411 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 2 | 19,116 | 10.5 | 6.3 | 2.0 | 1.000 | 567 | 8,969,599 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 2 | 9,680 | 20.7 | 11.9 | 1.1 | 0.628 | 305 | 4,502,188 | 6.8 |
| Non-Hodgkin Lymphoma | Female | - | 9,436 | - | - | 0.9 | 0.831 | 262 | 4,467,411 | 5.9 |
| Oral Cavity and Pharynx | Total | 2 | 19,116 | 10.5 | 6.7 | 0.9 | 0.442 | 264 | 8,969,599 | 2.9 |
| Oral Cavity and Pharynx | Male | 2 | 9,680 | 20.7 | 12.5 | 0.7 | 0.284 | 185 | 4,502,188 | 4.1 |
| Oral Cavity and Pharynx | Female | - | 9,436 | - | - | 0.2 | 1.000 | 79 | 4,467,411 | 1.8 |
| Ovary | Female | 1 | 9,436 | 10.6 | 7.1 | 1.1 | 1.000 | 349 | 4,467,411 | 7.8 |
| Pancreas | Total | 2 | 19,116 | 10.5 | 6.5 | 4.1 | 0.452 | 1,188 | 8,969,599 | 13.2 |
| Pancreas | Male | 2 | 9,680 | 20.7 | 12.1 | 2.3 | 1.000 | 640 | 4,502,188 | 14.2 |
| Pancreas | Female | - | 9,436 | - | - | 1.8 | 0.340 | 548 | 4,467,411 | 12.3 |
| Prostate | Male | 5 | 9,680 | 51.7 | 27.4 | 3.8 | 0.675 | 944 | 4,502,188 | 21.0 |
| Stomach | Total | 1 | 19,116 | 5.2 | 3.4 | 0.6 | 0.945 | 197 | 8,969,599 | 2.2 |
| Stomach | Male | - | 9,680 | - | - | 0.4 | 1.000 | 121 | 4,502,188 | 2.7 |
| Stomach | Female | 1 | 9,436 | 10.6 | 7.5 | 0.2 | 0.405 | 76 | 4,467,411 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ )
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Lewis County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 85.7\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) Cancer Screening | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 9.1\% |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | . |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 (2018, 2020) | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% | . |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) Tobacco Use | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | . |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 31.5\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 23.5\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 70.8\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 15.6\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 16.7\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^30]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged 50-75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# LINCOLN COUNTY CANCPR PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 112 cases of invasive cancer were diagnosed among Lincoln County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Lincoln County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Lincoln <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 112 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 15 | 6,687 |
| Prostate | 20 | 6,417 |
| Lung \& Bronchus | 20 | 4,887 |
| Colorectal | 3 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Lincoln County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Lincoln County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Lincoln County was 419.4 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (520.3) gives an estimate of the relative burden of disease in Lincoln County.

The age- and sex-adjusted incidence rate of invasive cancer in Lincoln County, all sites combined, was 457.7 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Lincoln County (112) than expected (127.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 40 Lincoln County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Lincoln County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Lincoln <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 216 | 77,431 |
| Cancer Deaths | 40 | 15,121 |
| \% of All Deaths | $18.5 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 12 | 2,961 |
| Colorectal | 2 | 1,319 |
| Pancreas | 1 | 1,190 |
| Female Breast | 2 | 1,086 |
| Prostate | 3 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Lincoln County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Lincoln County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Lincoln County, all sites combined, was 165.1 deaths per 100,000 persons per year during 2017-2021, compared with 168.3 for the remainder of the state. There were fewer cancer deaths in Lincoln County (40) than expected (40.8) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020 COMPARISON BETWEEN LINCOLN COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Lincoln County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person Years | Crude <br> Rate (1) | A.A.I. <br> Rate (1,2) | Expected <br> Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 112 | 26,708 | 419.4 | 457.7 | 127.3 | 0.186 | 45,498 | 8,745,120 | 520.3 |
| All Sites Combined | Male | 59 | 13,835 | 426.5 | 452.5 | 72.1 | 0.132 | 24,230 | 4,383,075 | 552.8 |
| All Sites Combined | Female | 53 | 12,873 | 411.7 | 459.7 | 56.2 | 0.733 | 21,268 | 4,362,045 | 487.6 |
| Bladder | Total | 5 | 26,708 | 18.7 | 21.0 | 5.9 | 0.916 | 2,179 | 8,745,120 | 24.9 |
| Bladder | Male | 4 | 13,835 | 28.9 | 31.0 | 5.1 | 0.831 | 1,747 | 4,383,075 | 39.9 |
| Bladder | Female | 1 | 12,873 | 7.8 | 9.0 | 1.1 | 1.000 | 432 | 4,362,045 | 9.9 |
| Brain - malignant | Total | 1 | 26,708 | 3.7 | 4.0 | 1.8 | 0.925 | 624 | 8,745,120 | 7.1 |
| Brain - malignant | Male | - | 13,835 | - | - | 1.1 | 0.639 | 375 | 4,383,075 | 8.6 |
| Brain - malignant | Female | 1 | 12,873 | 7.8 | 8.4 | 0.7 | 0.986 | 249 | 4,362,045 | 5.7 |
| Brain and other CNS - non-malignant | Total | 2 | 26,708 | 7.5 | 8.0 | 4.0 | 0.464 | 1,422 | 8,745,120 | 16.3 |
| Brain and other CNS - non-malignant | Male | 1 | 13,835 | 7.2 | 7.5 | 1.5 | 1.000 | 479 | 4,383,075 | 10.9 |
| Brain and other CNS - non-malignant | Female | 1 | 12,873 | 7.8 | 8.7 | 2.5 | 0.575 | 943 | 4,362,045 | 21.6 |
| Breast | Total | 16 | 26,708 | 59.9 | 64.3 | 19.1 | 0.561 | 6,730 | 8,745,120 | 77.0 |
| Breast | Male | 1 | 13,835 | 7.2 | 7.6 | 0.2 | 0.319 | 58 | 4,383,075 | 1.3 |
| Breast | Female | 15 | 12,873 | 116.5 | 129.0 | 17.8 | 0.607 | 6,672 | 4,362,045 | 153.0 |
| Breast - in situ | Total | 1 | 26,708 | 3.7 | 4.0 | 3.6 | 0.261 | 1,238 | 8,745,120 | 14.2 |
| Breast - in situ | Male | - | 13,835 | - | - | 0.0 | 1.000 | 5 | 4,383,075 | 0.1 |
| Breast - in situ | Female | 1 | 12,873 | 7.8 | 8.5 | 3.3 | 0.313 | 1,233 | 4,362,045 | 28.3 |
| Cervix | Female | 1 | 12,873 | 7.8 | 8.0 | 0.9 | 1.000 | 303 | 4,362,045 | 6.9 |
| Colorectal | Total | 3 | 26,708 | 11.2 | 12.2 | 9.7 | 0.026 << | 3,448 | 8,745,120 | 39.4 |
| Colorectal | Male | 3 | 13,835 | 21.7 | 22.6 | 5.8 | 0.348 | 1,900 | 4,383,075 | 43.3 |
| Colorectal | Female | - | 12,873 | - | - | 4.0 | 0.035 << | 1,548 | 4,362,045 | 35.5 |
| Corpus Uteri | Female | 4 | 12,873 | 31.1 | 34.2 | 3.6 | 0.950 | 1,326 | 4,362,045 | 30.4 |
| Esophagus | Total | - | 26,708 | - | - | 1.4 | 0.490 | 506 | 8,745,120 | 5.8 |
| Esophagus | Male | - | 13,835 | - | - | 1.3 | 0.564 | 424 | 4,383,075 | 9.7 |
| Esophagus | Female | - | 12,873 | - | - | 0.2 | 1.000 | 82 | 4,362,045 | 1.9 |
| Hodgkin Lymphoma | Total | - | 26,708 | - | - | 0.6 | 1.000 | 210 | 8,745,120 | 2.4 |
| Hodgkin Lymphoma | Male | - | 13,835 | - | - | 0.4 | 1.000 | 118 | 4,383,075 | 2.7 |
| Hodgkin Lymphoma | Female | - | 12,873 | - | - | 0.3 | 1.000 | 92 | 4,362,045 | 2.1 |
| Kidney and Renal Pelvis | Total | 6 | 26,708 | 22.5 | 24.4 | 5.1 | 0.799 | 1,809 | 8,745,120 | 20.7 |
| Kidney and Renal Pelvis | Male | 4 | 13,835 | 28.9 | 30.3 | 3.5 | 0.945 | 1,178 | 4,383,075 | 26.9 |
| Kidney and Renal Pelvis | Female | 2 | 12,873 | 15.5 | 17.5 | 1.7 | 0.985 | 631 | 4,362,045 | 14.5 |
| Larynx | Total | - | 26,708 | - | - | 0.6 | 1.000 | 215 | 8,745,120 | 2.5 |
| Larynx | Male | - | 13,835 | - | - | 0.5 | 1.000 | 160 | 4,383,075 | 3.7 |
| Larynx | Female | - | 12,873 | - 7 | - | 0.1 | 1.000 | 55 | 4,362,045 | 1.3 |
| Leukemia | Total | 2 | 26,708 | 7.5 | 8.2 | 4.6 | 0.336 | 1,629 | 8,745,120 | 18.6 |
| Leukemia | Male | 2 | 13,835 | 14.5 | 15.2 | 3.0 | 0.862 | 987 | 4,383,075 | 22.5 |
| Leukemia | Female | - | 12,873 | - | - | 1.7 | 0.376 | 642 | 4,362,045 | 14.7 |
| Liver and Bile Duct | Total | 2 | 26,708 | 7.5 | 8.2 | 2.3 | 1.000 | 827 | 8,745,120 | 9.5 |
| Liver and Bile Duct | Male | 1 | 13,835 | 7.2 | 7.7 | 1.8 | 0.955 | 589 | 4,383,075 | 13.4 |
| Liver and Bile Duct | Female | 1 | 12,873 | 7.8 | 8.9 | 0.6 | 0.920 | 238 | 4,362,045 | 5.5 |
| Lung and Bronchus | Total | 20 | 26,708 | 74.9 | 84.0 | 13.2 | 0.099 | 4,867 | 8,745,120 | 55.7 |
| Lung and Bronchus | Male | 9 | 13,835 | 65.1 | 70.3 | 7.1 | 0.579 | 2,443 | 4,383,075 | 55.7 |
| Lung and Bronchus | Female | 11 | 12,873 | 85.5 | 99.0 | 6.2 | 0.101 | 2,424 | 4,362,045 | 55.6 |
| Melanoma of the Skin | Total | 6 | 26,708 | 22.5 | 24.3 | 8.3 | 0.556 | 2,936 | 8,745,120 | 33.6 |
| Melanoma of the Skin | Male | 3 | 13,835 | 21.7 | 22.8 | 5.3 | 0.453 | 1,762 | 4,383,075 | 40.2 |
| Melanoma of the Skin | Female | 3 | 12,873 | 23.3 | 25.5 | 3.2 | 1.000 | 1,174 | 4,362,045 | 26.9 |
| Myeloma | Total | - | 26,708 | - | - | 1.9 | 0.287 | 708 | 8,745,120 | 8.1 |
| Myeloma | Male | - | 13,835 | - | - | 1.3 | 0.548 | 441 | 4,383,075 | 10.1 |
| Myeloma | Female | - | 12,873 | - | - | 0.7 | 1.000 | 267 | 4,362,045 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 4 | 26,708 | 15.0 | 16.4 | 5.4 | 0.743 | 1,936 | 8,745,120 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 2 | 13,835 | 14.5 | 15.3 | 3.4 | 0.695 | 1,127 | 4,383,075 | 25.7 |
| Non-Hodgkin Lymphoma | Female | 2 | 12,873 | 15.5 | 17.5 | 2.1 | 1.000 | 809 | 4,362,045 | 18.5 |
| Oral Cavity and Pharynx | Total | 4 | 26,708 | 15.0 | 16.2 | 3.6 | 0.984 | 1,291 | 8,745,120 | 14.8 |
| Oral Cavity and Pharynx | Male | 4 | 13,835 | 28.9 | 30.3 | 2.8 | 0.618 | 932 | 4,383,075 | 21.3 |
| Oral Cavity and Pharynx | Female | - | 12,873 | - | - | 0.9 | 0.778 | 359 | 4,362,045 | 8.2 |
| Ovary | Female | 3 | 12,873 | 23.3 | 25.8 | 1.4 | 0.340 | 530 | 4,362,045 | 12.2 |
| Pancreas | Total | 2 | 26,708 | 7.5 | 8.3 | 3.9 | 0.505 | 1,421 | 8,745,120 | 16.2 |
| Pancreas | Male | 1 | 13,835 | 7.2 | 7.7 | 2.3 | 0.651 | 783 | 4,383,075 | 17.9 |
| Pancreas | Female | 1 | 12,873 | 7.8 | 9.0 | 1.6 | 1.000 | 638 | 4,362,045 | 14.6 |
| Prostate | Male | 20 | 13,835 | 144.6 | 155.1 | 18.8 | 0.845 | 6,397 | 4,383,075 | 145.9 |
| Stomach | Total | 2 | 26,708 | 7.5 | 8.2 | 1.3 | 0.746 | 465 | 8,745,120 | 5.3 |
| Stomach | Male | 1 | 13,835 | 7.2 | 7.6 | 0.9 | 1.000 | 308 | 4,383,075 | 7.0 |
| Stomach | Female | 1 | 12,873 | 7.8 | 8.8 | 0.4 | 0.672 | 157 | 4,362,045 | 3.6 |
| Testis | Male | - | 13,835 | - | - | 0.8 | 0.897 | 265 | 4,383,075 | 6.0 |
| Thyroid | Total | 2 | 26,708 | 7.5 | 7.8 | 3.6 | 0.614 | 1,218 | 8,745,120 | 13.9 |
| Thyroid | Male | - | 13,835 | - | - | 1.1 | 0.677 | 355 | 4,383,075 | 8.1 |
| Thyroid | Female | 2 | 12,873 | 15.5 | 16.2 | 2.4 | 1.000 | 863 | 4,362,045 | 19.8 |
| Pediatric Age 0 to 19 | Total | 1 | 8,431 | 11.9 | 12.0 | 1.4 | 1.000 | 420 | 2,452,092 | 17.1 |
| Pediatric Age 0 to 19 | Male | 1 | 4,353 | 23.0 | 23.2 | 0.8 | 1.000 | 222 | 1,252,157 | 17.7 |
| Pediatric Age 0 to 19 | Female | - | 4,078 | - | - | 0.7 | 1.000 | 198 | 1,199,935 | 16.5 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).
Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN LINCOLN COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Lincoln County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 216 | 26,686 | 809.4 | 885.2 | 210.2 | 0.708 | 77,214 | 8,962,029 | 861.6 |
| All Causes of Death | Male | 116 | 13,829 | 838.8 | 858.0 | 123.1 | 0.561 | 40,940 | 4,498,039 | 910.2 |
| All Causes of Death | Female | 100 | 12,857 | 777.8 | 912.6 | 89.0 | 0.269 | 36,274 | 4,463,990 | 812.6 |
| All Malignant Cancers | Total | 40 | 26,686 | 149.9 | 165.1 | 40.8 | 0.989 | 15,081 | 8,962,029 | 168.3 |
| All Malignant Cancers | Male | 19 | 13,829 | 137.4 | 143.5 | 24.0 | 0.360 | 8,157 | 4,498,039 | 181.3 |
| All Malignant Cancers | Female | 21 | 12,857 | 163.3 | 187.8 | 17.3 | 0.438 | 6,924 | 4,463,990 | 155.1 |
| Bladder | Total |  | 26,686 |  | - | 1.3 | 0.543 | 489 | 8,962,029 | 5.5 |
| Bladder | Male | - | 13,829 | - | - | 1.1 | 0.638 | 378 | 4,498,039 | 8.4 |
| Bladder | Female | - | 12,857 |  | - | 0.3 | 1.000 | 111 | 4,463,990 | 2.5 |
| Brain and Other Nervous System | Total | 2 | 26,686 | 7.5 | 8.0 | 1.4 | 0.815 | 502 | 8,962,029 | 5.6 |
| Brain and Other Nervous System | Male |  | 13,829 |  | - | 0.9 | 0.827 | 298 | 4,498,039 | 6.6 |
| Brain and Other Nervous System | Female | 2 | 12,857 | 15.6 | 17.1 | 0.5 | 0.202 | 204 | 4,463,990 | 4.6 |
| Breast | Total | 2 | 26,686 | 7.5 | 8.1 | 3.0 | 0.837 | 1,100 | 8,962,029 | 12.3 |
| Breast | Male |  | 13,829 |  | - | 0.0 | 1.000 | 16 | 4,498,039 | 0.4 |
| Breast | Female | 2 | 12,857 | 15.6 | 17.6 | 2.8 | 0.961 | 1,084 | 4,463,990 | 24.3 |
| Cervix | Female | - | 12,857 | - | - | 0.2 | 1.000 | 83 | 4,463,990 | 1.9 |
| Colorectal | Total | 2 | 26,686 | 7.5 | 8.2 | 3.6 | 0.605 | 1,317 | 8,962,029 | 14.7 |
| Colorectal | Male | 2 | 13,829 | 14.5 | 15.0 | 2.1 | 1.000 | 717 | 4,498,039 | 15.9 |
| Colorectal | Female | - | 12,857 | - | - | 1.5 | 0.445 | 600 | 4,463,990 | 13.4 |
| Corpus Uteri | Female | - | 12,857 | - | - | 0.4 | 1.000 | 173 | 4,463,990 | 3.9 |
| Esophagus | Total | - | 26,686 |  | - | 1.3 | 0.547 | 477 | 8,962,029 | 5.3 |
| Esophagus | Male | - | 13,829 | - | - | 1.2 | 0.618 | 401 | 4,498,039 | 8.9 |
| Esophagus | Female | - | 12,857 | - | - | 0.2 | 1.000 | 76 | 4,463,990 | 1.7 |
| Hodgkin Lymphoma | Total | - | 26,686 | - | - | 0.1 | 1.000 | 29 | 8,962,029 | 0.3 |
| Hodgkin Lymphoma | Male | - | 13,829 | - | - | 0.0 | 1.000 | 14 | 4,498,039 | 0.3 |
| Hodgkin Lymphoma | Female | - | 12,857 | - | - | 0.0 | 1.000 | 15 | 4,463,990 | 0.3 |
| Kidney | Total | 2 | 26,686 | 7.5 | 8.3 | 1.0 | 0.550 | 383 | 8,962,029 | 4.3 |
| Kidney | Male | 2 | 13,829 | 14.5 | 15.2 | 0.7 | 0.314 | 240 | 4,498,039 | 5.3 |
| Kidney | Female | - | 12,857 | - | - | 0.3 | 1.000 | 143 | 4,463,990 | 3.2 |
| Larynx | Total | - | 26,686 | - | - | 0.2 | 1.000 | 71 | 8,962,029 | 0.8 |
| Larynx | Male | - | 13,829 | - | - | 0.2 | 1.000 | 58 | 4,498,039 | 1.3 |
| Larynx | Female | - | 12,857 | - | - | 0.0 | 1.000 | 13 | 4,463,990 | 0.3 |
| Leukemia | Total | - | 26,686 |  | - | 1.8 | 0.339 | 660 | 8,962,029 | 7.4 |
| Leukemia | Male | - | 13,829 | - | - | 1.1 | 0.638 | 386 | 4,498,039 | 8.6 |
| Leukemia | Female | - | 12,857 | - | - | 0.7 | 1.000 | 274 | 4,463,990 | 6.1 |
| Liver and Bile Duct | Total | 1 | 26,686 | 3.7 | 4.1 | 1.6 | 1.000 | 602 | 8,962,029 | 6.7 |
| Liver and Bile Duct | Male | - | 13,829 | - | - | 1.2 | 0.611 | 408 | 4,498,039 | 9.1 |
| Liver and Bile Duct | Female | 1 | 12,857 | 7.8 | 8.9 | 0.5 | 0.771 | 194 | 4,463,990 | 4.3 |
| Lung and Bronchus | Total | 12 | 26,686 | 45.0 | 50.2 | 7.9 | 0.206 | 2,949 | 8,962,029 | 32.9 |
| Lung and Bronchus | Male | 6 | 13,829 | 43.4 | 46.3 | 4.5 | 0.583 | 1,550 | 4,498,039 | 34.5 |
| Lung and Bronchus | Female | 6 | 12,857 | 46.7 | 54.1 | 3.5 | 0.278 | 1,399 | 4,463,990 | 31.3 |
| Melanoma of the Skin | Total | - | 26,686 |  | - | 0.8 | 0.907 | 289 | 8,962,029 | 3.2 |
| Melanoma of the Skin | Male | - | 13,829 | - | - | 0.6 | 1.000 | 192 | 4,498,039 | 4.3 |
| Melanoma of the Skin | Female | - | 12,857 | - | - | 0.2 | 1.000 | 97 | 4,463,990 | 2.2 |
| Myeloma | Total | - | 26,686 | - | - | 0.9 | 0.833 | 331 | 8,962,029 | 3.7 |
| Myeloma | Male | - | 13,829 | - | - | 0.6 | 1.000 | 196 | 4,498,039 | 4.4 |
| Myeloma | Female | - | 12,857 | - | - | 0.3 | 1.000 | 135 | 4,463,990 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 3 | 26,686 | 11.2 | 12.4 | 1.5 | 0.394 | 566 | 8,962,029 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 2 | 13,829 | 14.5 | 15.1 | 0.9 | 0.454 | 305 | 4,498,039 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 1 | 12,857 | 7.8 | 9.2 | 0.6 | 0.943 | 261 | 4,463,990 | 5.8 |
| Oral Cavity and Pharynx | Total | 1 | 26,686 | 3.7 | 4.1 | 0.7 | 1.000 | 265 | 8,962,029 | 3.0 |
| Oral Cavity and Pharynx | Male | - | 13,829 | - | - | 0.5 | 1.000 | 187 | 4,498,039 | 4.2 |
| Oral Cavity and Pharynx | Female | 1 | 12,857 | 7.8 | 8.8 | 0.2 | 0.359 | 78 | 4,463,990 | 1.7 |
| Ovary | Female | 1 | 12,857 | 7.8 | 8.8 | 0.9 | 1.000 | 349 | 4,463,990 | 7.8 |
| Pancreas | Total | 1 | 26,686 | 3.7 | 4.2 | 3.2 | 0.344 | 1,189 | 8,962,029 | 13.3 |
| Pancreas | Male | - | 13,829 | - | - | 1.9 | 0.311 | 642 | 4,498,039 | 14.3 |
| Pancreas | Female | 1 | 12,857 | 7.8 | 9.0 | 1.4 | 1.000 | 547 | 4,463,990 | 12.3 |
| Prostate | Male | 3 | 13,829 | 21.7 | 22.2 | 2.8 | 1.000 | 946 | 4,498,039 | 21.0 |
| Stomach | Total | 1 | 26,686 | 3.7 | 4.0 | 0.5 | 0.838 | 197 | 8,962,029 | 2.2 |
| Stomach | Male | - | 13,829 | - | - | 0.4 | 1.000 | 121 | 4,498,039 | 2.7 |
| Stomach | Female | 1 | 12,857 | 7.8 | 8.8 | 0.2 | 0.351 | 76 | 4,463,990 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Lincoln County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 76.5\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 11.4\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% |  |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | . |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 17.2\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 25.9\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 69.0\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 18.1\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 14.2\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^31]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and 25.4\% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# MADISON COUNTY CANCPR PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 466 cases of invasive cancer were diagnosed among Madison County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Madison County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Madison <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 466 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 72 | 6,687 |
| Prostate | 15 | 6,417 |
| Lung \& Bronchus | 35 | 4,887 |
| Colorectal | 3,451 |  |

Table 3 (Cancer Incidence 2016-2020, Comparison between Madison County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Madison County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Madison County was 234.6 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (526.6) gives an estimate of the relative burden of disease in Madison County.

The age- and sex-adjusted incidence rate of invasive cancer in Madison County, all sites combined, was 469.7 cases per 100,000 persons per year during 2016-2020. There were statistically significantly fewer cases of cancer in Madison County (466) than expected (522.4) based upon rates in the remainder of the state $(p=.013)$.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 112 Madison County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Madison County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Madison <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 911 | 77,431 |
| Cancer Deaths | 112 | 15,121 |
| \% of All Deaths | $12.3 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 8 | 2,961 |
| Colorectal | 11 | 1,319 |
| Pancreas | 11 | 1,190 |
| Female Breast | 11 | 1,086 |
| Prostate | 10 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Madison County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Madison County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Madison County, all sites combined, was 110.8 deaths per 100,000 persons per year during 2017-2021, compared with 171.0 for the remainder of the state. There were statistically significantly fewer cancer deaths in Madison County (112) than expected (172.9) based upon rates in the remainder of the state ( $p<.001$ ).

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020 COMPARISON BETWEEN MADISON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Madison County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 466 | 198,625 | 234.6 | 469.7 | 522.4 | 0.013 << | 45,144 | 8,573,203 | 526.6 |
| All Sites Combined | Male | 233 | 100,762 | 231.2 | 482.4 | 270.4 | 0.022 << | 24,056 | 4,296,148 | 559.9 |
| All Sites Combined | Female | 233 | 97,863 | 238.1 | 458.1 | 250.8 | 0.274 | 21,088 | 4,277,055 | 493.0 |
| Bladder | Total | 10 | 198,625 | 5.0 | 11.1 | 22.8 | 0.004 << | 2,174 | 8,573,203 | 25.4 |
| Bladder | Male | 8 | 100,762 | 7.9 | 18.0 | 18.0 | 0.014 << | 1,743 | 4,296,148 | 40.6 |
| Bladder | Female | 2 | 97,863 | 2.0 | 4.3 | 4.6 | 0.318 | 431 | 4,277,055 | 10.1 |
| Brain - malignant | Total | 8 | 198,625 | 4.0 | 6.4 | 9.0 | 0.916 | 617 | 8,573,203 | 7.2 |
| Brain - malignant | Male | 5 | 100,762 | 5.0 | 7.9 | 5.4 | 1.000 | 370 | 4,296,148 | 8.6 |
| Brain - malignant | Female | 3 | 97,863 | 3.1 | 4.9 | 3.6 | 1.000 | 247 | 4,277,055 | 5.8 |
| Brain and other CNS - non-malignant | Total | 22 | 198,625 | 11.1 | 20.2 | 17.8 | 0.379 | 1,402 | 8,573,203 | 16.4 |
| Brain and other CNS - non-malignant | Male | 7 | 100,762 | 6.9 | 12.3 | 6.3 | 0.870 | 473 | 4,296,148 | 11.0 |
| Brain and other CNS - non-malignant | Female | 15 | 97,863 | 15.3 | 28.0 | 11.6 | 0.393 | 929 | 4,277,055 | 21.7 |
| Breast | Total | 74 | 198,625 | 37.3 | 77.0 | 74.8 | 0.988 | 6,672 | 8,573,203 | 77.8 |
| Breast | Male | 2 | 100,762 | 2.0 | 4.4 | 0.6 | 0.246 | 57 | 4,296,148 | 1.3 |
| Breast | Female | 72 | 97,863 | 73.6 | 149.0 | 74.8 | 0.808 | 6,615 | 4,277,055 | 154.7 |
| Breast - in situ | Total | 7 | 198,625 | 3.5 | 7.4 | 13.7 | 0.076 | 1,232 | 8,573,203 | 14.4 |
| Breast - in situ | Male | - | 100,762 | - | - | 0.1 | 1.000 | 5 | 4,296,148 | 0.1 |
| Breast - in situ | Female | 7 | 97,863 | 7.2 | 14.6 | 13.7 | 0.073 | 1,227 | 4,277,055 | 28.7 |
| Cervix | Female | 4 | 97,863 | 4.1 | 6.8 | 4.1 | 1.000 | 300 | 4,277,055 | 7.0 |
| Colorectal | Total | 35 | 198,625 | 17.6 | 35.8 | 39.0 | 0.591 | 3,416 | 8,573,203 | 39.8 |
| Colorectal | Male | 15 | 100,762 | 14.9 | 31.3 | 21.1 | 0.218 | 1,888 | 4,296,148 | 43.9 |
| Colorectal | Female | 20 | 97,863 | 20.4 | 40.1 | 17.8 | 0.666 | 1,528 | 4,277,055 | 35.7 |
| Corpus Uteri | Female | 17 | 97,863 | 17.4 | 35.7 | 14.6 | 0.601 | 1,313 | 4,277,055 | 30.7 |
| Esophagus | Total | 2 | 198,625 | 1.0 | 2.2 | 5.4 | 0.192 | 504 | 8,573,203 | 5.9 |
| Esophagus | Male | 1 | 100,762 | 1.0 | 2.2 | 4.5 | 0.125 | 423 | 4,296,148 | 9.8 |
| Esophagus | Female | 1 | 97,863 | 1.0 | 2.2 | 0.9 | 1.000 | 81 | 4,277,055 | 1.9 |
| Hodgkin Lymphoma | Total | 1 | 198,625 | 0.5 | 0.5 | 5.2 | 0.070 | 209 | 8,573,203 | 2.4 |
| Hodgkin Lymphoma | Male | - | 100,762 | - | - | 2.6 | 0.142 | 118 | 4,296,148 | 2.7 |
| Hodgkin Lymphoma | Female | 1 | 97,863 | 1.0 | 0.8 | 2.6 | 0.551 | 91 | 4,277,055 | 2.1 |
| Kidney and Renal Pelvis | Total | 14 | 198,625 | 7.0 | 14.4 | 20.4 | 0.179 | 1,801 | 8,573,203 | 21.0 |
| Kidney and Renal Pelvis | Male | 9 | 100,762 | 8.9 | 18.8 | 13.0 | 0.325 | 1,173 | 4,296,148 | 27.3 |
| Kidney and Renal Pelvis | Female | 5 | 97,863 | 5.1 | 10.1 | 7.3 | 0.528 | 628 | 4,277,055 | 14.7 |
| Larynx | Total | 2 | 198,625 | 1.0 | 2.0 | 2.4 | 1.000 | 213 | 8,573,203 | 2.5 |
| Larynx | Male | 2 | 100,762 | 2.0 | 4.4 | 1.7 | 0.992 | 158 | 4,296,148 | 3.7 |
| Larynx | Female | - | 97,863 | - | - | 0.7 | 0.950 | 55 | 4,277,055 | 1.3 |
| Leukemia | Total | 17 | 198,625 | 8.6 | 15.4 | 20.7 | 0.488 | 1,614 | 8,573,203 | 18.8 |
| Leukemia | Male | 11 | 100,762 | 10.9 | 20.4 | 12.3 | 0.855 | 978 | 4,296,148 | 22.8 |
| Leukemia | Female | 6 | 97,863 | 6.1 | 10.5 | 8.5 | 0.517 | 636 | 4,277,055 | 14.9 |
| Liver and Bile Duct | Total | 6 | 198,625 | 3.0 | 6.4 | 9.0 | 0.417 | 823 | 8,573,203 | 9.6 |
| Liver and Bile Duct | Male | 4 | 100,762 | 4.0 | 8.8 | 6.2 | 0.510 | 586 | 4,296,148 | 13.6 |
| Liver and Bile Duct | Female | 2 | 97,863 | 2.0 | 4.1 | 2.7 | 0.990 | 237 | 4,277,055 | 5.5 |
| Lung and Bronchus | Total | 15 | 198,625 | 7.6 | 16.7 | 51.2 | 0.000 << | 4,872 | 8,573,203 | 56.8 |
| Lung and Bronchus | Male | 5 | 100,762 | 5.0 | 11.3 | 25.2 | 0.000 << | 2,447 | 4,296,148 | 57.0 |
| Lung and Bronchus | Female | 10 | 97,863 | 10.2 | 21.9 | 25.9 | 0.001 << | 2,425 | 4,277,055 | 56.7 |
| Melanoma of the Skin | Total | 29 | 198,625 | 14.6 | 27.9 | 35.3 | 0.325 | 2,913 | 8,573,203 | 34.0 |
| Melanoma of the Skin | Male | 16 | 100,762 | 15.9 | 32.6 | 20.0 | 0.447 | 1,749 | 4,296,148 | 40.7 |
| Melanoma of the Skin | Female | 13 | 97,863 | 13.3 | 23.4 | 15.1 | 0.703 | 1,164 | 4,277,055 | 27.2 |
| Myeloma | Total | 7 | 198,625 | 3.5 | 7.7 | 7.4 | 1.000 | 701 | 8,573,203 | 8.2 |
| Myeloma | Male | 3 | 100,762 | 3.0 | 6.7 | 4.6 | 0.666 | 438 | 4,296,148 | 10.2 |
| Myeloma | Female | 4 | 97,863 | 4.1 | 8.7 | 2.8 | 0.630 | 263 | 4,277,055 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 23 | 198,625 | 11.6 | 22.1 | 23.2 | 1.000 | 1,917 | 8,573,203 | 22.4 |
| Non-Hodgkin Lymphoma | Male | 15 | 100,762 | 14.9 | 28.5 | 13.6 | 0.783 | 1,114 | 4,296,148 | 25.9 |
| Non-Hodgkin Lymphoma | Female | 8 | 97,863 | 8.2 | 15.7 | 9.6 | 0.770 | 803 | 4,277,055 | 18.8 |
| Oral Cavity and Pharynx | Total | 8 | 198,625 | 4.0 | 8.5 | 14.1 | 0.118 | 1,287 | 8,573,203 | 15.0 |
| Oral Cavity and Pharynx | Male | 6 | 100,762 | 6.0 | 13.0 | 10.0 | 0.262 | 930 | 4,296,148 | 21.6 |
| Oral Cavity and Pharynx | Female | 2 | 97,863 | 2.0 | 4.1 | 4.0 | 0.469 | 357 | 4,277,055 | 8.3 |
| Ovary | Female | 7 | 97,863 | 7.2 | 13.2 | 6.5 | 0.952 | 526 | 4,277,055 | 12.3 |
| Pancreas | Total | 16 | 198,625 | 8.1 | 17.5 | 15.0 | 0.872 | 1,407 | 8,573,203 | 16.4 |
| Pancreas | Male | 11 | 100,762 | 10.9 | 24.3 | 8.2 | 0.399 | 773 | 4,296,148 | 18.0 |
| Pancreas | Female | 5 | 97,863 | 5.1 | 10.8 | 6.9 | 0.637 | 634 | 4,277,055 | 14.8 |
| Prostate | Male | 70 | 100,762 | 69.5 | 158.5 | 65.3 | 0.589 | 6,347 | 4,296,148 | 147.7 |
| Stomach | Total | 2 | 198,625 | 1.0 | 2.1 | 5.2 | 0.223 | 465 | 8,573,203 | 5.4 |
| Stomach | Male | 2 | 100,762 | 2.0 | 4.3 | 3.3 | 0.722 | 307 | 4,296,148 | 7.1 |
| Stomach | Female | - | 97,863 | - | - | 1.8 | 0.320 | 158 | 4,277,055 | 3.7 |
| Testis | Male | 10 | 100,762 | 9.9 | 7.9 | 7.5 | 0.458 | 255 | 4,296,148 | 5.9 |
| Thyroid | Total | 40 | 198,625 | 20.1 | 27.0 | 20.4 | 0.000 >> | 1,180 | 8,573,203 | 13.8 |
| Thyroid | Male | 10 | 100,762 | 9.9 | 15.5 | 5.2 | 0.078 | 345 | 4,296,148 | 8.0 |
| Thyroid | Female | 30 | 97,863 | 30.7 | 39.3 | 14.9 | 0.001 >> | 835 | 4,277,055 | 19.5 |
| Pediatric Age 0 to 19 | Total | 8 | 68,037 | 11.8 | 10.8 | 12.8 | 0.217 | 413 | 2,392,486 | 17.3 |
| Pediatric Age 0 to 19 | Male | 4 | 31,564 | 12.7 | 11.9 | 6.0 | 0.571 | 219 | 1,224,946 | 17.9 |
| Pediatric Age 0 to 19 | Female | 4 | 36,473 | 11.0 | 9.5 | 7.0 | 0.341 | 194 | 1,167,540 | 16.6 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ )

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN MADISON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Madison County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 911 | 213,395 | 426.9 | 822.6 | 965.7 | 0.079 | 76,519 | 8,775,320 | 872.0 |
| All Causes of Death | Male | 457 | 108,581 | 420.9 | 792.6 | 531.6 | 0.001 << | 40,599 | 4,403,287 | 922.0 |
| All Causes of Death | Female | 454 | 104,814 | 433.1 | 859.0 | 434.2 | 0.355 | 35,920 | 4,372,033 | 821.6 |
| All Malignant Cancers | Total | 112 | 213,395 | 52.5 | 110.8 | 172.9 | 0.000 << | 15,009 | 8,775,320 | 171.0 |
| All Malignant Cancers | Male | 59 | 108,581 | 54.3 | 117.1 | 92.9 | $0.000 \ll$ | 8,117 | 4,403,287 | 184.3 |
| All Malignant Cancers | Female | 53 | 104,814 | 50.6 | 104.6 | 79.9 | 0.002 << | 6,892 | 4,372,033 | 157.6 |
| Bladder | Total | 6 | 213,395 | 2.8 | 6.1 | 5.4 | 0.901 | 483 | 8,775,320 | 5.5 |
| Bladder | Male | 6 | 108,581 | 5.5 | 12.3 | 4.1 | 0.474 | 372 | 4,403,287 | 8.4 |
| Bladder | Female | - | 104,814 | - |  | 1.2 | 0.581 | 111 | 4,372,033 | 2.5 |
| Brain and Other Nervous System | Total | 5 | 213,395 | 2.3 | 4.2 | 6.7 | 0.678 | 499 | 8,775,320 | 5.7 |
| Brain and Other Nervous System | Male | 3 | 108,581 | 2.8 | 4.9 | 4.1 | 0.831 | 295 | 4,403,287 | 6.7 |
| Brain and Other Nervous System | Female | 2 | 104,814 | 1.9 | 3.6 | 2.6 | 1.000 | 204 | 4,372,033 | 4.7 |
| Breast | Total | 12 | 213,395 | 5.6 | 11.9 | 12.6 | 1.000 | 1,090 | 8,775,320 | 12.4 |
| Breast | Male | 1 | 108,581 | 0.9 | 2.0 | 0.2 | 0.311 | 15 | 4,403,287 | 0.3 |
| Breast | Female | 11 | 104,814 | 10.5 | 21.7 | 12.5 | 0.816 | 1,075 | 4,372,033 | 24.6 |
| Cervix | Female | - | 104,814 | - | - | 1.1 | 0.642 | 83 | 4,372,033 | 1.9 |
| Colorectal | Total | 11 | 213,395 | 5.2 | 10.9 | 15.1 | 0.359 | 1,308 | 8,775,320 | 14.9 |
| Colorectal | Male | 5 | 108,581 | 4.6 | 9.9 | 8.2 | 0.344 | 714 | 4,403,287 | 16.2 |
| Colorectal | Female | 6 | 104,814 | 5.7 | 11.9 | 6.8 | 0.945 | 594 | 4,372,033 | 13.6 |
| Corpus Uteri | Female | - | 104,814 | - | - | 2.0 | 0.282 | 173 | 4,372,033 | 4.0 |
| Esophagus | Total | 3 | 213,395 | 1.4 | 3.0 | 5.3 | 0.440 | 474 | 8,775,320 | 5.4 |
| Esophagus | Male | 3 | 108,581 | 2.8 | 6.1 | 4.4 | 0.705 | 398 | 4,403,287 | 9.0 |
| Esophagus | Female | - | 104,814 | - | - | 0.9 | 0.842 | 76 | 4,372,033 | 1.7 |
| Hodgkin Lymphoma | Total | - | 213,395 |  | - | 0.5 | 1.000 | 29 | 8,775,320 | 0.3 |
| Hodgkin Lymphoma | Male | - | 108,581 | - | - | 0.3 | 1.000 | 14 | 4,403,287 | 0.3 |
| Hodgkin Lymphoma | Female | - | 104,814 | - | - | 0.2 | 1.000 | 15 | 4,372,033 | 0.3 |
| Kidney | Total | 2 | 213,395 | 0.9 | 2.0 | 4.3 | 0.393 | 383 | 8,775,320 | 4.4 |
| Kidney | Male | 1 | 108,581 | 0.9 | 2.0 | 2.7 | 0.497 | 241 | 4,403,287 | 5.5 |
| Kidney | Female | 1 | 104,814 | 1.0 | 2.0 | 1.6 | 1.000 | 142 | 4,372,033 | 3.2 |
| Larynx | Total | - | 213,395 | - | - | 0.8 | 0.890 | 71 | 8,775,320 | 0.8 |
| Larynx | Male | - | 108,581 | - | - | 0.7 | 1.000 | 58 | 4,403,287 | 1.3 |
| Larynx | Female | - | 104,814 | - | - | 0.1 | 1.000 | 13 | 4,372,033 | 0.3 |
| Leukemia | Total | 10 | 213,395 | 4.7 | 9.3 | 8.0 | 0.557 | 650 | 8,775,320 | 7.4 |
| Leukemia | Male | 7 | 108,581 | 6.4 | 12.8 | 4.7 | 0.396 | 379 | 4,403,287 | 8.6 |
| Leukemia | Female | 3 | 104,814 | 2.9 | 5.7 | 3.3 | 1.000 | 271 | 4,372,033 | 6.2 |
| Liver and Bile Duct | Total | 5 | 213,395 | 2.3 | 5.1 | 6.7 | 0.671 | 598 | 8,775,320 | 6.8 |
| Liver and Bile Duct | Male | 3 | 108,581 | 2.8 | 6.1 | 4.5 | 0.675 | 405 | 4,403,287 | 9.2 |
| Liver and Bile Duct | Female | 2 | 104,814 | 1.9 | 4.0 | 2.2 | 1.000 | 193 | 4,372,033 | 4.4 |
| Lung and Bronchus | Total | 8 | 213,395 | 3.7 | 8.2 | 32.9 | 0.000 << | 2,953 | 8,775,320 | 33.7 |
| Lung and Bronchus | Male | 2 | 108,581 | 1.8 | 4.1 | 17.1 | $0.000 \ll$ | 1,554 | 4,403,287 | 35.3 |
| Lung and Bronchus | Female | 6 | 104,814 | 5.7 | 12.1 | 15.8 | $0.009 \ll$ | 1,399 | 4,372,033 | 32.0 |
| Melanoma of the Skin | Total | 1 | 213,395 | 0.5 | 1.0 | 3.4 | 0.286 | 288 | 8,775,320 | 3.3 |
| Melanoma of the Skin | Male | - | 108,581 | - | - | 2.2 | 0.217 | 192 | 4,403,287 | 4.4 |
| Melanoma of the Skin | Female | 1 | 104,814 | 1.0 | 1.8 | 1.2 | 1.000 | 96 | 4,372,033 | 2.2 |
| Myeloma | Total | 6 | 213,395 | 2.8 | 6.1 | 3.6 | 0.318 | 325 | 8,775,320 | 3.7 |
| Myeloma | Male | 4 | 108,581 | 3.7 | 8.3 | 2.1 | 0.328 | 192 | 4,403,287 | 4.4 |
| Myeloma | Female | 2 | 104,814 | 1.9 | 4.0 | 1.5 | 0.887 | 133 | 4,372,033 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 3 | 213,395 | 1.4 | 2.9 | 6.6 | 0.208 | 566 | 8,775,320 | 6.4 |
| Non-Hodgkin Lymphoma | Male | 2 | 108,581 | 1.8 | 3.8 | 3.6 | 0.590 | 305 | 4,403,287 | 6.9 |
| Non-Hodgkin Lymphoma | Female | 1 | 104,814 | 1.0 | 2.0 | 3.0 | 0.407 | 261 | 4,372,033 | 6.0 |
| Oral Cavity and Pharynx | Total | - | 213,395 | - | - | 3.0 | 0.100 | 266 | 8,775,320 | 3.0 |
| Oral Cavity and Pharynx | Male | - | 108,581 | - | - | 2.1 | 0.251 | 187 | 4,403,287 | 4.2 |
| Oral Cavity and Pharynx | Female | - | 104,814 | - | - | 0.9 | 0.807 | 79 | 4,372,033 | 1.8 |
| Ovary | Female | 6 | 104,814 | 5.7 | 12.0 | 3.9 | 0.408 | 344 | 4,372,033 | 7.9 |
| Pancreas | Total | 11 | 213,395 | 5.2 | 11.2 | 13.2 | 0.665 | 1,179 | 8,775,320 | 13.4 |
| Pancreas | Male | 5 | 108,581 | 4.6 | 10.3 | 7.1 | 0.587 | 637 | 4,403,287 | 14.5 |
| Pancreas | Female | 6 | 104,814 | 5.7 | 12.1 | 6.1 | 1.000 | 542 | 4,372,033 | 12.4 |
| Prostate | Male | 10 | 108,581 | 9.2 | 20.5 | 10.4 | 1.000 | 939 | 4,403,287 | 21.3 |
| Stomach | Total | 1 | 213,395 | 0.5 | 1.0 | 2.3 | 0.667 | 197 | 8,775,320 | 2.2 |
| Stomach | Male | 1 | 108,581 | 0.9 | 2.0 | 1.4 | 1.000 | 120 | 4,403,287 | 2.7 |
| Stomach | Female | - | 104,814 | - | - | 0.9 | 0.802 | 77 | 4,372,033 | 1.8 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Madison County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 89.9\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 11.0\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 70.5\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% | 66.8\% |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 62.0\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 5.4\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 36.2\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 84.5\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 21.3\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 15.2\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to 64.8\% of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^32]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged $50-74$ reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# MINIDOKA COUNTY CANCER PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 509 cases of invasive cancer were diagnosed among Minidoka County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Minidoka County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Minidoka <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 509 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 63 | 6,687 |
| Prostate | 42 | 6,417 |
| Lung \& Bronchus | 48 | 4,887 |
| Colorectal | 3,451 |  |

Table 3 (Cancer Incidence 2016-2020, Comparison between Minidoka County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Minidoka County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Minidoka County was 489.0 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (520.3) gives an estimate of the relative burden of disease in Minidoka County.

The age- and sex-adjusted incidence rate of invasive cancer in Minidoka County, all sites combined, was 484.8 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Minidoka County (509) than expected (546.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 178 Minidoka County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Minidoka County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Minidoka <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 1,051 | 77,431 |
| Cancer Deaths | 178 | 15,121 |
| \% of All Deaths | $16.9 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 19 | 2,961 |
| Colorectal | 17 | 1,319 |
| Pancreas | 16 | 1,190 |
| Female Breast | 12 | 1,086 |
| Prostate | 15 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Minidoka County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Minidoka County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Minidoka County, all sites combined, was 160.7 deaths per 100,000 persons per year during 2017-2021, compared with 168.2 for the remainder of the state. There were fewer cancer deaths in Minidoka County (178) than expected (186.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020 COMPARISON BETWEEN MINIDOKA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

|  |  | Minidoka County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person Years | Crude <br> Rate (1) | A.A.I. <br> Rate (1,2) | $\begin{aligned} & \text { Expected } \\ & \text { Cases (3) } \end{aligned}$ | P-Value (4) | Observed Cases | Person Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 509 | 104,085 | 489.0 | 484.8 | 546.3 | 0.113 | 45,101 | 8,667,743 | 520.3 |
| All Sites Combined | Male | 278 | 52,090 | 533.7 | 527.1 | 291.5 | 0.450 | 24,011 | 4,344,820 | 552.6 |
| All Sites Combined | Female | 231 | 51,995 | 444.3 | 443.4 | 254.2 | 0.152 | 21,090 | 4,322,923 | 487.9 |
| Bladder | Total | 29 | 104,085 | 27.9 | 26.6 | 27.1 | 0.765 | 2,155 | 8,667,743 | 24.9 |
| Bladder | Male | 23 | 52,090 | 44.2 | 42.3 | 21.6 | 0.828 | 1,728 | 4,344,820 | 39.8 |
| Bladder | Female | 6 | 51,995 | 11.5 | 11.1 | 5.4 | 0.895 | 427 | 4,322,923 | 9.9 |
| Brain - malignant | Total | 11 | 104,085 | 10.6 | 10.5 | 7.4 | 0.257 | 614 | 8,667,743 | 7.1 |
| Brain - malignant | Male | 10 | 52,090 | 19.2 | 19.3 | 4.3 | 0.028 >> | 365 | 4,344,820 | 8.4 |
| Brain - malignant | Female | 1 | 51,995 | 1.9 | 1.9 | 3.0 | 0.384 | 249 | 4,322,923 | 5.8 |
| Brain and other CNS - non-malignant | Total | 20 | 104,085 | 19.2 | 19.1 | 17.0 | 0.524 | 1,404 | 8,667,743 | 16.2 |
| Brain and other CNS - non-malignant | Male | 5 | 52,090 | 9.6 | 9.5 | 5.7 | 0.976 | 475 | 4,344,820 | 10.9 |
| Brain and other CNS - non-malignant | Female | 15 | 51,995 | 28.8 | 28.7 | 11.2 | 0.325 | 929 | 4,322,923 | 21.5 |
| Breast | Total | 79 | 104,085 | 75.9 | 76.9 | 79.0 | 1.000 | 6,667 | 8,667,743 | 76.9 |
| Breast | Male | 1 | 52,090 | 1.9 | 1.8 | 0.7 | 1.000 | 58 | 4,344,820 | 1.3 |
| Breast | Female | 78 | 51,995 | 150.0 | 153.2 | 77.9 | 1.000 | 6,609 | 4,322,923 | 152.9 |
| Breast - in situ | Total | 15 | 104,085 | 14.4 | 14.9 | 14.2 | 0.898 | 1,224 | 8,667,743 | 14.1 |
| Breast - in situ | Male |  | 52,090 | - |  | 0.1 | 1.000 | 5 | 4,344,820 | 0.1 |
| Breast - in situ | Female | 15 | 51,995 | 28.8 | 30.2 | 14.0 | 0.862 | 1,219 | 4,322,923 | 28.2 |
| Cervix | Female | 5 | 51,995 | 9.6 | 10.4 | 3.3 | 0.485 | 299 | 4,322,923 | 6.9 |
| Colorectal | Total | 48 | 104,085 | 46.1 | 45.3 | 41.6 | 0.360 | 3,403 | 8,667,743 | 39.3 |
| Colorectal | Male | 31 | 52,090 | 59.5 | 58.7 | 22.8 | 0.115 | 1,872 | 4,344,820 | 43.1 |
| Colorectal | Female | 17 | 51,995 | 32.7 | 31.9 | 18.9 | 0.779 | 1,531 | 4,322,923 | 35.4 |
| Corpus Uteri | Female | 24 | 51,995 | 46.2 | 47.4 | 15.3 | 0.047 >> | 1,306 | 4,322,923 | 30.2 |
| Esophagus | Total | 7 | 104,085 | 6.7 | 6.6 | 6.1 | 0.828 | 499 | 8,667,743 | 5.8 |
| Esophagus | Male | 7 | 52,090 | 13.4 | 13.1 | 5.1 | 0.508 | 417 | 4,344,820 | 9.6 |
| Esophagus | Female | - | 51,995 | - |  | 1.0 | 0.725 | 82 | 4,322,923 | 1.9 |
| Hodgkin Lymphoma | Total | 3 | 104,085 | 2.9 | 3.0 | 2.4 | 0.862 | 207 | 8,667,743 | 2.4 |
| Hodgkin Lymphoma | Male | 1 | 52,090 | 1.9 | 2.0 | 1.4 | 1.000 | 117 | 4,344,820 | 2.7 |
| Hodgkin Lymphoma | Female | 2 | 51,995 | 3.8 | 3.9 | 1.1 | 0.569 | 90 | 4,322,923 | 2.1 |
| Kidney and Renal Pelvis | Total | 31 | 104,085 | 29.8 | 29.7 | 21.5 | 0.062 | 1,784 | 8,667,743 | 20.6 |
| Kidney and Renal Pelvis | Male | 20 | 52,090 | 38.4 | 38.3 | 14.0 | 0.149 | 1,162 | 4,344,820 | 26.7 |
| Kidney and Renal Pelvis | Female | 11 | 51,995 | 21.2 | 21.0 | 7.5 | 0.279 | 622 | 4,322,923 | 14.4 |
| Larynx | Total | 6 | 104,085 | 5.8 | 5.7 | 2.5 | 0.090 | 209 | 8,667,743 | 2.4 |
| Larynx | Male | 3 | 52,090 | 5.8 | 5.7 | 1.9 | 0.598 | 157 | 4,344,820 | 3.6 |
| Larynx | Female |  | 51,995 | 5.8 | 5.7 | 0.6 | 0.053 | 52 | 4,322,923 | 1.2 |
| Leukemia | Total | 16 | 104,085 | 15.4 | 14.8 | 20.1 | 0.427 | 1,615 | 8,667,743 | 18.6 |
| Leukemia | Male | 11 | 52,090 | 21.1 | 20.4 | 12.1 | 0.897 | 978 | 4,344,820 | 22.5 |
| Leukemia | Female | 5 | 51,995 | 9.6 | 9.2 | 8.0 | 0.387 | 637 | 4,322,923 | 14.7 |
| Liver and Bile Duct | Total | 3 | 104,085 | 2.9 | 2.9 | 9.9 | 0.022 << | 826 | 8,667,743 | 9.5 |
| Liver and Bile Duct | Male | 3 | 52,090 | 5.8 | 5.8 | 7.0 | 0.159 | 587 | 4,344,820 | 13.5 |
| Liver and Bile Duct | Female | - | 51,995 | - | - | 2.9 | 0.108 | 239 | 4,322,923 | 5.5 |
| Lung and Bronchus | Total | 42 | 104,085 | 40.4 | 39.1 | 60.0 | 0.018 < | 4,845 | 8,667,743 | 55.9 |
| Lung and Bronchus | Male | 25 | 52,090 | 48.0 | 46.8 | 29.9 | 0.431 | 2,427 | 4,344,820 | 55.9 |
| Lung and Bronchus | Female | 17 | 51,995 | 32.7 | 31.6 | 30.1 | 0.014 < | 2,418 | 4,322,923 | 55.9 |
| Melanoma of the Skin | Total | 29 | 104,085 | 27.9 | 27.8 | 35.0 | 0.351 | 2,913 | 8,667,743 | 33.6 |
| Melanoma of the Skin | Male | 19 | 52,090 | 36.5 | 36.0 | 21.2 | 0.736 | 1,746 | 4,344,820 | 40.2 |
| Melanoma of the Skin | Female | 10 | 51,995 | 19.2 | 19.6 | 13.8 | 0.382 | 1,167 | 4,322,923 | 27.0 |
| Myeloma | Total | 7 | 104,085 | 6.7 | 6.5 | 8.7 | 0.731 | 701 | 8,667,743 | 8.1 |
| Myeloma | Male | 4 | 52,090 | 7.7 | 7.5 | 5.4 | 0.753 | 437 | 4,344,820 | 10.1 |
| Myeloma | Female | 3 | 51,995 | 5.8 | 5.6 | 3.3 | 1.000 | 264 | 4,322,923 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 16 | 104,085 | 15.4 | 15.1 | 23.4 | 0.139 | 1,924 | 8,667,743 | 22.2 |
| Non-Hodgkin Lymphoma | Male | 7 | 52,090 | 17.3 | 17.1 | 13.6 | 0.264 | 1,120 | 4,344,820 | 25.8 |
| Non-Hodgkin Lymphoma | Female | 7 | 51,995 | 13.5 | 13.2 | 9.9 | 0.460 | 804 | 4,322,923 | 18.6 |
| Oral Cavity and Pharynx | Total | 12 | 104,085 | 11.5 | 11.6 | 15.3 | 0.483 | 1,283 | 8,667,743 | 14.8 |
| Oral Cavity and Pharynx | Male | 7 | 52,090 | 13.4 | 13.5 | 11.1 | 0.272 | 929 | 4,344,820 | 21.4 |
| Oral Cavity and Pharynx | Female | 5 | 51,995 | 9.6 | 9.6 | 4.2 | 0.839 | 354 | 4,322,923 | 8.2 |
| Ovary | Female | 8 | 51,995 | 15.4 | 15.5 | 6.3 | 0.590 | 525 | 4,322,923 | 12.1 |
| Pancreas | Total | 16 | 104,085 | 15.4 | 14.8 | 17.5 | 0.837 | 1,407 | 8,667,743 | 16.2 |
| Pancreas | Male | 12 | 52,090 | 23.0 | 22.4 | 9.5 | 0.504 | 772 | 4,344,820 | 17.8 |
| Pancreas | Female | 4 | 51,995 | 7.7 | 7.4 | 8.0 | 0.202 | 635 | 4,322,923 | 14.7 |
| Prostate | Male | 63 | 52,090 | 120.9 | 121.5 | 75.8 | 0.151 | 6,354 | 4,344,820 | 146.2 |
| Stomach | Total | 4 | 104,085 | 3.8 | 3.7 | 5.7 | 0.645 | 463 | 8,667,743 | 5.3 |
| Stomach | Male | 1 | 52,090 | 1.9 | 1.9 | 3.8 | 0.218 | 308 | 4,344,820 | 7.1 |
| Stomach | Female | 3 | 51,995 | 5.8 | 5.5 | 1.9 | 0.618 | 155 | 4,322,923 | 3.6 |
| Testis | Male |  | 52,090 | 5.8 | 6.1 | 2.9 | 1.000 | 262 | 4,344,820 | 6.0 |
| Thyroid | Total | 11 | 104,085 | 10.6 | 11.1 | 13.8 | 0.550 | 1,209 | 8,667,743 | 13.9 |
| Thyroid | Male | 6 | 52,090 | 11.5 | 11.9 | 4.1 | 0.449 | 349 | 4,344,820 | 8.0 |
| Thyroid | Female | 5 | 51,995 | 9.6 | 10.2 | 9.7 | 0.157 | 860 | 4,322,923 | 19.9 |
| Pediatric Age 0 to 19 | Total | 3 | 32,401 | 9.3 | 9.3 | 5.5 | 0.397 | 418 | 2,428,122 | 17.2 |
| Pediatric Age 0 to 19 | Male | - | 16,437 | - | - | 3.0 | 0.104 | 223 | 1,240,073 | 18.0 |
| Pediatric Age 0 to 19 | Female | 3 | 15,964 | 18.8 | 19.2 | 2.6 | 0.943 | 195 | 1,188,049 | 16.4 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).
Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN MINIDOKA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Minidoka County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 1,051 | 105,431 | 996.9 | 909.2 | 993.9 | 0.074 | 76,379 | 8,883,284 | 859.8 |
| All Causes of Death | Male | 578 | 52,768 | 1,095.4 | 1,027.7 | 510.5 | 0.004 >> | 40,478 | 4,459,100 | 907.8 |
| All Causes of Death | Female | 473 | 52,663 | 898.2 | 795.3 | 482.6 | 0.683 | 35,901 | 4,424,184 | 811.5 |
| All Malignant Cancers | Total | 178 | 105,431 | 168.8 | 160.7 | 186.3 | 0.574 | 14,943 | 8,883,284 | 168.2 |
| All Malignant Cancers | Male | 107 | 52,768 | 202.8 | 194.3 | 99.6 | 0.486 | 8,069 | 4,459,100 | 181.0 |
| All Malignant Cancers | Female | 71 | 52,663 | 134.8 | 127.8 | 86.3 | 0.104 | 6,874 | 4,424,184 | 155.4 |
| Bladder | Total | 9 | 105,431 | 8.5 | 7.6 | 6.4 | 0.387 | 480 | 8,883,284 | 5.4 |
| Bladder | Male | 7 | 52,768 | 13.3 | 12.0 | 4.9 | 0.439 | 371 | 4,459,100 | 8.3 |
| Bladder | Female | 2 | 52,663 | 3.8 | 3.4 | 1.4 | 0.848 | 109 | 4,424,184 | 2.5 |
| Brain and Other Nervous System | Total | 7 | 105,431 | 6.6 | 6.6 | 5.9 | 0.753 | 497 | 8,883,284 | 5.6 |
| Brain and Other Nervous System | Male | 6 | 52,768 | 11.4 | 11.4 | 3.4 | 0.269 | 292 | 4,459,100 | 6.5 |
| Brain and Other Nervous System | Female | 1 | 52,663 | 1.9 | 1.9 | 2.4 | 0.596 | 205 | 4,424,184 | 4.6 |
| Breast | Total | 12 | 105,431 | 11.4 | 10.9 | 13.5 | 0.824 | 1,090 | 8,883,284 | 12.3 |
| Breast | Male |  | 52,768 |  |  | 0.2 | 1.000 | 16 | 4,459,100 | 0.4 |
| Breast | Female | 12 | 52,663 | 22.8 | 21.9 | 13.3 | 0.860 | 1,074 | 4,424,184 | 24.3 |
| Cervix | Female | 1 | 52,663 | 1.9 | 2.0 | 0.9 | 1.000 | 82 | 4,424,184 | 1.9 |
| Colorectal | Total | 17 | 105,431 | 16.1 | 15.4 | 16.2 | 0.904 | 1,302 | 8,883,284 | 14.7 |
| Colorectal | Male | 9 | 52,768 | 17.1 | 16.6 | 8.6 | 0.987 | 710 | 4,459,100 | 15.9 |
| Colorectal | Female | 8 | 52,663 | 15.2 | 14.1 | 7.6 | 0.971 | 592 | 4,424,184 | 13.4 |
| Corpus Uteri | Female | 1 | 52,663 | 1.9 | 1.9 | 2.1 | 0.766 | 172 | 4,424,184 | 3.9 |
| Esophagus | Total | 3 | 105,431 | 2.8 | 2.8 | 5.8 | 0.345 | 474 | 8,883,284 | 5.3 |
| Esophagus | Male | 3 | 52,768 | 5.7 | 5.6 | 4.8 | 0.589 | 398 | 4,459,100 | 8.9 |
| Esophagus | Female | - | 52,663 | - | - | 1.0 | 0.765 | 76 | 4,424,184 | 1.7 |
| Hodgkin Lymphoma | Total | - | 105,431 |  | - | 0.4 | 1.000 | 29 | 8,883,284 | 0.3 |
| Hodgkin Lymphoma | Male | - | 52,768 | - | - | 0.2 | 1.000 | 14 | 4,459,100 | 0.3 |
| Hodgkin Lymphoma | Female | - | 52,663 | - | - | 0.2 | 1.000 | 15 | 4,424,184 | 0.3 |
| Kidney | Total | 4 | 105,431 | 3.8 | 3.6 | 4.8 | 0.964 | 381 | 8,883,284 | 4.3 |
| Kidney | Male | 3 | 52,768 | 5.7 | 5.5 | 2.9 | 1.000 | 239 | 4,459,100 | 5.4 |
| Kidney | Female | 1 | 52,663 | 1.9 | 1.7 | 1.8 | 0.898 | 142 | 4,424,184 | 3.2 |
| Larynx | Total | 1 | 105,431 | 0.9 | 0.9 | 0.9 | 1.000 | 70 | 8,883,284 | 0.8 |
| Larynx | Male | 1 | 52,768 | 1.9 | 1.8 | 0.7 | 1.000 | 57 | 4,459,100 | 1.3 |
| Larynx | Female | - | 52,663 | - | - | 0.2 | 1.000 | 13 | 4,424,184 | 0.3 |
| Leukemia | Total | 8 | 105,431 | 7.6 | 7.0 | 8.4 | 1.000 | 652 | 8,883,284 | 7.3 |
| Leukemia | Male | 5 | 52,768 | 9.5 | 8.9 | 4.8 | 1.000 | 381 | 4,459,100 | 8.5 |
| Leukemia | Female | 3 | 52,663 | 5.7 | 5.2 | 3.6 | 1.000 | 271 | 4,424,184 | 6.1 |
| Liver and Bile Duct | Total | 8 | 105,431 | 7.6 | 7.5 | 7.1 | 0.846 | 595 | 8,883,284 | 6.7 |
| Liver and Bile Duct | Male | 6 | 52,768 | 11.4 | 11.3 | 4.8 | 0.689 | 402 | 4,459,100 | 9.0 |
| Liver and Bile Duct | Female | 2 | 52,663 | 3.8 | 3.7 | 2.4 | 1.000 | 193 | 4,424,184 | 4.4 |
| Lung and Bronchus | Total | 19 | 105,431 | 18.0 | 17.3 | 36.3 | 0.002 << | 2,942 | 8,883,284 | 33.1 |
| Lung and Bronchus | Male | 10 | 52,768 | 19.0 | 18.5 | 18.8 | 0.041 << | 1,546 | 4,459,100 | 34.7 |
| Lung and Bronchus | Female | 9 | 52,663 | 17.1 | 16.2 | 17.5 | $0.040 \ll$ | 1,396 | 4,424,184 | 31.6 |
| Melanoma of the Skin | Total | 2 | 105,431 | 1.9 | 1.8 | 3.5 | 0.629 | 287 | 8,883,284 | 3.2 |
| Melanoma of the Skin | Male | - | 52,768 | - | - | 2.4 | 0.187 | 192 | 4,459,100 | 4.3 |
| Melanoma of the Skin | Female | 2 | 52,663 | 3.8 | 3.7 | 1.2 | 0.643 | 95 | 4,424,184 | 2.1 |
| Myeloma | Total | 6 | 105,431 | 5.7 | 5.3 | 4.1 | 0.466 | 325 | 8,883,284 | 3.7 |
| Myeloma | Male | 5 | 52,768 | 9.5 | 9.0 | 2.4 | 0.188 | 191 | 4,459,100 | 4.3 |
| Myeloma | Female | 1 | 52,663 | 1.9 | 1.8 | 1.7 | 0.977 | 134 | 4,424,184 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 8 | 105,431 | 7.6 | 7.1 | 7.1 | 0.840 | 561 | 8,883,284 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 5 | 52,768 | 9.5 | 9.1 | 3.7 | 0.640 | 302 | 4,459,100 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 3 | 52,663 | 5.7 | 5.2 | 3.4 | 1.000 | 259 | 4,424,184 | 5.9 |
| Oral Cavity and Pharynx | Total | 1 | 105,431 | 0.9 | 0.9 | 3.2 | 0.339 | 265 | 8,883,284 | 3.0 |
| Oral Cavity and Pharynx | Male | - | 52,768 | - | - | 2.2 | 0.213 | 187 | 4,459,100 | 4.2 |
| Oral Cavity and Pharynx | Female | 1 | 52,663 | 1.9 | 1.8 | 1.0 | 1.000 | 78 | 4,424,184 | 1.8 |
| Ovary | Female | 3 | 52,663 | 5.7 | 5.5 | 4.2 | 0.774 | 347 | 4,424,184 | 7.8 |
| Pancreas | Total | 16 | 105,431 | 15.2 | 14.7 | 14.4 | 0.733 | 1,174 | 8,883,284 | 13.2 |
| Pancreas | Male | 12 | 52,768 | 22.7 | 22.3 | 7.6 | 0.172 | 630 | 4,459,100 | 14.1 |
| Pancreas | Female | 4 | 52,663 | 7.6 | 7.3 | 6.7 | 0.399 | 544 | 4,424,184 | 12.3 |
| Prostate | Male | 15 | 52,768 | 28.4 | 25.7 | 12.2 | 0.496 | 934 | 4,459,100 | 20.9 |
| Stomach | Total | 5 | 105,431 | 4.7 | 4.5 | 2.4 | 0.191 | 193 | 8,883,284 | 2.2 |
| Stomach | Male | 3 | 52,768 | 5.7 | 5.5 | 1.4 | 0.354 | 118 | 4,459,100 | 2.6 |
| Stomach | Female | 2 | 52,663 | 3.8 | 3.6 | 0.9 | 0.491 | 75 | 4,424,184 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Minidoka County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 78.9\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 9.6\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 65.5\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 65.1\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 23.1\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 19.8\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 71.0\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 13.9\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 18.3\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to 64.8\% of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^33]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged $50-74$ reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# NDZ PERCE COUNTY CANCPR PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 1,221 cases of invasive cancer were diagnosed among Nez Perce County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Nez Perce County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Nez Perce <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 1,221 | 45,610 |
| Female Breast | 179 | 6,687 |
| Prostate | 162 | 6,417 |
| Lung \& Bronchus | 184 | 4,887 |
| Colorectal | 99 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Nez Perce County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Nez Perce County. The table also shows the number of observed cases,
person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Nez Perce County was 603.4 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.0) gives an estimate of the relative burden of disease in Nez Perce County.

The age- and sex-adjusted incidence rate of invasive cancer in Nez Perce County, all sites combined, was 503.5 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Nez Perce County $(1,221)$ than expected $(1,256.2)$ based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 502 Nez Perce County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Nez Perce County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Nez Perce <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 2,695 | 77,431 |
| Cancer Deaths | 502 | 15,121 |
| \% of All Deaths | $18.6 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 119 | 2,961 |
| Colorectal | 43 | 1,319 |
| Pancreas | 36 | 1,190 |
| Female Breast | 28 | 1,086 |
| Prostate | 35 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Nez Perce County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Nez Perce County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Nez Perce County, all sites combined, was 189.1 deaths per 100,000 persons per year during 2017-2021, compared with 166.4 for the remainder of the state. There were statistically significantly more cancer deaths in Nez Perce County (502) than expected (441.8) based upon rates in the remainder of the state $(p=.005)$.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020 COMPARISON BETWEEN NEZ PERCE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Nez Perce County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person Years | Crude <br> Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 1,221 | 202,340 | 603.4 | 503.5 | 1,256.2 | 0.328 | 44,389 | 8,569,488 | 518.0 |
| All Sites Combined | Male | 642 | 99,902 | 642.6 | 534.5 | 661.0 | 0.474 | 23,647 | 4,297,008 | 550.3 |
| All Sites Combined | Female | 579 | 102,438 | 565.2 | 475.1 | 591.7 | 0.621 | 20,742 | 4,272,480 | 485.5 |
| Bladder | Total | 52 | 202,340 | 25.7 | 20.1 | 64.4 | 0.130 | 2,132 | 8,569,488 | 24.9 |
| Bladder | Male | 40 | 99,902 | 40.0 | 31.5 | 50.5 | 0.152 | 1,711 | 4,297,008 | 39.8 |
| Bladder | Female | 12 | 102,438 | 11.7 | 9.2 | 12.9 | 0.945 | 421 | 4,272,480 | 9.9 |
| Brain - malignant | Total | 19 | 202,340 | 9.4 | 8.3 | 16.2 | 0.555 | 606 | 8,569,488 | 7.1 |
| Brain - malignant | Male | 12 | 99,902 | 12.0 | 10.7 | 9.5 | 0.491 | 363 | 4,297,008 | 8.4 |
| Brain - malignant | Female | 7 | 102,438 | 6.8 | 5.9 | 6.7 | 1.000 | 243 | 4,272,480 | 5.7 |
| Brain and other CNS - non-malignant | Total | 28 | 202,340 | 13.8 | 11.7 | 38.8 | 0.087 | 1,396 | 8,569,488 | 16.3 |
| Brain and other CNS - non-malignant | Male | 6 | 99,902 | 6.0 | 5.2 | 12.7 | 0.062 | 474 | 4,297,008 | 11.0 |
| Brain and other CNS - non-malignant | Female | 22 | 102,438 | 21.5 | 18.0 | 26.4 | 0.461 | 922 | 4,272,480 | 21.6 |
| Breast | Total | 179 | 202,340 | 88.5 | 76.3 | 179.8 | 0.992 | 6,567 | 8,569,488 | 76.6 |
| Breast | Male |  | 99,902 |  |  | 1.7 | 0.358 | 59 | 4,297,008 | 1.4 |
| Breast | Female | 179 | 102,438 | 174.7 | 150.9 | 180.6 | 0.942 | 6,508 | 4,272,480 | 152.3 |
| Breast - in situ | Total | 31 | 202,340 | 15.3 | 13.6 | 32.0 | 0.949 | 1,208 | 8,569,488 | 14.1 |
| Breast - in situ | Male |  | 99,902 |  |  | 0.1 | 1.000 | 5 | 4,297,008 | 0.1 |
| Breast - in situ | Female | 31 | 102,438 | 30.3 | 27.0 | 32.3 | 0.906 | 1,203 | 4,272,480 | 28.2 |
| Cervix | Female | 4 | 102,438 | 3.9 | 3.8 | 7.4 | 0.278 | 300 | 4,272,480 | 7.0 |
| Colorectal | Total | 99 | 202,340 | 48.9 | 40.3 | 96.0 | 0.786 | 3,352 | 8,569,488 | 39.1 |
| Colorectal | Male | 54 | 99,902 | 54.1 | 45.2 | 51.4 | 0.755 | 1,849 | 4,297,008 | 43.0 |
| Colorectal | Female | 45 | 102,438 | 43.9 | 35.7 | 44.4 | 0.968 | 1,503 | 4,272,480 | 35.2 |
| Corpus Uteri | Female | 33 | 102,438 | 32.2 | 28.0 | 35.7 | 0.727 | 1,297 | 4,272,480 | 30.4 |
| Esophagus | Total | 16 | 202,340 | 7.9 | 6.4 | 14.2 | 0.710 | 490 | 8,569,488 | 5.7 |
| Esophagus | Male | 12 | 99,902 | 12.0 | 9.8 | 11.8 | 1.000 | 412 | 4,297,008 | 9.6 |
| Esophagus | Female | 4 | 102,438 | 3.9 | 3.2 | 2.3 | 0.401 | 78 | 4,272,480 | 1.8 |
| Hodgkin Lymphoma | Total | 3 | 202,340 | 1.5 | 1.4 | 5.1 | 0.515 | 207 | 8,569,488 | 2.4 |
| Hodgkin Lymphoma | Male | 1 | 99,902 | 1.0 | 1.0 | 2.8 | 0.455 | 117 | 4,297,008 | 2.7 |
| Hodgkin Lymphoma | Female | 2 | 102,438 | 2.0 | 1.9 | 2.2 | 1.000 | 90 | 4,272,480 | 2.1 |
| Kidney and Renal Pelvis | Total | 48 | 202,340 | 23.7 | 20.1 | 49.2 | 0.937 | 1,767 | 8,569,488 | 20.6 |
| Kidney and Renal Pelvis | Male | 32 | 99,902 | 32.0 | 27.3 | 31.4 | 0.962 | 1,150 | 4,297,008 | 26.8 |
| Kidney and Renal Pelvis | Female | 16 | 102,438 | 15.6 | 13.2 | 17.6 | 0.829 | 617 | 4,272,480 | 14.4 |
| Larynx | Total | 8 | 202,340 | 4.0 | 3.3 | 5.9 | 0.487 | 207 | 8,569,488 | 2.4 |
| Larynx | Male | 6 | 99,902 | 6.0 | 4.9 | 4.4 | 0.544 | 154 | 4,297,008 | 3.6 |
| Larynx | Female | 2 | 102,438 | 2.0 | 1.6 | 1.5 | 0.895 | 53 | 4,272,480 | 1.2 |
| Leukemia | Total | 36 | 202,340 | 17.8 | 14.7 | 45.7 | 0.165 | 1,595 | 8,569,488 | 18.6 |
| Leukemia | Male | 22 | 99,902 | 22.0 | 18.4 | 27.0 | 0.393 | 967 | 4,297,008 | 22.5 |
| Leukemia | Female | 14 | 102,438 | 13.7 | 11.1 | 18.5 | 0.353 | 628 | 4,272,480 | 14.7 |
| Liver and Bile Duct | Total | 21 | 202,340 | 10.4 | 8.7 | 22.8 | 0.803 | 808 | 8,569,488 | 9.4 |
| Liver and Bile Duct | Male | 13 | 99,902 | 13.0 | 10.9 | 16.0 | 0.552 | 577 | 4,297,008 | 13.4 |
| Liver and Bile Duct | Female | 8 | 102,438 | 7.8 | 6.4 | 6.8 | 0.729 | 231 | 4,272,480 | 5.4 |
| Lung and Bronchus | Total | 184 | 202,340 | 90.9 | 72.6 | 139.1 | 0.000 >> | 4,703 | 8,569,488 | 54.9 |
| Lung and Bronchus | Male | 86 | 99,902 | 86.1 | 69.5 | 68.1 | 0.041 >> | 2,366 | 4,297,008 | 55.1 |
| Lung and Bronchus | Female | 98 | 102,438 | 95.7 | 75.8 | 70.7 | $0.002 \gg$ | 2,337 | 4,272,480 | 54.7 |
| Melanoma of the Skin | Total | 64 | 202,340 | 31.6 | 26.8 | 80.1 | 0.075 | 2,878 | 8,569,488 | 33.6 |
| Melanoma of the Skin | Male | 34 | 99,902 | 34.0 | 28.4 | 48.2 | 0.041 << | 1,731 | 4,297,008 | 40.3 |
| Melanoma of the Skin | Female | 30 | 102,438 | 29.3 | 25.6 | 31.4 | 0.893 | 1,147 | 4,272,480 | 26.8 |
| Myeloma | Total | 15 | 202,340 | 7.4 | 5.9 | 20.4 | 0.274 | 693 | 8,569,488 | 8.1 |
| Myeloma | Male | 11 | 99,902 | 11.0 | 8.9 | 12.4 | 0.842 | 430 | 4,297,008 | 10.0 |
| Myeloma | Female | 4 | 102,438 | 3.9 | 3.1 | 7.9 | 0.214 | 263 | 4,272,480 | 6.2 |
| Non-Hodgkin Lymphoma | Total | 53 | 202,340 | 26.2 | 21.8 | 53.6 | 1.000 | 1,887 | 8,569,488 | 22.0 |
| Non-Hodgkin Lymphoma | Male | 31 | 99,902 | 31.0 | 26.2 | 30.2 | 0.934 | 1,098 | 4,297,008 | 25.6 |
| Non-Hodgkin Lymphoma | Female | 22 | 102,438 | 21.5 | 17.5 | 23.2 | 0.915 | 789 | 4,272,480 | 18.5 |
| Oral Cavity and Pharynx | Total | 34 | 202,340 | 16.8 | 14.2 | 35.2 | 0.923 | 1,261 | 8,569,488 | 14.7 |
| Oral Cavity and Pharynx | Male | 27 | 99,902 | 27.0 | 22.9 | 25.0 | 0.734 | 909 | 4,297,008 | 21.2 |
| Oral Cavity and Pharynx | Female | 7 | 102,438 | 6.8 | 5.7 | 10.1 | 0.429 | 352 | 4,272,480 | 8.2 |
| Ovary | Female | 9 | 102,438 | 8.8 | 7.5 | 14.8 | 0.153 | 524 | 4,272,480 | 12.3 |
| Pancreas | Total | 42 | 202,340 | 20.8 | 16.5 | 41.1 | 0.924 | 1,381 | 8,569,488 | 16.1 |
| Pancreas | Male | 28 | 99,902 | 28.0 | 22.6 | 21.8 | 0.228 | 756 | 4,297,008 | 17.6 |
| Pancreas | Female | 14 | 102,438 | 13.7 | 10.7 | 19.1 | 0.285 | 625 | 4,272,480 | 14.6 |
| Prostate | Male | 162 | 99,902 | 162.2 | 136.3 | 173.0 | 0.426 | 6,255 | 4,297,008 | 145.6 |
| Stomach | Total | 13 | 202,340 | 6.4 | 5.2 | 13.3 | 1.000 | 454 | 8,569,488 | 5.3 |
| Stomach | Male | 8 | 99,902 | 8.0 | 6.6 | 8.5 | 1.000 | 301 | 4,297,008 | 7.0 |
| Stomach | Female | 5 | 102,438 | 4.9 | 3.9 | 4.6 | 0.984 | 153 | 4,272,480 | 3.6 |
| Testis | Male | 4 | 99,902 | 4.0 | 4.1 | 6.0 | 0.580 | 261 | 4,297,008 | 6.1 |
| Thyroid | Total | 27 | 202,340 | 13.3 | 12.6 | 29.8 | 0.697 | 1,193 | 8,569,488 | 13.9 |
| Thyroid | Male |  | 99,902 | 8.0 | 7.4 | 8.8 | 0.972 | 347 | 4,297,008 | 8.1 |
| Thyroid | Female | 19 | 102,438 | 18.5 | 17.8 | 21.1 | 0.754 | 846 | 4,272,480 | 19.8 |
| Pediatric Age 0 to 19 | Total | 7 | 48,091 | 14.6 | 14.4 | 8.3 | 0.813 | 414 | 2,412,432 | 17.2 |
| Pediatric Age 0 to 19 | Male | 2 | 24,492 | 8.2 | 8.1 | 4.4 | 0.363 | 221 | 1,232,018 | 17.9 |
| Pediatric Age 0 to 19 | Female | 5 | 23,599 | 21.2 | 20.9 | 3.9 | 0.709 | 193 | 1,180,414 | 16.4 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN NEZ PERCE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Nez Perce County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 2,695 | 204,594 | 1,317.2 | 967.0 | 2,371.1 | 0.000 >> | 74,735 | 8,784,121 | 850.8 |
| All Causes of Death | Male | 1,397 | 100,999 | 1,383.2 | 1,059.9 | 1,185.1 | 0.000 >> | 39,659 | 4,410,869 | 899.1 |
| All Causes of Death | Female | 1,298 | 103,595 | 1,253.0 | 882.5 | 1,179.7 | $0.001 \gg$ | 35,076 | 4,373,252 | 802.1 |
| All Malignant Cancers | Total | 502 | 204,594 | 245.4 | 189.1 | 441.8 | $0.005 \gg$ | 14,619 | 8,784,121 | 166.4 |
| All Malignant Cancers | Male | 281 | 100,999 | 278.2 | 216.6 | 232.2 | 0.002 >> | 7,895 | 4,410,869 | 179.0 |
| All Malignant Cancers | Female | 221 | 103,595 | 213.3 | 163.5 | 207.9 | 0.380 | 6,724 | 4,373,252 | 153.8 |
| Bladder | Total | 19 | 204,594 | 9.3 | 6.5 | 15.6 | 0.449 | 470 | 8,784,121 | 5.4 |
| Bladder | Male | 14 | 100,999 | 13.9 | 9.9 | 11.7 | 0.580 | 364 | 4,410,869 | 8.3 |
| Bladder | Female | 5 | 103,595 | 4.8 | 3.4 | 3.6 | 0.583 | 106 | 4,373,252 | 2.4 |
| Brain and Other Nervous System | Total | 17 | 204,594 | 8.3 | 7.1 | 13.3 | 0.380 | 487 | 8,784,121 | 5.5 |
| Brain and Other Nervous System | Male | 11 | 100,999 | 10.9 | 9.3 | 7.7 | 0.310 | 287 | 4,410,869 | 6.5 |
| Brain and Other Nervous System | Female | 6 | 103,595 | 5.8 | 4.9 | 5.6 | 0.974 | 200 | 4,373,252 | 4.6 |
| Breast | Total | 28 | 204,594 | 13.7 | 10.7 | 31.9 | 0.563 | 1,074 | 8,784,121 | 12.2 |
| Breast | Male |  | 100,999 |  |  | 0.5 | 1.000 | 16 | 4,410,869 | 0.4 |
| Breast | Female | 28 | 103,595 | 27.0 | 21.2 | 32.0 | 0.548 | 1,058 | 4,373,252 | 24.2 |
| Cervix | Female | 3 | 103,595 | 2.9 | 2.6 | 2.1 | 0.704 | 80 | 4,373,252 | 1.8 |
| Colorectal | Total | 43 | 204,594 | 21.0 | 16.3 | 38.2 | 0.479 | 1,276 | 8,784,121 | 14.5 |
| Colorectal | Male | 18 | 100,999 | 17.8 | 14.3 | 20.0 | 0.765 | 701 | 4,410,869 | 15.9 |
| Colorectal | Female | 25 | 103,595 | 24.1 | 18.1 | 18.2 | 0.147 | 575 | 4,373,252 | 13.1 |
| Corpus Uteri | Female | 4 | 103,595 | 3.9 | 3.1 | 5.0 | 0.867 | 169 | 4,373,252 | 3.9 |
| Esophagus | Total | 14 | 204,594 | 6.8 | 5.4 | 13.6 | 0.976 | 463 | 8,784,121 | 5.3 |
| Esophagus | Male | 9 | 100,999 | 8.9 | 7.2 | 11.1 | 0.653 | 392 | 4,410,869 | 8.9 |
| Esophagus | Female | 5 | 103,595 | 4.8 | 3.7 | 2.2 | 0.150 | 71 | 4,373,252 | 1.6 |
| Hodgkin Lymphoma | Total |  | 204,594 | - | - | 0.8 | 0.862 | 29 | 8,784,121 | 0.3 |
| Hodgkin Lymphoma | Male | - | 100,999 | - | - | 0.4 | 1.000 | 14 | 4,410,869 | 0.3 |
| Hodgkin Lymphoma | Female | - | 103,595 |  |  | 0.5 | 1.000 | 15 | 4,373,252 | 0.3 |
| Kidney | Total | 13 | 204,594 | 6.4 | 4.8 | 11.4 | 0.707 | 372 | 8,784,121 | 4.2 |
| Kidney | Male | 9 | 100,999 | 8.9 | 7.0 | 6.8 | 0.485 | 233 | 4,410,869 | 5.3 |
| Kidney | Female | 4 | 103,595 | 3.9 | 2.8 | 4.5 | 1.000 | 139 | 4,373,252 | 3.2 |
| Larynx | Total | 1 | 204,594 | 0.5 | 0.4 | 2.1 | 0.766 | 70 | 8,784,121 | 0.8 |
| Larynx | Male | 1 | 100,999 | 1.0 | 0.8 | 1.7 | 0.995 | 57 | 4,410,869 | 1.3 |
| Larynx | Female | - | 103,595 |  | - | 0.4 | 1.000 | 13 | 4,373,252 | 0.3 |
| Leukemia | Total | 21 | 204,594 | 10.3 | 7.7 | 19.9 | 0.859 | 639 | 8,784,121 | 7.3 |
| Leukemia | Male | 14 | 100,999 | 13.9 | 10.7 | 11.1 | 0.450 | 372 | 4,410,869 | 8.4 |
| Leukemia | Female | 7 | 103,595 | 6.8 | 4.9 | 8.7 | 0.722 | 267 | 4,373,252 | 6.1 |
| Liver and Bile Duct | Total | 12 | 204,594 | 5.9 | 4.7 | 17.1 | 0.264 | 591 | 8,784,121 | 6.7 |
| Liver and Bile Duct | Male | 7 | 100,999 | 6.9 | 5.7 | 11.2 | 0.257 | 401 | 4,410,869 | 9.1 |
| Liver and Bile Duct | Female | 5 | 103,595 | 4.8 | 3.8 | 5.7 | 0.987 | 190 | 4,373,252 | 4.3 |
| Lung and Bronchus | Total | 119 | 204,594 | 58.2 | 45.2 | 85.2 | 0.001 >> | 2,842 | 8,784,121 | 32.4 |
| Lung and Bronchus | Male | 63 | 100,999 | 62.4 | 49.3 | 43.2 | 0.006 >> | 1,493 | 4,410,869 | 33.8 |
| Lung and Bronchus | Female | 56 | 103,595 | 54.1 | 41.3 | 41.8 | $0.042 \gg$ | 1,349 | 4,373,252 | 30.8 |
| Melanoma of the Skin | Total | 4 | 204,594 | 2.0 | 1.5 | 8.4 | 0.156 | 285 | 8,784,121 | 3.2 |
| Melanoma of the Skin | Male | 4 | 100,999 | 4.0 | 3.1 | 5.5 | 0.721 | 188 | 4,410,869 | 4.3 |
| Melanoma of the Skin | Female | - | 103,595 | - | - | 2.9 | 0.114 | 97 | 4,373,252 | 2.2 |
| Myeloma | Total | 12 | 204,594 | 5.9 | 4.4 | 9.9 | 0.591 | 319 | 8,784,121 | 3.6 |
| Myeloma | Male | 10 | 100,999 | 9.9 | 7.5 | 5.6 | 0.121 | 186 | 4,410,869 | 4.2 |
| Myeloma | Female | 2 | 103,595 | 1.9 | 1.4 | 4.2 | 0.409 | 133 | 4,373,252 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 21 | 204,594 | 10.3 | 7.7 | 17.0 | 0.391 | 548 | 8,784,121 | 6.2 |
| Non-Hodgkin Lymphoma | Male | 10 | 100,999 | 9.9 | 7.7 | 8.7 | 0.759 | 297 | 4,410,869 | 6.7 |
| Non-Hodgkin Lymphoma | Female | 11 | 103,595 | 10.6 | 7.7 | 8.2 | 0.414 | 251 | 4,373,252 | 5.7 |
| Oral Cavity and Pharynx | Total | 11 | 204,594 | 5.4 | 4.3 | 7.4 | 0.264 | 255 | 8,784,121 | 2.9 |
| Oral Cavity and Pharynx | Male | 7 | 100,999 | 6.9 | 5.6 | 5.1 | 0.498 | 180 | 4,410,869 | 4.1 |
| Oral Cavity and Pharynx | Female | 4 | 103,595 | 3.9 | 3.0 | 2.3 | 0.393 | 75 | 4,373,252 | 1.7 |
| Ovary | Female | 7 | 103,595 | 6.8 | 5.3 | 10.3 | 0.394 | 343 | 4,373,252 | 7.8 |
| Pancreas | Total | 36 | 204,594 | 17.6 | 13.8 | 34.2 | 0.799 | 1,154 | 8,784,121 | 13.1 |
| Pancreas | Male | 17 | 100,999 | 16.8 | 13.5 | 17.9 | 0.958 | 625 | 4,410,869 | 14.2 |
| Pancreas | Female | 19 | 103,595 | 18.3 | 14.2 | 16.2 | 0.544 | 529 | 4,373,252 | 12.1 |
| Prostate | Male | 35 | 100,999 | 34.7 | 24.8 | 29.3 | 0.333 | 914 | 4,410,869 | 20.7 |
| Stomach | Total | 11 | 204,594 | 5.4 | 4.2 | 5.6 | 0.053 | 187 | 8,784,121 | 2.1 |
| Stomach | Male | 9 | 100,999 | 8.9 | 7.1 | 3.2 | 0.012 >> | 112 | 4,410,869 | 2.5 |
| Stomach | Female | 2 | 103,595 | 1.9 | 1.5 | 2.3 | 1.000 | 75 | 4,373,252 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Nez Perce County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 86.5\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) Cancer Screening | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 10.8\% |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 77.0\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 (2018, 2020) | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% | 72.1\% |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) Tobacco Use | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 75.1\% |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 23.1\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 28.2\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 77.2\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 18.3\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 18.8\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, 12.6\% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^34]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# ONPIDA COUNTY CANCPR PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 104 cases of invasive cancer were diagnosed among Oneida County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Oneida County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Oneida <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 104 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 9 | 6,687 |
| Prostate | 12 | 6,417 |
| Lung \& Bronchus | 11 | 4,887 |
| Colorectal | 7 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Oneida County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Oneida County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Oneida County was 469.7 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (520.1) gives an estimate of the relative burden of disease in Oneida County.

The age- and sex-adjusted incidence rate of invasive cancer in Oneida County, all sites combined, was 398.0 cases per 100,000 persons per year during 2016-2020. There were statistically significantly fewer cases of cancer in Oneida County (104) than expected (135.9) based upon rates in the remainder of the state ( $p=.005$ ).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 35 Oneida County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Oneida County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Oneida <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 249 | 77,431 |
| Cancer Deaths | 35 | 15,121 |
| \% of All Deaths | $14.1 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 4 | 2,961 |
| Colorectal | 1 | 1,319 |
| Pancreas | 2 | 1,190 |
| Female Breast | 2 | 1,086 |
| Prostate | 6 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Oneida County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Oneida County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Oneida County, all sites combined, was 121.6 deaths per 100,000 persons per year during 2017-2021, compared with 168.3 for the remainder of the state. There were fewer cancer deaths in Oneida County (35) than expected (48.4) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN ONEIDA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

|  |  | Oneida County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected <br> Cases (3) | P-Value (4) | Observed Cases | Person Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 104 | 22,144 | 469.7 | 398.0 | 135.9 | 0.005 < | 45,506 | 8,749,684 | 520.1 |
| All Sites Combined | Male | 68 | 11,095 | 612.9 | 499.4 | 75.2 | 0.445 | 24,221 | 4,385,815 | 552.3 |
| All Sites Combined | Female | 36 | 11,049 | 325.8 | 285.8 | 61.4 | $0.001 \ll$ | 21,285 | 4,363,869 | 487.8 |
| Bladder | Total | 7 | 22,144 | 31.6 | 25.0 | 7.0 | 1.000 | 2,177 | 8,749,684 | 24.9 |
| Bladder | Male | 7 | 11,095 | 63.1 | 48.5 | 5.7 | 0.705 | 1,744 | 4,385,815 | 39.8 |
| Bladder | Female | - | 11,049 | - | - | 1.3 | 0.522 | 433 | 4,363,869 | 9.9 |
| Brain - malignant | Total | 2 | 22,144 | 9.0 | 8.1 | 1.8 | 1.000 | 623 | 8,749,684 | 7.1 |
| Brain - malignant | Male | 2 | 11,095 | 18.0 | 16.0 | 1.1 | 0.577 | 373 | 4,385,815 | 8.5 |
| Brain - malignant | Female | - | 11,049 | - | - | 0.7 | 0.981 | 250 | 4,363,869 | 5.7 |
| Brain and other CNS - non-malignant | Total | 1 | 22,144 | 4.5 | 3.9 | 4.1 | 0.164 | 1,423 | 8,749,684 | 16.3 |
| Brain and other CNS - non-malignant | Male | 1 | 11,095 | 9.0 | 7.8 | 1.4 | 1.000 | 479 | 4,385,815 | 10.9 |
| Brain and other CNS - non-malignant | Female | - | 11,049 | - | - | 2.7 | 0.132 | 944 | 4,363,869 | 21.6 |
| Breast | Total | 9 | 22,144 | 40.6 | 35.7 | 19.4 | 0.014 << | 6,737 | 8,749,684 | 77.0 |
| Breast | Male | - | 11,095 | 81.5 | 73 | 0.2 | $1.000<$ | 59 | 4,385,815 | 1.3 |
| Breast | Female | 9 | 11,049 | 81.5 | 73.3 | 18.8 | $0.020 \ll$ | 6,678 | 4,363,869 | 153.0 |
| Breast - in situ | Total | 4 | 22,144 | 18.1 | 16.4 | 3.4 | 0.902 | 1,235 | 8,749,684 | 14.1 |
| Breast - in situ | Male | - | 11,095 | - | - | 0.0 | 1.000 | 5 | 4,385,815 | 0.1 |
| Breast - in situ | Female | 4 | 11,049 | 36.2 | 33.7 | 3.3 | 0.860 | 1,230 | 4,363,869 | 28.2 |
| Cervix | Female | - | 11,049 | - | - | 0.8 | 0.942 | 304 | 4,363,869 | 7.0 |
| Colorectal | Total | 7 | 22,144 | 31.6 | 26.6 | 10.3 | 0.382 | 3,444 | 8,749,684 | 39.4 |
| Colorectal | Male | 5 | 11,095 | 45.1 | 37.4 | 5.8 | 0.964 | 1,898 | 4,385,815 | 43.3 |
| Colorectal | Female | 2 | 11,049 | 18.1 | 15.4 | 4.6 | 0.324 | 1,546 | 4,363,869 | 35.4 |
| Corpus Uteri | Female | 1 | 11,049 | 9.1 | 8.2 | 3.7 | 0.228 | 1,329 | 4,363,869 | 30.5 |
| Esophagus | Total | 1 | 22,144 | 4.5 | 3.7 | 1.6 | 1.000 | 505 | 8,749,684 | 5.8 |
| Esophagus | Male | 1 | 11,095 | 9.0 | 7.2 | 1.3 | 1.000 | 423 | 4,385,815 | 9.6 |
| Esophagus | Female | - | 11,049 | - | - | 0.2 | 1.000 | 82 | 4,363,869 | 1.9 |
| Hodgkin Lymphoma | Total | - | 22,144 | - | - | 0.5 | 1.000 | 210 | 8,749,684 | 2.4 |
| Hodgkin Lymphoma | Male | - | 11,095 | - | - | 0.3 | 1.000 | 118 | 4,385,815 | 2.7 |
| Hodgkin Lymphoma | Female | - | 11,049 | - | - | 0.2 | 1.000 | 92 | 4,363,869 | 2.1 |
| Kidney and Renal Pelvis | Total | 6 | 22,144 | 27.1 | 23.3 | 5.3 | 0.880 | 1,809 | 8,749,684 | 20.7 |
| Kidney and Renal Pelvis | Male | 5 | 11,095 | 45.1 | 38.0 | 3.5 | 0.562 | 1,177 | 4,385,815 | 26.8 |
| Kidney and Renal Pelvis | Female | 1 | 11,049 | 9.1 | 7.9 | 1.8 | 0.908 | 632 | 4,363,869 | 14.5 |
| Larynx | Total | - | 22,144 | - | - | 0.7 | 1.000 | 215 | 8,749,684 | 2.5 |
| Larynx | Male | - | 11,095 | - | - | 0.5 | 1.000 | 160 | 4,385,815 | 3.6 |
| Larynx | Female | - | 11,049 | - | - | 0.2 | 1.000 | 55 | 4,363,869 | 1.3 |
| Leukemia | Total | 7 | 22,144 | 31.6 | 26.3 | 4.9 | 0.461 | 1,624 | 8,749,684 | 18.6 |
| Leukemia | Male | 6 | 11,095 | 54.1 | 44.2 | 3.0 | 0.177 | 983 | 4,385,815 | 22.4 |
| Leukemia | Female | 1 | 11,049 | 9.1 | 7.6 | 1.9 | 0.852 | 641 | 4,363,869 | 14.7 |
| Liver and Bile Duct | Total | 3 | 22,144 | 13.5 | 11.4 | 2.5 | 0.906 | 826 | 8,749,684 | 9.4 |
| Liver and Bile Duct | Male | 3 | 11,095 | 27.0 | 22.0 | 1.8 | 0.554 | 587 | 4,385,815 | 13.4 |
| Liver and Bile Duct | Female | - | 11,049 | - | - | 0.7 | 0.986 | 239 | 4,363,869 | 5.5 |
| Lung and Bronchus | Total | 11 | 22,144 | 49.7 | 40.0 | 15.3 | 0.329 | 4,876 | 8,749,684 | 55.7 |
| Lung and Bronchus | Male | 8 | 11,095 | 72.1 | 56.4 | 7.9 | 1.000 | 2,444 | 4,385,815 | 55.7 |
| Lung and Bronchus | Female | 3 | 11,049 | 27.2 | 22.5 | 7.4 | 0.123 | 2,432 | 4,363,869 | 55.7 |
| Melanoma of the Skin | Total | 7 | 22,144 | 31.6 | 27.5 | 8.5 | 0.760 | 2,935 | 8,749,684 | 33.5 |
| Melanoma of the Skin | Male | 5 | 11,095 | 45.1 | 37.3 | 5.4 | 1.000 | 1,760 | 4,385,815 | 40.1 |
| Melanoma of the Skin | Female | 2 | 11,049 | 18.1 | 16.6 | 3.2 | 0.743 | 1,175 | 4,363,869 | 26.9 |
| Myeloma | Total | 1 | 22,144 | 4.5 | 3.7 | 2.2 | 0.710 | 707 | 8,749,684 | 8.1 |
| Myeloma | Male | 1 | 11,095 | 9.0 | 7.1 | 1.4 | 1.000 | 440 | 4,385,815 | 10.0 |
| Myeloma | Female | - | 11,049 | - | - | 0.8 | 0.890 | 267 | 4,363,869 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 3 | 22,144 | 13.5 | 11.4 | 5.8 | 0.337 | 1,937 | 8,749,684 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 1 | 11,095 | 9.0 | 7.4 | 3.5 | 0.282 | 1,128 | 4,385,815 | 25.7 |
| Non-Hodgkin Lymphoma | Female | 2 | 11,049 | 18.1 | 15.4 | 2.4 | 1.000 | 809 | 4,363,869 | 18.5 |
| Oral Cavity and Pharynx | Total | - | 22,144 | - | - | 3.8 | 0.044 < | 1,295 | 8,749,684 | 14.8 |
| Oral Cavity and Pharynx | Male | - | 11,095 | - | - | 2.8 | 0.116 | 936 | 4,385,815 | 21.3 |
| Oral Cavity and Pharynx | Female | - | 11,049 | - | - | 1.0 | 0.710 | 359 | 4,363,869 | 8.2 |
| Ovary | Female | 4 | 11,049 | 36.2 | 32.2 | 1.5 | 0.133 | 529 | 4,363,869 | 12.1 |
| Pancreas | Total | 3 | 22,144 | 13.5 | 10.9 | 4.5 | 0.698 | 1,420 | 8,749,684 | 16.2 |
| Pancreas | Male | 2 | 11,095 | 18.0 | 14.2 | 2.5 | 1.000 | 782 | 4,385,815 | 17.8 |
| Pancreas | Female | 1 | 11,049 | 9.1 | 7.4 | 2.0 | 0.826 | 638 | 4,363,869 | 14.6 |
| Prostate | Male | 12 | 11,095 | 108.2 | 87.8 | 20.0 | 0.079 | 6,405 | 4,385,815 | 146.0 |
| Stomach | Total | 1 | 22,144 | 4.5 | 3.7 | 1.4 | 1.000 | 466 | 8,749,684 | 5.3 |
| Stomach | Male | 1 | 11,095 | 9.0 | 7.2 | 1.0 | 1.000 | 308 | 4,385,815 | 7.0 |
| Stomach | Female | - | 11,049 | - | - | 0.5 | 1.000 | 158 | 4,363,869 | 3.6 |
| Testis | Male | - | 11,095 | - | - | 0.6 | 1.000 | 265 | 4,385,815 | 6.0 |
| Thyroid | Total | 2 | 22,144 | 9.0 | 9.1 | 3.1 | 0.818 | 1,218 | 8,749,684 | 13.9 |
| Thyroid | Male | - | 11,095 | - | - | 0.9 | 0.774 | 355 | 4,385,815 | 8.1 |
| Thyroid | Female | 2 | 11,049 | 18.1 | 18.7 | 2.1 | 1.000 | 863 | 4,363,869 | 19.8 |
| Pediatric Age 0 to 19 | Total | 3 | 6,798 | 44.1 | 45.0 | 1.1 | 0.214 | 418 | 2,453,725 | 17.0 |
| Pediatric Age 0 to 19 | Male | - | 3,480 | - | - | 0.6 | 1.000 | 223 | 1,253,030 | 17.8 |
| Pediatric Age 0 to 19 | Female | 3 | 3,318 | 90.4 | 92.6 | 0.5 | 0.033 >> | 195 | 1,200,695 | 16.2 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).
Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN ONEIDA COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

|  |  | Oneida County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cause of Death Cancer Site/Type | Sex | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate $(1,2)$ | Expected <br> Deaths (3) | P-Value (4) | Observed Deaths | Person <br> Years | Crude Rate (1) |
| All Causes of Death | Total | 249 | 22,453 | 1,109.0 | 833.4 | 257.2 | 0.637 | 77,181 | 8,966,262 | 860.8 |
| All Causes of Death | Male | 145 | 11,293 | 1,284.0 | 984.5 | 133.9 | 0.357 | 40,911 | 4,500,575 | 909.0 |
| All Causes of Death | Female | 104 | 11,160 | 931.9 | 679.9 | 124.2 | 0.071 | 36,270 | 4,465,687 | 812.2 |
| All Malignant Cancers | Total | 35 | 22,453 | 155.9 | 121.6 | 48.4 | 0.054 | 15,086 | 8,966,262 | 168.3 |
| All Malignant Cancers | Male | 25 | 11,293 | 221.4 | 168.9 | 26.8 | 0.824 | 8,151 | 4,500,575 | 181.1 |
| All Malignant Cancers | Female | 10 | 11,160 | 89.6 | 71.4 | 21.8 | 0.008 < | 6,935 | 4,465,687 | 155.3 |
| Bladder | Total | 1 | 22,453 | 4.5 | 3.2 | 1.7 | 0.986 | 488 | 8,966,262 | 5.4 |
| Bladder | Male | 1 | 11,293 | 8.9 | 6.3 | 1.3 | 1.000 | 377 | 4,500,575 | 8.4 |
| Bladder | Female | - | 11,160 | - | - | 0.4 | 1.000 | 111 | 4,465,687 | 2.5 |
| Brain and Other Nervous System | Total | 2 | 22,453 | 8.9 | 7.6 | 1.5 | 0.865 | 502 | 8,966,262 | 5.6 |
| Brain and Other Nervous System | Male | 2 | 11,293 | 17.7 | 14.8 | 0.9 | 0.448 | 296 | 4,500,575 | 6.6 |
| Brain and Other Nervous System | Female | - | 11,160 | - | - | 0.6 | 1.000 | 206 | 4,465,687 | 4.6 |
| Breast | Total | 2 | 22,453 | 8.9 | 7.1 | 3.5 | 0.660 | 1,100 | 8,966,262 | 12.3 |
| Breast | Male | - | 11,293 | - | - | 0.1 | 1.000 | 16 | 4,500,575 | 0.4 |
| Breast | Female | 2 | 11,160 | 17.9 | 14.6 | 3.3 | 0.705 | 1,084 | 4,465,687 | 24.3 |
| Cervix | Female | - | 11,160 | - | - | 0.2 | 1.000 | 83 | 4,465,687 | 1.9 |
| Colorectal | Total | 1 | 22,453 | 4.5 | 3.5 | 4.2 | 0.159 | 1,318 | 8,966,262 | 14.7 |
| Colorectal | Male | 1 | 11,293 | 8.9 | 7.0 | 2.3 | 0.671 | 718 | 4,500,575 | 16.0 |
| Colorectal | Female | - | 11,160 | - | - | 1.9 | 0.293 | 600 | 4,465,687 | 13.4 |
| Corpus Uteri | Female | - | 11,160 | - | - | 0.5 | 1.000 | 173 | 4,465,687 | 3.9 |
| Esophagus | Total | 1 | 22,453 | 4.5 | 3.6 | 1.5 | 1.000 | 476 | 8,966,262 | 5.3 |
| Esophagus | Male | 1 | 11,293 | 8.9 | 6.9 | 1.3 | 1.000 | 400 | 4,500,575 | 8.9 |
| Esophagus | Female | - | 11,160 | - | - | 0.2 | 1.000 | 76 | 4,465,687 | 1.7 |
| Hodgkin Lymphoma | Total | - | 22,453 | - | - | 0.1 | 1.000 | 29 | 8,966,262 | 0.3 |
| Hodgkin Lymphoma | Male | - | 11,293 | - | - | 0.0 | 1.000 | 14 | 4,500,575 | 0.3 |
| Hodgkin Lymphoma | Female | - | 11,160 | - | - | 0.0 | 1.000 | 15 | 4,465,687 | 0.3 |
| Kidney | Total | 2 | 22,453 | 8.9 | 6.9 | 1.2 | 0.707 | 383 | 8,966,262 | 4.3 |
| Kidney | Male | 2 | 11,293 | 17.7 | 13.6 | 0.8 | 0.370 | 240 | 4,500,575 | 5.3 |
| Kidney | Female | - | 11,160 | - | - | 0.5 | 1.000 | 143 | 4,465,687 | 3.2 |
| Larynx | Total | 1 | 22,453 | 4.5 | 3.5 | 0.2 | 0.400 | 70 | 8,966,262 | 0.8 |
| Larynx | Male | 1 | 11,293 | 8.9 | 6.6 | 0.2 | 0.347 | 57 | 4,500,575 | 1.3 |
| Larynx | Female | - | 11,160 | - | - | 0.0 | 1.000 | 13 | 4,465,687 | 0.3 |
| Leukemia | Total | 1 | 22,453 | 4.5 | 3.4 | 2.2 | 0.722 | 659 | 8,966,262 | 7.3 |
| Leukemia | Male | 1 | 11,293 | 8.9 | 6.7 | 1.3 | 1.000 | 385 | 4,500,575 | 8.6 |
| Leukemia | Female | - | 11,160 | - | - | 0.9 | 0.805 | 274 | 4,465,687 | 6.1 |
| Liver and Bile Duct | Total | 1 | 22,453 | 4.5 | 3.6 | 1.9 | 0.892 | 602 | 8,966,262 | 6.7 |
| Liver and Bile Duct | Male | 1 | 11,293 | 8.9 | 7.0 | 1.3 | 1.000 | 407 | 4,500,575 | 9.0 |
| Liver and Bile Duct | Female | - | 11,160 | - | - | 0.6 | 1.000 | 195 | 4,465,687 | 4.4 |
| Lung and Bronchus | Total | 4 | 22,453 | 17.8 | 13.9 | 9.5 | 0.082 | 2,957 | 8,966,262 | 33.0 |
| Lung and Bronchus | Male | 4 | 11,293 | 35.4 | 27.1 | 5.1 | 0.849 | 1,552 | 4,500,575 | 34.5 |
| Lung and Bronchus | Female | - | 11,160 | - | - | 4.4 | 0.024 << | 1,405 | 4,465,687 | 31.5 |
| Melanoma of the Skin | Total | - | 22,453 | - | - | 0.9 | 0.808 | 289 | 8,966,262 | 3.2 |
| Melanoma of the Skin | Male | - | 11,293 | - | - | 0.6 | 1.000 | 192 | 4,500,575 | 4.3 |
| Melanoma of the Skin | Female | - | 11,160 | - | - | 0.3 | 1.000 | 97 | 4,465,687 | 2.2 |
| Myeloma | Total | 1 | 22,453 | 4.5 | 3.4 | 1.1 | 1.000 | 330 | 8,966,262 | 3.7 |
| Myeloma | Male | 1 | 11,293 | 8.9 | 6.6 | 0.7 | 0.967 | 195 | 4,500,575 | 4.3 |
| Myeloma | Female | - | 11,160 | - | - | 0.4 | 1.000 | 135 | 4,465,687 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 3 | 22,453 | 13.4 | 10.2 | 1.9 | 0.569 | 566 | 8,966,262 | 6.3 |
| Non-Hodgkin Lymphoma | Male | - | 11,293 | - | - | 1.0 | 0.728 | 307 | 4,500,575 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 3 | 11,160 | 26.9 | 20.3 | 0.9 | 0.112 | 259 | 4,465,687 | 5.8 |
| Oral Cavity and Pharynx | Total | - | 22,453 | - | - | 0.8 | 0.877 | 266 | 8,966,262 | 3.0 |
| Oral Cavity and Pharynx | Male | - | 11,293 | - | - | 0.6 | 1.000 | 187 | 4,500,575 | 4.2 |
| Oral Cavity and Pharynx | Female | - | 11,160 | - | - | 0.2 | 1.000 | 79 | 4,465,687 | 1.8 |
| Ovary | Female | 1 | 11,160 | 9.0 | 7.4 | 1.1 | 1.000 | 349 | 4,465,687 | 7.8 |
| Pancreas | Total | 2 | 22,453 | 8.9 | 7.1 | 3.8 | 0.553 | 1,188 | 8,966,262 | 13.2 |
| Pancreas | Male | 1 | 11,293 | 8.9 | 6.9 | 2.1 | 0.775 | 641 | 4,500,575 | 14.2 |
| Pancreas | Female | 1 | 11,160 | 9.0 | 7.2 | 1.7 | 0.989 | 547 | 4,465,687 | 12.2 |
| Prostate | Male | 6 | 11,293 | 53.1 | 37.7 | 3.3 | 0.242 | 943 | 4,500,575 | 21.0 |
| Stomach | Total | - | 22,453 | - | - | 0.6 | 1.000 | 198 | 8,966,262 | 2.2 |
| Stomach | Male | - | 11,293 | - | - | 0.4 | 1.000 | 121 | 4,500,575 | 2.7 |
| Stomach | Female | - | 11,160 | - | - | 0.2 | 1.000 | 77 | 4,465,687 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Oneida County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 91.6\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 12.0\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% |  |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 56.3\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 26.1\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 30.6\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 66.8\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 11.1\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 12.6\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, 12.6\% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^35]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked 49 ${ }^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# OWYHPD COUNTY CANCER PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 309 cases of invasive cancer were diagnosed among Owyhee County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Owyhee County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Owyhee <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 309 | 45,610 |
| Female Breast | 56 | 6,687 |
| Prostate | 42 | 6,417 |
| Lung \& Bronchus | 30 | 4,887 |
| Colorectal | 22 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Owyhee County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Owyhee County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Owyhee County was 527.1 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (519.9) gives an estimate of the relative burden of disease in Owyhee County.

The age- and sex-adjusted incidence rate of invasive cancer in Owyhee County, all sites combined, was 481.6 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Owyhee County (309) than expected (333.6) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 112 Owyhee County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Owyhee County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Owyhee <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 591 | 77,431 |
| Cancer Deaths | 112 | 15,121 |
| \% of All Deaths | $19.0 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 16 | 2,961 |
| Colorectal | 14 | 1,319 |
| Pancreas | 16 | 1,190 |
| Female Breast | 5 | 1,086 |
| Prostate | 9 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Owyhee County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Owyhee County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Owyhee County, all sites combined, was 170.3 deaths per 100,000 persons per year during 2017-2021, compared with 168.1 for the remainder of the state. There were more cancer deaths in Owyhee County (112) than expected (110.5) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN OWYHEE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

|  |  | Owyhee County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 309 | 58,620 | 527.1 | 481.6 | 333.6 | 0.185 | 45,301 | 8,713,208 | 519.9 |
| All Sites Combined | Male | 163 | 29,887 | 545.4 | 474.1 | 190.0 | 0.051 | 24,126 | 4,367,023 | 552.5 |
| All Sites Combined | Female | 146 | 28,733 | 508.1 | 483.4 | 147.1 | 0.968 | 21,175 | 4,346,185 | 487.2 |
| Bladder | Total | 9 | 58,620 | 15.4 | 13.8 | 16.3 | 0.074 | 2,175 | 8,713,208 | 25.0 |
| Bladder | Male | 9 | 29,887 | 30.1 | 25.5 | 14.1 | 0.210 | 1,742 | 4,367,023 | 39.9 |
| Bladder | Female | - | 28,733 | - | - | 3.0 | 0.096 | 433 | 4,346,185 | 10.0 |
| Brain - malignant | Total | 2 | 58,620 | 3.4 | 3.2 | 4.5 | 0.356 | 623 | 8,713,208 | 7.2 |
| Brain - malignant | Male | 1 | 29,887 | 3.3 | 3.1 | 2.8 | 0.464 | 374 | 4,367,023 | 8.6 |
| Brain - malignant | Female | 1 | 28,733 | 3.5 | 3.4 | 1.7 | 0.981 | 249 | 4,346,185 | 5.7 |
| Brain and other CNS - non-malignant | Total | 7 | 58,620 | 11.9 | 11.1 | 10.2 | 0.397 | 1,417 | 8,713,208 | 16.3 |
| Brain and other CNS - non-malignant | Male | 2 | 29,887 | 6.7 | 6.1 | 3.6 | 0.602 | 478 | 4,367,023 | 10.9 |
| Brain and other CNS - non-malignant | Female | 5 | 28,733 | 17.4 | 16.6 | 6.5 | 0.740 | 939 | 4,346,185 | 21.6 |
| Breast | Total | 56 | 58,620 | 95.5 | 88.1 | 48.8 | 0.338 | 6,690 | 8,713,208 | 76.8 |
| Breast | Male | - | 29,887 | - | - | 0.5 | 1.000 | 59 | 4,367,023 | 1.4 |
| Breast | Female | 56 | 28,733 | 194.9 | 184.7 | 46.3 | 0.180 | 6,631 | 4,346,185 | 152.6 |
| Breast - in situ | Total | 9 | 58,620 | 15.4 | 14.2 | 9.0 | 1.000 | 1,230 | 8,713,208 | 14.1 |
| Breast - in situ | Male | - | 29,887 | - | - | 0.0 | 1.000 | 5 | 4,367,023 | 0.1 |
| Breast - in situ | Female | 9 | 28,733 | 31.3 | 29.5 | 8.6 | 0.980 | 1,225 | 4,346,185 | 28.2 |
| Cervix | Female | 2 | 28,733 | 7.0 | 7.0 | 2.0 | 1.000 | 302 | 4,346,185 | 6.9 |
| Colorectal | Total | 22 | 58,620 | 37.5 | 34.2 | 25.3 | 0.596 | 3,429 | 8,713,208 | 39.4 |
| Colorectal | Male | 15 | 29,887 | 50.2 | 43.9 | 14.8 | 1.000 | 1,888 | 4,367,023 | 43.2 |
| Colorectal | Female | 7 | 28,733 | 24.4 | 23.1 | 10.7 | 0.323 | 1,541 | 4,346,185 | 35.5 |
| Corpus Uteri | Female | 12 | 28,733 | 41.8 | 39.6 | 9.2 | 0.434 | 1,318 | 4,346,185 | 30.3 |
| Esophagus | Total | 1 | 58,620 | 1.7 | 1.5 | 3.8 | 0.220 | 505 | 8,713,208 | 5.8 |
| Esophagus | Male | 1 | 29,887 | 3.3 | 2.9 | 3.4 | 0.299 | 423 | 4,367,023 | 9.7 |
| Esophagus | Female | - | 28,733 | - | - | 0.6 | 1.000 | 82 | 4,346,185 | 1.9 |
| Hodgkin Lymphoma | Total | 2 | 58,620 | 3.4 | 3.4 | 1.4 | 0.824 | 208 | 8,713,208 | 2.4 |
| Hodgkin Lymphoma | Male | 2 | 29,887 | 6.7 | 6.6 | 0.8 | 0.388 | 116 | 4,367,023 | 2.7 |
| Hodgkin Lymphoma | Female | - | 28,733 | - | - | 0.6 | 1.000 | 92 | 4,346,185 | 2.1 |
| Kidney and Renal Pelvis | Total | 15 | 58,620 | 25.6 | 23.4 | 13.2 | 0.698 | 1,800 | 8,713,208 | 20.7 |
| Kidney and Renal Pelvis | Male | 12 | 29,887 | 40.2 | 35.4 | 9.1 | 0.409 | 1,170 | 4,367,023 | 26.8 |
| Kidney and Renal Pelvis | Female | 3 | 28,733 | 10.4 | 9.9 | 4.4 | 0.717 | 630 | 4,346,185 | 14.5 |
| Larynx | Total | 3 | 58,620 | 5.1 | 4.6 | 1.6 | 0.426 | 212 | 8,713,208 | 2.4 |
| Larynx | Male | 3 | 29,887 | 10.0 | 8.5 | 1.3 | 0.269 | 157 | 4,367,023 | 3.6 |
| Larynx | Female | - | 28,733 | - | - | 0.4 | 1.000 | 55 | 4,346,185 | 1.3 |
| Leukemia | Total | 7 | 58,620 | 11.9 | 10.9 | 12.0 | 0.183 | 1,624 | 8,713,208 | 18.6 |
| Leukemia | Male | 5 | 29,887 | 16.7 | 14.6 | 7.7 | 0.442 | 984 | 4,367,023 | 22.5 |
| Leukemia | Female | 2 | 28,733 | 7.0 | 6.6 | 4.5 | 0.355 | 640 | 4,346,185 | 14.7 |
| Liver and Bile Duct | Total | 7 | 58,620 | 11.9 | 10.8 | 6.1 | 0.822 | 822 | 8,713,208 | 9.4 |
| Liver and Bile Duct | Male | 4 | 29,887 | 13.4 | 11.6 | 4.6 | 1.000 | 586 | 4,367,023 | 13.4 |
| Liver and Bile Duct | Female | 3 | 28,733 | 10.4 | 9.8 | 1.7 | 0.462 | 236 | 4,346,185 | 5.4 |
| Lung and Bronchus | Total | 30 | 58,620 | 51.2 | 45.8 | 36.5 | 0.319 | 4,857 | 8,713,208 | 55.7 |
| Lung and Bronchus | Male | 17 | 29,887 | 56.9 | 48.4 | 19.6 | 0.659 | 2,435 | 4,367,023 | 55.8 |
| Lung and Bronchus | Female | 13 | 28,733 | 45.2 | 42.3 | 17.1 | 0.387 | 2,422 | 4,346,185 | 55.7 |
| Melanoma of the Skin | Total | 12 | 58,620 | 20.5 | 19.0 | 21.3 | 0.043 << | 2,930 | 8,713,208 | 33.6 |
| Melanoma of the Skin | Male | 8 | 29,887 | 26.8 | 23.5 | 13.7 | 0.144 | 1,757 | 4,367,023 | 40.2 |
| Melanoma of the Skin | Female | 4 | 28,733 | 13.9 | 13.5 | 8.0 | 0.200 | 1,173 | 4,346,185 | 27.0 |
| Myeloma | Total | 2 | 58,620 | 3.4 | 3.1 | 5.3 | 0.205 | 706 | 8,713,208 | 8.1 |
| Myeloma | Male | 2 | 29,887 | 6.7 | 5.7 | 3.5 | 0.640 | 439 | 4,367,023 | 10.1 |
| Myeloma | Female | - | 28,733 | - | - | 1.9 | 0.308 | 267 | 4,346,185 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 21 | 58,620 | 35.8 | 32.7 | 14.1 | 0.103 | 1,919 | 8,713,208 | 22.0 |
| Non-Hodgkin Lymphoma | Male | 8 | 29,887 | 26.8 | 23.6 | 8.7 | 0.995 | 1,121 | 4,367,023 | 25.7 |
| Non-Hodgkin Lymphoma | Female | 13 | 28,733 | 45.2 | 42.9 | 5.6 | 0.010 >> | 798 | 4,346,185 | 18.4 |
| Oral Cavity and Pharynx | Total | 10 | 58,620 | 17.1 | 15.5 | 9.5 | 0.955 | 1,285 | 8,713,208 | 14.7 |
| Oral Cavity and Pharynx | Male | 8 | 29,887 | 26.8 | 23.4 | 7.3 | 0.881 | 928 | 4,367,023 | 21.3 |
| Oral Cavity and Pharynx | Female | 2 | 28,733 | 7.0 | 6.6 | 2.5 | 1.000 | 357 | 4,346,185 | 8.2 |
| Ovary | Female | 8 | 28,733 | 27.8 | 26.4 | 3.7 | 0.066 | 525 | 4,346,185 | 12.1 |
| Pancreas | Total | 17 | 58,620 | 29.0 | 26.1 | 10.5 | 0.079 | 1,406 | 8,713,208 | 16.1 |
| Pancreas | Male | 9 | 29,887 | 30.1 | 25.7 | 6.2 | 0.349 | 775 | 4,367,023 | 17.7 |
| Pancreas | Female | 8 | 28,733 | 27.8 | 26.3 | 4.4 | 0.159 | 631 | 4,346,185 | 14.5 |
| Prostate | Male | 42 | 29,887 | 140.5 | 121.4 | 50.5 | 0.257 | 6,375 | 4,367,023 | 146.0 |
| Stomach | Total | 4 | 58,620 | 6.8 | 6.2 | 3.4 | 0.897 | 463 | 8,713,208 | 5.3 |
| Stomach | Male | 4 | 29,887 | 13.4 | 11.5 | 2.4 | 0.457 | 305 | 4,367,023 | 7.0 |
| Stomach | Female | - | 28,733 | - | - | 1.1 | 0.680 | 158 | 4,346,185 | 3.6 |
| Testis | Male | 1 | 29,887 | 3.3 | 3.6 | 1.7 | 1.000 | 264 | 4,367,023 | 6.0 |
| Thyroid | Total | 5 | 58,620 | 8.5 | 8.4 | 8.3 | 0.334 | 1,215 | 8,713,208 | 13.9 |
| Thyroid | Male | 3 | 29,887 | 10.0 | 9.5 | 2.5 | 0.932 | 352 | 4,367,023 | 8.1 |
| Thyroid | Female | 2 | 28,733 | 7.0 | 7.0 | 5.7 | 0.154 | 863 | 4,346,185 | 19.9 |
| Pediatric Age 0 to 19 | Total | 2 | 16,664 | 12.0 | 12.0 | 2.9 | 0.913 | 419 | 2,443,859 | 17.1 |
| Pediatric Age 0 to 19 | Male | 1 | 8,485 | 11.8 | 11.8 | 1.5 | 1.000 | 222 | 1,248,025 | 17.8 |
| Pediatric Age 0 to 19 | Female | 1 | 8,179 | 12.2 | 12.2 | 1.3 | 1.000 | 197 | 1,195,834 | 16.5 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN OWYHEE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Owyhee County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 591 | 59,588 | 991.8 | 906.6 | 561.0 | 0.214 | 76,839 | 8,929,127 | 860.5 |
| All Causes of Death | Male | 350 | 30,387 | 1,151.8 | 986.7 | 322.2 | 0.131 | 40,706 | 4,481,481 | 908.3 |
| All Causes of Death | Female | 241 | 29,201 | 825.3 | 805.3 | 243.1 | 0.925 | 36,133 | 4,447,646 | 812.4 |
| All Malignant Cancers | Total | 112 | 59,588 | 188.0 | 170.3 | 110.5 | 0.914 | 15,009 | 8,929,127 | 168.1 |
| All Malignant Cancers | Male | 68 | 30,387 | 223.8 | 190.6 | 64.5 | 0.700 | 8,108 | 4,481,481 | 180.9 |
| All Malignant Cancers | Female | 44 | 29,201 | 150.7 | 143.8 | 47.5 | 0.679 | 6,901 | 4,447,646 | 155.2 |
| Bladder | Total | 2 | 59,588 | 3.4 | 3.0 | 3.6 | 0.602 | 487 | 8,929,127 | 5.5 |
| Bladder | Male | 1 | 30,387 | 3.3 | 2.7 | 3.1 | 0.368 | 377 | 4,481,481 | 8.4 |
| Bladder | Female | 1 | 29,201 | 3.4 | 3.3 | 0.7 | 1.000 | 110 | 4,447,646 | 2.5 |
| Brain and Other Nervous System | Total |  | 59,588 | - | - | 3.6 | 0.052 | 504 | 8,929,127 | 5.6 |
| Brain and Other Nervous System | Male |  | 30,387 | - | - | 2.3 | 0.206 | 298 | 4,481,481 | 6.6 |
| Brain and Other Nervous System | Female | - | 29,201 | - | - | 1.4 | 0.486 | 206 | 4,447,646 | 4.6 |
| Breast | Total | 5 | 59,588 | 8.4 | 7.7 | 8.0 | 0.382 | 1,097 | 8,929,127 | 12.3 |
| Breast | Male |  | 30,387 |  | - | 0.1 | 1.000 | 16 | 4,481,481 | 0.4 |
| Breast | Female | 5 | 29,201 | 17.1 | 16.4 | 7.4 | 0.503 | 1,081 | 4,447,646 | 24.3 |
| Cervix | Female | - | 29,201 | - | - | 0.6 | 1.000 | 83 | 4,447,646 | 1.9 |
| Colorectal | Total | 14 | 59,588 | 23.5 | 21.4 | 9.6 | 0.213 | 1,305 | 8,929,127 | 14.6 |
| Colorectal | Male | 11 | 30,387 | 36.2 | 31.3 | 5.6 | 0.054 | 708 | 4,481,481 | 15.8 |
| Colorectal | Female | 3 | 29,201 | 10.3 | 9.8 | 4.1 | 0.829 | 597 | 4,447,646 | 13.4 |
| Corpus Uteri | Female | 2 | 29,201 | 6.8 | 6.5 | 1.2 | 0.660 | 171 | 4,447,646 | 3.8 |
| Esophagus | Total | 3 | 59,588 | 5.0 | 4.6 | 3.5 | 1.000 | 474 | 8,929,127 | 5.3 |
| Esophagus | Male | 3 | 30,387 | 9.9 | 8.5 | 3.1 | 1.000 | 398 | 4,481,481 | 8.9 |
| Esophagus | Female | - | 29,201 | - | - | 0.5 | 1.000 | 76 | 4,447,646 | 1.7 |
| Hodgkin Lymphoma | Total | - | 59,588 |  | - | 0.2 | 1.000 | 29 | 8,929,127 | 0.3 |
| Hodgkin Lymphoma | Male | - | 30,387 | - | - | 0.1 | 1.000 | 14 | 4,481,481 | 0.3 |
| Hodgkin Lymphoma | Female | - | 29,201 | - | - | 0.1 | 1.000 | 15 | 4,447,646 | 0.3 |
| Kidney | Total | 5 | 59,588 | 8.4 | 7.6 | 2.8 | 0.306 | 380 | 8,929,127 | 4.3 |
| Kidney | Male | 2 | 30,387 | 6.6 | 5.6 | 1.9 | 1.000 | 240 | 4,481,481 | 5.4 |
| Kidney | Female | 3 | 29,201 | 10.3 | 9.8 | 1.0 | 0.147 | 140 | 4,447,646 | 3.1 |
| Larynx | Total | - | 59,588 | - | - | 0.5 | 1.000 | 71 | 8,929,127 | 0.8 |
| Larynx | Male | - | 30,387 | - | - | 0.5 | 1.000 | 58 | 4,481,481 | 1.3 |
| Larynx | Female | - | 29,201 | - | - | 0.1 | 1.000 | 13 | 4,447,646 | 0.3 |
| Leukemia | Total | 2 | 59,588 | 3.4 | 3.0 | 4.8 | 0.278 | 658 | 8,929,127 | 7.4 |
| Leukemia | Male | 1 | 30,387 | 3.3 | 2.8 | 3.1 | 0.379 | 385 | 4,481,481 | 8.6 |
| Leukemia | Female | 1 | 29,201 | 3.4 | 3.3 | 1.9 | 0.885 | 273 | 4,447,646 | 6.1 |
| Liver and Bile Duct | Total | 4 | 59,588 | 6.7 | 6.1 | 4.4 | 1.000 | 599 | 8,929,127 | 6.7 |
| Liver and Bile Duct | Male | 3 | 30,387 | 9.9 | 8.5 | 3.2 | 1.000 | 405 | 4,481,481 | 9.0 |
| Liver and Bile Duct | Female | 1 | 29,201 | 3.4 | 3.2 | 1.3 | 1.000 | 194 | 4,447,646 | 4.4 |
| Lung and Bronchus | Total | 16 | 59,588 | 26.9 | 24.2 | 21.8 | 0.249 | 2,945 | 8,929,127 | 33.0 |
| Lung and Bronchus | Male | 6 | 30,387 | 19.7 | 16.9 | 12.3 | 0.077 | 1,550 | 4,481,481 | 34.6 |
| Lung and Bronchus | Female | 10 | 29,201 | 34.2 | 32.4 | 9.7 | 1.000 | 1,395 | 4,447,646 | 31.4 |
| Melanoma of the Skin | Total | 2 | 59,588 | 3.4 | 3.1 | 2.1 | 1.000 | 287 | 8,929,127 | 3.2 |
| Melanoma of the Skin | Male | 1 | 30,387 | 3.3 | 2.8 | 1.5 | 1.000 | 191 | 4,481,481 | 4.3 |
| Melanoma of the Skin | Female | 1 | 29,201 | 3.4 | 3.3 | 0.7 | 0.966 | 96 | 4,447,646 | 2.2 |
| Myeloma | Total | 3 | 59,588 | 5.0 | 4.5 | 2.4 | 0.884 | 328 | 8,929,127 | 3.7 |
| Myeloma | Male | 3 | 30,387 | 9.9 | 8.3 | 1.6 | 0.411 | 193 | 4,481,481 | 4.3 |
| Myeloma | Female | - | 29,201 |  | - | 0.9 | 0.781 | 135 | 4,447,646 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 4 | 59,588 | 6.7 | 6.0 | 4.2 | 1.000 | 565 | 8,929,127 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 2 | 30,387 | 6.6 | 5.6 | 2.4 | 1.000 | 305 | 4,481,481 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 2 | 29,201 | 6.8 | 6.5 | 1.8 | 1.000 | 260 | 4,447,646 | 5.8 |
| Oral Cavity and Pharynx | Total | 2 | 59,588 | 3.4 | 3.0 | 1.9 | 1.000 | 264 | 8,929,127 | 3.0 |
| Oral Cavity and Pharynx | Male | 1 | 30,387 | 3.3 | 2.8 | 1.5 | 1.000 | 186 | 4,481,481 | 4.2 |
| Oral Cavity and Pharynx | Female | 1 | 29,201 | 3.4 | 3.3 | 0.5 | 0.829 | 78 | 4,447,646 | 1.8 |
| Ovary | Female | 1 | 29,201 | 3.4 | 3.3 | 2.4 | 0.611 | 349 | 4,447,646 | 7.8 |
| Pancreas | Total | 16 | 59,588 | 26.9 | 24.3 | 8.7 | $0.032 \gg$ | 1,174 | 8,929,127 | 13.1 |
| Pancreas | Male | 10 | 30,387 | 32.9 | 28.3 | 5.0 | 0.063 | 632 | 4,481,481 | 14.1 |
| Pancreas | Female | 6 | 29,201 | 20.5 | 19.5 | 3.7 | 0.352 | 542 | 4,447,646 | 12.2 |
| Prostate | Male | 9 | 30,387 | 29.6 | 24.4 | 7.7 | 0.741 | 940 | 4,481,481 | 21.0 |
| Stomach | Total | 4 | 59,588 | 6.7 | 6.1 | 1.4 | 0.112 | 194 | 8,929,127 | 2.2 |
| Stomach | Male | 4 | 30,387 | 13.2 | 11.3 | 0.9 | 0.030 >> | 117 | 4,481,481 | 2.6 |
| Stomach | Female | - | 29,201 | - | - | 0.5 | 1.000 | 77 | 4,447,646 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Owyhee County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 69.1\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 12.2\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% |  |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% |  |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 22.1\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 23.4\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 71.5\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 25.9\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 16.7\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, 12.6\% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^36]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged $50-74$ reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

## PAYDTMD COUNTY

 CANCDR PROFILEA publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 737 cases of invasive cancer were diagnosed among Payette County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Payette County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Payette <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 737 | 45,610 |
| Female Breast | 98 | 6,687 |
| Prostate | 92 | 6,417 |
| Lung \& Bronchus | 116 | 4,887 |
| Colorectal | 68 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Payette County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Payette County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Payette County was 621.8 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.6) gives an estimate of the relative burden of disease in Payette County.

The age- and sex-adjusted incidence rate of invasive cancer in Payette County, all sites combined, was 558.3 cases per 100,000 persons per year during 2016-2020. There were statistically significantly more cases of cancer in Payette County (737) than expected (684.6) based upon rates in the remainder of the state $(p=.049)$.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 287 Payette County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Payette County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Payette <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 1,346 | 77,431 |
| Cancer Deaths | 287 | 15,121 |
| \% of All Deaths | $21.3 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 73 | 2,961 |
| Colorectal | 29 | 1,319 |
| Pancreas | 17 | 1,190 |
| Female Breast | 26 | 1,086 |
| Prostate | 18 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Payette County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Payette County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Payette County, all sites combined, was 204.6 deaths per 100,000 persons per year during 2017-2021, compared with 167.3 for the remainder of the state. There were statistically significantly more cancer deaths in Payette County (287) than expected (234.7) based upon rates in the remainder of the state $(p=.001)$.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020 COMPARISON BETWEEN PAYETTE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

|  |  | Payette County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person Years | Crude <br> Rate (1) | A.A.I. <br> Rate (1,2) | Expected <br> Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 737 | 118,527 | 621.8 | 558.3 | 684.6 | 0.049 >> | 44,873 | 8,653,301 | 518.6 |
| All Sites Combined | Male | 403 | 59,188 | 680.9 | 596.3 | 372.2 | 0.119 | 23,886 | 4,337,722 | 550.7 |
| All Sites Combined | Female | 334 | 59,339 | 562.9 | 515.5 | 315.1 | 0.300 | 20,987 | 4,315,579 | 486.3 |
| Bladder | Total | 27 | 118,527 | 22.8 | 19.7 | 34.2 | 0.247 | 2,157 | 8,653,301 | 24.9 |
| Bladder | Male | 20 | 59,188 | 33.8 | 28.3 | 28.2 | 0.133 | 1,731 | 4,337,722 | 39.9 |
| Bladder | Female | 7 | 59,339 | 11.8 | 10.5 | 6.6 | 0.964 | 426 | 4,315,579 | 9.9 |
| Brain - malignant | Total | 8 | 118,527 | 6.7 | 6.3 | 9.1 | 0.890 | 617 | 8,653,301 | 7.1 |
| Brain - malignant | Male | 4 | 59,188 | 6.8 | 6.3 | 5.5 | 0.726 | 371 | 4,337,722 | 8.6 |
| Brain - malignant | Female | 4 | 59,339 | 6.7 | 6.3 | 3.6 | 0.974 | 246 | 4,315,579 | 5.7 |
| Brain and other CNS - non-malignant | Total | 16 | 118,527 | 13.5 | 12.3 | 21.1 | 0.315 | 1,408 | 8,653,301 | 16.3 |
| Brain and other CNS - non-malignant | Male | 5 | 59,188 | 8.4 | 7.7 | 7.1 | 0.569 | 475 | 4,337,722 | 11.0 |
| Brain and other CNS - non-malignant | Female | 11 | 59,339 | 18.5 | 17.1 | 13.9 | 0.531 | 933 | 4,315,579 | 21.6 |
| Breast | Total | 99 | 118,527 | 83.5 | 76.3 | 99.6 | 1.000 | 6,647 | 8,653,301 | 76.8 |
| Breast | Male | 1 | 59,188 | 1.7 | 1.4 | 0.9 | 1.000 | 58 | 4,337,722 | 1.3 |
| Breast | Female | 98 | 59,339 | 165.2 | 151.8 | 98.6 | 1.000 | 6,589 | 4,315,579 | 152.7 |
| Breast - in situ | Total | 16 | 118,527 | 13.5 | 12.5 | 18.1 | 0.726 | 1,223 | 8,653,301 | 14.1 |
| Breast - in situ | Male | - | 59,188 | - | - | 0.1 | 1.000 | 5 | 4,337,722 | 0.1 |
| Breast - in situ | Female | 16 | 59,339 | 27.0 | 24.9 | 18.1 | 0.724 | 1,218 | 4,315,579 | 28.2 |
| Cervix | Female | 9 | 59,339 | 15.2 | 15.0 | 4.1 | $0.049 \gg$ | 295 | 4,315,579 | 6.8 |
| Colorectal | Total | 68 | 118,527 | 57.4 | 51.3 | 51.8 | $0.035 \gg$ | 3,383 | 8,653,301 | 39.1 |
| Colorectal | Male | 45 | 59,188 | 76.0 | 67.0 | 28.8 | 0.006 >> | 1,858 | 4,337,722 | 42.8 |
| Colorectal | Female | 23 | 59,339 | 38.8 | 35.2 | 23.1 | 1.000 | 1,525 | 4,315,579 | 35.3 |
| Corpus Uteri | Female | 12 | 59,339 | 20.2 | 18.7 | 19.6 | 0.095 | 1,318 | 4,315,579 | 30.5 |
| Esophagus | Total | 7 | 118,527 | 5.9 | 5.2 | 7.7 | 0.982 | 499 | 8,653,301 | 5.8 |
| Esophagus | Male | 6 | 59,188 | 10.1 | 8.8 | 6.6 | 1.000 | 418 | 4,337,722 | 9.6 |
| Esophagus | Female | 1 | 59,339 | 1.7 | 1.5 | 1.2 | 1.000 | 81 | 4,315,579 | 1.9 |
| Hodgkin Lymphoma | Total | 2 | 118,527 | 1.7 | 1.7 | 2.9 | 0.909 | 208 | 8,653,301 | 2.4 |
| Hodgkin Lymphoma | Male | 1 | 59,188 | 1.7 | 1.7 | 1.6 | 1.000 | 117 | 4,337,722 | 2.7 |
| Hodgkin Lymphoma | Female | 1 | 59,339 | 1.7 | 1.7 | 1.3 | 1.000 | 91 | 4,315,579 | 2.1 |
| Kidney and Renal Pelvis | Total | 32 | 118,527 | 27.0 | 24.3 | 27.2 | 0.398 | 1,783 | 8,653,301 | 20.6 |
| Kidney and Renal Pelvis | Male | 25 | 59,188 | 42.2 | 37.6 | 17.7 | 0.119 | 1,157 | 4,337,722 | 26.7 |
| Kidney and Renal Pelvis | Female | 7 | 59,339 | 11.8 | 10.7 | 9.5 | 0.536 | 626 | 4,315,579 | 14.5 |
| Larynx | Total | 6 | 118,527 | 5.1 | 4.5 | 3.2 | 0.212 | 209 | 8,653,301 | 2.4 |
| Larynx | Male | 6 | 59,188 | 10.1 | 8.8 | 2.4 | 0.073 | 154 | 4,337,722 | 3.6 |
| Larynx | Female | - | 59,339 | - | - | 0.8 | 0.876 | 55 | 4,315,579 | 1.3 |
| Leukemia | Total | 27 | 118,527 | 22.8 | 20.2 | 24.8 | 0.712 | 1,604 | 8,653,301 | 18.5 |
| Leukemia | Male | 18 | 59,188 | 30.4 | 26.4 | 15.3 | 0.550 | 971 | 4,337,722 | 22.4 |
| Leukemia | Female | 9 | 59,339 | 15.2 | 13.7 | 9.7 | 1.000 | 633 | 4,315,579 | 14.7 |
| Liver and Bile Duct | Total | 19 | 118,527 | 16.0 | 14.4 | 12.3 | 0.093 | 810 | 8,653,301 | 9.4 |
| Liver and Bile Duct | Male | 14 | 59,188 | 23.7 | 21.1 | 8.8 | 0.130 | 576 | 4,337,722 | 13.3 |
| Liver and Bile Duct | Female | 5 | 59,339 | 8.4 | 7.6 | 3.6 | 0.572 | 234 | 4,315,579 | 5.4 |
| Lung and Bronchus | Total | 116 | 118,527 | 97.9 | 84.7 | 75.5 | 0.000 >> | 4,771 | 8,653,301 | 55.1 |
| Lung and Bronchus | Male | 58 | 59,188 | 98.0 | 82.8 | 38.7 | $0.004 \gg$ | 2,394 | 4,337,722 | 55.2 |
| Lung and Bronchus | Female | 58 | 59,339 | 97.7 | 86.3 | 37.0 | $0.002 \gg$ | 2,377 | 4,315,579 | 55.1 |
| Melanoma of the Skin | Total | 26 | 118,527 | 21.9 | 20.0 | 43.8 | 0.005 < | 2,916 | 8,653,301 | 33.7 |
| Melanoma of the Skin | Male | 19 | 59,188 | 32.1 | 28.3 | 27.1 | 0.134 | 1,746 | 4,337,722 | 40.3 |
| Melanoma of the Skin | Female | 7 | 59,339 | 11.8 | 11.1 | 17.1 | 0.010 < | 1,170 | 4,315,579 | 27.1 |
| Myeloma | Total | 10 | 118,527 | 8.4 | 7.3 | 11.0 | 0.918 | 698 | 8,653,301 | 8.1 |
| Myeloma | Male | 6 | 59,188 | 10.1 | 8.6 | 7.0 | 0.897 | 435 | 4,337,722 | 10.0 |
| Myeloma | Female | 4 | 59,339 | 6.7 | 6.0 | 4.1 | 1.000 | 263 | 4,315,579 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 38 | 118,527 | 32.1 | 28.7 | 29.1 | 0.128 | 1,902 | 8,653,301 | 22.0 |
| Non-Hodgkin Lymphoma | Male | 14 | 59,188 | 23.7 | 21.0 | 17.2 | 0.535 | 1,115 | 4,337,722 | 25.7 |
| Non-Hodgkin Lymphoma | Female | 24 | 59,339 | 40.4 | 36.7 | 11.9 | $0.003 \gg$ | 787 | 4,315,579 | 18.2 |
| Oral Cavity and Pharynx | Total | 19 | 118,527 | 16.0 | 14.6 | 19.2 | 1.000 | 1,276 | 8,653,301 | 14.7 |
| Oral Cavity and Pharynx | Male | 13 | 59,188 | 22.0 | 19.7 | 14.0 | 0.927 | 923 | 4,337,722 | 21.3 |
| Oral Cavity and Pharynx | Female | 6 | 59,339 | 10.1 | 9.3 | 5.3 | 0.872 | 353 | 4,315,579 | 8.2 |
| Ovary | Female | 9 | 59,339 | 15.2 | 14.0 | 7.8 | 0.756 | 524 | 4,315,579 | 12.1 |
| Pancreas | Total | 21 | 118,527 | 17.7 | 15.5 | 21.9 | 0.952 | 1,402 | 8,653,301 | 16.2 |
| Pancreas | Male | 13 | 59,188 | 22.0 | 18.8 | 12.3 | 0.920 | 771 | 4,337,722 | 17.8 |
| Pancreas | Female | 8 | 59,339 | 13.5 | 12.1 | 9.7 | 0.735 | 631 | 4,315,579 | 14.6 |
| Prostate | Male | 92 | 59,188 | 155.4 | 137.4 | 97.6 | 0.614 | 6,325 | 4,337,722 | 145.8 |
| Stomach | Total | 3 | 118,527 | 2.5 | 2.2 | 7.2 | 0.146 | 464 | 8,653,301 | 5.4 |
| Stomach | Male | 3 | 59,188 | 5.1 | 4.4 | 4.9 | 0.572 | 306 | 4,337,722 | 7.1 |
| Stomach | Female | - | 59,339 | - | - | 2.4 | 0.188 | 158 | 4,315,579 | 3.7 |
| Testis | Male | 2 | 59,188 | 3.4 | 3.7 | 3.3 | 0.738 | 263 | 4,337,722 | 6.1 |
| Thyroid | Total | 22 | 118,527 | 18.6 | 18.3 | 16.6 | 0.236 | 1,198 | 8,653,301 | 13.8 |
| Thyroid | Male | 9 | 59,188 | 15.2 | 14.6 | 4.9 | 0.124 | 346 | 4,337,722 | 8.0 |
| Thyroid | Female | 13 | 59,339 | 21.9 | 21.7 | 11.8 | 0.810 | 852 | 4,315,579 | 19.7 |
| Pediatric Age 0 to 19 | Total | 9 | 33,858 | 26.6 | 26.8 | 5.7 | 0.249 | 412 | 2,426,665 | 17.0 |
| Pediatric Age 0 to 19 | Male | 4 | 17,594 | 22.7 | 22.9 | 3.1 | 0.747 | 219 | 1,238,916 | 17.7 |
| Pediatric Age 0 to 19 | Female | 5 | 16,264 | 30.7 | 31.0 | 2.6 | 0.250 | 193 | 1,187,749 | 16.2 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN PAYETTE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Payette County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 1,346 | 121,950 | 1,103.7 | 965.1 | 1,196.7 | 0.000 >> | 76,084 | 8,866,765 | 858.1 |
| All Causes of Death | Male | 768 | 61,008 | 1,258.9 | 1,055.9 | 658.4 | 0.000 >> | 40,288 | 4,450,860 | 905.2 |
| All Causes of Death | Female | 578 | 60,942 | 948.4 | 867.0 | 540.4 | 0.113 | 35,796 | 4,415,905 | 810.6 |
| All Malignant Cancers | Total | 287 | 121,950 | 235.3 | 204.6 | 234.7 | 0.001 >> | 14,834 | 8,866,765 | 167.3 |
| All Malignant Cancers | Male | 162 | 61,008 | 265.5 | 222.3 | 131.2 | 0.010 >> | 8,014 | 4,450,860 | 180.1 |
| All Malignant Cancers | Female | 125 | 60,942 | 205.1 | 183.6 | 105.1 | 0.064 | 6,820 | 4,415,905 | 154.4 |
| Bladder | Total | 10 | 121,950 | 8.2 | 6.9 | 7.8 | 0.512 | 479 | 8,866,765 | 5.4 |
| Bladder | Male | 9 | 61,008 | 14.8 | 11.7 | 6.4 | 0.386 | 369 | 4,450,860 | 8.3 |
| Bladder | Female | 1 | 60,942 | 1.6 | 1.4 | 1.7 | 0.973 | 110 | 4,415,905 | 2.5 |
| Brain and Other Nervous System | Total | 8 | 121,950 | 6.6 | 6.0 | 7.5 | 0.951 | 496 | 8,866,765 | 5.6 |
| Brain and Other Nervous System | Male | 2 | 61,008 | 3.3 | 2.9 | 4.5 | 0.341 | 296 | 4,450,860 | 6.7 |
| Brain and Other Nervous System | Female | 6 | 60,942 | 9.8 | 9.1 | 3.0 | 0.167 | 200 | 4,415,905 | 4.5 |
| Breast | Total | 26 | 121,950 | 21.3 | 19.0 | 16.6 | 0.040 >> | 1,076 | 8,866,765 | 12.1 |
| Breast | Male |  | 61,008 |  |  | 0.3 | 1.000 | 16 | 4,450,860 | 0.4 |
| Breast | Female | 26 | 60,942 | 42.7 | 38.9 | 16.1 | 0.027 >> | 1,060 | 4,415,905 | 24.0 |
| Cervix | Female | - | 60,942 |  | - | 1.2 | 0.612 | 83 | 4,415,905 | 1.9 |
| Colorectal | Total | 29 | 121,950 | 23.8 | 20.9 | 20.2 | 0.075 | 1,290 | 8,866,765 | 14.5 |
| Colorectal | Male | 19 | 61,008 | 31.1 | 26.8 | 11.1 | 0.039 >> | 700 | 4,450,860 | 15.7 |
| Colorectal | Female | 10 | 60,942 | 16.4 | 14.8 | 9.0 | 0.836 | 590 | 4,415,905 | 13.4 |
| Corpus Uteri | Female | 2 | 60,942 | 3.3 | 3.0 | 2.6 | 1.000 | 171 | 4,415,905 | 3.9 |
| Esophagus | Total | 8 | 121,950 | 6.6 | 5.7 | 7.4 | 0.913 | 469 | 8,866,765 | 5.3 |
| Esophagus | Male | 8 | 61,008 | 13.1 | 11.2 | 6.3 | 0.592 | 393 | 4,450,860 | 8.8 |
| Esophagus | Female | - | 60,942 | - | - | 1.2 | 0.617 | 76 | 4,415,905 | 1.7 |
| Hodgkin Lymphoma | Total | - | 121,950 | - | - | 0.4 | 1.000 | 29 | 8,866,765 | 0.3 |
| Hodgkin Lymphoma | Male | - | 61,008 | - | - | 0.2 | 1.000 | 14 | 4,450,860 | 0.3 |
| Hodgkin Lymphoma | Female | - | 60,942 |  | - | 0.2 | 1.000 | 15 | 4,415,905 | 0.3 |
| Kidney | Total | 4 | 121,950 | 3.3 | 2.8 | 6.0 | 0.559 | 381 | 8,866,765 | 4.3 |
| Kidney | Male | 4 | 61,008 | 6.6 | 5.6 | 3.9 | 1.000 | 238 | 4,450,860 | 5.3 |
| Kidney | Female | - | 60,942 | - | - | 2.2 | 0.219 | 143 | 4,415,905 | 3.2 |
| Larynx | Total | - | 121,950 |  | - | 1.1 | 0.653 | 71 | 8,866,765 | 0.8 |
| Larynx | Male | - | 61,008 | - | - | 1.0 | 0.772 | 58 | 4,450,860 | 1.3 |
| Larynx | Female | - | 60,942 | - | - | 0.2 | 1.000 | 13 | 4,415,905 | 0.3 |
| Leukemia | Total | 11 | 121,950 | 9.0 | 7.7 | 10.4 | 0.943 | 649 | 8,866,765 | 7.3 |
| Leukemia | Male | 9 | 61,008 | 14.8 | 12.2 | 6.3 | 0.364 | 377 | 4,450,860 | 8.5 |
| Leukemia | Female | 2 | 60,942 | 3.3 | 2.9 | 4.2 | 0.408 | 272 | 4,415,905 | 6.2 |
| Liver and Bile Duct | Total | 10 | 121,950 | 8.2 | 7.2 | 9.2 | 0.887 | 593 | 8,866,765 | 6.7 |
| Liver and Bile Duct | Male | 8 | 61,008 | 13.1 | 11.4 | 6.3 | 0.598 | 400 | 4,450,860 | 9.0 |
| Liver and Bile Duct | Female | 2 | 60,942 | 3.3 | 2.9 | 3.0 | 0.856 | 193 | 4,415,905 | 4.4 |
| Lung and Bronchus | Total | 73 | 121,950 | 59.9 | 51.5 | 46.2 | 0.000 >> | 2,888 | 8,866,765 | 32.6 |
| Lung and Bronchus | Male | 40 | 61,008 | 65.6 | 55.0 | 24.8 | $0.006 \gg$ | 1,516 | 4,450,860 | 34.1 |
| Lung and Bronchus | Female | 33 | 60,942 | 54.1 | 47.6 | 21.6 | 0.026 >> | 1,372 | 4,415,905 | 31.1 |
| Melanoma of the Skin | Total | 4 | 121,950 | 3.3 | 2.9 | 4.5 | 1.000 | 285 | 8,866,765 | 3.2 |
| Melanoma of the Skin | Male | 2 | 61,008 | 3.3 | 2.8 | 3.1 | 0.820 | 190 | 4,450,860 | 4.3 |
| Melanoma of the Skin | Female |  | 60,942 | 3.3 | 2.9 | 1.5 | 0.858 | 95 | 4,415,905 | 2.2 |
| Myeloma | Total | 4 | 121,950 | 3.3 | 2.8 | 5.4 | 0.760 | 327 | 8,866,765 | 3.7 |
| Myeloma | Male | 3 | 61,008 | 4.9 | 4.0 | 3.3 | 1.000 | 193 | 4,450,860 | 4.3 |
| Myeloma | Female | 1 | 60,942 | 1.6 | 1.4 | 2.2 | 0.733 | 134 | 4,415,905 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 12 | 121,950 | 9.8 | 8.4 | 9.0 | 0.392 | 557 | 8,866,765 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 4 | 61,008 | 6.6 | 5.4 | 5.0 | 0.879 | 303 | 4,450,860 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 8 | 60,942 | 13.1 | 11.5 | 4.0 | 0.102 | 254 | 4,415,905 | 5.8 |
| Oral Cavity and Pharynx | Total | 7 | 121,950 | 5.7 | 5.0 | 4.1 | 0.234 | 259 | 8,866,765 | 2.9 |
| Oral Cavity and Pharynx | Male | 5 | 61,008 | 8.2 | 7.1 | 2.9 | 0.336 | 182 | 4,450,860 | 4.1 |
| Oral Cavity and Pharynx | Female | 2 | 60,942 | 3.3 | 3.0 | 1.2 | 0.660 | 77 | 4,415,905 | 1.7 |
| Ovary | Female | 8 | 60,942 | 13.1 | 11.8 | 5.3 | 0.324 | 342 | 4,415,905 | 7.7 |
| Pancreas | Total | 17 | 121,950 | 13.9 | 12.1 | 18.6 | 0.829 | 1,173 | 8,866,765 | 13.2 |
| Pancreas | Male | 11 | 61,008 | 18.0 | 15.3 | 10.2 | 0.887 | 631 | 4,450,860 | 14.2 |
| Pancreas | Female | 6 | 60,942 | 9.8 | 8.7 | 8.4 | 0.528 | 542 | 4,415,905 | 12.3 |
| Prostate | Male | 18 | 61,008 | 29.5 | 23.4 | 16.1 | 0.703 | 931 | 4,450,860 | 20.9 |
| Stomach | Total | 1 | 121,950 | 0.8 | 0.7 | 3.1 | 0.376 | 197 | 8,866,765 | 2.2 |
| Stomach | Male | 1 | 61,008 | 1.6 | 1.4 | 1.9 | 0.844 | 120 | 4,450,860 | 2.7 |
| Stomach | Female | - | 60,942 | - | - | 1.2 | 0.631 | 77 | 4,415,905 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Payette County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 78.4\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 15.8\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 75.3\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 77.9\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 28.6\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 26.7\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 73.3\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 14.1\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 14.8\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, 12.6\% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^37]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

## POWER COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 160 cases of invasive cancer were diagnosed among Power County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Power County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Power <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 160 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 24 | 6,687 |
| Prostate | 20 | 6,417 |
| Lung \& Bronchus | 15 | 4,887 |
| Colorectal | 15 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Power County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Power County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Power County was 419.1 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (520.4) gives an estimate of the relative burden of disease in Power County.

The age- and sex-adjusted incidence rate of invasive cancer in Power County, all sites combined, was 429.1 cases per 100,000 persons per year during 2016-2020. There were statistically significantly fewer cases of cancer in Power County (160) than expected (194.1) based upon rates in the remainder of the state $(p=.013)$.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 58 Power County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Power County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Power <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 344 | 77,431 |
| Cancer Deaths | 58 | 15,121 |
| \% of All Deaths | $16.9 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 9 | 2,961 |
| Colorectal | 7 | 1,319 |
| Pancreas | 3 | 1,190 |
| Female Breast | 5 | 1,086 |
| Prostate | 4 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Power County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Power County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Power County, all sites combined, was 152.4 deaths per 100,000 persons per year during 2017-2021, compared with 168.3 for the remainder of the state. There were fewer cancer deaths in Power County (58) than expected (64.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN POWER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

|  |  | Power County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate $(1,2)$ | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 160 | 38,173 | 419.1 | 429.1 | 194.1 | 0.013 << | 45,450 | 8,733,655 | 520.4 |
| All Sites Combined | Male | 82 | 19,348 | 423.8 | 420.2 | 107.9 | 0.011 << | 24,207 | 4,377,562 | 553.0 |
| All Sites Combined | Female | 78 | 18,825 | 414.3 | 436.1 | 87.2 | 0.351 | 21,243 | 4,356,093 | 487.7 |
| Bladder | Total | 5 | 38,173 | 13.1 | 13.2 | 9.4 | 0.183 | 2,179 | 8,733,655 | 24.9 |
| Bladder | Male | 4 | 19,348 | 20.7 | 20.3 | 7.9 | 0.214 | 1,747 | 4,377,562 | 39.9 |
| Bladder | Female | 1 | 18,825 | 5.3 | 5.5 | 1.8 | 0.926 | 432 | 4,356,093 | 9.9 |
| Brain - malignant | Total | 1 | 38,173 | 2.6 | 2.7 | 2.7 | 0.507 | 624 | 8,733,655 | 7.1 |
| Brain - malignant | Male | - | 19,348 | - | - | 1.6 | 0.386 | 375 | 4,377,562 | 8.6 |
| Brain - malignant | Female | 1 | 18,825 | 5.3 | 5.4 | 1.1 | 1.000 | 249 | 4,356,093 | 5.7 |
| Brain and other CNS - non-malignant | Total | 7 | 38,173 | 18.3 | 18.9 | 6.0 | 0.788 | 1,417 | 8,733,655 | 16.2 |
| Brain and other CNS - non-malignant | Male | 2 | 19,348 | 10.3 | 10.5 | 2.1 | 1.000 | 478 | 4,377,562 | 10.9 |
| Brain and other CNS - non-malignant | Female | 5 | 18,825 | 26.6 | 28.0 | 3.9 | 0.686 | 939 | 4,356,093 | 21.6 |
| Breast | Total | 24 | 38,173 | 62.9 | 65.3 | 28.3 | 0.487 | 6,722 | 8,733,655 | 77.0 |
| Breast | Male | - | 19,348 | - | - | 0.3 | 1.000 | 59 | 4,377,562 | 1.3 |
| Breast | Female | 24 | 18,825 | 127.5 | 135.3 | 27.1 | 0.630 | 6,663 | 4,356,093 | 153.0 |
| Breast - in situ | Total | 7 | 38,173 | 18.3 | 19.2 | 5.1 | 0.520 | 1,232 | 8,733,655 | 14.1 |
| Breast - in situ | Male | - | 19,348 | - | - | 0.0 | 1.000 | 5 | 4,377,562 | 0.1 |
| Breast - in situ | Female | 7 | 18,825 | 37.2 | 39.7 | 5.0 | 0.468 | 1,227 | 4,356,093 | 28.2 |
| Cervix | Female | 1 | 18,825 | 5.3 | 5.9 | 1.2 | 1.000 | 303 | 4,356,093 | 7.0 |
| Colorectal | Total | 15 | 38,173 | 39.3 | 40.3 | 14.7 | 0.998 | 3,436 | 8,733,655 | 39.3 |
| Colorectal | Male | 13 | 19,348 | 67.2 | 67.0 | 8.4 | 0.168 | 1,890 | 4,377,562 | 43.2 |
| Colorectal | Female | 2 | 18,825 | 10.6 | 11.1 | 6.4 | 0.095 | 1,546 | 4,356,093 | 35.5 |
| Corpus Uteri | Female | 6 | 18,825 | 31.9 | 33.6 | 5.4 | 0.918 | 1,324 | 4,356,093 | 30.4 |
| Esophagus | Total | 2 | 38,173 | 5.2 | 5.3 | 2.2 | 1.000 | 504 | 8,733,655 | 5.8 |
| Esophagus | Male | 2 | 19,348 | 10.3 | 10.2 | 1.9 | 1.000 | 422 | 4,377,562 | 9.6 |
| Esophagus | Female | - | 18,825 | - | - | 0.3 | 1.000 | 82 | 4,356,093 | 1.9 |
| Hodgkin Lymphoma | Total | 1 | 38,173 | 2.6 | 2.7 | 0.9 | 1.000 | 209 | 8,733,655 | 2.4 |
| Hodgkin Lymphoma | Male | 1 | 19,348 | 5.2 | 5.4 | 0.5 | 0.783 | 117 | 4,377,562 | 2.7 |
| Hodgkin Lymphoma | Female | - | 18,825 | - | - | 0.4 | 1.000 | 92 | 4,356,093 | 2.1 |
| Kidney and Renal Pelvis | Total | 11 | 38,173 | 28.8 | 29.6 | 7.7 | 0.308 | 1,804 | 8,733,655 | 20.7 |
| Kidney and Renal Pelvis | Male | 8 | 19,348 | 41.3 | 41.5 | 5.2 | 0.303 | 1,174 | 4,377,562 | 26.8 |
| Kidney and Renal Pelvis | Female | 3 | 18,825 | 15.9 | 16.6 | 2.6 | 0.968 | 630 | 4,356,093 | 14.5 |
| Larynx | Total | 1 | 38,173 | 2.6 | 2.7 | 0.9 | 1.000 | 214 | 8,733,655 | 2.5 |
| Larynx | Male | 1 | 19,348 | 5.2 | 5.1 | 0.7 | 1.000 | 159 | 4,377,562 | 3.6 |
| Larynx | Female | - | 18,825 | - | - | 0.2 | 1.000 | 55 | 4,356,093 | 1.3 |
| Leukemia | Total | 9 | 38,173 | 23.6 | 23.7 | 7.0 | 0.554 | 1,622 | 8,733,655 | 18.6 |
| Leukemia | Male | 1 | 19,348 | 5.2 | 5.1 | 4.4 | 0.128 | 988 | 4,377,562 | 22.6 |
| Leukemia | Female | 8 | 18,825 | 42.5 | 43.7 | 2.7 | 0.012 >> | 634 | 4,356,093 | 14.6 |
| Liver and Bile Duct | Total | - | 38,173 | - | - | 3.6 | 0.056 | 829 | 8,733,655 | 9.5 |
| Liver and Bile Duct | Male | - | 19,348 | - | - | 2.6 | 0.143 | 590 | 4,377,562 | 13.5 |
| Liver and Bile Duct | Female | - | 18,825 | - | - | 1.0 | 0.740 | 239 | 4,356,093 | 5.5 |
| Lung and Bronchus | Total | 15 | 38,173 | 39.3 | 39.6 | 21.1 | 0.214 | 4,872 | 8,733,655 | 55.8 |
| Lung and Bronchus | Male | 8 | 19,348 | 41.3 | 40.5 | 11.0 | 0.460 | 2,444 | 4,377,562 | 55.8 |
| Lung and Bronchus | Female | 7 | 18,825 | 37.2 | 38.5 | 10.1 | 0.418 | 2,428 | 4,356,093 | 55.7 |
| Melanoma of the Skin | Total | 9 | 38,173 | 23.6 | 24.5 | 12.4 | 0.425 | 2,933 | 8,733,655 | 33.6 |
| Melanoma of the Skin | Male | 5 | 19,348 | 25.8 | 25.9 | 7.7 | 0.431 | 1,760 | 4,377,562 | 40.2 |
| Melanoma of the Skin | Female | 4 | 18,825 | 21.2 | 22.7 | 4.7 | 0.972 | 1,173 | 4,356,093 | 26.9 |
| Myeloma | Total | 1 | 38,173 | 2.6 | 2.7 | 3.0 | 0.385 | 707 | 8,733,655 | 8.1 |
| Myeloma | Male | 1 | 19,348 | 5.2 | 5.1 | 2.0 | 0.825 | 440 | 4,377,562 | 10.1 |
| Myeloma | Female | - | 18,825 | - | - | 1.1 | 0.665 | 267 | 4,356,093 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 2 | 38,173 | 5.2 | 5.3 | 8.3 | 0.022 << | 1,938 | 8,733,655 | 22.2 |
| Non-Hodgkin Lymphoma | Male | - | 19,348 | - | - | 5.0 | 0.013 << | 1,129 | 4,377,562 | 25.8 |
| Non-Hodgkin Lymphoma | Female | 2 | 18,825 | 10.6 | 11.1 | 3.3 | 0.700 | 809 | 4,356,093 | 18.6 |
| Oral Cavity and Pharynx | Total | 3 | 38,173 | 7.9 | 8.0 | 5.5 | 0.399 | 1,292 | 8,733,655 | 14.8 |
| Oral Cavity and Pharynx | Male | 1 | 19,348 | 5.2 | 5.1 | 4.2 | 0.161 | 935 | 4,377,562 | 21.4 |
| Oral Cavity and Pharynx | Female | 2 | 18,825 | 10.6 | 11.2 | 1.5 | 0.863 | 357 | 4,356,093 | 8.2 |
| Ovary | Female | 2 | 18,825 | 10.6 | 11.2 | 2.2 | 1.000 | 531 | 4,356,093 | 12.2 |
| Pancreas | Total | 6 | 38,173 | 15.7 | 16.0 | 6.1 | 1.000 | 1,417 | 8,733,655 | 16.2 |
| Pancreas | Male | 4 | 19,348 | 20.7 | 20.4 | 3.5 | 0.923 | 780 | 4,377,562 | 17.8 |
| Pancreas | Female | 2 | 18,825 | 10.6 | 11.0 | 2.6 | 1.000 | 637 | 4,356,093 | 14.6 |
| Prostate | Male | 20 | 19,348 | 103.4 | 101.9 | 28.7 | 0.115 | 6,397 | 4,377,562 | 146.1 |
| Stomach | Total | 3 | 38,173 | 7.9 | 8.0 | 2.0 | 0.640 | 464 | 8,733,655 | 5.3 |
| Stomach | Male | 1 | 19,348 | 5.2 | 5.1 | 1.4 | 1.000 | 308 | 4,377,562 | 7.0 |
| Stomach | Female | 2 | 18,825 | 10.6 | 11.2 | 0.6 | 0.269 | 156 | 4,356,093 | 3.6 |
| Testis | Male | - | 19,348 | - | - | 1.1 | 0.699 | 265 | 4,377,562 | 6.1 |
| Thyroid | Total | 4 | 38,173 | 10.5 | 11.3 | 4.9 | 0.902 | 1,216 | 8,733,655 | 13.9 |
| Thyroid | Male | 1 | 19,348 | 5.2 | 5.4 | 1.5 | 1.000 | 354 | 4,377,562 | 8.1 |
| Thyroid | Female | 3 | 18,825 | 15.9 | 17.4 | 3.4 | 1.000 | 862 | 4,356,093 | 19.8 |
| Pediatric Age 0 to 19 | Total | 3 | 12,818 | 23.4 | 23.7 | 2.2 | 0.736 | 418 | 2,447,705 | 17.1 |
| Pediatric Age 0 to 19 | Male | - | 6,525 | - | - | 1.2 | 0.628 | 223 | 1,249,985 | 17.8 |
| Pediatric Age 0 to 19 | Female | 3 | 6,293 | 47.7 | 48.7 | 1.0 | 0.161 | 195 | 1,197,720 | 16.3 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).
Statistical Note: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN POWER COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Power County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 344 | 38,470 | 894.2 | 901.5 | 328.7 | 0.411 | 77,086 | 8,950,245 | 861.3 |
| All Causes of Death | Male | 177 | 19,514 | 907.0 | 898.6 | 179.2 | 0.906 | 40,879 | 4,492,354 | 910.0 |
| All Causes of Death | Female | 167 | 18,956 | 881.0 | 899.1 | 150.9 | 0.206 | 36,207 | 4,457,891 | 812.2 |
| All Malignant Cancers | Total | 58 | 38,470 | 150.8 | 152.4 | 64.1 | 0.493 | 15,063 | 8,950,245 | 168.3 |
| All Malignant Cancers | Male | 34 | 19,514 | 174.2 | 171.8 | 35.9 | 0.841 | 8,142 | 4,492,354 | 181.2 |
| All Malignant Cancers | Female | 24 | 18,956 | 126.6 | 130.6 | 28.5 | 0.458 | 6,921 | 4,457,891 | 155.3 |
| Bladder | Total | 1 | 38,470 | 2.6 | 2.6 | 2.1 | 0.760 | 488 | 8,950,245 | 5.5 |
| Bladder | Male | 1 | 19,514 | 5.1 | 5.0 | 1.7 | 0.998 | 377 | 4,492,354 | 8.4 |
| Bladder | Female | - | 18,956 | - | - | 0.5 | 1.000 | 111 | 4,457,891 | 2.5 |
| Brain and Other Nervous System | Total | 1 | 38,470 | 2.6 | 2.7 | 2.1 | 0.750 | 503 | 8,950,245 | 5.6 |
| Brain and Other Nervous System | Male |  | 19,514 | - | - | 1.3 | 0.549 | 298 | 4,492,354 | 6.6 |
| Brain and Other Nervous System | Female | 1 | 18,956 | 5.3 | 5.5 | 0.8 | 1.000 | 205 | 4,457,891 | 4.6 |
| Breast | Total | 5 | 38,470 | 13.0 | 13.3 | 4.6 | 0.980 | 1,097 | 8,950,245 | 12.3 |
| Breast | Male |  | 19,514 |  | - | 0.1 | 1.000 | 16 | 4,492,354 | 0.4 |
| Breast | Female | 5 | 18,956 | 26.4 | 27.4 | 4.4 | 0.905 | 1,081 | 4,457,891 | 24.2 |
| Cervix | Female | 1 | 18,956 | 5.3 | 5.7 | 0.3 | 0.548 | 82 | 4,457,891 | 1.8 |
| Colorectal | Total | 7 | 38,470 | 18.2 | 18.5 | 5.5 | 0.643 | 1,312 | 8,950,245 | 14.7 |
| Colorectal | Male | 5 | 19,514 | 25.6 | 25.5 | 3.1 | 0.410 | 714 | 4,492,354 | 15.9 |
| Colorectal | Female | 2 | 18,956 | 10.6 | 10.9 | 2.5 | 1.000 | 598 | 4,457,891 | 13.4 |
| Corpus Uteri | Female | - | 18,956 | - | - | 0.7 | 0.987 | 173 | 4,457,891 | 3.9 |
| Esophagus | Total | 1 | 38,470 | 2.6 | 2.6 | 2.0 | 0.801 | 476 | 8,950,245 | 5.3 |
| Esophagus | Male | 1 | 19,514 | 5.1 | 5.1 | 1.8 | 0.954 | 400 | 4,492,354 | 8.9 |
| Esophagus | Female | - | 18,956 | - | - | 0.3 | 1.000 | 76 | 4,457,891 | 1.7 |
| Hodgkin Lymphoma | Total | - | 38,470 |  | - | 0.1 | 1.000 | 29 | 8,950,245 | 0.3 |
| Hodgkin Lymphoma | Male | - | 19,514 | - | - | 0.1 | 1.000 | 14 | 4,492,354 | 0.3 |
| Hodgkin Lymphoma | Female | - | 18,956 | - | - | 0.1 | 1.000 | 15 | 4,457,891 | 0.3 |
| Kidney | Total | 1 | 38,470 | 2.6 | 2.6 | 1.6 | 1.000 | 384 | 8,950,245 | 4.3 |
| Kidney | Male | 1 | 19,514 | 5.1 | 5.1 | 1.1 | 1.000 | 241 | 4,492,354 | 5.4 |
| Kidney | Female | - | 18,956 | - | - | 0.6 | 1.000 | 143 | 4,457,891 | 3.2 |
| Larynx | Total | - | 38,470 | - | - | 0.3 | 1.000 | 71 | 8,950,245 | 0.8 |
| Larynx | Male | - | 19,514 | - | - | 0.3 | 1.000 | 58 | 4,492,354 | 1.3 |
| Larynx | Female | - | 18,956 | - | - | 0.1 | 1.000 | 13 | 4,457,891 | 0.3 |
| Leukemia | Total | 3 | 38,470 | 7.8 | 7.8 | 2.8 | 1.000 | 657 | 8,950,245 | 7.3 |
| Leukemia | Male | 1 | 19,514 | 5.1 | 5.0 | 1.7 | 0.987 | 385 | 4,492,354 | 8.6 |
| Leukemia | Female | 2 | 18,956 | 10.6 | 10.8 | 1.1 | 0.628 | 272 | 4,457,891 | 6.1 |
| Liver and Bile Duct | Total | - | 38,470 | - | - | 2.6 | 0.155 | 603 | 8,950,245 | 6.7 |
| Liver and Bile Duct | Male | - | 19,514 | - | - | 1.8 | 0.335 | 408 | 4,492,354 | 9.1 |
| Liver and Bile Duct | Female | - | 18,956 | - | - | 0.8 | 0.894 | 195 | 4,457,891 | 4.4 |
| Lung and Bronchus | Total | 9 | 38,470 | 23.4 | 23.5 | 12.6 | 0.387 | 2,952 | 8,950,245 | 33.0 |
| Lung and Bronchus | Male | 6 | 19,514 | 30.7 | 30.3 | 6.8 | 0.948 | 1,550 | 4,492,354 | 34.5 |
| Lung and Bronchus | Female | , | 18,956 | 15.8 | 16.2 | 5.8 | 0.338 | 1,402 | 4,457,891 | 31.4 |
| Melanoma of the Skin | Total | 1 | 38,470 | 2.6 | 2.7 | 1.2 | 1.000 | 288 | 8,950,245 | 3.2 |
| Melanoma of the Skin | Male | - | 19,514 | - | - | 0.8 | 0.866 | 192 | 4,492,354 | 4.3 |
| Melanoma of the Skin | Female | 1 | 18,956 | 5.3 | 5.5 | 0.4 | 0.646 | 96 | 4,457,891 | 2.2 |
| Myeloma | Total |  | 38,470 |  | - | 1.4 | 0.481 | 331 | 8,950,245 | 3.7 |
| Myeloma | Male | - | 19,514 | - | - | 0.9 | 0.835 | 196 | 4,492,354 | 4.4 |
| Myeloma | Female | - | 18,956 | - | - | 0.6 | 1.000 | 135 | 4,457,891 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 3 | 38,470 | 7.8 | 7.8 | 2.4 | 0.874 | 566 | 8,950,245 | 6.3 |
| Non-Hodgkin Lymphoma | Male | - | 19,514 | - | - | 1.4 | 0.515 | 307 | 4,492,354 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 3 | 18,956 | 15.8 | 16.2 | 1.1 | 0.191 | 259 | 4,457,891 | 5.8 |
| Oral Cavity and Pharynx | Total | - | 38,470 | - | - | 1.1 | 0.649 | 266 | 8,950,245 | 3.0 |
| Oral Cavity and Pharynx | Male | - | 19,514 | - | - | 0.8 | 0.883 | 187 | 4,492,354 | 4.2 |
| Oral Cavity and Pharynx | Female | - | 18,956 | - | - | 0.3 | 1.000 | 79 | 4,457,891 | 1.8 |
| Ovary | Female | 4 | 18,956 | 21.1 | 21.9 | 1.4 | 0.112 | 346 | 4,457,891 | 7.8 |
| Pancreas | Total | 3 | 38,470 | 7.8 | 7.9 | 5.0 | 0.520 | 1,187 | 8,950,245 | 13.3 |
| Pancreas | Male | 3 | 19,514 | 15.4 | 15.3 | 2.8 | 1.000 | 639 | 4,492,354 | 14.2 |
| Pancreas | Female | - | 18,956 | - | - | 2.3 | 0.208 | 548 | 4,457,891 | 12.3 |
| Prostate | Male | 4 | 19,514 | 20.5 | 20.0 | 4.2 | 1.000 | 945 | 4,492,354 | 21.0 |
| Stomach | Total | 1 | 38,470 | 2.6 | 2.7 | 0.8 | 1.000 | 197 | 8,950,245 | 2.2 |
| Stomach | Male | - | 19,514 |  | - | 0.5 | 1.000 | 121 | 4,492,354 | 2.7 |
| Stomach | Female | 1 | 18,956 | 5.3 | 5.5 | 0.3 | 0.531 | 76 | 4,457,891 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Power County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 75.7\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 17.5\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% |  |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% |  |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 22.5\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 19.8\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 69.5\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 16.2\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 21.0\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, 12.6\% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^38]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# SHOSHONE COUNTY CANCPR PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 500 cases of invasive cancer were diagnosed among Shoshone County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Shoshone County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Shoshone <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 500 | 45,610 |
| Female Breast | 49 | 6,687 |
| Prostate | 72 | 6,417 |
| Lung \& Bronchus | 93 | 4,887 |
| Colorectal | 52 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Shoshone County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Shoshone County. The table also shows the number of observed cases,
person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Shoshone County was 787.4 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.0) gives an estimate of the relative burden of disease in Shoshone County.

The age- and sex-adjusted incidence rate of invasive cancer in Shoshone County, all sites combined, was 582.1 cases per 100,000 persons per year during 2016-2020. There were statistically significantly more cases of cancer in Shoshone County (500) than expected (444.9) based upon rates in the remainder of the state $(p=.011)$.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 171 Shoshone County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Shoshone County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Shoshone <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 998 | 77,431 |
| Cancer Deaths | 171 | 15,121 |
| \% of All Deaths | $17.1 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 53 | 2,961 |
| Colorectal | 19 | 1,319 |
| Pancreas | 14 | 1,190 |
| Female Breast | 6 | 1,086 |
| Prostate | 12 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Shoshone County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Shoshone County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Shoshone County, all sites combined, was 190.1 deaths per 100,000 persons per year during 2017-2021, compared with 167.5 for the remainder of the state. There were more cancer deaths in Shoshone County (171) than expected (150.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

|  |  | Shoshone County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 500 | 63,499 | 787.4 | 582.1 | 444.9 | 0.011 >> | 45,110 | 8,708,329 | 518.0 |
| All Sites Combined | Male | 295 | 31,957 | 923.1 | 666.9 | 243.2 | 0.001 >> | 23,994 | 4,364,953 | 549.7 |
| All Sites Combined | Female | 205 | 31,542 | 649.9 | 492.9 | 202.2 | 0.862 | 21,116 | 4,343,376 | 486.2 |
| Bladder | Total | 21 | 63,499 | 33.1 | 23.2 | 22.5 | 0.867 | 2,163 | 8,708,329 | 24.8 |
| Bladder | Male | 17 | 31,957 | 53.2 | 37.4 | 18.1 | 0.927 | 1,734 | 4,364,953 | 39.7 |
| Bladder | Female | 4 | 31,542 | 12.7 | 9.0 | 4.4 | 1.000 | 429 | 4,343,376 | 9.9 |
| Brain - malignant | Total | 4 | 63,499 | 6.3 | 5.1 | 5.6 | 0.671 | 621 | 8,708,329 | 7.1 |
| Brain - malignant | Male | 2 | 31,957 | 6.3 | 5.0 | 3.4 | 0.673 | 373 | 4,364,953 | 8.5 |
| Brain - malignant | Female | 2 | 31,542 | 6.3 | 5.1 | 2.3 | 1.000 | 248 | 4,343,376 | 5.7 |
| Brain and other CNS - non-malignant | Total | 11 | 63,499 | 17.3 | 13.5 | 13.2 | 0.664 | 1,413 | 8,708,329 | 16.2 |
| Brain and other CNS - non-malignant | Male | 3 | 31,957 | 9.4 | 7.5 | 4.4 | 0.719 | 477 | 4,364,953 | 10.9 |
| Brain and other CNS - non-malignant | Female | 8 | 31,542 | 25.4 | 19.7 | 8.8 | 0.976 | 936 | 4,343,376 | 21.6 |
| Breast | Total | 50 | 63,499 | 78.7 | 59.8 | 64.3 | 0.077 | 6,696 | 8,708,329 | 76.9 |
| Breast | Male | 1 | 31,957 | 3.1 | 2.3 | 0.6 | 0.884 | 58 | 4,364,953 | 1.3 |
| Breast | Female | 49 | 31,542 | 155.3 | 119.2 | 62.8 | 0.084 | 6,638 | 4,343,376 | 152.8 |
| Breast - in situ | Total | 7 | 63,499 | 11.0 | 8.4 | 11.7 | 0.204 | 1,232 | 8,708,329 | 14.1 |
| Breast - in situ | Male | - | 31,957 | - | - | 0.0 | 1.000 | 5 | 4,364,953 | 0.1 |
| Breast - in situ | Female | 7 | 31,542 | 22.2 | 17.3 | 11.4 | 0.233 | 1,227 | 4,343,376 | 28.2 |
| Cervix | Female | 4 | 31,542 | 12.7 | 11.8 | 2.3 | 0.415 | 300 | 4,343,376 | 6.9 |
| Colorectal | Total | 52 | 63,499 | 81.9 | 60.9 | 33.3 | $0.003 \gg$ | 3,399 | 8,708,329 | 39.0 |
| Colorectal | Male | 31 | 31,957 | 97.0 | 71.9 | 18.5 | 0.010 >> | 1,872 | 4,364,953 | 42.9 |
| Colorectal | Female | 21 | 31,542 | 66.6 | 49.6 | 14.9 | 0.157 | 1,527 | 4,343,376 | 35.2 |
| Corpus Uteri | Female | 16 | 31,542 | 50.7 | 38.5 | 12.6 | 0.402 | 1,314 | 4,343,376 | 30.3 |
| Esophagus | Total | 4 | 63,499 | 6.3 | 4.5 | 5.1 | 0.840 | 502 | 8,708,329 | 5.8 |
| Esophagus | Male | 4 | 31,957 | 12.5 | 8.9 | 4.3 | 1.000 | 420 | 4,364,953 | 9.6 |
| Esophagus | Female | - | 31,542 | - | - | 0.8 | 0.867 | 82 | 4,343,376 | 1.9 |
| Hodgkin Lymphoma | Total | - | 63,499 | - | - | 1.6 | 0.394 | 210 | 8,708,329 | 2.4 |
| Hodgkin Lymphoma | Male | - | 31,957 | - | - | 0.9 | 0.779 | 118 | 4,364,953 | 2.7 |
| Hodgkin Lymphoma | Female | - | 31,542 | - | - | 0.7 | 1.000 | 92 | 4,343,376 | 2.1 |
| Kidney and Renal Pelvis | Total | 18 | 63,499 | 28.3 | 21.2 | 17.6 | 0.978 | 1,797 | 8,708,329 | 20.6 |
| Kidney and Renal Pelvis | Male | 11 | 31,957 | 34.4 | 25.5 | 11.6 | 1.000 | 1,171 | 4,364,953 | 26.8 |
| Kidney and Renal Pelvis | Female | 7 | 31,542 | 22.2 | 16.7 | 6.0 | 0.796 | 626 | 4,343,376 | 14.4 |
| Larynx | Total | 2 | 63,499 | 3.1 | 2.3 | 2.2 | 1.000 | 213 | 8,708,329 | 2.4 |
| Larynx | Male | 1 | 31,957 | 3.1 | 2.2 | 1.6 | 1.000 | 159 | 4,364,953 | 3.6 |
| Larynx | Female | 1 | 31,542 | 3.2 | 2.3 | 0.5 | 0.822 | 54 | 4,343,376 | 1.2 |
| Leukemia | Total | 18 | 63,499 | 28.3 | 21.2 | 15.7 | 0.628 | 1,613 | 8,708,329 | 18.5 |
| Leukemia | Male | 13 | 31,957 | 40.7 | 30.5 | 9.5 | 0.332 | 976 | 4,364,953 | 22.4 |
| Leukemia | Female | 5 | 31,542 | 15.9 | 11.9 | 6.2 | 0.833 | 637 | 4,343,376 | 14.7 |
| Liver and Bile Duct | Total | 12 | 63,499 | 18.9 | 13.6 | 8.3 | 0.266 | 817 | 8,708,329 | 9.4 |
| Liver and Bile Duct | Male | 8 | 31,957 | 25.0 | 17.8 | 6.0 | 0.510 | 582 | 4,364,953 | 13.3 |
| Liver and Bile Duct | Female | 4 | 31,542 | 12.7 | 9.3 | 2.3 | 0.415 | 235 | 4,343,376 | 5.4 |
| Lung and Bronchus | Total | 93 | 63,499 | 146.5 | 102.6 | 49.9 | 0.000 >> | 4,794 | 8,708,329 | 55.1 |
| Lung and Bronchus | Male | 54 | 31,957 | 169.0 | 117.5 | 25.3 | $0.000 \gg$ | 2,398 | 4,364,953 | 54.9 |
| Lung and Bronchus | Female | 39 | 31,542 | 123.6 | 87.4 | 24.6 | $0.009 \gg$ | 2,396 | 4,343,376 | 55.2 |
| Melanoma of the Skin | Total | 16 | 63,499 | 25.2 | 19.3 | 27.9 | 0.021 << | 2,926 | 8,708,329 | 33.6 |
| Melanoma of the Skin | Male | 13 | 31,957 | 40.7 | 30.2 | 17.3 | 0.367 | 1,752 | 4,364,953 | 40.1 |
| Melanoma of the Skin | Female | 3 | 31,542 | 9.5 | 7.6 | 10.6 | 0.013 << | 1,174 | 4,343,376 | 27.0 |
| Myeloma | Total | 5 | 63,499 | 7.9 | 5.6 | 7.2 | 0.549 | 703 | 8,708,329 | 8.1 |
| Myeloma | Male | 1 | 31,957 | 3.1 | 2.2 | 4.6 | 0.117 | 440 | 4,364,953 | 10.1 |
| Myeloma | Female | 4 | 31,542 | 12.7 | 9.1 | 2.7 | 0.557 | 263 | 4,343,376 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 16 | 63,499 | 25.2 | 18.7 | 18.9 | 0.600 | 1,924 | 8,708,329 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 7 | 31,957 | 21.9 | 16.3 | 11.1 | 0.279 | 1,122 | 4,364,953 | 25.7 |
| Non-Hodgkin Lymphoma | Female | 9 | 31,542 | 28.5 | 21.1 | 7.9 | 0.784 | 802 | 4,343,376 | 18.5 |
| Oral Cavity and Pharynx | Total | 16 | 63,499 | 25.2 | 18.5 | 12.7 | 0.425 | 1,279 | 8,708,329 | 14.7 |
| Oral Cavity and Pharynx | Male | 14 | 31,957 | 43.8 | 31.7 | 9.3 | 0.183 | 922 | 4,364,953 | 21.1 |
| Oral Cavity and Pharynx | Female | 2 | 31,542 | 6.3 | 4.7 | 3.5 | 0.653 | 357 | 4,343,376 | 8.2 |
| Ovary | Female | 5 | 31,542 | 15.9 | 12.1 | 5.0 | 1.000 | 528 | 4,343,376 | 12.2 |
| Pancreas | Total | 16 | 63,499 | 25.2 | 18.0 | 14.4 | 0.738 | 1,407 | 8,708,329 | 16.2 |
| Pancreas | Male | 7 | 31,957 | 21.9 | 15.6 | 8.0 | 0.911 | 777 | 4,364,953 | 17.8 |
| Pancreas | Female | 9 | 31,542 | 28.5 | 20.4 | 6.4 | 0.392 | 630 | 4,343,376 | 14.5 |
| Prostate | Male | 72 | 31,957 | 225.3 | 156.5 | 66.9 | 0.564 | 6,345 | 4,364,953 | 145.4 |
| Stomach | Total | 4 | 63,499 | 6.3 | 4.6 | 4.6 | 1.000 | 463 | 8,708,329 | 5.3 |
| Stomach | Male | 4 | 31,957 | 12.5 | 9.0 | 3.1 | 0.752 | 305 | 4,364,953 | 7.0 |
| Stomach | Female | - | 31,542 | - | - | 1.5 | 0.429 | 158 | 4,343,376 | 3.6 |
| Testis | Male | 5 | 31,957 | 15.6 | 17.4 | 1.7 | 0.061 | 260 | 4,364,953 | 6.0 |
| Thyroid | Total | 7 | 63,499 | 11.0 | 9.9 | 9.8 | 0.469 | 1,213 | 8,708,329 | 13.9 |
| Thyroid | Male | 5 | 31,957 | 15.6 | 13.2 | 3.0 | 0.383 | 350 | 4,364,953 | 8.0 |
| Thyroid | Female | 2 | 31,542 | 6.3 | 5.9 | 6.7 | 0.072 | 863 | 4,343,376 | 19.9 |
| Pediatric Age 0 to 19 | Total | 3 | 14,059 | 21.3 | 21.0 | 2.4 | 0.882 | 418 | 2,446,464 | 17.1 |
| Pediatric Age 0 to 19 | Male | 3 | 7,242 | 41.4 | 40.4 | 1.3 | 0.289 | 220 | 1,249,268 | 17.6 |
| Pediatric Age 0 to 19 | Female | - | 6,817 | - | - | 1.1 | 0.642 | 198 | 1,197,196 | 16.5 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN SHOSHONE COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Shoshone County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 998 | 64,683 | 1,542.9 | 1,131.9 | 755.2 | 0.000 >> | 76,432 | 8,924,032 | 856.5 |
| All Causes of Death | Male | 553 | 32,642 | 1,694.1 | 1,303.0 | 383.8 | 0.000 >> | 40,503 | 4,479,226 | 904.2 |
| All Causes of Death | Female | 445 | 32,041 | 1,388.8 | 966.1 | 372.3 | 0.000 >> | 35,929 | 4,444,806 | 808.3 |
| All Malignant Cancers | Total | 171 | 64,683 | 264.4 | 190.1 | 150.7 | 0.111 | 14,950 | 8,924,032 | 167.5 |
| All Malignant Cancers | Male | 100 | 32,642 | 306.4 | 223.8 | 80.6 | 0.040 >> | 8,076 | 4,479,226 | 180.3 |
| All Malignant Cancers | Female | 71 | 32,041 | 221.6 | 158.1 | 69.4 | 0.884 | 6,874 | 4,444,806 | 154.7 |
| Bladder | Total | 2 | 64,683 | 3.1 | 2.2 | 5.0 | 0.245 | 487 | 8,924,032 | 5.5 |
| Bladder | Male | 2 | 32,642 | 6.1 | 4.6 | 3.7 | 0.577 | 376 | 4,479,226 | 8.4 |
| Bladder | Female | - | 32,041 |  | - | 1.2 | 0.619 | 111 | 4,444,806 | 2.5 |
| Brain and Other Nervous System | Total | 3 | 64,683 | 4.6 | 3.5 | 4.8 | 0.600 | 501 | 8,924,032 | 5.6 |
| Brain and Other Nervous System | Male | 1 | 32,642 | 3.1 | 2.3 | 2.9 | 0.444 | 297 | 4,479,226 | 6.6 |
| Brain and Other Nervous System | Female | 2 | 32,041 | 6.2 | 4.8 | 1.9 | 1.000 | 204 | 4,444,806 | 4.6 |
| Breast | Total | 7 | 64,683 | 10.8 | 8.0 | 10.8 | 0.320 | 1,095 | 8,924,032 | 12.3 |
| Breast | Male | 1 | 32,642 | 3.1 | 2.3 | 0.1 | 0.276 | 15 | 4,479,226 | 0.3 |
| Breast | Female | 6 | 32,041 | 18.7 | 13.6 | 10.7 | 0.185 | 1,080 | 4,444,806 | 24.3 |
| Cervix | Female | - | 32,041 |  | - | 0.7 | 0.988 | 83 | 4,444,806 | 1.9 |
| Colorectal | Total | 19 | 64,683 | 29.4 | 21.5 | 12.9 | 0.131 | 1,300 | 8,924,032 | 14.6 |
| Colorectal | Male | 11 | 32,642 | 33.7 | 25.1 | 6.9 | 0.185 | 708 | 4,479,226 | 15.8 |
| Colorectal | Female | 8 | 32,041 | 25.0 | 17.7 | 6.0 | 0.516 | 592 | 4,444,806 | 13.3 |
| Corpus Uteri | Female | 2 | 32,041 | 6.2 | 4.5 | 1.7 | 1.000 | 171 | 4,444,806 | 3.8 |
| Esophagus | Total | 6 | 64,683 | 9.3 | 6.7 | 4.8 | 0.681 | 471 | 8,924,032 | 5.3 |
| Esophagus | Male | 6 | 32,642 | 18.4 | 13.3 | 4.0 | 0.426 | 395 | 4,479,226 | 8.8 |
| Esophagus | Female | - | 32,041 | - | - | 0.8 | 0.921 | 76 | 4,444,806 | 1.7 |
| Hodgkin Lymphoma | Total |  | 64,683 | - | - | 0.3 | 1.000 | 29 | 8,924,032 | 0.3 |
| Hodgkin Lymphoma | Male | - | 32,642 | - | - | 0.1 | 1.000 | 14 | 4,479,226 | 0.3 |
| Hodgkin Lymphoma | Female | - | 32,041 |  | - | 0.1 | 1.000 | 15 | 4,444,806 | 0.3 |
| Kidney | Total | 7 | 64,683 | 10.8 | 7.7 | 3.9 | 0.193 | 378 | 8,924,032 | 4.2 |
| Kidney | Male | 4 | 32,642 | 12.3 | 8.9 | 2.4 | 0.442 | 238 | 4,479,226 | 5.3 |
| Kidney | Female | 3 | 32,041 | 9.4 | 6.4 | 1.5 | 0.365 | 140 | 4,444,806 | 3.1 |
| Larynx | Total | - | 64,683 |  | - | 0.7 | 0.966 | 71 | 8,924,032 | 0.8 |
| Larynx | Male | - | 32,642 | - | - | 0.6 | 1.000 | 58 | 4,479,226 | 1.3 |
| Larynx | Female | - | 32,041 | - | - | 0.1 | 1.000 | 13 | 4,444,806 | 0.3 |
| Leukemia | Total | 3 | 64,683 | 4.6 | 3.3 | 6.6 | 0.210 | 657 | 8,924,032 | 7.4 |
| Leukemia | Male | 3 | 32,642 | 9.2 | 6.8 | 3.8 | 0.964 | 383 | 4,479,226 | 8.6 |
| Leukemia | Female | - | 32,041 | - | - | 2.8 | 0.119 | 274 | 4,444,806 | 6.2 |
| Liver and Bile Duct | Total | 10 | 64,683 | 15.5 | 11.1 | 6.0 | 0.167 | 593 | 8,924,032 | 6.6 |
| Liver and Bile Duct | Male | 8 | 32,642 | 24.5 | 17.5 | 4.1 | 0.112 | 400 | 4,479,226 | 8.9 |
| Liver and Bile Duct | Female | 2 | 32,041 | 6.2 | 4.5 | 1.9 | 1.000 | 193 | 4,444,806 | 4.3 |
| Lung and Bronchus | Total | 53 | 64,683 | 81.9 | 57.9 | 29.8 | 0.000 >> | 2,908 | 8,924,032 | 32.6 |
| Lung and Bronchus | Male | 29 | 32,642 | 88.8 | 63.1 | 15.7 | $0.003 \gg$ | 1,527 | 4,479,226 | 34.1 |
| Lung and Bronchus | Female | 24 | 32,041 | 74.9 | 52.6 | 14.2 | $0.021 \gg$ | 1,381 | 4,444,806 | 31.1 |
| Melanoma of the Skin | Total | 6 | 64,683 | 9.3 | 6.8 | 2.8 | 0.130 | 283 | 8,924,032 | 3.2 |
| Melanoma of the Skin | Male | 3 | 32,642 | 9.2 | 6.9 | 1.8 | 0.563 | 189 | 4,479,226 | 4.2 |
| Melanoma of the Skin | Female | 3 | 32,041 | 9.4 | 6.9 | 0.9 | 0.131 | 94 | 4,444,806 | 2.1 |
| Myeloma | Total | 2 | 64,683 | 3.1 | 2.2 | 3.4 | 0.675 | 329 | 8,924,032 | 3.7 |
| Myeloma | Male | - | 32,642 | - | - | 2.0 | 0.270 | 196 | 4,479,226 | 4.4 |
| Myeloma | Female | 2 | 32,041 | 6.2 | 4.3 | 1.4 | 0.806 | 133 | 4,444,806 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 2 | 64,683 | 3.1 | 2.2 | 5.8 | 0.144 | 567 | 8,924,032 | 6.4 |
| Non-Hodgkin Lymphoma | Male | 1 | 32,642 | 3.1 | 2.2 | 3.0 | 0.386 | 306 | 4,479,226 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 1 | 32,041 | 3.1 | 2.1 | 2.7 | 0.482 | 261 | 4,444,806 | 5.9 |
| Oral Cavity and Pharynx | Total | 3 | 64,683 | 4.6 | 3.3 | 2.6 | 0.987 | 263 | 8,924,032 | 2.9 |
| Oral Cavity and Pharynx | Male | 3 | 32,642 | 9.2 | 6.6 | 1.9 | 0.572 | 184 | 4,479,226 | 4.1 |
| Oral Cavity and Pharynx | Female | - | 32,041 | - | - | 0.8 | 0.902 | 79 | 4,444,806 | 1.8 |
| Ovary | Female | 3 | 32,041 | 9.4 | 6.7 | 3.5 | 1.000 | 347 | 4,444,806 | 7.8 |
| Pancreas | Total | 14 | 64,683 | 21.6 | 15.4 | 11.9 | 0.625 | 1,176 | 8,924,032 | 13.2 |
| Pancreas | Male | 7 | 32,642 | 21.4 | 15.4 | 6.5 | 0.932 | 635 | 4,479,226 | 14.2 |
| Pancreas | Female | 7 | 32,041 | 21.8 | 15.5 | 5.5 | 0.622 | 541 | 4,444,806 | 12.2 |
| Prostate | Male | 12 | 32,642 | 36.8 | 27.2 | 9.2 | 0.441 | 937 | 4,479,226 | 20.9 |
| Stomach | Total | 1 | 64,683 | 1.5 | 1.1 | 1.9 | 0.851 | 197 | 8,924,032 | 2.2 |
| Stomach | Male | 1 | 32,642 | 3.1 | 2.3 | 1.2 | 1.000 | 120 | 4,479,226 | 2.7 |
| Stomach | Female | - | 32,041 | - | - | 0.7 | 0.948 | 77 | 4,444,806 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Shoshone County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 87.0\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 11.6\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 52.2\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 58.3\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 29.0\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 28.5\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 75.5\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 19.0\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 29.2\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to 64.8\% of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^39]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged $50-74$ reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 220 cases of invasive cancer were diagnosed among Teton County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Teton County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Teton <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 220 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 35 | 6,687 |
| Prostate | 15 | 6,417 |
| Lung \& Bronchus | 11 | 4,887 |
| Colorectal | 3,451 |  |

Table 3 (Cancer Incidence 2016-2020, Comparison between Teton County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Teton County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Teton County was 373.6 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (520.9) gives an estimate of the relative burden of disease in Teton County.

The age- and sex-adjusted incidence rate of invasive cancer in Teton County, all sites combined, was 427.9 cases per 100,000 persons per year during 2016-2020. There were statistically significantly fewer cases of cancer in Teton County (220) than expected (267.8) based upon rates in the remainder of the state $(p=.003)$.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 70 Teton County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Teton County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Teton <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | $\mathbf{2 6 4}$ | $\mathbf{7 7 , 4 3 1}$ |
| Cancer Deaths | 70 | 15,121 |
| \% of All Deaths | $26.5 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 13 | 2,961 |
| Colorectal | 8 | 1,319 |
| Pancreas | 9 | 1,190 |
| Female Breast | 4 | 1,086 |
| Prostate | 0 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Teton County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Teton County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Teton County, all sites combined, was 147.8 deaths per 100,000 persons per year during 2017-2021, compared with 168.6 for the remainder of the state. There were fewer cancer deaths in Teton County (70) than expected (79.8) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020 COMPARISON BETWEEN TETON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Teton County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 220 | 58,879 | 373.6 | 427.9 | 267.8 | 0.003 << | 45,390 | 8,712,949 | 520.9 |
| All Sites Combined | Male | 135 | 30,793 | 438.4 | 497.1 | 150.2 | 0.226 | 24,154 | 4,366,117 | 553.2 |
| All Sites Combined | Female | 85 | 28,086 | 302.6 | 346.3 | 119.9 | 0.001 << | 21,236 | 4,346,832 | 488.5 |
| Bladder | Total | 6 | 58,879 | 10.2 | 13.2 | 11.4 | 0.130 | 2,178 | 8,712,949 | 25.0 |
| Bladder | Male | 6 | 30,793 | 19.5 | 24.3 | 9.9 | 0.277 | 1,745 | 4,366,117 | 40.0 |
| Bladder | Female | - | 28,086 | - | - | 2.1 | 0.235 | 433 | 4,346,832 | 10.0 |
| Brain - malignant | Total | 4 | 58,879 | 6.8 | 7.3 | 3.9 | 1.000 | 621 | 8,712,949 | 7.1 |
| Brain - malignant | Male | 4 | 30,793 | 13.0 | 13.6 | 2.5 | 0.486 | 371 | 4,366,117 | 8.5 |
| Brain - malignant | Female | - | 28,086 | - | - | 1.5 | 0.466 | 250 | 4,346,832 | 5.8 |
| Brain and other CNS - non-malignant | Total | 6 | 58,879 | 10.2 | 11.2 | 8.7 | 0.470 | 1,418 | 8,712,949 | 16.3 |
| Brain and other CNS - non-malignant | Male | 3 | 30,793 | 9.7 | 10.3 | 3.2 | 1.000 | 477 | 4,366,117 | 10.9 |
| Brain and other CNS - non-malignant | Female | 3 | 28,086 | 10.7 | 12.1 | 5.3 | 0.439 | 941 | 4,346,832 | 21.6 |
| Breast | Total | 36 | 58,879 | 61.1 | 64.9 | 42.7 | 0.343 | 6,710 | 8,712,949 | 77.0 |
| Breast | Male | 1 | 30,793 | 3.2 | 3.9 | 0.3 | 0.576 | 58 | 4,366,117 | 1.3 |
| Breast | Female | 35 | 28,086 | 124.6 | 135.3 | 39.6 | 0.527 | 6,652 | 4,346,832 | 153.0 |
| Breast - in situ | Total | 8 | 58,879 | 13.6 | 13.7 | 8.2 | 1.000 | 1,231 | 8,712,949 | 14.1 |
| Breast - in situ | Male | - | 30,793 | - | - | 0.0 | 1.000 | 5 | 4,366,117 | 0.1 |
| Breast - in situ | Female | 8 | 28,086 | 28.5 | 29.5 | 7.6 | 0.991 | 1,226 | 4,346,832 | 28.2 |
| Cervix | Female | - | 28,086 | - | - | 2.2 | 0.217 | 304 | 4,346,832 | 7.0 |
| Colorectal | Total | 11 | 58,879 | 18.7 | 21.3 | 20.4 | 0.035 << | 3,440 | 8,712,949 | 39.5 |
| Colorectal | Male | 7 | 30,793 | 22.7 | 24.9 | 12.2 | 0.161 | 1,896 | 4,366,117 | 43.4 |
| Colorectal | Female | 4 | 28,086 | 14.2 | 17.0 | 8.4 | 0.160 | 1,544 | 4,346,832 | 35.5 |
| Corpus Uteri | Female | 5 | 28,086 | 17.8 | 19.3 | 7.9 | 0.401 | 1,325 | 4,346,832 | 30.5 |
| Esophagus | Total | 3 | 58,879 | 5.1 | 6.1 | 2.8 | 1.000 | 503 | 8,712,949 | 5.8 |
| Esophagus | Male | 3 | 30,793 | 9.7 | 11.2 | 2.6 | 0.950 | 421 | 4,366,117 | 9.6 |
| Esophagus | Female | - | 28,086 | - | - | 0.4 | 1.000 | 82 | 4,346,832 | 1.9 |
| Hodgkin Lymphoma | Total | 1 | 58,879 | 1.7 | 1.8 | 1.4 | 1.000 | 209 | 8,712,949 | 2.4 |
| Hodgkin Lymphoma | Male | 1 | 30,793 | 3.2 | 3.3 | 0.8 | 1.000 | 117 | 4,366,117 | 2.7 |
| Hodgkin Lymphoma | Female | - | 28,086 | - | - | 0.5 | 1.000 | 92 | 4,346,832 | 2.1 |
| Kidney and Renal Pelvis | Total | 5 | 58,879 | 8.5 | 9.4 | 11.0 | 0.074 | 1,810 | 8,712,949 | 20.8 |
| Kidney and Renal Pelvis | Male | 3 | 30,793 | 9.7 | 10.4 | 7.8 | 0.099 | 1,179 | 4,366,117 | 27.0 |
| Kidney and Renal Pelvis | Female | 2 | 28,086 | 7.1 | 8.3 | 3.5 | 0.636 | 631 | 4,346,832 | 14.5 |
| Larynx | Total | 2 | 58,879 | 3.4 | 4.0 | 1.2 | 0.695 | 213 | 8,712,949 | 2.4 |
| Larynx | Male | 2 | 30,793 | 6.5 | 7.4 | 1.0 | 0.514 | 158 | 4,366,117 | 3.6 |
| Larynx | Female | - | 28,086 | - | - | 0.3 | 1.000 | 55 | 4,346,832 | 1.3 |
| Leukemia | Total | 12 | 58,879 | 20.4 | 24.4 | 9.1 | 0.418 | 1,619 | 8,712,949 | 18.6 |
| Leukemia | Male | 11 | 30,793 | 35.7 | 41.3 | 6.0 | 0.082 | 978 | 4,366,117 | 22.4 |
| Leukemia | Female | 1 | 28,086 | 3.6 | 4.4 | 3.3 | 0.311 | 641 | 4,346,832 | 14.7 |
| Liver and Bile Duct | Total | 2 | 58,879 | 3.4 | 3.9 | 4.9 | 0.273 | 827 | 8,712,949 | 9.5 |
| Liver and Bile Duct | Male | 1 | 30,793 | 3.2 | 3.6 | 3.8 | 0.217 | 589 | 4,366,117 | 13.5 |
| Liver and Bile Duct | Female | 1 | 28,086 | 3.6 | 4.4 | 1.3 | 1.000 | 238 | 4,346,832 | 5.5 |
| Lung and Bronchus | Total | 15 | 58,879 | 25.5 | 32.3 | 26.0 | 0.029 << | 4,872 | 8,712,949 | 55.9 |
| Lung and Bronchus | Male | 6 | 30,793 | 19.5 | 23.7 | 14.2 | 0.025 << | 2,446 | 4,366,117 | 56.0 |
| Lung and Bronchus | Female | 9 | 28,086 | 32.0 | 42.2 | 11.9 | 0.503 | 2,426 | 4,346,832 | 55.8 |
| Melanoma of the Skin | Total | 28 | 58,879 | 47.6 | 52.4 | 17.9 | $0.032 \gg$ | 2,914 | 8,712,949 | 33.4 |
| Melanoma of the Skin | Male | 17 | 30,793 | 55.2 | 61.1 | 11.1 | 0.122 | 1,748 | 4,366,117 | 40.0 |
| Melanoma of the Skin | Female | 11 | 28,086 | 39.2 | 41.8 | 7.1 | 0.206 | 1,166 | 4,346,832 | 26.8 |
| Myeloma | Total | 3 | 58,879 | 5.1 | 6.3 | 3.8 | 0.929 | 705 | 8,712,949 | 8.1 |
| Myeloma | Male | 1 | 30,793 | 3.2 | 3.9 | 2.6 | 0.537 | 440 | 4,366,117 | 10.1 |
| Myeloma | Female | 2 | 28,086 | 7.1 | 9.1 | 1.3 | 0.778 | 265 | 4,346,832 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 8 | 58,879 | 13.6 | 15.8 | 11.2 | 0.422 | 1,932 | 8,712,949 | 22.2 |
| Non-Hodgkin Lymphoma | Male | 7 | 30,793 | 22.7 | 25.4 | 7.1 | 1.000 | 1,122 | 4,366,117 | 25.7 |
| Non-Hodgkin Lymphoma | Female | 1 | 28,086 | 3.6 | 4.3 | 4.3 | 0.141 | 810 | 4,346,832 | 18.6 |
| Oral Cavity and Pharynx | Total | 9 | 58,879 | 15.3 | 16.9 | 7.9 | 0.779 | 1,286 | 8,712,949 | 14.8 |
| Oral Cavity and Pharynx | Male | 7 | 30,793 | 22.7 | 24.3 | 6.1 | 0.831 | 929 | 4,366,117 | 21.3 |
| Oral Cavity and Pharynx | Female | 2 | 28,086 | 7.1 | 8.2 | 2.0 | 1.000 | 357 | 4,346,832 | 8.2 |
| Ovary | Female | 2 | 28,086 | 7.1 | 7.9 | 3.1 | 0.813 | 531 | 4,346,832 | 12.2 |
| Pancreas | Total | 9 | 58,879 | 15.3 | 18.9 | 7.7 | 0.734 | 1,414 | 8,712,949 | 16.2 |
| Pancreas | Male | 6 | 30,793 | 19.5 | 23.0 | 4.7 | 0.647 | 778 | 4,366,117 | 17.8 |
| Pancreas | Female | 3 | 28,086 | 10.7 | 13.9 | 3.2 | 1.000 | 636 | 4,346,832 | 14.6 |
| Prostate | Male | 35 | 30,793 | 113.7 | 127.5 | 40.1 | 0.474 | 6,382 | 4,366,117 | 146.2 |
| Stomach | Total | - | 58,879 | - | - | 2.6 | 0.141 | 467 | 8,712,949 | 5.4 |
| Stomach | Male | - | 30,793 | - | - | 1.9 | 0.303 | 309 | 4,366,117 | 7.1 |
| Stomach | Female | - | 28,086 | - | - | 0.8 | 0.857 | 158 | 4,346,832 | 3.6 |
| Testis | Male | 1 | 30,793 | 3.2 | 3.1 | 2.0 | 0.837 | 264 | 4,366,117 | 6.0 |
| Thyroid | Total | 4 | 58,879 | 6.8 | 6.5 | 8.6 | 0.144 | 1,216 | 8,712,949 | 14.0 |
| Thyroid | Male | 2 | 30,793 | 6.5 | 6.3 | 2.6 | 1.000 | 353 | 4,366,117 | 8.1 |
| Thyroid | Female | 2 | 28,086 | 7.1 | 6.8 | 5.8 | 0.139 | 863 | 4,346,832 | 19.9 |
| Pediatric Age 0 to 19 | Total | 3 | 15,658 | 19.2 | 19.6 | 2.6 | 0.974 | 418 | 2,444,865 | 17.1 |
| Pediatric Age 0 to 19 | Male | 1 | 8,086 | 12.4 | 12.5 | 1.4 | 1.000 | 222 | 1,248,424 | 17.8 |
| Pediatric Age 0 to 19 | Female | 2 | 7,572 | 26.4 | 27.3 | 1.2 | 0.675 | 196 | 1,196,441 | 16.4 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN TETON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Teton County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 264 | 59,967 | 440.2 | 583.0 | 391.4 | 0.000 << | 77,166 | 8,928,748 | 864.2 |
| All Causes of Death | Male | 143 | 31,343 | 456.2 | 558.8 | 233.7 | 0.000 << | 40,913 | 4,480,525 | 913.1 |
| All Causes of Death | Female | 121 | 28,624 | 422.7 | 607.1 | 162.4 | $0.001 \ll$ | 36,253 | 4,448,223 | 815.0 |
| All Malignant Cancers | Total | 70 | 59,967 | 116.7 | 147.8 | 79.8 | 0.295 | 15,051 | 8,928,748 | 168.6 |
| All Malignant Cancers | Male | 39 | 31,343 | 124.4 | 151.3 | 46.8 | 0.283 | 8,137 | 4,480,525 | 181.6 |
| All Malignant Cancers | Female | 31 | 28,624 | 108.3 | 141.6 | 34.0 | 0.682 | 6,914 | 4,448,223 | 155.4 |
| Bladder | Total | 2 | 59,967 | 3.3 | 4.9 | 2.2 | 1.000 | 487 | 8,928,748 | 5.5 |
| Bladder | Male | 2 | 31,343 | 6.4 | 8.7 | 1.9 | 1.000 | 376 | 4,480,525 | 8.4 |
| Bladder | Female | - | 28,624 | - | - | 0.5 | 1.000 | 111 | 4,448,223 | 2.5 |
| Brain and Other Nervous System | Total | 1 | 59,967 | 1.7 | 1.8 | 3.1 | 0.379 | 503 | 8,928,748 | 5.6 |
| Brain and Other Nervous System | Male | 1 | 31,343 | 3.2 | 3.4 | 1.9 | 0.845 | 297 | 4,480,525 | 6.6 |
| Brain and Other Nervous System | Female | - | 28,624 |  | - | 1.2 | 0.619 | 206 | 4,448,223 | 4.6 |
| Breast | Total | 6 | 59,967 | 10.0 | 11.8 | 6.2 | 1.000 | 1,096 | 8,928,748 | 12.3 |
| Breast | Male | 2 | 31,343 | 6.4 | 7.3 | 0.1 | 0.007 >> | 14 | 4,480,525 | 0.3 |
| Breast | Female | 4 | 28,624 | 14.0 | 17.1 | 5.7 | 0.654 | 1,082 | 4,448,223 | 24.3 |
| Cervix | Female | 1 | 28,624 | 3.5 | 3.3 | 0.6 | 0.847 | 82 | 4,448,223 | 1.8 |
| Colorectal | Total | 8 | 59,967 | 13.3 | 16.2 | 7.3 | 0.883 | 1,311 | 8,928,748 | 14.7 |
| Colorectal | Male | 4 | 31,343 | 12.8 | 14.4 | 4.4 | 1.000 | 715 | 4,480,525 | 16.0 |
| Colorectal | Female | 4 | 28,624 | 14.0 | 18.4 | 2.9 | 0.666 | 596 | 4,448,223 | 13.4 |
| Corpus Uteri | Female | - | 28,624 |  | - | 0.9 | 0.814 | 173 | 4,448,223 | 3.9 |
| Esophagus | Total | 1 | 59,967 | 1.7 | 2.0 | 2.6 | 0.522 | 476 | 8,928,748 | 5.3 |
| Esophagus | Male | 1 | 31,343 | 3.2 | 3.7 | 2.4 | 0.607 | 400 | 4,480,525 | 8.9 |
| Esophagus | Female | - | 28,624 | - | - | 0.4 | 1.000 | 76 | 4,448,223 | 1.7 |
| Hodgkin Lymphoma | Total |  | 59,967 | - | - | 0.2 | 1.000 | 29 | 8,928,748 | 0.3 |
| Hodgkin Lymphoma | Male | - | 31,343 | - | - | 0.1 | 1.000 | 14 | 4,480,525 | 0.3 |
| Hodgkin Lymphoma | Female | - | 28,624 |  | - | 0.1 | 1.000 | 15 | 4,448,223 | 0.3 |
| Kidney | Total | 2 | 59,967 | 3.3 | 4.3 | 2.0 | 1.000 | 383 | 8,928,748 | 4.3 |
| Kidney | Male | - | 31,343 | - | - | 1.4 | 0.483 | 242 | 4,480,525 | 5.4 |
| Kidney | Female | 2 | 28,624 | 7.0 | 10.0 | 0.6 | 0.266 | 141 | 4,448,223 | 3.2 |
| Larynx | Total | - | 59,967 |  | - | 0.4 | 1.000 | 71 | 8,928,748 | 0.8 |
| Larynx | Male | - | 31,343 | - | - | 0.3 | 1.000 | 58 | 4,480,525 | 1.3 |
| Larynx | Female | - | 28,624 | - | - | 0.1 | 1.000 | 13 | 4,448,223 | 0.3 |
| Leukemia | Total | 3 | 59,967 | 5.0 | 6.8 | 3.2 | 1.000 | 657 | 8,928,748 | 7.4 |
| Leukemia | Male | 3 | 31,343 | 9.6 | 12.2 | 2.1 | 0.702 | 383 | 4,480,525 | 8.5 |
| Leukemia | Female | - | 28,624 | - | - | 1.2 | 0.595 | 274 | 4,448,223 | 6.2 |
| Liver and Bile Duct | Total | 2 | 59,967 | 3.3 | 4.0 | 3.4 | 0.687 | 601 | 8,928,748 | 6.7 |
| Liver and Bile Duct | Male | 1 | 31,343 | 3.2 | 3.6 | 2.5 | 0.569 | 407 | 4,480,525 | 9.1 |
| Liver and Bile Duct | Female | 1 | 28,624 | 3.5 | 4.5 | 1.0 | 1.000 | 194 | 4,448,223 | 4.4 |
| Lung and Bronchus | Total | 13 | 59,967 | 21.7 | 27.9 | 15.4 | 0.658 | 2,948 | 8,928,748 | 33.0 |
| Lung and Bronchus | Male | 8 | 31,343 | 25.5 | 31.0 | 8.9 | 0.937 | 1,548 | 4,480,525 | 34.5 |
| Lung and Bronchus | Female | 5 | 28,624 | 17.5 | 23.8 | 6.6 | 0.705 | 1,400 | 4,448,223 | 31.5 |
| Melanoma of the Skin | Total | 2 | 59,967 | 3.3 | 4.0 | 1.6 | 0.942 | 287 | 8,928,748 | 3.2 |
| Melanoma of the Skin | Male | - | 31,343 | - | - | 1.1 | 0.644 | 192 | 4,480,525 | 4.3 |
| Melanoma of the Skin | Female | 2 | 28,624 | 7.0 | 8.5 | 0.5 | 0.183 | 95 | 4,448,223 | 2.1 |
| Myeloma | Total | 3 | 59,967 | 5.0 | 7.0 | 1.6 | 0.425 | 328 | 8,928,748 | 3.7 |
| Myeloma | Male | - | 31,343 | - | - | 1.0 | 0.705 | 196 | 4,480,525 | 4.4 |
| Myeloma | Female | 3 | 28,624 | 10.5 | 15.4 | 0.6 | 0.042 >> | 132 | 4,448,223 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 2 | 59,967 | 3.3 | 4.5 | 2.8 | 0.921 | 567 | 8,928,748 | 6.4 |
| Non-Hodgkin Lymphoma | Male | 2 | 31,343 | 6.4 | 7.9 | 1.7 | 1.000 | 305 | 4,480,525 | 6.8 |
| Non-Hodgkin Lymphoma | Female | - | 28,624 | - | - | 1.1 | 0.638 | 262 | 4,448,223 | 5.9 |
| Oral Cavity and Pharynx | Total | 3 | 59,967 | 5.0 | 6.0 | 1.5 | 0.369 | 263 | 8,928,748 | 2.9 |
| Oral Cavity and Pharynx | Male | 2 | 31,343 | 6.4 | 7.3 | 1.1 | 0.623 | 185 | 4,480,525 | 4.1 |
| Oral Cavity and Pharynx | Female | 1 | 28,624 | 3.5 | 4.4 | 0.4 | 0.658 | 78 | 4,448,223 | 1.8 |
| Ovary | Female | 1 | 28,624 | 3.5 | 4.4 | 1.8 | 0.927 | 349 | 4,448,223 | 7.8 |
| Pancreas | Total | 9 | 59,967 | 15.0 | 18.8 | 6.3 | 0.378 | 1,181 | 8,928,748 | 13.2 |
| Pancreas | Male | 7 | 31,343 | 22.3 | 26.5 | 3.7 | 0.172 | 635 | 4,480,525 | 14.2 |
| Pancreas | Female | 2 | 28,624 | 7.0 | 9.2 | 2.7 | 1.000 | 546 | 4,448,223 | 12.3 |
| Prostate | Male | - | 31,343 | - | - | 4.8 | 0.016 < | 949 | 4,480,525 | 21.2 |
| Stomach | Total |  | 59,967 |  |  | 1.1 | 0.656 | 198 | 8,928,748 | 2.2 |
| Stomach | Male | - | 31,343 | - | - | 0.7 | 0.959 | 121 | 4,480,525 | 2.7 |
| Stomach | Female | - | 28,624 | - | - | 0.4 | 1.000 | 77 | 4,448,223 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Teton County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 79.8\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 9.6\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% |  |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% |  |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 21.4\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 46.9\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 84.6\% |
| Meet Physical Activity Guidelines ( $2011,2013,2015,2017,2019)$ | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 20.5\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 40.6\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^40]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# TWIN FALLS COUNTY CANCER PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 2,116 cases of invasive cancer were diagnosed among Twin Falls County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Twin Falls County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Twin Falls <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 2,116 | 45,610 |
| Female Breast | 266 | 6,687 |
| Prostate | 222 | 6,417 |
| Lung \& Bronchus | 243 | 4,887 |
| Colorectal | 166 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Twin Falls County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Twin Falls County. The table also shows the number of observed cases,
person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Twin Falls County was 491.0 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (521.5) gives an estimate of the relative burden of disease in Twin Falls County.

The age- and sex-adjusted incidence rate of invasive cancer in Twin Falls County, all sites combined, was 507.0 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Twin Falls County $(2,116)$ than expected $(2,176.2)$ based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 772 Twin Falls County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Twin Falls County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Twin Falls <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 4,315 | 77,431 |
| Cancer Deaths | 772 | 15,121 |
| \% of All Deaths | $17.9 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 156 | 2,961 |
| Colorectal | 62 | 1,319 |
| Pancreas | 53 | 1,190 |
| Female Breast | 44 | 1,086 |
| Prostate | 57 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Twin Falls County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Twin Falls County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Twin Falls County, all sites combined, was 177.3 deaths per 100,000 persons per year during 2017-2021, compared with 167.8 for the remainder of the state. There were more cancer deaths in Twin Falls County (772) than expected (731.0) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN TWIN FALLS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Twin Falls County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person <br> Years | Crude <br> Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person Years | Crude Rate (1) |
| All Sites Combined | Total | 2,116 | 430,990 | 491.0 | 507.0 | 2,176.2 | 0.199 | 43,494 | 8,340,838 | 521.5 |
| All Sites Combined | Male | 1,125 | 212,388 | 529.7 | 553.7 | 1,124.7 | 1.000 | 23,164 | 4,184,522 | 553.6 |
| All Sites Combined | Female | 991 | 218,602 | 453.3 | 465.8 | 1,040.6 | 0.126 | 20,330 | 4,156,316 | 489.1 |
| Bladder | Total | 124 | 430,990 | 28.8 | 29.2 | 104.9 | 0.074 | 2,060 | 8,340,838 | 24.7 |
| Bladder | Male | 108 | 212,388 | 50.9 | 52.6 | 80.6 | 0.004 >> | 1,643 | 4,184,522 | 39.3 |
| Bladder | Female | 16 | 218,602 | 7.3 | 7.4 | 21.8 | 0.254 | 417 | 4,156,316 | 10.0 |
| Brain - malignant | Total | 29 | 430,990 | 6.7 | 6.9 | 30.1 | 0.937 | 596 | 8,340,838 | 7.1 |
| Brain - malignant | Male | 16 | 212,388 | 7.5 | 7.8 | 17.7 | 0.813 | 359 | 4,184,522 | 8.6 |
| Brain - malignant | Female | 13 | 218,602 | 5.9 | 6.0 | 12.3 | 0.913 | 237 | 4,156,316 | 5.7 |
| Brain and other CNS - non-malignant | Total | 66 | 430,990 | 15.3 | 15.7 | 68.5 | 0.827 | 1,358 | 8,340,838 | 16.3 |
| Brain and other CNS - non-malignant | Male | 20 | 212,388 | 9.4 | 9.7 | 22.6 | 0.679 | 460 | 4,184,522 | 11.0 |
| Brain and other CNS - non-malignant | Female | 46 | 218,602 | 21.0 | 21.4 | 46.3 | 1.000 | 898 | 4,156,316 | 21.6 |
| Breast | Total | 268 | 430,990 | 62.2 | 65.0 | 320.1 | $0.003 \ll$ | 6,478 | 8,340,838 | 77.7 |
| Breast | Male | 2 | 212,388 | 0.9 | 1.0 | 2.8 | 0.934 | 57 | 4,184,522 | 1.4 |
| Breast | Female | 266 | 218,602 | 121.7 | 127.2 | 323.1 | $0.001 \ll$ | 6,421 | 4,156,316 | 154.5 |
| Breast - in situ | Total | 32 | 430,990 | 7.4 | 7.9 | 58.7 | $0.000 \ll$ | 1,207 | 8,340,838 | 14.5 |
| Breast - in situ | Male | - | 212,388 | - | - | 0.2 | 1.000 | 5 | 4,184,522 | 0.1 |
| Breast - in situ | Female | 32 | 218,602 | 14.6 | 15.6 | 59.2 | 0.000 << | 1,202 | 4,156,316 | 28.9 |
| Cervix | Female | 10 | 218,602 | 4.6 | 4.7 | 14.9 | 0.245 | 294 | 4,156,316 | 7.1 |
| Colorectal | Total | 166 | 430,990 | 38.5 | 39.6 | 165.2 | 0.968 | 3,285 | 8,340,838 | 39.4 |
| Colorectal | Male | 94 | 212,388 | 44.3 | 46.1 | 88.2 | 0.562 | 1,809 | 4,184,522 | 43.2 |
| Colorectal | Female | 72 | 218,602 | 32.9 | 33.4 | 76.5 | 0.658 | 1,476 | 4,156,316 | 35.5 |
| Corpus Uteri | Female | 77 | 218,602 | 35.2 | 37.2 | 62.5 | 0.083 | 1,253 | 4,156,316 | 30.1 |
| Esophagus | Total | 27 | 430,990 | 6.3 | 6.4 | 24.0 | 0.599 | 479 | 8,340,838 | 5.7 |
| Esophagus | Male | 21 | 212,388 | 9.9 | 10.3 | 19.6 | 0.811 | 403 | 4,184,522 | 9.6 |
| Esophagus | Female | 6 | 218,602 | 2.7 | 2.8 | 3.9 | 0.400 | 76 | 4,156,316 | 1.8 |
| Hodgkin Lymphoma | Total | 16 | 430,990 | 3.7 | 3.8 | 9.8 | 0.086 | 194 | 8,340,838 | 2.3 |
| Hodgkin Lymphoma | Male | 13 | 212,388 | 6.1 | 6.3 | 5.2 | 0.006 >> | 105 | 4,184,522 | 2.5 |
| Hodgkin Lymphoma | Female | 3 | 218,602 | 1.4 | 1.4 | 4.6 | 0.647 | 89 | 4,156,316 | 2.1 |
| Kidney and Renal Pelvis | Total | 74 | 430,990 | 17.2 | 17.8 | 86.8 | 0.181 | 1,741 | 8,340,838 | 20.9 |
| Kidney and Renal Pelvis | Male | 51 | 212,388 | 24.0 | 25.1 | 54.9 | 0.664 | 1,131 | 4,184,522 | 27.0 |
| Kidney and Renal Pelvis | Female | 23 | 218,602 | 10.5 | 10.8 | 31.3 | 0.151 | 610 | 4,156,316 | 14.7 |
| Larynx | Total | 13 | 430,990 | 3.0 | 3.1 | 10.1 | 0.430 | 202 | 8,340,838 | 2.4 |
| Larynx | Male | 8 | 212,388 | 3.8 | 3.9 | 7.4 | 0.911 | 152 | 4,184,522 | 3.6 |
| Larynx | Female | 5 | 218,602 | 2.3 | 2.4 | 2.5 | 0.228 | 50 | 4,156,316 | 1.2 |
| Leukemia | Total | 88 | 430,990 | 20.4 | 20.7 | 78.8 | 0.326 | 1,543 | 8,340,838 | 18.5 |
| Leukemia | Male | 46 | 212,388 | 21.7 | 22.2 | 46.7 | 0.997 | 943 | 4,184,522 | 22.5 |
| Leukemia | Female | 42 | 218,602 | 19.2 | 19.3 | 31.5 | 0.084 | 600 | 4,156,316 | 14.4 |
| Liver and Bile Duct | Total | 21 | 430,990 | 4.9 | 5.1 | 40.0 | 0.001 << | 808 | 8,340,838 | 9.7 |
| Liver and Bile Duct | Male | 12 | 212,388 | 5.7 | 6.0 | 27.7 | 0.001 << | 578 | 4,184,522 | 13.8 |
| Liver and Bile Duct | Female | 9 | 218,602 | 4.1 | 4.2 | 11.9 | 0.509 | 230 | 4,156,316 | 5.5 |
| Lung and Bronchus | Total | 243 | 430,990 | 56.4 | 57.7 | 234.5 | 0.597 | 4,644 | 8,340,838 | 55.7 |
| Lung and Bronchus | Male | 131 | 212,388 | 61.7 | 64.3 | 113.0 | 0.106 | 2,321 | 4,184,522 | 55.5 |
| Lung and Bronchus | Female | 112 | 218,602 | 51.2 | 51.8 | 120.9 | 0.449 | 2,323 | 4,156,316 | 55.9 |
| Melanoma of the Skin | Total | 152 | 430,990 | 35.3 | 36.3 | 140.3 | 0.341 | 2,790 | 8,340,838 | 33.4 |
| Melanoma of the Skin | Male | 90 | 212,388 | 42.4 | 44.0 | 81.9 | 0.397 | 1,675 | 4,184,522 | 40.0 |
| Melanoma of the Skin | Female | 62 | 218,602 | 28.4 | 29.1 | 57.1 | 0.550 | 1,115 | 4,156,316 | 26.8 |
| Myeloma | Total | 30 | 430,990 | 7.0 | 7.1 | 34.3 | 0.527 | 678 | 8,340,838 | 8.1 |
| Myeloma | Male | 22 | 212,388 | 10.4 | 10.8 | 20.5 | 0.796 | 419 | 4,184,522 | 10.0 |
| Myeloma | Female | 8 | 218,602 | 3.7 | 3.7 | 13.5 | 0.159 | 259 | 4,156,316 | 6.2 |
| Non-Hodgkin Lymphoma | Total | 110 | 430,990 | 25.5 | 26.3 | 91.9 | 0.073 | 1,830 | 8,340,838 | 21.9 |
| Non-Hodgkin Lymphoma | Male | 59 | 212,388 | 27.8 | 28.9 | 52.1 | 0.374 | 1,070 | 4,184,522 | 25.6 |
| Non-Hodgkin Lymphoma | Female | 51 | 218,602 | 23.3 | 23.7 | 39.3 | 0.083 | 760 | 4,156,316 | 18.3 |
| Oral Cavity and Pharynx | Total | 67 | 430,990 | 15.5 | 16.3 | 60.5 | 0.439 | 1,228 | 8,340,838 | 14.7 |
| Oral Cavity and Pharynx | Male | 49 | 212,388 | 23.1 | 24.4 | 42.6 | 0.361 | 887 | 4,184,522 | 21.2 |
| Oral Cavity and Pharynx | Female | 18 | 218,602 | 8.2 | 8.5 | 17.3 | 0.939 | 341 | 4,156,316 | 8.2 |
| Ovary | Female | 31 | 218,602 | 14.2 | 14.7 | 25.4 | 0.316 | 502 | 4,156,316 | 12.1 |
| Pancreas | Total | 70 | 430,990 | 16.2 | 16.6 | 68.5 | 0.890 | 1,353 | 8,340,838 | 16.2 |
| Pancreas | Male | 44 | 212,388 | 20.7 | 21.6 | 36.1 | 0.222 | 740 | 4,184,522 | 17.7 |
| Pancreas | Female | 26 | 218,602 | 11.9 | 11.9 | 32.1 | 0.321 | 613 | 4,156,316 | 14.7 |
| Prostate | Male | 222 | 212,388 | 104.5 | 111.1 | 295.7 | 0.000 << | 6,195 | 4,184,522 | 148.0 |
| Stomach | Total | 22 | 430,990 | 5.1 | 5.2 | 22.6 | 1.000 | 445 | 8,340,838 | 5.3 |
| Stomach | Male | 12 | 212,388 | 5.7 | 5.9 | 14.5 | 0.623 | 297 | 4,184,522 | 7.1 |
| Stomach | Female | 10 | 218,602 | 4.6 | 4.6 | 7.8 | 0.516 | 148 | 4,156,316 | 3.6 |
| Testis | Male | 20 | 212,388 | 9.4 | 9.5 | 12.3 | 0.054 | 245 | 4,184,522 | 5.9 |
| Thyroid | Total | 46 | 430,990 | 10.7 | 11.0 | 58.7 | 0.103 | 1,174 | 8,340,838 | 14.1 |
| Thyroid | Male | 11 | 212,388 | 5.2 | 5.4 | 16.9 | 0.178 | 344 | 4,184,522 | 8.2 |
| Thyroid | Female | 35 | 218,602 | 16.0 | 16.6 | 42.2 | 0.302 | 830 | 4,156,316 | 20.0 |
| Pediatric Age 0 to 19 | Total | 29 | 128,767 | 22.5 | 22.8 | 21.4 | 0.136 | 392 | 2,331,756 | 16.8 |
| Pediatric Age 0 to 19 | Male | 17 | 65,255 | 26.1 | 26.1 | 11.3 | 0.131 | 206 | 1,191,255 | 17.3 |
| Pediatric Age 0 to 19 | Female | 12 | 63,512 | 18.9 | 19.3 | 10.1 | 0.640 | 186 | 1,140,501 | 16.3 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN TWIN FALLS COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Twin Falls County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude <br> Rate (1) | A.A.M. <br> Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 4,315 | 439,386 | 982.1 | 966.9 | 3,816.6 | 0.000 >> | 73,115 | 8,549,329 | 855.2 |
| All Causes of Death | Male | 2,208 | 216,870 | 1,018.1 | 1,037.8 | 1,924.4 | $0.000 \gg$ | 38,848 | 4,294,998 | 904.5 |
| All Causes of Death | Female | 2,107 | 222,516 | 946.9 | 904.4 | 1,876.5 | 0.000 >> | 34,267 | 4,254,331 | 805.5 |
| All Malignant Cancers | Total | 772 | 439,386 | 175.7 | 177.3 | 731.0 | 0.136 | 14,349 | 8,549,329 | 167.8 |
| All Malignant Cancers | Male | 418 | 216,870 | 192.7 | 198.8 | 379.7 | 0.055 | 7,758 | 4,294,998 | 180.6 |
| All Malignant Cancers | Female | 354 | 222,516 | 159.1 | 158.3 | 346.4 | 0.697 | 6,591 | 4,254,331 | 154.9 |
| Bladder | Total | 28 | 439,386 | 6.4 | 6.2 | 24.3 | 0.502 | 461 | 8,549,329 | 5.4 |
| Bladder | Male | 21 | 216,870 | 9.7 | 9.8 | 17.9 | 0.516 | 357 | 4,294,998 | 8.3 |
| Bladder | Female | 7 | 222,516 | 3.1 | 3.0 | 5.7 | 0.678 | 104 | 4,254,331 | 2.4 |
| Brain and Other Nervous System | Total | 23 | 439,386 | 5.2 | 5.4 | 23.9 | 0.955 | 481 | 8,549,329 | 5.6 |
| Brain and Other Nervous System | Male | 9 | 216,870 | 4.1 | 4.3 | 14.0 | 0.219 | 289 | 4,294,998 | 6.7 |
| Brain and Other Nervous System | Female | 14 | 222,516 | 6.3 | 6.4 | 9.8 | 0.243 | 192 | 4,254,331 | 4.5 |
| Breast | Total | 44 | 439,386 | 10.0 | 10.2 | 53.6 | 0.210 | 1,058 | 8,549,329 | 12.4 |
| Breast | Male |  | 216,870 | - | - | 0.8 | 0.920 | 16 | 4,294,998 | 0.4 |
| Breast | Female | 44 | 222,516 | 19.8 | 19.9 | 54.2 | 0.183 | 1,042 | 4,254,331 | 24.5 |
| Cervix | Female | 5 | 222,516 | 2.2 | 2.3 | 3.9 | 0.707 | 78 | 4,254,331 | 1.8 |
| Colorectal | Total | 62 | 439,386 | 14.1 | 14.3 | 63.9 | 0.882 | 1,257 | 8,549,329 | 14.7 |
| Colorectal | Male | 36 | 216,870 | 16.6 | 17.2 | 33.3 | 0.680 | 683 | 4,294,998 | 15.9 |
| Colorectal | Female | 26 | 222,516 | 11.7 | 11.5 | 30.4 | 0.485 | 574 | 4,254,331 | 13.5 |
| Corpus Uteri | Female | 10 | 222,516 | 4.5 | 4.6 | 8.3 | 0.648 | 163 | 4,254,331 | 3.8 |
| Esophagus | Total | 20 | 439,386 | 4.6 | 4.7 | 22.9 | 0.631 | 457 | 8,549,329 | 5.3 |
| Esophagus | Male | 13 | 216,870 | 6.0 | 6.3 | 18.8 | 0.213 | 388 | 4,294,998 | 9.0 |
| Esophagus | Female | 7 | 222,516 | 3.1 | 3.2 | 3.6 | 0.147 | 69 | 4,254,331 | 1.6 |
| Hodgkin Lymphoma | Total |  | 439,386 |  |  | 1.5 | 0.456 | 29 | 8,549,329 | 0.3 |
| Hodgkin Lymphoma | Male | - | 216,870 | - | - | 0.7 | 1.000 | 14 | 4,294,998 | 0.3 |
| Hodgkin Lymphoma | Female | - | 222,516 | - | - | 0.8 | 0.908 | 15 | 4,254,331 | 0.4 |
| Kidney | Total | 21 | 439,386 | 4.8 | 4.8 | 18.5 | 0.626 | 364 | 8,549,329 | 4.3 |
| Kidney | Male | 16 | 216,870 | 7.4 | 7.7 | 11.0 | 0.183 | 226 | 4,294,998 | 5.3 |
| Kidney | Female | 5 | 222,516 | 2.2 | 2.2 | 7.4 | 0.504 | 138 | 4,254,331 | 3.2 |
| Larynx | Total | 4 | 439,386 | 0.9 | 0.9 | 3.4 | 0.876 | 67 | 8,549,329 | 0.8 |
| Larynx | Male | 3 | 216,870 | 1.4 | 1.4 | 2.7 | 1.000 | 55 | 4,294,998 | 1.3 |
| Larynx | Female | 1 | 222,516 | 0.4 | 0.5 | 0.6 | 0.902 | 12 | 4,254,331 | 0.3 |
| Leukemia | Total | 40 | 439,386 | 9.1 | 9.0 | 32.2 | 0.205 | 620 | 8,549,329 | 7.3 |
| Leukemia | Male | 24 | 216,870 | 11.1 | 11.3 | 17.9 | 0.197 | 362 | 4,294,998 | 8.4 |
| Leukemia | Female | 16 | 222,516 | 7.2 | 6.9 | 14.0 | 0.656 | 258 | 4,254,331 | 6.1 |
| Liver and Bile Duct | Total | 27 | 439,386 | 6.1 | 6.3 | 28.7 | 0.843 | 576 | 8,549,329 | 6.7 |
| Liver and Bile Duct | Male | 19 | 216,870 | 8.8 | 9.2 | 18.7 | 1.000 | 389 | 4,294,998 | 9.1 |
| Liver and Bile Duct | Female | 8 | 222,516 | 3.6 | 3.6 | 9.7 | 0.737 | 187 | 4,254,331 | 4.4 |
| Lung and Bronchus | Total | 156 | 439,386 | 35.5 | 36.0 | 142.2 | 0.265 | 2,805 | 8,549,329 | 32.8 |
| Lung and Bronchus | Male | 86 | 216,870 | 39.7 | 41.2 | 71.4 | 0.102 | 1,470 | 4,294,998 | 34.2 |
| Lung and Bronchus | Female | 70 | 222,516 | 31.5 | 31.3 | 70.2 | 1.000 | 1,335 | 4,254,331 | 31.4 |
| Melanoma of the Skin | Total | 13 | 439,386 | 3.0 | 3.0 | 14.1 | 0.918 | 276 | 8,549,329 | 3.2 |
| Melanoma of the Skin | Male | 6 | 216,870 | 2.8 | 2.8 | 9.1 | 0.390 | 186 | 4,294,998 | 4.3 |
| Melanoma of the Skin | Female | 7 | 222,516 | 3.1 | 3.2 | 4.7 | 0.390 | 90 | 4,254,331 | 2.1 |
| Myeloma | Total | 21 | 439,386 | 4.8 | 4.8 | 16.0 | 0.264 | 310 | 8,549,329 | 3.6 |
| Myeloma | Male | 12 | 216,870 | 5.5 | 5.7 | 9.1 | 0.407 | 184 | 4,294,998 | 4.3 |
| Myeloma | Female | 9 | 222,516 | 4.0 | 4.0 | 6.7 | 0.476 | 126 | 4,254,331 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 33 | 439,386 | 7.5 | 7.5 | 27.6 | 0.352 | 536 | 8,549,329 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 19 | 216,870 | 8.8 | 9.0 | 14.1 | 0.250 | 288 | 4,294,998 | 6.7 |
| Non-Hodgkin Lymphoma | Female | 14 | 222,516 | 6.3 | 6.1 | 13.4 | 0.944 | 248 | 4,254,331 | 5.8 |
| Oral Cavity and Pharynx | Total | 20 | 439,386 | 4.6 | 4.7 | 12.3 | 0.054 | 246 | 8,549,329 | 2.9 |
| Oral Cavity and Pharynx | Male | 11 | 216,870 | 5.1 | 5.3 | 8.5 | 0.475 | 176 | 4,294,998 | 4.1 |
| Oral Cavity and Pharynx | Female | 9 | 222,516 | 4.0 | 4.1 | 3.6 | 0.025 >> | 70 | 4,254,331 | 1.6 |
| Ovary | Female | 19 | 222,516 | 8.5 | 8.6 | 17.1 | 0.707 | 331 | 4,254,331 | 7.8 |
| Pancreas | Total | 53 | 439,386 | 12.1 | 12.3 | 57.3 | 0.626 | 1,137 | 8,549,329 | 13.3 |
| Pancreas | Male | 34 | 216,870 | 15.7 | 16.3 | 29.5 | 0.453 | 608 | 4,294,998 | 14.2 |
| Pancreas | Female | 19 | 222,516 | 8.5 | 8.6 | 27.6 | 0.111 | 529 | 4,254,331 | 12.4 |
| Prostate | Male | 57 | 216,870 | 26.3 | 26.6 | 44.6 | 0.082 | 892 | 4,294,998 | 20.8 |
| Stomach | Total | 7 | 439,386 | 1.6 | 1.6 | 9.7 | 0.495 | 191 | 8,549,329 | 2.2 |
| Stomach | Male | 4 | 216,870 | 1.8 | 1.9 | 5.7 | 0.652 | 117 | 4,294,998 | 2.7 |
| Stomach | Female | 3 | 222,516 | 1.3 | 1.3 | 3.9 | 0.898 | 74 | 4,254,331 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Twin Falls County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 81.7\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 12.0\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 65.7\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% | 66.1\% |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 62.1\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 22.3\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 27.3\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 75.2\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 20.8\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 16.8\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^41]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# VALLDY COUNTY CANCPR PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 379 cases of invasive cancer were diagnosed among Valley County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Valley County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Valley <br> County |  |
| :--- | ---: | ---: | | State of |
| :---: |
| Idaho |$|$| All Sites/Types | 379 | 45,610 |
| :--- | ---: | ---: |
| Female Breast | 53 | 6,687 |
| Prostate | 73 | 6,417 |
| Lung \& Bronchus | 28 | 4,887 |
| Colorectal | 26 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Valley County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Valley County. The table also shows the number of observed cases, person-
years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Valley County was 683.8 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.9) gives an estimate of the relative burden of disease in Valley County.

The age- and sex-adjusted incidence rate of invasive cancer in Valley County, all sites combined, was 478.1 cases per 100,000 persons per year during 2016-2020. There were fewer cases of cancer in Valley County (379) than expected (411.3) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 104 Valley County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Valley County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Valley <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 414 | 77,431 |
| Cancer Deaths | 104 | 15,121 |
| \% of All Deaths | $25.1 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 16 | 2,961 |
| Colorectal | 7 | 1,319 |
| Pancreas | 7 | 1,190 |
| Female Breast | 7 | 1,086 |
| Prostate | 7 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Valley County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Valley County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Valley County, all sites combined, was 128.0 deaths per 100,000 persons per year during 2017-2021, compared with 168.1 for the remainder of the state. There were statistically significantly fewer cancer deaths in Valley County (104) than expected (136.6) based upon rates in the remainder of the state $(p=.004)$.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2016-2020
COMPARISON BETWEEN VALLEY COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cancer Site/Type | Sex | Valley County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Cases | Person Years | Crude Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person Years | Crude Rate (1) |
| All Sites Combined | Total | 379 | 55,427 | 683.8 | 478.1 | 411.3 | 0.114 | 45,231 | 8,716,401 | 518.9 |
| All Sites Combined | Male | 231 | 28,610 | 807.4 | 519.1 | 245.1 | 0.386 | 24,058 | 4,368,300 | 550.7 |
| All Sites Combined | Female | 148 | 26,817 | 551.9 | 416.3 | 173.1 | 0.057 | 21,173 | 4,348,101 | 486.9 |
| Bladder | Total | 20 | 55,427 | 36.1 | 24.5 | 20.2 | 1.000 | 2,164 | 8,716,401 | 24.8 |
| Bladder | Male | 17 | 28,610 | 59.4 | 37.0 | 18.2 | 0.896 | 1,734 | 4,368,300 | 39.7 |
| Bladder | Female | 3 | 26,817 | 11.2 | 8.2 | 3.6 | 1.000 | 430 | 4,348,101 | 9.9 |
| Brain - malignant | Total | 3 | 55,427 | 5.4 | 4.1 | 5.2 | 0.486 | 622 | 8,716,401 | 7.1 |
| Brain - malignant | Male | 2 | 28,610 | 7.0 | 5.1 | 3.4 | 0.697 | 373 | 4,368,300 | 8.5 |
| Brain - malignant | Female | 1 | 26,817 | 3.7 | 3.0 | 1.9 | 0.867 | 249 | 4,348,101 | 5.7 |
| Brain and other CNS - non-malignant | Total | 1 | 55,427 | 1.8 | 1.4 | 12.1 | 0.000 << | 1,423 | 8,716,401 | 16.3 |
| Brain and other CNS - non-malignant | Male |  | 28,610 | - | - | 4.3 | 0.026 << | 480 | 4,368,300 | 11.0 |
| Brain and other CNS - non-malignant | Female | 1 | 26,817 | 3.7 | 2.9 | 7.4 | 0.010 << | 943 | 4,348,101 | 21.7 |
| Breast | Total | 53 | 55,427 | 95.6 | 67.7 | 60.1 | 0.398 | 6,693 | 8,716,401 | 76.8 |
| Breast | Male |  | 28,610 |  |  | 0.6 | 1.000 | 59 | 4,368,300 | 1.4 |
| Breast | Female | 53 | 26,817 | 197.6 | 146.2 | 55.3 | 0.825 | 6,634 | 4,348,101 | 152.6 |
| Breast - in situ | Total | 9 | 55,427 | 16.2 | 11.4 | 11.2 | 0.643 | 1,230 | 8,716,401 | 14.1 |
| Breast - in situ | Male |  | 28,610 | - |  | 0.0 | 1.000 | 5 | 4,368,300 | 0.1 |
| Breast - in situ | Female | 9 | 26,817 | 33.6 | 24.3 | 10.4 | 0.810 | 1,225 | 4,348,101 | 28.2 |
| Cervix | Female | 3 | 26,817 | 11.2 | 9.8 | 2.1 | 0.716 | 301 | 4,348,101 | 6.9 |
| Colorectal | Total | 26 | 55,427 | 46.9 | 33.7 | 30.3 | 0.499 | 3,425 | 8,716,401 | 39.3 |
| Colorectal | Male | 18 | 28,610 | 62.9 | 42.4 | 18.3 | 1.000 | 1,885 | 4,368,300 | 43.2 |
| Colorectal | Female | 8 | 26,817 | 29.8 | 23.0 | 12.3 | 0.269 | 1,540 | 4,348,101 | 35.4 |
| Corpus Uteri | Female | 7 | 26,817 | 26.1 | 18.7 | 11.4 | 0.240 | 1,323 | 4,348,101 | 30.4 |
| Esophagus | Total | 4 | 55,427 | 7.2 | 4.9 | 4.7 | 0.994 | 502 | 8,716,401 | 5.8 |
| Esophagus | Male | 3 | 28,610 | 10.5 | 6.7 | 4.3 | 0.743 | 421 | 4,368,300 | 9.6 |
| Esophagus | Female | 1 | 26,817 | 3.7 | 2.7 | 0.7 | 0.994 | 81 | 4,348,101 | 1.9 |
| Hodgkin Lymphoma | Total | 3 | 55,427 | 5.4 | 5.0 | 1.4 | 0.347 | 207 | 8,716,401 | 2.4 |
| Hodgkin Lymphoma | Male | 3 | 28,610 | 10.5 | 9.1 | 0.9 | 0.116 | 115 | 4,368,300 | 2.6 |
| Hodgkin Lymphoma | Female | - | 26,817 | - | - | 0.6 | 1.000 | 92 | 4,348,101 | 2.1 |
| Kidney and Renal Pelvis | Total | 15 | 55,427 | 27.1 | 19.1 | 16.2 | 0.896 | 1,800 | 8,716,401 | 20.7 |
| Kidney and Renal Pelvis | Male | 11 | 28,610 | 38.4 | 25.7 | 11.5 | 1.000 | 1,171 | 4,368,300 | 26.8 |
| Kidney and Renal Pelvis | Female | 4 | 26,817 | 14.9 | 11.2 | 5.2 | 0.819 | 629 | 4,348,101 | 14.5 |
| Larynx | Total | 1 | 55,427 | 1.8 | 1.2 | 2.0 | 0.810 | 214 | 8,716,401 | 2.5 |
| Larynx | Male | 1 | 28,610 | 3.5 | 2.2 | 1.6 | 1.000 | 159 | 4,368,300 | 3.6 |
| Larynx | Female | - | 26,817 | - | - | 0.5 | 1.000 | 55 | 4,348,101 | 1.3 |
| Leukemia | Total | 13 | 55,427 | 23.5 | 17.2 | 14.0 | 0.920 | 1,618 | 8,716,401 | 18.6 |
| Leukemia | Male | 8 | 28,610 | 28.0 | 19.1 | 9.4 | 0.813 | 981 | 4,368,300 | 22.5 |
| Leukemia | Female | 5 | 26,817 | 18.6 | 14.6 | 5.0 | 1.000 | 637 | 4,348,101 | 14.7 |
| Liver and Bile Duct | Total | 6 | 55,427 | 10.8 | 7.2 | 7.9 | 0.662 | 823 | 8,716,401 | 9.4 |
| Liver and Bile Duct | Male | 5 | 28,610 | 17.5 | 10.9 | 6.1 | 0.849 | 585 | 4,368,300 | 13.4 |
| Liver and Bile Duct | Female | 1 | 26,817 | 3.7 | 2.7 | 2.0 | 0.797 | 238 | 4,348,101 | 5.5 |
| Lung and Bronchus | Total | 28 | 55,427 | 50.5 | 33.7 | 46.3 | 0.005 << | 4,859 | 8,716,401 | 55.7 |
| Lung and Bronchus | Male | 11 | 28,610 | 38.4 | 23.6 | 26.1 | 0.002 << | 2,441 | 4,368,300 | 55.9 |
| Lung and Bronchus | Female | 17 | 26,817 | 63.4 | 45.8 | 20.6 | 0.501 | 2,418 | 4,348,101 | 55.6 |
| Melanoma of the Skin | Total | 36 | 55,427 | 65.0 | 47.3 | 25.3 | 0.053 | 2,906 | 8,716,401 | 33.3 |
| Melanoma of the Skin | Male | 21 | 28,610 | 73.4 | 49.1 | 17.1 | 0.401 | 1,744 | 4,368,300 | 39.9 |
| Melanoma of the Skin | Female | 15 | 26,817 | 55.9 | 44.1 | 9.1 | 0.089 | 1,162 | 4,348,101 | 26.7 |
| Myeloma | Total | 10 | 55,427 | 18.0 | 12.3 | 6.5 | 0.247 | 698 | 8,716,401 | 8.0 |
| Myeloma | Male | 6 | 28,610 | 21.0 | 13.3 | 4.5 | 0.596 | 435 | 4,368,300 | 10.0 |
| Myeloma | Female | 4 | 26,817 | 14.9 | 10.9 | 2.2 | 0.367 | 263 | 4,348,101 | 6.0 |
| Non-Hodgkin Lymphoma | Total | 16 | 55,427 | 28.9 | 20.4 | 17.3 | 0.882 | 1,924 | 8,716,401 | 22.1 |
| Non-Hodgkin Lymphoma | Male | 12 | 28,610 | 41.9 | 27.9 | 11.0 | 0.839 | 1,117 | 4,368,300 | 25.6 |
| Non-Hodgkin Lymphoma | Female | 4 | 26,817 | 14.9 | 11.2 | 6.6 | 0.425 | 807 | 4,348,101 | 18.6 |
| Oral Cavity and Pharynx | Total | 19 | 55,427 | 34.3 | 23.4 | 11.9 | 0.070 | 1,276 | 8,716,401 | 14.6 |
| Oral Cavity and Pharynx | Male | 17 | 28,610 | 59.4 | 38.4 | 9.3 | 0.030 >> | 919 | 4,368,300 | 21.0 |
| Oral Cavity and Pharynx | Female | 2 | 26,817 | 7.5 | 5.4 | 3.0 | 0.837 | 357 | 4,348,101 | 8.2 |
| Ovary | Female | 4 | 26,817 | 14.9 | 11.3 | 4.3 | 1.000 | 529 | 4,348,101 | 12.2 |
| Pancreas | Total | 6 | 55,427 | 10.8 | 7.4 | 13.1 | 0.049 << | 1,417 | 8,716,401 | 16.3 |
| Pancreas | Male | 2 | 28,610 | 7.0 | 4.4 | 8.1 | 0.026 << | 782 | 4,368,300 | 17.9 |
| Pancreas | Female | 4 | 26,817 | 14.9 | 11.2 | 5.2 | 0.800 | 635 | 4,348,101 | 14.6 |
| Prostate | Male | 73 | 28,610 | 255.2 | 154.1 | 68.8 | 0.646 | 6,344 | 4,368,300 | 145.2 |
| Stomach | Total | 1 | 55,427 | 1.8 | 1.3 | 4.2 | 0.160 | 466 | 8,716,401 | 5.3 |
| Stomach | Male | 1 | 28,610 | 3.5 | 2.3 | 3.1 | 0.370 | 308 | 4,368,300 | 7.1 |
| Stomach | Female | - | 26,817 | - | - | 1.2 | 0.587 | 158 | 4,348,101 | 3.6 |
| Testis | Male | 2 | 28,610 | 7.0 | 7.9 | 1.5 | 0.898 | 263 | 4,368,300 | 6.0 |
| Thyroid | Total | 4 | 55,427 | 7.2 | 6.1 | 9.1 | 0.103 | 1,216 | 8,716,401 | 14.0 |
| Thyroid | Male | 1 | 28,610 | 3.5 | 2.7 | 3.0 | 0.398 | 354 | 4,368,300 | 8.1 |
| Thyroid | Female | 3 | 26,817 | 11.2 | 9.9 | 6.0 | 0.297 | 862 | 4,348,101 | 19.8 |
| Pediatric Age 0 to 19 | Total | 1 | 10,886 | 9.2 | 9.3 | 1.8 | 0.898 | 420 | 2,449,637 | 17.1 |
| Pediatric Age 0 to 19 | Male | 1 | 5,599 | 17.9 | 17.9 | 1.0 | 1.000 | 222 | 1,250,911 | 17.7 |
| Pediatric Age 0 to 19 | Female | - | 5,287 | - | - | 0.9 | 0.852 | 198 | 1,198,726 | 16.5 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

TABLE 4: CANCER MORTALITY 2017-2021
COMPARISON BETWEEN VALLEY COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Valley County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 414 | 57,230 | 723.4 | 549.4 | 649.8 | 0.000 << | 77,016 | 8,931,485 | 862.3 |
| All Causes of Death | Male | 234 | 29,499 | 793.2 | 542.0 | 393.2 | $0.000 \ll$ | 40,822 | 4,482,369 | 910.7 |
| All Causes of Death | Female | 180 | 27,731 | 649.1 | 552.0 | 265.3 | $0.000 \ll$ | 36,194 | 4,449,116 | 813.5 |
| All Malignant Cancers | Total | 104 | 57,230 | 181.7 | 128.0 | 136.6 | 0.004 << | 15,017 | 8,931,485 | 168.1 |
| All Malignant Cancers | Male | 56 | 29,499 | 189.8 | 121.7 | 83.3 | 0.002 << | 8,120 | 4,482,369 | 181.2 |
| All Malignant Cancers | Female | 48 | 27,731 | 173.1 | 132.8 | 56.0 | 0.315 | 6,897 | 4,449,116 | 155.0 |
| Bladder | Total | 5 | 57,230 | 8.7 | 6.4 | 4.2 | 0.829 | 484 | 8,931,485 | 5.4 |
| Bladder | Male | 3 | 29,499 | 10.2 | 6.6 | 3.8 | 0.955 | 375 | 4,482,369 | 8.4 |
| Bladder | Female | 2 | 27,731 | 7.2 | 5.8 | 0.8 | 0.413 | 109 | 4,449,116 | 2.4 |
| Brain and Other Nervous System | Total | 5 | 57,230 | 8.7 | 6.2 | 4.5 | 0.925 | 499 | 8,931,485 | 5.6 |
| Brain and Other Nervous System | Male | 4 | 29,499 | 13.6 | 9.2 | 2.9 | 0.645 | 294 | 4,482,369 | 6.6 |
| Brain and Other Nervous System | Female | 1 | 27,731 | 3.6 | 2.7 | 1.7 | 0.990 | 205 | 4,449,116 | 4.6 |
| Breast | Total | 7 | 57,230 | 12.2 | 8.8 | 9.7 | 0.489 | 1,095 | 8,931,485 | 12.3 |
| Breast | Male |  | 29,499 |  |  | 0.2 | 1.000 | 16 | 4,482,369 | 0.4 |
| Breast | Female | 7 | 27,731 | 25.2 | 19.5 | 8.7 | 0.718 | 1,079 | 4,449,116 | 24.3 |
| Cervix | Female | 1 | 27,731 | 3.6 | 2.9 | 0.6 | 0.936 | 82 | 4,449,116 | 1.8 |
| Colorectal | Total | 7 | 57,230 | 12.2 | 8.8 | 11.7 | 0.209 | 1,312 | 8,931,485 | 14.7 |
| Colorectal | Male | 3 | 29,499 | 10.2 | 6.7 | 7.1 | 0.152 | 716 | 4,482,369 | 16.0 |
| Colorectal | Female | 4 | 27,731 | 14.4 | 11.4 | 4.7 | 0.992 | 596 | 4,449,116 | 13.4 |
| Corpus Uteri | Female | 1 | 27,731 | 3.6 | 2.6 | 1.5 | 1.000 | 172 | 4,449,116 | 3.9 |
| Esophagus | Total |  | 57,230 |  | - | 4.4 | 0.023 << | 477 | 8,931,485 | 5.3 |
| Esophagus | Male | - | 29,499 | - | - | 4.2 | 0.031 << | 401 | 4,482,369 | 8.9 |
| Esophagus | Female | - | 27,731 | - | - | 0.6 | 1.000 | 76 | 4,449,116 | 1.7 |
| Hodgkin Lymphoma | Total | - | 57,230 | - | - | 0.2 | 1.000 | 29 | 8,931,485 | 0.3 |
| Hodgkin Lymphoma | Male | - | 29,499 | - | - | 0.1 | 1.000 | 14 | 4,482,369 | 0.3 |
| Hodgkin Lymphoma | Female | - | 27,731 | - | - | 0.1 | 1.000 | 15 | 4,449,116 | 0.3 |
| Kidney | Total | 1 | 57,230 | 1.7 | 1.2 | 3.5 | 0.262 | 384 | 8,931,485 | 4.3 |
| Kidney | Male | 1 | 29,499 | 3.4 | 2.1 | 2.5 | 0.569 | 241 | 4,482,369 | 5.4 |
| Kidney | Female | - | 27,731 | - | - | 1.1 | 0.633 | 143 | 4,449,116 | 3.2 |
| Larynx | Total | 1 | 57,230 | 1.7 | 1.2 | 0.6 | 0.951 | 70 | 8,931,485 | 0.8 |
| Larynx | Male |  | 29,499 | - | - | 0.6 | 1.000 | 58 | 4,482,369 | 1.3 |
| Larynx | Female | 1 | 27,731 | 3.6 | 2.5 | 0.1 | 0.203 | 12 | 4,449,116 | 0.3 |
| Leukemia | Total | 7 | 57,230 | 12.2 | 9.0 | 5.7 | 0.689 | 653 | 8,931,485 | 7.3 |
| Leukemia | Male | 5 | 29,499 | 16.9 | 11.2 | 3.8 | 0.658 | 381 | 4,482,369 | 8.5 |
| Leukemia | Female | 2 | 27,731 | 7.2 | 5.9 | 2.1 | 1.000 | 272 | 4,449,116 | 6.1 |
| Liver and Bile Duct | Total | 5 | 57,230 | 8.7 | 5.8 | 5.7 | 0.977 | 598 | 8,931,485 | 6.7 |
| Liver and Bile Duct | Male | 4 | 29,499 | 13.6 | 8.4 | 4.3 | 1.000 | 404 | 4,482,369 | 9.0 |
| Liver and Bile Duct | Female | 1 | 27,731 | 3.6 | 2.6 | 1.7 | 1.000 | 194 | 4,449,116 | 4.4 |
| Lung and Bronchus | Total | 16 | 57,230 | 28.0 | 19.0 | 27.8 | 0.023 << | 2,945 | 8,931,485 | 33.0 |
| Lung and Bronchus | Male | 6 | 29,499 | 20.3 | 12.6 | 16.5 | 0.006 << | 1,550 | 4,482,369 | 34.6 |
| Lung and Bronchus | Female | 10 | 27,731 | 36.1 | 27.0 | 11.6 | 0.775 | 1,395 | 4,449,116 | 31.4 |
| Melanoma of the Skin | Total |  | 57,230 | 5.2 | 3.8 | 2.6 | 0.942 | 286 | 8,931,485 | 3.2 |
| Melanoma of the Skin | Male | 1 | 29,499 | 3.4 | 2.2 | 1.9 | 0.858 | 191 | 4,482,369 | 4.3 |
| Melanoma of the Skin | Female | 2 | 27,731 | 7.2 | 5.6 | 0.8 | 0.358 | 95 | 4,449,116 | 2.1 |
| Myeloma | Total | 5 | 57,230 | 8.7 | 6.1 | 3.0 | 0.367 | 326 | 8,931,485 | 3.7 |
| Myeloma | Male | 2 | 29,499 | 6.8 | 4.3 | 2.0 | 1.000 | 194 | 4,482,369 | 4.3 |
| Myeloma | Female | 3 | 27,731 | 10.8 | 8.4 | 1.1 | 0.184 | 132 | 4,449,116 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 5 | 57,230 | 8.7 | 6.3 | 5.0 | 1.000 | 564 | 8,931,485 | 6.3 |
| Non-Hodgkin Lymphoma | Male | 4 | 29,499 | 13.6 | 8.8 | 3.1 | 0.731 | 303 | 4,482,369 | 6.8 |
| Non-Hodgkin Lymphoma | Female | 1 | 27,731 | 3.6 | 2.9 | 2.1 | 0.784 | 261 | 4,449,116 | 5.9 |
| Oral Cavity and Pharynx | Total | 1 | 57,230 | 1.7 | 1.2 | 2.5 | 0.584 | 265 | 8,931,485 | 3.0 |
| Oral Cavity and Pharynx | Male | 1 | 29,499 | 3.4 | 2.1 | 1.9 | 0.846 | 186 | 4,482,369 | 4.1 |
| Oral Cavity and Pharynx | Female | - | 27,731 | - | - | 0.6 | 1.000 | 79 | 4,449,116 | 1.8 |
| Ovary | Female | - | 27,731 | - | - | 2.9 | 0.105 | 350 | 4,449,116 | 7.9 |
| Pancreas | Total | 7 | 57,230 | 12.2 | 8.3 | 11.1 | 0.270 | 1,183 | 8,931,485 | 13.2 |
| Pancreas | Male | 3 | 29,499 | 10.2 | 6.4 | 6.7 | 0.197 | 639 | 4,482,369 | 14.3 |
| Pancreas | Female | 4 | 27,731 | 14.4 | 10.7 | 4.6 | 1.000 | 544 | 4,449,116 | 12.2 |
| Prostate | Male | 7 | 29,499 | 23.7 | 15.3 | 9.6 | 0.517 | 942 | 4,482,369 | 21.0 |
| Stomach | Total | 1 | 57,230 | 1.7 | 1.3 | 1.7 | 0.984 | 197 | 8,931,485 | 2.2 |
| Stomach | Male | 1 | 29,499 | 3.4 | 2.3 | 1.2 | 1.000 | 120 | 4,482,369 | 2.7 |
| Stomach | Female | - | 27,731 | - | - | 0.6 | 1.000 | 77 | 4,449,116 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020.

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

## Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Valley County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 78.0\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 13.4\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% |  |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 $(2018,2020)$ | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | . |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) Other Cancer-Related | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 25.5\% |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 46.7\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 83.5\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 26.1\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 29.5\% |

## Access to Care

## Have Health Insurance - 2015-2021

Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, $12.6 \%$ of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^42]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged 50-74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked $49^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.

# WASHINGTON COUNTY CANCPR PROFILE 

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

## Cancer Incidence 2016-2020 Cancer Mortality 2017-2021 BRFSS 2011-2021

## RISK FACTORS AND INTERVENTIONS


#### Abstract

Aging: As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.


## Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

## Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

## Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

Cancer Data Registry of Idaho
P.O. Box 1278

Boise, ID 83701
208-489-1380
https://www.idcancer.org

National Cancer Institute Cancer Information Services 1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society
https://www.cancer.org

## CANCER INCIDENCE 2016-2020

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2016-2020, 45,610 cases of invasive cancer were diagnosed among Idaho residents, and 405 cases of invasive cancer were diagnosed among Washington County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Washington County and the State of Idaho, 2016-2020

| Cancer Incidence <br> 2016-2020 | Washington <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Sites/Types | 405 | 45,610 |
| Female Breast | 49 | 6,687 |
| Prostate | 62 | 6,417 |
| Lung \& Bronchus | 45 | 4,887 |
| Colorectal | 42 | 3,451 |

Table 3 (Cancer Incidence 2016-2020, Comparison between Washington County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Washington County. The table also shows the number of observed cases,
person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, nonmalignant brain and other central nervous system tumors, and pediatric (0-19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Washington County was 799.7 cases per 100,000 person-years per year during 2016-2020. Comparing this crude rate with the crude rate for the remainder of Idaho (518.3) gives an estimate of the relative burden of disease in Washington County.

The age- and sex-adjusted incidence rate of invasive cancer in Washington County, all sites combined, was 573.8 cases per 100,000 persons per year during 2016-2020. There were statistically significantly more cases of cancer in Washington County (405) than expected (365.9) based upon rates in the remainder of the state $(p=.046)$.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

## CANCER MORTALITY 2017-2021

During 2017-2021, cancer was the second leading cause of death in Idaho; 15,121 Idaho residents and 152 Washington County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Washington County and the State of Idaho, 2017-2021

| Mortality <br> 2017-2021 | Washington <br> County | State of <br> Idaho |
| :--- | ---: | ---: |
| All Deaths | 712 | 77,431 |
| Cancer Deaths | 152 | 15,121 |
| \% of All Deaths | $21.3 \%$ | $19.5 \%$ |
| Lung \& Bronchus | 32 | 2,961 |
| Colorectal | 15 | 1,319 |
| Pancreas | 15 | 1,190 |
| Female Breast | 6 | 1,086 |
| Prostate | 6 | 949 |

Table 4 (Cancer Mortality 2017-2021, Comparison between Washington County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and $p$-values for tests comparing the number of observed and expected deaths for Washington County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Washington County, all sites combined, was 195.5 deaths per 100,000 persons per year during 2017-2021, compared with 167.5 for the remainder of the state. There were more cancer deaths in Washington County (152) than expected (130.2) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

|  |  | Washington County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Cancer Site/Type | Sex | Observed Cases | Person <br> Years | Crude Rate (1) | A.A.I. <br> Rate (1,2) | Expected Cases (3) | P-Value (4) | Observed Cases | Person <br> Years | Crude <br> Rate (1) |
| All Sites Combined | Total | 405 | 50,641 | 799.7 | 573.8 | 365.9 | 0.046 >> | 45,205 | 8,721,187 | 518.3 |
| All Sites Combined | Male | 223 | 25,185 | 885.4 | 599.4 | 204.8 | 0.219 | 24,066 | 4,371,725 | 550.5 |
| All Sites Combined | Female | 182 | 25,456 | 715.0 | 541.3 | 163.4 | 0.161 | 21,139 | 4,349,462 | 486.0 |
| Bladder | Total | 18 | 50,641 | 35.5 | 23.3 | 19.2 | 0.899 | 2,166 | 8,721,187 | 24.8 |
| Bladder | Male | 13 | 25,185 | 51.6 | 32.2 | 16.1 | 0.538 | 1,738 | 4,371,725 | 39.8 |
| Bladder | Female | 5 | 25,456 | 19.6 | 13.6 | 3.6 | 0.595 | 428 | 4,349,462 | 9.8 |
| Brain - malignant | Total | 1 | 50,641 | 2.0 | 1.6 | 4.6 | 0.114 | 624 | 8,721,187 | 7.2 |
| Brain - malignant | Male | - | 25,185 | - | - | 2.8 | 0.123 | 375 | 4,371,725 | 8.6 |
| Brain - malignant | Female | 1 | 25,456 | 3.9 | 3.1 | 1.8 | 0.913 | 249 | 4,349,462 | 5.7 |
| Brain and other CNS - non-malignant | Total | 14 | 50,641 | 27.6 | 21.0 | 10.8 | 0.400 | 1,410 | 8,721,187 | 16.2 |
| Brain and other CNS - non-malignant | Male | 5 | 25,185 | 19.9 | 15.1 | 3.6 | 0.590 | 475 | 4,371,725 | 10.9 |
| Brain and other CNS - non-malignant | Female | 9 | 25,456 | 35.4 | 27.3 | 7.1 | 0.568 | 935 | 4,349,462 | 21.5 |
| Breast | Total | 49 | 50,641 | 96.8 | 72.9 | 51.6 | 0.787 | 6,697 | 8,721,187 | 76.8 |
| Breast | Male | - | 25,185 | - | - | 0.5 | 1.000 | 59 | 4,371,725 | 1.3 |
| Breast | Female | 49 | 25,456 | 192.5 | 149.0 | 50.2 | 0.942 | 6,638 | 4,349,462 | 152.6 |
| Breast - in situ | Total | 7 | 50,641 | 13.8 | 10.7 | 9.2 | 0.601 | 1,232 | 8,721,187 | 14.1 |
| Breast - in situ | Male | - | 25,185 | - | - | 0.0 | 1.000 | 5 | 4,371,725 | 0.1 |
| Breast - in situ | Female | 7 | 25,456 | 27.5 | 21.8 | 9.0 | 0.639 | 1,227 | 4,349,462 | 28.2 |
| Cervix | Female | 1 | 25,456 | 3.9 | 3.8 | 1.8 | 0.918 | 303 | 4,349,462 | 7.0 |
| Colorectal | Total | 42 | 50,641 | 82.9 | 59.8 | 27.5 | 0.012 >> | 3,409 | 8,721,187 | 39.1 |
| Colorectal | Male | 19 | 25,185 | 75.4 | 53.1 | 15.4 | 0.425 | 1,884 | 4,371,725 | 43.1 |
| Colorectal | Female | 23 | 25,456 | 90.4 | 66.7 | 12.1 | 0.007 >> | 1,525 | 4,349,462 | 35.1 |
| Corpus Uteri | Female | 8 | 25,456 | 31.4 | 24.4 | 10.0 | 0.670 | 1,322 | 4,349,462 | 30.4 |
| Esophagus | Total | 8 | 50,641 | 15.8 | 10.9 | 4.2 | 0.127 | 498 | 8,721,187 | 5.7 |
| Esophagus | Male | 7 | 25,185 | 27.8 | 18.5 | 3.6 | 0.150 | 417 | 4,371,725 | 9.5 |
| Esophagus | Female | 1 | 25,456 | 3.9 | 2.8 | 0.7 | 0.973 | 81 | 4,349,462 | 1.9 |
| Hodgkin Lymphoma | Total | - | 50,641 | - | - | 1.3 | 0.545 | 210 | 8,721,187 | 2.4 |
| Hodgkin Lymphoma | Male | - | 25,185 | - | - | 0.7 | 0.950 | 118 | 4,371,725 | 2.7 |
| Hodgkin Lymphoma | Female | - | 25,456 | - | - | 0.6 | 1.000 | 92 | 4,349,462 | 2.1 |
| Kidney and Renal Pelvis | Total | 15 | 50,641 | 29.6 | 21.7 | 14.3 | 0.918 | 1,800 | 8,721,187 | 20.6 |
| Kidney and Renal Pelvis | Male | 12 | 25,185 | 47.6 | 33.9 | 9.5 | 0.488 | 1,170 | 4,371,725 | 26.8 |
| Kidney and Renal Pelvis | Female | 3 | 25,456 | 11.8 | 8.9 | 4.9 | 0.556 | 630 | 4,349,462 | 14.5 |
| Larynx | Total | 3 | 50,641 | 5.9 | 4.1 | 1.8 | 0.517 | 212 | 8,721,187 | 2.4 |
| Larynx | Male | 3 | 25,185 | 11.9 | 7.9 | 1.4 | 0.312 | 157 | 4,371,725 | 3.6 |
| Larynx | Female | - | 25,456 | - | - | 0.4 | 1.000 | 55 | 4,349,462 | 1.3 |
| Leukemia | Total | 16 | 50,641 | 31.6 | 22.4 | 13.2 | 0.513 | 1,615 | 8,721,187 | 18.5 |
| Leukemia | Male | 7 | 25,185 | 27.8 | 19.1 | 8.2 | 0.841 | 982 | 4,371,725 | 22.5 |
| Leukemia | Female | 9 | 25,456 | 35.4 | 25.8 | 5.1 | 0.147 | 633 | 4,349,462 | 14.6 |
| Liver and Bile Duct | Total | 13 | 50,641 | 25.7 | 18.2 | 6.7 | 0.040 >> | 816 | 8,721,187 | 9.4 |
| Liver and Bile Duct | Male | 6 | 25,185 | 23.8 | 16.4 | 4.9 | 0.729 | 584 | 4,371,725 | 13.4 |
| Liver and Bile Duct | Female | 7 | 25,456 | 27.5 | 19.9 | 1.9 | $0.006 \gg$ | 232 | 4,349,462 | 5.3 |
| Lung and Bronchus | Total | 45 | 50,641 | 88.9 | 58.7 | 42.6 | 0.751 | 4,842 | 8,721,187 | 55.5 |
| Lung and Bronchus | Male | 20 | 25,185 | 79.4 | 50.0 | 22.3 | 0.732 | 2,432 | 4,371,725 | 55.6 |
| Lung and Bronchus | Female | 25 | 25,456 | 98.2 | 67.7 | 20.4 | 0.366 | 2,410 | 4,349,462 | 55.4 |
| Melanoma of the Skin | Total | 16 | 50,641 | 31.6 | 23.6 | 22.8 | 0.179 | 2,926 | 8,721,187 | 33.6 |
| Melanoma of the Skin | Male | 11 | 25,185 | 43.7 | 30.3 | 14.6 | 0.432 | 1,754 | 4,371,725 | 40.1 |
| Melanoma of the Skin | Female | 5 | 25,456 | 19.6 | 15.9 | 8.5 | 0.306 | 1,172 | 4,349,462 | 26.9 |
| Myeloma | Total | 11 | 50,641 | 21.7 | 14.6 | 6.0 | 0.087 | 697 | 8,721,187 | 8.0 |
| Myeloma | Male | 9 | 25,185 | 35.7 | 23.0 | 3.9 | 0.036 >> | 432 | 4,371,725 | 9.9 |
| Myeloma | Female | 2 | 25,456 | 7.9 | 5.5 | 2.2 | 1.000 | 265 | 4,349,462 | 6.1 |
| Non-Hodgkin Lymphoma | Total | 23 | 50,641 | 45.4 | 32.5 | 15.6 | 0.091 | 1,917 | 8,721,187 | 22.0 |
| Non-Hodgkin Lymphoma | Male | 15 | 25,185 | 59.6 | 41.5 | 9.2 | 0.097 | 1,114 | 4,371,725 | 25.5 |
| Non-Hodgkin Lymphoma | Female | 8 | 25,456 | 31.4 | 23.0 | 6.4 | 0.634 | 803 | 4,349,462 | 18.5 |
| Oral Cavity and Pharynx | Total | 9 | 50,641 | 17.8 | 13.0 | 10.2 | 0.858 | 1,286 | 8,721,187 | 14.7 |
| Oral Cavity and Pharynx | Male | 5 | 25,185 | 19.9 | 14.1 | 7.6 | 0.471 | 931 | 4,371,725 | 21.3 |
| Oral Cavity and Pharynx | Female | 4 | 25,456 | 15.7 | 11.8 | 2.8 | 0.604 | 355 | 4,349,462 | 8.2 |
| Ovary | Female | 4 | 25,456 | 15.7 | 12.1 | 4.0 | 1.000 | 529 | 4,349,462 | 12.2 |
| Pancreas | Total | 15 | 50,641 | 29.6 | 20.0 | 12.1 | 0.480 | 1,408 | 8,721,187 | 16.1 |
| Pancreas | Male | 12 | 25,185 | 47.6 | 31.0 | 6.8 | 0.092 | 772 | 4,371,725 | 17.7 |
| Pancreas | Female | 3 | 25,456 | 11.8 | 8.2 | 5.3 | 0.440 | 636 | 4,349,462 | 14.6 |
| Prostate | Male | 62 | 25,185 | 246.2 | 164.1 | 54.9 | 0.372 | 6,355 | 4,371,725 | 145.4 |
| Stomach | Total | 3 | 50,641 | 5.9 | 4.1 | 3.9 | 0.922 | 464 | 8,721,187 | 5.3 |
| Stomach | Male | 2 | 25,185 | 7.9 | 5.3 | 2.7 | 1.000 | 307 | 4,371,725 | 7.0 |
| Stomach | Female | 1 | 25,456 | 3.9 | 2.9 | 1.3 | 1.000 | 157 | 4,349,462 | 3.6 |
| Testis | Male | 1 | 25,185 | 4.0 | 4.7 | 1.3 | 1.000 | 264 | 4,371,725 | 6.0 |
| Thyroid | Total | 3 | 50,641 | 5.9 | 5.5 | 7.6 | 0.109 | 1,217 | 8,721,187 | 14.0 |
| Thyroid | Male | 1 | 25,185 | 4.0 | 3.4 | 2.4 | 0.611 | 354 | 4,371,725 | 8.1 |
| Thyroid | Female | 2 | 25,456 | 7.9 | 7.6 | 5.2 | 0.215 | 863 | 4,349,462 | 19.8 |
| Pediatric Age 0 to 19 | Total | 1 | 12,774 | 7.8 | 7.8 | 2.2 | 0.711 | 420 | 2,447,749 | 17.2 |
| Pediatric Age 0 to 19 | Male | 1 | 6,428 | 15.6 | 15.6 | 1.1 | 1.000 | 222 | 1,250,082 | 17.8 |
| Pediatric Age 0 to 19 | Female | - | 6,346 | - | - | 1.1 | 0.694 | 198 | 1,197,667 | 16.5 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $p=.05$ ).

COMPARISON BETWEEN WASHINGTON COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

| Cause of Death Cancer Site/Type | Sex | Washington County |  |  |  |  |  | Remainder of Idaho |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Observed Deaths | Person Years | Crude Rate (1) | A.A.M. Rate (1,2) | Expected Deaths (3) | P-Value (4) | Observed Deaths | Person Years | Crude Rate (1) |
| All Causes of Death | Total | 712 | 51,509 | 1,382.3 | 914.4 | 668.4 | 0.098 | 76,718 | 8,937,206 | 858.4 |
| All Causes of Death | Male | 368 | 25,661 | 1,434.1 | 929.9 | 358.9 | 0.646 | 40,688 | 4,486,207 | 907.0 |
| All Causes of Death | Female | 344 | 25,848 | 1,330.9 | 890.8 | 312.6 | 0.084 | 36,030 | 4,450,999 | 809.5 |
| All Malignant Cancers | Total | 152 | 51,509 | 295.1 | 195.5 | 130.2 | 0.067 | 14,969 | 8,937,206 | 167.5 |
| All Malignant Cancers | Male | 81 | 25,661 | 315.7 | 198.9 | 73.5 | 0.410 | 8,095 | 4,486,207 | 180.4 |
| All Malignant Cancers | Female | 71 | 25,848 | 274.7 | 190.3 | 57.6 | 0.097 | 6,874 | 4,450,999 | 154.4 |
| Bladder | Total | 3 | 51,509 | 5.8 | 3.6 | 4.5 | 0.673 | 486 | 8,937,206 | 5.4 |
| Bladder | Male | 1 | 25,661 | 3.9 | 2.3 | 3.7 | 0.238 | 377 | 4,486,207 | 8.4 |
| Bladder | Female | 2 | 25,848 | 7.7 | 5.0 | 1.0 | 0.514 | 109 | 4,450,999 | 2.4 |
| Brain and Other Nervous System | Total | 2 | 51,509 | 3.9 | 2.9 | 3.9 | 0.500 | 502 | 8,937,206 | 5.6 |
| Brain and Other Nervous System | Male | 2 | 25,661 | 7.8 | 5.5 | 2.4 | 1.000 | 296 | 4,486,207 | 6.6 |
| Brain and Other Nervous System | Female | - | 25,848 | - |  | 1.6 | 0.415 | 206 | 4,450,999 | 4.6 |
| Breast | Total | 6 | 51,509 | 11.6 | 8.1 | 9.1 | 0.395 | 1,096 | 8,937,206 | 12.3 |
| Breast | Male |  | 25,661 |  |  | 0.1 | 1.000 | 16 | 4,486,207 | 0.4 |
| Breast | Female | 6 | 25,848 | 23.2 | 16.6 | 8.8 | 0.460 | 1,080 | 4,450,999 | 24.3 |
| Cervix | Female | - | 25,848 |  | - | 0.6 | 1.000 | 83 | 4,450,999 | 1.9 |
| Colorectal | Total | 15 | 51,509 | 29.1 | 19.9 | 11.0 | 0.294 | 1,304 | 8,937,206 | 14.6 |
| Colorectal | Male | 7 | 25,661 | 27.3 | 18.3 | 6.1 | 0.812 | 712 | 4,486,207 | 15.9 |
| Colorectal | Female | 8 | 25,848 | 31.0 | 21.4 | 5.0 | 0.261 | 592 | 4,450,999 | 13.3 |
| Corpus Uteri | Female | 2 | 25,848 | 7.7 | 5.4 | 1.4 | 0.827 | 171 | 4,450,999 | 3.8 |
| Esophagus | Total | 3 | 51,509 | 5.8 | 3.9 | 4.0 | 0.849 | 474 | 8,937,206 | 5.3 |
| Esophagus | Male | 2 | 25,661 | 7.8 | 5.1 | 3.5 | 0.638 | 399 | 4,486,207 | 8.9 |
| Esophagus | Female | 1 | 25,848 | 3.9 | 2.7 | 0.6 | 0.937 | 75 | 4,450,999 | 1.7 |
| Hodgkin Lymphoma | Total |  | 51,509 | - | - | 0.2 | 1.000 | 29 | 8,937,206 | 0.3 |
| Hodgkin Lymphoma | Male |  | 25,661 | - | - | 0.1 | 1.000 | 14 | 4,486,207 | 0.3 |
| Hodgkin Lymphoma | Female | - | 25,848 | - | - | 0.1 | 1.000 | 15 | 4,450,999 | 0.3 |
| Kidney | Total | 2 | 51,509 | 3.9 | 2.5 | 3.4 | 0.686 | 383 | 8,937,206 | 4.3 |
| Kidney | Male | 2 | 25,661 | 7.8 | 5.0 | 2.2 | 1.000 | 240 | 4,486,207 | 5.3 |
| Kidney | Female | - | 25,848 | - | - | 1.3 | 0.570 | 143 | 4,450,999 | 3.2 |
| Larynx | Total | 2 | 51,509 | 3.9 | 2.6 | 0.6 | 0.240 | 69 | 8,937,206 | 0.8 |
| Larynx | Male | 2 | 25,661 | 7.8 | 4.9 | 0.5 | 0.188 | 56 | 4,486,207 | 1.2 |
| Larynx | Female | - | 25,848 |  |  | 0.1 | 1.000 | 13 | 4,450,999 | 0.3 |
| Leukemia | Total | 3 | 51,509 | 5.8 | 3.8 | 5.8 | 0.330 | 657 | 8,937,206 | 7.4 |
| Leukemia | Male |  | 25,661 | - | - | 3.6 | 0.057 | 386 | 4,486,207 | 8.6 |
| Leukemia | Female | 3 | 25,848 | 11.6 | 7.7 | 2.4 | 0.839 | 271 | 4,450,999 | 6.1 |
| Liver and Bile Duct | Total | 11 | 51,509 | 21.4 | 14.5 | 5.0 | 0.029 >> | 592 | 8,937,206 | 6.6 |
| Liver and Bile Duct | Male | 5 | 25,661 | 19.5 | 12.7 | 3.5 | 0.561 | 403 | 4,486,207 | 9.0 |
| Liver and Bile Duct | Female | 6 | 25,848 | 23.2 | 16.2 | 1.6 | 0.011 >> | 189 | 4,450,999 | 4.2 |
| Lung and Bronchus | Total | 32 | 51,509 | 62.1 | 40.4 | 26.0 | 0.280 | 2,929 | 8,937,206 | 32.8 |
| Lung and Bronchus | Male | 16 | 25,661 | 62.4 | 38.7 | 14.2 | 0.697 | 1,540 | 4,486,207 | 34.3 |
| Lung and Bronchus | Female | 16 | 25,848 | 61.9 | 41.9 | 11.9 | 0.297 | 1,389 | 4,450,999 | 31.2 |
| Melanoma of the Skin | Total | 1 | 51,509 | 1.9 | 1.3 | 2.4 | 0.603 | 288 | 8,937,206 | 3.2 |
| Melanoma of the Skin | Male | 1 | 25,661 | 3.9 | 2.5 | 1.7 | 0.998 | 191 | 4,486,207 | 4.3 |
| Melanoma of the Skin | Female | - | 25,848 | - | - | 0.8 | 0.922 | 97 | 4,450,999 | 2.2 |
| Myeloma | Total | 4 | 51,509 | 7.8 | 4.9 | 3.0 | 0.710 | 327 | 8,937,206 | 3.7 |
| Myeloma | Male | 3 | 25,661 | 11.7 | 6.9 | 1.9 | 0.573 | 193 | 4,486,207 | 4.3 |
| Myeloma | Female | 1 | 25,848 | 3.9 | 2.6 | 1.2 | 1.000 | 134 | 4,450,999 | 3.0 |
| Non-Hodgkin Lymphoma | Total | 11 | 51,509 | 21.4 | 13.7 | 5.0 | 0.027 >> | 558 | 8,937,206 | 6.2 |
| Non-Hodgkin Lymphoma | Male | 6 | 25,661 | 23.4 | 14.6 | 2.7 | 0.121 | 301 | 4,486,207 | 6.7 |
| Non-Hodgkin Lymphoma | Female | 5 | 25,848 | 19.3 | 12.8 | 2.3 | 0.158 | 257 | 4,450,999 | 5.8 |
| Oral Cavity and Pharynx | Total | 2 | 51,509 | 3.9 | 2.6 | 2.2 | 1.000 | 264 | 8,937,206 | 3.0 |
| Oral Cavity and Pharynx | Male | 1 | 25,661 | 3.9 | 2.5 | 1.6 | 1.000 | 186 | 4,486,207 | 4.1 |
| Oral Cavity and Pharynx | Female | 1 | 25,848 | 3.9 | 2.7 | 0.6 | 0.949 | 78 | 4,450,999 | 1.8 |
| Ovary | Female | 4 | 25,848 | 15.5 | 10.9 | 2.8 | 0.637 | 346 | 4,450,999 | 7.8 |
| Pancreas | Total | 15 | 51,509 | 29.1 | 19.3 | 10.2 | 0.193 | 1,175 | 8,937,206 | 13.1 |
| Pancreas | Male | 12 | 25,661 | 46.8 | 29.7 | 5.7 | 0.027 >> | 630 | 4,486,207 | 14.0 |
| Pancreas | Female | 3 | 25,848 | 11.6 | 8.0 | 4.6 | 0.648 | 545 | 4,450,999 | 12.2 |
| Prostate | Male | 6 | 25,661 | 23.4 | 13.7 | 9.2 | 0.374 | 943 | 4,486,207 | 21.0 |
| Stomach | Total | 4 | 51,509 | 7.8 | 5.4 | 1.6 | 0.160 | 194 | 8,937,206 | 2.2 |
| Stomach | Male | 2 | 25,661 | 7.8 | 5.1 | 1.0 | 0.551 | 119 | 4,486,207 | 2.7 |
| Stomach | Female | 2 | 25,848 | 7.7 | 5.6 | 0.6 | 0.242 | 75 | 4,450,999 | 1.7 |

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).
2. Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.
3. Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).
4. P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.
"<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected ( $\mathrm{p}=.05$ ).
Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.
Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.
Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2020

## Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys (BRFS) since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for the major causes of death, including cancer. DPH provided data sets containing Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2021 to CDRI staff, who performed the analyses reported in these County Profiles. Analysis weights were poststratified to 2020 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. A minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring Comprehensive Cancer Alliance for Idaho objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011-2021

| Measure | State of Idaho | HD 1 | HD 2 | HD 3 | HD 4 | HD 5 | HD 6 | HD 7 | Washington County |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Access to Care |  |  |  |  |  |  |  |  |  |
| Have Health Insurance, Age <65 (2015-2021) | 83.1\% | 82.8\% | 85.1\% | 77.2\% | 85.8\% | 78.9\% | 85.4\% | 85.4\% | 77.8\% |
| Not See Doctor Due to Cost in Past Year (2015-2021) | 12.6\% | 11.4\% | 11.8\% | 14.5\% | 12.4\% | 12.3\% | 11.8\% | 12.9\% | 14.5\% |
| Cancer Screening |  |  |  |  |  |  |  |  |  |
| Mammogram Past 2 Years, Age 50-74 (2014, 2016, 2018, 2020) | 69.1\% | 67.0\% | 73.8\% | 68.2\% | 73.2\% | 64.8\% | 64.5\% | 67.1\% | 70.5\% |
| Pap Test Past 3 Years, Cervix Intact Age 21-65 (2018, 2020) | 71.2\% | 73.6\% | 73.6\% | 70.8\% | 72.9\% | 69.1\% | 69.5\% | 65.9\% |  |
| Colorectal Cancer Screening, Age 50-75 (2018, 2020) | 67.9\% | 66.9\% | 73.6\% | 71.4\% | 70.6\% | 61.7\% | 61.5\% | 64.7\% | 62.0\% |
| Tobacco Use |  |  |  |  |  |  |  |  |  |
| Current Tobacco User (2016-2021) | 22.3\% | 26.7\% | 23.1\% | 23.6\% | 21.8\% | 21.4\% | 22.7\% | 16.9\% | 29.1\% |
| Other Cancer-Related |  |  |  |  |  |  |  |  |  |
| Healthy Weight by Body Mass Index, Age 20+ (2015-2021) | 32.1\% | 32.8\% | 31.7\% | 27.9\% | 36.1\% | 29.8\% | 27.9\% | 31.9\% | 25.7\% |
| Any Physical Activity Besides Job Past 30 Days (2015-2021) | 78.7\% | 79.2\% | 78.1\% | 74.5\% | 83.2\% | 73.4\% | 76.3\% | 79.7\% | 70.0\% |
| Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019) | 21.9\% | 22.8\% | 19.4\% | 20.0\% | 25.2\% | 19.5\% | 20.4\% | 20.2\% | 23.2\% |
| Home Ever Tested for Radon (2016, 2018, 2020) | 23.0\% | 30.9\% | 18.2\% | 16.9\% | 25.1\% | 19.9\% | 23.0\% | 21.8\% | 14.2\% |

## Access to Care

Have Health Insurance - 2015-2021
Statewide, $83.1 \%$ of adults aged 18-64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with $86.0 \%$ of white non-Hispanics, compared to $64.8 \%$ of Hispanics and $83.3 \%$ of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (33.3\%) than Englishspeaking respondents (84.2\%). Health care coverage differed significantly by age of respondent, with $79.8 \%$ of persons aged $18-29$, and $87.8 \%$ of persons aged $50-64$, having health insurance. Health care coverage differed significantly by county, with a range of $62.1 \%$ in Adams County to $91.6 \%$ in Oneida County having health insurance.

Not See Doctor Due to Cost in Past Year - 2015-2021
Statewide, 12.6\% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity ( $11.5 \%$ of white non-Hispanics, $19.2 \%$ of Hispanics, and $21.0 \%$ of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (24.9\% for less than \$15,000, 6.1\% for greater than $\$ 50,000$ ). Inability to see a doctor due to cost differed significantly by county, with a range of $7.4 \%$ in Franklin County to $17.5 \%$ in Power County.

[^43]
## Cancer Screening

Mammogram - 2014, 2016, 2018, 2020
Statewide, $69.1 \%$ of women aged $50-74$ reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years ( $72.1 \%$ versus $36.7 \%$ ). Mammography rates differed significantly by county, with a range in screening of $45.9 \%$ in Benewah County to $77.0 \%$ in Nez Perce County. In 2020, Idaho ranked $48^{\text {th }}$ among states and the District of Columbia for mammography screening rates among women aged 50-74 and also $48^{\text {th }}$ among ages 40+.

Pap Test - 2018, 2020
Statewide, $71.2 \%$ of women with an intact cervix and aged 2165 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women ( $75.1 \%$ versus $52.6 \%$ screened in the past 3 years). Pap screening differed significantly by county, with a range of $50.7 \%$ in Bingham County to $78.9 \%$ in Bannock County. In 2020, Idaho ranked 49 ${ }^{\text {th }}$ among states and the District of Columbia for Pap screening rate.

Colorectal Cancer Screening - 2018, 2020
Statewide, $67.9 \%$ of adults aged $50-75$ reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2020, Idaho ranked $47^{\text {th }}$ among states and the District of Columbia in the percentage of adults aged 50-75 and older who reported being up-to-date for colorectal cancer screening.

## Cancer Screening and Risk Factors

## Tobacco Use

Current Tobacco Use - 2016-2021
Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, $22.3 \%$ of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with $29.9 \%$ of persons aged $18-29$, and $11.1 \%$ of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white nonHispanics (22.4\%) than among Native Americans (40.0\%). Tobacco use differed significantly by county, with a range of $5.4 \%$ in Madison County to $41.6 \%$ in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

## Other Cancer-Related

Healthy Weight by Body Mass Index - 2015-2021
Statewide, 32.1\% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5-24.9). BMI differed significantly by race/ethnicity, with $32.5 \%$ of white non-Hispanics, compared to 28.2\% of Hispanics and $24.6 \%$ of Native Americans, being in the healthy weight range. Males ( $25.5 \%$ ) were significantly less likely to be in the healthy weight range than females (38.6\%). BMI differed significantly by age of respondent, with $43.3 \%$ of persons aged $18-29$, and $26.0 \%$ of persons aged $50-64$, being in the healthy weight range. BMI differed significantly by county, with a range of $19.8 \%$ in Power County to $47.4 \%$ in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2015-2021
CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, $78.7 \%$ of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with $83.3 \%$ of persons aged $18-29$, and $72.3 \%$ of persons aged $65+$, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of $64.3 \%$ in Clark County to 84.6\% in Teton County.

Physical Activity Guidelines - 2011, 2013, 2015, 2017, 2019
Statewide, 21.9\% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with $26.3 \%$ of persons aged 18-29, and $19.2 \%$ of persons aged $50-64$, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.6\% in Franklin County to $30.6 \%$ in Blaine County.

Home Radon Testing - 2016, 2018, 2020
Statewide, 23.0\% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with $25.1 \%$ of white non-Hispanics, $7.4 \%$ of Hispanics, and $25.4 \%$ of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of $8.5 \%$ in Cassia County to $54.4 \%$ in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.


[^0]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^1]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^2]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^3]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^4]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^5]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^6]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^7]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^8]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^9]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^10]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^11]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^12]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^13]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^14]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^15]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^16]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^17]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^18]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^19]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^20]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^21]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^22]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^23]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^24]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^25]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^26]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^27]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^28]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^29]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^30]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^31]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^32]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^33]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^34]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^35]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^36]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^37]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^38]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^39]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^40]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^41]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^42]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

[^43]:    ** Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, or a colonoscopy in the past 10 years.

